0001104659-21-030112.txt : 20210301 0001104659-21-030112.hdr.sgml : 20210301 20210301170919 ACCESSION NUMBER: 0001104659-21-030112 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 116 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210301 DATE AS OF CHANGE: 20210301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cryoport, Inc. CENTRAL INDEX KEY: 0001124524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880313393 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34632 FILM NUMBER: 21699174 BUSINESS ADDRESS: STREET 1: 112 WESTWOOD PLACE, SUITE 350 CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: (949) 232-1900 MAIL ADDRESS: STREET 1: 112 WESTWOOD PLACE, SUITE 350 CITY: BRENTWOOD STATE: TN ZIP: 37027 FORMER COMPANY: FORMER CONFORMED NAME: CRYOPORT SYSTEMS LLC DATE OF NAME CHANGE: 20010614 FORMER COMPANY: FORMER CONFORMED NAME: CRYOPORT SYSTEMS INC DATE OF NAME CHANGE: 20000923 10-K 1 cyrx-20201231x10k.htm FORM 10-K
000001124524--12-312020FY2500002500003733978739837058P3YP7YP4YP3YP20YP45YtrueP0YP0YP0YP0Yfalse0001124524us-gaap:DomesticCountryMember2020-12-310001124524us-gaap:DomesticCountryMember2019-12-310001124524us-gaap:DomesticCountryMember2018-12-310001124524us-gaap:RetainedEarningsMemberus-gaap:PrivatePlacementMember2020-01-012020-12-310001124524us-gaap:PreferredClassAMemberus-gaap:PrivatePlacementMember2020-01-012020-12-310001124524us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2020-01-012020-12-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:PrivatePlacementMember2020-01-012020-12-310001124524cyrx:ClassCConvertiblePreferredStockMemberus-gaap:SubsequentEventMember2021-02-052021-02-050001124524us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2021-01-252021-01-250001124524us-gaap:PreferredClassBMemberus-gaap:PrivatePlacementMember2020-01-012020-12-310001124524us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2020-01-012020-12-310001124524us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2021-01-212021-01-210001124524srt:DirectorMember2020-01-012020-12-310001124524srt:DirectorMember2019-01-012019-12-310001124524us-gaap:RetainedEarningsMember2020-12-310001124524us-gaap:PreferredClassBMember2020-12-310001124524us-gaap:PreferredClassAMember2020-12-310001124524us-gaap:AdditionalPaidInCapitalMember2020-12-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001124524us-gaap:RetainedEarningsMember2019-12-310001124524us-gaap:PreferredClassAMember2019-12-310001124524us-gaap:AdditionalPaidInCapitalMember2019-12-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001124524us-gaap:RetainedEarningsMember2018-12-310001124524us-gaap:PreferredClassAMember2018-12-310001124524us-gaap:AdditionalPaidInCapitalMember2018-12-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001124524us-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2021-01-210001124524us-gaap:CommonStockMember2020-12-310001124524cyrx:PreferredClassCMember2020-12-310001124524us-gaap:PreferredClassBMember2019-12-310001124524us-gaap:CommonStockMember2019-12-310001124524us-gaap:PreferredClassBMember2018-12-310001124524us-gaap:CommonStockMember2018-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeTwoMember2020-01-012020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeThreeMember2020-01-012020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeSixMember2020-01-012020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeSevenMember2020-01-012020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeOneMember2020-01-012020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeFourMember2020-01-012020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeFiveMember2020-01-012020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeEightMember2020-01-012020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeTwoMember2020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeThreeMember2020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeSixMember2020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeSevenMember2020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeOneMember2020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeFourMember2020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeFiveMember2020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:RangeEightMember2020-12-310001124524us-gaap:EmployeeStockOptionMember2019-12-310001124524us-gaap:WarrantMember2018-12-310001124524us-gaap:EmployeeStockOptionMember2018-12-310001124524us-gaap:WarrantMember2018-01-012018-12-310001124524us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:Plan2018Member2020-12-310001124524us-gaap:EmployeeStockOptionMembercyrx:Plan2018Member2018-05-310001124524srt:MinimumMember2019-01-012019-12-310001124524srt:MaximumMember2019-01-012019-12-310001124524us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001124524us-gaap:CostOfSalesMember2020-01-012020-12-310001124524cyrx:EngineeringAndDevelopmentMember2020-01-012020-12-310001124524us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-310001124524us-gaap:CostOfSalesMember2019-01-012019-12-310001124524cyrx:EngineeringAndDevelopmentMember2019-01-012019-12-310001124524us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001124524cyrx:HumanReproductiveMedicineMembercyrx:GlobalLogisticsSolutionsMember2020-01-012020-12-310001124524cyrx:BiopharmaceuticalMembercyrx:GlobalLogisticsSolutionsMember2020-01-012020-12-310001124524cyrx:AnimalHealthMembercyrx:GlobalLogisticsSolutionsMember2020-01-012020-12-310001124524us-gaap:EMEAMember2020-01-012020-12-310001124524srt:AsiaPacificMember2020-01-012020-12-310001124524srt:AmericasMember2020-01-012020-12-310001124524cyrx:GlobalLogisticsSolutionsMember2020-01-012020-12-310001124524cyrx:ForeignCustomersMember2020-01-012020-12-310001124524cyrx:HumanReproductiveMedicineMembercyrx:GlobalLogisticsSolutionsMember2019-01-012019-12-310001124524cyrx:BiopharmaceuticalMembercyrx:GlobalLogisticsSolutionsMember2019-01-012019-12-310001124524cyrx:AnimalHealthMembercyrx:GlobalLogisticsSolutionsMember2019-01-012019-12-310001124524us-gaap:EMEAMember2019-01-012019-12-310001124524srt:AsiaPacificMember2019-01-012019-12-310001124524srt:AmericasMember2019-01-012019-12-310001124524cyrx:GlobalLogisticsSolutionsMember2019-01-012019-12-310001124524cyrx:ForeignCustomersMember2019-01-012019-12-310001124524srt:MinimumMemberus-gaap:ComputerEquipmentMember2020-01-012020-12-310001124524srt:MinimumMemberus-gaap:BuildingMember2020-01-012020-12-310001124524srt:MinimumMembercyrx:TruckAndAutoMember2020-01-012020-12-310001124524srt:MinimumMembercyrx:FreezerMember2020-01-012020-12-310001124524srt:MinimumMembercyrx:EquipmentAndFurnitureMember2020-01-012020-12-310001124524srt:MaximumMemberus-gaap:ComputerEquipmentMember2020-01-012020-12-310001124524srt:MaximumMembercyrx:TruckAndAutoMember2020-01-012020-12-310001124524srt:MaximumMembercyrx:FreezerMember2020-01-012020-12-310001124524srt:MaximumMembercyrx:EquipmentAndFurnitureMember2020-01-012020-12-310001124524us-gaap:WarrantMember2019-01-012019-12-310001124524us-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2021-01-212021-01-2100011245242019-06-242019-06-2400011245242019-06-240001124524us-gaap:ConvertiblePreferredStockMember2020-12-310001124524cyrx:ClassCConvertiblePreferredStockMember2020-12-310001124524cyrx:ClassBConvertiblePreferredStockMember2020-12-310001124524cyrx:ClassCConvertiblePreferredStockMemberus-gaap:PrivatePlacementMember2020-10-010001124524us-gaap:ConvertiblePreferredStockMember2019-12-310001124524cyrx:ClassCConvertiblePreferredStockMember2019-12-310001124524cyrx:ClassBConvertiblePreferredStockMember2019-12-310001124524cyrx:ClassCConvertiblePreferredStockMemberus-gaap:SubsequentEventMember2021-02-050001124524cyrx:MveCryobiologicalStorageBusinessMember2020-08-242020-08-2400011245242020-05-012020-05-310001124524us-gaap:USTreasurySecuritiesMember2020-12-310001124524cyrx:MutualFundsMember2020-12-310001124524us-gaap:USTreasurySecuritiesMember2019-12-310001124524cyrx:MutualFundsMember2019-12-310001124524us-gaap:StateAndLocalJurisdictionMember2019-12-310001124524us-gaap:DomesticCountryMember2019-12-310001124524cyrx:FederalTaxIncomeMember2019-12-310001124524cyrx:InstallmentTwoMembercyrx:CryopdpMember2020-12-310001124524cyrx:InstallmentOneMembercyrx:CryopdpMember2020-12-310001124524cyrx:CryopdpMember2020-12-310001124524us-gaap:ForeignCountryMember2020-01-012020-12-310001124524us-gaap:DomesticCountryMember2020-01-012020-12-310001124524us-gaap:ForeignCountryMember2019-01-012019-12-310001124524us-gaap:DomesticCountryMember2019-01-012019-12-310001124524us-gaap:UseRightsMember2020-01-012020-12-310001124524us-gaap:TrademarksAndTradeNamesMember2020-01-012020-12-310001124524us-gaap:TechnologyBasedIntangibleAssetsMember2020-01-012020-12-310001124524us-gaap:NoncompeteAgreementsMember2020-01-012020-12-310001124524us-gaap:CustomerRelationshipsMember2020-01-012020-12-310001124524cyrx:AgentNetworkMember2020-01-012020-12-310001124524us-gaap:TrademarksAndTradeNamesMember2019-01-012019-12-310001124524us-gaap:TechnologyBasedIntangibleAssetsMember2019-01-012019-12-310001124524us-gaap:NoncompeteAgreementsMember2019-01-012019-12-310001124524us-gaap:CustomerRelationshipsMember2019-01-012019-12-310001124524cyrx:PatentsAndTrademarksMember2019-01-012019-12-310001124524us-gaap:UseRightsMember2020-12-310001124524us-gaap:TrademarksAndTradeNamesMember2020-12-310001124524us-gaap:TechnologyBasedIntangibleAssetsMember2020-12-310001124524us-gaap:OrderOrProductionBacklogMember2020-12-310001124524us-gaap:NoncompeteAgreementsMember2020-12-310001124524us-gaap:CustomerRelationshipsMember2020-12-310001124524cyrx:PatentsAndTrademarksMember2020-12-310001124524cyrx:AgentNetworkMember2020-12-310001124524us-gaap:TrademarksAndTradeNamesMember2019-12-310001124524us-gaap:TechnologyBasedIntangibleAssetsMember2019-12-310001124524us-gaap:NoncompeteAgreementsMember2019-12-310001124524us-gaap:CustomerRelationshipsMember2019-12-310001124524cyrx:PatentsAndTrademarksMember2019-12-310001124524us-gaap:EmployeeStockOptionMember2020-01-012020-12-3100011245242020-10-012020-12-3100011245242020-07-012020-09-3000011245242020-04-012020-06-3000011245242020-01-012020-03-3100011245242019-10-012019-12-3100011245242019-07-012019-09-3000011245242019-04-012019-06-3000011245242019-01-012019-03-310001124524cyrx:UsEmployeesMember2020-01-012020-12-310001124524cyrx:UsEmployeesMember2019-01-012019-12-310001124524cyrx:DeferredIncomeTaxLiabilitiesNetMember2020-12-310001124524cyrx:DeferredIncomeTaxLiabilitiesNetMember2019-12-310001124524us-gaap:OtherNoncurrentAssetsMember2020-12-310001124524cyrx:UsEmployeesMember2020-12-310001124524cyrx:NonUsEmployeesMember2020-12-310001124524cyrx:UsEmployeesMember2019-12-310001124524cyrx:NonUsEmployeesMember2019-12-310001124524us-gaap:ConvertibleDebtMember2018-12-140001124524us-gaap:PrivatePlacementMember2020-05-3100011245242020-05-310001124524us-gaap:SeniorNotesMember2020-12-310001124524us-gaap:WarrantMember2020-01-012020-12-310001124524us-gaap:SeniorNotesMember2020-01-012020-12-310001124524us-gaap:ServiceMember2020-01-012020-12-310001124524us-gaap:ProductMember2020-01-012020-12-310001124524us-gaap:ServiceMember2019-01-012019-12-310001124524cyrx:ClassCConvertiblePreferredStockMember2020-10-010001124524cyrx:ForeignCustomersMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-12-310001124524cyrx:CustomerTwoMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-12-310001124524cyrx:CustomerOneMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-12-310001124524us-gaap:RevenueFromContractWithCustomerMember2020-01-012020-12-310001124524us-gaap:AccountsReceivableMember2020-01-012020-12-310001124524cyrx:ForeignCustomersMemberus-gaap:RevenueFromContractWithCustomerMember2019-01-012019-12-310001124524cyrx:CustomerTwoMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310001124524cyrx:CustomerOneMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310001124524us-gaap:RevenueFromContractWithCustomerMember2019-01-012019-12-310001124524us-gaap:AccountsReceivableMember2019-01-012019-12-3100011245242019-10-310001124524us-gaap:CommonStockMemberus-gaap:SubsequentEventMember2021-02-050001124524us-gaap:EmployeeStockOptionMember2020-12-310001124524cyrx:ClassCConvertiblePreferredStockMember2020-12-310001124524us-gaap:WarrantMember2020-12-310001124524us-gaap:WarrantMember2019-12-3100011245242018-12-310001124524cyrx:CryogenePartnersMember2020-12-310001124524cyrx:MveCryobiologicalStorageBusinessMemberus-gaap:UseRightsMember2020-10-010001124524cyrx:MveCryobiologicalStorageBusinessMemberus-gaap:TrademarksAndTradeNamesMember2020-10-010001124524cyrx:MveCryobiologicalStorageBusinessMemberus-gaap:OrderOrProductionBacklogMember2020-10-010001124524cyrx:MveCryobiologicalStorageBusinessMemberus-gaap:DevelopedTechnologyRightsMember2020-10-010001124524cyrx:MveCryobiologicalStorageBusinessMemberus-gaap:CustomerRelationshipsMember2020-10-010001124524cyrx:CryopdpMemberus-gaap:TrademarksAndTradeNamesMember2020-10-010001124524cyrx:CryopdpMemberus-gaap:CustomerRelationshipsMember2020-10-010001124524cyrx:CryopdpMemberus-gaap:ComputerSoftwareIntangibleAssetMember2020-10-010001124524cyrx:CryopdpMembercyrx:AgentNetworkMember2020-10-010001124524cyrx:CryogenePartnersMemberus-gaap:TrademarksAndTradeNamesMember2019-05-140001124524cyrx:CryogenePartnersMemberus-gaap:TechnologyBasedIntangibleAssetsMember2019-05-140001124524cyrx:CryogenePartnersMemberus-gaap:NoncompeteAgreementsMember2019-05-140001124524cyrx:CryogenePartnersMemberus-gaap:CustomerRelationshipsMember2019-05-1400011245242020-10-010001124524cyrx:CryogenePartnersMember2019-05-142019-05-140001124524cyrx:CryogenePartnersMember2019-05-042019-05-040001124524cyrx:MveCryobiologicalStorageBusinessMember2020-01-012020-12-310001124524cyrx:CryogenePartnersMember2019-01-012019-12-310001124524cyrx:CryogenePartnersMember2019-05-140001124524us-gaap:USTreasuryNotesSecuritiesMember2020-12-310001124524us-gaap:USTreasuryNotesSecuritiesMember2019-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2020-12-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-12-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2020-12-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-12-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2020-12-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2020-12-310001124524us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-12-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:FairValueMeasurementsRecurringMember2020-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2019-12-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2019-12-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2019-12-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2019-12-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2019-12-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2019-12-310001124524us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001124524us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryNotesSecuritiesMember2019-12-310001124524us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2019-12-310001124524us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001124524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001124524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001124524us-gaap:FairValueMeasurementsRecurringMember2019-12-310001124524us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001124524cyrx:ConvertibleSeniorNotesMember2020-01-012020-12-310001124524us-gaap:WarrantMember2019-01-012019-12-310001124524us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001124524cyrx:MveCryobiologicalStorageBusinessMember2020-10-012020-10-010001124524cyrx:CryopdpMember2020-10-012020-10-010001124524cyrx:CryogenePartnersMember2020-01-012020-12-310001124524us-gaap:GeneralAndAdministrativeExpenseMember2019-10-012019-12-310001124524us-gaap:PrivatePlacementMember2020-01-012020-12-310001124524cyrx:ClassCConvertiblePreferredStockMember2020-01-012020-12-310001124524cyrx:PublicOfferingMember2019-01-012019-12-310001124524cyrx:MveCryobiologicalStorageBusinessMemberus-gaap:UseRightsMember2020-10-012020-10-010001124524cyrx:MveCryobiologicalStorageBusinessMemberus-gaap:OrderOrProductionBacklogMember2020-10-012020-10-010001124524cyrx:MveCryobiologicalStorageBusinessMemberus-gaap:DevelopedTechnologyRightsMember2020-10-012020-10-010001124524cyrx:MveCryobiologicalStorageBusinessMemberus-gaap:CustomerRelationshipsMember2020-10-012020-10-010001124524cyrx:CryopdpMemberus-gaap:CustomerRelationshipsMember2020-10-012020-10-010001124524cyrx:CryopdpMemberus-gaap:ComputerSoftwareIntangibleAssetMember2020-10-012020-10-010001124524cyrx:CryopdpMembercyrx:AgentNetworkMember2020-10-012020-10-010001124524cyrx:CryogenePartnersMemberus-gaap:TrademarksAndTradeNamesMember2019-05-142019-05-140001124524cyrx:CryogenePartnersMemberus-gaap:TechnologyBasedIntangibleAssetsMember2019-05-142019-05-140001124524cyrx:CryogenePartnersMemberus-gaap:NoncompeteAgreementsMember2019-05-142019-05-140001124524cyrx:CryogenePartnersMemberus-gaap:CustomerRelationshipsMember2019-05-142019-05-1400011245242020-06-3000011245242021-02-190001124524us-gaap:PrivatePlacementMember2020-05-012020-05-3100011245242020-06-292020-06-290001124524cyrx:PreferredStockRedemptionPeriodOneMembercyrx:ClassCConvertiblePreferredStockMemberus-gaap:SubsequentEventMember2021-02-052021-02-050001124524cyrx:PreferredStockRedemptionPeriodTwoMembercyrx:ClassCConvertiblePreferredStockMember2020-10-012020-10-010001124524cyrx:PreferredStockRedemptionPeriodThreeMembercyrx:ClassCConvertiblePreferredStockMember2020-10-012020-10-010001124524cyrx:PreferredStockRedemptionPeriodOneMembercyrx:ClassCConvertiblePreferredStockMember2020-10-012020-10-010001124524us-gaap:CommonStockMemberus-gaap:SubsequentEventMember2021-02-052021-02-050001124524cyrx:CryopdpMember2020-08-212020-08-210001124524cyrx:CryopdpMember2020-01-012020-12-310001124524cyrx:ClassCConvertiblePreferredStockMember2020-10-012020-10-010001124524us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2020-10-012020-10-010001124524cyrx:ClassCConvertiblePreferredStockMemberus-gaap:PrivatePlacementMember2020-10-012020-10-010001124524us-gaap:PrivatePlacementMember2020-10-012020-10-010001124524srt:MinimumMember2020-01-012020-12-310001124524srt:MaximumMember2020-01-012020-12-310001124524cyrx:MveCryobiologicalStorageBusinessMember2019-01-012019-12-3100011245242020-10-012020-10-010001124524cyrx:ScenarioOneMember2020-01-012020-12-310001124524cyrx:ScenarioTwoMember2020-01-012020-12-310001124524cyrx:MveCryobiologicalStorageBusinessMember2020-10-010001124524cyrx:CryopdpMember2020-10-0100011245242020-12-3100011245242019-12-310001124524us-gaap:RetainedEarningsMember2020-01-012020-12-310001124524us-gaap:PreferredClassBMember2020-01-012020-12-310001124524us-gaap:PreferredClassAMember2020-01-012020-12-310001124524us-gaap:CommonStockMember2020-01-012020-12-310001124524us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001124524cyrx:PreferredClassCMember2020-01-012020-12-3100011245242020-01-012020-12-310001124524us-gaap:RetainedEarningsMember2019-01-012019-12-310001124524us-gaap:PreferredClassBMember2019-01-012019-12-310001124524us-gaap:PreferredClassAMember2019-01-012019-12-310001124524us-gaap:CommonStockMember2019-01-012019-12-310001124524us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001124524us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-3100011245242019-01-012019-12-31iso4217:USDiso4217:USDxbrli:sharescyrx:itemxbrli:purexbrli:sharesiso4217:EURcyrx:segment

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

⌧

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

​

​

For the fiscal year ended December 31, 2020

​

​

◻

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

​

​

For the transition period from       to      .

​

Commission File Number: 001-34632

Graphic

​

CRYOPORT, INC.

(Exact Name of Registrant as Specified in its Charter)

​

Nevada

88-0313393

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

​

112 Westwood Place, Suite 350

Brentwood, TN 37027

(Address of principal executive offices, including zip code)

(949) 470-2300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

​

Title of Each Class

​

Trading Symbol(s)

​

Name of Each Exchange on Which Registered

Common Stock, $0.001 par value

​

CYRX

​

The NASDAQ Stock Market LLC
(The Nasdaq Capital Market)

​

Securities registered pursuant to Section 12(g) of the Act:

Warrants to purchase Common Stock

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes  ⌧    No  ◻

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes  ◻    No  ⌧

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ⌧    No  ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  ⌧    No  ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer

⌧

Accelerated filer

◻

 

 

 

 

Non-accelerated filer

◻

Smaller reporting company

☒

 

 

 

 

 

Emerging growth company

◻

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ◻    No   ⌧

The aggregate market value of common stock held by non-affiliates of the registrant as of June 30, 2020 was $881,352,700 based on the closing sale price of such common equity on such date (excluding 29,135,627 shares of common stock held by directors and officers, and any stockholders whose ownership exceeds five percent of the shares outstanding as of June 30, 2020).

As of February 19, 2021, there were 45,581,661 shares of the registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

​

Portions of the registrant’s proxy statement for the 2021 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2020.

​

​

​

​

TABLE OF CONTENTS

​

Page

PART I

Item 1.

Business

4

Item 1A.

Risk Factors

20

Item 1B.

Unresolved Staff Comments

35

Item 2.

Properties

36

Item 3.

Legal Proceedings

36

Item 4.

Mine Safety Disclosures

36

PART II

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

37

Item 6.

Selected Financial Data

38

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

39

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

50

Item 8.

Financial Statements and Supplementary Data

50

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

50

Item 9A.

Controls and Procedures

50

Item 9B.

Other Information

51

PART III

Item 10.

Directors, Executive Officers and Corporate Governance

53

Item 11.

Executive Compensation

53

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

53

Item 13.

Certain Relationships and Related Transactions, and Director Independence

53

Item 14.

Principal Accountant Fees and Services

53

PART IV

Item 15.

Exhibits and Financial Statement Schedules

54

Item 16.

Form 10-K Summary

57

Signatures

58

​

​

​

​

2

FORWARD-LOOKING STATEMENTS

References to the “Company,” “Cryoport,” “we,” “us,” “our” and other similar words refer to Cryoport Inc. and its consolidated subsidiaries, unless the context suggests otherwise.  This Annual Report on Form 10-K (this “Form 10-K”) contains certain forward-looking statements. These forward-looking statements involve a number of risks and uncertainties. These forward-looking statements can generally be identified as such because the context of the statement will include certain words, including but not limited to, “believes,” “may,” “will,” “expects,” “intends,” “estimates,” “anticipates,” “plans,” “seeks,” “continues,” “predicts,” “potential,” “likely,” or “opportunity,” and also contains predictions, estimates and other forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Readers of this Form 10-K should not put undue reliance on these forward-looking statements, which speak only as of the time this Form 10-K was filed with the Securities and Exchange Commission (the “SEC”). Reference is made in particular to forward-looking statements regarding our expectations about future business plans, new products or services, regulatory approvals, strategies, development timelines, prospective financial performance and opportunities, including potential acquisitions, expectations about future benefits of our acquisitions, including Cryogene Partners, CRYOPDP and MVE Biological Solutions, our ability to successfully integrate those businesses and our plans related thereto; liquidity and capital resources; projected trends in the market in which we operate; anticipated impacts from the coronavirus strain COVID-19 (“COVID-19”) on us, including to our business operations, results of operations, cash flows, and financial position, and our future responses to the COVID-19 pandemic; our expectations about securing and maintaining strategic relationships with global couriers or large clinical research organizations; our future capital needs and ability to raise capital on favorable terms or at all; results of our research and development efforts; and approval of our patent applications.  Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company’s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this Form 10-K, including the “Risk Factors” in “Part I, Item 1A — Risk Factors”, and in “Part II, Item 7 — Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

​

Past financial or operating performance is not necessarily a reliable indicator of future performance, and you should not use our historical performance to anticipate results or future period trends. We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our results of operations and financial condition. Except as required by law, we do not undertake to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this Form 10-K.

​

3

PART I

Item 1. Business

Overview

We are redefining the temperature-controlled supply chain for the life sciences industry by providing a unique and evolving platform of critical products and solutions including advanced packaging, informatics, specialty logistics services, biostorage services, and cryogenic life sciences equipment. With over 625 employees spread across 30 locations worldwide, we are engaged in providing global solutions to the biopharma/pharma, animal health, and human reproductive medicne markets. Our primary focus is on addressing the critical temperature-controlled supply chain needs within the biopharmaceutical space with an emphasis on serving the rapidly growing cell and gene therapy, or C&GT, market.

Our Strategy

We are focused on establishing best-in-class, comprehensive temperature-controlled supply chain solutions that support the expanding global landscape of the life sciences industry. We believe our growth strategy aligns with the growth of the markets we serve and our customers within them. In particular, we have identified the C&GT market as a high growth market, with unmet supply chain needs that we believe can benefit significantly from our solutions. The global C&GT market was valued at approximately $4.2 billion in 2019 and is projected to grow to over $33.1 billion by 2024.

Over the last several years, we have grown to become a leader in supporting C&GT clinical trials globally. As of the end of the fourth quarter of 2020, we supported 528 clinical trials and five commercial therapies, including KYMRIAH by Novartis and YESCARTA by Gilead/Kite. In addition, seven additional Cryoport supported therapies filed for commercial approval with the U.S. Food and Drug Administration, or FDA, or the European Medicines Agency, or EMA, as of the end of the fourth quarter of 2020. Based on publicly disclosed information, industry data, and internal forecasts, we estimate that up to 21 additional Cryoport supported C&GTs, currently in clinical trials, may file for regulatory approval during the course of 2021. Commercial approvals of these therapies provide an opportunity to become significant revenue drivers for us in the future as each of them requires comprehensive temperature-controlled supply chain support and services at commercial scale, and we expect that many will select us as their critical supply chain solution as a result of our work in connection with their respective clinical trials.

We intend to build on our recent history of developing market-leading, temperature-controlled supply chain solutions and delivering strong growth through the following strategies:

●Superior service to our clients. We strive to provide our clients with best-in-class solutions to help manage some of the most critical aspects of their evolving businesses with advanced temperature-controlled supply chain solutions tailored to their specific requirements.
●Continuous innovation. We plan to capitalize on our internal technological expertise to develop products and solutions that address unmet needs in the global supply chain of the C&GT market and the other life sciences markets we serve. We plan to strengthen our existing products and solutions with complementary products, solutions and innovative technologies that are designed to provide our customers with tailored solutions to manage the critical aspects of the supply chain effectively and efficiently.
●Geographical expansion. We intend to expand our global commercial presence by continuing to broaden our capabilities within our existing network and selectively build out new global supply chain centers, manufacturing facilities, and infrastructure in support of known and anticipated growth in demand for our solutions and equipment.

4

●Strategic logistics alliances and collaborations. We have been successful in establishing strategic alliances around the world as a means for our current and prospective client base to utilize our solutions. We have focused our efforts on market leading companies in the logistics services industry as well as participants in the life sciences industry. These strategies drive integration of our solutions into our alliance partners’ services. We currently support the three largest integrators in the world: FedEx, DHL and UPS, with advanced cryogenic logistics solutions for the life sciences industry. Our Compliance Unified Ecosystem(TM) includes alliance partners such as McKesson Specialty Health, a division of McKesson Corporation, Be The Match BioTherapies, Brooks Life Sciences, EVERSANA, Lonza, Medipal and Vineti. The overarching goal of these partnerships is to provide fully integrated solutions including, but not limited to, process optimization that reduces risk, increases transparency, and improves certainty.
●Targeted acquisitions. We intend to continue to selectively pursue acquisitions that may include innovative technologies and solutions and/or geographic competencies and capabilities to ensure we further enhance and broaden our market leadership and enable our clients to successfully bring products and life-saving therapies to market.
●Setting industry standards. Our supply chain solutions are designed to support our clients’ initiatives through early-stage studies, clinical trials, and their global commercialization. We believe our ‘first mover’ advantage and the experience we have gained in supporting the C&GT market have positioned us as a market leader in the space with a strong platform of comprehensive solutions, products and service that have been adopted by many leading life sciences companies. A key strategy for further accelerating market adoption of our enabling solutions is to maintain and extend our position as the industry leader in the markets we serve. We believe this approach can further strengthen our market position, expand the breadth of services our clients utilize, increase our competitive advantage and contribute to our long-term growth.

Our Solutions

We use our competencies and capabilities to develop comprehensive and reliable, technology-centric solutions that address the specific needs of our customers. Our platform of temperature-controlled supply chain solutions, products and service includes cold-chain and cryogenic life sciences equipment, advanced packaging, informatics, specialty logistics services, biostorage services, kitting, labeling, fulfillment and consulting. These solutions, products and services are utilized for temperature-controlled supply chain services in the life sciences industry for personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain and specific ranges of precision-controlled temperatures and environments.

Our Cryoport solutions are comprised primarily of a sophisticated, cloud-based, logistics management platform, which is branded as the Cryoportal Logistics Management Platform®, or the Cryoportal, Cryoport Express® Shippers and the SmartPak Condition Monitoring System®, or the SmartPak®. The Cryoportal® supports the management of shipments through a single interface, which includes order entry, document preparation, customs documentation, courier management, near real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements. In addition, it provides unique and incisive information dashboards and validation documentation for every shipment through data collected by the SmartPak®. The Cryoportal® can record and retain a fully documented history of all Cryoport Express® Shippers, including chain-of-custody, chain-of-condition, chain-of-identity, and Chain of Compliance® information for each shipment, which is used to ensure that the stability of shipped biologic commodities are maintained throughout the shipping cycle. At the client’s option, recorded information is archived, allowing the client to meet exacting requirements necessary for scientific work and/or proof of regulatory compliance during the logistics process.

During 2018 we introduced our Chain of Compliance® solution, as a new industry standard within the C&GT market. Our Chain of Compliance® goes beyond chain of condition, chain of custody and chain of identity by providing traceability of the equipment, equipment components and processes supporting each client or patient therapy. The Chain of Compliance enables us to recall any single or every transport that an individual Cryoport Express Shipper has taken, the client(s) it supported, the commodity transported, its performance during transit, and each step that we perform before the shipper is put back into service. This includes Cryoport Express Shipper performance and requalification history, commodity history, courier handling and performance history, calibration history, and correlation competencies that can link in field events to equipment performance. Many of these standards have now been incorporated in the recently released ISO-21973 standard and we believe they are likely to become regulatory requirements in the near future.

5

In September of 2019, the Cryoport Express Advanced Therapy Shipper™ was launched to address specific needs of biopharma companies developing and commercializing C&GTs. The Cryoport Express Advanced Therapy Shippers provide verification processes to ensure that it has only been used for human-based therapies and materials and employ advanced validated cleaning methods to minimize the risk of cross-contamination of equipment and materials during use, delivery, and distribution of biopharmaceutical materials.

We further extended our solutions, capabilities, and global logistics network through the following recent acquisitions:

In October 2020, we further expanded our capabilities by acquiring CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions for high value, time critical and temperature-sensitive pharmaceuticals. CRYOPDP covers a significant portion of the healthcare temperature-controlled supply chain including packaging, pick-pack kit preparation, premium services and specialty biopharma/pharma courier support. This acquisition increased our global presence to a network of 27 global supply chain centers in 13 countries. This expanded network gives us a new advantage when serving global multi-national customers and also provides redundancies and backup that reduce supply chain risk for our customers. CRYOPDP has also developed a cloud-based logistics platform branded as UnITy™, which we plan to integrate with our Cryoportal Logistics Management Platform. UnITy™, provides functionalities such as a Transport Management System, Warehousing Management System, Quality Management System, a Customer Experience portal, mobile apps for track and trace during transport and storage as well as integration with transportation agents and business partners.

Also in October 2020, we made a second acquisition, acquiring MVE Biological Solutions from Chart Industries, Inc. MVE Biological Solutions, or MVE, provides cryobiological storage and transportation solutions for the life sciences industry through its advanced line of cryogenic stainless-steel freezers, aluminum dewars and related ancillary equipment used in the storage and transport of life sciences commodities, which includes the rapidly growing C&GT business. With three primary facilities, located in Ball Ground, Georgia, New Prague, Minnesota and Cheng-du, China, MVE Biological Solutions is a leader in serving the life sciences industry throughout the world. The acquisition is a vertical integration that, in addition to expanding our footprint to handle the growing demand driven by the growth in the C&GT market, helps to secure our supply of cryogenic shippers and biostorage equipment. MVE strengthens Cryoport’s presence in its Animal Health, Reproductive and Biopharma/Pharma markets.  Its cryobiological storage and transport clients include cell and gene therapy, medical laboratories, biotech/pharmaceutical research facilities, blood and tissue banks, breeders, veterinary laboratories, large-scale bio-repositories, and fertility clinics. The addition of MVE Biological Solutions allows us to capture a greater share of the global spend on supply chain products and services that supports C&GT.

In May 2019, we expanded our capabilities by acquiring Cryogene Partners, a Texas general partnership doing business as Cryogene Labs, or Cryogene. Cryogene is an expanding state-of-the-art temperature-controlled biostorage solutions business strategically located in Houston, Texas. Cryogene is an industry leader in the management of pre-clinical services which include critical biological commodities to support clinical research, the advancement of C&GTs, GMP biologics, and public health research. It provides customized, end-to-end chain of custody/chain of condition solutions for its clients.

As demonstrated by our organic growth and acquisitions, we are continually focused on establishing comprehensive temperature-controlled supply chain solutions to support the rapidly expanding global landscape of the life sciences industry.

The Markets We Serve

Biopharma/Pharma.   In the biopharma/pharma market we are focused on supporting the saving of lives. From clinical research and development to clinical research organizations to clinical trials for C&GTs to the storage and delivery of life-saving C&GTs to the customers of biopharmaceutical and biotechnology organizations to crucial points of care, we strive to address fundamental-to-advanced temperature-controlled storage, transport, packaging, fulfillment, and information challenges. In particular, C&GTs have become a rapidly growing area of biological drug development, with over 1,000 global clinical trials underway in 2020. This therapeutic approach has certain supply chain challenges that we believe our solutions are tailored to address.

Animal Health. In the animal health market we provide support for animal reproduction, which primarily involves the production of protein for sustaining life. We also support the health of recreational and companion animals. Animal disease prevention and control rely on the safe transport and storage of vaccines and other biological materials around the world. Our temperature-controlled supply chain solutions are designed to help avoid costly delays through nonstop monitoring and complete fleet management from and to the origin and destination points as well as provide cryobiological storage equipment.

6

Human Reproductive Medicine. In the human reproductive medicine market we are focused on the support of the creation of human life by supporting In Vitro Fertilization, or IVF, and related technologies along with clinical networks globally. Through our CryoStork services, we transport reproductive materials through dedicated medical transport services to help ensure that IVF materials are on the next flight out to their destination. IVF materials also receive one-on-one handling and individualized attention during the entire logistics process. In addition, we also provide cryobiological storage equipment to fertility clinics around the world.

Acquisitions

On October 1, 2020, we completed our acquisition of CRYOPDP for a cash consideration of €49 million, subject to cash, net debt, working capital and other adjustments. CRYOPDP, based in France, is a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets. CRYOPDP conducts its business activities mainly through entities based in the United Kingdom, the United States, the Asia-Pacific region, and India.

Also, on October 1, 2020, we completed our acquisition of MVE Biological Solutions for cash consideration of $320 million, subject to customary closing working capital and other adjustments. We financed a portion of the closing cash payment of the MVE Biological Solutions acquisition with the net proceeds of the Blackstone Private Placement, as further discussed below. MVE Biological Solutions is a global leader in manufactured vacuum insulated products and cryogenic freezer systems for the life sciences industry. MVE Biological Solutions has manufacturing and distribution operations in the United States, Europe, and Asia.

As a result of the acquisitions, we have approximately 625 employees: 605 full-time, 10 part-time, and 10 temporary, of which 250 are located in the Americas, 158 in Europe, the Middle East and Africa, or EMEA, and 217 in Asia Pacific, or APAC. We believe that we have assembled a strong management/leadership team with the experience and expertise needed to execute our business strategy. We anticipate hiring additional personnel as needs dictate to implement our global growth strategy.

After the acquisitions, we lease or own various corporate, research and development, biostorage, global logistics and supply chain centers at 27 total sites across the Americas, EMEA and APAC regions.

Blackstone Private Placement

In connection with the MVE Biological Solutions acquisition, on October 1, 2020, we completed a private placement with an investment vehicle of funds affiliated with The Blackstone Group Inc., consisting of the issuance and sale of (i) 250,000 shares of a newly designated 4.0% Series C Convertible Preferred Stock, par value $0.001 per share, or the Series C Convertible Preferred Stock, at a price of $1,000 per share, for $250 million, and (ii) 675,536 shares of our common stock for $25.0 million, for an aggregate purchase price of $275.0 million, pursuant to a Securities Purchase Agreement, dated August 24, 2020, between us and Blackstone Freeze Parent L.P. (f/k/a BTO Freeze Parent L.P.). On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Company’s 4.0% Series C Convertible Preferred Stock, resulting in the issuance of an aggregate of 1,312,860 shares of Common Stock (See Note 18 “Subsequent Events” in our accompanying consolidated financial statements for additional information).

January 2021 Public Offering

On January 25, 2021, the Company completed an underwritten public offering (the “Offering”) of 4,356,059 shares of its common stock, par value $0.001 per share (the “Shares”). The Shares were issued and sold pursuant to an underwriting agreement (the “Underwriting Agreement”), dated January 20, 2021, by and among the Company, on the one hand, and Morgan Stanley & Co. LLC, Jefferies LLC, SVB Leerink LLC and UBS Securities LLC, as representatives of certain underwriters (collectively, the “Underwriters”) at a public offering price per share of $66.00, before deducting underwriting discounts and commissions. The Shares include 568,181 shares issued and sold pursuant to the Underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the Underwriting Agreement. The Company received net proceeds of approximately $269.7 million from the Offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

7

Change in Segment Reporting

The Company continually monitors and reviews its segment reporting structure in accordance with authoritative guidance to determine whether any changes have occurred that would impact its reportable operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The chief operating decision maker (“CODM”) is our Chief Executive Officer.  Up until the fourth quarter of 2020, we managed, reported and evaluated our business in the following two reportable operating segments: Global Logistics Solutions and Global Bioservices. During the fourth quarter of 2020, our CODM changed how he makes operating decisions, assesses the performance of the business and allocates resources in a manner that caused our operating segments to change as a result of the MVE and CRYOPDP acquisitions. In consideration of Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC"), Segment Reporting, we determined that we are not organized around specific products and services, geographic regions or regulatory environments. Accordingly, beginning with the fourth quarter of 2020 we realigned our reporting structure, resulting in a single reportable segment. The Company has adjusted its financial statements for historical periods to reflect this change in segment reporting and show its financial results without segments for all periods presented. See Part II, Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations, in this Annual Report on Form 10-K for further discussion.

Government Regulation

Globally, we are subject to numerous domestic federal, state and local laws and regulations and the laws and regulations of global jurisdictions relating to matters regarding shipments, customs, import, export, safe working conditions, manufacturing practices, environmental protection and disposal of hazardous or potentially hazardous substances. In addition, we have to ensure compliance with economic sanctions and/or restrictions on individuals, corporations or countries, and other government regulations affecting trade that may apply to our international cross border business activities. We may incur significant costs to comply with such laws and regulations now or in the future.

The shipping of biologic products, biologic commodities, diagnostic specimens, infectious substances and dangerous goods, whether via air or ground, falls under the jurisdiction of many state, federal and international agencies. The quality of the packaging that protects a product or biologic commodity is critical in determining whether it will arrive at its destination in a satisfactory condition. Currently the most stringent regulations we are subject to are the dangerous goods regulations. Many of the regulations for transporting dangerous goods in the United States are determined by international rules formulated under the auspices of the United Nations. Dangerous goods are usually one-time shipments and are not a part of our standard service. When we ship dangerous goods, we follow strict and stringent guidelines.

International Civic Aviation Organization ("ICAO") is the United Nations organization that develops regulations (Technical Instructions) for the safe transport of dangerous goods by air. If shipment is by air, compliance with the rules established by the International Air Transport Association ("IATA") is required. IATA is a trade association made up of airlines and air cargo couriers that publishes annual editions of the IATA Dangerous Goods Regulations. These regulations interpret and add to the ICAO Technical Instructions to reflect industry practices. Additionally, the Centers for Disease Control (“CDC”) has regulations (published in the Code of Federal Regulations) for interstate shipping of specimens.

Our Cryoport Express® Shippers meet Packing Instructions 602 and 650 and are certified for the shipment of Class 6.2 Dangerous Goods per the requirements of the ICAO Technical Instructions for the Safe Transport of Dangerous Goods by Air and IATA. Our present and planned future versions of the Cryoport SmartPak™ Condition Monitoring Systems will likely be subject to regulation by the Federal Aviation Administration (“FAA”), Federal Communications Commission (“FCC”), Food and Drug Administration (“FDA”), IATA and possibly other agencies which may be difficult to determine on a global basis. Additionally, our Chain of Compliance™ processes comply fully with ISO 21973 recommendations.

Our MVE Biological Solutions cryogenic stainless-steel freezers and aluminum dewars are certified to the Medical Device Directive (MDD) in the European Union. Additionally, registrations for import are in place for various countries with these requirements.

8

Storage of biological materials that are classified as drug products for human therapeutic use (either for investigational use or commercially approved) or materials used in the manufacture of drug products for human therapeutic use, is regulated by the FDA under Title 21 Code of Federal Regulations (“CFR”) part 210 & 211. Facilities must be compliant with current Good Manufacturing Practice (“GMP”) regulations which are enforced by the FDA through registration and audit. If the drug product is exported to other countries, then the storage needs to comply with the relevant local regulations.

For additional information, see "Part I, Item 1A - Risk Factors-Risks Related to Regulatory and Legal Matters" in this Form 10-K.

Manufacturing and Raw Materials

Manufacturing. We source components for our products from multiple suppliers that manufacture to our engineering specifications using in part proprietary technology and know-how to mitigate supply chain risks.  We also use “off-the-shelf” products, which we may modify to meet our requirements. Through the acquisition of MVE, we are able to vertically integrate and secure Cryoport’s supply of cryogenic shippers and storage equipment. For some components, there are relatively few alternate sources of supply and the establishment of additional or replacement suppliers may or may not be accomplished immediately. Should this occur, we endeavor to mitigate risk by an increase in our inventory level to cover our total forecasted demand giving us time to secure additional qualified suppliers. The central electronic devices currently used in our SmartPak Condition Monitoring Systems have been acquired from a single source with calibration and alterations done by an independent third party.

Our vendor/partner relationships allow us to concentrate on further advancing and expanding our platform of solutions for the life sciences to meet the growing and varied demands for validated temperature-controlled solutions in the life sciences industry. We believe our current supply structure provides us the opportunity to rapidly scale to support our client’s commercialization activities; however, we continue to work to improve our current sourcing and to continue to mitigate risks therein.

Raw Materials. Various common raw materials are used in the manufacture of our shippers and in the development of our technologies. These raw materials are generally available from several alternate distributors and manufacturers. We have not experienced any significant difficulty in obtaining these raw materials.

Patents, Copyrights, Trademarks and Proprietary Rights

In order to remain competitive, we must develop and maintain protection on the proprietary aspects of our platform of technologies. We rely on a combination of patents, copyrights, trademarks, trade secret laws and confidentiality agreements to protect our intellectual property rights.

We file patent applications to protect innovations arising from our research, development and design.  We currently own approximately 28 issued patents and are pursuing approximately 56 pending patent applications throughout the world.  Our patents generally protect certain aspects of our products related technology. We also own certain copyrights relating to certain aspects of our products and services. We currently own approximately 116 registered U.S. trademarks and approximately 57 additional trademark applications are pending in the U.S. and foreign countries.  Many of our trademark rights in foreign countries are filed under the Madrid Protocol and designate China, Japan, Australia, Singapore, or the European Union.  Our trademarks generally protect the names of our company, products, and key service brands.

Our success is influenced, in part, by our ability to continue to develop proprietary products and technologies. It is desirable to obtain patent coverage for these products and technologies; however, some are protected as trade secrets.  We intend to file trademark and patent applications covering any newly developed products, methods and technologies. However, there can be no guarantee that any of our pending or future filed applications will be issued as patents or registered as trademarks. There can be no guarantee that the various patent and trademark governmental agencies from around the world or some third party will not initiate an interference proceeding involving any of our pending applications or issued patents. Finally, there can be no guarantee that our issued patents or future issued patents, if any, will provide adequate protection from competition.

9

Patents provide some degree of protection for our proprietary technology. However, the pursuit and assertion of patent rights involve complex legal and factual determinations and, therefore, are characterized by significant uncertainty. In addition, the laws governing patent issuance and the scope of patent coverage continue to evolve. Moreover, the patent rights we possess or are pursuing generally cover our technologies to varying degrees. As a result, we cannot ensure that patents will issue from any of our patent applications, or that any of the issued patents will offer meaningful protection. In addition, our issued patents may be successfully challenged, invalidated, circumvented or rendered unenforceable so that our patent rights may not create an effective barrier to competition. We must also pay maintenance fees at set intervals for our patents to not expire prematurely. The laws of some foreign countries may not protect our proprietary rights to the same extent as the laws of the United States. There can be no assurance that any patents issued to us will provide a legal basis for establishing an exclusive market for our products or provide us with any competitive advantages, or that patents of others will not have an adverse effect on our ability to do business or to continue to use our technologies freely. As with all patents, we may be subject to third parties filing claims that our technologies or products infringe on their intellectual property. We cannot predict whether third parties will assert such claims against us or whether those claims will hurt our business. If we are forced to defend against such claims, regardless of their merit, we may face costly litigation and diversion of management’s attention and resources. As a result of any such disputes, we may have to develop, at a substantial cost, non-infringing technology or enter into licensing agreements. These agreements may be unavailable on terms acceptable to such third parties, or at all, which could seriously harm our business or financial condition.

With respect to our trademarks, we file and pursue trademark registrations on words, symbols, logos, and other source identifiers that consumers use to associate our products and services with us. Although our registered trademarks carry a presumption of validity, they can be challenged and invalidated and as such, we cannot guarantee that any trademark registration is infallible.

We also rely on trade secret protection of our intellectual property. We attempt to protect trade secrets by entering into confidentiality agreements with employees, consultants and third parties, although, in the past, we have not always obtained such agreements. It is possible that these agreements may be breached, invalidated or rendered unenforceable, and if so, our trade secrets could be disclosed to our competitors. Despite the measures we have taken to protect our intellectual property, parties to such agreements may breach confidentiality provisions in our contracts or infringe or misappropriate our patents, copyrights, trademarks, trade secrets and other proprietary rights. In addition, third parties may independently discover or invent competitive technologies, or reverse engineer our trade secrets or other technology. Therefore, the measures we are taking to protect our proprietary technology may not be adequate.

Customers and Distribution

As a result of growing globalization, including in such areas as biologics, biopharma, biotechnology, clinical trials, distribution of biopharmaceutical products and reproductive medicine, the requirement for effective and reliable solutions for keeping clinical samples, pharmaceutical products and other specimen at controlled temperatures takes on added significance due to more sophisticated supply chain challenges including complex shipping routes, extended shipping times, potential custom delays, general logistics challenges, distribution and storage requirements. We believe that our platform of solutions, expertise and geographic footprint enable us to take advantage of the growing demand for effective and efficient international transport and storage of temperature sensitive life sciences commodities/products. This is especially the case for the new therapies being developed in the regenerative medicine market, such as CAR-T cell therapies, that require cryogenic temperatures to maintain safety and efficacy.

No customers accounted for over 10% of our total revenues during the year ended December 21, 2020.Two customers accounted for 24.1% and 12.8% of our total revenues during the year ended December 31, 2019.  No other single customers accounted for over 10% of our total revenues during the year ended December 31, 2019.

Our geographical revenues, by origin, for the years ended December 31, 2020 and 2019, were as follows:

​

​

​

​

​

​

​

    

2020

    

2019

 

Americas

 

63.0

%  

84.9

%

Europe, the Middle East and Africa (EMEA)

 

25.8

%  

13.3

%

Asia Pacific (APAC)

 

11.2

%  

1.8

%

​

10

Customer types

Clinical Trials -  Every pharmaceutical or biotech company developing a new drug or therapy must seek development protocol approval by regulatory bodies like the FDA. These clinical trials are designed to test the safety and efficacy of the potential new drug/therapy among other things. In connection with the clinical trials, due to globalization, companies can enroll patients from all over the world and may need to regularly submit a blood or other specimen at the local hospital, doctor’s offices or laboratories. These samples are then sent to specified testing laboratories, which may be local or in another country. In addition, the therapies used by the patients may require biostorage and time critical and/or temperature-controlled shipping to the sites of the clinical trials. Importantly, clinical trial specimens are often irreplaceable because each one represents clinical data at a prescribed point in time, in a series of specimens on a given patient, who may be participating in a trial for years. Sample integrity during the shipping process is vital to retaining the maximum number of patients in each trial and keeping the trial on schedule  This can also include  the return and destruction of Investigational Medicinal Products. Clinical trial support involves a full ecosystem of Clinical Research Organizations and requires very flexible and highly qualified logistics and end-to-end supply chain solutions. Our global network of temperature-controlled supply chain solutions are ideally suited for this market. Furthermore, the IATA requires that all airborne shipments of laboratory specimens be transmitted in either IATA Instruction 650 or 602 certified packaging. We have developed and obtained IATA certification of our Cryoport Express® platform.

Biotechnology and Diagnostic Companies - The biotechnology market includes basic and applied research and development in diverse areas such as stem cells, gene therapy, DNA tumor vaccines, tissue engineering, genomics, and blood products. Companies participating in the foregoing fields rely on the frozen storage and temperature-controlled transport of specimens in connection with their research and development efforts, for which our suite of supply chain solutions are ideally suited.

Cell Therapy Companies - Rapid advancements are underway in the research and development of cell-based therapies, which involve cellular material being infused into a patient. In allogeneic cell therapies, the donor is a different person than the recipient of the cells. Autologous cell therapy is a personalized therapeutic intervention that uses an individual’s cells, which are cultured and expanded outside the body, and reintroduced into the individual. Once cells are manufactured into a cellular therapy, in either case, they must be stored and shipped cryogenically for which our Cryoport Express® Shipper solutions and MVE’s stainless steel cryogenic freezers are ideally suited.

Contract Research, Development & Manufacturing Companies - Increasingly, as evidenced by our strategic partnership with Lonza, CROs and Contract Development and Manufacturing Organizations ("CDMOs) are engaging our services exclusively in conjunction with their contract services platform in order to provide a higher level of service to our mutual client base. We anticipate that these relationships, which are mutually beneficial to both parties as well as our client base will accelerate and expand to include our entire portfolio of services in the coming months and years.

Central Laboratories - With the increase and globalization of clinical studies and trials, logistics has become more complex and ensuring sample integrity has become more challenging. International courier costs are now consuming a significant portion of global protocol budgets. We believe laboratories performing the testing of samples collected during the conduct of these global multi-site studies are looking for reliable state-of-the-art supply chain solutions. CRYOPDP’s global network of logistic centers have successfully supported central labs throughout the world.

Pharmaceutical or Therapy Distribution - The current focus for our products and solutions also includes the area of bio-pharmaceutical supply chain. There are a significant number of therapeutic therapies currently or anticipated soon to be undergoing clinical trials. After the FDA or regional or national authorities in EMEA or APAC approve them for commercial marketing, it will be necessary for the manufacturers to have a reliable and economical method of bio-storage and distribution to the physician who will administer the product to the patient. It is likely that the most efficient and reliable method of distribution will be to ship a single dosage to the administering physician. These therapies are typically identified to individual patients and therefore will require a complete tracking history from the manufacturer to the patient. The most reliable method of doing this is to ship a unit dosage specifically for each patient. If such therapies require temperature-controlled logistics, we can provide the technology to meet this need. This supply chain management also includes the support of Managed Access Programs, whereby patients with serious diseases sometimes require specific therapies that are not yet available and/or approved by local regulatory authorities. We have the experience in providing these specialty therapies into over 150 countries.

11

Fertility Clinics and In Vitro Fertilization (“IVF”). Maintaining cryogenic temperatures during shipping and transfer of in vitro fertilization specimens like eggs, sperm, or embryos is critical for cell integrity in order to retain viability, stabilize the cells, and ensure reproducible results and successful IVF treatment. We believe that Cryoport Systems solutions for this market, branded as CryoStork® services, are very compelling and well received. Additionally, MVE supplies stainless steel cryogenic freezers to fertility clinics that wish to store reproductive materials on site.  The global IVF services revenue market generated $12.5 billion in 2018 and is projected to reach $26.4 billion by 2026, growing at a compound annual growth rate (CAGR) of 9.8% from 2019 to 2026. The Assisted Reproductive Technology (“ART”) industry is also starting to undergo a significant change due to the consolidation of clinic networks into large corporations or venture backed organizations, which we believe will allow us to further build out our leadership position and set industry standards.

Animal Health Companies. The global animal health market size is expected to reach $73.6 billion by 2027, representing a CAGR of 5.8% from 2016 through 2027. The market is largely driven by a significant rise in the zoonotic and food-borne diseases globally. This unprecedented disease prevalence has encouraged companies to produce advanced vaccines and pharmaceuticals. The high demand has also resulted in the subsequent rise in the number of companies making consistent efforts to control risks of pathogen contamination and food-borne diseases, which is contributing to market growth. In addition to food animal production, companion animal support is another emerging area in which companies are investing heavily. This can be attributed to the fact that in the U.S. alone, 68 percent of households now include a pet, up from 58 percent in 1988, with total U.S. pet industry expenditures projected to rise. Globally, 62% of animal health revenue is driven by food animals and 38% companion animals.  Cryoport’s temperature-controlled supply chain solutions are well positioned to support storage and distribution needs of veterinary laboratories, large-scale repositories, and artificial insemination, particularly in the beef and dairy industry on a global basis.

University Research Facilities. Research is conducted globally at major universities.  Storage at cryogenic temperatures provides the most secure long-term storage for high value samples. Our broad line of products provides solutions tailored to university bio-repositories as well as individual researchers.

Sales and Marketing

We serve customers throughout the life sciences and our sales and marketing initiatives are global in nature, focusing on addressing each customer’s pain points and anticipated needs through best-in-call supply chain solutions. Our business development team has resources in the Americas, EMEA and the APAC regions to proactively support our customers and to ensure efficient business development with respect to the customer’s geographic activity, size and decision-making structure. Our marketing teams design and implement targeted digital campaigns to support our commercial strategy and promote our innovative portfolio of solutions and capabilities. Our marketing initiatives are designed to drive our business development, program management, consulting, other related activities and increase awareness of our advanced temperature-controlled supply chain solutions. Given the global nature of our business and the high focus on customers development and acquisition, we plan to continue to extend our sales and marketing team’s reach in the Americas, EMEA and the APAC regions by further strengthen our marketing initiatives, hiring additional resources and expanding our distributor and alliance network.

Industry and Competition

Our products and services are sold into a rapidly growing segment of the temperature-controlled supply chain industry focused on the temperature sensitive packaging, shipping and storing of cell therapies, biopharmaceuticals and other life sciences commodities. This growth is fueled in part by the advancements in biology and its continued commercial globalization. The pace of growth is expected to increase even more in the future as domestic and international biotechnology firms expand their clinical trials and introduce new products into the market that require continuous transportation and storage at rigorously controlled temperatures. This principle also applies to the animal health and human reproductive medicine markets. We believe these advances will require a greater dependence on passively controlled temperature transport systems (i.e., systems having no external power source). In addition, we expect that industry standards and regulations will be introduced globally, requiring more comprehensive tracking and validation of shipping temperatures.

We believe that advancements and growth in the following markets have resulted in the need for increased reliability, efficiencies and greater flexibility in the temperature sensitive segment of the life sciences logistics and supply chain market for:

●biopharmaceuticals
●cell-based therapies

12

●gene therapy
●stem cell technology
●cell lines
●vaccines
●biopharmaceutical product distribution
●clinical trials, including transport of tissue culture samples
●diagnostic specimens
●infectious sample materials
●inter/intra-laboratory diagnostic testing
●temperature-sensitive specimens
●biological samples, in general
●environmental sampling
●human reproductive material for in vitro fertilization (IVF)
●animal health

Our platform of temperature-controlled supply chain solutions includes advanced packaging, informatics, specialty logistics services, biostorage services, and low-temperature and cryogenic life sciences equipment.  Our equipment, solutions and services are comprehensive and integrated for maximum reliability, economy and total effectiveness. For example, our Cryoport Express® Solutions platform enables life sciences companies to utilize their superior liquid nitrogen dry vapor technology without having to make capital investments or developing in-house logistics expertise and systems by offering a completely outsourced solution, which includes the cloud-based Cryoportal® and UnITyTM logistics management platforms, the SmartPak™ Condition Monitoring Systems and our 24/7/365 logistics support. Cryoport allows the clients to outsource their supply chain requirements and focus on their core competencies while maintaining visibility of all supply chain related information.

Companies that offer services that could be considered competitive to certain components of our platform of solutions include specialty couriers, such as World Courier Group, Inc., Marken Limited, and Quick Life Science Group and Air Liquide S.A., Biolife Solutions, Inc. and IC Biomedical. In addition, life science companies can develop their own inhouse temperature-controlled supply chain solutions, systems and procedures to cover their needs.

We have not identified any competition that offers a solution that is as comprehensive as our platform of solutions and that has been proven in the global market to the same extent as our solutions have.

13

Engineering and Development

Our research, development and engineering efforts are focused on continually investigating new technologies that can improve our services and improving the features of our products and solutions, which includes our cloud-based Cryoportal® Logistics Management Platform, Cryoport Express® Shippers, secondary packaging solutions, our SmartPak II™ and other condition monitoring systems, technology used to enhance our specialty courier solutions,  as well as our advanced line of stainless-steel freezers, aluminum dewars and related ancillary equipment used in the storage and transport of life sciences commodities. These efforts are expected to lead to, based on market requirements, the introduction of additional systems and features, including dewars and other shippers of varying sizes and for various temperature ranges, bio-storage units of varying sizes and for varying ranges, , further advanced informatics and improved monitoring systems. We are continuously researching alternative and new technologies, lower cost materials, utilization of higher volume assembly methods, improved manufacturing methods and enabling technologies that will make it practical to provide a wider range of effective and advances solutions.

Alternative technologies and materials and/or new information and communication technologies may be used in the future to expand our potential market for our products and solutions. Examples of Cryoport’s continuing advancement of its engineered products include:

●Advanced shippers for shipping temperature ranges to include 2°C - 8°C, Controlled Room Temperature and -80°C temperature ranges
●Development of hard shell re-useable shipping solutions equipped with intelligence, security and access control for select temperature ranges.
●Continuing development work on the patent pending CryosphereTM shipper. This revolutionary cryogenic dry-vapor shipper utilizes novel technology and design to passively stabilize the payload through an internal gravitational sphere, thereby keeping the payload in an upright orientation regardless of the external shipper orientation. This mitigates one of the key risks during handling and transport: reduction and/or loss of temperature and conditions holding time. The Cryosphere is expected to be launched during the second half of 2021
●Research and development of advanced real-time condition monitoring systems
●Predictive performance, maintenance and failure using Artificial Intelligence and Machine Learning methodologies
●Continuous improvement of the Cryoportal® and UnITyTM and further integration with Cryoport’s business systems
●Self-sustaining liquid nitrogen freezers that utilize sterling acoustic cryocooler technology to reliquefy evaporating nitrogen and provide continuous cooling; and
●Variable-temperature liquid nitrogen freezer that afford the user a cryogenic storage device that offers a selectable temperature range from -20C to -190C. It presents a solution that future-proofs storage equipment needs, by providing variable temperature ranges.

Cryoport’s Quality Assurance and Regulatory Affairs Program

We are committed to quality assurance and foster a culture of continuous improvement throughout our organization. Cryoport’s Quality Management System has been designed, implemented, and certified to meet ISO 9001:2015 standards in key global supply chain centers, demonstrating the discipline necessary to maintain a positive compliance profile.  With a strong foundation in ISO 9001:2015, we leverage our industry-specific experience, along with applicable regulatory requirements, to create processes and procedures that incorporate instructions with strong operational practices of checks with verification. This Quality Management System ensures proper controls from customer education, through the initial contract, processing, shipping and storage, accumulation and communication of proper monitoring and data collection, culminating in the successful completion of each transaction or shipment.

14

The Cryoport Quality Management System incorporates notable good practice quality guidelines and regulations (GxP) elements, beyond those stipulated in ISO 9001:2015, to ensure the customer base is supported in the manner necessary to maintain standards and to secure a positive compliance profile as a supplier.  Notable elements include, but are not limited to, Good Documentation Practices, Archival processes and procedures, Supplier Controls (and approval), and Corrective Action and Preventive Action (CAPA) procedures, to highlight a few examples.

Via procedural requirements, Cryoport provides substantial risk-mitigation strategies throughout the full product line of services provided, routinely supporting and maintaining customer confidence.  Metrics are accumulated and on a routine basis are reported to the senior management ensuring appropriate decisions are made regarding resource allocation, corrective actions are taken, and that quality-driven initiatives are supported throughout the organization.

Our manufacturing operations are ISO 13485 qualified medical manufacturing facilities and are audited on a regular basis by authorized authorities for compliance.

Environmental, Social and Governance (“ESG”) Program

The launch of our ESG program marks our first disclosure of ESG information based on the Sustainability Accounting Standards Board (SASB) and the Taskforce on Climate-related Financial Disclosures (TCFD), which are leading global sustainability frameworks.  As a company focused on delivering lifesaving therapies by providing reliable and comprehensive temperature-controlled supply chain solutions for the life sciences industry, sustainability has always been integral to our work; however, in 2020 we began a formal evaluation of our ESG initiative and we have elevated sustainability to be one of our key priorities for guiding our operating philosophy and corporate governance as we move forward. The following information provides a snapshot of our commitment to and practice of good corporate and global citizenship and overall Sustainability and Environmental, Social, and Governance (ESG) performance. As we move forward, we are committed to continuing to grow our Sustainability and ESG programs through increased focus on substantive issues and transparency in our reporting.

Environmental

As Cryoport continues to grow its business in a way that is considerate of our global community, we are committed to protecting our planet by using our world’s resources sensibly and minimizing our emissions and waste on a global basis. From an environmental standpoint, one example of our sustainability efforts is our cryogenic Cryoport Express® Shipper, which uses the non-hazardous dry vapor form of liquid nitrogen and proprietary informatics to drive efficiencies in the use of resources throughout our company. This service offering also employs multi-use and recyclable packaging. Knowing that there is much more to do to aid in our environmental efforts, we have recently developed a system to collect data on a global scale for the purpose of quantifying the impact of all our environmental initiatives so that we may demonstrate our performance on this important matter to our shareholders, customers and other interested stakeholders.

Material Efficiency

Cryoport strives to operate in an efficient manner to ensure the optimization of raw materials, equipment, energy and labor. As an example of this in our manufacturing operations, Cryoport measures the effectiveness and efficiency of our production practices by tracking the amount of scrap material disposed of or sold on an annual basis. Comparing 2019 and 2020, Cryoport saw an improvement in scrap volumes of approximately 50%, with 414 scrap units generated in 2019 vs. 215 generated in 2020. Cryoport’s targeted goal for 2021 is to reduce this number by an additional 20%.

15

Energy Efficiency of Products

Cryoport understands the importance of energy conservation as it relates to the reduction of its operational carbon footprint, efficient use of resource and cost management. The area that has the largest impact on energy efficiency associated with our products is thermal efficiency. One example is our Global Logistics Center Network which utilizes the International Safe Transit Association (ISTA) standard 7E to test and evaluate thermal performance against stated requirements of 10+ days of maintaining internal temperatures at or below negative 150oC. Our products comply with this standard, and in turn, the products insulative properties require less energy to maintain prescribed temperature levels. Another example is from our manufacturing operations: our dewars do not consume any electricity, and our freezer units utilize liquid nitrogen as a cooling agent, which is the by-product of other processes, creating a closed-loop resource that reduces additional energy associated with sourcing, procuring, and delivery of resources purchased from third parties. Our efforts in these areas have a positive environmental outcome for Cryoport and its customers.

Materials of Concern

At Cryoport, we currently utilize minimal materials of concern in our operations, primarily in the form of isopropanol, epoxies, butyl cellosolve, lacquer thinner, paint, hyamine and isopropyl alcohol. We manage the minimal hazardous wastes generated in our production facilities in compliance with all state and federal regulations, and review opportunities to eliminate materials of concern and other managed waste streams on a regular cadence. As part of our strategy to reduce or eliminate materials of concern from our operations, in 2020 we began an initiative to discontinue the use of lacquer thinner as part of a larger paint line upgrade, which will significantly reduce the generation of hazardous waste throughout certain of our plants. Any hazardous waste that is generated is tracked and managed with an overall goal of eliminating hazardous materials where possible.

Environmental Footprint

Cryoport makes efforts where possible to minimize the environmental impact of our operations. We strive for a product base with long use phases to minimize impact associated with production of new product. At our MVE Biological Solutions production facility, we manufacture fusion freezer units that utilize 1/587 of the energy used by conventional mechanical freezers used for similar applications.  Our biostorage plant in Houston is powered exclusively by carbonless energy sources, translating to a significant reduction in carbon emissions compared to energy provided by coal-fired power plants. In 2020, the plant consumed 3,564,102 kWh of energy, which would have generated 3,487,702 pounds of greenhouse gas emissions if the plant was powered by traditional coal-fired power plants. This emissions savings is the equivalent of removing 544 passenger vehicles driven in one year.  Recently, our Paris, France operations moved into a new facility, which is designed with the highest French environmental standards and equipped with solar panels to reduce energy consumption and greenhouse gas emissions.

Social

Cryoport’s social efforts are focused on our global team of employees and communities. Our employees are our most valuable resource, from our teams on the front line in our global supply chain and logistics centers, to our manufacturing operations, to our business development personnel, to the engineers who design our products and services, to our quality assurance and regulatory teams that assure the safety, quality, compliance, and integrity of our products. Across our Company, we are committed to inclusion, equity and diverse representation in our employees. Cryoport’s Employee Health & Safety (EHS) programs have resulted in strong safety performance, as demonstrated by our total injury rate (TIR) and lost time injury rate (LTIR) being significantly lower than the global industry averages. Facilitated by our culture of continuous improvement, we are committed to continue to work toward reducing our TIR and LTIR numbers even further. Constructive supplier relationships are essential to our ability to meet customer requirements for quality solutions. We expect also our business partners to share our commitment to ethics, integrity, compliance, safety, human rights and environmental protection. By the same token, as a provider accountable to thousands of companies worldwide, we pledge, through our ESG performance, to meet or exceed our clients’ requirements for the same.

16

Diversity

Cryoport is an Equal Employment Opportunity employer and currently tracks gender distribution across its operations and management. We maintain clear policies related to anti-harassment, discrimination and retaliation, and provide and anonymous, third party-managed reporting hotline for employees to report incidents of harassment, discrimination, and policy violations. In 2021, Cryoport will enhance and roll out new online corporate training programs related to diversity, harassment and discrimination, so that all employees will receive, at minimum, annual training on the topics of harassment, diversity and inclusion, business ethics and code of conduct. In addition, Cryoport’s recruiting programs include targeted outreach to a variety of under-represented constituents, including minorities, women, veterans, and disabled populations to help improve recruiting efforts while gaining valuable insights from a diverse set of recruits. Cryoport has partnered with or targeted organizations like Hire Heroes, Career OneStop, recruiting at Historical Black Colleges, Accounting and Financial Women’s Alliance, and Women in Technology.

Suppliers

Temperature controlled supply chain support to the life sciences industry is critical to all that Cryoport does; therefore, we currently take steps to conduct reviews and audit our existing and potential suppliers to ensure that appropriate compliance, health, safety, and labor practices are in place. Cryoport currently maintains a supplier questionnaire delivered prior to vendor approval and as part of a vendor auditing process to help verify that programs exist to manage specific risk areas. For example, we ask our transportation suppliers if they employ or work with a Dangerous Goods Safety Advisor, a credentialed role responsible for overseeing activities associated with dangerous goods, including but not limited to, employee training and coaching, reporting, and monitoring of activities associated with the transportation of dangerous goods. The purpose of this inquiry is to gauge the degree of oversight over dangerous goods management by our suppliers to help ensure product and employee welfare.

Research and Development

We do not conduct clinical trials, animal testing or use human tissue of any kind in the manufacture or design of our products, and our Code of Conduct governs the ethical behavior of our employees across Cryoport operations.

Data Security

Cryoport uses an outside Center for Internet Security (CIS) assessment firm to evaluate its data security controls in an effort protect our business and secure the information of our employees and customers. The evaluation process utilizes the CIS Critical Security Controls Capability Maturity Model Integration (CMMI) methodology, and is an ongoing initiative used to continuously improve the CMMI rating for the company.

Governance

Integrity is one of our four Core Values as an organization, and we commit to operating with honesty, truthfulness and transparency in accordance to the highest ethical and corporate governance standards – mutual respect, integrity and trust are our foundation. As an ethical operator, we have developed a strong Code of Conduct and hold ourselves accountable to it in all we do. All of our employees across our operations are provided with training and reference materials to reinforce this commitment to integrity and ethics in our business. Our policies are clearly defined and include guidance on topics including, but not limited to: Corruption; Anti-Trust and Anti-Competitive Behavior; Insider Dealings; Gifts; Conflicts of Interest; Intellectual Property; Truthful and accurate reporting; Interactions with Healthcare professionals and Whistleblower protections.

In addition to our Code of Conduct, our senior leadership team actively oversees the governance of our ethics programs to help ensure that commitment is driven from the top down, and that program owners are accountable for successful program compliance.

17

Cryoport Impact Statements

Examples of some of our positive environmental impacts include the following:

●Our 2020 freezer production displaced annual energy consumption by 115,508,192 kWh from what would otherwise be consumed from alternative products. This amount of energy saved would power 10,847 homes (sized at 2,500 square feet) annually. This reduction in energy consumption from our freezer lines alone equates to 109,547,623 pounds of GHG emissions avoided or the emissions equivalent to 17,644 passenger vehicles driven for one year.
●In another case, one of our facilities uses carbonless energy consumption, which prevented the emission of 3,487,702 pounds of GHGs in 2020.  This use of carbonless energy prevented emissions equal to 544 passenger vehicles driven for one year.
●Recently, our Paris, France operations moved into a new facility, which is designed with the highest French environmental standards and equipped with solar panels to reduce energy consumption and greenhouse gas emissions.
●Our temperature-controlled supply chain solutions focused on cell and gene therapies include logistics, which can boast a 99.8% delivery success rate and due to this performance 9,586 additional patients were able to receive therapies over the past 24 months and 690 intended parents are potentially able to have successful cycles resulting in the birth of a child on an annual basis because of our CryoStork® solution.

Impact of COVID-19

In late 2019, a novel strain of coronavirus that causes coronavirus disease (COVID-19) was reported to have surfaced in Wuhan, China, which has since spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic.  Further, the COVID-19 outbreak has resulted in government authorities around the world implementing numerous measures to try to reduce the impact of COVID-19, such as travel bans and restrictions, quarantines, shelter in place or total lock-down orders. Many countries around the world have also implemented the temporary closure of non-essential businesses and other material limitations on the conduct of business. As a provider of life saving therapies, Cryoport is deemed to be an essential business and has remained fully open and operational.  However, the full extent and duration of this pandemic is still unknown at this point and the related governmental, business and travel restrictions in order to contain this virus are continuing to evolve globally. Accordingly, there is significant uncertainty related to the ultimate impact that this global pandemic will have on the results of our operations.

For example, several life sciences companies, including some of our clients, announced earlier in 2020 the temporary suspension of clinical studies and trials as well as other COVID-19 related risks that may impact their preclinical and clinical trials, including delays in patient enrollment or difficulties in initiating or expanding clinical trials, interruption of clinical trial activity, and diversion of healthcare resources to focus on COVID-19 activities. While these temporary suspensions and restrictions have been lifted, these may be reinstated, and other measures may be implemented. In addition, with respect to the impact of the pandemic on the human reproductive medicine market, the American Society for Reproductive Medicine (ASRM) and European Society of Human Reproduction and Embryology (ESHRE) both issued recommendations in March of 2020 to temporarily defer fertility treatments and related activities. Both organizations have since updated and recently reaffirmed their recommendation to gradually and judiciously resume activities. While these actions have negatively impacted our revenue in the markets we serve temporarily during 2020, we cannot determine the longer-term impact at this point. A number of public announcements by government and clients indicate a regional or partially reinstating of COVID-19 related restrictions and while we have experienced revenue ramping back up gradually over time, this may be curtailed by new restrictions. Further, virus containment efforts as a result of governmental actions or policies or other initiatives could lead to further disruption in the supply chain and as a result, we may have difficulties sourcing raw materials and equipment or may incur additional direct costs to provide our solutions.

While longer-term client demand for our services overall remains strong, the effects of the COVID-19 pandemic, including the measures above taken by some of our clients have adversely impacted our revenue growth. See Risk Factors, “The recent global pandemic caused by COVID-19 has and could adversely affect our business operations, financial performance and results of operations, the extent of which is uncertain and difficult to predict.”

18

Employees

We refer to our employees as our “team.” They are critical to our success. We are in constant communication and training. We believe that we have assembled a strong management/leadership  team with the experience and expertise needed to execute our business strategy.  As of December 31, 2020, we had 625 employees: 605 full-time, 10 part-time, and 10 temporary, of which 250 are located in the Americas, 158 in EMEA and 217 in APAC.  This is an increase of 500 employees since December 31, 2019, primarily as a result of two acquisitions completed during the fourth quarter of 2020 and the further build out of our organization to support the expected growth in the markets we serve. We anticipate hiring additional personnel as needs dictate to implement our global growth strategy.

Corporate History and Structure

We are a Nevada corporation originally incorporated under the name G.T.5-Limited (“GT5”) on May 25, 1990. In connection with a Share Exchange Agreement, on March 15, 2005 we changed our name to Cryoport, Inc. and acquired all of the issued and outstanding shares of common stock of Cryoport Systems, Inc., a California corporation, in exchange for 200,901 shares of our common stock (which represented approximately 81% of the total issued and outstanding shares of common stock following the close of the transaction). Cryoport Systems, Inc., which was originally formed in 1999 as a California limited liability company, was reorganized into a California corporation on December 11, 2000 and converted into Cryoport Systems, LLC, a California limited liability company, on September 17, 2020, remains one of our operating companies under Cryoport, Inc. Our principal executive offices are located at 112 Westwood Place, Suite 350, Brentwood, TN 37027. The telephone number of our principal executive office is (949) 470-2300, and our main corporate website is www.cryoport.com. The information on or that can be accessed through our website is not part of this Form 10-K.

The Company became public via a reverse merger with a shell company in May 2005. Over time the Company has transitioned from being a development company to a fully operational public company, providing a platform of temperature-controlled logistics solutions to the life sciences industry globally.

Information about our Executive Officers

The following are our executive officers as of the filing date of this Form 10-K:

Jerrell W. Shelton. Mr. Shelton became a member of our board of directors in October 2012 and was appointed President and Chief Executive Officer of the Company in November 2012.  He was appointed Chairman of the Board in October 2015.  He served on the Board of Directors and standing committees of Solera Holdings, Inc. from April 2007 through November 2011.  From June 2004 to May 2006, Mr. Shelton was the Chairman and CEO of Wellness, Inc., a provider of advanced, integrated hospital and clinical environments.  Prior to that, he served as Visiting Executive to IBM Research and Head of IBM’s WebFountain.  From October 1998 to October 1999, Mr. Shelton was Chairman, President and CEO of NDC Holdings II, Inc.  Between October 1996 and July 1998, he was President and CEO of Continental Graphics Holdings, Inc.  And from October 1991 to July 1996, Mr. Shelton served as President and CEO of Thomson Business Information Group.  Mr. Shelton has a B.S. in Business Administration from the University of Tennessee and an M.B.A. from Harvard University.   Mr. Shelton’s extensive leadership, management, strategic planning and financial expertise through his various leadership and directorship roles in public, private and global companies, makes him well-qualified to serve as a member of the board of directors.

Robert S. Stefanovich. Mr. Stefanovich became Chief Financial Officer and Treasurer for the Company in June 2011. In 2019, he was also given the title Senior Vice President. From 2011 to 2019, Mr. Stefanovich served as the Secretary of the Company. From June 15, 2012 to November 4, 2012, Mr. Stefanovich served as the Principal Executive Officer of the Company. From November 2007 through March 2011, Mr. Stefanovich served as Chief Financial Officer of Novalar Pharmaceuticals, Inc., a venture-backed specialty pharmaceutical company. Prior to that, he held several senior positions, including interim Chief Financial Officer of Xcorporeal, Inc., a publicly traded medical device company, Executive Vice President and Chief Financial Officer of Artemis International Solutions Corporation, a publicly traded software company, Chief Financial Officer and Secretary of Aethlon Medical Inc., a publicly traded medical device company and Vice President of Administration at SAIC, a Fortune 500 company. Mr. Stefanovich also served as a member of the Software Advisory Group and an Audit Manager with Price Waterhouse LLP’s (now PricewaterhouseCoopers) hi-tech practice in San Jose, CA and Frankfurt, Germany. He currently also serves as a board member of Project InVision International, a provider of business performance improvement solutions. He received his Master of Business Administration and Engineering from University of Darmstadt, Germany.

19

Mark Sawicki, Ph.D. Dr. Sawicki became President and Chief Executive Officer of Cryoport Systems, LLC, a wholly-owned subsidiary of the Company, and the Senior Vice President and Chief Scientific Officer of the Company in September 2020 and served as the Chief Commercial Officer of Cryoport Systems from January 2015 to August 2020. Dr. Sawicki brings over 20 years of business development and sales management experience, having consistently delivered on corporate revenue and market share goals in the pharmaceutical and biotechnology industries. Dr. Sawicki previously served as the Chief Business Officer at AAIPharma Services Corporation/Cambridge Major Laboratories Inc. (now Alcami Corporation), a contract development, testing, and manufacturing organization for pharma and biotech companies. Additionally, he has served in senior business development roles at CMC Biologics, a provider of biopharmaceutical contract manufacturing services, and Albany Molecular Research Inc. (AMRI), a contract research and manufacturing organization. Dr. Sawicki holds a bachelor's in biochemistry from the State University of New York at Buffalo and a Ph.D. in biochemistry from the State University of New York at Buffalo, School of Medicine and Biomedical Sciences. He also received graduate training at the Hauptman Woodard Medical Research Institute. Sawicki has authored a dozen scientific publications in drug discovery with a focus on oncology and immunology.

Available Information

Our main corporate website address is www.cryoport.com. The information on or that can be accessed through our website is not part of this Form 10-K. We electronically file with the Securities and Exchange Commission (SEC) our Annual Report on Form 10‑K, Quarterly Reports on Form 10‑Q, Current Reports on Form 8‑K and amendments to the reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make available free of charge on or through our website copies of these reports as soon as reasonably practicable after we electronically file these reports with, or furnish them to, the SEC. The SEC also maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov.

​

ITEM 1A. RISK FACTORS

The following risk factors could materially and adversely affect our business, financial condition and results of operations. These risk factors do not identify all of the risks that we face. Our business, financial condition and results of operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial.

Risks Related to Our Business Combinations

The MVE Biological Solutions and CRYOPDP acquisitions have resulted in organizational change and significant growth to our business. If we fail to effectively manage this growth and change to our business in a manner that preserves our reputation with customers and the key aspects of our corporate culture, our business, financial condition and results of operations could be harmed.

The MVE Biological Solutions and CRYOPDP acquisitions have resulted in significant growth in our operations and personnel, adding approximately 460 employees to our headcount, bringing our total headcount as of December 31, 2020 to approximately 625 employees, adding significant operations in the US, Europe and Asia, while expanding our product offerings into new temperature-controlled ranges and cryogenic equipment. We will continue to incur significant expenditures and the allocation of management time to assimilate the MVE Biological Solutions and CRYOPDP businesses in a manner that preserves the key aspects of our corporate culture, including a focus on strong customer satisfaction, but there can be no assurance that we will be successful in our efforts. If we do not effectively integrate, train and manage our combined employee base and maintain strong relationships with both our existing and new customers, our corporate culture could be undermined, the quality of our products and customer service could suffer, and our reputation could be harmed, each of which could adversely impact our business, financial condition and results of operations.

The actual impact of the MVE Biological Solutions and CRYOPDP acquisitions on our financial results may be worse than the assumptions we have used.

We have made certain assumptions relating to the impact on our financial results of the MVE Biological Solutions and CRYOPDP  acquisitions. These assumptions relate to numerous matters, including the acquisition costs, including transaction and integration costs, and other financial and strategic risks of the acquisitions. If one or more of these assumptions are incorrect, it could have an adverse effect on our business and operating results, and the perceived benefits from the acquisitions may not be realized.

20

The integration and operation of acquired businesses, including MVE Biological Solutions and CRYOPDP, may disrupt our business and create additional expenses, and we may not achieve the anticipated benefits of the acquisitions.

Integration of an acquired business involves numerous risks, including assimilation of operations of the acquired business, such as MVE Biological Solutions and CRYOPDP, and difficulties in the convergence of systems and processes, the diversion of management’s attention from other business concerns, risks of entering markets in which we have had no or only limited direct experience, assumption of unknown or unquantifiable liabilities, difficulties in completing strategic initiatives already underway in the acquired company, and unfamiliarity with partners of the acquired company, each of which could have a material adverse effect on our business, results of operations and financial condition. In particular, the integration of businesses the size of MVE Biological Solutions and CRYOPDP into our business may be more difficult and time consuming than anticipated, and we may be unable to achieve the expected synergies and operating efficiencies within the expected time frames or at all. We cannot assure that these risks or other unforeseen factors will not offset the intended benefits of the acquisitions, in whole or in part.

Additionally, potential acquisition opportunities become available to us from time to time, and we periodically engage in discussions or negotiations relating to potential acquisitions, including acquisitions that may be material in size or scope to our business. Any acquisition may or may not occur and, if an acquisition does occur, it may not be successful in enhancing our business for one or more of the following reasons:

●Any business acquired may not be integrated successfully and may not prove profitable;
●The price we pay for any business acquired may overstate the value of that business or otherwise be too high;
●Liabilities we take on through the acquisition may prove to be higher than we expected;
●We may fail to achieve acquisition synergies; or
●The focus on the integration of operations of acquired entities may divert management’s attention from the day-to-day operation of our businesses.

Acquisitions and strategic investments and alliances may also require us to integrate and collaborate with a different company culture, management team, business model, business infrastructure and sales and distribution methodology and assimilate and retain geographically dispersed, decentralized operations and personnel. Depending on the size and complexity of an acquisition, our successful integration of the entity depends on a variety of factors, including introducing new products and meeting revenue targets as expected, the retention of key employees and key customers, increased exposure to certain governmental regulations and compliance requirements and increased costs and use of resources. Further, the integration of acquired businesses is likely to result in our systems and internal controls becoming increasingly complex and more difficult to manage. Any difficulties in the assimilation of acquired businesses into our control system could harm our operating results or cause us to fail to meet our financial reporting obligations.

Even if we are able to successfully integrate acquired businesses, we may not be able to realize the revenue and other synergies and growth that we anticipated from the acquisition in the time frame that we expected, and the costs of achieving these benefits may be higher than what we expected. As a result, the acquisition and integration of acquired businesses may not contribute to our earnings as expected and we may not achieve the other anticipated strategic and financial benefits of such transactions.

Risks Related to Our Business

Our products and services may contain errors or defects, which could result in damage to our reputation, lost revenues, diverted development resources and increased service costs, litigation and product recalls.

Our products and services must meet stringent requirements and we must develop our products and services solutions quickly to keep pace with the rapidly changing market. Product and services as sophisticated as ours could contain undetected errors or defects, especially when first introduced or when new equipment or versions of our software are released. If our product and services are not free from errors or defects, we may incur an injury to our reputation, lost revenues, diverted development resources, increased customer service and support costs, product recalls and litigation. The costs incurred in correcting any product errors or defects may be substantial and could adversely affect our business, results of operations and financial condition.

21

Due to the low temperatures at which some of our products are used  and the fact that some of our products are relied upon by our customers or end users in their facilities or operations or are manufactured for relatively broad medical, transportation, or consumer use, we face an inherent risk of exposure to claims (which MVE Biological Solutions has been subject to from time to time and some of which were substantial) in the event that the failure, use, or misuse of our products results, or is alleged to result, in death, bodily injury, property or sample damage, or economic loss. For example, during 2019, MVE Biological Solutions’ products were the subject of numerous lawsuits (including purported class action lawsuits filed in the U.S. District Court for the Northern District of California) with respect to the alleged failure of a stainless steel cryobiological storage tank at the Pacific Fertility Center in San Francisco, California. In addition, Cryogene specializes in the secure storage of biological specimens, materials and samples covering the full range of temperatures from cryogenic through controlled room temperature. Any damage to these specimens, materials and samples may be attributed to a failure of Cryogene’s storage systems or services, which could lead to claims for damages made by customers and could also harm our relationship with customers and damage our reputation in the life sciences industry, resulting in material harm to our business. Although we currently maintain product liability coverage, which we believe is adequate for product liability claims and for the continued operation of our business, it includes customary exclusions and conditions, it may not cover certain specialized applications and it generally does not cover warranty claims. Additionally, such insurance may become difficult to obtain or be unobtainable in the future on terms acceptable to us. A successful product liability claim or series of claims against us, including one or more consumer claims purporting to constitute class actions or claims resulting from extraordinary loss events, in excess of or outside our insurance coverage, or a significant warranty claim or series of claims against us, could materially decrease our liquidity, impair our financial condition, and adversely affect our results of operations.  See “—Risks Related to Our Business—Our products and services may expose us to liability in excess of our current insurance coverage” for additional information.

In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things, costs of litigation, distraction of management’s attention from our primary business, the inability to commercialize our existing or new products, decreased demand for our products or, if cleared or approved, products in development, damage to our business reputation, product recalls or withdrawals from the market, withdrawal of clinical trial participants, substantial monetary awards to patients or other claimants, or loss of revenue.

While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of our products may delay the supply of those products to our customers and may impact our reputation. We can provide no assurance that we will be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future or that these efforts will have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Additionally, any recall could result in significant costs to us and significant adverse publicity, which could harm our ability to market our products in the future. Such recalls and withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by patients as a safety risk when considering the use of our products. Though it may not be possible to quantify the economic impact of a recall, it could have a material adverse effect on our business, financial condition and results of operations.

Additionally, for some of our products we offer a limited warranty for product returns which are due to defects in quality and workmanship. We attempt to estimate our potential liability for future product returns and establish reserves on our financial statements in amounts that we believe will be sufficient to address our warranty obligations; however, our actual liability for product returns may significantly exceed the amount of our reserves. If we underestimate our potential liability for future product returns, or if unanticipated events result in returns that exceed our historical experience, our financial condition and operating results could be materially and adversely affected.

The recent global pandemic caused by COVID-19 has already and may continue to adversely affect our business operations, financial performance and results of operations, the extent of which is uncertain and difficult to predict.

In late 2019, a novel strain of coronavirus (“COVID-19”) was reported to have surfaced in Wuhan, China, which has since spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic. Further, the COVID-19 outbreak has resulted in government authorities around the world implementing numerous measures to try to reduce the impact of COVID-19, such as travel bans and restrictions, quarantines, shelter in place or total lock-down orders. Many countries around the world have also implemented the temporary closure of non-essential businesses and other material limitations on the conduct of business. As a result of the COVID-19 outbreak and the related responses from government authorities, our business operations, financial performance and results of operations have been adversely affected as a result of reduced demand for our services in all markets. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations–Recent Developments – Impact of COVID-19” for additional information.

22

Additionally, our business operations, financial performance and results of operations have been and could be further adversely impacted in a number of ways, including, but not limited to, the following:

●disruptions to our operations, including a shutdown of one or more of our global logistics centers or our biostorage facility; restrictions on our operations and sales, marketing and distribution efforts; and interruptions to our research and development activities, engineering, design and manufacturing processes and other important business activities;
●further reduced demand for our products and services due to disruptions to the businesses and operations of our customers, which may, in particular, result from lower volumes of clinical studies and trials or reduced activity in the human reproductive medicine markets due to social distancing restrictions; and reduction in our animal health market due to reduced demand;
●interruptions, unavailability or delays in global shipping to transport our products;
●a slowdown or stoppage in the supply chain for our products;
●our ability to set up global supply chain centers in certain geographic regions;
●limitations on employee resources and availability, including due to sickness, government restrictions, the desire of employees to avoid contact with large groups of people or mass transit disruptions;
●a fluctuation in foreign currency exchange rates or interest rates could result from market uncertainties;
●an increase in the cost or the difficulty to obtain debt or equity financing could affect our financial condition or our ability to fund operations or future investment opportunities; and
●an increase in regulatory restrictions or continued market volatility could hinder our ability to execute strategic business activities, including acquisitions, as well as negatively impact our stock price.

The spread of COVID-19 has caused us to modify our business practices (including employee travel, employee work locations, and cancellation of physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, customers, partners, and suppliers. There is no certainty that such measures will be sufficient to mitigate the risks posed by the virus, and our ability to perform critical functions could be harmed.

Additionally, COVID-19 could negatively affect our internal controls over financial reporting as a portion of our workforce is required to work from home and therefore new processes, procedures, and controls could be required to respond to changes in our business environment. Further, should any key employees become ill from COVID-19 and unable to work, the attention of the management team could be diverted.

The potential effects of COVID-19 may also impact and potentially heighten many of our other risk factors discussed in this “Risk Factors” section. The degree to which COVID-19 impacts our business operations, financial performance and results of operations will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact and how quickly and to what extent normal economic and operating conditions can resume.

As an increasingly global business, we are exposed to economic, political, and other risks in different countries which could materially reduce our sales, profitability or cash flows, or materially increase our liabilities.

Since we manufacture and sell our products worldwide, our business is subject to risks associated with doing business internationally. Our future results could be harmed by a variety of factors, including:

●changes in foreign currency exchange rates, exchange controls and currency restrictions;

23

●changes in a specific country’s or region’s political, social or economic conditions;
●civil unrest, turmoil or outbreak of disease or illness, such as COVID-19, in any of the countries in which we sell our products or in which we or our suppliers operate;
●tariffs, other trade protection measures, and import or export licensing requirements;
●potentially negative consequences from changes in U.S. and international tax laws;
●difficulty in staffing and managing geographically widespread operations;
●requirements relating to withholding taxes on remittances and other payments by subsidiaries;
●restrictions on our ability to own or operate subsidiaries, make investments or acquire new businesses in these jurisdictions;
●restrictions on our ability to repatriate dividends from our foreign subsidiaries;
●difficulty in collecting international accounts receivable;
●difficulty in enforcement of contractual obligations under non-U.S. law;
●transportation delays or interruptions; and
●changes in regulatory requirements including as it relates to protection of our intellectual property.

We will have difficulty increasing our revenues if we experience delays, difficulties or unanticipated costs in establishing the sales, marketing and distribution capabilities necessary to successfully commercialize our solutions.

We plan to further enhance our sales, marketing and distribution capabilities in the Americas, EMEA, and APAC, including through our recent acquisitions of MVE Biological Solutions and CRYOPDP, which expands our sales, marketing and distribution capabilities in these regions. It will be expensive and time-consuming for us to develop and integrate our global marketing and sales network and thus we intend to further broaden our strategic alliances with domestic and international providers of shipping services and other solutions providers to the life sciences industry to incorporate use of our platform of solutions in their service offerings. We may not be able to provide adequate incentive to our sales force or to establish and maintain favorable distribution and marketing collaborations with others to promote our solutions. In addition, any third party with whom we have established a marketing and distribution relationship may not devote sufficient time to the marketing and sales of our solutions, thereby exposing us to potential expenses in exiting such distribution agreements. We, and any of our alliance partners, must also market our services in compliance with federal, state, local and international laws relating to the provision of incentives and inducements. Violation of these laws can result in substantial penalties. Therefore, if we are unable to successfully motivate and expand our marketing and sales force and further develop our sales and marketing capabilities, or if our alliance partners fail to promote our solutions, we will have difficulty increasing our revenues and the revenue may not offset the additional expense of expansion.

The adoption cycle of our target customers tends to be very lengthy, which has, and is expected to continue to, adversely affect our ability to increase revenues quickly.

We offer our solutions to companies in the life sciences industry. These companies operate within a heavily regulated environment and as such, changing vendors and distribution practices typically require a number of steps, which may include the audit of our facilities, review of our procedures, qualifying us as a vendor, and performing test shipments. This process can take several months or longer to complete, involving multiple levels of approval, prior to a company fully adopting our platform and products. The logistics management of many companies is decentralized adding to the time needed to effect adaptation of our solutions. In addition, any such adoption may be on a gradual basis such that the customer progressively ramps up use of our solutions following adoption. The slow adoption process has, and is expected to continue to, adversely affect our ability to increase revenues quickly.

24

We depend on the availability of certain component products used in our solutions; if we experience delays in the procurement of components manufactured by third parties, then we may experience customer dissatisfaction and our reputation could suffer.

If we fail to procure sufficient components used in our products from our third-party manufacturers, we may be unable to deliver our solutions to our customers on a timely basis, which could lead to customer dissatisfaction and could harm our reputation and ability to compete. We currently acquire various component parts for our solutions from various independent manufacturers, some of which are sole sourced. We would likely experience significant delays or cessation in producing some of these components if a labor strike, natural disaster, public health crisis or other supply disruption were to occur, including as a result of the COVID-19 pandemic, at any of our main suppliers. If we are unable to procure a component from one of our manufacturers, we may be required to enter into arrangements with one or more alternative manufacturing companies, which may cause delays in producing components or result in significant increase in costs. To date, we have not experienced any material delay that has adversely impacted our operations, but this does not mean that we will continue to have timely access to adequate supplies of essential materials and components in the future or that supplies of these materials and components will be available on satisfactory terms when needed. If our vendors for these materials and components are unable to meet our requirements, fail to make shipments in a timely manner, or ship defective materials or components, we could experience a shortage or delay in supply or fail to meet our contractual requirements, which would adversely affect our results of operations and negatively impact our cash flow and profitability.

We expect to base our equipment and inventory purchasing decisions on our forecasts of customers’ demand, and if our forecasts are inaccurate, our operating results could be materially harmed.

As our customer base increases, we expect the need to purchase additional equipment and inventory. Our forecasts will be based on multiple assumptions, each of which may cause our estimates to be inaccurate, affecting our ability to provide products to our customers. When demand for our products increases significantly, we may not be able to meet demand on a timely basis, and we may need to expend a significant amount of time working with our customers to allocate limited supply and maintain positive customer relations, or we may incur additional costs in order to rush the manufacture and delivery of additional products. If we underestimate customers’ demand, we may forego revenue opportunities, lose market share and damage our customer relationships. Conversely, if we overestimate customer demand, we may purchase more equipment and inventory than we are able to use or sell at any given time or at all. As a result of our failure to properly estimate demand for our products, we could have excess or obsolete equipment and/or inventory, resulting in a decline in the value of our equipment and/or inventory, which would increase our costs of revenues and reduce our liquidity. Our failure to accurately manage our equipment purchases and inventory relative to demand would adversely affect our operating results.

If we suffer a loss to our factories, facilities or distribution system due to factors outside of our control our operations could be seriously harmed.

We rely on our distribution system including third-party shipment and carrier services to transport our shippers containing biological material. These third-party operations could be subject to natural disasters, adverse weather conditions, other business disruptions, and carrier error, which could cause delays in the delivery of our shippers, which in turn could cause serious harm to the biological material being shipped. As a result, any prolonged delay in shipment, whether due to technical difficulties, power failures, break-ins, destruction or damage to carrier facilities as a result of a natural disaster, fire, or any other reason, including as a result of the COVID-19 pandemic, could result in damage to the contents of the shipper.

Additionally, our factories, facilities and distribution system may be subject to catastrophic loss due to fire, flood, terrorism, increasing severity or frequency of extreme weather events, or other natural or man-made disasters. Certain components of our key product are manufactured in China and the extent to which our ability to produce products is affected by COVID-19 will largely continue to depend on future developments, which are highly uncertain and cannot be accurately predicted. Additionally, we operate facilities in Irvine, California, Livingston, New Jersey, Ball Ground, Georgia, New Prague, Minnesota, Houston, Texas and Hoofddorp, Netherlands, some of which specialize in the secure storage of biological specimens, materials and samples. If natural disasters or similar events, like hurricanes, fires or explosions or large-scale accidents or power outages, were to occur that prevented us from using all or a significant portion of these facilities, damaged critical infrastructure or our customers’ biological samples, or otherwise disrupted operations at such facility, this could affect our ability to maintain ongoing operations and cause us to incur significant expenses. Insurance coverage may not be adequate to fully cover losses in any particular case.

25

Our products and services may expose us to liability in excess of our current insurance coverage.

Our platform of products and services involve significant risks of liability, which may substantially exceed the revenues we derive from them. We cannot predict the magnitude of these potential liabilities. We currently maintain general liability insurance and product liability insurance. Claims may be made against us that exceed the limits of these policies.

Our liability policy is an “occurrence” based policy. Thus, our policy is complete when we purchased it and following cancellation of the policy it continues to provide coverage for future claims based on conduct that took place during the policy term. Our insurance coverage, however, may not protect us against all liability because our policies typically have various exceptions to the claims covered and also require us to assume some costs of the claim even though a portion of the claim may be covered. In addition, if we expand into new markets, we may not be aware of the need for, or be able to obtain insurance coverage for such activities or, if insurance is obtained, the dollar amount of any liabilities incurred could exceed our insurance coverage. A partially or completely uninsured claim, if successful and of significant magnitude, could have a material adverse effect on our business, financial condition and results of operations.

If we use biological and hazardous materials in a manner that causes injury, we could be liable for damages.

Our customers may ship potentially harmful biological materials in our dewars. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our resources or any applicable insurance coverage we may have. Additionally, we are subject to, on an ongoing basis, federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. In the event of an accident, we could be held liable for damages.

We operate in a competitive industry and if we cannot compete effectively, we will lose business.

We expect to continue to experience significant and increasing levels of competition in the future. While there are technological and marketing barriers to entry, we cannot guarantee that these barriers will be sufficient to defend our market share against current and future competitors. Our principal competitive considerations in our market include:

●financial resources to allocate to proper marketing and an appropriate sales effort;
●acceptance of our solutions model;
●acceptance of our solutions including per use fee structures and other charges for services;
●keeping up technologically with ongoing development of enhanced features and benefits;
●reductions in the delivery costs of competitors’ solutions;
●the ability to develop and maintain and expand strategic alliances;
●establishing our brand name;
●our ability to deliver our solutions to our customers when requested;
●our timing of introductions of new solutions, and services; and
●financial resources to support working capital needs and required capital investments in infrastructure.

Our future revenue stream depends to a large degree on our ability to bring new solutions and services to market on a timely basis. We generally sell our products in industries that are characterized by increased competition through frequent innovation, rapid technological changes and changing industry standards. Without the timely introduction of new products, services and enhancements, our products and services may become obsolete over time, in which case our revenue and operating results could suffer.

26

There may also be other companies which are currently developing competitive products and services or which may in the future develop technologies and products that are comparable, superior or less costly than our own. For example, some specialty couriers and packaging manufacturers with greater resources currently provide temperature controlled packaging solutions and may develop other products or solutions in the future, both of which compete with our products. A competitor that has greater resources than us may be able to develop and expand their networks and product offerings more quickly, devote greater resources to the marketing and sale of their solutions and adopt more aggressive pricing policies. We may not be able to successfully compete with a competitor that has greater resources and such competition may adversely affect our business.

If we successfully develop products and/or services, but those products and/or services do not achieve and maintain market acceptance, our business will not be profitable.

The degree of acceptance of our platform of our existing products or any future products or services by our current target markets, and any other markets to which we attempt to sell our products and services, and our profitability and growth will depend on a number of factors including, among others, our shippers’ ability to perform and preserve the integrity of the materials shipped, relative convenience and ease of use of our shippers and/or Cryoportal®, availability of alternative products or new technologies that make our solutions offering less desirable or competitive, pricing and cost effectiveness, effectiveness of our or our collaborators’ sales and marketing strategy and the adoption cycles of our targeted customers.

In addition, even if our products and services achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or services are introduced that are more favorably received than our products and services, are more cost effective, or render our products obsolete. Although we are not aware of any other treatments or methods currently being developed that would directly compete with the methods we employ, there can be no assurance that future developments in technology will not make our technology non-competitive or obsolete, or significantly reduce our operating margins or the demand for our offerings, or otherwise negatively impact our ability to be profitable.

Risks Associated with Our Intellectual Property

Our success depends, in part, on our ability to obtain patent protection for our solutions, preserve our trade secrets, and operate without infringing the proprietary rights of others.

Our policy is to seek to protect our proprietary position by, among other methods, filing United States patent applications related to our technology, inventions and improvements that are important to the development of our business. Our patents or patent applications may be challenged, invalidated or circumvented in the future or the rights granted may not provide a competitive advantage. We intend to vigorously protect and defend our intellectual property. Costly and time-consuming litigation brought by us may be necessary to enforce our patents and to protect our trade secrets and know-how, or to determine the enforceability, scope and validity of the proprietary rights of others.

We also rely upon trade secrets, technical know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect these trade secrets, in part, by entering into confidentiality agreements and inventions assignment and work for hire agreements in connection with their employment, consulting, or advisory relationships. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.  Additionally, our competitors may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our proprietary technology, or we may not be able to meaningfully protect our rights in unpatented proprietary technology.

While we are not aware of any third party that is infringing any of our patents or trademarks nor do we believe that we are infringing on the patents or trademarks of any other person or organization, we cannot guarantee that our current and potential competitors and other third parties have not filed (or in the future will not file) patent applications for (or have not received or in the future will not receive) patents or obtain additional proprietary rights that will prevent, limit or interfere with our ability to make, use or sell our solutions either in the United States or internationally. Additionally, we may face assertions of claims by holders of patents alleging that we are infringing upon their patent rights, which claims may be without merit, but may nonetheless result in our incurring substantial costs of defense.

27

We are dependent on third parties for the continued development and maintenance of our Cryoportal® software.

Our proprietary Cryoportal® is a logistics platform software used by our customers, business partners and client care team to automate the entry of orders, prepare customs documentation and facilitate status and location monitoring of shipped orders while in transit. The continued development of the Cryoportal® platform is in part contracted to outside software development companies. If these companies become unable or unwilling to continue work on scheduled projects, and an alternative software development company cannot be secured, we may not be able to implement needed enhancements to the system. Failure to proceed with enhancements to the system would adversely affect our ability to generate new business and serve existing customers, resulting in a reduction in revenue.

Our customers could also become the target of litigation relating to the patent and other intellectual property rights of others.

Any litigation relating to the intellectual property rights of others could trigger technical support and indemnification obligations in licenses or customer agreements that we may enter into. These obligations could result in substantial expenses, including the payment by us of costs and damages relating to claims of intellectual property infringement. In addition to the time and expense required for us to provide support or indemnification to our customers, any such litigation could disrupt the businesses of our customers, which in turn could hurt our relationships with such customers and cause the sale of our products to decrease. No assurance can be given that claims for indemnification will not be made, or that if made, such claims would not have a material adverse effect on our business, operating results or financial conditions.

We rely upon certain critical information systems, including our Cryoportal® software platform, for the operation of our business and the failure of any critical information system could adversely impact our reputation and future revenues and we may be required to increase our spending on data and system security.

We rely upon certain critical information systems, including our Cryoportal® software platform which is used by our customers and business partners to automate the entry of orders, prepare customs documentation and facilitate status and location monitoring of shipped orders while in transit. In addition, the provision of service to our customers and the operation of our networks and systems involve the storage and transmission of significant amounts of proprietary information and sensitive or confidential data, including personal information of customers, employees and others. Our technology infrastructure and critical information systems are subject to damage or interruption from a number of potential sources, including unauthorized intrusions, cyber-attacks, software viruses or other malware, natural disasters, power failures, employee error or malfeasances and other events. Despite our best efforts, no cybersecurity or emergency recovery process is failsafe, and if our safeguards fail or our technology infrastructure or critical information systems are compromised, the safety and efficiency of our operations could be materially harmed, our reputation could suffer, and we could face additional costs, liabilities, costly legal challenges. Additionally, an actual or alleged failure to comply with applicable United States or foreign data protection regulations or other data protection standards may expose us to litigation, fines, sanctions or other penalties. We do not have cyber security insurance and we may incur significant costs in the event of a successful cyber-attack against us. The cost and operational consequences of implementing, maintaining and enhancing further data or system protection measures could increase significantly to overcome increasingly intense, complex and sophisticated global cyber threats.

28

Risks Related to Regulatory and Legal Matters

Complying with certain regulations that apply to shipments using our solutions can limit our activities and increase our cost of operations.

Shipments using our solutions and services are subject to various regulations in the various countries in which we operate. For example, shipments using our solutions may be required to comply with the shipping requirements promulgated by the Centers for Disease Control (“CDC”), the Occupational Safety and Health Organization (“OSHA”), the Department of Transportation (“DOT”) as well as rules established by the IATA and the ICAO. Additionally, our data logger may be subject to regulation and certification by the Food and Drug Administration (“FDA”), Federal Communications Commission (“FCC”), and the Federal Aviation Administration (“FAA”). We will need to ensure that our solutions and services comply with relevant rules and regulations to make our solutions and services marketable, and in some cases compliance is difficult to determine. Significant changes in such regulations could require costly changes to our solutions and services or prevent use of our shippers for an extended period of time while we seek to comply with changed regulations. If we are unable to comply with any of these rules or regulations or fail to obtain any required approvals, our ability to market our solutions and services may be adversely affected. In addition, even if we are able to comply with these rules and regulations, compliance can result in increased costs. In either event, our financial results and condition may be adversely affected. We depend on our business partners and unrelated and frequently unknown third-party agents in foreign countries to act on our behalf to complete the importation process and to make delivery of our shippers to the final user. The failure of these third parties to perform their duties could result in damage to the contents of the shipper resulting in customer dissatisfaction or liability to us, even if we are not at fault.

Changes in U.S. trade policy, tariff and import/export regulations may have a material adverse effect on our business, financial condition and results of operations.

Our international operations and transactions also depend upon favorable trade relations between the United States and the foreign countries in which our customers and suppliers have operations. Changes in U.S. or international social, political, regulatory and economic conditions or in laws and policies governing foreign trade, manufacturing, development and investment in the territories or countries where we currently sell our products or conduct our business, as well as any negative sentiment toward the United States as a result of such changes, could adversely affect our business. The current U.S. presidential administration has instituted or proposed changes in trade policies that include the negotiation or termination of trade agreements, the imposition of higher tariffs on imports into the United States, economic sanctions on individuals, corporations or countries, and other government regulations affecting trade between the United States and other countries where we conduct our business. It may be time consuming and expensive for us to alter our business operations in order to adapt to or comply with any such changes.

As a result of certain policy changes of the U.S. presidential administration and from certain U.S. government proposals, there may be greater restrictions and economic disincentives on international trade. The new tariffs and other changes in U.S. trade policy could trigger retaliatory actions by affected countries, and certain foreign governments have instituted or are considering imposing trade sanctions on certain U.S. goods. We do a significant amount of business that would be impacted by changes to the trade policies of the United States and foreign countries (including governmental action related to tariffs, international trade agreements, or economic sanctions). Such changes have the potential to adversely impact the U.S. economy or certain sectors thereof, our industry and the global demand for our products. We may not succeed in developing and implementing policies and strategies to counter the foregoing factors effectively in each location where we do business and the foregoing factors may cause a reduction in our sales, profitability or cash flows, or cause an increase in our liabilities.

29

We, along with our customers, are subject to various international governmental regulations. Compliance with or changes in such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.

We, along with our customers, are subject to various significant international, federal, state and local regulations, including but not limited to regulations in the areas of health and safety, packaging, product content, employment, labor and immigration, import/export controls, trade restrictions and anti-competition. In addition, as a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal, sensitive and/or patient health data in the course of our business. The EU's General Data Protection Regulation (“GDPR”), which became effective in May 2018, applies to our activities related to products and services that we offer to EU customers and workers. The GDPR established new requirements regarding the handling of personal data and includes significant penalties for non-compliance (including possible fines of up to 4 percent of total company revenue). Other governmental authorities around the world have passed or are considering similar types of legislative and regulatory proposals concerning data protection. Each of these privacy, security and data protection laws and regulations could impose significant limitations and increase our cost of providing our products and services where we process end user personal data and could harm our results of operations and expose us to significant fines, penalties and other damages.

We must also comply with complex foreign and U.S. laws and regulations, such as the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and other local laws prohibiting corrupt payments to governmental officials, anti-competition regulations and sanctions imposed by the U.S. Office of Foreign Assets Control and other similar laws and regulations. Violations of these laws and regulations could result in fines and penalties, criminal sanctions, restrictions on our business conduct and on our ability to offer our products in one or more countries, and could also materially affect our brand, our ability to attract and retain employees, our international operations, our business and our operating results. Although we have implemented policies and procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our employees, contractors, or agents will not violate our policies.

These regulations are complex, change frequently and have tended to become more stringent over time. We may be required to incur significant expenses to comply with these regulations or to remedy any violations of these regulations. Any failure by us to comply with applicable government regulations could also result in the cessation of our operations or portions of our operations, product recalls or impositions of fines and restrictions on our ability to carry on or expand our operations. In addition, because many of our products are regulated or sold into regulated industries, we must comply with additional regulations in marketing our products. Any significant change in these regulations could reduce demand for our products, force us to modify our products to comply with new regulations or increase our costs of producing these products. If demand for our products is adversely affected or our costs increase, our operating results and business would suffer.

We are subject to regulation by the FDA or certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations.

Certain of our operations are subject to regulation by the FDA or similar foreign regulatory agencies. For example, we are aware that China’s National Medical Products Administration has had discussions that may require certain of our products to be registered as Class II medical devices. In addition, we may in the future develop products that are subject to regulation as medical devices by the FDA and similar foreign regulatory agencies. The regulations enforced by the FDA and similar regulatory agencies govern a wide variety of product-related activities, including the research, development, testing, manufacture, quality control, approval, clearance, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, post-approval monitoring and reporting, pricing, and export and import of pharmaceutical products. If we or any of our customers, suppliers or distributors fail to comply with FDA and other applicable regulatory requirements or are perceived to potentially have failed to comply, we may face, among other things, warning letters; adverse publicity affecting both us and our customers; investigations or notices of non-compliance, fines, injunctions, and civil penalties; import or export restrictions; partial suspensions or total shutdown of production facilities or the imposition of operating restrictions; increased difficulty in obtaining required FDA clearances or approvals or foreign equivalents; seizures or recalls of our products or those of our customers; or the inability to sell our products. Any such FDA or other regulatory agency actions could disrupt our business and operations, lead to significant remedial costs and have a material adverse impact on our financial position and results of operations.

30

Risks Related to Our Financial Condition

Historically, we have incurred significant losses and we may incur losses in the future.

As of December 31, 2020, we had an accumulated deficit of $192 million. In order to achieve and sustain revenue growth in the future, we must expand our market presence and revenues from existing and new customers. We may continue to incur losses in the future and may never generate revenues sufficient to become profitable or to sustain profitability. Continuing losses may impair our ability to raise the additional capital required to continue and expand our operations.

Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.

We have a substantial amount of indebtedness.  As of December 31, 2020, we had approximately $169.7 million of indebtedness and other liabilities, including trade payables, on a consolidated basis. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:

●increasing our vulnerability to adverse economic and industry conditions;
●limiting our ability to obtain additional financing;
●requiring the dedication of a substantial portion of our cash flow from operations to service our
●indebtedness, which will reduce the amount of cash available for other purposes;
●limiting our flexibility to plan for, or react to, changes in our business;
●diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon
●conversion of the notes; and
●placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have
●better access to capital.

Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under our indebtedness, including our 3.00% convertible senior notes due 2025 (the “Convertible Senior Notes”), and our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.

31

We may need to raise additional capital in the future, and if we are unable to secure adequate funds on terms acceptable to us, we could be unable to execute our business plan.

To remain competitive, we must continue to make investments in the development and broadening of our platform of solutions, the expansion of our sales and marketing activities, and the expansion of our global logistics operations infrastructure as we increase sales domestically and internationally. If cash on hand, short-term investment and cash generated from our operations is insufficient to fund such growth, we could be required to raise additional funds through the issuance of equity or debt securities in the public or private markets, or through a collaborative arrangement. Any future issuance of equity securities or securities convertible into equity securities could result in substantial dilution to our stockholders, and the securities issued in such a financing could have rights, preferences or privileges senior to those of our common stock. In addition, if we raise additional funds through debt financing, we could be subject to debt covenants that place limitations on our operations. We may not be able to raise additional capital on reasonable terms, or at all, or we could use capital more rapidly than anticipated. If we cannot raise the required capital when needed, we may not be able to satisfy the demands of existing and prospective customers, we could lose revenue and market share and we may have to curtail our capital expenditures. A number of factors including market conditions, our results of operations, the perception of our business in the capital markets and our business prospects, among others, could affect our ability to obtain additional financing on favorable terms or at all.

If we are unable to obtain sufficient capital in the future, we could have to curtail our capital expenditures. Any curtailment of our capital expenditures could result in a reduction in net revenue, reduced quality of our products, increased manufacturing costs for our products, harm to our reputation, or reduced manufacturing efficiencies and could have a material adverse effect on our business, financial condition, and results of operations.

Risks Related to Our Preferred Stock

The issuance of shares of our Series C Preferred Stock reduces the relative voting power of holders of our Common Stock, dilutes the ownership of such holders, and may adversely affect the market price of our Common Stock.

In connection with financing our acquisition of MVE Biological Solutions, we completed the sale of 250,000 shares of a newly designated Series C Preferred Stock, par value $0.001, at a price of $1,000 per share, the original purchase price, to funds affiliated with The Blackstone Group Inc., or Blackstone. The holders of our Series C Preferred Stock are entitled to dividends at a rate of 4.0% per annum, paid-in-kind, accruing daily and paid quarterly in arrears and are also entitled to participate in dividends declared or paid on the Common Stock on an as-converted basis.

The holder of our Series C Preferred Stock has the right, at its option, to convert its Series C Preferred Stock, in whole or in part, into Common Stock at a conversion price equal to $38.6152 per share subject to certain customary adjustments. After October 1, 2022, subject to certain conditions, we may, at our option, require conversion of all of the outstanding shares of Series C Preferred Stock to Common Stock if, for at least 20 trading days during the 30 consecutive trading days immediately preceding the date we notify the Series C Preferred Stockholders of the election to convert, the closing price of our Common Stock is at least 150% of the conversion price. On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Company’s 4.0% Series C Convertible Preferred Stock, resulting in the issuance of an aggregate of 1,312,860 shares of Common Stock.

Similarly, as it relates to our Convertible Senior Notes, at any time before the close of business on the scheduled trading day immediately before June 1, 2025, the holders of our Convertible Senior Notes may convert their notes into shares of Common Stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. The initial conversion rate is 41.8261 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $23.91 per share of common stock.  The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

Any conversion of shares of the Series C Preferred Stock or the Convertible Senior Notes to shares of our Common Stock would dilute the ownership interest of existing holders of our Common Stock, and any sale in the public market of shares of our Common Stock issuable upon conversion of the Series C Preferred Stock or the Convertible Senior Notes could adversely affect prevailing market prices of our Common Stock. We granted the Preferred Stock Investors and the holders of the Convertible Senior Notes customary registration rights in respect of their securities. These registration rights facilitate the resale of such securities into the public market, and any such resale would increase the number of shares of our Common Stock available for public trading.

32

The Series C Preferred Stockholders may exercise influence over us, including through their ability to designate a member of our board of directors.

The Series C Preferred Stockholders are generally entitled to vote with the holders of the shares of Common Stock on all matters submitted for a vote of holders of shares of Common Stock (voting together with the holders of shares of Common Stock as one class) on an as-converted basis, subject to certain NASDAQ voting limitations, if applicable. Additionally, the consent of the holders of a majority of the outstanding shares of Series C Preferred Stock is required for so long as any shares of the Series C Preferred Stock remain outstanding for (i) amendments to the Company’s organizational documents that have an adverse effect on the holders of Series C Preferred Stock and (ii) issuances by the Company of securities that are senior to, or equal in priority with, the Series C Preferred Stock, including any shares of the Company’s Series A Preferred Stock or Series B Preferred Stock. In addition, for so long as 75% of the Series C Preferred Stock issued in connection with the Securities Purchase Agreement remains outstanding, consent of the Holders of a majority of the outstanding shares of Series C Preferred Stock will be required for (i) any voluntary dissolution, liquidation, bankruptcy, winding up or deregistration or delisting and (ii) incurrence by Cryoport of any indebtedness unless our ratio of debt to LTM EBITDA (as defined in the Series C Certificate of Designation) would be less than a ratio of 5-to-1 on a pro forma basis giving effect to such incurrence and the use of proceeds therefrom.

Additionally, an affiliate of Blackstone has the right to nominate for election one member to our board of directors for so long as certain parties hold 66.67% of the Series C Preferred Stock issued in the Blackstone financing transaction.  The director designated by Blackstone is entitled to serve on committees of our board of directors, subject to applicable law and NASDAQ rules. Notwithstanding the fact that all directors will be subject to fiduciary duties to us and to applicable law, the interests of the director designated by Blackstone may differ from the interests of our security holders as a whole or of our other directors.

As a result, the Series C Preferred Stockholders have the ability to influence the outcome of certain matters affecting our governance and capitalization. The sponsors of the Series C Preferred Stockholders are in the business of making or advising on investments in companies, including businesses that may directly or indirectly compete with certain portions of our business, and they may have interests that diverge from, or even conflict with, those of our other shareholders. They may also pursue acquisition opportunities that may be complementary to our business, and, as a result, those acquisition opportunities may not be available to us. Our obligations to the holders of Series C Preferred Stock could also limit our ability to obtain additional financing or increase our borrowing costs, which could have an adverse effect on our financial condition.

Our Series C Preferred Stock has rights, preferences, and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock, which could adversely affect our liquidity and financial condition.

The holders have the right under the Series C Certificate of Designation to receive a liquidation preference entitling them to be paid an amount per share equal to the greater of (i) the original purchase price, plus all accrued and unpaid dividends and (ii) the amount that the holder would have been entitled to receive at such time if the Series C Preferred Stock were converted into Common Stock. In addition, the holders are entitled to dividends at a rate of 4.0% per annum, paid-in-kind, accruing daily and paid quarterly in arrears. The holders are also entitled to participate in dividends declared or paid on the Common Stock on an as-converted basis.

Risks Related to Ownership of Our Common Stock

Certain of our existing stockholders own and have the right to acquire a substantial number of shares of common stock.

As of February 19, 2021, our directors, executive officers and beneficial owners of 5% or more of our outstanding common stock beneficially owned 24,274,179 shares of common stock assuming their exercise of all outstanding Series C Preferred Stock and options that are exercisable within 60 days of February 19, 2021 or approximately 48.6 % of our outstanding common stock. As such, the concentration of beneficial ownership of our common stock may have the effect of delaying or preventing a change in control of Cryoport and may adversely affect the voting or other rights of other holders of our common stock.

33

The sale of substantial shares of our common stock may depress our stock price.

As of February 19, 2021, there were 45,581,661 shares of our common stock outstanding. Substantially all of these shares of common stock are eligible for trading in the public market. The market price of our common stock may decline if our stockholders sell a large number of shares of our common stock in the public market, or the market perceives that such sales may occur. We could also issue up to an additional 8,399,909 shares of our common stock upon exercise of outstanding options or reserved for future issuance under our stock incentive plans, up to an additional 5,260,162 shares of our common stock upon conversion of Series C Preferred Stock , and up to an additional 4,810,002 shares of our common stock upon conversion of the Convertible Senior Notes.

Our stock price has been and will likely continue to be volatile.

The market price of our common stock has been highly volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control, including, but not limited to technological innovations or new solutions and services by us or our competitors, additions or departures of key personnel, sales of our common stock, our ability to execute our business plan, our operating results being below expectations, loss of any strategic relationship, industry developments, economic and other external factors and period-to-period fluctuations in our financial results.

In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of companies. These market fluctuations may also materially and adversely affect the market price of our common stock and warrants.

We are at risk of securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because our stock price and those of other biotechnology and life sciences companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business. We do maintain insurance, but the coverage may not be sufficient and may not be available in all instances.

We have not paid dividends on our common stock in the past and do not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.

We have never paid cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. The payment of dividends on our common stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as the Board of Directors may consider the payment of any such dividends. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if the price of our common stock appreciates.

Our Articles of Incorporation allows our Board of Directors to issue up to 2,500,000 shares of “blank check” preferred stock.

Our Articles of Incorporation allows our board of directors to issue up to 2,500,000 shares of “blank check” preferred stock, without action by our stockholders. We have designated 800,000 shares as Class A Preferred Stock, 585,000 shares as Class B Preferred Stock and 250,000 shares of Series C Preferred Stock, of which 200,000 shares of Series C Preferred Stock are issued and outstanding at February 19, 2021. Without limiting the foregoing, (i) such shares of preferred stock could have liquidation rights that are senior to the liquidation preference applicable to our common stock and Preferred Stock, (ii) such shares of preferred stock could have voting or conversion rights, which could adversely affect the voting power of the holders of our common stock and Preferred Stock and (iii) the ownership interest of holders of our common stock will be diluted following the issuance of any such shares of preferred stock. In addition, the issuance of such shares of blank check preferred stock could have the effect of discouraging, delaying or preventing a change of control of our Company.

34

Provisions in our bylaws and Nevada law might discourage, delay or prevent a change of control of our Company or changes in our management and, as a result, may depress the trading price of our common stock.

Provisions of our bylaws and Nevada law may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. The relevant bylaw provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. These provisions include advance notice requirements for stockholder proposals and nominations, and the ability of our Board of Directors to make, alter or repeal our bylaws.

Absent approval of our Board of Directors, our bylaws may only be amended or repealed by the affirmative vote of the holders of at least a majority of our outstanding shares of capital stock entitled to vote.

In addition, Section 78.438 of the Nevada Revised Statutes prohibits a publicly-held Nevada corporation from engaging in a business combination with an interested stockholder (generally defined as a person which together with its affiliates owns, or within the last three years has owned, 10% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder) unless the business combination is approved in a prescribed manner.

The existence of the foregoing provisions and other potential anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our Company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition.

General Risk Factors

Our ability to grow and compete in our industry will be hampered if we are unable to retain the continued service of our key professionals or to identify, hire and retain additional qualified professionals.

Our success in implementing our business strategy depends largely on the skills, experience and performance of key members of our executive management team and others in key management positions. The collective efforts of each of these persons working as a team will be critical to us as we continue to develop our technologies, tests and engineering and development and sales programs. As a result of the difficulty in locating qualified new management, the loss or incapacity of existing members of our executive management team could adversely affect our operations. If we were to lose one or more of these key employees, we could experience difficulties in finding qualified successors, competing effectively, developing our technologies and implementing our business strategy. We do not maintain "key person" insurance on any of our employees.

In addition, a critical factor to our business is our ability to attract and retain qualified professionals including key employees and consultants. We are continually at risk of losing current professionals or being unable to hire additional professionals as needed. If we are unable to attract new qualified employees, our ability to grow will be adversely affected. If we are unable to retain current employees or strategic consultants, our financial condition and ability to maintain operations may be adversely affected.

If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common stock, the price of our common stock could decline.

The trading market for our common stock relies in part on the research and reports that equity research analysts publish about us and our business. We do not control these analysts. The price of our common stock could decline if one or more equity analyst downgrades our stock or if analysts downgrade our stock or issue other unfavorable commentary or cease publishing reports about us or our business.

​

ITEM 1B. Unresolved Staff Comments

Not applicable.

​

35

ITEM 2. Properties

Our principal executive office is located in Brentwood, Tennessee.  We lease or own various corporate, global logistics and supply chain centers, biostorage, manufacturing, research and development at 37 sites across the Americas, EMEA and APAC regions.

The following table summarizes our principal facilities and other materially important physical properties as of December 31, 2020:

Location

    

Ownership

    

Use

Brentwood, Tennessee

​

Leased

​

Principle Executive Office

Irvine, California

​

Leased

​

Administrative, Global Supply Chain Center and Research and Development Center

Livingston, New Jersey

​

Leased

​

Global Supply Chain Center

Houston, Texas

​

Leased

​

Administrative, Global Supply Chain Center and Biostorage Center

Hoofddorp, the Netherlands

​

Leased

​

Global Supply Chain Center

Ball Ground, Georgia

​

Leased

​

Administrative, Manufacturing, and Research and Development Center

New Prague, Minnesota

​

Owned

​

Manufacturing

Chengdu, China

​

Owned

​

Administrative and Manufacturing

Lisbon, Portugal

​

Leased

​

Administrative

Tremblay-en-France, France

​

Leased

​

Administrative and Global Logistics Center

​

We believe that these facilities are adequate, suitable and of sufficient capacity to support our immediate needs.

​

ITEM 3. Legal Proceedings

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including product liability claims. We currently are not aware of any such legal proceedings or claim that we believe will have, individually or in the aggregate, a material adverse effect on our business, operating results or cash flows. It is our practice to accrue for open claims based on our historical experience and available insurance coverage.

​

ITEM 4. Mine Safety Disclosures

Not applicable

​

36

PART II

ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Common Stock

As of February 19, 2021 there were 45,581,661 shares of common stock outstanding and 187 stockholders of record. Because many shares of our common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these stockholders of record.

Market Information

The Company’s common stock is currently listed on the NASDAQ Capital Market and is traded under the symbol “CYRX.”

Stock Performance Graph (1)

The graph below matches Cryoport’s cumulative 5-year total shareholder return on common stock with the cumulative total returns of the Russell 3000®. The graph tracks the performance of a $100 investment in our common stock and index from December 31, 2015 to December 31, 2020.

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*

Among Cryoport, Inc. and the Russell 3000®

Graphic

*$100 invested on 12/31/15 in stock or index. Fiscal year ending December 31.

(1)

The information contained in the performance graph shall not be deemed to be “soliciting material” or to be “filed” with the SEC, and such information shall not be incorporated by reference into any future filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), except to the extent that Cryoport specifically incorporates it by reference into such filing.

​

37

Dividends

No dividends on common stock have been declared or paid by the Company.  The Company intends to employ all available funds for the development of its business and, accordingly, does not intend to pay any cash dividends in the foreseeable future.

Recent Sale of Unregistered Securities

There were no unregistered sales of equity securities during the fiscal year ended December 31, 2020 other than as reported in our Current Reports on Form 8-K filed with the SEC.

Issuer Purchases of Equity Securities

On October 9, 2019, the Company announced that its board of directors authorized a share repurchase program to purchase up to $15,000,000 of the Company’s common stock.  Repurchases may be made from time to time on the open market or otherwise, in such quantities, at such prices, and in such manner as determined by management at its discretion and will depend on a number of factors, including the market price of Company’s common stock, general market and economic conditions, and applicable legal requirements. The repurchase program expired on December 31, 2020.  The Company has not purchased any shares under this program in 2019 and through December 31, 2020.

​

ITEM 6.  Selected Consolidated Financial Data

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

​

​

​

​

38

ITEM 7.  Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of our operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Form 10-K. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors. See “Forward-Looking Statements” in this Form 10-K.

General Overview

We are redefining the temperature-controlled supply chain for the life sciences industry by providing a unique and evolving platform of critical products and solutions including advanced packaging, informatics, specialty logistics services, biostorage services, and cryogenic life sciences equipment. With over 600 employees in 30 locations worldwide, we are engaged in providing global solutions to the biopharma/pharma, animal health, and human reproductive medicine markets. Our primary focus is on addressing the critical temperature-controlled supply chain needs within the biopharmaceutical space with an emphasis on serving the rapidly growing cell and gene therapy, or C&GT, market.

See the “Business” section in Part I, Item 1 of this Form 10-K for additional information.

Impact of COVID-19

In late 2019, a novel strain of coronavirus that causes coronavirus disease (COVID-19) was reported to have surfaced in Wuhan, China, which has since spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic.  Further, the COVID-19 outbreak has resulted in government authorities around the world implementing numerous measures to try to reduce the impact of COVID-19, such as travel bans and restrictions, quarantines, shelter in place or total lock-down orders. Many countries around the world have also implemented the temporary closure of non-essential businesses and other material limitations on the conduct of business. As a provider of life saving therapies, Cryoport is deemed to be an essential business and has remained fully open and operational.  However, the full extent and duration of this pandemic is still unknown at this point and the related governmental, business and travel restrictions in order to contain this virus are continuing to evolve globally. Accordingly, there is significant uncertainty related to the ultimate impact that this global pandemic will have on the results of our operations.

For example, several life sciences companies, including some of our clients, announced during 2020 the temporary suspension of clinical studies and trials as well as other COVID-19 related risks that may impact their preclinical and clinical trials, including delays in patient enrollment or difficulties in initiating or expanding clinical trials, interruption of clinical trial activity, and diversion of healthcare resources to focus on COVID-19 activities. While these temporary suspensions and restrictions have been lifted, these may be reinstated, and other measures may be implemented. In addition, with respect to the impact of the pandemic on the human reproductive medicine market, the American Society for Reproductive Medicine (ASRM) and European Society of Human Reproduction and Embryology (ESHRE) both issued recommendations in March of 2020 to temporarily defer fertility treatments and related activities. Both organizations have since updated and recently reaffirmed their recommendation to gradually and judiciously resume activities. While these actions have negatively impacted our revenue in the markets we serve temporarily, we cannot determine the longer-term impact at this point. A number of public announcements by government and clients indicate a regional or partially reinstating of COVID-19 related restrictions and while we have experienced revenue ramping back up gradually over time, this may be curtailed by new restrictions. Further, virus containment efforts as a result of governmental actions or policies or other initiatives could lead to further disruption in the supply chain and as a result, we may have difficulties sourcing raw materials and equipment or may incur additional direct costs to provide our solutions.

While longer-term client demand for our services overall remains strong, the effects of the COVID-19 pandemic, including the measures above taken by some of our clients have adversely impacted our revenue growth.  We continue to monitor the evolving situation caused by the COVID-19 pandemic, and we may take further actions required by governmental authorities or that we determine are prudent to support the well-being of our employees, customers, suppliers, business partners and others. The degree to which COVID-19 impacts our business operations, financial performance and results of operations will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact and how quickly and to what extent normal economic and operating conditions can resume.   See “Risk Factors—Risk Related to Our Business—The recent global pandemic caused by COVID-19 has already and may continue to adversely affect our business operations, financial performance and results of operations, the extent of which is uncertain and difficult to predict.”

39

Segment Reporting

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The chief operating decision maker (“CODM”) is our Chief Executive Officer.  We previously reported results based on two reportable operating segments: Global Logistics Solutions and Global Bioservices. During the fourth quarter of 2020, our CODM changed how he makes operating decisions, assesses the performance of the business and allocates resources in a manner that caused our operating segments to change as a result of the MVE and CRYOPDP acquisitions. In consideration of the FASB ASC 280, Segment Reporting, we determined that we are not organized around specific products and services, geographic regions or regulatory environments. Accordingly, beginning with the fourth quarter of 2020, we operate in one reportable operating segment.

Critical Accounting Policies and Estimates

Our discussion and analysis of our consolidated financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in conformity with accounting principles generally accepted in the U.S., or U.S. GAAP. While our significant accounting policies are more fully described in the notes to our consolidated financial statements, we have identified the policies and estimates below as being critical to our business operations and the understanding of our results of operations. These policies require management’s most difficult, subjective or complex judgements, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The impact of and any associated risks related to these policies on our business operations are discussed throughout “Management’s Discussion and Analysis of Financial Condition,” including in the “Results of Operations” section, where such policies affect our reported and expected financial results. Although we believe that our estimates, assumptions, and judgements are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.

The SEC defines critical accounting policies as those that are, in management’s view, most important to the portrayal of our financial condition and results of operations and most demanding of our judgment. We consider the following policies to be critical to an understanding of our consolidated financial statements and the uncertainties associated with the complex judgments made by us that could impact our results of operations, financial position and cash flows: Revenue Recognition, Business Combinations, Intangible Assets and Goodwill, Series C Preferred Stock, Stock-based Compensation, Convertible Senior Notes and Income Taxes. See Note 2: “Summary of Significant Accounting Policies” of our accompanying consolidated financial statements for a description of our critical accounting policies and estimates.

Revenue Recognition

Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

Performance Obligations

At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.

For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.

40

Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.

Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within one year from a given reporting date.

Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying consolidated statements of operations.

Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.

Business Combinations

Amounts paid for acquisitions are allocated to the tangible and intangible assets acquired and liabilities assumed, if any, based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.

We use the income approach to determine the fair value of certain identifiable intangible assets such as customer relationships. This approach determines fair value by estimating after-tax cash flows attributable to these assets over their respective useful lives and then discounting these after-tax cash flows back to a present value. We base our assumptions on estimates of future cash flows, expected growth rates, expected trends in technology, etc. We base the discount rates used to arrive at a present value as of the date of acquisition on the time value of money and certain industry-specific risk factors. We believe the estimated purchased customer relationships, agent networks, software, developed technologies, and trademarks/tradenames so determined represent the fair value at the date of acquisition and do not exceed the amount a third party would pay for the assets.

41

Intangible Assets and Goodwill

Intangible assets

Intangible assets with a definite life are amortized over their useful lives using the straight-line method, which is the best estimate of the value we are receiving over the useful life of the intangible asset and another systematic method was not deemed more appropriate. The amortization expense is recorded within selling, general and administrative expense in the consolidated statements of operations. Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s products. If impairment indicators are present, the Company determines whether the underlying intangible asset is recoverable through estimated future undiscounted cash flows. If the asset is not found to be recoverable, it is written down to the estimated fair value of the asset based on the sum of the future discounted cash flows expected to result from the use and disposition of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its definite-lived intangible assets are recoverable at December 31, 2020.  There has been no impairment of our intangible assets for the periods presented.

Goodwill

We test goodwill for impairment on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business, and an adverse action or assessment by a regulator. Accounting guidance also permits an optional qualitative assessment for goodwill to determine whether it is more likely than not that the carrying value of a reporting unit exceeds its fair value. If, after this qualitative assessment, we determine that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then no further quantitative testing would be necessary. A quantitative assessment is performed if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the reporting unit’s carrying value exceeds its fair value. As a result of our 2020 quantitative assessment, we concluded that goodwill is not impaired as of December 31, 2020.

Series C Preferred Stock

On the October 1, 2020 issuance date, the effective conversion price per share was less than the fair value of the underlying Common Stock and, as a result, the Company determined that there was a beneficial conversion feature on that date. Accordingly, the Company recognized the resulting beneficial conversion feature amount of approximately $39.5 million as a deemed dividend, equal to the number of common shares into which the Series C Preferred Stock is convertible multiplied by the difference between the fair value of the Common Stock and the effective conversion price per share on that date. Because the Series C Preferred Stock does not have a stated conversion date and was immediately convertible at the issuance date, the dividend is reflected as a one-time, non-cash, deemed dividend to the Holders of the Series C Preferred Stock on the date of issuance.  

Additionally, the Company determined that the nature of the Series C Preferred Stock is more akin to an equity instrument and that the economic characteristics and risks of the embedded conversion options are clearly and closely related to the Series C Preferred Stock. As such, the conversion options were not required to be bifurcated from the host under ASC 815, Derivatives and Hedging.

Since the paid-in-kind dividends are nondiscretionary, the Company measured the beneficial conversion feature in the paid-in-kind dividend on the issuance date of the preferred stock and recorded such amount when the paid-in-kind dividend was accrued. Accordingly, the associated paid-in-kind dividends for the year ended December 31, 2020 generated a beneficial conversion feature amount of $344,000. On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Company’s 4.0% Series C Convertible Preferred Stock, par value $0.001 per share (See Note 18).

42

The Company evaluated the Series C Preferred Stock for liability or equity classification under the applicable accounting guidance including ASC 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the Series  C Preferred Stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series C Preferred Stock would be recorded as permanent equity given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company.

The Company also evaluated the embedded put and call options within the Series C Preferred Stock in accordance with the accounting guidance for derivatives to determine if bifurcation is required.  The Company determined that the economic characteristics and risks of the embedded put and call options are not clearly and closely related to the Series C Preferred Stock. Therefore, the Company assessed the put and call options further and determined they did not meet the definition of a derivative under ASC 815.

Under the same analysis, the Company determined that the economic characteristics and risks of the embedded participating dividend feature are considered clearly and closely related to the equity host. Accordingly, the participating dividend feature is not required to be bifurcated under ASC 815. Also, the Company determined that the value of the contingent dividend feature is minimal and insignificant relative to the other components of the Series C Preferred Stock due to the circumstances surrounding the scenarios under which the provision would be triggered.

Convertible Senior Notes

The Senior Notes are accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options (“ASC 470-20”) and ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”). Under ASC 815-40, to qualify for equity classification (or nonbifurcation, if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer’s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company’s analysis, it was determined the Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20, the proceeds received from the issuance of the convertible debt was recorded as a liability on the consolidated balance sheet.

Stock-based Compensation

We use the Black-Scholes option pricing model to calculate the fair value of stock option awards on the grant date. The expected option life assumption is estimated based on the simplified method.  Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term.  The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the average of the historical volatility and the implied volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.

We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest. For the years ended December 31, 2020 and 2019, we recorded stock-based compensation expense of $8.9 million and $16.5 million, respectively, for share-based awards granted under all of the Company’s stock plans.

As of December 31, 2020, there was $21.1 million of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 3.1 years. We expect 1,692,183 unvested options to vest over the next four years.

43

Income Taxes

Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate our tax position on a quarterly basis. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.

Results of Operations

Results of Operations for the Year Ended December 31, 2020 Compared to the Year Ended December 31, 2019

The following table summarizes certain information derived from our consolidated statements of operations (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

​

​

​

​

​

 

​

    

2020

    

2019

    

$ Change

    

% Change

 

Service revenues

 

$

55,299

​

$

33,942

​

$

21,357

 

62.9

%

Product revenues

​

 

23,397

​

 

—

​

 

23,397

 

100

%

Total revenues

​

 

78,696

​

 

33,942

​

 

44,754

 

131.9

%

Cost of service revenues

​

​

(29,521)

​

​

(16,590)

​

​

(12,931)

​

77.9

%

Cost of product revenues

​

​

(12,841)

​

​

—

​

​

(12,841)

​

100

%

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross margin

​

 

36,334

​

 

17,352

​

 

18,982

 

109.4

%

Selling, general and administrative expenses

​

 

(56,860)

​

 

(31,286)

​

 

(25,574)

 

81.7

%

Engineering and development expenses

​

 

(9,484)

​

 

(3,741)

​

 

(5,743)

 

153.6

%

Investment income

​

​

761

​

​

583

​

​

178

​

30.6

%

Interest expense

​

 

(2,560)

​

 

(1,367)

​

 

(1,193)

 

87.2

%

Other income (expense), net

​

 

(929)

​

 

189

​

 

(1,118)

 

(591.3)

%

Benefit from (provision for) income taxes

​

 

45

​

 

(62)

​

 

107

 

(172.5)

%

​

​

 

  

​

 

  

​

 

​

 

​

​

Net loss

​

$

(32,693)

​

$

(18,332)

​

$

(14,361)

 

78.3

%

Deemed dividend on Series C convertible preferred stock

​

​

(39,492)

​

​

—

​

​

(39,492)

​

100.0

%

Paid-in-kind dividend on Series C convertible preferred stock

​

​

(2,844)

​

​

—

​

​

(2,844)

​

100.0

%

Net loss attributable to common stockholders

​

$

(75,029)

​

$

(18,332)

​

$

(56,697)

 

309.3

%

​

Total revenues by market

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

​

​

​

​

​

 

​

    

2020

    

2019

    

$ Change

    

% Change

 

Biopharma/Pharma

​

$

66,394

​

$

30,032

​

$

36,362

 

121

%

Animal Health

​

 

7,846

​

 

996

​

 

6,850

 

687

%

Human Reproductive Medicine

​

 

4,456

​

 

2,914

​

 

1,542

 

53

%

​

​

​

​

​

​

​

​

​

​

​

​

​

Total revenues

​

$

78,696

​

$

33,942

​

$

44,754

 

132

%

​

44

Revenues. Revenues increased $44.8 million, or 132%, to $78.7 million for year ended December 31, 2020, as compared to $33.9 million for the year ended December 31, 2019. This increase was primarily driven by revenue from the acquisition of MVE and CRYOPDP on October 1, 2020, which contributed $23.0 million and $12.9 million, respectively, and the increase in revenue by $8.9 million, primarily driven by our biopharmaceutical customers. This includes an increase in revenue of $2.2 million resulting from the acquisition of Cryogene in May 2019. During 2020 we experienced an increase in the number of customers utilizing our services, the number of clinical trials we support and an increase in revenue related to commercialized cell therapies.

Service revenues increased by $21.4 million, or 62.9%, to $55.3 million for year ended December 31, 2020, as compared to $33.9 million for the year ended December 31, 2019. This increase was driven by the acquisition of CRYOPDP on October 1, 2020, which contributed $12.9 million in revenue from temperature-controlled specialty courier services and supply chain services, including packaging, pick-pack kit preparation, the continuing ramp of revenue from our Cryoport Express® solutions, which increased by $6.7 million, or 22%, and revenue from our biostorage services, which increased by $2.2 million, or 74%.

Product revenues were $23.4 million and $0 for 2020 and 2019, respectively, and are primarily a result of the acquisition of MVE on October 1, 2020, representing revenue from the product line of cryonic stainless-steel freezers, aluminum dewars and related ancillary equipment used in the storage and transport of life sciences commodities, which includes the rapidly growing Cell and Gene Therapy market through a global network of distributors and direct client relationships,

Revenues by market

Revenue from the biopharma/pharma market increased $36.4 million, or 121%, to $66.4 million, as compared to the year ended December 31, 2019. This increase was driven by revenue from the acquisition of MVE and CRYOPDP on October 1, 2020, which contributed $15.4 million and $12.9 million, respectively, and the increase in revenue by $5.9 million from clinical trial and commercial revenue. This includes an increase in revenue of $2.2 million resulting from the acquisition of Cryogene in May 2019. We now support 528 clinical trials, of which 419 are in the Americas, 84 are in EMEA and 25 are in APAC, compared to 436 clinical trials supported as of December 31, 2019 (361 in the Americas, 61 in EMEA and 14 APAC). The number of Phase III clinical trials supported increased to 69 trials as of December 31, 2020, of which 49 are in the Americas, 19 are in EMEA, and 1 is in APAC. This compares to 56 Phase III trials (40 in the Americas, 15 in EMEA and 1 APAC) supported as of December 31, 2019. The activity in the clinical trial space, particularly in the Cell and Gene Therapy market is expected to drive future revenue growth as these clinical trials advance and resulting therapies are commercialized on a global basis.

Our revenue from the animal health market increased $6.9 million, or 687%, to $7.8 million for the year ended December 31, 2020, as compared to the same period in 2019. This increase is driven by the acquisition of MVE on October 1, 2020.

Revenues in the human reproductive medicine market increased $1.5 million, or 53%, to 4.5 million for the year ended December 31, 2020, as compared to the same period in 2019. This increase was driven by a 31.3% increase in revenues in the U.S. market through continued success of our CryoStork®-branded offering and a 43.5% increase in revenues in the international markets, which was primarily a result of our marketing initiatives and growing brand recognition.

Gross margin and cost of revenues. Gross margin for the year ended December 31, 2020 was 46.2% of total revenues, as compared to 51.1% of total revenues for the year ended December 31, 2019. The decrease in gross margin is primarily a result of the lower margin contributions from the acquisitions of MVE and CRYOPDP . Cost of total revenues increased $25.7 million to $42.3 million for the year ended December 31, 2020, as compared to $16.6 million in the same period in 2019. The increase in cost of total revenues is commensurate with the increase in business volume and the addition of cost of revenue from the acquisitions of MVE and CRYOPDP for the fourth quarter of 2020.

Gross margin for our service revenues was 46.7% of service revenues, as compared to 51.1% of service revenues for the year ended December 31, 2019. This decrease is a result of the lower margin contribution from the acquisition of CRYOPDP during the fourth quarter of 2020. Our cost of revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions.

45

Gross margin for our product revenues was 45.1% of product revenues. Product revenues, related cost of revenues and resulting gross margins are primarily a result of the acquisition of MVE during the fourth quarter of 2020. Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.

Selling, general and administrative expenses. Selling, general and administrative (“SG&A”) expenses include the costs associated with selling our products and services and costs required to support our marketing efforts including legal, accounting, patent, shareholder services, amortization of intangible assets and other administrative functions.

For 2020, SG&A expenses increased by $25.6 million, or 81.7% as compared to 2019. The increase is primarily due to the addition of $11.5 million of SG&A expenses from the acquisition of MVE and CRYOPDP effective October 1, 2020, as well as the continued expansion of our infrastructure to support the acquisitions and expected future growth. Intangible asset amortization expense is included in SG&A and consists of charges related to the amortization of intangible assets associated with the acquisitions of CRYOPDP and MVE in 2020 and Cryogene in 2019, in which we acquired definite-lived intangible assets.  Intangible asset amortization expense increased by $6.3 million, from $0.3 million in 2019, to $6.6 million in 2020. SG&A also includes acquisition and integration costs related to MVE and CRYOPDP acquisitions in 2020 of $11.1 million, compared to $0.4 million related to the acquisition of Cryogene in 2019. Stock compensation expense decreased by $6.4 million in 2020 compared to 2019, primarily resulting from accelerated vesting of certain stock option awards as a result of meeting defined financial targets in the amount of $8.4 million in 2019, which did not occur in 2020.

Engineering and development expenses. Engineering and development expenses increased $5.7 million, or 153.6%, for year ended December 31, 2020, as compared to the same period in 2019. The increase is primarily due to an increase of $4.2 million in consulting costs directed at further enhancing our logistics and supply chain solutions and $1.6 million in wages and associated employee costs to add software development and engineering resources. These increases were partially offset by a decrease in stock-based compensation expense of $0.5 million which was driven by $0.9 million in accelerated vesting for certain stock option awards during 2019 as a result of meeting defined financial targets. We continually strive to improve and expand the features of our Cryoport Express® Solutions and portfolio of services and products. Our primary developments are directed towards facilitating the safe, reliable and efficient transport and storage of life science commodities through innovative and technology-based solutions. This includes significantly enhancing our Cryoportal® Logistics Management Platform and related technology solutions as well as developments to expand our Cryoport Express® Shipper fleet, such as the CryosphereTM shipper, a cryogenic dry-vapor shipper utilizing patent pending technology that passively stabilizes the payload through an internal gravitational sphere, thereby further mitigating transport risks. In addition, engineering and development efforts are also focused on MVE’s portfolio of advanced cryogenic stainless-steel freezers, aluminum dewars and related ancillary equipment used in the storage and transport of life sciences commodities. We supplement our internal engineering and development resources with subject matter experts and consultants to enhance our capabilities and shorten development cycles.

Investment Income. Investment income increased by $0.2 million, from $0.6 million to $0.8 million for the year ended December 31, 2020, as compared to the prior year as a result of higher average invested cash balances offset by lower interest rates on such invested cash balances.

Interest expense. Interest expense increased by $1.2 million, from $1.4 million to $2.6 million for the year ended December 31, 2020, as compared to the prior year primarily as a result of the issuance of $115.0 million aggregate principal amount of 3.00% convertible senior notes in May 2020 and amortization of the related debt discount.

Other income, net.  The increase in other income, net for the year ended December 31, 2020 is primarily due to realized and unrealized gains and losses on short-term investments and foreign currency fluctuations.  

Dividends on Series C preferred convertible stock. The dividends in the aggregate amount of $42.3 million for the year ended December 31, 2020 represent a non-cash deemed dividend in the amount of $39.5 million resulting from a beneficial conversion feature and a paid-in-kind dividend of $2.8 million, both from the private placement of Series C Preferred Stock with Blackstone.  

46

Non-GAAP Financial Measures

We provide adjusted EBITDA as a supplemental measure to GAAP measures regarding our operating performance. This financial measure excludes the impact of certain acquisition related items and other expenses and, therefore, has not been calculated in accordance with GAAP. A detailed explanation and a reconciliation of this non-GAAP financial measure to its most comparable GAAP financial measure is described below.

We include this financial information because we believe this measure provides a more accurate comparison of our financial results between periods and more accurately reflects how management reviews its financial results. We excluded the impact of certain acquisition related items because we believe that the resulting charges do not accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Cryoport, Inc. and Subsidiaries

Adjusted EBITDA Reconciliation

(Unaudited, in thousands)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended 

​

Year Ended 

​

​

December 31,

​

December 31,

​

    

2020

    

2019

    

2020

    

2019

GAAP net loss

    

$

(11,530)

    

$

(948)

    

​

(32,693)

​

$

(18,332)

Non-GAAP adjustments to net loss:

​

 

  

​

 

  

 

​

  

​

 

  

Depreciation and amortization expense

​

 

7,370

​

 

825

 

​

9,869

​

 

2,415

Acquisition and integration costs

​

 

3,700

​

 

—

 

​

11,163

​

 

383

Inventory step-up charges

​

 

727

​

 

—

 

​

727

​

 

—

Other non-recurring charges

​

 

225

​

 

—

 

​

225

​

 

—

Investment income

​

 

(150)

​

 

(291)

 

​

(761)

​

 

(543)

Interest expense

​

 

1,077

​

 

446

 

​

2,560

​

 

1,367

Stock-based compensation expense

​

 

2,561

​

 

382

 

​

8,916

​

 

16,523

Income taxes

​

 

(98)

​

 

51

 

​

(45)

​

 

62

Adjusted EBITDA

​

$

3,882

​

$

465

 

​

(39)

​

$

1,876

​

Adjusted EBITDA is measured by taking net income/loss as reported in accordance with GAAP, excluding depreciation and intangible amortization expenses, acquisition and integration costs, inventory step-up charges, other non-recurring charges, stock-based compensation expense, investment income, interest expense and taxes included in the consolidated statements of operations.

Liquidity and Capital Resources

As of December 31, 2020, the Company had cash and cash equivalents of $36.9 million, short-term investments of $56.4 million and working capital of $112.1 million. Historically, we have financed our operations primarily through sales of equity securities and debt instruments. We believe that our pre-existing cash and cash equivalents and short-term investments, together with the net proceeds of approximately $265.4 million raised through an underwritten public offering in January 2021 will be sufficient to fund our operations, including capital expenditures and absent any acquisitions, for at least the next three years.

Cash flows

​

​

​

​

​

​

​

​

​

​

​

​

For the Year Ended December 31,

​

​

​

​

​

2020

​

2019

​

$ Change

​

​

(in thousands)

​

​

​

Operating activities

    

$

(14,866)

    

$

(1,324)

    

$

(13,542)

Investing activities

​

 

(382,312)

​

 

(62,927)

​

 

(319,385)

Financing activities

​

 

385,585

​

 

74,151

​

 

311,434

Effect of exchange rate changes on cash and cash equivalents

​

 

1,231

​

 

8

​

 

1,223

Net change in cash and cash equivalents

​

$

(10,362)

​

$

9,908

​

$

(20,270)

​

47

Operating activities

For the year ended December 31, 2020, we used $14.9 million of cash for operations primarily as a result of the net loss of $32.7 million adjusted for non-cash expenses of $20.1 million comprised of $8.9 million of stock-based compensation, as well as $10.3 million of amortization of debt discounts, depreciation and amortization. Also contributing to the cash impact of our net operating loss, excluding non-cash items, was an increase in accounts receivable of $2.6 million, an increase in prepaids and other current assets of $7.5 million and an increase in net deferred tax assets of $0.5 million, which was partially offset by a decrease of $1.3 million in inventory and an increase in accounts payable and other accrued expenses of $4.2 million and an increase in accrued compensation and related expenses of $3.1 million.  

Investing activities

Net cash used in investing activities of $382.3 million was primarily due to the $314.5 million and $48.6 million acquisitions of the MVE and CRYOPDP businesses, respectively, on October 1, 2020,  $158.7 million purchases of short-term investments, and $8.9 million for the capitalization of software development costs for our CryoportalTM Logistics Management Platform, and additional purchases of Cryoport Express® Shippers, Smartpak IITM Condition Monitoring Systems, freezers and computer equipment, partially offset by the maturity of short-term investments of $149.2 million.

In 2019, net cash used in investing activities of $62.9 million was primarily due to the $20.3 million acquisition of the Cryogene business on May 14, 2019,  $43.2 million purchases of short-term investments, and $5.3 million for the capitalization of software development costs for our CryoportalTM Logistics Management Platform, and additional purchases of Cryoport Express® Shippers, SmartPakTM Condition Monitoring Systems, freezers and computer equipment, partially offset by the maturity of short-term investments of $6.0 million.

Financing Activity

Net cash provided by financing activities totaled $385.6 million during the year ended December 31, 2020, primarily as a result of net proceeds of $111.3 million from the issuance of 3% convertible senior notes issued in May 2020 and $265.4 million as a result of the net proceeds from the private placement of common stock and issuance of the Series C Preferred Stock. Proceeds from stock option and warrant exercises during 2020 were $9.4 million. Offsetting these activities were the payment of deferred financing costs and finance lease obligations of $4.2 million.

In 2019, net cash provided by financing activities of $74.2 million was primarily as a result of $68.8 million in net proceeds from our June 2019 public offering of common stock and $5.4 million in proceeds from the exercise of stock options and warrants.

January 2021 Public Offering

On January 25, 2021, the Company completed an underwritten public offering of 4,356,059 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement, dated January 20, 2021, by and among the Company, on the one hand, and Morgan Stanley & Co. LLC, Jefferies LLC, SVB Leerink LLC and UBS Securities LLC, as representatives of certain underwriters at a public offering price per share of $66.00, before deducting underwriting discounts and commissions. The shares include 568,181 shares issued and sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the underwriting agreement. The Company received net proceeds of approximately $269.7 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. See Note 18: “Subsequent Events” of our accompanying consolidated financial statements for additional information.

48

Blackstone Private Placement

In connection with the MVE Acquisition, on October 1, 2020, the Company completed a private placement with an investment vehicle of funds affiliated with The Blackstone Group Inc., consisting of (i) 250,000 shares of a newly designated 4.0% Series C Convertible Preferred Stock, par value $0.001 per share (“Series C Preferred Stock”), at a price of $1,000 per share, for $250.0 million, and (ii) 675,536 shares of common stock of the Company, par value $0.001 per share for $25.0 million, for an aggregate purchase price of $275.0 million. The net proceeds of this transaction were $263.6 million. The Series C Preferred Stock ranks senior to the shares of the Company’s common stock, with respect to dividend rights and rights upon the voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company.  On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Company’s 4.0% Series C Convertible Preferred Stock, resulting in the issuance of an aggregate of 1,312,860 shares of Common Stock. See Note 15: “Stockholders’ Equity—Blackstone Private Placement” and Note 18: “Subsequent Events” of our accompanying consolidated financial statements for additional information.

Convertible Senior Notes

In May 2020, the Company issued $115.0 million aggregate principal amount of 3.00% convertible senior notes due in 2025, which includes the initial purchasers’ exercise in full of their option to purchase an additional $15.0 million principal amount of the Convertible Senior Notes, in a private placement exempt from registration under the Securities Act.  The Company received $111.3 million from the offering, net of underwriting discounts and commissions of $3.7 million, and incurred approximately $345,200 in third-party offering related costs. The Convertible Senior Notes bear cash interest at a rate of 3.00%, payable semi-annually on June 1 and December 1 of each year, beginning on December 1, 2020 and will mature on June 1, 2025, unless earlier repurchased, redeemed, or converted in accordance with the terms of the Convertible Senior Notes. The Convertible Senior Notes comprise the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Convertible Senior Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.  See Note 10 : “Convertible Senior Notes” and Note 18: “Subsequent Events” of our accompanying consolidated financial statements for additional information.

June 2019 Public Offering

In June 2019, the Company completed an underwritten public offering of 4,312,500 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement, dated June 19, 2019, by and among the Company, on the one hand, and Jefferies LLC and SVB Leerink LLC, as representatives of certain underwriters at a public offering price per share of $17.00, before deducting underwriting discounts and commissions. The shares include 562,500 shares issued and sold pursuant to the Underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the Underwriting Agreement. The Company received net proceeds of approximately $68.8 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

The Company’s management recognizes that the Company may need to obtain additional capital to fund its operations until sustained profitable operations are achieved.  Additional funding plans may include obtaining additional capital through equity and/or debt funding sources.  No assurance can be given that additional capital, if needed, will be available when required or upon terms acceptable to the Company.  See “— Risks Related to Our Financial Condition —  We may need to raise additional capital in the future, and if we are unable to secure adequate funds on terms acceptable to us, we could be unable to execute our business plan” in the “Risk Factors” section in Part I, Item 1A of this Form 10-K for additional information.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

49

Impact of Inflation

From time to time, Cryoport experiences price increases from third party manufacturers and these increases cannot always be passed on to Cryoport’s customers. While these price increases have not had a material impact on Cryoport’s historical operations or profitability in the past, they could affect revenues in the future.

​

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Not applicable

​

Item 8. Financial Statements and Supplementary Data

Our annual consolidated financial statements are included in Part IV, Item 15 of this Form 10-K and are incorporated into this Item 8 by reference.

​

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

​

Item 9A. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

The term “disclosure controls and procedures” (as defined in Rule 13a-15(e) under the Exchange Act) refers to the controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2020. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2020.

(b) Management’s Report on Internal Control Over Financial Reporting.

Management’s Report on Internal Control Over Financial Reporting which appears on the following page is incorporated herein by reference.

As permitted by SEC guidance for newly acquired businesses, management’s assessment of our internal control over financial reporting (as defined in Rule 14a-15(f) and 15d-15(f) under the Exchange Act) did not include an assessment of internal control over financial reporting of MVE and CRYOPDP, which were acquired October 1, 2020.  MVE and CRYOPDP accounted for 60% and 19% of total assets 84% and 9% of net assets, respectively, as of December 31, 2020 and 29% and 16% of revenues and (5%) and 5% of net loss, respectively, for the year then ended.

Ernst & Young LLP, an independent registered public accounting firm, has audited the effectiveness of our internal control over financial reporting as of December 31, 2020, as stated in its attestation report included in Item 8. “Financial Statements and Supplementary Data” included elsewhere in this Form 10-K.

50

(c) Changes In Internal Control Over Financial Reporting

During the fourth quarter ended December 31, 2020, we began the process to extend our oversight and monitoring processes that support internal control over financial reporting to include the operations of MVE and CRYOPDP in order to assist us in the preparation and disclosure of financial information associated with these acquisitions. We are continuing to integrate the acquired operations of MVE and CRYOPDP into the Company’s overall internal control over financial reporting process. However, we have excluded MVE and CRYOPDP from our assessment of internal controls over financial reporting as set forth above. There were no other changes in our internal control over financial reporting during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

Item 9B.  Other Information

None.

​

​

51

CRYOPORT, INC.

MANAGEMENT’S REPORT ON

INTERNAL CONTROL OVER FINANCIAL REPORTING

​

The management of the Company is responsible for establishing and maintaining effective internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) and for the assessment of the effectiveness of internal control over financial reporting. The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

The Company’s internal control over financial reporting is supported by written policies and procedures that:

●pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets;
●provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Company’s management and directors; and
●provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the consolidated financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In connection with the preparation of the Company’s annual consolidated financial statements, management of the Company has undertaken an assessment of the effectiveness of the Company’s internal control over financial reporting based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management’s assessment included an evaluation of the design of the Company’s internal control over financial reporting and testing of the operational effectiveness of the Company’s internal control over financial reporting.

Based on this assessment, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2020. The Company acquired MVE Biological Solutions and CRYOPDP on October 1, 2020. MVE Biological Solutions and CRYOPDP constituted 60% and 19% of total assets and 84% and 9% of net assets, respectively, as of December 31, 2020 and 29% and 16% of revenues and (5%) and 5% of net loss in our consolidated financial statement for the fiscal year ended December 31, 2020. As these acquisitions occurred in the fourth quarter of 2020, the scope of management’s assessment of internal control over financial reporting does not include MVE Biological Solutions or CRYOPDP. This exclusion is in accordance with the SEC’s general guidance that an assessment of a recently acquired business may be omitted from our scope in the year of acquisition.

By:

/s/ JERRELL W. SHELTON

 

 

Jerrell W. Shelton,

 

 

Chief Executive Officer and Director

 

​

By:

/s/ ROBERT STEFANOVICH

 

 

Robert Stefanovich,

 

 

Chief Financial Officer

 

​

March 1, 2021

​

​

52

PART III

Item 10. Directors, Executive Officers and Corporate Governance

A list of our executive officers and their respective biographical information appears in Part I, Item 1 of this Form 10-K.

We have adopted a corporate code of conduct that applies to our directors and all employees, including our Chief Executive Officer and Chief Financial Officer. We have posted the text of our corporate code of conduct on our website at www.cryoport.com on the “Investor Relations: Corporate Governance” page under the heading “Governance Documents”.  We intend to satisfy the requirement under Item 5.05 of Form 8-K regarding disclosure of amendments to, or waivers from, provisions of our corporate code of conduct by posting such information on our website.

The other information required under this item is incorporated by reference from our definitive proxy statement related to our 2021 Annual Meeting of Stockholders, or the Proxy Statement, to be filed with the SEC within 120 days of our fiscal year ended December 31, 2020.

​

Item 11. Executive Compensation

The information required by this item can be found in our Proxy Statement and is incorporated herein by reference.

​

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this item can be found in our Proxy Statement and is incorporated herein by reference.

​

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this item can be found in our Proxy Statement and is incorporated herein by reference.

​

Item 14. Principal Accountant Fees and Services

The information required by this item can be found in our Proxy Statement and is incorporated herein by reference.

​

53

PART IV

Item 15. Exhibits and Financial Statement Schedules

(a)(1) Consolidated Financial Statements:

Page  

Reports of Independent Registered Public Accounting Firm

F-2

Consolidated Balance Sheets as of December 31, 2020 and 2019

F-6

Consolidated Statements of Operations for the years ended December 31, 2020 and 2019

F-7

Consolidated Statements of Comprehensive Loss for the years ended December 31, 2020 and 2019

F-8

Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2020 and 2019

F-9

Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019

F-10

Notes to Consolidated Financial Statements

F-11

​

(a)(2) Financial Statement Schedules: All financial statement schedules are omitted because they are not applicable or the required information is included in the Consolidated Financial Statements or notes thereto.

​

(a)(3) Exhibits.

54

Index to Exhibits

​

​

Exhibit No.  

    

Description

​

2.1˄

​

Asset Purchase Agreement, dated May 14, 2019, by and between Cryogene, Inc. and CryoGene Partners. Incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K dated May 14, 2019.

​

​

​

​

​

2.2˄

​

Purchase Agreement, dated as of August 24, 2020, by and between Cryoport, Inc. and Chart Industries, Inc.  Incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K dated August 25, 2020.  

​

 

​

 

​

3.1

​

Amended and Restated Articles of Incorporation of the Company, as amended. Incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2012.  

​

 

​

 

​

3.2

​

Amended and Restated Bylaws of the Company.  Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated February 8, 2016.

​

3.3

​

Amended and Restated Certificate of Designation of Class A Preferred Stock. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated March 30, 2015.

​

 

​

 

​

3.4

​

Certificate of Designation of Class B Preferred Stock. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated February 20, 2015.

​

 

​

 

​

3.5

​

Amendment to Certificate of Designation of Class B Preferred Stock.  Incorporated by reference to the Company’s Amendment No. 1 to Registration Statement on Form S-1 dated April 17, 2015 and referred to as Exhibit 3.6.

​

 

​

 

​

3.6

​

Certificate of Change filed with the Nevada Secretary of State on May 12, 2015.  Incorporated by reference to Exhibit 3.7 of the Company’s Annual Report on Form 10-K filed with the SEC on May 19, 2015.

​

 

​

 

​

3.7

​

Amendment to Certificate of Designation of Class A Preferred Stock. Incorporated by reference to the Company’s Amendment No. 4 to Registration Statement on Form S-1 dated June 22, 2015 and referred to as Exhibit 3.8.

​

 

​

 

​

3.8

​

 Amendment to Certificate of Designation of Class B Preferred Stock. Incorporated by reference to the Company’s Amendment No. 4 to Registration Statement on Form S-1 dated June 22, 2015 and referred to as Exhibit 3.9.

​

 

​

 

​

3.9

​

Amendment to Certificate of Designation of Class A Preferred Stock. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated September 1, 2015.

​

 

​

 

​

3.10

​

Amendment to Certificate of Designation of Class B Preferred Stock. Incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K dated September 1, 2015.

​

 

​

 

​

3.11

​

Certificate of Amendment filed with the Nevada Secretary of State on November 23, 2015. Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated November 23, 2015.

​

 

​

 

​

3.12

​

Certificate of Amendment filed with the Nevada Secretary of State on May 30, 2018.  Incorporated by reference to Exhibit 3.12 of the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2019.

​

 

​

​

​

3.13

​

Certificate of Designation of the Company.  Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K dated October 1, 2020.

​

 

​

 

​

4.1+

​

Description of the Company's securities.

​

 

​

 

​

4.2

​

Indenture, dated May 26, 2020, between Cryoport, Inc. and U.S. Bank National Association.  Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K dated May 27, 2020.

​

 

​

 

​

4.3

​

Form of 3.00% Convertible Senior Note due 2025.  Incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K dated May 27, 2020.

​

55

​

Exhibit No.  

    

Description

​

10.1*

​

2011 Stock Incentive Plan (as amended and restated).  Incorporated by reference to Exhibit B of the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on July 30, 2012.

​

 

​

 

​

10.2*

​

Stock Option Agreement dated November 5, 2012 between the Company and Jerrell Shelton. Incorporated by reference to Exhibit 10.28 to the Company’s Annual Report on Form 10-K filed with the SEC on June 25, 2013.

​

 

​

​

​

10.3*

​

Stock Option Agreement dated December 18, 2014 between the Company and Jerrell Shelton. Incorporated by reference to Exhibit 10.42 of the Company’s Annual Report on Form 10-K filed with the SEC on May 19, 2015.

​

 

​

 

​

10.4*

​

2015 Omnibus Equity Incentive Plan. Incorporated by reference to Appendix A of the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on October 1, 2015.

​

 

​

 

​

10.5*

​

Cryoport, Inc. 2018 Omnibus Equity Incentive Plan.  Incorporated by reference to Appendix A of the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 9, 2018.

​

 

​

 

​

10.6*+

​

Form of Stock Option Award Agreement under the 2018 Omnibus Equity Incentive Plan.

​

 

​

 

​

10.7*+

​

Form of Non-Qualified Stock Option Award Agreement under the 2018 Omnibus Equity Incentive Plan.

​

 

​

 

​

10.8+

​

Form of Restrictive Stock Right Award Agreement under the 2018 Omnibus Equity Incentive Plan

​

​

​

​

​

10.9*

​

Annual Management Incentive Plan.  Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated March 28, 2018.

​

 

​

 

​

10.10*

​

Employment Agreement effective as of November 1, 2019 between the Company and Robert S. Stefanovich.  Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated October 28, 2019.

​

 

​

 

​

10.11*

​

First Amendment to Employment Agreement effective as of November 1, 2019 between the Company and Jerrell W. Shelton.  Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K dated October 28, 2019.

​

 

​

 

​

10.12

​

Registration Rights Agreement, dated May 26, 2020, among Cryoport, Inc., Jefferies LLC and SVB Leerink LLC.  Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated May 27, 2020.

​

 

​

 

​

10.13

​

Securities Purchase Agreement, dated August 21, 2020, between Cryoport, Inc. and each of the Sellers identified therein.  Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated August 21, 2020.

​

 

​

​

​

10.14˄

​

Securities Purchase Agreement, dated as of August 24, 2020, by and between Cryoport, Inc. and BTO Freeze Parent L.P. Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated August 25, 2020.

​

 

​

​

​

10.15

​

Registration Rights Agreement, dated as of October 1, 2020, by and among Cryoport, Inc., BTO Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P.  Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K dated October 1, 2020.

​

 

​

​

​

10.16

​

Amendment No. 1 to Securities Purchase Agreement, dated October 1, 2020, by and among Cryoport Inc., Cryoport Netherlands B.V. and the other parties thereto.  Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K dated October 1, 2020.

​

 

​

 

​

16.1

​

Letter to Securities and Exchange Commission from KMJ Corbin & Company LLP dated August 16, 2019. Incorporated by reference to Exhibit 16.1 of the Company’s Current Report on Form 8-K dated August 20, 2019.

​

 

​

 

​

21+

​

Subsidiaries of Registrant.

​

 

​

 

​

56

​

Exhibit No.  

    

Description

​

23.1+

​

Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.

​

 

​

 

​

31.1+

​

Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.

​

 

​

 

​

31.2+

​

Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.

​

​

​

​

​

32.1+

​

Certification of Principal Executive Officer, pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.  

​

 

​

 

​

32.2+

​

Certification of Principal Financial Officer, pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.

​

 

​

 

​

101.INS+

​

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

​

 

​

 

​

101.SCH+

​

XBRL Taxonomy Extension Schema Document.

​

 

​

 

​

101.CAL+

​

XBRL Taxonomy Extension Calculation Linkbase Document.

​

 

​

 

​

101.DEF+

​

XBRL Taxonomy Extension Definition Linkbase Document.

​

 

​

 

​

101.LAB+

​

XBRL Taxonomy Extension Label Linkbase Document.

​

 

​

 

​

101.PRE+

​

XBRL Taxonomy Extension Presentation Linkbase Document.

​

 

​

​

​

104

​

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

​

˄Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) or Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies of such omitted materials supplementally upon request by the SEC.

*

Indicates a management contract or compensatory plan or arrangement.

+

Filed or furnished herewith.

​

Item 16. Form 10-K Summary

None.

​

​

57

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Cryoport, Inc.

 

 

 

 

By:

/s/ JERRELL W. SHELTON

 

 

Jerrell W. Shelton

 

 

Chief Executive Officer and Director

​

Date:  March 1, 2021

​

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

Signature

    

Title

    

Date

 

 

​

 

​

 

​

/s/ JERRELL W. SHELTON

​

Chief Executive Officer and Director

​

March 1, 2021

​

Jerrell W. Shelton  

​

 (Principal Executive Officer)  

​

 

​

 

​

 

​

 

​

/s/ ROBERT S. STEFANOVICH  

​

Chief Financial Officer

​

March 1, 2021

​

Robert S. Stefanovich  

​

 (Principal Financial and Accounting Officer)  

​

 

​

 

​

 

​

 

​

/s/ RICHARD BERMAN

​

Director

​

March 1, 2021

​

Richard Berman  

​

 

​

 

​

 

​

 

​

 

​

/s/ DANIEL M. HANCOCK

​

Director

​

March 1, 2021

​

Daniel M. Hancock  

​

 

​

 

​

 

​

 

​

 

​

/s/ ROBERT HARIRI, M.D., PH.D.  

​

Director

​

March 1, 2021

​

Robert Hariri, M.D., Ph.D.  

​

 

​

 

​

 

​

 

​

 

​

/s/ RAMKUMAR MANDALAM, PH.D.  

​

Director

​

March 1, 2021

​

Ramkumar Mandalam, Ph.D.  

​

 

​

 

​

 

​

 

​

 

​

/s/ EDWARD ZECCHINI

​

Director

​

March 1, 2021

​

Edward Zecchini  

​

 

​

 

​

 

​

​

​

​

​

/s/ RAM JAGANNATH

​

Director

​

March 1, 2021

​

Ram Jagannath

​

 

​

 

​

​

​

​

​

58

Cryoport, Inc. and Subsidiaries

Consolidated Financial Statements

As of December 31, 2020 and 2019

Years Ended December 31, 2020 and 2019

​

​

​

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Cryoport, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Cryoport, Inc. and subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March 1, 2021 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

F-2

​

​

Business Combinations

Description of the Matter

​

As described in Note 3 to the consolidated financial statements, the Company completed its acquisitions of CRYOPDP for net consideration of €49 million and MVE for net consideration of $317.4 million on October 1, 2020. Both acquisitions were accounted for as a business combination.

Auditing the Company’s accounting for its acquisitions of the entities required significant auditor judgment due to the significant estimation uncertainty in determining the fair value of identified intangible assets. The estimation uncertainty was primarily due to the complexity of the valuation models utilized by management to measure the fair value of the customer relationships and trade name/trademark intangible assets and the sensitivity of the respective fair values to the significant underlying assumptions. The significant assumptions used to estimate the value of the customer relationships and trade name/trademark intangible assets included revenue growth rates, customer attrition rates, discount rates, contributory asset charges and royalty rates.  These significant assumptions are especially challenging to audit as they are forward looking and could be affected by future economic and market conditions.

How We Addressed the Matter in Our Audit

​

We obtained an understanding, evaluated the design and tested the operating effectiveness of the Company’s controls over its accounting for acquisitions. We tested controls over the estimation process supporting the recognition and measurement of the identified intangible assets and management’s review of assumptions and completeness and accuracy of data used in the valuation models.  

To test the estimated fair values of the identified intangible assets, our audit procedures included, among others, involvement of a specialist to assist us in the evaluation of the Company’s valuation methodologies and testing of the significant assumptions. We obtained an understanding of management’s approach to developing the prospective financial information, and we compared significant assumptions including the revenue growth rates, customer attrition rates, discount rates, contributory asset charges and royalty rates and other forecast assumptions to historical, industry and market trends. Additionally, we tested the completeness and accuracy of the underlying data supporting the significant assumptions and estimates. Further, we evaluated the Company’s assumptions in light of any contrary evidence.

​

/s/ Ernst & Young LLP

​

We have served as the Company’s auditor since 2019.

​

Irvine, CA

March 1, 2021

​

​

F-3

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Cryoport, Inc.

Opinion on Internal Control Over Financial Reporting

We have audited Cryoport, Inc. and subsidiaries’ internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Cryoport, Inc. and subsidiaries’ (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.

As indicated in the accompanying Management’s Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of MVE Biological Solutions and CRYOPDP, which are included in the 2020 consolidated financial statements of the Company and constituted 60% and 19% of total assets and 84% and 9% of net assets, respectively, as of December 31, 2020 and 29% and 16% of revenues and (5%) and 5% of net loss, respectively, for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of MVE Biological Solutions or CRYOPDP.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2020, and the related notes and our report dated March 1, 2021 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

F-4

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP

​

Irvine, California

March 1, 2021

​

​

F-5

Cryoport, Inc. and Subsidiaries

Consolidated Balance Sheets

(in thousands, except share data)

​

​

​

​

​

​

​

​

​

​

​

December 31, 

​

​

2020

    

2019

ASSETS

​

​

​

​

​

​

Current Assets:

​

​

  

​

​

  

Cash and cash equivalents

​

$

36,873

​

$

47,235

Short-term investments

​

 

56,444

​

 

47,061

Accounts receivable, net of allowance for doubtful accounts of $ 1.1 million and $0.1 million, respectively

​

 

31,377

​

 

7,098

Inventories

​

 

10,535

​

 

474

Prepaid expenses and other current assets

​

 

11,928

​

 

1,097

Total current assets

​

 

147,157

​

 

102,965

Property and equipment, net

​

 

30,036

​

 

11,833

Operating lease right-of-use assets

​

​

14,044

​

​

4,460

Intangible assets, net

​

 

213,908

​

 

5,178

Goodwill

​

​

145,282

​

​

11,000

Deposits

​

 

1,184

​

 

437

Other long-term assets

​

​

794

​

​

—

Total assets

​

$

552,405

​

$

135,873

​

​

​

​

​

​

​

LIABILITIES AND STOCKHOLDERS’ EQUITY

​

 

  

​

 

  

Current Liabilities:

​

 

  

​

 

  

Accounts payable and other accrued expenses

​

$

24,844

​

$

2,498

Accrued compensation and related expenses

​

 

7,441

​

 

1,904

Deferred revenue

​

 

445

​

 

368

Operating lease liabilities

​

​

2,231

​

​

666

Finance lease liabilities

​

 

59

​

 

25

Total current liabilities

​

 

35,020

​

 

5,461

Convertible senior notes, net of discount of $3.7 million

​

 

111,344

​

 

—

Note payable

​

​

4,912

​

​

—

Operating lease liabilities, net of current portion

​

​

12,261

​

​

4,101

Finance lease liabilities, net of current portion

​

​

112

​

​

9

Deferred tax liability

​

​

5,882

​

​

21

Other long-term liabilities

​

​

176

​

​

—

Total liabilities

​

 

169,707

​

 

9,592

​

​

​

​

​

​

​

Commitments and contingencies

​

 

  

​

 

  

Stockholders’ Equity:

​

 

  

​

 

  

Preferred stock, $0.001 par value; 2,500,000 shares authorized:

​

 

  

​

 

  

Class A convertible preferred stock, $0.001 par value; 800,000 shares authorized; none issued and outstanding

​

 

—

​

 

—

Class B convertible preferred stock, $0.001 par value; 585,000 shares authorized; none issued and outstanding

​

 

—

​

 

—

Class C convertible preferred stock, $0.001 par value; 250,000 shares authorized; 250,000 issued and outstanding

​

​

2,844

​

​

—

Common stock; $0.001 par value; 100,000,000 shares authorized; 39,837,058 and 37,339,787 issued and outstanding at December 31, 2020 and 2019, respectively

​

​

40

​

​

37

Additional paid-in capital

​

 

566,451

​

 

285,609

Accumulated deficit

​

 

(192,013)

​

 

(159,320)

Accumulated other comprehensive income (loss)

​

 

5,376

​

 

(45)

Total stockholders’ equity

​

 

382,698

​

 

126,281

Total liabilities and stockholders’ equity

​

$

552,405

​

$

135,873

​

See accompanying notes to consolidated financial statements.

​

F-6

Cryoport, Inc. and Subsidiaries

Consolidated Statements of Operations

(in thousands, except share and per share data)

​

​

​

​

​

​

​

​

​

​

Years Ended

​

​

December 31, 

​

    

2020

    

2019

Service revenues

​

$

55,299

​

$

33,942

Product revenues

​

​

23,397

​

​

—

Total revenues

​

​

78,696

​

​

33,942

​

​

​

​

​

 

​

Cost of service revenues

​

 

29,521

​

​

16,590

Cost of product revenues

​

​

12,841

​

​

—

Total cost of revenues

​

​

42,362

​

​

16,590

Gross margin

​

 

36,334

​

 

17,352

​

​

 

  

​

 

  

Operating costs and expenses:

​

 

  

​

 

  

Selling, general and administrative

​

 

56,860

​

 

31,286

Engineering and development

​

 

9,484

​

 

3,741

​

​

​

​

​

​

​

Total operating costs and expenses

​

 

66,344

​

 

35,027

​

​

 

  

​

 

  

Loss from operations

​

 

(30,010)

​

 

(17,675)

Other income (expense):

​

 

  

​

 

  

Investment income

​

​

761

​

​

583

Interest expense

​

 

(2,560)

​

 

(1,367)

Other income (expense), net

​

 

(929)

​

 

189

Total other expense, net

​

​

(2,728)

​

 

(595)

Loss before provision for income taxes

​

 

(32,738)

​

 

(18,270)

Benefit from (provision for) income taxes

​

 

45

​

 

(62)

Net loss

​

$

(32,693)

​

$

(18,332)

Deemed dividend on Series C convertible preferred stock

​

​

(39,492)

​

​

—

Paid-in-kind dividend on Series C convertible preferred stock

​

​

(2,844)

​

​

—

Net loss attributable to common stockholders

​

$

(75,029)

​

$

(18,332)

Net loss per share attributable to common stockholders – basic and diluted

​

$

(1.94)

​

$

(0.55)

Weighted average common shares outstanding – basic and diluted

​

 

38,582,432

​

 

33,394,285

​

See accompanying notes to consolidated financial statements.

​

F-7

Cryoport, Inc. and Subsidiaries

Consolidated Statements of Comprehensive Loss

(in thousands)

​

​

​

​

​

​

​

​

​

​

Years Ended

​

​

December 31, 

​

    

2020

    

2019

Net loss

​

$

(32,693)

​

$

(18,332)

Other comprehensive income (loss), net of tax:

​

 

  

​

 

  

Net unrealized gain (loss) on available-for-sale debt securities

​

 

161

​

 

(28)

Reclassification of realized (gain) loss on available-for-sale debt securities to earnings

​

​

(3)

​

​

(23)

Foreign currency translation adjustments

​

 

5,263

​

 

3

Other comprehensive income (loss)

​

 

5,421

​

 

(48)

Total comprehensive loss

​

$

(27,272)

​

$

(18,380)

​

See accompanying notes to consolidated financial statements.

​

​

​

​

F-8

Cryoport, Inc. and Subsidiaries

Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Accumulated

​

​

​

​

​

Class A

​

Class B

​

Class C

​

​

​

​

​

​

Additional

​

​

​

​

Other

​

Total

​

​

Preferred Stock

​

Preferred Stock

​

Preferred Stock

​

Common Stock

​

Paid–In

​

Accumulated

​

Comprehensive

​

Stockholders'

​

    

Shares

    

Amount

    

Shares

    

Amount

​

Shares

​

Amount

    

Shares

    

Amount

​

Capital

    

Deficit

    

Income(Loss)

    

Equity (Deficit)

​

​

  

​

  

​

​

  

​

  

​

​

​

​

​

​

​

  

​

  

​

​

  

​

​

  

​

​

  

​

​

  

​

Balance at December 30, 2018

 

—

​

$

—

 

—

​

$

—

​

—

​

$

—

 

30,319,038

​

$

30

​

$

179,502

​

$

(140,988)

​

$

3

​

$

38,547

Net loss

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

—

​

 

—

​

 

—

​

 

(18,332)

​

 

—

​

 

(18,332)

Other comprehensive loss, net of taxes

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

—

​

 

—

​

 

—

​

 

—

​

 

(48)

​

 

(48)

Stock-based compensation expense

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

—

​

 

—

​

 

6,871

​

 

—

​

 

—

​

 

6,871

Accelerated stock-based compensation expense

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

—

​

 

—

​

 

9,562

​

 

—

​

 

—

​

 

9,562

Proceeds from public offering net of costs of $103,000

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

4,312,500

​

 

4

​

 

68,806

​

 

—

​

 

—

​

 

68,810

Issuance of common stock for convertible debt and accrued interest

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

1,172,305

​

 

1

​

 

15,416

​

 

—

​

 

—

​

 

15,417

Issuance of common stock for board of director compensation

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

5,753

​

 

—

​

 

91

​

 

—

​

 

—

​

 

91

Proceeds from exercise of common stock options and warrants

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

1,530,191

​

 

2

​

 

5,361

​

 

—

​

 

—

​

 

5,363

Balance at December 31, 2019

 

—

​

$

—

 

—

​

$

—

​

—

​

$

—

 

37,339,787

​

$

37

​

$

285,609

​

$

(159,320)

​

$

(45)

​

$

126,281

Net loss

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

—

​

 

—

​

 

—

​

 

(32,693)

​

 

—

​

 

(32,693)

Other comprehensive income, net of taxes

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

—

​

 

—

​

 

—

​

 

—

​

 

5,421

​

 

5,421

Stock-based compensation expense

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

—

​

 

—

​

 

8,833

​

 

—

​

 

—

​

 

8,833

Issuance of common stock for board of director compensation

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

2,869

​

​

—

​

​

83

​

​

—

​

​

—

​

​

83

Issuance of common stock in private placement, net of costs of $914,200

​

—

​

​

—

​

—

​

​

—

​

—

​

​

—

​

675,536

​

​

1

​

​

28,159

​

​

—

​

​

—

​

​

28,160

Issuance of Series C convertible preferred stock in private placement, net of costs of $7.7 million

​

—

​

​

—

​

—

​

​

—

​

250,000

​

​

—

​

—

​

​

—

​

​

237,225

​

​

—

​

​

—

​

​

237,225

Beneficial conversion feature of the Series C convertible preferred stock

​

—

​

​

—

​

—

​

​

—

​

—

​

​

(39,492)

​

—

​

​

—

​

​

39,492

​

​

—

​

​

—

​

​

—

Deemed dividend on the Series C convertible preferred stock

​

—

​

​

—

​

—

​

​

—

​

—

​

​

39,492

​

—

​

​

—

​

​

(39,492)

​

​

—

​

​

—

​

​

—

Paid-in-kind preferred stock dividend, including beneficial conversion feature

 

—

​

 

—

 

—

​

 

—

​

—

​

​

2,844

 

—

​

 

—

​

 

(2,844)

​

 

—

​

 

—

​

 

—

Proceeds from exercise of stock options and warrants

 

—

​

 

—

 

—

​

 

—

​

—

​

​

—

 

1,818,866

​

 

2

​

 

9,386

​

 

—

​

 

—

​

 

9,388

Balance at December 31, 2020

 

—

​

$

—

 

—

​

$

—

​

250,000

​

$

2,844

 

39,837,058

​

$

40

​

$

566,451

​

$

(192,013)

​

$

5,376

​

$

382,698

​

See accompanying notes to consolidated financial statements.

​

​

F-9

Cryoport, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Cash Flows From Operating Activities:

 

​

  

 

​

  

Net loss

​

$

(32,693)

​

$

(18,332)

Adjustments to reconcile net loss to net cash used in operating activities:

​

 

  

​

 

​

Depreciation and amortization

​

 

9,869

​

 

2,415

Amortization of debt discount

​

 

437

​

 

288

Interest expense on convertible note settled by issuance of common stock

​

​

—

​

​

418

Unrealized (gain) loss on investments in equity securities

​

 

(845)

​

 

102

Realized loss on investments in equity securities

​

​

1,090

​

​

—

Realized (gain) loss on available-for-sale debt securities

​

​

32

​

​

(82)

Stock-based compensation expense

​

 

8,916

​

 

6,962

Accelerated stock-based compensation expense

​

​

—

​

​

9,562

Loss on disposal of property and equipment

​

 

384

​

 

274

Provision for bad debt

​

 

197

​

 

42

Changes in operating assets and liabilities, net of effects of acquisition:

​

​

​

​

​

​

Accounts receivable

​

 

(2,617)

​

 

(3,596)

Inventories

​

 

1,322

​

 

(253)

Prepaid expenses and other current assets

​

 

(7,520)

​

 

(345)

Deposits

​

 

(152)

​

 

(86)

Change in operating lease right-of-use assets and lease liabilities

​

​

134

​

​

(6)

Accounts payable and other accrued expenses

​

 

4,245

​

 

570

Accrued compensation and related expenses

​

 

3,143

​

 

641

Deferred revenue

​

 

(309)

​

 

81

Net deferred tax (asset) liability

​

​

(499)

​

​

21

Net cash used in operating activities

​

 

(14,866)

​

 

(1,324)

​

​

 

  

​

 

​

Cash Flows From Investing Activities:

​

 

  

​

 

​

Purchases of property and equipment

​

 

(8,918)

​

 

(5,336)

Purchases of short-term investments

​

 

(158,736)

​

 

(43,196)

Sales/maturities of short-term investments

​

​

149,233

​

​

5,995

Patent and trademark costs

​

 

(200)

​

 

(73)

Software development costs

​

​

(551)

​

​

—

Cash paid for acquisitions

​

​

(363,140)

​

​

(20,317)

​

​

​

​

​

​

​

Net cash used in investing activities

​

 

(382,312)

​

 

(62,927)

​

​

 

  

​

 

​

Cash Flows From Financing Activities:

​

 

  

​

 

​

Proceeds from exercise of stock options and warrants

​

 

9,388

​

 

5,363

Proceeds from issuance of Series C convertible preferred stock, net of issuance costs

​

​

237,225

​

​

—

Proceeds from issuance of common stock, net of issuance costs

​

​

28,160

​

​

—

Proceeds from public offering, net of offering costs

​

 

—

​

 

68,811

Repayment of finance lease liabilities

​

​

(70)

​

​

(23)

Proceeds from issuance of convertible senior notes

​

​

115,000

​

​

—

Payment of deferred financing costs

​

 

(4,118)

​

 

—

​

​

​

​

​

​

​

Net cash provided by financing activities

​

 

385,585

​

 

74,151

​

​

 

​

​

 

​

Effect of exchange rate changes on cash and cash equivalents

​

 

1,231

​

 

8

Net change in cash and cash equivalents

​

​

(10,362)

​

 

9,908

Cash and cash equivalents — beginning of year

​

 

47,235

​

 

37,327

​

​

​

​

​

​

​

Cash and cash equivalents — end of year

​

$

36,873

​

$

47,235

​

​

​

​

​

​

​

Supplemental Disclosure of Cash Flow Information:

​

​

​

​

​

​

​

​

​

​

​

​

​

Cash paid for interest

​

$

1,823

​

$

707

​

​

​

​

​

​

​

Cash paid for income taxes

​

$

60

​

$

14

​

​

​

​

​

​

​

Supplemental Disclosure of Non-Cash Investing and Financing Activities:

​

​

​

​

​

​

​

​

​

​

​

​

​

Net unrealized gain (loss) on available-for-sale debt securities

​

$

161

​

$

(28)

​

​

​

​

​

​

​

Reclassification of realized gain on available-for-sale debt securities to earnings

​

$

3

​

$

23

​

​

​

​

​

​

​

Fixed assets included in accounts payable and accrued liabilities

​

$

499

​

$

261

​

​

​

​

​

​

​

Purchase of equipment through finance lease obligations

​

$

205

​

$

—

​

​

​

​

​

​

​

Paid-in-kind preferred stock dividend, including beneficial conversion feature

​

$

2,844

​

$

—

​

​

​

​

​

​

​

Common stock issued for conversion of debt and accrued interest

​

$

—

​

$

15,418

​

See accompanying notes to consolidated financial statements.

​

F-10

Cryoport, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

Note 1. Nature of the Business

Cryoport, Inc. (“Cryoport”, “we”, or “our”) is a life sciences services company that is an integral part of the temperature-controlled supply chain supporting the biopharma/pharma, animal health, and human reproductive medicine markets. We are redefining logistics for the life sciences industry by providing a unique platform of critical solutions including highly differentiated temperature-controlled supply chain solutions, which include advanced packaging, informatics, specialty logistics services, biostorage services and cryogenic life sciences equipment. Through our products, services and expertise, we enable our clients to ship, store and deliver cellular-based materials and drug products as well as other life sciences commodities in a precise, defined temperature-controlled state.

Cryoport’s advanced platform, comprised of comprehensive and technology-centric systems and solutions are designed to support the global high-volume distribution of commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA) and other international regulatory bodies for distribution in the Americas, EMEA (Europe, the Middle East, and Africa) and APAC (Asia-Pacific) regions. Cryoport’s solutions are also designed to support pre-clinical, clinical trials, Biologics License Applications (BLA), Investigational New Drug Applications (IND), New Drug Applications (NDA) and Commercialized Products with the FDA, as well as global clinical trials and commercialized products initiated in other countries, where strict regulatory compliance and quality assurance is mandated. Our industry standard setting Chain of ComplianceTM solutions, which include vital analytics, such as ‘chain-of-condition’ and ‘chain-of-custody’ information in a single data stream, empower our clients’ continuous vigilance over their respective commodities. In addition, our Chain of ComplianceTM standard ensures full traceability of all equipment used and the processes employed, further supporting each client’s goal of minimizing risk and maximizing success of their respective biologics or other products and therapies as they are introduced into the global markets.

On August 21, 2020, the Company entered into a Securities Purchase Agreement to acquire CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets, headquartered in Paris, France. Under the terms of the Securities Purchase Agreement, the Company acquired 100% of the equity interests in Advanced Therapy Logistics and Solutions, a company organized under the laws of France, which is the holding company that owns CRYOPDP (the “CRYOPDP Acquisition”). The base purchase price under the Securities Purchase Agreement was €49 million (approximately $58.0 million) and is subject to a cash, net debt, working capital and other adjustments.

On August 24, 2020, the Company entered into a Purchase Agreement with Chart Industries, Inc. (“Chart”) pursuant to which the Company acquired Chart’s MVE Biological Solutions’ cryobiological storage business (the “MVE Acquisition”) for a cash purchase price at closing of $320 million, subject to customary closing working capital and other adjustments. The MVE Acquisition was structured as the acquisition of certain equity interests and assets and the transfer of certain liabilities in connection therewith.

On October 1, 2020, the Company completed both the MVE Acquisition and the CRYOPDP Acquisition, which are further discussed in Note 3.

On May 14, 2019, the Company acquired substantially all of the assets of Cryogene Partners, a Texas general partnership doing business as Cryogene Labs (“Cryogene”).  Cryogene operates a temperature-controlled biostorage solutions business in Houston, Texas (See Note 3).

The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”

​

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

F-11

Change in Segment Reporting

The Company continually monitors and reviews its segment reporting structure in accordance with authoritative guidance to determine whether any changes have occurred that would impact its reportable operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The chief operating decision maker (“CODM”) is our Chief Executive Officer. Up until the fourth quarter of 2020, we managed, reported and evaluated our business in the following two reportable operating segments: Global Logistics Solutions and Global Bioservices. During the fourth quarter of 2020, our CODM changed how he makes operating decisions, assesses the performance of the business and allocates resources in a manner that caused our operating segments to change as a result of the MVE and CRYOPDP acquisitions. In consideration of Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”), 280, Segment Reporting, we determined that we are not organized around specific products and services, geographic regions or regulatory environments. Accordingly, beginning with the fourth quarter of 2020, we realigned our reporting structure, resulting in a single reportable segment. The Company has adjusted its financial statements for historical periods to reflect this change in segment reporting and show its financial results without segments for all periods presented.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries, Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions US LLC, and Cryoport Netherlands B.V. and subsidiaries (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.

Cash and Cash Equivalents

Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.

Short-Term Investments

Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.

Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.

Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.

Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.

F-12

Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.

Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, note payable, and the Company’s 3.00% convertible senior notes due in 2025 (the “Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, note payable and the Senior Notes, approximates fair value at December 31, 2020 due to their short-term nature. The carrying value of finance lease liabilities approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the note payable and the Senior Notes, see Note 5.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2020 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.

Our investment policy requires that purchased instruments in marketable securities may only be in highly rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.

Customers

The Company grants credit to customers within the U.S. and to international customers and does not require collateral. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables is affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at December 31, 2020, and 2019 are net of reserves for doubtful accounts of $1.1 million and $0.1 million, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.

The Company’s customers are in the biotechnology, pharmaceutical, animal health, human reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. As of December 31, 2019, there were two customers that accounted for 31.0% and 20.7%, respectively, of net accounts receivable. There were no other single customer that owed us more than 10%of net accounts receivable at December 31, 2020 and 2019.

The Company has revenue from foreign customers primarily in United Kingdom, Switzerland, France, Netherlands, Singapore, China and India. During the years ended December 31, 2020 and 2019, the Company had revenues from foreign customers of approximately $29.1 million and $5.1 million, respectively, which constituted approximately 37.0% and 15.1%, respectively, of total revenues. There  were two customers that accounted for 24.1% and 12.8% of revenues during the year ended December 31, 2019. No other single customer generated over 10% of revenues during the years ended December 31, 2020 and 2019.

F-13

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation.  We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally three to twelve years for computer hardware and software, seven to ten years for freezers, four to ten years for trucks and autos, three to fifteen years for furniture and equipment and over the shorter of the lease term or useful live of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from 20 to 45 years. Maintenance and repairs are expensed as incurred.

Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.

Leases

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.

Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received.  Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees.  Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company accounts for lease and non-lease components as a single lease component for all its leases.

Business Combinations

Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.

F-14

Goodwill

The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company compares the fair value of the reporting unit’s with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting units fair value up to the total amount of goodwill allocated to the reporting unit. The Company assessed  triggering events indicating potential goodwill impairment, including the effects of the COVID-19 pandemic, and after assessment, concluded that there was no impairment during the year ended December 31, 2020.

Intangible Assets

Intangible assets are comprised of patents, trademarks, software development costs and the intangible assets acquired in the MVE, CRYOPDP and Cryogene acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights, acquired in the MVE, CRYOPDP and Cryogene acquisitions are amortized using the straight-line method over the estimated useful lives (see Note 8). The Company uses the following valuation methodologies to value the significant intangible assets acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology.

The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. There was no impairment of intangible assets during the year ended December 31, 2020.

Other Long-lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through December 31, 2020.

Deferred Financing Costs

Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.

Income Taxes

The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, “Income Taxes”, or ASC 740. As of December 31, 2020 and 2019, there were no material unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate.

F-15

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the US based net deferred tax assets be realized. Therefore, the Company has recorded a full valuation allowance against its US based net deferred tax assets. With respect to the foreign based deferred tax assets, the Company's management has reviewed these deferred tax assets on a jurisdictional basis. Based on the weight of each jurisdiction's evidence available, the Company's management has made separate determinations for each foreign jurisdiction regarding whether it is more likely than not that a net deferred tax asset within a particular jurisdiction will be not be realized. The Company has recorded full valuation allowances in jurisdictions where deferred tax assets are not deemed more likely than not to be realized.

Additionally, the Company maintains a deferred tax liability related to indefinite-lived assets that have been netted against deferred tax assets that also allow for indefinite carryforward periods subject to limitations.  The remaining taxable temporary difference cannot serve as a source for future taxable income to realize federal net operating losses, due to the fact that post-2017 federal net operating losses are only eligible to offset  80% of income in a given year or in the case of state net operating losses, the state net operating losses will expire prior to the reversal of the taxable temporary difference.

F-16

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company has immaterial accruals for interest or penalties on its consolidated balance sheets at December 31, 2020 and 2019 and has recorded only immaterial interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2020 and 2019. The Company is subject to taxation in the U.S., various state jurisdictions and in various foreign countries. As of December 31, 2020, the Company is no longer subject to U.S. federal examinations for years before 2017 and for California franchise and income tax examinations for years before 2016. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax. The Company's subsidiary in India is currently under examination by the Indian tax authorities for 2012-2013, 2013-2014 and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local taxing authorities.

In December of 2019, the FASB issued ASU 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 31, 2020. Early adoption is permitted, including adoption in an interim period. Different components of the guidance require retrospective, modified retrospective or prospective adoption. The Company has elected to early adopt ASU 2019-12 on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.

On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. At December 31, 2020, the Company has not recorded any income tax provision/(benefit) resulting from the CARES Act mainly due the Company’s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.

On December 27, 2020, the United States enacted the Consolidated Appropriations Act of 2021 (“CAA”).  The CAA includes provisions extending certain CARES Act provisions and adds coronavirus relief, tax and health extenders. The Company will continue to evaluate the impact of the CAA and its impact on our financial statements in 2021 and beyond.

In June 29, 2020, the state of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&D credit usage for the same period (for credit usages in excess of $5M). These suspensions were considered in preparation of the 2020 financial statements.

Revenue Recognition

Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

Performance Obligations

At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to

F-17

payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.

For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.

Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.

Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within one year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.

Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying consolidated statements of operations.

Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.

Significant Payment Terms

Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15 to 60 days from the date of the invoice (except for any amounts disputed by the customer in good faith).  Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component.

Variable Consideration

When a contract includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained. Variable consideration is estimated at the most likely amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Variable consideration estimates are updated at each reporting date. Revenues are recorded net of variable consideration, such as discounts and allowances.

Warranties

The Company provides product warranties with varying terms and durations for some of its products. The Company estimates product warranty costs and accrues for these costs as products are sold with a charge to cost of sales. Factors considered in estimating warranty costs include historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside of typical experience. Warranty accruals are evaluated and adjusted as necessary based on actual claims experience and changes in future claim and cost estimates.

Product warranty accrued liabilities totaled $0.2 million and $0 at December 31, 2020 and 2019, respectively, and are included in accounts payable and other accrued expenses. Warranty expense was not material for the years ended December 31, 2020 and 2019.

F-18

Incremental Direct Costs

Incremental direct costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as promised goods and services are transferred to a customer. Incremental direct costs were not material for the years ended December 31, 2020 and 2019.

Contract Assets

Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable, which are recognized when payment is unconditional and only the passage of time is required before payment is due. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed.

Contract Liabilities (Deferred Revenue)

Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $0.4 million at December 31, 2020 and 2019. During the years ended December 31, 2020 and 2019, the Company recognized revenues of $0.4 million and $0.1 million from the related contract liabilities outstanding as the services were performed.

Nature of Goods and Services

The Company provides Cryoport Express® Shippers to its customers and charges a fee in exchange for the use of the Cryoport Express® Shipper under long-term master service agreements with customers. The Company’s arrangements convey to the customers the right to use the Cryoport Express® Shippers over a period of time. The Company retains title to the Cryoport Express® Shippers and provides its customers the use of the Cryoport Express® Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Cryoport Express® Shipper is returned to the Company.

The Company recognizes revenue for the use of the Cryoport Express® Shippers at the time of the delivery of the Cryoport Express® Shipper to the end user of the enclosed materials, and at the time that collectability is probable.

The Company also provides vacuum insulated aluminum dewars and cryogenic freezers systems to its customers. Revenue is recognized when the Company satisfies performance obligations by transferring the equipment to a customer, and at the time that collectability is probable.

The Company also provides global temperature-controlled logistics services, support and management. Revenue is recognized for these services as services are rendered and at the time that collectability is probable.

The Company also provides comprehensive and integrated temperature-controlled biostorage solutions to customers in the life sciences industry and charges a fee under long-term master service agreements with customers. These services include (1) biological specimen cryopreservation storage and maintenance, (2) archiving, monitoring, tracking, receipt and delivery of samples, (3) transport of frozen biological specimens to and from customer locations, and (4) management of incoming and outgoing biological specimens. The Company recognizes revenue for its biostorage solutions as services are rendered over time and at the time that collectability is probable.

The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services over time as the customer simultaneously receives and consumes the benefit of these services as they are performed.

A significant portion of our revenues are covered under long-term agreements. We have determined that individual Statements of Work or Scope of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle) for the Cryoport Express® solutions and up to 12 months for biostorage solutions. Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services.  Prices under these agreements are generally fixed.

F-19

Revenue Disaggregation

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major markets for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Biopharma/Pharma

​

$

66,394

​

$

30,032

Animal Health

​

 

7,846

​

 

996

Human Reproductive Medicine

​

​

4,456

​

​

2,914

Total revenues

​

$

78,696

​

$

33,942

​

Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the years ended December 31, 2020 and 2019, were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Americas

​

$

49,555

​

$

28,801

Europe, the Middle East and Africa (EMEA)

​

 

20,316

​

 

4,523

Asia Pacific (APAC)

​

 

8,825

​

 

618

Total revenues

​

$

78,696

​

$

33,942

​

Cost of Services Revenues

Our cost of services revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions.

Cost of Product Revenues

Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.

Engineering and Development Expenses

Expenditures relating to engineering and development are expensed in the period incurred to engineering and development expense in the consolidated statements of operations.

Acquisition Costs

Acquisition costs consist of legal, accounting, third-party valuations, and other due diligence costs related to our MVE, CRYOPDP, and Cryogene acquisitions (See Note 3).

F-20

Stock-Based Compensation

The Company accounts for stock-based payments in accordance with stock-based payment accounting guidance which requires all stock-based payments to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.  The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and expected term. The Company accounts for forfeitures of unvested awards as they occur.

The Company’s stock-based compensation plans are discussed further in Note 16.

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

Issuances of the Company’s common stock for acquiring goods or services are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the estimated fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current estimated fair values.

Basic and Diluted Net Loss Per Share

We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt outstanding during the periods.

The following shows the amounts used in computing net loss per share (in thousands except per share data):

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Net loss

​

$

(32,693)

​

$

(18,332)

Deemed dividend on Series C convertible preferred stock

​

​

(39,492)

​

​

—

Paid-in-kind dividend on Series C convertible preferred stock

​

 

(2,844)

​

 

—

Net loss attributable to common shareholders

​

$

(75,029)

​

$

(18,332)

Weighted average common shares outstanding - basic and diluted

​

​

38,582,432

​

​

33,394,285

Basic and diluted net loss per share

​

$

(1.94)

​

$

(0.55)

​

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Stock options

​

5,920,886

 

3,636,806

Warrants

​

—

 

753,211

Series C convertible preferred stock

​

6,474,135

​

—

Convertible senior notes

​

4,810,002

 

—

​

​

17,205,023

 

4,390,017

​

Foreign Currency Transactions

Management has determined that the functional currency of its subsidiaries is the local currency.  The Company translates the assets and liabilities of its foreign subsidiaries into U.S. dollars at exchange rates in effect at the end of the reporting period.  Income

F-21

and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity.  The translation gain (loss) adjustment totaled $5.2 million and 2,900 for the years ended December 31, 2020 and 2019, respectively.  Foreign currency gains and losses from transactions denominated in other than respective local currencies are included in earnings.

Off Balance Sheet Arrangements

We do not currently have any off balance sheet arrangements.

Reclassification

Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.

Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of U.S. GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income).  ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12 on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.  

In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement," which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. We adopted this guidance on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.

In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which is intended to simplify the subsequent accounting for goodwill acquired in a business combination. Prior guidance required utilizing a two-step process to review goodwill for impairment. A second step was required if there was an indication that an impairment may exist, and the second step required calculating the potential impairment by comparing the implied fair value of the reporting unit's goodwill (as if purchase accounting were performed on the testing date) with the carrying amount of the goodwill. The new guidance eliminates the second step from the goodwill impairment test. Under the new guidance, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount, and then recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value (although the loss should not exceed the total amount of goodwill allocated to the reporting unit). The guidance requires prospective adoption and is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019.  We adopted this guidance on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.

Accounting Guidance Issued but Not Adopted at December 31, 2020

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new

F-22

guidance also requires the if-converted method to be applied for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted in fiscal years beginning after December 15, 2020. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. In November 2019, the FASB issued ASU 2019-10 "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which deferred the effective date of ASU 2016-13 by three years for smaller reporting companies. The one-time determination of whether an entity is eligible to be a smaller reporting company is based on the entity's most recent determination as of November 15, 2019 in accordance with SEC regulations.  As a result, ASU 2016-13, as subsequently amended, is effective for the Company for fiscal years beginning after December 15, 2022 based on the Company's smaller reporting company determination as of November 15, 2019.  We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.  The Company currently believes the main impact of the new standard will relate to the Company’s assessment of its allowance for doubtful accounts on trade receivables.

​

​

Note 3. Acquisitions

2020 Acquisitions – CRYOPDP and MVE

CRYOPDP Acquisition

On October 1, 2020, the Company completed its acquisition of CRYOPDP for a cash consideration of €48.3 million ($57.0 million, the “CRYOPDP Acquisition”). This acquisition was funded with existing cash on hand. CRYOPDP, based in France, is a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets. CRYOPDP conducts its business activities in the Americas, EMEA and APAC. As a result of the CRYOPDP Acquisition, the Company has extended its solutions to include broader temperature-controlled logistics and specialty courier services and has significantly expanded its global network through CRYOPDP’s 22 facilities in 12 countries.

The CRYOPDP Acquisition was accounted for under the acquisition method of accounting in accordance with FASB ASC Topic 805, “Business Combinations,” and, therefore, the total purchase price was allocated to the identifiable tangible and intangible assets acquired and the liabilities assumed based on their respective fair values on the acquisition date. Fair values were determined by management based in part on an independent valuation performed by a third-party valuation specialist and required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable; however, actual results may differ from these estimates.

F-23

The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):

​

​

​

​

Total purchase consideration paid

    

$

56,971

​

​

​

​

Purchase price allocation:

​

 

  

Cash and cash equivalents

​

 

8,346

Accounts receivable

​

 

10,603

Inventories

​

 

644

Prepaid and other current assets

​

 

2,905

Property and equipment

​

 

2,863

Operating lease right-of-use assets

​

 

1,856

Intangible assets

​

 

28,235

Other long-term assets

​

 

569

Accounts payable and other accrued expenses

​

 

(11,110)

Accrued compensation and related expenses

​

​

(1,194)

Deferred revenue

​

​

(370)

Note payable

​

​

(4,690)

Operating lease liabilities

​

 

(1,856)

Deferred tax liability

​

 

(5,311)

Other long-term liabilities

​

 

(64)

Total identifiable net assets

​

 

31,426

Goodwill

​

 

25,545

​

​

$

56,971

​

The following table summarizes the estimated fair values of CRYOPDP’s identifiable intangible assets at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

    

    

    

    

Annual

​

​

Estimated

​

Estimated

​

Amortization

​

Amortization

​

​

Fair Value

​

Useful Life

​

Method

​

Expense

Software

​

$

3,578

 

7

 

Straight-line

​

$

511

Customer relationships

​

 

5,871

 

11.5

 

Straight-line

​

 

511

Agent network

​

 

8,219

 

4

 

Straight-line

​

 

2,055

Trade name/trademarks

​

 

10,567

 

Indefinite

 

—

​

 

—

Total

​

$

28,235

​

​

​

​

​

$

3,077

​

Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Among the factors that contributed to a purchase price in excess of the fair value of the net tangible and intangible assets acquired were the acquisition of an assembled workforce, the expected synergies, and other benefits that we believe will result from combining the operations of CRYOPDP with our operations. The goodwill recognized of $25.5 million is not expected to be deductible for income tax purposes.

Our estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management’s analysis related to certain matters, including income taxes, accounts receivable, note payable and other accounts and certain valuation balances. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. Although the final determination may result in asset and liability fair values that are different than the preliminary estimates of these amounts included herein, it is not expected that those differences will be material to our consolidated financial position.

Acquisition-related transaction costs (included in selling, general and administrative expenses) totaled approximately $1.4 million.

F-24

MVE Acquisition

On October 1, 2020, the Company completed its acquisition of Chart Industries, Inc.’s MVE cryobiological storage business (the “MVE Acquisition”) for a cash consideration of $317.5 million, subject to customary closing working capital and other adjustments. The Company financed a portion of the closing cash payment of the MVE Acquisition with the net proceeds of the Blackstone Private Placement, as further discussed in Note 13. MVE is a global leader in manufactured vacuum insulated products and cryogenic freezer systems for the life sciences industry. MVE has manufacturing and distribution operations in the Americas, EMEA and APAC. As a result of the MVE Acquisition, the Company has extended its integrated logistics solutions to provide a broad range of cryogenic dewars and freezers to the life sciences industry.

The MVE Acquisition was accounted for under the acquisition method of accounting in accordance with FASB ASC Topic 805, “Business Combinations,” and, therefore, the total purchase price was allocated to the identifiable tangible and intangible assets acquired and the liabilities assumed based on their respective fair values on the acquisition date. Fair values were determined by management based in part on an independent valuation performed by a third-party valuation specialist and required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable; however, actual results may differ from these estimates.

The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):

​

​

​

​

Total purchase consideration paid

    

$

317,470

​

​

​

​

Purchase price allocation:

​

 

  

Cash and cash equivalents

​

 

2,955

Accounts receivable

​

 

10,645

Inventories

​

 

10,627

Prepaid and other current assets

​

 

256

Property and equipment

​

 

9,050

Operating lease right-of-use assets

​

 

2,154

Intangible assets

​

 

184,991

Other long-term assets

​

 

358

Accounts payable and other accrued expenses

​

 

(6,036)

Accrued compensation and related expenses

​

​

(1,139)

Operating lease liabilities

​

 

(2,160)

Deferred tax liability

​

 

(393)

Other long-term liabilities

​

 

(64)

Total identifiable net assets

​

 

211,244

Goodwill

​

 

106,226

​

​

$

317,470

​

The following table summarizes the estimated fair values of MVE’s identifiable intangible assets and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

    

​

​

    

  

    

  

    

Annual

​

​

Estimated

​

Estimated

​

Amortization

​

Amortization

​

​

Fair Value

​

Useful Life

​

Method

​

Expense

Order backlog

 

​

2,600

 

0.125

 

Straight-line

​

$

—

Customer relationships

 

​

118,600

 

14.5

 

Straight-line

​

 

8,179

Developed technology

 

​

28,700

 

12

 

Straight-line

​

 

2,392

Land use rights

 

​

2,291

 

38

 

Straight-line

​

 

63

Trade name/trademarks

 

​

32,800

 

Indefinite

 

—

​

 

—

Total

​

$

184,991

​

​

​

​

​

$

10,634

​

F-25

Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Among the factors that contributed to a purchase price in excess of the fair value of the net tangible and intangible assets acquired were the acquisition of an assembled workforce, the expected synergies, and other benefits that we believe will result from combining the operations of MVE with our operations. Of the $106.2 million goodwill recognized, approximately $62.5 million is allocated to the U.S. and Germany and is expected to be deductible for income tax purposes.

Our estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management’s analysis related to certain matters, including income taxes and certain other accounts and certain valuation balances. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. Although the final determination may result in asset and liability fair values that are different than the preliminary estimates of these amounts included herein, it is not expected that those differences will be material to our consolidated financial position.

Acquisition-related transaction costs (included in selling, general and administrative expenses) totaled approximately $8.8 million.

Revenue, Net Income and Pro Forma Presentation – CRYOPDP and MVE Acquisitions

The operating results of the CRYOPDP and MVE acquisitions have been included in our consolidated financial statements from the acquisition date through December 31, 2020. Our results for the year ended December 31, 2020, include revenue for CRYOPDP of $12.9 million and net loss of $1.8 million and revenue for MVE of $23.0 million and net income of $1.8 million.

The following unaudited pro forma information presents our combined results as if the CRYOPDP and MVE acquisitions had occurred on January 1, 2019. The unaudited pro forma financial information was prepared to give effect to events that are (1) directly attributable to the acquisition, (2) factually supportable, and (3) expected to have a continuing impact on the combined company’s results. The 2019 period includes the elimination of revenues of $1.8 million and related cost of goods sold of $0.9 million recorded by MVE from the Company. There were no transactions between the Company and CRYOPDP during the periods presented that are required to be eliminated. The unaudited pro forma combined financial information does not reflect any cost savings, operating synergies, or revenue enhancements that the combined companies may achieve as a result of the acquisitions or the costs to integrate the operations or the costs necessary to achieve cost savings, operating synergies, or revenue enhancements.

The following table presents the unaudited, pro forma consolidated results of operations for the year ended December 31, 2020 and 2019 as if the acquisition of the assets of CRYOPDP and MVE had occurred as of January 1, 2019.  The pro forma information provided below is compiled from the audited financial statements of CRYOPDP and MVE, which includes pro forma adjustments for intangible assets amortization expense and depreciation expense on the step up in fair value of property and equipment.

​

​

​

​

​

​

​

​

​

    

Year Ended

    

Year Ended

(in thousands except per share data)

​

December 31, 2020

​

December 31, 2019

​

​

(unaudited)

​

(unaudited)

Revenues

​

$

172,147

​

$

163,217

Net loss

​

$

(18,562)

​

$

(3,149)

Basic and diluted net loss per share

​

$

(2.08)

​

$

(0.09)

​

The pro forma results are not necessarily indicative of the consolidated results of operations that we would have reported had the acquisitions been completed as of January 1, 2019 and should not be taken as representative of our consolidated results of operations following the acquisitions. In addition, the unaudited proforma consolidated financial information is not intended to project the future results of operations of the Company.

Acquisition – Cryogene Partners

On May 14, 2019, Cryogene, Inc., a Texas corporation and a wholly owned subsidiary of the Company, entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) for the acquisition of the assets of Cryogene Partners, a Texas general partnership doing business as Cryogene Labs (“Cryogene”). The closing of the transaction contemplated in the Asset Purchase Agreement occurred simultaneously with the execution of the Asset Purchase Agreement on May 14, 2019.

F-26

Pursuant to the terms and subject to the conditions of the Asset Purchase Agreement, the Company acquired substantially all of the assets of Cryogene, including, without limitation, tangible personal property, intellectual property assets, and certain contracts related to Cryogene’s temperature-controlled biostorage solutions business located in Houston, Texas (the foregoing, the “Purchased Assets”), and assumed certain related liabilities.

The aggregate purchase price for the Purchased Assets was $20.3 million in cash.

As a result of this acquisition, the Company has extended its integrated logistics solutions and services to provide comprehensive temperature-controlled sample management solutions to the life sciences industry, including specimen storage, sample processing, collection, and retrieval.

Purchase Price Allocation

We funded this acquisition through available cash and accounted for it as an acquisition of a business in accordance with FASB ASC Topic 805, “Business Combinations”.  Assets acquired and liabilities assumed in connection with the acquisition have been recorded at their fair values.  Fair values were determined by management based in part on an independent valuation performed by a third-party valuation specialist.  The Company has performed a valuation analysis of the fair value of Cryogene’s assets and liabilities.  The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):

​

​

​

​

​

Total purchase price

    

$

20,317

​

​

​

​

Purchase price allocation:

​

 

  

Property and equipment

​

 

4,257

Intangible assets

​

 

5,280

Deferred revenue

​

 

(220)

Total identifiable net assets

​

 

9,317

Goodwill

​

 

11,000

​

​

$

20,317

​

The following table summarizes the fair value of intangible assets acquired at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Annual

​

    

Estimated

    

Estimated

    

Amortization

    

Amortization

​

​

Fair Value

​

Useful Life

​

Method

​

Expense

Non-compete agreement

​

$

390

 

5

 

Straight-line

​

$

78

Technology

​

 

510

 

5

 

Straight-line

​

 

102

Customer relationships

​

 

3,900

 

12

 

Straight-line

​

 

325

Trade name/trademark

​

 

480

 

15

 

Straight-line

​

 

32

Total

​

$

5,280

​

​

​

​

​

$

537

​

Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Among the factors that contributed to a purchase price in excess of the fair value of the net tangible and intangible assets acquired were the acquisition of an assembled workforce, the expected synergies, and other benefits that we believe will result from combining the operations of Cryogene with our operations. The goodwill recognized of $11.0 million is expected to be deductible for income tax purposes.

Acquisition-related transaction costs (included in selling, general and administrative expenses) totaled approximately $0.3 million.

The operating results of the Cryogene acquisition have been included in our consolidated financial statements from the acquisition date through December 31, 2019. Our results for the year ended December 31, 2020 and 2019, include Cryogene sales of $3.0 million and net income of $437,100.

​

F-27

Note 4. Cash, Cash Equivalents and Short-term Investments

Cash, cash equivalents and short-term investments consisted of the following as of December 31, 2019 and 2018 (in thousands):

​

​

​

​

​

​

​

​

​

​

Carrying Value

​

    

2020

    

2019

Cash

​

$

25,053

​

$

3,547

Cash equivalents:

​

 

​

​

​

​

Money market mutual funds

​

 

11,820

​

​

43,688

Total cash and cash equivalents

​

 

36,873

​

​

47,235

Short-term investments:

​

 

​

​

​

​

U.S. Treasury notes and bills

​

 

23,309

​

​

21,094

Mutual funds

​

 

33,135

​

​

25,967

Total short-term investments

​

 

56,444

​

​

47,061

Cash, cash equivalents and short-term investments

​

$

93,317

​

$

94,296

​

Available-for-sale debt securities

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale debt securities by type of security at December 31, 2020 were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Amortized

    

Unrealized

    

Unrealized

    

​

​

​

​

Cost

​

Gains

​

Losses

​

Fair Value

U.S. Treasury notes

​

$

23,179

​

$

173

​

$

(43)

​

$

23,309

Total available-for-sale investments

​

$

23,179

​

$

173

​

$

(43)

​

$

23,309

​

The following table summarizes the fair value of available-for-sale debt securities based on stated contractual maturities as of December 31, 2020 (in thousands):

​

​

​

​

​

​

​

​

​

    

Amortized Cost

    

Fair Value

Due within one year

​

$

14,084

​

$

14,111

Due between one and two years

​

 

9,095

​

 

9,198

​

​

​

​

​

​

​

Total

​

$

23,179

​

$

23,309

​

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale debt securities by type of security at December 31, 2019 were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Amortized 

    

Unrealized 

    

Unrealized 

    

​

​

​

​

Cost

​

Gains

​

Losses

​

Fair Value

U.S. Treasury notes and bills

​

$

21,122

 

$

26

 

$

(54)

​

$

21,094

Total available-for-sale investments

​

$

21,122

 

$

26

​

$

(54)

​

$

21,094

​

The following table summarizes the fair value of available-for-sale debt securities based on stated contractual maturities as of December 31, 2019 (in thousands):

​

​

​

​

​

​

​

​

​

    

Amortized Cost

    

Fair Value

Due within one year

​

$

12,044

 

$

12,047

Due between one and two years

​

 

9,078

 

 

9,047

Total

​

$

21,122

 

$

21,094

​

There were no individual securities that have been in a continuous loss position of 12 months or greater as of December 31, 2019.

F-28

The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.

We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis, as well as adverse conditions related specifically to the security such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security.

During the years ended December 31, 2020 and 2019, we had $32,400 and $81,700 realized losses on available-for-sale investments, respectively.

Equity Investments

We held investments in equity securities with readily determinable fair values of $33.1 million and $26.0 million at December 31, 2020 and 2019, respectively. These investments consist of mutual funds that invest primarily in tax free municipal bonds and treasury inflation protected securities.

Unrealized gains (losses) during 2020 and 2019 related to equity securities held at December 31, 2020 and 2019 are as follows (in thousands):

​

​

​

​

​

​

​

​

​

    

2020

    

2019

Net losses recognized during the year on equity securities

​

$

(245)

​

$

(102)

Less: net losses recognized during the year on equity securities sold during the year

​

 

(1,090)

​

​

—

Unrealized gains (losses) recognized during the year on equity securities still held at December 31, 2020 and 2019

​

$

845

​

$

(102)

​

​

Note 5. Fair Value Measurements

We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.

We did not elect the fair value option, as allowed, to account for financial assets and liabilities that were not previously carried at fair value. Therefore, material financial assets and liabilities that are not carried at fair value, such as trade accounts receivable and payable, are reported at their historical carrying values.

F-29

The carrying values of our assets that are required to be measured at fair value on a recurring basis as of December 31, 2020 and 2019 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Fair Value Measurements

​

    

Level 1

    

Level 2

    

Level 3

    

Total

December 31, 2020

 

​

  

 

​

  

 

​

  

 

​

  

Cash equivalents:

 

​

  

 

​

  

 

​

  

 

​

  

Money market mutual fund

​

$

11,820

​

$

—

​

$

—

​

$

11,820

Marketable equity securities:

​

 

  

​

 

  

​

 

  

​

 

  

Mutual funds

​

 

33,135

​

 

—

​

 

—

​

 

33,135

Available-for-sale debt securities:

​

 

​

​

 

  

​

 

  

​

 

​

U.S. Treasury notes

​

 

23,309

​

 

—

​

 

—

​

 

23,309

​

​

$

68,264

​

$

—

​

$

—

​

$

68,264

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Fair Value Measurements 

​

 

Level 1

 

Level 2

 

Level 3

 

Total

December 31, 2019

    

​

  

    

​

  

    

​

  

    

​

  

Cash equivalents:

 

​

  

 

​

  

 

​

  

 

​

  

Money market mutual fund

​

$

43,688

​

$

—

​

$

—

​

$

43,688

Marketable equity securities:

​

 

  

​

 

  

​

 

  

​

 

  

Mutual funds

​

 

25,967

​

 

—

​

 

—

​

 

25,967

Available-for-sale debt securities:

​

 

  

​

 

  

​

 

  

​

 

  

U.S. Treasury notes

​

 

21,094

​

 

—

​

 

—

​

 

21,094

​

​

$

90,749

​

$

—

​

$

—

​

$

90,749

​

Our equity securities and available-for-sale debt securities, including U.S. treasury notes are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.

We did not have any financial liabilities measured at fair value on a recurring basis as of December 31, 2020.

We carry the convertible senior notes (see Note 10) at face value less the unamortized discount and issuance costs on our consolidated balance sheets and present fair value for disclosure purposes only. As of December 31, 2020, the estimated fair value of the Notes was $108.2 million and was determined using the net present value of the payments, discounted at an interest rate that is consistent with market and risk-adjusted interest rates, which is a Level 2 input.

​

Note 6. Inventories

Inventories consist of the following (in thousands):

​

​

​

​

​

​

​

​

​

    

December 31, 

    

December 31, 

​

​

2020

​

2019

Raw materials

​

$

7,544

​

$

357

Work-in-process

​

​

227

​

​

—

Finished goods

​

 

2,764

​

 

117

​

​

$

10,535

​

$

474

​

​

The inventory balance at December 31, 2020 includes an $0.8 million step up in inventory related to the acquisition of MVE.

​

F-30

Note 7. Property and Equipment

Property and equipment consist of the following (in thousands):

​

​

​

​

​

​

​

​

​

    

December 31, 

    

December 31, 

​

​

2020

​

2019

Cryogenic shippers and data loggers

​

$

5,625

​

$

4,296

Freezers

​

​

4,473

​

​

3,414

Furniture and fixtures

​

 

2,727

​

 

291

Computers and software

​

 

1,469

​

 

646

Machinery and equipment

​

 

11,998

​

 

1,093

Trucks and autos

​

​

437

​

​

37

Leasehold improvements

​

 

4,599

​

 

2,246

Buildings

​

​

5,359

​

​

—

Land

​

​

790

​

​

—

Fixed assets in process

​

 

8,070

​

 

3,407

​

​

 

45,547

​

 

15,430

Less accumulated depreciation and amortization

​

 

(15,511)

​

 

(3,597)

​

​

$

30,036

​

$

11,833

​

Total depreciation and amortization expense related to property and equipment amounted to $3.2 million and $2.1 million for the years ended December 31, 2020 and 2019, respectively.

The Company leases equipment under finance leases, with a total cost of $279,400 and $71,000, respectively, and accumulated amortization of $78,700 and $22,800 as of December 31, 2020 and 2019, respectively.

​

Note 8. Goodwill and Intangible Assets

Goodwill

The following table represents the changes in the carrying value of goodwill for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

    

December 31

    

December 31,

​

​

2020

​

2019

Balance at beginning of year

​

$

11,000

​

$

—

Goodwill related to Cryogene acquisition

​

 

—

​

 

11,000

Goodwill related to MVE acquisition

​

 

107,504

​

 

—

Goodwill related to CRYOPDP acquisition

​

 

26,778

​

 

—

Balance at end of year

​

$

145,282

​

$

11,000

​

F-31

Intangible Assets

The following table presents our intangible assets as of December 31, 2020 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

​

Net

​

Average

​

​

Gross

​

Accumulated

​

Carrying

​

Amortization

​

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

​

$

390

​

$

123

​

$

267

 

3

Technology

​

​

34,245

​

​

1,630

​

​

32,615

​

11

Customer relationships

​

​

128,640

​

​

2,708

​

​

125,932

​

14

Cryogene trade name/trademark

​

​

480

​

​

51

​

​

429

​

13

CRYOPDP agent network

​

​

8,597

​

​

537

​

​

8,060

​

4

MVE Order backlog

​

​

2,600

​

​

2,600

​

​

—

​

—

MVE land use rights

​

​

2,378

​

​

16

​

​

2,362

​

37

Patents and trademarks

​

​

44,312

​

​

69

​

​

44,243

​

—

Total

​

$

221,642

​

$

7,734

​

$

213,908

​

​

​

The following table presents our intangible assets as of December 31, 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

​

Net

​

Average

​

​

Gross

​

Accumulated

​

Carrying

​

Amortization

​

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

​

$

390

​

$

45

​

$

345

 

5

Technology

​

​

510

​

​

59

​

​

451

​

5

Customer relationships

​

​

3,900

​

​

190

​

​

3,710

​

12

Cryogene trade name/trademark

​

​

480

​

​

19

​

​

461

​

15

Cryoport patents and trademarks

​

​

258

​

​

47

​

​

211

 

—

Total

​

$

5,538

​

$

360

​

$

5,178

​

​

​

Amortization expense for intangible assets for the years ended December 31, 2020 and 2019 was $6.6 million and $0.3 million, respectively.

​

Expected future amortization of intangible assets as of December 31, 2020 is as follows (in thousands):

​

​

​

​

​

Years Ending December 31, 

    

Amount

2021

​

 

14,438

2022

​

 

14,438

2023

​

 

14,438

2024

​

 

13,795

2025

​

 

12,108

Thereafter

​

 

100,124

​

​

$

169,341

​

​

Note 9. Accrued Compensation and Related Expenses

Accrued compensation and related expenses consist of the following (in thousands):

​

​

​

​

​

​

​

​

​

    

December 31, 

    

December 31, 

​

​

2020

​

2019

Accrued salaries and wages

​

$

6,048

​

$

1,386

Accrued paid time off

​

 

1,393

​

 

518

​

​

$

7,441

​

$

1,904

​

F-32

​

Note 10. Convertible Senior Notes

In May 2020, the Company issued $115.0 million aggregate principal amount of 3.00% convertible senior notes due in 2025 (the "Senior Notes"), which includes the initial purchasers’ exercise in full of their option to purchase an additional $15.0 million principal amount of the Senior Notes, in a private placement exempt from registration under the Securities Act of 1933. The Senior Notes are governed by an indenture (the “Indenture”) dated May 26, 2020 between the Company, as issuer, and U.S. Bank National Association, as trustee (the “Trustee”). The Company received $111.3 million from the offering, net of underwriting discounts and commissions of $3.7 million, and incurred approximately $0.3 million in third-party offering related costs. The Senior Notes bear cash interest at a rate of 3.00%, payable semi-annually on June 1 and December 1 of each year, beginning on December 1, 2020 and will mature on June 1, 2025, unless earlier repurchased, redeemed, or converted in accordance with the terms of the Senior Notes. At December 31, 2020, accrued interest of $0.3 million is included in accounts payable and accrued liabilities in the accompanying consolidated financial statements.  The Notes comprise the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Senior Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.

At any time before the close of business on the scheduled trading day immediately before the maturity date, holders of the Senior Notes may convert their Senior Notes at their option into shares of the Company’s common stock. The Senior Notes are initially convertible into approximately 4,810,002 shares of the Company’s common stock based on the initial conversion rate of 41.8261 shares of the Company’s common stock per $1,000 principal amount of the Senior Notes, which represents an initial conversion price of approximately $23.91 per share of the Company’s common stock. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Also, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time and is determined by reference to a make-whole table set forth in the Indenture governing the Senior Notes. However, in no event will the conversion rate be increased to an amount that exceeds 48.10 shares of the Company’s common stock per $1,000 principal amount of Senior Notes. In addition, the holders of the Senior Notes may require the Company to repurchase the Senior Notes at par value plus accrued and unpaid interest following the occurrence of a “Fundamental Change” (as described in the Indenture).

On or after June 5, 2023, we may redeem the Senior Notes at our option, in whole and not in part, at a cash redemption price equal to the principal amount of the Senior Notes to be redeemed, plus accrued and unpaid interest, if any, if:

(1)The last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company send the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice; and
(2)A registration statement covering the resale of the shares of the Company’s common stock issuable upon conversion of the Senior Notes is effective and available for use and is expected to remain effective and available during the redemption period as of the date the redemption notice is sent.

The Senior Notes contain customary terms and events of default. If an event of default arising out of certain events of bankruptcy, insolvency, or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to the Company, the principal amount of the Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable. If any other event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding Senior Notes may declare the principal amount of the Senior Notes to be due and payable immediately by notice to the Company. There were no events of default at December 31, 2020.

F-33

The Senior Notes are accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options (“ASC 470-20”) and ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”). Under ASC 815-40, to qualify for equity classification (or nonbifurcation, if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer’s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company’s analysis, it was determined the Senior Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20, the proceeds received from the issuance of the convertible debt was recorded as a liability on the consolidated balance sheet.

The Company incurred approximately $4.1 million of debt issuance costs relating to the issuance of the Senior Notes, which were recorded as a reduction to the Senior Notes on the consolidated balance sheet. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Senior Notes using the effective interest rate method. We determined the expected life of the debt is equal to the five-year term of the Senior Notes. The effective interest rate on the Senior Notes is 3.74%.

Senior Notes payable consisted of the following at December 31, 2020 (in thousands):

​

​

​

​

​

    

December 31, 2020

Principal amount of Senior Notes

​

$

115,000

Unamortized debt issuance costs

​

 

(3,656)

Net carrying value of Senior Notes payable

​

$

111,344

​

Interest expense incurred in connection with the Notes consisted of the following for the year ended December 31, 2020 (in thousands):

​

​

​

​

​

    

Year Ended

​

​

December 31, 2020

Coupon interest

​

$

2,108

Amortization of debt issuance costs

​

​

437

Total interest expense on Senior Notes

​

$

2,545

​

The Company’s Senior Notes payable of $115.0 are due and payable in 2025.

In connection with the issuance of the Senior Notes, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) to use its best efforts to file a registration statement for the resale of the Senior Notes and the shares of the Company’s common stock issuable upon conversion of the Senior Notes, to cause the registration statement to become effective by January 31, 2021, and to keep the registration statement continuously effective for a specified period of time. If the Company fails to satisfy certain of its obligations under the Registration Rights Agreement (a “Registration Default”), it will be required to pay additional interest on the Senior Notes. Such additional interest will accrue at a rate per annum equal to 0.25% of the principal amount thereof for the first 90 days beginning on, and including the date on which such Registration Default occurs and, thereafter, at a rate per annum equal to 0.50% of the principal amount thereof. However, in no event will such additional interest, together with any special interest that accrues pursuant to the Indenture accrue on any day on a Note at a combined rate per annum that exceeds 0.50%. Additionally, if a Registration Default exists on the maturity date for the Senior Notes, then, in addition to any additional interest otherwise payable, the Company will be required to make a cash payment to each noteholder in an amount equal to 3% of the principal amount of Senior Notes outstanding and held by such holder as of the close of business on the business day immediately before the maturity date.  As of December 31, 2020, the Company has not accrued any fees or expenses associated with the Registration Rights Agreement as no Registration Default exists and, therefore, it is not probable that a payment would be required.  In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Senior Notes and the shares of the Company’s common stock issuable upon conversion of the Senior Notes.

​

​

​

F-34

Note 11. Note Payable

In connection with the acquisition of CRYOPDP, the Company assumed an interest free unsecured note payable of €4.0 million ($4.9 million) repayable in two installments of €0.5 million ($0.6 million) to be repaid in 2025 and €3.5 million ($4.3 million) to be repaid in 2028.

​

Note 12. Leases

The Company has operating and finance leases for corporate offices and certain equipment. These leases have remaining lease terms of one year to approximately nine years, some of which include options to extend the leases for multiple renewal periods of five years each. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs. As of December 31, 2020 and 2019, assets recorded under finance leases were $279,400 and $71,000, respectively, and accumulated depreciation associated with finance leases was $78,700 and $22,800, respectively.

​

The components of lease cost were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Operating lease cost

​

$

1,835

​

$

758

Finance lease cost:

​

​

​

​

 

  

Amortization of right-of-use assets

​

​

56

​

​

10

Interest on finance lease liabilities

​

​

10

​

​

3

​

​

​

66

​

 

13

Total lease cost

​

$

1,901

​

$

771

​

Other information related to leases was as follows (in thousands):

​

​

​

​

​

​

​

​

Year Ended

 

Supplemental Cash Flows Information

    

December 31, 2020

 

Cash paid for amounts included in the measurement of lease liabilities:

 

​

​

​

Operating cash flows from operating leases

 

$

1,680

​

Operating cash flows from finance leases

 

$

77

​

Financing cash flows from finance leases

​

$

67

​

​

​

​

​

​

Right-of-use assets obtained in exchange for lease liabilities (in thousands):

​

​

​

​

Operating leases

 

$

10,708

​

Finance leases

​

$

203

​

​

​

​

​

​

Weighted-Average Remaining Lease Term

​

​

​

​

Operating leases

​

 

6.6 years

​

Finance leases

​

 

2.9 years

​

​

​

​

​

​

Weighted-Average Discount Rate

​

​

​

​

Operating leases

​

​

5.5

%

Finance leases

​

​

5.4

%

​

F-35

Future minimum lease payments under non-cancellable leases that have commenced as of December 31, 2020 were as follows (in thousands):

​

​

​

​

​

​

​

​

Years Ending December 31

    

Operating Leases

    

Finance Leases

2021

 

$

3,103

 

$

67

2022

 

​

3,261

 

​

57

2023

 

​

2,498

 

​

60

2024

 

​

1,985

 

​

—

2025

 

​

1,696

 

​

—

Thereafter

 

​

5,402

 

​

—

Total future minimum lease payments

 

​

17,945

 

​

184

Less imputed interest

 

​

(3,453)

 

​

(13)

Total

​

$

14,492

​

$

171

​

​

​

​

​

​

​

​

​

​

Operating

​

Finance 

Reported as of December 31, 2020

    

 Leases

    

Leases

Current lease liabilities

​

$

2,231

​

$

59

Noncurrent lease liabilities

​

 

12,261

​

 

112

Total

​

$

14,492

​

$

171

​

​

Note 13. Employee Benefit Plans

401K Plan

The Company provides a 401(k) Plan (“Plan”) to provide retirement and incidental benefits for our eligible U.S. based employees.  Employees may contribute up to 100% of their eligible compensation, limited to a maximum annual dollar amount set periodically by the Internal Revenue Service.  The Company matches employee contributions dollar for dollar up to a maximum of 4% per year per person.  All matching contributions vest immediately.  During the years ended December 31, 2020 and 2019, we recognized expense of $0.3 million and $0.2 million, respectively, related to matching contributions.

Non-U.S. Employee Benefit Plans

Eligible employees outside the U.S. generally receive retirement benefits under various defined benefit plans and defined contribution plans based upon factors such as years of service and employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements. The employee benefit plan costs and liabilities with regard to the defined benefit plans are determined by actuarial valuations.

Employees of the Company who are in India participate in an employee benefit plan (the “Gratuity Plan”), which is required by local law and provides a lump sum payment to vested employees upon retirement, death, incapacitation, or termination of employment based on the respective employee’s salary and the tenure of employment. The benefit costs and liabilities with regard to the Gratuity Plan are determined by actuarial valuations. The Company makes annual contributions to the employees’ gratuity fund established with Life Insurance Corporation of India, which calculates the annual contribution required to be made by the Company and manages the Gratuity Plan, including any required payouts. The Gratuity Plan is partially funded. The obligation under the Gratuity Plan is not significant at December 31, 2020.

Benefit costs associated with the non-U.S. employee benefit plans totaled $0.1 million and $0 million for the years ended December 31, 2020 and 2019, respectively. Total benefit obligation associated with the non-U.S. employee benefit plans totaled $0.3 million and $0 million at December 31, 2020 and 2019, respectively.

​

F-36

Note 14. Commitments and Contingencies

Facility and Equipment Leases

We lease various corporate, global logistics and supply chain centers, biostorage, manufacturing, and research and development facilities in Tennessee, California, New Jersey, the Netherlands, Texas, Georgia, Minnesota, China, Portugal and France under operating leases. These lease agreements contain certain scheduled annual rent increases which are accounted for on a straight-line basis.   In addition, we lease certain equipment which expires through July 2024 (See Note 12).

Employment Agreements

We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.

Litigation

The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. We record a loss contingency when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We also disclose material contingencies when we believe a loss is not probable but reasonably possible. Accounting for contingencies requires us to use judgment related to both the likelihood of a loss and the estimate of the amount or range of loss. The outcomes of our legal proceedings are inherently unpredictable, subject to significant uncertainties, and could be material to our financial condition, results of operations, and cash flows for a particular period.

Indemnities and Guarantees

The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheets.

The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility and equipment leases, the Company has indemnified its lessors for certain claims arising from the use of the facilities and equipment. The duration of the guarantees and indemnities varies and is generally tied to the life of the agreements.

​

Note 15. Stockholders’ Equity

Authorized Stock

The Company has 100,000,000 authorized shares of common stock with a par value of $0.001 per share, and 2,500,000 undesignated or "blank check" preferred stock, with a par value of $0.001, of which, 800,000 shares have been designated as Class A Convertible Preferred Stock, 585,000 shares have been designated as Class B Convertible Preferred Stock and 250,000 shares have been designated as Class C Convertible Preferred Stock.

Common Stock Issuances For Services

During the year ended December 31, 2020, 2,869 shares of common stock with a fair value of $82,700 were issued to two members of the board of directors as compensation for services.

During the year ended December 31, 2019, 5,753 shares of common stock with a fair value of $91,000 were issued to three members of the board of directors as compensation for services.

F-37

Blackstone Private Placement

In connection with the MVE Acquisition, on October 1 , 2020 (the “Closing Date”), the Company completed a private placement with an investment vehicle of funds affiliated with The Blackstone Group Inc. (collectively, Blackstone), consisting of (i) 250,000 shares of a newly designated 4.0% Series C Convertible Preferred Stock, par value $0.001 per share (“Series C Preferred Stock”), at a price of $1,000 per share, for $250.0 million, and (ii) 675,536 shares of common stock of the Company, par value $0.001 per share (“Common Stock”) for $25.0 million, for an aggregate purchase price of $275.0 million. The Company paid Blackstone $1.0 million as reimbursement for transactional expenses incurred in connection with the private placement at the Closing Date. Also, the Company incurred direct and incremental expenses of approximately $8.6 million, including financial advisory fees, closing costs, legal expenses and other offering-related expenses. The Company allocated the net proceeds of $265.4 on a relative fair value basis to the Series C Preferred Stock and the Common Stock, resulting in allocated proceeds of $28.2 and $237.2, respectively.

The Series C Preferred Stock ranks senior to the shares of the Company’s Common Stock, with respect to dividend rights and rights upon the voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company (a “Liquidation”). The Series C Preferred Stock has the following rights, preferences and privileges:

Dividend Rights. Holders of the Series C Preferred Stock (the “Holders”) are entitled to dividends at the rate of 4.0% per annum, paid-in-kind, accruing daily and paid quarterly in arrears when and if declared by the Board of Directors. The Holders are also entitled to participate in dividends declared or paid on the Common Stock on an as-converted basis. The Company and Holders do not have the option to pay dividends in kind, in cash, or in other form. Paid in-kind dividends for the year ended December 31, 2020 were $2.5 million.

Liquidation Preference. Upon a Liquidation, each share of Series C Preferred Stock is entitled to receive an amount per share equal to the greater of (i) $1,000 per share, plus all accrued and unpaid dividends and (ii) the amount that the Holders of the Series C Preferred Stock would have been entitled to receive at such time if the Series C Preferred Stock were converted into Common Stock (the ”Liquidation Preference”).

Conversion Features. The Series C Preferred Stock is convertible at the option of the Holders at any time into shares of Common Stock at a conversion price of $38.6152 per share and a conversion rate of 25.90 shares of Common Stock per share of Series C Preferred Stock. The maximum number of Common Stock that could be required to be issued if converted is 6,474,135 shares. The conversion price is subject to certain customary adjustments in the event of certain adjustments to the Company’s Common Stock, including stock dividends, splits, combinations, tender offers, and exchange offers.

After the second anniversary of the Closing Date, subject to certain conditions, the Company may at its option require conversion of all of the outstanding shares of the Series C Preferred Stock to Common Stock if, for at least 20 trading days during the 30 consecutive trading days immediately preceding the date the Company notifies the Holders of the election to convert, the closing price of the Common Stock is at least 150% of the conversion price.

On the October 1, 2020 issuance date, the effective conversion price per share was less than the fair value of the underlying Common Stock and, as a result, the Company determined that there was a beneficial conversion feature on that date. Accordingly, the Company recognized the resulting beneficial conversion feature amount of $39.5 million as a deemed dividend, equal to the number of common shares into which the Series C Preferred Stock is convertible multiplied by the difference between the fair value of the Common Stock and the effective conversion price per share on that date. Because the Series C Preferred Stock does not have a stated conversion date and was immediately convertible at the issuance date, the dividend is reflected as a one-time, non-cash, deemed dividend to the Holders of the Series C Preferred Stock on the date of issuance.  

Additionally, the Company determined that the nature of the Series C Preferred Stock is more akin to an equity instrument and that the economic characteristics and risks of the embedded conversion options are clearly and closely related to the Series C Preferred Stock. As such, the conversion options were not required to be bifurcated from the host under ASC 815, Derivatives and Hedging.

F-38

Since the paid-in-kind dividends are nondiscretionary, the Company measures the beneficial conversion feature in the paid-in-kind dividend on the issuance date of the preferred stock and records such amount when the paid-in-kind dividend are accrued. Accordingly, the associated paid-in-kind dividends for the year ended December 31, 2020 generated a beneficial conversion feature amount of $0.3 million. On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Series C Preferred Stock (See Note 18).

Redemption Rights. The Company may redeem the Series C Preferred Stock for cash, as follows:

(i)Within 6 months of the Closing Date, up to 50,000 shares of the Series C Preferred Stock at a price equal to 125% of the purchase price paid plus any accrued and unpaid dividends (See Note 18).
(ii)At any time beginning five years after the Closing Date (but prior to six years after the Closing Date), all of the Series C Preferred Stock at a price equal to 105% of the purchase price paid plus any accrued and unpaid dividends.
(iii)At any time beginning six years after the Closing Date, all of the Series C Preferred Stock at a price equal to 100% of the purchase price paid plus any accrued and unpaid dividends.

Upon a “Fundamental Change” (involving a change of control or de-listing of the Company as further described in the Certificate of Designation), each Holder has the right to require the Company to redeem all or any part of the Holder’s Series C Preferred Stock for an amount equal to the Liquidation Preference plus any accrued and unpaid dividends.  If the Company does not have sufficient funds legally available to pay the repurchase price, then the Company is required to (a) pay the maximum amount of the repurchase price that can be paid out of funds legally available for payment, and (b) purchase any shares of the Series C Preferred Stock not purchased because of the foregoing limitations at the repurchase price as soon as practicable after the Company is able to make such purchase out of assets legally available for the purchase of such shares. If the Company fails to pay the repurchase price in full when due, then the Company will pay dividends on such shares not repurchased at a rate of 5.5% per annum until such shares are repurchased, payable quarterly in arrears.

The Company evaluated the Series C Preferred Stock for liability or equity classification under the applicable accounting guidance including ASC 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the Series  C Preferred Stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series C Preferred Stock would be recorded as permanent equity given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company.

The Company also evaluated the embedded put and call options within the Series C Preferred Stock in accordance with the accounting guidance for derivatives to determine if bifurcation is required.  The Company determined that the economic characteristics and risks of the embedded put and call options are not clearly and closely related to the Series C Preferred Stock. Therefore, the Company assessed the put and call options further and determined they did not meet the definition of a derivative under ASC 815.

Under the same analysis, the Company determined that the economic characteristics and risks of the embedded participating dividend feature are considered clearly and closely related to the equity host. Accordingly, the participating dividend feature is not required to be bifurcated under ASC 815. Also, the Company determined that the value of the contingent dividend feature is minimal and insignificant relative to the other components of the Series C Preferred Stock due to the circumstances surrounding the scenarios under which the provision would be triggered.

Voting Rights. Holders of the Series C Preferred Stock are generally entitled to vote with the holders of the shares of Common Stock on an as-converted basis, subject to certain Nasdaq voting limitations, if applicable. Also, the consent of the Holders of a majority of the outstanding shares of the Series C Preferred Stock is required with respect to (i) amendments to the Company’s organizational documents that have an adverse effect on the Holders of the Series C Preferred Stock, and (ii) issuances by the Company of securities that are senior to, or equal in priority with, the Series C Preferred Stock. Holders of the Series C Preferred Stock have the right to nominate for election one member to the board of directors of the Company for so long as they hold 66.67% of the Series C Preferred Stock.

F-39

Registration Rights. Holders of the Series C Preferred Stock have certain customary registration rights with respect to the Series C Preferred Stock and the shares of common stock into which they are converted, pursuant to the terms of a registration rights agreement. The Company is required to file within 90 days of the Closing Date, and use its commercially reasonable efforts to cause to go effective as promptly as practicable, a registration statement covering the sale or distribution of Common Stock issued or issuable upon conversion of the Series C Preferred Stock.   In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Common Stock issued or issuable upon conversion of the Series C Preferred Stock.

Share Repurchase Program

In October 2019, the Company’s Board of Directors authorized a share repurchase program (the “Repurchase Program”) authorizing repurchase of common stock in the amount of up to $15.0 million from time to time, in amounts, at prices, and at such times as management deems appropriate and will depend on a number of factors, including the market price of Cryoport’s common stock, general market and economic conditions, and applicable legal requirements. The repurchase program expired on December 31, 2020. The Company has not purchased any shares under this program in 2019 and through December 31, 2020.

June 2019 Public Offering

On June 24, 2019, the Company completed an underwritten public offering  of 4,312,500 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement, dated June 19, 2019, by and among the Company, on the one hand, and Jefferies LLC and SVB Leerink LLC, as representatives of certain underwriters at a public offering price per share of $17.00, before deducting underwriting discounts and commissions. The shares include 562,500 shares issued and sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the underwriting agreement. The Company received net proceeds of approximately $68.8 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Common Stock Reserved for Future Issuance

As of December 31, 2020, approximately 18.8 million shares of common stock were issuable upon exercise of stock options and the conversion of convertible senior notes and Series C Preferred stock, as follows:

​

​

​

​

Exercise of stock options

    

7,554,305

Conversion of Series C Preferred stock

​

6,474,135

Conversion of convertible senior notes

​

4,810,002

Total shares of common stock reserved for future issuances

 

18,838,442

​

​

F-40

Note 16. Stock-Based Compensation

Warrants

We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants.   A summary of warrant activity is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

​

​

    

Weighted-

    

​

​

​

​

​

​

Weighted-

​

Average

​

​

​

​

​

​

​

Average

​

Remaining

​

Aggregate

​

​

Number of

​

Exercise

​

Contractual

​

Intrinsic

​

    

Shares

    

Price/Share

    

Term (Years)

    

Value (1)

Outstanding — December 31, 2018

 

2,049,534

​

$

4.03

 

  

 

​

  

Issued

 

—

​

 

—

 

  

 

​

  

Exercised

 

(1,027,546)

​

 

3.95

 

  

 

​

  

Expired

 

(20,960)

​

 

17.78

 

  

 

​

  

Outstanding — December 31, 2019

 

1,001,028

​

​

3.83

 

  

 

​

  

Issued

 

—

​

 

—

 

  

 

​

  

Exercised

 

(963,149)

​

 

3.80

 

  

 

​

  

Expired

 

(37,879)

​

 

4.58

 

  

 

​

  

Outstanding — December 31, 2020

 

—

​

$

—

 

—

​

$

—

Vested (exercisable) — December 31, 2020

 

—

​

$

—

 

—

​

$

—

(1)Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of the Company’s common stock on December 31, 2020, which was $43.88 per share.

During the year ended December 31, 2020, the Company issued 963,149 shares of common stock in connection with the exercise of warrants for proceeds of $3.7 million.

During the year ended December 31, 2019, the Company issued 985,626 shares of common stock in connection with the exercise of warrants for proceeds of $3.4 million. In addition, during the year ended December 31, 2019, the Company issued 117,663 shares of common stock in connection with the cashless exercise of warrants to purchase 159,583 shares of common stock.

The total intrinsic value of warrants exercised during the years ended December 31, 2020 and 2019 was $17.6 million and $12.4 million, respectively.

Stock Options

We have five stock incentive plans: the 2002 Stock Incentive Plan (the “2002 Plan”), the 2009 Stock Incentive Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”), the 2015 Omnibus Equity Incentive Plan (the “2015 Plan”), and the 2018 Omnibus Equity Incentive Plan (the “2018 Plan”), (collectively, the “Plans”). The 2002 Plan, the 2009 Plan, the 2011 Plan and the 2015 Plan (the “Prior Plans”) have been superseded by the 2018 Plan. In May 2018, the stockholders approved the 2018 Plan for issuance up to 3,730,179 shares. The Prior Plans will remain in effect until all awards granted under such Prior Plans have been exercised, forfeited, cancelled, or have otherwise expired or terminated in accordance with the terms of such awards, but no awards will be made pursuant to the Prior Plans after the effectiveness of the 2018 Plan. As of December 31, 2020, the Company had 921,288 shares available for future awards under the 2018 Plan.

F-41

During the years ended December 31, 2020 and 2019, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following assumptions:

​

​

​

​

​

​

​

​

​

December 31, 

    

December 31, 

  

​

    

2020

    

2019

​

Expected life (years)

​

5.3 – 6.3

​

5.2 – 6.2

 

Risk-free interest rate

​

0.31% - 1.70

%  

1.42% - 2.57

%

Volatility

​

69.8% - 82.7

%  

70.6% - 99.2

%

Dividend yield

​

0

%  

0

%

​

The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the average of the historical volatility and the implied volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.

We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest.

Total stock-based compensation expense related to our share-based payment awards is comprised of the following (in thousands):

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

​

    

2020

    

2019

Cost of revenues

​

$

371

​

$

1,479

Selling, general and administrative

​

 

7,862

​

 

13,946

Engineering and development

​

 

683

​

 

1,098

​

​

$

8,916

​

$

16,523

​

For the year ended December 31, 2019, we recognized expense of $9.6 million due to the accelerated vesting under the terms of certain outstanding stock option grants as a result of the Company meeting certain financial performance criteria defined in such grants. Of this amount, $0.4 million, $9.4 million, and $0.9 million are included in cost of revenues, selling, general and administrative and engineering and development, respectively.

​

A summary of stock option activity is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

​

​

    

Weighted-

    

​

​

​

​

​

​

Weighted-

​

Average

​

​

​

​

​

​

​

Average

​

Remaining

​

Aggregate

​

​

Number of

​

Exercise

​

Contractual

​

Intrinsic

​

​

Shares

​

Price/Share

​

Term (Years)

​

Value (1)

Outstanding — December 31, 2018

 

5,757,305

​

$

5.16

 

  

 

​

  

Granted (weighted-average fair value of $13.55 per share)

 

1,544,850

​

​

13.55

 

  

 

​

  

Exercised

 

(544,565)

 

​

3.91

 

  

 

​

  

Forfeited

 

(78,009)

 

​

10.66

 

  

 

​

  

Outstanding — December 31, 2019

 

6,679,581

​

​

7.14

 

  

 

​

  

Granted (weighted-average fair value of $13.21 per share)

​

1,789,000

​

​

20.46

​

  

​

​

​

Exercised

 

(855,717)

 

​

6.73

 

  

 

​

​

Forfeited

 

(56,475)

 

​

13.39

 

  

 

​

​

Expired

 

(2,084)

 

​

19.56

 

  

 

​

​

Outstanding — December 31, 2020

 

7,554,305

​

$

10.29

 

6.6

​

$

254,393,000

Vested (exercisable) — December 31, 2020

 

5,862,122

​

$

7.41

 

5.9

​

$

213,769,400

Expected to vest after December 31, 2020 (unexercisable)

 

1,692,183

​

$

20.24

 

9.2

​

$

40,623,600

(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on December 31, 2020, which was $43.88 per share.

F-42

The following table summarizes information with respect to stock options outstanding and exercisable at December 31, 2020:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

Weighted-

    

​

​

    

​

    

​

​

​

​

​

​

Average

​

Weighted-

​

​

​

Weighted-

​

​

​

​

Remaining

​

Average

​

​

​

Average

​

​

Number

​

Contractual

​

Exercise

​

Number

​

Exercise

Exercise Price

​

Outstanding

​

Life (Years)

​

Price

​

Exercisable

​

Price

$1.08 – 3.07

 

894,024

 

4.7

​

$

2.25

 

894,024

​

$

2.25

$3.19 – 3.44

 

839,001

 

4.5

​

$

3.30

 

839,001

​

$

3.30

$4.56 – 4.92

 

658,437

 

4.5

​

$

4.80

 

658,437

​

$

4.80

$5.00 – 7.67

 

769,694

 

4.6

​

$

5.04

 

769,694

​

$

5.04

$7.80 – 8.65

 

961,979

 

6.0

​

$

8.28

 

952,229

​

$

8.28

$9.29 – 12.79

 

1,153,291

 

8.0

​

$

11.85

 

1,083,688

​

$

11.84

$13.37 – 16.95

 

1,598,304

 

9.0

​

$

16.41

 

498,801

​

$

15.73

$17.36 – 55.48

 

679,575

 

9.3

​

$

26.54

 

166,248

​

$

18.53

​

 

7,554,305

 

​

​

​

​

​

5,862,122

​

​

​

​

As of December 31, 2020, there was unrecognized compensation expense of $21.1 million related to unvested stock options, which we expect to recognize over a weighted average period of 3.1 years.

The total intrinsic value of options exercised during the years ended December 31, 2020 and 2019 was $24.1 million and $6.5 million, respectively.

​

Note 17. Income Taxes

Income (loss) before provision for income taxes was attributed to the following jurisdictions for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

United States

​

$

(32,873)

​

$

(18,321)

Foreign

​

 

135

​

 

51

​

​

$

(32,738)

​

$

(18,270)

​

The provision (benefit) for income taxes consists of the following for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Current:

 

​

  

 

​

  

Federal

​

$

11

​

$

—

State

​

 

110

​

 

41

Foreign

​

 

361

​

 

—

Total current expense

​

 

482

​

 

41

​

​

​

​

​

​

​

Deferred:

​

 

​

​

 

​

Federal

​

 

(8,245)

​

 

(2,125)

State

​

 

(832)

​

 

5

Foreign

​

 

(738)

​

 

9

Change in valuation allowance

​

 

9,288

​

 

2,132

Total deferred expense

​

 

(527)

​

 

21

Total provision (benefit) for income taxes

​

$

(45)

​

$

62

​

F-43

The provision (benefit) for income taxes differs from that computed using the federal statutory rate applied to loss before provision for income taxes as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Computed tax benefit at federal statutory rate

​

$

(6,875)

​

$

(3,837)

State tax, net of federal benefit

​

 

(1,077)

​

 

(610)

Stock compensation

​

 

(2,683)

​

 

480

Interest expense

​

​

—

​

​

286

Permanent differences and other

​

 

(375)

​

 

(126)

Transaction cost

​

​

528

​

​

—

Executive compensation

​

​

609

​

​

985

Rate changes

​

​

408

​

​

—

Contingencies

​

 

112

​

 

753

Valuation allowance

​

 

9,308

​

 

2,131

​

​

$

(45)

​

$

62

​

Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2020 and 2019 are shown below (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Deferred tax assets:

 

​

Net operating loss carryforward

​

$

27,106

​

$

17,031

Expenses recognized for granting of options and warrants

​

 

4,119

​

 

3,816

Accrued expenses and reserves

​

 

913

​

 

383

Lease liability

​

​

2,740

​

​

1,217

Total deferred tax assets

​

​

34,878

​

​

22,447

Valuation allowance

​

 

(32,913)

​

 

(21,220)

​

​

$

1,965

​

$

1,227

Deferred tax liabilities:

​

​

​

​

​

​

Goodwill

​

$

(529)

​

$

(110)

Right-of-use assets

​

​

(2,631)

​

​

(1,138)

Intangibles

​

​

(4,253)

​

​

​

Total deferred tax liability

​

​

(7,413)

​

​

(1,248)

Net deferred tax liability

​

$

(5,448)

​

$

(21)

​

Our net deferred tax liability as presented in our consolidated balance sheet consist of the following items (in thousands):

​

​

​

​

​

​

​

​

​

December 31,

​

    

2020

    

2019

Deferred tax assets

​

$

434

​

$

—

Deferred tax liabilities

​

 

(5,882)

​

 

(21)

Net deferred tax liability

​

$

(5,448)

​

$

(21)

​

The Company’s net deferred tax liabilities increased by $5.7 million as a result of our MVE and CRYOPDP acquisitions on October 1, 2020. During the years ended December 31, 2020 and 2019, the Company’s valuation allowance on deferred tax assets increased by $11.7 million and $2.1 million, respectively.  The increase in the valuation allowance during 2020 and 2019 was principally the result of net operating losses sustained during each of the years.  Our valuation allowance also increased during 2020 as a result of valuation allowances recorded against deferred tax assets on the opening balance sheets of some of our acquired foreign subsidiaries.

At December 31, 2020, the Company has federal and state net operating loss carryforwards of approximately $57.6 million and $60.9 million, respectively, which will begin to expire in 2021, unless previously utilized, and will begin to expire for state purposes in 2028. In addition, the Company has federal net operating loss carryforwards of $38.6 million generated after 2017 that can be carried over indefinitely and may be used to offset up to 80% of federal taxable income. At December 31, 2020, the Company has foreign net

F-44

operating loss carryforwards of approximately $9.8 million, which begin to expire in 2022. At December 31, 2020, the Company has federal and California research and development tax credits of approximately $0.4 million and $0.3 million, respectively. The federal research tax credit begins to expire in 2026 unless previously utilized and the California research tax credit has no expiration date.

Utilization of the net operating loss ("NOL") and research and development ("R&D") carryforwards maybe subject to a substantial annual limitation due to ownership change limitations that might have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state and foreign provisions. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company’s formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition.

The Company has not completed a study to assess whether an ownership change or changes have occurred. If the Company has experienced an ownership change, utilization of the NOL or R&D credit carryforwards would be subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL or R&D credit carryforwards before utilization. Further, until a study is complete and any limitation is known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance.

A reconciliation of the beginning and ending amounts of unrecognized tax benefits (“UTBs”) are as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

UTBs, beginning of period

​

$

963

​

$

48

Gross increase – current period tax positions

​

 

358

​

 

239

Gross decrease – prior period tax positions

​

 

(113)

​

 

—

Gross increase – prior period tax positions

​

 

64

​

 

676

Expiration of statute of limitations

​

 

—

​

 

—

UTBs, end of period

​

$

1,272

​

$

963

​

As if December 31, 2020, we had an immaterial amount of UTBs, which if recognized, would affect our effective tax rate. Prior to 2020, the Company did not have any UTBs that would impact the effective rate. The Company does not expect any significant increases or decreases to the Company's unrecognized tax positions within the next 12 months.

We recognize interest accrued related to UTBs and penalties as income tax expense.  We accrued an immaterial amount of interest expense during 2020 in our statement of operations and as of December 31, 2020 have and an immaterial accrual for interest in our consolidated balance sheet. During 2019, there were no accrued penalties or interest as of December 31, 2019.

Due to the NOL carryforwards, the U.S. federal and state returns are open to examination by the Internal Revenue Service and state jurisdictions for all years beginning with the year ended March 31, 2001. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax.  The Company’s subsidiary in India is currently under examination by the Office of the Commissioner of Income Tax in India for 2012-2013, 2013-2014, and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local tax authorities.  

​

F-45

Note 18. Subsequent Events

January 2021 Public Offering

On January 25, 2021, the Company completed an underwritten public offering of 4,356,059 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement dated January 20, 2021, by and among the Company, on the one hand, and Morgan Stanley & Co. LLC, Jefferies LLC, SVB Leerink LLC and UBS Securities LLC, as representatives of certain underwriters at a public offering price per share of $66.00, before deducting underwriting discounts and commissions. The shares include 568,181 shares issued and sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the underwriting agreement. The Company received net proceeds of approximately $269.7 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Blackstone Conversion

On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. to convert an aggregate of 50,000 shares of the Company’s Series C Preferred Stock. Pursuant to the terms of the waiver and conversion notice, the Company also agreed to waive its right under the certificate of designations of the Series C Preferred Stock to redeem up to 50,000 shares of the Series C Preferred Stock prior to the 180-day anniversary of October 1, 2020, the issue date of the Series C Preferred Stock. Each share of Series C Preferred Stock has a liquidation preference of $1,000 per share plus any accumulated and unpaid dividends and is convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price of $38.6152 per share. The forgoing conversion, effective as of February 5, 2021, resulted in the issuance of an aggregate of 1,312,860 shares of Common Stock. The foregoing shares were issued pursuant to an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.

​

Note 19. Quarterly Financial Data (Unaudited)

A summary of quarterly financial data is as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Quarter Ended

​

    

March 31

    

June 30

    

September 30

    

December 31

Year ended December 31, 2020

 

​

  

 

​

  

 

​

  

 

​

  

Total revenues

​

$

9,774

​

$

9,389

​

$

11,172

​

$

48,361

Gross margin

​

$

5,258

​

$

5,127

​

$

6,055

​

$

19,894

Loss from operations

​

$

(3,586)

​

$

(5,845)

​

$

(10,732)

​

$

(9,847)

Net loss attributable to common stockholders

​

$

(3,943)

​

$

(5,803)

​

$

(11,418)

​

$

(53,866)

Net loss per share attributable to common stockholders - basic and diluted

​

$

(0.11)

​

$

(0.15)

​

$

(0.29)

​

$

(1.32)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Year ended December 31, 2019

​

 

  

​

 

  

​

 

  

​

 

  

Total revenues

​

$

6,653

​

$

8,464

​

$

9,583

​

$

9,242

Gross margin

​

$

3,454

​

$

4,338

​

$

4,627

​

$

4,932

Loss from operations

​

$

(2,141)

​

$

(2,304)

​

$

(12,352)

​

$

(878)

Net loss

​

$

(2,387)

​

$

(2,528)

​

$

(12,469)

​

$

(948)

Net loss per share - basic and diluted

​

$

(0.08)

​

$

(0.08)

​

$

(0.35)

​

$

(0.03)

​

Earnings per basic and diluted shares are computed independently for each of the quarters presented based on basic and diluted shares outstanding per quarter and, therefore, may not sum to the totals for the periods shown.

F-46

In the fourth quarter of 2019, management identified an error in the Company's historical interim financial statements for the third quarter of fiscal year 2019 relating to its stock-based compensation expense. Specifically, in the third quarter of 2019, the Company incorrectly recorded $1,227,890 of accelerated stock-based compensation expense for nonemployee directors who were not eligible for the accelerated vesting under their stock option awards. The error impacts only the previously issued historical interim financial statements for the third quarter of fiscal year 2019. The Company corrected the error in the fourth quarter of 2019, which resulted in a reduction of $765,099 of stock-based compensation expense included in selling, general and administrative expense. The Company concluded the error is not material to the third and fourth quarter of 2019.

​

​

F-47

 EX-4.1 2 cyrx-20201231xex4d1.htm EXHIBIT 4.1

EXHIBIT 4.1

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

As of December 31, 2020, Cryoport, Inc. (“we,” “us,” “Cryoport” or the “Company”) had the following classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) common stock, $0.001 par value per share (“Common Stock”); and (ii) warrants to purchase Common Stock at an exercise price of $3.30 per share (the “Warrants”).

Our authorized capital stock consists of 100,000,000 authorized shares of Common Stock and 2,500,000 shares of undesignated or “blank check” preferred stock, par value of $0.001, of which, 800,000 shares have been designated as Class A Preferred Stock, 585,000 shares have been designated as Class B Preferred Stock and 250,000 shares have been designated as Class C Preferred Stock. As of December 31, 2020, there were 39,837,058 shares of common stock outstanding, no shares of Class A Preferred Stock outstanding, no shares of Class B Preferred Stock outstanding and 250,000 shares of Class C Preferred Stock outstanding.  The following description is a summary and is qualified in its entirety by our Amended and Restated Articles of Incorporation, as amended to date (the “Charter”), and our Amended and Restated Bylaws, as currently in effect (the “Bylaws”), copies of which are referenced as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2020, as well as the provisions of the Nevada Revised Statutes.

Common Stock

Subject to the preferential rights of any outstanding preferred stock, each holder of Common Stock is entitled to receive ratable dividends, if any, as may be declared by our board of directors out of funds legally available for the payment of dividends. No dividends on Common Stock have been declared or paid by the Company. The Company intends to employ all available funds for the development of its business and, accordingly, does not intend to pay any cash dividends in the foreseeable future.

Holders of Common Stock are entitled to one vote for each share held of record. There are no cumulative voting rights in the election of directors. Thus, the holders of more than 50% of the outstanding shares of Common Stock can elect all of our directors if they choose to do so.

The holders of our Common Stock have no preemptive, subscription, conversion or redemption rights. There are no sinking fund provisions applicable to the Common Stock.  Upon our liquidation, dissolution or winding-up, the holders of our Common Stock are entitled to receive our assets pro rata, subject to prior satisfaction of all outstanding debts and other liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding preferred stock. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

Warrants

The Warrants were exercisable at an exercise price of $3.30 per share of Common Stock, subject to certain adjustments. The Warrants were exercisable on or after February 25, 2010 and expired on February 24, 2015. As of December 31, 2019, there were no Warrants outstanding.

Anti-Takeover Provisions

Nevada Law

Nevada Revised Statutes sections 78.378 to 78.3793 provide state regulation over the acquisition of a controlling interest in certain Nevada corporations unless the articles of incorporation or bylaws of the corporation provide that the provisions of these sections do not apply. This statute currently does not apply to our Company because in order to be applicable, we would need to have a specified number of Nevada residents as shareholders, and we would have to do business in Nevada directly or through an affiliate.

Nevada Revised Statutes sections 78.411 to 78.444 prohibit certain business “combinations” between certain Nevada corporations and any person deemed to be an “interested stockholder” for two years after such person first becomes an “interested stockholder” unless (i) the corporation’s Board of Directors approves the combination (or the transaction by which such person becomes an “interested stockholder”) in advance, or (ii) the combination is approved by the Board of Directors and sixty percent of the corporation’s voting power not beneficially owned by the interested stockholder, its affiliates and associates. Furthermore, in the absence of prior approval, certain restrictions may apply even after such two-year period. For purposes of these statutes, an “interested stockholder” is any person who is (x) the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the outstanding voting shares of the corporation, or (y) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the then outstanding shares of the corporation. The definition of the term “combination” is sufficiently broad to cover most significant transactions between the corporation and an “interested stockholder”.

​

Subject to certain timing requirements set forth in the statutes, a corporation may elect not to be governed by these statutes. We have not included any such provision in our articles of incorporation. The effect of these statutes may be to potentially discourage parties interested in taking control of the Company from doing so if it cannot obtain the approval of our Board of Directors.

Charter and Bylaws Provisions

In addition, the Charter and Bylaws contain provisions that may make the acquisition of our company more difficult, including, but not limited to, the following:

·

requiring at least 75% of outstanding voting stock in order to call a special meeting of stockholders;

·

not allowing stockholders to take action by written consent in lieu of a meeting;

·

setting forth specific procedures regarding how our stockholders may present proposals or nominate directors for election at stockholder meetings;

·

requiring advance notice and duration of ownership requirements for stockholder proposals;

·

permitting our board of directors to issue preferred stock without stockholder approval; and

·

limiting the rights of stockholders to amend our bylaws.

Transfer Agent and Registrar for Common Stock

The transfer agent and registrar for our Common Stock is Continental Stock Transfer & Trust Company, Attn: Corporate Actions Department, 1 State Street, 30th Floor, New York, New York 10004-1561.

NASDAQ Capital Market

Our Common Stock is currently traded on the Nasdaq Capital Market under the symbol “CYRX”.

 EX-10.6 3 cyrx-20201231xex10d6.htm EXHIBIT 10.6

Exhibit 10.6

Cryoport, Inc.

2018 Omnibus Equity Incentive Plan

NOTICE OF GRANT OF INCENTIVE STOCK OPTIONS

This Incentive Stock Option Agreement consists of this Notice of Grant of Incentive Stock Options (the “Grant Notice”) and the Incentive Stock Option Award Agreement immediately following. The Incentive Stock Option Agreement sets forth the specific terms and conditions governing Incentive Stock Option Awards under the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (the “Plan”).  All of the terms of the Plan are incorporated herein by reference.

​

​

​

Name of Optionee:

​

Total No. of shares of Stock
   subject to the Option:

​

Grant Date:

​

Expiration Date:

​

Exercise Price:

​

Vesting Schedule:

​

​

​

BY EXECUTING THIS INCENTIVE STOCK OPTION AGREEMENT, OPTIONEE ACCEPTS PARTICIPATION IN THE PLAN, ACKNOWLEDGES THAT HE OR SHE HAS READ AND UNDERSTANDS THE PROVISIONS OF THIS GRANT NOTICE AND THE PLAN, AND AGREES THAT THIS GRANT NOTICE, THE AWARD AGREEMENT AND THE PLAN SHALL GOVERN THE TERMS AND CONDITIONS OF THIS AWARD.

IN WITNESS WHEREOF, the Company and Optionee have duly executed this Incentive Stock Option Agreement, and this Incentive Stock Option Agreement shall be effective as of the Grant Date set forth above.

​

​

​

​

    

CRYOPORT, INC.

​

​

​

​

​

Date

​

By:

​

​

​

​

Name:

​

​

​

​

Title:

​

​

​

​

​

​

INCENTIVE STOCK OPTION AWARD AGREEMENT

Under the Cryoport, Inc.

2018 Omnibus Equity Incentive Plan

This Incentive Stock Option Award Agreement (this “Agreement”) is between Cryoport, Inc. (the “Company”) and the individual (the “Optionee”) identified in the Notice of Grant of Incentive Stock Options (the “Grant Notice”), and is effective as of the grant date referenced in the Grant Notice (the “Grant Date”).  This Agreement supplements the Grant Notice to which it is attached, and, together, with the Grant Notice, constitutes the “Incentive Stock Option Agreement” referenced in the Grant Notice.

RECITALS

A.The Board of Directors of the Company (the “Board”) has adopted and the stockholders have approved the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (the “Plan”) to promote the interests and long-term success of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the continued growth and profitability of the Company.

B.The Committee has approved the grant of Incentive Stock Options to Optionee pursuant to Section 6.2 of the Plan.

C.To the extent not specifically defined in this Agreement, all capitalized terms used in this Agreement shall have the meaning set forth in the Plan.

D.In consideration of the mutual covenants and conditions hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Optionee agree as follows:

AGREEMENT

1.Grant of Option.  Subject to the terms of this Agreement and Section 6.1 of the Plan, the Company grants to Optionee the right and option to purchase from the Company all or any part of the aggregate number of shares of Stock specified in the Grant Notice (“Option”).  The Option granted under this Agreement is intended to be an “Incentive Stock Option” under Section 422 of the Code.

2.Exercise Price.  The exercise price under this Agreement is the exercise price per share of Stock specified in the Grant Notice, as determined by the Committee, which shall not be less than the Fair Market Value of a share of Stock on the Grant Date.

3.Vesting of Option.  Subject to the Optionee’s continued employment and the provisions of Section 7, below, the Option shall vest and become exercisable according to the vesting schedule set forth in the Grant Notice.

4.Exercise of Option.  This Option may be exercised in whole or in part at any time after it vests in accordance with Section 3 and before the Option expires by delivery of a written notice of exercise (under Section 5 below) and payment of the exercise price.  The exercise price may be paid in cash, or shares of Stock (through actual tender or by attestation), or such other method permitted by the Committee (including broker-assisted “cashless exercise” arrangements) and communicated to Optionee before the date Optionee exercises the Option.

​

​

5.Method of Exercising Option.  Subject to the terms of this Agreement, the Option may be exercised by timely delivery to the Company of written notice, which notice shall be effective on the date received by the Company.  The notice shall state Optionee’s election to exercise the Option and the number of underlying shares in respect of which an election to exercise has been made.  Such notice shall be signed by Optionee, or if the Option is exercised by a person or persons other than Optionee because of Optionee’s death, such notice must be signed by such other person or persons and shall be accompanied by proof acceptable to the Committee of the legal right of such person or persons to exercise the Option.

6.Term of Option.  The Option granted under this Agreement expires, unless sooner terminated, ten (10) years from the Grant Date, through and including the normal close of business of the Company on the tenth (10th) anniversary of the Grant Date (the “Expiration Date”).

7.Termination of Employment.

(a)If Optionee’s employment is terminated by the Company by reason of death or Disability, the Option shall lapse (to the extent not exercised) on the earlier of: (i) the Expiration Date; or (ii) twelve (12) months after the date Optionee terminates employment. The Option may be exercised pursuant to this Section 7(a) only if the Option was exercisable by Optionee immediately prior to his or her termination of employment.  In no event shall the Option be exercisable after the Expiration Date.

(b)If Optionee’s employment is terminated for any reason other than those described in Section 7(a), the Option shall lapse (to the extent not exercised) on the earlier of: (i) the Expiration Date; or (ii) ninety (90) days after the date Optionee terminates employment; provided, however, that if Optionee’s employment is terminated for Cause, the Option shall immediately lapse which means that the Option shall not be exercisable by Optionee regardless of whether the Option is already vested.  The Option may be exercised pursuant to this Section 7(b) only if the Option was exercisable by Optionee immediately prior to his or her termination of employment.  In no event shall the Option be exercisable after the Expiration Date.

(c)For the purposes of this Section 7, a termination of employment will occur on the date the Optionee ceases to provide all services to the Company (including, without limitation, any services the Optionee may provide as a Consultant or Non-Employee Director following his or her termination of employment). For example, if an Optionee incurs a termination of employment but continues to provide post-termination services as a Consultant pursuant to a bona fide consulting arrangement with the Company, then for purposes of this Section 7, such employee’s employment will not terminate until such employee ceases to provide services a Consultant to the Company. For any Options to continue to vest and remain outstanding, following a termination of employment, such post-termination consulting arrangement must be memorialized in a written document by and between the Optionee and the Company.

8.Withholding.  As described in Article 15 of the Plan, the Company shall have the right to deduct or withhold, or to require Optionee to remit to the Company, up to the maximum statutory amount necessary, in the applicable jurisdiction, to satisfy any federal, state, and local tax withholding requirements on any Award under the Plan. To the extent that alternative methods of withholding are available under applicable tax laws, the Committee shall have the power to choose among such methods.

9.Nontransferability of Options.  The Options granted by this Agreement shall not be transferable by Optionee or any other person claiming through Optionee, either voluntarily or involuntarily, except by will or the laws of descent and distribution or as otherwise provided by the Committee pursuant to Article 11 of the Plan.

10.No Right to Continued Employment (or Service).  This Agreement shall not be construed to confer upon Optionee any right to continue employment (or service) with the Company and

​

shall not limit the right of the Company, in its sole and absolute discretion, to terminate Optionee’s employment (or service) at any time.

11.Administration.  This Agreement shall at all times be subject to the terms and conditions of the Plan and the Plan shall in all respects be administered by the Committee in accordance with the terms of and as provided in the Plan.  The Committee shall have the sole and complete discretion with respect to all matters reserved to it by the Plan and decisions of the Committee with respect thereto and to this Agreement shall be final and binding upon Optionee and the Company.  In the event of any conflict between the terms and conditions of this Agreement and the Plan, the provisions of the Plan shall control.

12.Adjustments.  The number of shares of Stock issued to Optionee pursuant to this Agreement shall be adjusted by the Committee pursuant to Section 5.3 of the Plan, in its discretion, in the event of a change in the Company’s capital structure.

13.Securities Laws Compliance.  The Company shall not be required to deliver any shares of Stock pursuant to the exercise of the Option if, in the opinion of counsel for the Company, such issuance would violate the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other applicable federal or state securities laws or regulations.

14.No Shareholders Rights.  Optionee will have no voting rights or any other rights as a shareholder of the Company with respect to the Option until the Company issues the stock certificates representing the shares of Stock underlying the Option.

15.Copy of Plan.  By the execution of this Agreement, Optionee acknowledges receipt of a copy of the Plan.

16.Governing Law.  This Agreement shall be interpreted and administered under the laws of the State of California.

17.Amendment.  Except as otherwise provided in the Plan, this Agreement may be amended only by a written agreement executed by the Company and Optionee.  The provisions of this Agreement may not be waived or modified unless such waiver or modification is in writing and signed by a representative of the Committee.

18.Clawback.  Pursuant to Section 12.5 of the Plan, every Award issued pursuant to the Plan is subject to potential forfeiture or “clawback” to the fullest extent called for by applicable federal or state law or any policy of the Company.  By accepting this Award, Optionee agrees to be bound by, and comply with, the terms of any such forfeiture or “clawback” provision imposed by applicable federal or state law or prescribed by any policy of the Company.

MANY OF THE PROVISION OF THIS AWARD AGREEMENT ARE SUMMARIES OF SIMILAR PERTINENT PROVISIONS OF THE PLAN.  TO THE EXTENT THAT THIS AGREEMENT IS SILENT ON AN ISSUE OR THERE IS A CONFLICT BETWEEN THE PLAN AND THIS AGREEMENT, THE PLAN PROVISIONS SHALL CONTROL.

 EX-10.7 4 cyrx-20201231xex10d7.htm EXHIBIT 10.7

Exhibit 10.7

Cryoport, Inc.

2018 Omnibus Equity Incentive Plan

NOTICE OF GRANT OF NON-QUALIFIED STOCK OPTIONS (EMPLOYEE FORM)

This Non-Qualified Stock Option Agreement consists of this Notice of Grant of Non-Qualified Stock Options (the “Grant Notice”) and the Non-Qualified Stock Option Award Agreement immediately following. The Non-Qualified Stock Option Agreement sets forth the specific terms and conditions governing Non-Qualified Stock Option Awards under the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (the “Plan”).  All the terms of the Plan are incorporated herein by reference.

​

​

​

Name of Optionee:

​

Total No. of shares of Stock
subject to the Option:

​

Grant Date:

​

Expiration Date:

​

Exercise Price:

​

Vesting Schedule:

​

​

BY EXECUTING THIS NON-QUALIFIED STOCK OPTION AGREEMENT, OPTIONEE ACCEPTS PARTICIPATION IN THE PLAN, ACKNOWLEDGES THAT HE OR SHE HAS READ AND UNDERSTANDS THE PROVISIONS OF THIS GRANT NOTICE AND THE PLAN, AND AGREES THAT THIS GRANT NOTICE, THE AWARD AGREEMENT AND THE PLAN SHALL GOVERN THE TERMS AND CONDITIONS OF THIS AWARD.

IN WITNESS WHEREOF, the Company has duly executed this Non-Qualified Stock Option Agreement, and this Non-Qualified Stock Option Agreement shall be effective as of the Grant Date set forth above.

​

​

​

​

    

CRYOPORT, INC.

​

​

​

​

​

Date

​

By:

​

​

​

​

Name:

​

​

​

​

Title:

​

​

​

​

NON-QUALIFIED STOCK OPTION AWARD AGREEMENT

Under the Cryoport, Inc.

2018 Omnibus Equity Incentive Plan

This Non-Qualified Stock Option Award Agreement (this “Agreement”) is between Cryoport, Inc. (the “Company”) and the individual (the “Optionee”) identified in the Notice of Grant of Non-Qualified Stock Options (the “Grant Notice”), and is effective as of the grant date referenced in the Grant Notice (the “Grant Date”).  This Agreement supplements the Grant Notice to which it is attached, and, together, with the Grant Notice, constitutes the “Non-Qualified Stock Option Agreement” referenced in the Grant Notice.

RECITALS

A.The Board of Directors of the Company (the “Board”) has adopted and the stockholders have approved the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (the “Plan”) to promote the interests and long-term success of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the continued growth and profitability of the Company.

B.The Committee has approved the grant of Non-Qualified Stock Options to Optionee pursuant to Section 6.1 of the Plan.

C.To the extent not specifically defined in this Agreement, all capitalized terms used in this Agreement shall have the meaning set forth in the Plan.

D.In consideration of the mutual covenants and conditions hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Optionee agree as follows:

AGREEMENT

1.Grant of Option.  Subject to the terms of this Agreement and Section 6.1 of the Plan, the Company grants to Optionee the right and option to purchase from the Company all or any part of the aggregate number of shares of Stock specified in the Grant Notice (“Option”).  The Option granted under this Agreement is not intended to be an “Incentive Stock Option” under Section 422 of the Code.

2.Exercise Price.  The exercise price under this Agreement is the exercise price per share of Stock specified in the Grant Notice, as determined by the Committee, which shall not be less than the Fair Market Value of a share of Stock on the Grant Date.

3.Vesting of Option.  Subject to the Optionee’s continued employment and the provisions of Section 7, below, the Option shall vest and become exercisable according to the vesting schedule set forth in the Grant Notice.

4.Exercise of Option.  This Option may be exercised in whole or in part at any time after it vests in accordance with Section 3 and before the Option expires by delivery of a written notice of exercise (under Section 5 below) and payment of the exercise price.  The exercise price may be paid in cash, or shares of Stock (through actual tender or by attestation), or such other method permitted by the Committee (including broker-assisted “cashless exercise” arrangements) and communicated to Optionee before the date Optionee exercises the Option.

​

​

5.Method of Exercising Option.  Subject to the terms of this Agreement, the Option may be exercised by timely delivery to the Company of written notice, which notice shall be effective on the date received by the Company.  The notice shall state Optionee’s election to exercise the Option and the number of underlying shares in respect of which an election to exercise has been made.  Such notice shall be signed by Optionee, or if the Option is exercised by a person or persons other than Optionee because of Optionee’s death, such notice must be signed by such other person or persons and shall be accompanied by proof acceptable to the Committee of the legal right of such person or persons to exercise the Option.

6.Term of Option.  The Option granted under this Agreement expires, unless sooner terminated, ten (10) years from the Grant Date, through and including the normal close of business of the Company on the tenth (10th) anniversary of the Grant Date (the “Expiration Date”).

7.Termination of Employment.

(a)If Optionee’s employment is terminated by the Company by reason of death or Disability, the Option shall lapse (to the extent not exercised) on the earlier of: (i) the Expiration Date; or (ii) twelve (12) months after the date Optionee terminates employment. The Option may be exercised pursuant to this Section 7(a) only if the Option was exercisable by Optionee immediately prior to his or her termination of employment.  In no event shall the Option be exercisable after the Expiration Date.

(b)If Optionee’s employment is terminated for any reason other than those described in Section 7(a), the Option shall lapse (to the extent not exercised) on the earlier of: (i) the Expiration Date; or (ii) ninety (90) days after the date Optionee terminates employment; provided, however, that if Optionee’s employment is terminated for Cause, the Option shall immediately lapse which means that the Option shall not be exercisable by Optionee regardless of whether the Option is already vested.  The Option may be exercised pursuant to this Section 7(b) only if the Option was exercisable by Optionee immediately prior to his or her termination of employment.  In no event shall the Option be exercisable after the Expiration Date.

(c)For the purposes of this Section 7, a termination of employment will occur on the date the Optionee ceases to provide all services to the Company (including, without limitation, any services the Optionee may provide as a Consultant or Non-Employee Director following his or her termination of employment). For example, if an Optionee incurs a termination of employment but continues to provide post-termination services as a Consultant pursuant to a bona fide consulting arrangement with the Company, then for purposes of this Section 7, such employee’s employment will not terminate until such employee ceases to provide services a Consultant to the Company. For any Options to continue to vest and remain outstanding, following a termination of employment, such post-termination consulting arrangement must be memorialized in a written document by and between the Optionee and the Company.

8.Withholding.  As described in Article 15 of the Plan, the Company shall have the right to deduct or withhold, or to require Optionee to remit to the Company, up to the maximum statutory amount necessary, in the applicable jurisdiction, to satisfy any federal, state, and local tax withholding requirements on any Award under the Plan. To the extent that alternative methods of withholding are available under applicable tax laws, the Committee shall have the power to choose among such methods.

9.Nontransferability of Options.  The Options granted by this Agreement shall not be transferable by Optionee or any other person claiming through Optionee, either voluntarily or involuntarily, except by will or the laws of descent and distribution or as otherwise provided by the Committee pursuant to Article 11 of the Plan.

​

​

10.No Right to Continued Employment (or Service).  This Agreement shall not be construed to confer upon Optionee any right to continue employment (or service) with the Company and shall not limit the right of the Company, in its sole and absolute discretion, to terminate Optionee’s employment (or service) at any time.

11.Administration.  This Agreement shall at all times be subject to the terms and conditions of the Plan and the Plan shall in all respects be administered by the Committee in accordance with the terms of and as provided in the Plan.  The Committee shall have the sole and complete discretion with respect to all matters reserved to it by the Plan and decisions of the Committee with respect thereto and to this Agreement shall be final and binding upon Optionee and the Company.  In the event of any conflict between the terms and conditions of this Agreement and the Plan, the provisions of the Plan shall control.

12.Adjustments.  The number of shares of Stock issued to Optionee pursuant to this Agreement shall be adjusted by the Committee pursuant to Section 5.3 of the Plan, in its discretion, in the event of a change in the Company’s capital structure.

13.Securities Laws Compliance.  The Company shall not be required to deliver any shares of Stock pursuant to the exercise of the Option if, in the opinion of counsel for the Company, such issuance would violate the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other applicable federal or state securities laws or regulations.

14.No Shareholders Rights.  Optionee will have no voting rights or any other rights as a shareholder of the Company with respect to the Option until the Company issues the stock certificates representing the shares of Stock underlying the Option.

15.Copy of Plan.  By the execution of this Agreement, Optionee acknowledges receipt of a copy of the Plan.

16.Governing Law.  This Agreement shall be interpreted and administered under the laws of the State of California.

17.Amendment.  Except as otherwise provided in the Plan, this Agreement may be amended only by a written agreement executed by the Company and Optionee.  The provisions of this Agreement may not be waived or modified unless such waiver or modification is in writing and signed by a representative of the Committee.

18.Clawback.  Pursuant to Section 12.5 of the Plan, every Award issued pursuant to the Plan is subject to potential forfeiture or “clawback” to the fullest extent called for by applicable federal or state law or any policy of the Company.  By accepting this Award, Optionee agrees to be bound by, and comply with, the terms of any such forfeiture or “clawback” provision imposed by applicable federal or state law or prescribed by any policy of the Company.

MANY OF THE PROVISION OF THIS AWARD AGREEMENT ARE SUMMARIES OF SIMILAR PERTINENT PROVISIONS OF THE PLAN.  TO THE EXTENT THAT THIS AGREEMENT IS SILENT ON AN ISSUE OR THERE IS A CONFLICT BETWEEN THE PLAN AND THIS AGREEMENT, THE PLAN PROVISIONS SHALL CONTROL.

 EX-10.8 5 cyrx-20201231xex10d8.htm EXHIBIT 10.8

Exhibit 10.8

Cryoport, Inc.

2018 Omnibus Equity Incentive Plan

NOTICE OF GRANT OF RESTRICTED STOCK RIGHTS (EMPLOYEE FORM)

This Restricted Stock Right Agreement consists of this Notice of Grant of Restricted Stock Rights (the “Grant Notice”) and the Restricted Stock Right Award Agreement immediately following. The Restricted Stock Right Agreement sets forth the specific terms and conditions governing Restricted Stock Right Awards under the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (the “Plan”).  All of the terms of the Plan are incorporated herein by reference.

​

​

​

​

Name of Grantee:

​

Total No. of Restricted Stock
Rights:

​

Date of Grant:

​

Vesting Schedule:

Subject to Grantee’s continued employment:

​

.

​

BY ACCEPTING THIS RESTRICTED STOCK RIGHT AGREEMENT, WHETHER THROUGH ELECTRONIC SIGNATURE OR OTHER MEANS, GRANTEE ACCEPTS PARTICIPATION IN THE PLAN, ACKNOWLEDGES THAT HE OR SHE HAS READ AND UNDERSTANDS THE PROVISIONS OF THIS GRANT NOTICE, THE AWARD AGREEMENT AND THE PLAN, AND AGREES THAT THIS GRANT NOTICE, THE AWARD AGREEMENT AND THE PLAN SHALL GOVERN THE TERMS AND CONDITIONS OF THIS AWARD.

IN WITNESS WHEREOF, the Company and Grantee have duly executed this Restricted Stock Right Agreement, and this Restricted Stock Right Agreement shall be effective as of the Grant Date set forth above.

​

CRYOPORT, INC.

​

GRANTEE

​

  

​

By:

​

​

​

​

​

​

​

​

​

​

​

Print Name:

​

​

​

Signature

​

​

​

​

Its:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Print Name

​

​

1

​

RESTRICTED STOCK RIGHT AWARD AGREEMENT

Under the Cryoport, Inc.

2018 Omnibus Equity Incentive Plan

This Restricted Stock Right Award Agreement (this “Agreement”) is between Cryoport, Inc. (the “Company”) and the individual (the “Grantee”) identified in the Notice of Grant of Restricted Stock Rights (the “Grant Notice”) and is effective as of the date of grant referenced in the Grant Notice (the “Date of Grant”).  This Agreement supplements the Grant Notice to which it is attached, and, together, with the Grant Notice, constitutes the “Restricted Stock Right Agreement” referenced in the Grant Notice.

RECITALS

A.The Board of Directors of the Company (the “Board”) has adopted and the stockholders have approved the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (the “Plan”) to promote the interests and long-term success of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the continued growth and profitability of the Company.

B.The Committee has approved the grant of Restricted Stock Rights to Grantee pursuant to Section 7.2 of the Plan.

C.To the extent not specifically defined in this Agreement, all capitalized terms used in this Agreement shall have the meaning set forth in the Plan.

D.In consideration of the mutual covenants and conditions hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Grantee agree as follows:

AGREEMENT

1.Grant of Restricted Stock Rights.  Subject to the terms of this Agreement and Section 9.2 of the Plan, the Company grants to Grantee the aggregate number of Restricted Stock Rights specified in the Grant Notice.

2.Vesting of Restricted Stock Rights.  Subject to Grantee’s continued employment with the Company, the Restricted Stock Rights shall vest and become nonforfeitable according to the vesting schedule set forth in the Grant Notice.

3.Payment of Restricted Stock Rights.  The Restricted Stock Rights that become vested and nonforfeitable pursuant to Section 2 above will be paid in whole unrestricted and fully transferable shares of Stock within 30 days of each Vesting Date identified in the Grant Notice.

4.No Stockholder Rights.  During the restriction period and until the date of payment of Restricted Stock Rights pursuant to Section 3, the Grantee will not have any of the rights of a stockholder of the Company with respect to the Restricted Stock Right.

​

2

​

5.Withholding.  As described in Article 15 of the Plan, the Company shall have the right to deduct or withhold, or to require Grantee to remit to the Company, up to the maximum statutory amount necessary, in the applicable jurisdiction, to satisfy any federal, state, and local tax withholding requirements on any Award under the Plan. To the extent that alternative methods of withholding are available under applicable tax laws, the Committee shall have the power to choose among such methods.

6.No Right to Continued Employment. This Agreement shall not be construed to confer upon Grantee any right to continue employment with the Company and shall not limit the right of the Company, in its sole and absolute discretion, to terminate Grantee’s employment at any time.

7.Administration.  This Agreement shall at all times be subject to the terms and conditions of the Plan and the Plan shall in all respects be administered by the Committee in accordance with the terms of and as provided in the Plan.  The Committee shall have the sole and complete discretion with respect to all matters reserved to it by the Plan and decisions of the Committee with respect thereto and to this Agreement shall be final and binding upon Grantee and the Company.  In the event of any conflict between the terms and conditions of this Agreement and the Plan, the provisions of the Plan shall control.

8.Adjustments.  The number of shares of Stock issued to Grantee pursuant to this Agreement shall be adjusted by the Committee pursuant to Section 5.3 of the Plan, in its discretion, in the event of a change in the Company’s capital structure.

9.Securities Laws Compliance.  The Company shall not be required to deliver any shares of Stock pursuant to the settlement of this Award if, in the opinion of counsel for the Company, such issuance would violate the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other applicable federal or state securities laws or regulations.

10.Copy of Plan; Electronic Signature.  By accepting this Agreement (whether through electronic signature or other means), the Grantee acknowledges receipt of a copy of the Plan.  The Grantee acknowledges that the Grantee’s electronic signature has the same legal force and effect as a written or manual signature.

11.Amendment.  Except as otherwise provided in the Plan, this Agreement may be amended only by a written agreement executed by the Company and Grantee.  The provisions of this Agreement may not be waived or modified unless such waiver or modification is in writing and signed by a representative of the Committee.

12.Clawback.  Pursuant to Section 12.5 of the Plan, every Award issued pursuant to the Plan is subject to potential forfeiture or “clawback” to the fullest extent called for by applicable federal or state law or any policy of the Company.  By accepting this Award, Grantee agrees to be bound by, and comply with, the terms of any such forfeiture or “clawback” provision imposed by applicable federal or state law or prescribed by any policy of the Company.

13.Section 409A Compliance. The Restricted Stock Rights, if any, that become payable pursuant to this Notice may be considered “nonqualified deferred compensation” that is subject to the requirements of Section 409A of the Code.  The Company intends, but does not and cannot warrant or guaranty, that the Restricted Stock Rights will be paid in compliance with Section 409A of the Code or an applicable exception.  Neither the time nor the schedule of the payment of the Restricted Stock Rights may be accelerated or subject to a further deferral except as permitted pursuant to Section 409A of the Code and the applicable regulations.  Payment of the Restricted Stock Rights may be delayed only in accordance with Section 409A of the Code and the applicable regulations.  Grantee may not make any election regarding the time or the form of the payment of the Restricted Stock Rights.  This Notice shall be administered in

​

3

​

compliance with Section 409A of the Code or an exception thereto and each provision shall be interpreted, to the extent possible, to comply with Section 409A of the Code and the applicable regulations.

MANY OF THE PROVISION OF THIS AWARD AGREEMENT ARE SUMMARIES OF SIMILAR PERTINENT PROVISIONS OF THE PLAN.  TO THE EXTENT THAT THIS AGREEMENT IS SILENT ON AN ISSUE OR THERE IS A CONFLICT BETWEEN THE PLAN AND THIS AGREEMENT, THE PLAN PROVISIONS SHALL CONTROL.

4

 EX-21 6 cyrx-20201231xex21.htm EXHIBIT 21

​

 EXHIBIT 21

​

SUBSIDIARIES OF CRYOPORT, INC.

AND JURISDICTION OF INCORPORATION OR ORGANIZATION

​

Cryogene, Inc.

Texas

Cryoport Systems, LLC

California

MVE Biological Solutions US, LLC

Delaware

Cryoport Netherlands BV

The Netherlands

Cryoport Japan GK

Japan

Cryoport UK Limited

United Kingdom

MVE Biological Solutions Australia Pty Limited

Australia

MVE Biological Solutions Germany GmbH

Germany

MVE Biological Solutions (Chengdu) Co., Ltd.*

China

Advanced Therapy Logistics and Solutions

France

Atlas Bidco

France

Cryo International SA

France

Cryo Express SA

France

Cryo Express SP. ZO.O.

Poland

Cryo Express GmbH

Germany

Cryo Express Pty. Ltd.

Australia

SPL Services Limited

United Kingdom

CryoPDP Global Services, Unipessoal LDA

Portugal

I.C.S. Dry-Ice Express B.V.

The Netherlands

PDP Courier Services Limited

United Kingdom

PDP Courier Services (USA), Inc.

Delaware

PDP Couriers (Singapore) PTE. LTD

Singapore

PDP Couriers Korea Co., Ltd.

South Korea

PDP Life Science Logistics India Private Limited

India

​

*  Transfer and name change in process pending final approval of applicable regulatory bodies in China

 EX-23.1 7 cyrx-20201231xex23d1.htm EXHIBIT 23.1

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statement (Form S-3 No. 333-230237, 333-229395 and 333-251354 of Cryoport, Inc.;
(2)Registration Statement (Form S-8 No. 333-225387) pertaining to the 2018 Omnibus Equity Incentive Plan;
(3)Registration Statement (Form S-8 No. 333-208381) pertaining to the 2015 Omnibus Equity Incentive Plan;
(4)Registration Statement (Form S-8 No. 333-177168, 333-184543, and 333-197437) pertaining to the 2011 Stock Incentive Plan;

of our reports dated March 1, 2021, with respect to the consolidated financial statements of Cryoport, Inc. and the effectiveness of internal control over financial reporting of Cryoport, Inc. included in this Annual Report (Form 10-K) of Cryoport, Inc. for the year ended December 31, 2020.

/s/ Ernst & Young LLP

​

​

​

Irvine, California

​

March 1, 2021

​

​

 EX-31.1 8 cyrx-20201231xex31d1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Jerrell W. Shelton, certify that:

1.

I have reviewed this Annual Report on Form 10-K of Cryoport, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 1, 2021

​

​

/s/ JERRELL W. SHELTON

​

JERRELL W. SHELTON

​

Chief Executive Officer and Director

​

(Principal Executive Officer)

​

 EX-31.2 9 cyrx-20201231xex31d2.htm EXHIBIT 31.2

​

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Robert S. Stefanovich, certify that:

1.

I have reviewed this Annual Report on Form 10-K of Cryoport, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 1, 2021

​

​

/s/ ROBERT S. STEFANOVICH

​

Robert S. Stefanovich

​

Chief Financial Officer

​

(Principal Financial Officer)

​

 EX-32.1 10 cyrx-20201231xex32d1.htm EXHIBIT 32.1

​

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Cryoport, Inc. (the “Company”), hereby certifies, to such officer’s knowledge, that:

(i) the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 1, 2021

​

/s/ JERRELL W. SHELTON

​

Jerrell W. Shelton

​

Chief Executive Officer and Director

​

This certification accompanies this Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 EX-32.2 11 cyrx-20201231xex32d2.htm EXHIBIT 32.2

​

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Cryoport, Inc. (the “Company”), hereby certifies, to such officer’s knowledge, that:

(i) the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 1, 2021

​

/s/ ROBERT S. STEFANOVICH

​

Robert S. Stefanovich

​

Chief Financial Officer

​

This certification accompanies this Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 GRAPHIC 12 cyrx-20201231x10k004.jpg GRAPHIC begin 644 cyrx-20201231x10k004.jpg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end GRAPHIC 13 cyrx-20201231x10k008.jpg GRAPHIC begin 644 cyrx-20201231x10k008.jpg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end EX-101.SCH 14 cyrx-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Accrued Compensation and Related Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Convertible Senior Notes - Components of Convertible notes payable (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Leases - Components Of Lease Cost (Detail) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - Leases - Payments Under Non-Cancellable Leases (Details) link:presentationLink link:calculationLink link:definitionLink 41702 - Disclosure - Income Taxes (Expense For Income Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 41704 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 31603 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of the Business (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of Significant Accounting Policies - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Shares (Details) link:presentationLink link:calculationLink link:definitionLink 40205 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Acquisition of CryoGene Partners - Preliminary Fair Value of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Acquisition of CryoGene Partners - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details) link:presentationLink link:calculationLink link:definitionLink 40405 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Goodwill and Other Intangible Assets - Schedule of goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Convertible Senior Notes - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Note Payable (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Leases - Supplemental Cash Flows Information (Detail) link:presentationLink link:calculationLink link:definitionLink 41204 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Employee Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Stock-Based Compensation - Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41602 - Disclosure - Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 41603 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41604 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41605 - Disclosure - Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 41606 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - Income Taxes (Loss Before Provision For Income Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 41705 - Disclosure - Income Taxes - net deferred tax liability as presented in consolidated balance sheet (Details) link:presentationLink link:calculationLink link:definitionLink 41706 - Disclosure - Income Taxes (Schedule of unrecognized tax positions) (Details) link:presentationLink link:calculationLink link:definitionLink 41707 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 41801 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 41901 - Disclosure - Quarterly Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of the Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Cash, Cash Equivalents and Short-Term Investments link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Goodwill And Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Accrued Compensation and Related Expenses link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Convertible Senior Notes link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Note Payable link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11801 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 11901 - Disclosure - Quarterly Financial Data link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Accrued Compensation and Related Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Convertible Senior Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 31703 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 31903 - Disclosure - Quarterly Financial Data (Tables) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details) link:presentationLink link:calculationLink link:definitionLink 41703 - Disclosure - Income Taxes (Schedule of Income Tax Provision) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 cyrx-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 16 cyrx-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 17 cyrx-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 18 cyrx-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 19 cyrx-20201231x10k_htm.xml IDEA: XBRL DOCUMENT 0001124524 us-gaap:DomesticCountryMember 2020-12-31 0001124524 us-gaap:DomesticCountryMember 2019-12-31 0001124524 us-gaap:DomesticCountryMember 2018-12-31 0001124524 us-gaap:RetainedEarningsMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001124524 us-gaap:PreferredClassAMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001124524 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2021-02-05 2021-02-05 0001124524 us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2021-01-25 2021-01-25 0001124524 us-gaap:PreferredClassBMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001124524 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001124524 us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2021-01-21 2021-01-21 0001124524 srt:DirectorMember 2020-01-01 2020-12-31 0001124524 srt:DirectorMember 2019-01-01 2019-12-31 0001124524 us-gaap:RetainedEarningsMember 2020-12-31 0001124524 us-gaap:PreferredClassBMember 2020-12-31 0001124524 us-gaap:PreferredClassAMember 2020-12-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001124524 us-gaap:RetainedEarningsMember 2019-12-31 0001124524 us-gaap:PreferredClassAMember 2019-12-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001124524 us-gaap:RetainedEarningsMember 2018-12-31 0001124524 us-gaap:PreferredClassAMember 2018-12-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001124524 us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2021-01-21 0001124524 us-gaap:CommonStockMember 2020-12-31 0001124524 cyrx:PreferredClassCMember 2020-12-31 0001124524 us-gaap:PreferredClassBMember 2019-12-31 0001124524 us-gaap:CommonStockMember 2019-12-31 0001124524 us-gaap:PreferredClassBMember 2018-12-31 0001124524 us-gaap:CommonStockMember 2018-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeTwoMember 2020-01-01 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeThreeMember 2020-01-01 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeSixMember 2020-01-01 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeSevenMember 2020-01-01 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeOneMember 2020-01-01 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeFourMember 2020-01-01 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeFiveMember 2020-01-01 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeEightMember 2020-01-01 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeTwoMember 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeThreeMember 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeSixMember 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeSevenMember 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeOneMember 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeFourMember 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeFiveMember 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:RangeEightMember 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember 2019-12-31 0001124524 us-gaap:WarrantMember 2018-12-31 0001124524 us-gaap:EmployeeStockOptionMember 2018-12-31 0001124524 us-gaap:WarrantMember 2018-01-01 2018-12-31 0001124524 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:Plan2018Member 2020-12-31 0001124524 us-gaap:EmployeeStockOptionMember cyrx:Plan2018Member 2018-05-31 0001124524 srt:MinimumMember 2019-01-01 2019-12-31 0001124524 srt:MaximumMember 2019-01-01 2019-12-31 0001124524 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001124524 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001124524 cyrx:EngineeringAndDevelopmentMember 2020-01-01 2020-12-31 0001124524 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001124524 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001124524 cyrx:EngineeringAndDevelopmentMember 2019-01-01 2019-12-31 0001124524 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001124524 cyrx:HumanReproductiveMedicineMember cyrx:GlobalLogisticsSolutionsMember 2020-01-01 2020-12-31 0001124524 cyrx:BiopharmaceuticalMember cyrx:GlobalLogisticsSolutionsMember 2020-01-01 2020-12-31 0001124524 cyrx:AnimalHealthMember cyrx:GlobalLogisticsSolutionsMember 2020-01-01 2020-12-31 0001124524 us-gaap:EMEAMember 2020-01-01 2020-12-31 0001124524 srt:AsiaPacificMember 2020-01-01 2020-12-31 0001124524 srt:AmericasMember 2020-01-01 2020-12-31 0001124524 cyrx:GlobalLogisticsSolutionsMember 2020-01-01 2020-12-31 0001124524 cyrx:ForeignCustomersMember 2020-01-01 2020-12-31 0001124524 cyrx:HumanReproductiveMedicineMember cyrx:GlobalLogisticsSolutionsMember 2019-01-01 2019-12-31 0001124524 cyrx:BiopharmaceuticalMember cyrx:GlobalLogisticsSolutionsMember 2019-01-01 2019-12-31 0001124524 cyrx:AnimalHealthMember cyrx:GlobalLogisticsSolutionsMember 2019-01-01 2019-12-31 0001124524 us-gaap:EMEAMember 2019-01-01 2019-12-31 0001124524 srt:AsiaPacificMember 2019-01-01 2019-12-31 0001124524 srt:AmericasMember 2019-01-01 2019-12-31 0001124524 cyrx:GlobalLogisticsSolutionsMember 2019-01-01 2019-12-31 0001124524 cyrx:ForeignCustomersMember 2019-01-01 2019-12-31 0001124524 srt:MinimumMember us-gaap:ComputerEquipmentMember 2020-01-01 2020-12-31 0001124524 srt:MinimumMember us-gaap:BuildingMember 2020-01-01 2020-12-31 0001124524 srt:MinimumMember cyrx:TruckAndAutoMember 2020-01-01 2020-12-31 0001124524 srt:MinimumMember cyrx:FreezerMember 2020-01-01 2020-12-31 0001124524 srt:MinimumMember cyrx:EquipmentAndFurnitureMember 2020-01-01 2020-12-31 0001124524 srt:MaximumMember us-gaap:ComputerEquipmentMember 2020-01-01 2020-12-31 0001124524 srt:MaximumMember cyrx:TruckAndAutoMember 2020-01-01 2020-12-31 0001124524 srt:MaximumMember cyrx:FreezerMember 2020-01-01 2020-12-31 0001124524 srt:MaximumMember cyrx:EquipmentAndFurnitureMember 2020-01-01 2020-12-31 0001124524 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001124524 us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2021-01-21 2021-01-21 0001124524 2019-06-24 2019-06-24 0001124524 2019-06-24 0001124524 us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2020-12-31 0001124524 cyrx:ClassBConvertiblePreferredStockMember 2020-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2020-10-01 0001124524 us-gaap:ConvertiblePreferredStockMember 2019-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2019-12-31 0001124524 cyrx:ClassBConvertiblePreferredStockMember 2019-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2021-02-05 0001124524 cyrx:MveCryobiologicalStorageBusinessMember 2020-08-24 2020-08-24 0001124524 2020-05-01 2020-05-31 0001124524 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001124524 cyrx:MutualFundsMember 2020-12-31 0001124524 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001124524 cyrx:MutualFundsMember 2019-12-31 0001124524 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001124524 us-gaap:DomesticCountryMember 2019-12-31 0001124524 cyrx:FederalTaxIncomeMember 2019-12-31 0001124524 cyrx:InstallmentTwoMember cyrx:CryopdpMember 2020-12-31 0001124524 cyrx:InstallmentOneMember cyrx:CryopdpMember 2020-12-31 0001124524 cyrx:CryopdpMember 2020-12-31 0001124524 us-gaap:ForeignCountryMember 2020-01-01 2020-12-31 0001124524 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001124524 us-gaap:ForeignCountryMember 2019-01-01 2019-12-31 0001124524 us-gaap:DomesticCountryMember 2019-01-01 2019-12-31 0001124524 us-gaap:UseRightsMember 2020-01-01 2020-12-31 0001124524 us-gaap:TrademarksAndTradeNamesMember 2020-01-01 2020-12-31 0001124524 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-01-01 2020-12-31 0001124524 us-gaap:NoncompeteAgreementsMember 2020-01-01 2020-12-31 0001124524 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0001124524 cyrx:AgentNetworkMember 2020-01-01 2020-12-31 0001124524 us-gaap:TrademarksAndTradeNamesMember 2019-01-01 2019-12-31 0001124524 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0001124524 us-gaap:NoncompeteAgreementsMember 2019-01-01 2019-12-31 0001124524 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0001124524 cyrx:PatentsAndTrademarksMember 2019-01-01 2019-12-31 0001124524 us-gaap:UseRightsMember 2020-12-31 0001124524 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0001124524 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-12-31 0001124524 us-gaap:OrderOrProductionBacklogMember 2020-12-31 0001124524 us-gaap:NoncompeteAgreementsMember 2020-12-31 0001124524 us-gaap:CustomerRelationshipsMember 2020-12-31 0001124524 cyrx:PatentsAndTrademarksMember 2020-12-31 0001124524 cyrx:AgentNetworkMember 2020-12-31 0001124524 us-gaap:TrademarksAndTradeNamesMember 2019-12-31 0001124524 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0001124524 us-gaap:NoncompeteAgreementsMember 2019-12-31 0001124524 us-gaap:CustomerRelationshipsMember 2019-12-31 0001124524 cyrx:PatentsAndTrademarksMember 2019-12-31 0001124524 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001124524 2020-10-01 2020-12-31 0001124524 2020-07-01 2020-09-30 0001124524 2020-04-01 2020-06-30 0001124524 2020-01-01 2020-03-31 0001124524 2019-10-01 2019-12-31 0001124524 2019-07-01 2019-09-30 0001124524 2019-04-01 2019-06-30 0001124524 2019-01-01 2019-03-31 0001124524 cyrx:UsEmployeesMember 2020-01-01 2020-12-31 0001124524 cyrx:UsEmployeesMember 2019-01-01 2019-12-31 0001124524 cyrx:DeferredIncomeTaxLiabilitiesNetMember 2020-12-31 0001124524 cyrx:DeferredIncomeTaxLiabilitiesNetMember 2019-12-31 0001124524 us-gaap:OtherNoncurrentAssetsMember 2020-12-31 0001124524 cyrx:UsEmployeesMember 2020-12-31 0001124524 cyrx:NonUsEmployeesMember 2020-12-31 0001124524 cyrx:UsEmployeesMember 2019-12-31 0001124524 cyrx:NonUsEmployeesMember 2019-12-31 0001124524 us-gaap:ConvertibleDebtMember 2018-12-14 0001124524 us-gaap:PrivatePlacementMember 2020-05-31 0001124524 2020-05-31 0001124524 us-gaap:SeniorNotesMember 2020-12-31 0001124524 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001124524 us-gaap:SeniorNotesMember 2020-01-01 2020-12-31 0001124524 us-gaap:ServiceMember 2020-01-01 2020-12-31 0001124524 us-gaap:ProductMember 2020-01-01 2020-12-31 0001124524 us-gaap:ServiceMember 2019-01-01 2019-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2020-10-01 0001124524 cyrx:ForeignCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-12-31 0001124524 cyrx:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-12-31 0001124524 cyrx:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-12-31 0001124524 us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-12-31 0001124524 us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001124524 cyrx:ForeignCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2019-01-01 2019-12-31 0001124524 cyrx:CustomerTwoMember us-gaap:AccountsReceivableMember 2019-01-01 2019-12-31 0001124524 cyrx:CustomerOneMember us-gaap:AccountsReceivableMember 2019-01-01 2019-12-31 0001124524 us-gaap:RevenueFromContractWithCustomerMember 2019-01-01 2019-12-31 0001124524 us-gaap:AccountsReceivableMember 2019-01-01 2019-12-31 0001124524 2019-10-31 0001124524 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-02-05 0001124524 us-gaap:EmployeeStockOptionMember 2020-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2020-12-31 0001124524 us-gaap:WarrantMember 2020-12-31 0001124524 us-gaap:WarrantMember 2019-12-31 0001124524 2018-12-31 0001124524 cyrx:CryogenePartnersMember 2020-12-31 0001124524 cyrx:MveCryobiologicalStorageBusinessMember us-gaap:UseRightsMember 2020-10-01 0001124524 cyrx:MveCryobiologicalStorageBusinessMember us-gaap:TrademarksAndTradeNamesMember 2020-10-01 0001124524 cyrx:MveCryobiologicalStorageBusinessMember us-gaap:OrderOrProductionBacklogMember 2020-10-01 0001124524 cyrx:MveCryobiologicalStorageBusinessMember us-gaap:DevelopedTechnologyRightsMember 2020-10-01 0001124524 cyrx:MveCryobiologicalStorageBusinessMember us-gaap:CustomerRelationshipsMember 2020-10-01 0001124524 cyrx:CryopdpMember us-gaap:TrademarksAndTradeNamesMember 2020-10-01 0001124524 cyrx:CryopdpMember us-gaap:CustomerRelationshipsMember 2020-10-01 0001124524 cyrx:CryopdpMember us-gaap:ComputerSoftwareIntangibleAssetMember 2020-10-01 0001124524 cyrx:CryopdpMember cyrx:AgentNetworkMember 2020-10-01 0001124524 cyrx:CryogenePartnersMember us-gaap:TrademarksAndTradeNamesMember 2019-05-14 0001124524 cyrx:CryogenePartnersMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-05-14 0001124524 cyrx:CryogenePartnersMember us-gaap:NoncompeteAgreementsMember 2019-05-14 0001124524 cyrx:CryogenePartnersMember us-gaap:CustomerRelationshipsMember 2019-05-14 0001124524 2020-10-01 0001124524 cyrx:CryogenePartnersMember 2019-05-14 2019-05-14 0001124524 cyrx:CryogenePartnersMember 2019-05-04 2019-05-04 0001124524 cyrx:MveCryobiologicalStorageBusinessMember 2020-01-01 2020-12-31 0001124524 cyrx:CryogenePartnersMember 2019-01-01 2019-12-31 0001124524 cyrx:CryogenePartnersMember 2019-05-14 0001124524 us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001124524 us-gaap:USTreasuryNotesSecuritiesMember 2019-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2020-12-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2019-12-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2019-12-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2019-12-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2019-12-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2019-12-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2019-12-31 0001124524 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryNotesSecuritiesMember 2019-12-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2019-12-31 0001124524 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001124524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001124524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001124524 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001124524 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001124524 cyrx:ConvertibleSeniorNotesMember 2020-01-01 2020-12-31 0001124524 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001124524 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001124524 cyrx:MveCryobiologicalStorageBusinessMember 2020-10-01 2020-10-01 0001124524 cyrx:CryopdpMember 2020-10-01 2020-10-01 0001124524 cyrx:CryogenePartnersMember 2020-01-01 2020-12-31 0001124524 us-gaap:GeneralAndAdministrativeExpenseMember 2019-10-01 2019-12-31 0001124524 us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001124524 cyrx:PublicOfferingMember 2019-01-01 2019-12-31 0001124524 cyrx:MveCryobiologicalStorageBusinessMember us-gaap:UseRightsMember 2020-10-01 2020-10-01 0001124524 cyrx:MveCryobiologicalStorageBusinessMember us-gaap:OrderOrProductionBacklogMember 2020-10-01 2020-10-01 0001124524 cyrx:MveCryobiologicalStorageBusinessMember us-gaap:DevelopedTechnologyRightsMember 2020-10-01 2020-10-01 0001124524 cyrx:MveCryobiologicalStorageBusinessMember us-gaap:CustomerRelationshipsMember 2020-10-01 2020-10-01 0001124524 cyrx:CryopdpMember us-gaap:CustomerRelationshipsMember 2020-10-01 2020-10-01 0001124524 cyrx:CryopdpMember us-gaap:ComputerSoftwareIntangibleAssetMember 2020-10-01 2020-10-01 0001124524 cyrx:CryopdpMember cyrx:AgentNetworkMember 2020-10-01 2020-10-01 0001124524 cyrx:CryogenePartnersMember us-gaap:TrademarksAndTradeNamesMember 2019-05-14 2019-05-14 0001124524 cyrx:CryogenePartnersMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-05-14 2019-05-14 0001124524 cyrx:CryogenePartnersMember us-gaap:NoncompeteAgreementsMember 2019-05-14 2019-05-14 0001124524 cyrx:CryogenePartnersMember us-gaap:CustomerRelationshipsMember 2019-05-14 2019-05-14 0001124524 2020-06-30 0001124524 2021-02-19 0001124524 us-gaap:PrivatePlacementMember 2020-05-01 2020-05-31 0001124524 2020-06-29 2020-06-29 0001124524 cyrx:ClassCConvertiblePreferredStockMember us-gaap:SubsequentEventMember cyrx:PreferredStockRedemptionPeriodOneMember 2021-02-05 2021-02-05 0001124524 cyrx:ClassCConvertiblePreferredStockMember cyrx:PreferredStockRedemptionPeriodTwoMember 2020-10-01 2020-10-01 0001124524 cyrx:ClassCConvertiblePreferredStockMember cyrx:PreferredStockRedemptionPeriodThreeMember 2020-10-01 2020-10-01 0001124524 cyrx:ClassCConvertiblePreferredStockMember cyrx:PreferredStockRedemptionPeriodOneMember 2020-10-01 2020-10-01 0001124524 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-02-05 2021-02-05 0001124524 cyrx:CryopdpMember 2020-08-21 2020-08-21 0001124524 cyrx:CryopdpMember 2020-01-01 2020-12-31 0001124524 cyrx:ClassCConvertiblePreferredStockMember 2020-10-01 2020-10-01 0001124524 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2020-10-01 2020-10-01 0001124524 cyrx:ClassCConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2020-10-01 2020-10-01 0001124524 us-gaap:PrivatePlacementMember 2020-10-01 2020-10-01 0001124524 srt:MinimumMember 2020-01-01 2020-12-31 0001124524 srt:MaximumMember 2020-01-01 2020-12-31 0001124524 cyrx:MveCryobiologicalStorageBusinessMember 2019-01-01 2019-12-31 0001124524 2020-10-01 2020-10-01 0001124524 cyrx:ScenarioOneMember 2020-01-01 2020-12-31 0001124524 cyrx:ScenarioTwoMember 2020-01-01 2020-12-31 0001124524 cyrx:MveCryobiologicalStorageBusinessMember 2020-10-01 0001124524 cyrx:CryopdpMember 2020-10-01 0001124524 2020-12-31 0001124524 2019-12-31 0001124524 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001124524 us-gaap:PreferredClassBMember 2020-01-01 2020-12-31 0001124524 us-gaap:PreferredClassAMember 2020-01-01 2020-12-31 0001124524 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001124524 cyrx:PreferredClassCMember 2020-01-01 2020-12-31 0001124524 2020-01-01 2020-12-31 0001124524 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001124524 us-gaap:PreferredClassBMember 2019-01-01 2019-12-31 0001124524 us-gaap:PreferredClassAMember 2019-01-01 2019-12-31 0001124524 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001124524 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001124524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001124524 2019-01-01 2019-12-31 iso4217:USD iso4217:USD shares cyrx:item pure shares iso4217:EUR cyrx:segment 0 0 0001124524 --12-31 2020 FY 250000 250000 37339787 39837058 P3Y P7Y P4Y P3Y P20Y P45Y true P0Y P0Y P0Y P0Y false 10-K true 2020-12-31 false 001-34632 CRYOPORT, INC. NV 88-0313393 112 Westwood Place Suite 350 Brentwood TN 37027 949 470-2300 Common Stock, $0.001 par value CYRX NASDAQ Yes No Yes Yes Large Accelerated Filer true false true false 881352700 45581661 36873000 47235000 56444000 47061000 1100000 100000 31377000 7098000 10535000 474000 11928000 1097000 147157000 102965000 30036000 11833000 14044000 4460000 213908000 5178000 145282000 11000000 1184000 437000 794000 0 552405000 135873000 24844000 2498000 7441000 1904000 445000 368000 2231000 666000 59000 25000 35020000 5461000 3700000 111344000 0 4912000 0 12261000 4101000 112000 9000 5882000 21000 176000 0 169707000 9592000 0.001 0.001 2500000 2500000 0.001 0.001 800000 800000 0 0 0 0 0.001 0.001 585000 585000 0 0 0 0 0.001 0.001 250000 250000 250000 250000 2844000 0 0.001 0.001 100000000 100000000 39837058 37339787 40000 37000 566451000 285609000 -192013000 -159320000 5376000 -45000 382698000 126281000 552405000 135873000 55299000 33942000 23397000 78696000 33942000 29521000 16590000 12841000 42362000 16590000 36334000 17352000 56860000 31286000 9484000 3741000 66344000 35027000 -30010000 -17675000 761000 583000 2560000 1367000 -929000 189000 -2728000 -595000 -32738000 -18270000 -45000 62000 -32693000 -18332000 39492000 2844000 -75029000 -18332000 -1.94 -0.55 38582432 33394285 -32693000 -18332000 -161000 28000 3000 23000 5263000 3000 5421000 -48000 -27272000 -18380000 0 0 0 0 30319038 30000 179502000 -140988000 3000 38547000 0 0 0 0 0 0 0 -18332000 0 -18332000 0 0 0 0 0 0 0 0 -48000 -48000 0 0 0 0 0 0 6871000 0 0 6871000 0 0 0 0 0 0 9562000 0 0 9562000 103000 0 0 0 0 4312500 4000 68806000 0 0 68810000 0 0 0 0 1172305 1000 15416000 0 0 15417000 0 0 0 0 5753 0 91000 0 0 91000 0 0 0 0 1530191 2000 5361000 0 0 5363000 0 0 0 0 37339787 37000 285609000 -159320000 -45000 126281000 0 0 0 0 0 0 0 -32693000 0 -32693000 0 0 0 0 0 0 0 0 5421000 5421000 0 0 0 0 0 0 8833000 0 0 8833000 0 0 0 0 2869 0 83000 0 0 83000 914200 0 0 0 0 675536 1000 28159000 0 0 28160000 7700000 0 0 0 0 250000 0 0 237225000 0 0 237225000 0 0 0 0 -39492000 0 0 39492000 0 0 0 0 0 0 0 39492000 0 0 -39492000 0 0 0 0 0 0 0 2844000 0 0 -2844000 0 0 0 0 0 0 0 1818866 2000 9386000 0 0 9388000 0 0 0 0 250000 2844000 39837058 40000 566451000 -192013000 5376000 382698000 -32693000 -18332000 9869000 2415000 437000 288000 0 418000 845000 -102000 1090000 0 -32000 82000 8916000 6962000 0 9562000 -384000 -274000 197000 42000 2617000 3596000 -1322000 253000 7520000 345000 152000 86000 -134000 6000 4245000 570000 3143000 641000 -309000 81000 -499000 21000 -14866000 -1324000 8918000 5336000 158736000 43196000 149233000 5995000 200000 73000 551000 0 363140000 20317000 -382312000 -62927000 9388000 5363000 237225000 0 28160000 0 0 68811000 70000 23000 115000000 0 4118000 0 385585000 74151000 1231000 8000 -10362000 9908000 47235000 37327000 36873000 47235000 1823000 707000 60000 14000 161000 -28000 3000 23000 499000 261000 205000 0 2844000 0 0 15418000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cryoport, Inc. (“Cryoport”, “we”, or “our”) is a life sciences services company that is an integral part of the temperature-controlled supply chain supporting the biopharma/pharma, animal health, and human reproductive medicine markets. We are redefining logistics for the life sciences industry by providing a unique platform of critical solutions including highly differentiated temperature-controlled supply chain solutions, which include advanced packaging, informatics, specialty logistics services, biostorage services and cryogenic life sciences equipment. Through our products, services and expertise, we enable our clients to ship, store and deliver cellular-based materials and drug products as well as other life sciences commodities in a precise, defined temperature-controlled state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cryoport’s advanced platform, comprised of comprehensive and technology-centric systems and solutions are designed to support the global high-volume distribution of commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA) and other international regulatory bodies for distribution in the Americas, EMEA (Europe, the Middle East, and Africa) and APAC (Asia-Pacific) regions. Cryoport’s solutions are also designed to support pre-clinical, clinical trials, Biologics License Applications (BLA), Investigational New Drug Applications (IND), New Drug Applications (NDA) and Commercialized Products with the FDA, as well as global clinical trials and commercialized products initiated in other countries, where strict regulatory compliance and quality assurance is mandated. Our industry standard setting Chain of Compliance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> solutions, which include vital analytics, such as ‘chain-of-condition’ and ‘chain-of-custody’ information in a single data stream, empower our clients’ continuous vigilance over their respective commodities. In addition, our Chain of Compliance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> standard ensures full traceability of all equipment used and the processes employed, further supporting each client’s goal of minimizing risk and maximizing success of their respective biologics or other products and therapies as they are introduced into the global markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 21, 2020, the Company entered into a Securities Purchase Agreement to acquire CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets, headquartered in Paris, France. Under the terms of the Securities Purchase Agreement, the Company acquired 100% of the equity interests in Advanced Therapy Logistics and Solutions, a company organized under the laws of France, which is the holding company that owns CRYOPDP (the “CRYOPDP Acquisition”). The base purchase price under the Securities Purchase Agreement was €49 million (approximately $58.0 million) and is subject to a cash, net debt, working capital and other adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 24, 2020, the Company entered into a Purchase Agreement with Chart Industries, Inc. (“Chart”) pursuant to which the Company acquired Chart’s MVE Biological Solutions’ cryobiological storage business (the “MVE Acquisition”) for a cash purchase price at closing of $320 million, subject to customary closing working capital and other adjustments. The MVE Acquisition was structured as the acquisition of certain equity interests and assets and the transfer of certain liabilities in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2020, the Company completed both the MVE Acquisition and the CRYOPDP Acquisition, which are further discussed in Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 14, 2019, the Company acquired substantially all of the assets of Cryogene Partners, a Texas general partnership doing business as Cryogene Labs (“Cryogene”).  Cryogene operates a temperature-controlled biostorage solutions business in Houston, Texas (See Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”</p> 1 49000000 58000000.0 320000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Change in Segment Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company continually monitors and reviews its segment reporting structure in accordance with authoritative guidance to determine whether any changes have occurred that would impact its reportable operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The chief operating decision maker (“CODM”) is our Chief Executive Officer. Up until the fourth quarter of 2020, we managed, reported and evaluated our business in the following two reportable operating segments: Global Logistics Solutions and Global Bioservices. During the fourth quarter of 2020, our CODM changed how he makes operating decisions, assesses the performance of the business and allocates resources in a manner that caused our operating segments to change as a result of the MVE and CRYOPDP acquisitions. In consideration of Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”), 280, <i style="font-style:italic;">Segment Reporting</i>, we determined that we are not organized around specific products and services, geographic regions or regulatory environments. Accordingly, beginning with the fourth quarter of 2020, we realigned our reporting structure, resulting in a single reportable segment. The Company has adjusted its financial statements for historical periods to reflect this change in segment reporting and show its financial results without segments for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries, Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions US LLC, and Cryoport Netherlands B.V. and subsidiaries (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Short-Term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, note payable, and the Company’s 3.00% convertible senior notes due in 2025 (the “Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, note payable and the Senior Notes, approximates fair value at December 31, 2020 due to their short-term nature. The carrying value of finance lease liabilities approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the note payable and the Senior Notes, see Note 5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2020 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investment policy requires that purchased instruments in marketable securities may only be in highly rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants credit to customers within the U.S. and to international customers and does not require collateral. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables is affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at December 31, 2020, and 2019 are net of reserves for doubtful accounts of $1.1 million and $0.1 million, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s customers are in the biotechnology, pharmaceutical, animal health, human reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. As of December 31, 2019, there were two customers that accounted for 31.0% and 20.7%, respectively, of net accounts receivable. There were no other single customer that owed us more than 10%of net accounts receivable at December 31, 2020 and 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has revenue from foreign customers primarily in United Kingdom, Switzerland, France, Netherlands, Singapore, China and India. During the years ended December 31, 2020 and 2019, the Company had revenues from foreign customers of approximately $29.1 million and $5.1 million, respectively, which constituted approximately 37.0% and 15.1%, respectively, of total revenues. There  were two customers that accounted for 24.1% and 12.8% of revenues during the year ended December 31, 2019. No other single customer generated over 10% of revenues during the years ended December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, less accumulated depreciation.  We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally <span style="-sec-ix-hidden:Hidden_gFE5Gdd7YkmhMnRY2olGoA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to twelve years for computer hardware and software, <span style="-sec-ix-hidden:Hidden_9CgQBpu3jkObQRec4bqWBw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seven</span></span> to ten years for freezers, <span style="-sec-ix-hidden:Hidden_QRW71qFdLE2VmJjFcBxTRQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four</span></span> to ten years for trucks and autos, <span style="-sec-ix-hidden:Hidden_jU6ZyFp8zkuPWxs8KHtatw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to fifteen years for furniture and equipment and over the shorter of the lease term or useful live of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from <span style="-sec-ix-hidden:Hidden_ej74RWj0pU2GoyydWXICqA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">20</span></span> to <span style="-sec-ix-hidden:Hidden__B_byg2juk6my-mv7uo2IA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">45</span></span> years. Maintenance and repairs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received.  Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees.  Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for lease and non-lease components as a single lease component for all its leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combinations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company compares the fair value of the reporting unit’s with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting units fair value up to the total amount of goodwill allocated to the reporting unit. The Company assessed  triggering events indicating potential goodwill impairment, including the effects of the COVID-19 pandemic, and after assessment, concluded that there was no impairment during the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are comprised of patents, trademarks, software development costs and the intangible assets acquired in the MVE, CRYOPDP and Cryogene acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights, acquired in the MVE, CRYOPDP and Cryogene acquisitions are amortized using the straight-line method over the estimated useful lives (see Note 8). The Company uses the following valuation methodologies to value the significant intangible assets acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. There was no impairment of intangible assets during the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Financing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, “<i style="font-style:italic;">Income Taxes”</i>, or ASC 740. As of December 31, 2020 and 2019, there were no material unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the US based net deferred tax assets be realized. Therefore, the Company has recorded a full valuation allowance against its US based net deferred tax assets. With respect to the foreign based deferred tax assets, the Company's management has reviewed these deferred tax assets on a jurisdictional basis. Based on the weight of each jurisdiction's evidence available, the Company's management has made separate determinations for each foreign jurisdiction regarding whether it is more likely than not that a net deferred tax asset within a particular jurisdiction will be not be realized. The Company has recorded full valuation allowances in jurisdictions where deferred tax assets are not deemed more likely than not to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Company maintains a deferred tax liability related to indefinite-lived assets that have been netted against deferred tax assets that also allow for indefinite carryforward periods subject to limitations.  The remaining taxable temporary difference cannot serve as a source for future taxable income to realize federal net operating losses, due to the fact that post-2017 federal net operating losses are only eligible to offset  80% of income in a given year or in the case of state net operating losses, the state net operating losses will expire prior to the reversal of the taxable temporary difference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company has immaterial accruals for interest or penalties on its consolidated balance sheets at December 31, 2020 and 2019 and has recorded only immaterial interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2020 and 2019. The Company is subject to taxation in the U.S., various state jurisdictions and in various foreign countries. As of December 31, 2020, the Company is no longer subject to U.S. federal examinations for years before 2017 and for California franchise and income tax examinations for years before 2016. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax. The Company's subsidiary in India is currently under examination by the Indian tax authorities for 2012-2013, 2013-2014 and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local taxing authorities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December of 2019, the FASB issued ASU 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 31, 2020. Early adoption is permitted, including adoption in an interim period. Different components of the guidance require retrospective, modified retrospective or prospective adoption. The Company has elected to early adopt ASU 2019-12 on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. At December 31, 2020, the Company has not recorded any income tax provision/(benefit) resulting from the CARES Act mainly due the Company’s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 27, 2020, the United States enacted the Consolidated Appropriations Act of 2021 (“CAA”).  The CAA includes provisions extending certain CARES Act provisions and adds coronavirus relief, tax and health extenders. The Company will continue to evaluate the impact of the CAA and its impact on our financial statements in 2021 and beyond.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 29, 2020, the state of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&amp;D credit usage for the same period (for credit usages in excess of $5M). These suspensions were considered in preparation of the 2020 financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Performance Obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within <span style="-sec-ix-hidden:Hidden_T4YlnKocDk6BLy2PTQVKlw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">one</span></span> year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Significant Payment Terms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15 to 60 days from the date of the invoice (except for any amounts disputed by the customer in good faith).  Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Variable Consideration </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When a contract includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained. Variable consideration is estimated at the most likely amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Variable consideration estimates are updated at each reporting date. Revenues are recorded net of variable consideration, such as discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Warranties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides product warranties with varying terms and durations for some of its products. The Company estimates product warranty costs and accrues for these costs as products are sold with a charge to cost of sales. Factors considered in estimating warranty costs include historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside of typical experience. Warranty accruals are evaluated and adjusted as necessary based on actual claims experience and changes in future claim and cost estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product warranty accrued liabilities totaled $0.2 million and $0 at December 31, 2020 and 2019, respectively, and are included in accounts payable and other accrued expenses. Warranty expense was not material for the years ended December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Incremental Direct Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incremental direct costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as promised goods and services are transferred to a customer. Incremental direct costs were not material for the years ended December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Contract Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable, which are recognized when payment is unconditional and only the passage of time is required before payment is due. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Contract Liabilities (Deferred Revenue)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $0.4 million at December 31, 2020 and 2019. During the years ended December 31, 2020 and 2019, the Company recognized revenues of $0.4 million and $0.1 million from the related contract liabilities outstanding as the services were performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Nature of Goods and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers to its customers and charges a fee in exchange for the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper under long-term master service agreements with customers. The Company’s arrangements convey to the customers the right to use the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers over a period of time. The Company retains title to the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers and provides its customers the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper is returned to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue for the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers at the time of the delivery of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper to the end user of the enclosed materials, and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides vacuum insulated aluminum dewars and cryogenic freezers systems to its customers. Revenue is recognized when the Company satisfies performance obligations by transferring the equipment to a customer, and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides global temperature-controlled logistics services, support and management. Revenue is recognized for these services as services are rendered and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides comprehensive and integrated temperature-controlled biostorage solutions to customers in the life sciences industry and charges a fee under long-term master service agreements with customers. These services include (1) biological specimen cryopreservation storage and maintenance, (2) archiving, monitoring, tracking, receipt and delivery of samples, (3) transport of frozen biological specimens to and from customer locations, and (4) management of incoming and outgoing biological specimens. The Company recognizes revenue for its biostorage solutions as services are rendered over time and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services over time as the customer simultaneously receives and consumes the benefit of these services as they are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of our revenues are covered under long-term agreements. We have determined that individual Statements of Work or Scope of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle) for the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> solutions and up to 12 months for biostorage solutions. Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services.  Prices under these agreements are generally fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Revenue Disaggregation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major markets for the years ended December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Biopharma/Pharma</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,394</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,032</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Animal Health</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 996</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Human Reproductive Medicine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,456</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,914</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,942</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the years ended December 31, 2020 and 2019, were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,555</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,801</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, the Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,523</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,825</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 618</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">33,942</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Services Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cost of services revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers and supplies and consumables used for our solutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Product Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Engineering and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expenditures relating to engineering and development are expensed in the period incurred to engineering and development expense in the consolidated statements of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acquisition Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquisition costs consist of legal, accounting, third-party valuations, and other due diligence costs related to our MVE, CRYOPDP, and Cryogene acquisitions (See Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based payments in accordance with stock-based payment accounting guidance which requires all stock-based payments to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.  The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and expected term. The Company accounts for forfeitures of unvested awards as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s stock-based compensation plans are discussed further in Note 16.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Instruments Issued to Non-Employees for Acquiring Goods or Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuances of the Company’s common stock for acquiring goods or services are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the estimated fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basic and Diluted Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt outstanding during the periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following shows the amounts used in computing net loss per share (in thousands except per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,693)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,332)</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deemed dividend on Series C convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Paid-in-kind dividend on Series C convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,844)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75,029)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,332)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding - basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,582,432</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,394,285</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.94)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.55)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,920,886</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,636,806</p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753,211</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series C convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,474,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible senior notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,810,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,205,023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,390,017</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Currency Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Management has determined that the functional currency of its subsidiaries is the local currency.  The Company translates the assets and liabilities of its foreign subsidiaries into U.S. dollars at exchange rates in effect at the end of the reporting period.  Income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity.  The translation gain (loss) adjustment totaled $5.2 million and 2,900 for the years ended December 31, 2020 and 2019, respectively.  Foreign currency gains and losses from transactions denominated in other than respective local currencies are included in earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">We do not currently have any off balance sheet arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of U.S. GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income).  ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12 on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework<i style="font-style:italic;">—</i>Changes to the Disclosure Requirements for Fair Value Measurement," which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. We adopted this guidance on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which is intended to simplify the subsequent accounting for goodwill acquired in a business combination. Prior guidance required utilizing a two-step process to review goodwill for impairment. A second step was required if there was an indication that an impairment may exist, and the second step required calculating the potential impairment by comparing the implied fair value of the reporting unit's goodwill (as if purchase accounting were performed on the testing date) with the carrying amount of the goodwill. The new guidance eliminates the second step from the goodwill impairment test. Under the new guidance, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount, and then recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value (although the loss should not exceed the total amount of goodwill allocated to the reporting unit). The guidance requires prospective adoption and is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019.  We adopted this guidance on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounting Guidance Issued but Not Adopted at December 31, 2020 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">guidance also requires the if-converted method to be applied for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted in fiscal years beginning after December 15, 2020. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. In November 2019, the FASB issued ASU 2019-10 "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which deferred the effective date of ASU 2016-13 by three years for smaller reporting companies. The one-time determination of whether an entity is eligible to be a smaller reporting company is based on the entity's most recent determination as of November 15, 2019 in accordance with SEC regulations.  As a result, ASU 2016-13, as subsequently amended, is effective for the Company for fiscal years beginning after December 15, 2022 based on the Company's smaller reporting company determination as of November 15, 2019.  We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.  The Company currently believes the main impact of the new standard will relate to the Company’s assessment of its allowance for doubtful accounts on trade receivables.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Change in Segment Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company continually monitors and reviews its segment reporting structure in accordance with authoritative guidance to determine whether any changes have occurred that would impact its reportable operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The chief operating decision maker (“CODM”) is our Chief Executive Officer. Up until the fourth quarter of 2020, we managed, reported and evaluated our business in the following two reportable operating segments: Global Logistics Solutions and Global Bioservices. During the fourth quarter of 2020, our CODM changed how he makes operating decisions, assesses the performance of the business and allocates resources in a manner that caused our operating segments to change as a result of the MVE and CRYOPDP acquisitions. In consideration of Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”), 280, <i style="font-style:italic;">Segment Reporting</i>, we determined that we are not organized around specific products and services, geographic regions or regulatory environments. Accordingly, beginning with the fourth quarter of 2020, we realigned our reporting structure, resulting in a single reportable segment. The Company has adjusted its financial statements for historical periods to reflect this change in segment reporting and show its financial results without segments for all periods presented.</p> 2 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries, Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions US LLC, and Cryoport Netherlands B.V. and subsidiaries (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.</p> P90D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Short-Term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, note payable, and the Company’s 3.00% convertible senior notes due in 2025 (the “Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, note payable and the Senior Notes, approximates fair value at December 31, 2020 due to their short-term nature. The carrying value of finance lease liabilities approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the note payable and the Senior Notes, see Note 5.</p> 0.0300 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2020 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investment policy requires that purchased instruments in marketable securities may only be in highly rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants credit to customers within the U.S. and to international customers and does not require collateral. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables is affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at December 31, 2020, and 2019 are net of reserves for doubtful accounts of $1.1 million and $0.1 million, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s customers are in the biotechnology, pharmaceutical, animal health, human reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. As of December 31, 2019, there were two customers that accounted for 31.0% and 20.7%, respectively, of net accounts receivable. There were no other single customer that owed us more than 10%of net accounts receivable at December 31, 2020 and 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has revenue from foreign customers primarily in United Kingdom, Switzerland, France, Netherlands, Singapore, China and India. During the years ended December 31, 2020 and 2019, the Company had revenues from foreign customers of approximately $29.1 million and $5.1 million, respectively, which constituted approximately 37.0% and 15.1%, respectively, of total revenues. There  were two customers that accounted for 24.1% and 12.8% of revenues during the year ended December 31, 2019. No other single customer generated over 10% of revenues during the years ended December 31, 2020 and 2019.</p> 1100000 100000 0.310 0.207 0.10 0.10 29100000 5100000 0.370 0.151 0.241 0.128 0.10 0.10 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, less accumulated depreciation.  We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally <span style="-sec-ix-hidden:Hidden_gFE5Gdd7YkmhMnRY2olGoA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to twelve years for computer hardware and software, <span style="-sec-ix-hidden:Hidden_9CgQBpu3jkObQRec4bqWBw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seven</span></span> to ten years for freezers, <span style="-sec-ix-hidden:Hidden_QRW71qFdLE2VmJjFcBxTRQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">four</span></span> to ten years for trucks and autos, <span style="-sec-ix-hidden:Hidden_jU6ZyFp8zkuPWxs8KHtatw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to fifteen years for furniture and equipment and over the shorter of the lease term or useful live of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from <span style="-sec-ix-hidden:Hidden_ej74RWj0pU2GoyydWXICqA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">20</span></span> to <span style="-sec-ix-hidden:Hidden__B_byg2juk6my-mv7uo2IA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">45</span></span> years. Maintenance and repairs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.</p> P12Y P10Y P10Y P15Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received.  Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees.  Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for lease and non-lease components as a single lease component for all its leases.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combinations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company compares the fair value of the reporting unit’s with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting units fair value up to the total amount of goodwill allocated to the reporting unit. The Company assessed  triggering events indicating potential goodwill impairment, including the effects of the COVID-19 pandemic, and after assessment, concluded that there was no impairment during the year ended December 31, 2020.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are comprised of patents, trademarks, software development costs and the intangible assets acquired in the MVE, CRYOPDP and Cryogene acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights, acquired in the MVE, CRYOPDP and Cryogene acquisitions are amortized using the straight-line method over the estimated useful lives (see Note 8). The Company uses the following valuation methodologies to value the significant intangible assets acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. There was no impairment of intangible assets during the year ended December 31, 2020.</p> 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through December 31, 2020.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Financing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, “<i style="font-style:italic;">Income Taxes”</i>, or ASC 740. As of December 31, 2020 and 2019, there were no material unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the US based net deferred tax assets be realized. Therefore, the Company has recorded a full valuation allowance against its US based net deferred tax assets. With respect to the foreign based deferred tax assets, the Company's management has reviewed these deferred tax assets on a jurisdictional basis. Based on the weight of each jurisdiction's evidence available, the Company's management has made separate determinations for each foreign jurisdiction regarding whether it is more likely than not that a net deferred tax asset within a particular jurisdiction will be not be realized. The Company has recorded full valuation allowances in jurisdictions where deferred tax assets are not deemed more likely than not to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Company maintains a deferred tax liability related to indefinite-lived assets that have been netted against deferred tax assets that also allow for indefinite carryforward periods subject to limitations.  The remaining taxable temporary difference cannot serve as a source for future taxable income to realize federal net operating losses, due to the fact that post-2017 federal net operating losses are only eligible to offset  80% of income in a given year or in the case of state net operating losses, the state net operating losses will expire prior to the reversal of the taxable temporary difference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company has immaterial accruals for interest or penalties on its consolidated balance sheets at December 31, 2020 and 2019 and has recorded only immaterial interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2020 and 2019. The Company is subject to taxation in the U.S., various state jurisdictions and in various foreign countries. As of December 31, 2020, the Company is no longer subject to U.S. federal examinations for years before 2017 and for California franchise and income tax examinations for years before 2016. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax. The Company's subsidiary in India is currently under examination by the Indian tax authorities for 2012-2013, 2013-2014 and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local taxing authorities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December of 2019, the FASB issued ASU 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 31, 2020. Early adoption is permitted, including adoption in an interim period. Different components of the guidance require retrospective, modified retrospective or prospective adoption. The Company has elected to early adopt ASU 2019-12 on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. At December 31, 2020, the Company has not recorded any income tax provision/(benefit) resulting from the CARES Act mainly due the Company’s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 27, 2020, the United States enacted the Consolidated Appropriations Act of 2021 (“CAA”).  The CAA includes provisions extending certain CARES Act provisions and adds coronavirus relief, tax and health extenders. The Company will continue to evaluate the impact of the CAA and its impact on our financial statements in 2021 and beyond.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 29, 2020, the state of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&amp;D credit usage for the same period (for credit usages in excess of $5M). These suspensions were considered in preparation of the 2020 financial statements.</p> 0 0 0.80 P3Y 5000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Performance Obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within <span style="-sec-ix-hidden:Hidden_T4YlnKocDk6BLy2PTQVKlw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">one</span></span> year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Significant Payment Terms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15 to 60 days from the date of the invoice (except for any amounts disputed by the customer in good faith).  Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Variable Consideration </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When a contract includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained. Variable consideration is estimated at the most likely amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Variable consideration estimates are updated at each reporting date. Revenues are recorded net of variable consideration, such as discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Warranties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides product warranties with varying terms and durations for some of its products. The Company estimates product warranty costs and accrues for these costs as products are sold with a charge to cost of sales. Factors considered in estimating warranty costs include historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside of typical experience. Warranty accruals are evaluated and adjusted as necessary based on actual claims experience and changes in future claim and cost estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product warranty accrued liabilities totaled $0.2 million and $0 at December 31, 2020 and 2019, respectively, and are included in accounts payable and other accrued expenses. Warranty expense was not material for the years ended December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Incremental Direct Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incremental direct costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as promised goods and services are transferred to a customer. Incremental direct costs were not material for the years ended December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Contract Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable, which are recognized when payment is unconditional and only the passage of time is required before payment is due. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Contract Liabilities (Deferred Revenue)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $0.4 million at December 31, 2020 and 2019. During the years ended December 31, 2020 and 2019, the Company recognized revenues of $0.4 million and $0.1 million from the related contract liabilities outstanding as the services were performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Nature of Goods and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers to its customers and charges a fee in exchange for the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper under long-term master service agreements with customers. The Company’s arrangements convey to the customers the right to use the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers over a period of time. The Company retains title to the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers and provides its customers the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper is returned to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue for the use of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers at the time of the delivery of the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shipper to the end user of the enclosed materials, and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides vacuum insulated aluminum dewars and cryogenic freezers systems to its customers. Revenue is recognized when the Company satisfies performance obligations by transferring the equipment to a customer, and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides global temperature-controlled logistics services, support and management. Revenue is recognized for these services as services are rendered and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides comprehensive and integrated temperature-controlled biostorage solutions to customers in the life sciences industry and charges a fee under long-term master service agreements with customers. These services include (1) biological specimen cryopreservation storage and maintenance, (2) archiving, monitoring, tracking, receipt and delivery of samples, (3) transport of frozen biological specimens to and from customer locations, and (4) management of incoming and outgoing biological specimens. The Company recognizes revenue for its biostorage solutions as services are rendered over time and at the time that collectability is probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services over time as the customer simultaneously receives and consumes the benefit of these services as they are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of our revenues are covered under long-term agreements. We have determined that individual Statements of Work or Scope of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle) for the Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> solutions and up to 12 months for biostorage solutions. Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services.  Prices under these agreements are generally fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Revenue Disaggregation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major markets for the years ended December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Biopharma/Pharma</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,394</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,032</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Animal Health</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 996</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Human Reproductive Medicine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,456</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,914</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,942</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the years ended December 31, 2020 and 2019, were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,555</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,801</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, the Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,523</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,825</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 618</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">33,942</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Services Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cost of services revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> Shippers and supplies and consumables used for our solutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Product Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.</p> 200000 0 400000 400000 100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Biopharma/Pharma</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,394</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,032</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Animal Health</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 996</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Human Reproductive Medicine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,456</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,914</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,942</p></td></tr></table> 66394000 30032000 7846000 996000 4456000 2914000 78696000 33942000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the years ended December 31, 2020 and 2019, were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,555</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,801</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, the Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,523</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,825</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 618</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">33,942</p></td></tr></table> 49555000 28801000 20316000 4523000 8825000 618000 78696000 33942000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Engineering and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expenditures relating to engineering and development are expensed in the period incurred to engineering and development expense in the consolidated statements of operations. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acquisition Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquisition costs consist of legal, accounting, third-party valuations, and other due diligence costs related to our MVE, CRYOPDP, and Cryogene acquisitions (See Note 3).</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based payments in accordance with stock-based payment accounting guidance which requires all stock-based payments to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.  The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and expected term. The Company accounts for forfeitures of unvested awards as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s stock-based compensation plans are discussed further in Note 16.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Instruments Issued to Non-Employees for Acquiring Goods or Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuances of the Company’s common stock for acquiring goods or services are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the estimated fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current estimated fair values.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basic and Diluted Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt outstanding during the periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following shows the amounts used in computing net loss per share (in thousands except per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,693)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,332)</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deemed dividend on Series C convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Paid-in-kind dividend on Series C convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,844)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75,029)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,332)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding - basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,582,432</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,394,285</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.94)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.55)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,920,886</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,636,806</p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753,211</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series C convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,474,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible senior notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,810,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,205,023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,390,017</p></td></tr></table> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following shows the amounts used in computing net loss per share (in thousands except per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,693)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,332)</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deemed dividend on Series C convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Paid-in-kind dividend on Series C convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,844)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75,029)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,332)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding - basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,582,432</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,394,285</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.94)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.55)</p></td></tr></table> -32693000 -18332000 39492000 2844000 -75029000 -18332000 38582432 33394285 -1.94 -0.55 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,920,886</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,636,806</p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753,211</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series C convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,474,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible senior notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,810,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,205,023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,390,017</p></td></tr></table> 5920886 3636806 753211 6474135 4810002 17205023 4390017 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Currency Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Management has determined that the functional currency of its subsidiaries is the local currency.  The Company translates the assets and liabilities of its foreign subsidiaries into U.S. dollars at exchange rates in effect at the end of the reporting period.  Income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity.  The translation gain (loss) adjustment totaled $5.2 million and 2,900 for the years ended December 31, 2020 and 2019, respectively.  Foreign currency gains and losses from transactions denominated in other than respective local currencies are included in earnings.</p> 5200000 2900000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">We do not currently have any off balance sheet arrangements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of U.S. GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income).  ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12 on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework<i style="font-style:italic;">—</i>Changes to the Disclosure Requirements for Fair Value Measurement," which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. We adopted this guidance on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which is intended to simplify the subsequent accounting for goodwill acquired in a business combination. Prior guidance required utilizing a two-step process to review goodwill for impairment. A second step was required if there was an indication that an impairment may exist, and the second step required calculating the potential impairment by comparing the implied fair value of the reporting unit's goodwill (as if purchase accounting were performed on the testing date) with the carrying amount of the goodwill. The new guidance eliminates the second step from the goodwill impairment test. Under the new guidance, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount, and then recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value (although the loss should not exceed the total amount of goodwill allocated to the reporting unit). The guidance requires prospective adoption and is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019.  We adopted this guidance on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounting Guidance Issued but Not Adopted at December 31, 2020 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">guidance also requires the if-converted method to be applied for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted in fiscal years beginning after December 15, 2020. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. In November 2019, the FASB issued ASU 2019-10 "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which deferred the effective date of ASU 2016-13 by three years for smaller reporting companies. The one-time determination of whether an entity is eligible to be a smaller reporting company is based on the entity's most recent determination as of November 15, 2019 in accordance with SEC regulations.  As a result, ASU 2016-13, as subsequently amended, is effective for the Company for fiscal years beginning after December 15, 2022 based on the Company's smaller reporting company determination as of November 15, 2019.  We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.  The Company currently believes the main impact of the new standard will relate to the Company’s assessment of its allowance for doubtful accounts on trade receivables.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3. Acquisitions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2020 Acquisitions – CRYOPDP and MVE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CRYOPDP Acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2020, the Company completed its acquisition of CRYOPDP for a cash consideration of €48.3 million ($57.0 million, the “CRYOPDP Acquisition”). This acquisition was funded with existing cash on hand. CRYOPDP, based in France, is a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets. CRYOPDP conducts its business activities in the Americas, EMEA and APAC. As a result of the CRYOPDP Acquisition, the Company has extended its solutions to include broader temperature-controlled logistics and specialty courier services and has significantly expanded its global network through CRYOPDP’s 22 facilities in 12 countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The CRYOPDP Acquisition was <span style="background-color:#ffffff;">accounted for under the acquisition method of accounting </span>in accordance with FASB ASC Topic 805, “<i style="font-style:italic;">Business Combinations</i>,” <span style="background-color:#ffffff;">and, therefore, the total purchase price was allocated to the identifiable tangible and intangible assets acquired and the liabilities assumed based on their respective fair values on the acquisition date. </span>Fair values were determined by management based in part on an independent valuation performed by a third-party valuation specialist and required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable; however, actual results may differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total purchase consideration paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,971</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase price allocation:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,346</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,603</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 644</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,905</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,863</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,856</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,235</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other long-term assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 569</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,110)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued compensation and related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,194)</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (370)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Note payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,690)</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,856)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred tax liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,311)</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total identifiable net assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,426</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,545</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,971</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the estimated fair values of CRYOPDP’s identifiable intangible assets at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Annual</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Estimated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Estimated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amortization</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Useful Life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Expense</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Software</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,578</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 511</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 511</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agent network</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,219</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,055</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade name/trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,235</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,077</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Among the factors that contributed to a purchase price in excess of the fair value of the net tangible and intangible assets acquired were the acquisition of an assembled workforce, the expected synergies, and other benefits that we believe will result from combining the operations of CRYOPDP with our operations. The goodwill recognized of $25.5 million is not expected to be deductible for income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management’s analysis related to certain matters, including income taxes, accounts receivable, note payable and other accounts and certain valuation balances. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. Although the final determination may result in asset and liability fair values that are different than the preliminary estimates of these amounts included herein, it is not expected that those differences will be material to our consolidated financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquisition-related transaction costs (included in selling, general and administrative expenses) totaled approximately $1.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">MVE Acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2020, the Company completed its acquisition of Chart Industries, Inc.’s MVE cryobiological storage business (the “MVE Acquisition”) for a cash consideration of $317.5 million, subject to customary closing working capital and other adjustments. The Company financed a portion of the closing cash payment of the MVE Acquisition with the net proceeds of the Blackstone Private Placement, as further discussed in Note 13. MVE is a global leader in manufactured vacuum insulated products and cryogenic freezer systems for the life sciences industry. MVE has manufacturing and distribution operations in the Americas, EMEA and APAC. As a result of the MVE Acquisition, the Company has extended its integrated logistics solutions to provide a broad range of cryogenic dewars and freezers to the life sciences industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The MVE Acquisition was <span style="background-color:#ffffff;">accounted for under the acquisition method of accounting </span>in accordance with FASB ASC Topic 805, “<i style="font-style:italic;">Business Combinations</i>,” <span style="background-color:#ffffff;">and, therefore, the total purchase price was allocated to the identifiable tangible and intangible assets acquired and the liabilities assumed based on their respective fair values on the acquisition date. </span>Fair values were determined by management based in part on an independent valuation performed by a third-party valuation specialist and required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable; however, actual results may differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total purchase consideration paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 317,470</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase price allocation:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,955</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,645</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,627</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,050</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,154</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184,991</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other long-term assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 358</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,036)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued compensation and related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,139)</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,160)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred tax liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total identifiable net assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211,244</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,226</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 317,470</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the estimated fair values of MVE’s identifiable intangible assets and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Method</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expense</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Order backlog</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.125</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,179</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Developed technology</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,700</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,392</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Land use rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade name/trademarks</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,800</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,634</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Among the factors that contributed to a purchase price in excess of the fair value of the net tangible and intangible assets acquired were the acquisition of an assembled workforce, the expected synergies, and other benefits that we believe will result from combining the operations of MVE with our operations. Of the $106.2 million goodwill recognized, approximately $62.5 million is allocated to the U.S. and Germany and is expected to be deductible for income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management’s analysis related to certain matters, including income taxes and certain other accounts and certain valuation balances. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. Although the final determination may result in asset and liability fair values that are different than the preliminary estimates of these amounts included herein, it is not expected that those differences will be material to our consolidated financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquisition-related transaction costs (included in selling, general and administrative expenses) totaled approximately $8.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Revenue, Net Income and Pro Forma Presentation – CRYOPDP and MVE Acquisitions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The operating results of the CRYOPDP and MVE acquisitions have been included in our consolidated financial statements from the acquisition date through December 31, 2020. Our results for the year ended December 31, 2020, include revenue for CRYOPDP of $12.9 million and net loss of $1.8 million and revenue for MVE of $23.0 million and net income of $1.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following unaudited pro forma information presents our combined results as if the CRYOPDP and MVE acquisitions had occurred on January 1, 2019. The unaudited pro forma financial information was prepared to give effect to events that are (1) directly attributable to the acquisition, (2) factually supportable, and (3) expected to have a continuing impact on the combined company’s results. The 2019 period includes the elimination of revenues of $1.8 million and related cost of goods sold of $0.9 million recorded by MVE from the Company. There were no transactions between the Company and CRYOPDP during the periods presented that are required to be eliminated. The unaudited pro forma combined financial information does not reflect any cost savings, operating synergies, or revenue enhancements that the combined companies may achieve as a result of the acquisitions or the costs to integrate the operations or the costs necessary to achieve cost savings, operating synergies, or revenue enhancements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the unaudited, pro forma consolidated results of operations for the year ended December 31, 2020 and 2019 as if the acquisition of the assets of CRYOPDP and MVE had occurred as of January 1, 2019.  The pro forma information provided below is compiled from the audited financial statements of CRYOPDP and MVE, which includes pro forma adjustments for intangible assets amortization expense and depreciation expense on the step up in fair value of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands except per share data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(unaudited)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(unaudited)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 172,147</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 163,217</p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,149)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic and diluted net loss per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.08)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.09)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The pro forma results are not necessarily indicative of the consolidated results of operations that we would have reported had the acquisitions been completed as of January 1, 2019 and should not be taken as representative of our consolidated results of operations following the acquisitions. In addition, the unaudited proforma consolidated financial information is not intended to project the future results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Acquisition – Cryogene Partners</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 14, 2019, Cryogene, Inc., a Texas corporation and a wholly owned subsidiary of the Company, entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) for the acquisition of the assets of Cryogene Partners, a Texas general partnership doing business as Cryogene Labs (“Cryogene”). The closing of the transaction contemplated in the Asset Purchase Agreement occurred simultaneously with the execution of the Asset Purchase Agreement on May 14, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms and subject to the conditions of the Asset Purchase Agreement, the Company acquired substantially all of the assets of Cryogene, including, without limitation, tangible personal property, intellectual property assets, and certain contracts related to Cryogene’s temperature-controlled biostorage solutions business located in Houston, Texas (the foregoing, the “Purchased Assets”), and assumed certain related liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate purchase price for the Purchased Assets was $20.3 million in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of this acquisition, the Company has extended its integrated logistics solutions and services to provide comprehensive temperature-controlled sample management solutions to the life sciences industry, including specimen storage, sample processing, collection, and retrieval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Purchase Price Allocation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We funded this acquisition through available cash and accounted for it as an acquisition of a business in accordance with FASB ASC Topic 805, “<i style="font-style:italic;">Business Combinations</i>”.  Assets acquired and liabilities assumed in connection with the acquisition have been recorded at their fair values.  Fair values were determined by management based in part on an independent valuation performed by a third-party valuation specialist.  The Company has performed a valuation analysis of the fair value of Cryogene’s assets and liabilities.  The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total purchase price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,317</p></td></tr><tr><td style="vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase price allocation:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,257</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,280</p></td></tr><tr><td style="vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (220)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total identifiable net assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,317</p></td></tr><tr><td style="vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,317</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the fair value of intangible assets acquired at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Annual</p></td></tr><tr><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Estimated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Estimated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amortization</p></td></tr><tr><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Useful Life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Expense</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Non-compete agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78</p></td></tr><tr><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Straight-line</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Customer relationships</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,900</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 325</p></td></tr><tr><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Trade name/trademark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Straight-line</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,280</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 537</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Among the factors that contributed to a purchase price in excess of the fair value of the net tangible and intangible assets acquired were the acquisition of an assembled workforce, the expected synergies, and other benefits that we believe will result from combining the operations of Cryogene with our operations. The goodwill recognized of $11.0 million is expected to be deductible for income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquisition-related transaction costs (included in selling, general and administrative expenses) totaled approximately $0.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The operating results of the Cryogene acquisition have been included in our consolidated financial statements from the acquisition date through December 31, 2019. Our results for the year ended December 31, 2020 and 2019, include Cryogene sales of $3.0 million and net income of $437,100.</p> 48300000 57000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total purchase consideration paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,971</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase price allocation:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,346</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,603</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 644</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,905</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,863</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,856</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,235</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other long-term assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 569</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,110)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued compensation and related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,194)</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (370)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Note payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,690)</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,856)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred tax liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,311)</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total identifiable net assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,426</p></td></tr><tr><td style="vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,545</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,971</p></td></tr></table> 56971000 8346000 10603000 644000 2905000 2863000 1856000 28235000 569000 11110000 1194000 370000 4690000 1856000 5311000 64000 31426000 25545000 56971000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the estimated fair values of CRYOPDP’s identifiable intangible assets at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Annual</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Estimated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Estimated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amortization</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Useful Life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Expense</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Software</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,578</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 511</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 511</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agent network</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,219</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,055</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade name/trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,235</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,077</p></td></tr></table> 3578000 P7Y 511000 5871000 P11Y6M 511000 8219000 P4Y 2055000 10567000 28235000 3077000 25500000 1400000 317500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total purchase consideration paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 317,470</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase price allocation:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,955</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,645</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,627</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,050</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,154</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 184,991</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other long-term assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 358</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,036)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued compensation and related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,139)</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,160)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred tax liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total identifiable net assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211,244</p></td></tr><tr><td style="vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,226</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 317,470</p></td></tr></table> 317470000 2955000 10645000 10627000 256000 9050000 2154000 184991000 358000 6036000 1139000 2160000 393000 64000 211244000 106226000 317470000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the estimated fair values of MVE’s identifiable intangible assets and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Method</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expense</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Order backlog</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.125</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,179</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Developed technology</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,700</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,392</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Land use rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Straight-line</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade name/trademarks</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,800</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,634</p></td></tr></table> 2600000 P0Y1M15D 118600000 P14Y6M 8179000 28700000 P12Y 2392000 2291000 P38Y 63000 32800000 184991000 10634000 106200000 62500000 8800000 12900000 1800000 23000000.0 1800000 1800000 900000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands except per share data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(unaudited)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(unaudited)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 172,147</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 163,217</p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,149)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic and diluted net loss per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.08)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.09)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 172147000 163217000 -18562000 -3149000 -2.08 -0.09 20300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total purchase price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,317</p></td></tr><tr><td style="vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase price allocation:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,257</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,280</p></td></tr><tr><td style="vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (220)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total identifiable net assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,317</p></td></tr><tr><td style="vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,317</p></td></tr></table> 20317000 4257000 5280000 220000 9317000 11000000 20317000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the fair value of intangible assets acquired at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Annual</p></td></tr><tr><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Estimated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Estimated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amortization</p></td></tr><tr><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Useful Life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Expense</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Non-compete agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78</p></td></tr><tr><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Straight-line</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Customer relationships</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,900</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Straight-line</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 325</p></td></tr><tr><td style="vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Trade name/trademark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Straight-line</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,280</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 537</p></td></tr></table> 390 P5Y 78 510 P5Y 102 3900 P12Y 325 480 P15Y 32 5280 537 11000000.0 300000 3000000.0 3000000.0 437100 437100 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 4. Cash, Cash Equivalents and Short-term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Cash, cash equivalents and short-term investments consisted of the following as of December 31, 2019 and 2018 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,053</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,547</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,820</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,688</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,235</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury notes and bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,094</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,967</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,061</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and short-term investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,317</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,296</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Available-for-sale debt securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale debt securities by type of security at December 31, 2020 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,179</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total available-for-sale investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the fair value of available-for-sale debt securities based on stated contractual maturities as of December 31, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due within one year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,084</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,111</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due between one and two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,198</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale debt securities by type of security at December 31, 2019 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury notes and bills</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,094</p></td></tr><tr><td style="vertical-align:bottom;width:54.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total available-for-sale investments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,094</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the fair value of available-for-sale debt securities based on stated contractual maturities as of December 31, 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,044</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,047</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due between one and two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,047</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,094</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were no individual securities that have been in a continuous loss position of 12 months or greater as of December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis, as well as adverse conditions related specifically to the security such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2020 and 2019, we had $32,400 and $81,700 realized losses on available-for-sale investments, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We held investments in equity securities with readily determinable fair values of $33.1 million and $26.0 million at December 31, 2020 and 2019, respectively. These investments consist of mutual funds that invest primarily in tax free municipal bonds and treasury inflation protected securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Unrealized gains (losses) during 2020 and 2019 related to equity securities held at December 31, 2020 and 2019 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net losses recognized during the year on equity securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (245)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (102)</p></td></tr><tr><td style="vertical-align:bottom;width:73.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Less: net losses recognized during the year on equity securities sold during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gains (losses) recognized during the year on equity securities still held at December 31, 2020 and 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 845</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (102)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Cash, cash equivalents and short-term investments consisted of the following as of December 31, 2019 and 2018 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,053</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,547</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,820</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,688</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,235</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury notes and bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,094</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,967</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,061</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and short-term investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,317</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,296</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 25053000 3547000 11820000 43688000 36873000 47235000 23309000 21094000 33135000 25967000 56444000 47061000 93317000 94296000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale debt securities by type of security at December 31, 2020 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,179</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total available-for-sale investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale debt securities by type of security at December 31, 2019 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury notes and bills</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,094</p></td></tr><tr><td style="vertical-align:bottom;width:54.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total available-for-sale investments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,094</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 23179000 173000 43000 23309000 23179000 173000 43000 23309000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the fair value of available-for-sale debt securities based on stated contractual maturities as of December 31, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due within one year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,084</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,111</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due between one and two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,198</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the fair value of available-for-sale debt securities based on stated contractual maturities as of December 31, 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,044</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,047</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due between one and two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,047</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,094</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 14084000 14111000 9095000 9198000 23179000 23309000 21122000 26000 54000 21094000 21122000 26000 54000 21094000 12044000 12047000 9078000 9047000 21122000 21094000 32400 81700 33100000 26000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Unrealized gains (losses) during 2020 and 2019 related to equity securities held at December 31, 2020 and 2019 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net losses recognized during the year on equity securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (245)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (102)</p></td></tr><tr><td style="vertical-align:bottom;width:73.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Less: net losses recognized during the year on equity securities sold during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gains (losses) recognized during the year on equity securities still held at December 31, 2020 and 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 845</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (102)</p></td></tr></table> -245000 -102000 -1090000 0 845000 -102000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 5. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 1:</i> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 2:</i> Observable prices that are based on inputs not quoted on active markets but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 3:</i> Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We did not elect the fair value option, as allowed, to account for financial assets and liabilities that were not previously carried at fair value. Therefore, material financial assets and liabilities that are not carried at fair value, such as trade accounts receivable and payable, are reported at their historical carrying values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The carrying values of our assets that are required to be measured at fair value on a recurring basis as of December 31, 2020 and 2019 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market mutual fund</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,820</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,820</p></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable equity securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,135</p></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Available-for-sale debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,264</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,264</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements</b> </p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market mutual fund</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,688</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,688</p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable equity securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,967</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> —</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,967</p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Available-for-sale debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,094</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> —</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,094</p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,749</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our equity securities and available-for-sale debt securities, including U.S. treasury notes are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We did not have any financial liabilities measured at fair value on a recurring basis as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We carry the convertible senior notes (see Note 10) at face value less the unamortized discount and issuance costs on our consolidated balance sheets and present fair value for disclosure purposes only. As of December 31, 2020, the estimated fair value of the Notes was $108.2 million and was determined using the net present value of the payments, discounted at an interest rate that is consistent with market and risk-adjusted interest rates, which is a Level 2 input.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The carrying values of our assets that are required to be measured at fair value on a recurring basis as of December 31, 2020 and 2019 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market mutual fund</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,820</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,820</p></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable equity securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,135</p></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Available-for-sale debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,309</p></td></tr><tr><td style="vertical-align:bottom;width:54.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,264</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,264</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements</b> </p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market mutual fund</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,688</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,688</p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable equity securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Mutual funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,967</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> —</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,967</p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Available-for-sale debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,094</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> —</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,094</p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,749</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 11820000 0 0 11820000 33135000 0 0 33135000 23309000 0 0 23309000 68264000 0 0 68264000 43688000 0 0 43688000 25967000 0 0 25967000 21094000 0 0 21094000 90749000 0 0 90749000 108200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6. Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Inventories consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,544</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 357</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,764</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 474</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The inventory balance at December 31, 2020 includes an $0.8 million step up in inventory related to the acquisition of MVE.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Inventories consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,544</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 357</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,764</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 474</p></td></tr></table> 7544000 357000 227000 2764000 117000 10535000 474000 800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7. Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;">Property and equipment consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cryogenic shippers and data loggers</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,625</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,296</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Freezers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,473</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,414</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,727</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 291</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 646</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,998</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,093</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trucks and autos</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,599</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,246</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Buildings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Land</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 790</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,407</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,547</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,430</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,597)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,036</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,833</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total depreciation and amortization expense related to property and equipment amounted to $3.2 million and $2.1 million for the years ended December 31, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company leases equipment under finance leases, with a total cost of $279,400 and $71,000, respectively, and accumulated amortization of $78,700 and $22,800 as of December 31, 2020 and 2019, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;">Property and equipment consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cryogenic shippers and data loggers</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,625</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,296</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Freezers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,473</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,414</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,727</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 291</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 646</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,998</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,093</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trucks and autos</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,599</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,246</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Buildings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Land</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 790</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,407</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,547</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,430</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,597)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,036</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,833</p></td></tr></table> 5625000 4296000 4473000 3414000 2727000 291000 1469000 646000 11998000 1093000 437000 37000 4599000 2246000 5359000 0 790000 0 8070000 3407000 45547000 15430000 15511000 3597000 30036000 11833000 3200000 2100000 279400 71000 78700 22800 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 8. Goodwill and Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table represents the changes in the carrying value of goodwill for the years ended December 31, 2020 and 2019 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill related to Cryogene acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill related to MVE acquisition</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107,504</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill related to CRYOPDP acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at end of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,282</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents our intangible assets as of December 31, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period (years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-compete agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 267</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,640</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,708</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 125,932</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cryogene trade name/trademark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRYOPDP agent network</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,597</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 537</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,060</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_4yF91PJ6vUOvz_XqJrsiqQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 4</span></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MVE Order backlog</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MVE land use rights</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,378</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,362</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,642</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 213,908</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents our intangible assets as of December 31, 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period (years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-compete agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 345</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,900</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 190</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cryogene trade name/trademark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cryoport patents and trademarks</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 258</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_amo8wiuJnEKXYvnQM4Dd9A;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Amortization expense for intangible assets for the years ended December 31, 2020 and 2019 was $6.6 million and $0.3 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Expected future amortization of intangible assets as of December 31, 2020 is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.62%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,438</p></td></tr><tr><td style="vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,438</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,438</p></td></tr><tr><td style="vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,795</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,108</p></td></tr><tr><td style="vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,124</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 169,341</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table represents the changes in the carrying value of goodwill for the years ended December 31, 2020 and 2019 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill related to Cryogene acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill related to MVE acquisition</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107,504</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill related to CRYOPDP acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at end of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,282</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 11000000 11000000 107504000 26778000 145282000 11000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents our intangible assets as of December 31, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period (years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-compete agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 267</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,640</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,708</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 125,932</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cryogene trade name/trademark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRYOPDP agent network</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,597</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 537</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,060</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_4yF91PJ6vUOvz_XqJrsiqQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 4</span></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MVE Order backlog</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MVE land use rights</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,378</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,362</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,642</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 213,908</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents our intangible assets as of December 31, 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period (years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-compete agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 345</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,900</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 190</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cryogene trade name/trademark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cryoport patents and trademarks</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 258</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_amo8wiuJnEKXYvnQM4Dd9A;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 390000 123000 267000 P3Y 34245000 1630000 32615000 P11Y 128640000 2708000 125932000 P14Y 480000 51000 429000 P13Y 8597000 537000 8060000 2600000 2600000 2378000 16000 2362000 P37Y 44312000 69000 44243000 221642000 7734000 213908000 390000 45000 345000 P5Y 510000 59000 451000 P5Y 3900000 190000 3710000 P12Y 480000 19000 461000 P15Y 258000 47000 211000 5538000 360000 5178000 6600000 300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Expected future amortization of intangible assets as of December 31, 2020 is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.62%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ending December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,438</p></td></tr><tr><td style="vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,438</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,438</p></td></tr><tr><td style="vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,795</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,108</p></td></tr><tr><td style="vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,124</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 169,341</p></td></tr></table> 14438000 14438000 14438000 13795000 12108000 100124000 169341000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 9. Accrued Compensation and Related Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued compensation and related expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued salaries and wages</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,048</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,386</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 518</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,441</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,904</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued compensation and related expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued salaries and wages</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,048</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,386</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 518</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,441</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,904</p></td></tr></table> 6048000 1386000 1393000 518000 7441000 1904000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 10. Convertible Senior Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2020, the Company issued $115.0 million aggregate principal amount of 3.00% convertible senior notes due in 2025 (the "Senior Notes"), which includes the initial purchasers’ exercise in full of their option to purchase an additional $15.0 million principal amount of the Senior Notes, in a private placement exempt from registration under the Securities Act of 1933. The Senior Notes are governed by an indenture (the “Indenture”) dated May 26, 2020 between the Company, as issuer, and U.S. Bank National Association, as trustee (the “Trustee”). The Company received $111.3 million from the offering, net of underwriting discounts and commissions of $3.7 million, and incurred approximately $0.3 million in third-party offering related costs. The Senior Notes bear cash interest at a rate of 3.00%, payable semi-annually on June 1 and December 1 of each year, beginning on December 1, 2020 and will mature on June 1, 2025, unless earlier repurchased, redeemed, or converted in accordance with the terms of the Senior Notes. At December 31, 2020, accrued interest of $0.3 million is included in accounts payable and accrued liabilities in the accompanying consolidated financial statements.  The Notes comprise the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Senior Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any time before the close of business on the scheduled trading day immediately before the maturity date, holders of the Senior Notes may convert their Senior Notes at their option into shares of the Company’s common stock. The Senior Notes are initially convertible into approximately 4,810,002 shares of the Company’s common stock based on the initial conversion rate of 41.8261 shares of the Company’s common stock per $1,000 principal amount of the Senior Notes, which represents an initial conversion price of approximately $23.91 per share of the Company’s common stock. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Also, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time and is determined by reference to a make-whole table set forth in the Indenture governing the Senior Notes. However, in no event will the conversion rate be increased to an amount that exceeds 48.10 shares of the Company’s common stock per $1,000 principal amount of Senior Notes. In addition, the holders of the Senior Notes may require the Company to repurchase the Senior Notes at par value plus accrued and unpaid interest following the occurrence of a “Fundamental Change” (as described in the Indenture).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On or after June 5, 2023, we may redeem the Senior Notes at our option, in whole and not in part, at a cash redemption price equal to the principal amount of the Senior Notes to be redeemed, plus accrued and unpaid interest, if any, if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The last reported sale price per share of the Company’s common stock exceeds </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">130%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> of the conversion price on (i) each of at least </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">20</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> trading days, whether or not consecutive, during the </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">30</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> consecutive trading days ending on, and including, the trading day immediately before the date the Company send the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">A registration statement covering the resale of the shares of the Company’s common stock issuable upon conversion of the Senior Notes is effective and available for use and is expected to remain effective and available during the redemption period as of the date the redemption notice is sent.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Senior Notes contain customary terms and events of default. If an event of default arising out of certain events of bankruptcy, insolvency, or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to the Company, the principal amount of the Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable. If any other event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding Senior Notes may declare the principal amount of the Senior Notes to be due and payable immediately by notice to the Company. There were no events of default at December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Senior Notes are accounted for in accordance with ASC 470-20, <i style="font-style:italic;">Debt with Conversion and Other Options</i> (“ASC 470-20”) and ASC 815-40, <i style="font-style:italic;">Contracts in Entity’s Own Equity</i> (“ASC 815-40”)<i style="font-style:italic;">. </i>Under ASC 815-40, to qualify for equity classification (or nonbifurcation, if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer’s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company’s analysis, it was determined the Senior Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20<i style="font-style:italic;">, </i>the proceeds received from the issuance of the convertible debt was recorded as a liability on the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurred approximately $4.1 million of debt issuance costs relating to the issuance of the Senior Notes, which were recorded as a reduction to the Senior Notes on the consolidated balance sheet. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Senior Notes using the effective interest rate method. We determined the expected life of the debt is equal to the five-year term of the Senior Notes. The effective interest rate on the Senior Notes is 3.74%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Senior Notes payable consisted of the following at December 31, 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:82.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal amount of Senior Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,656)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying value of Senior Notes payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 111,344</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expense incurred in connection with the Notes consisted of the following for the year ended December 31, 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coupon interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,108</p></td></tr><tr><td style="vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 437</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total interest expense on Senior Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,545</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s Senior Notes payable of $115.0 are due and payable in 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the issuance of the Senior Notes, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) to use its best efforts to file a registration statement for the resale of the Senior Notes and the shares of the Company’s common stock issuable upon conversion of the Senior Notes, to cause the registration statement to become effective by January 31, 2021, and to keep the registration statement continuously effective for a specified period of time. If the Company fails to satisfy certain of its obligations under the Registration Rights Agreement (a “Registration Default”), it will be required to pay additional interest on the Senior Notes. Such additional interest will accrue at a rate per annum equal to 0.25% of the principal amount thereof for the first 90 days beginning on, and including the date on which such Registration Default occurs and, thereafter, at a rate per annum equal to 0.50% of the principal amount thereof. However, in no event will such additional interest, together with any special interest that accrues pursuant to the Indenture accrue on any day on a Note at a combined rate per annum that exceeds 0.50%. Additionally, if a Registration Default exists on the maturity date for the Senior Notes, then, in addition to any additional interest otherwise payable, the Company will be required to make a cash payment to each noteholder in an amount equal to 3% of the principal amount of Senior Notes outstanding and held by such holder as of the close of business on the business day immediately before the maturity date.  As of December 31, 2020, the Company has not accrued any fees or expenses associated with the Registration Rights Agreement as no Registration Default exists and, therefore, it is not probable that a payment would be required.  In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Senior Notes and the shares of the Company’s common stock issuable upon conversion of the Senior Notes.</p> 115000000.0 115000000.0 0.0300 0.0300 15000000.0 15000000.0 111300000 111300000 3700000 3700000 300000 0.0300 0.0300 300000 300000 4810002 41.8261 1000 23.91 48.10 1000 130 20 30 4100000 4100000 P5Y 0.0374 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Senior Notes payable consisted of the following at December 31, 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:82.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal amount of Senior Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,656)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying value of Senior Notes payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 111,344</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 115000000 3656000 111344000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expense incurred in connection with the Notes consisted of the following for the year ended December 31, 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coupon interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,108</p></td></tr><tr><td style="vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 437</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total interest expense on Senior Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,545</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 2108000 437000 2545000 115000000.0 115000000.0 0.0025 0.0025 0.0050 0.0050 0.0050 0.0050 0.03 0.03 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 11. Note Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the acquisition of CRYOPDP, the Company assumed an interest free unsecured note payable of €4.0 million ($4.9 million) repayable in two installments of €0.5 million ($0.6 million) to be repaid in 2025 and €3.5 million ($4.3 million) to be repaid in 2028.</p> 4000000.0 4900000 2 500000 600000 3500000 4300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 12. Leases </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has operating and finance leases for corporate offices and certain equipment. These leases have remaining lease terms of one year to approximately nine years, some of which include options to extend the leases for multiple renewal periods of five years each. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs. As of December 31, 2020 and 2019, assets recorded under finance leases were $279,400 and $71,000, respectively, and accumulated depreciation associated with finance leases was $78,700 and $22,800, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The components of lease cost were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,835</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 758</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of right-of-use assets </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 771</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other information related to leases was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Supplemental Cash Flows Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows from finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows from finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets obtained in exchange for lease liabilities (in thousands):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,708</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Remaining Lease Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.6 years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.9 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Discount Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Future minimum lease payments under non-cancellable leases that have commenced as of December 31, 2020 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> Years Ending December 31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,103</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,498</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,696</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,945</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,453)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,492</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 171</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported as of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Current lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,231</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Noncurrent lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 112</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,492</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 171</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> P1Y P9Y P5Y 279400 71000 78700 22800 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,835</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 758</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of right-of-use assets </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 771</p></td></tr></table> 1835000 758000 56000 10000 10000 3000 66000 13000 1901000 771000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other information related to leases was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Supplemental Cash Flows Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows from finance leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows from finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets obtained in exchange for lease liabilities (in thousands):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,708</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Remaining Lease Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.6 years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.9 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted-Average Discount Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 1680000 77000 67000 10708000 203000 P6Y7M6D P2Y10M24D 0.055 0.054 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Future minimum lease payments under non-cancellable leases that have commenced as of December 31, 2020 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> Years Ending December 31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,103</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,498</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,696</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,945</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,453)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,492</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 171</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported as of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Current lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,231</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td></tr><tr><td style="vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Noncurrent lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 112</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,492</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 171</p></td></tr></table> 3103000 67000 3261000 57000 2498000 60000 1985000 1696000 5402000 17945000 184000 3453000 13000 14492000 171000 2231000 59000 12261000 112000 14492000 171000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 13. Employee Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">401K Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides a 401(k) Plan (“Plan”) to provide retirement and incidental benefits for our eligible U.S. based employees.  Employees may contribute up to 100% of their eligible compensation, limited to a maximum annual dollar amount set periodically by the Internal Revenue Service.  The Company matches employee contributions dollar for dollar up to a maximum of 4% per year per person.  All matching contributions vest immediately.  During the years ended December 31, 2020 and 2019, we recognized expense of $0.3 million and $0.2 million, respectively, related to matching contributions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Non-U.S. Employee Benefit Plans </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Eligible employees outside the U.S. generally receive retirement benefits under various defined benefit plans and defined contribution plans based upon factors such as years of service and employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements. The employee benefit plan costs and liabilities with regard to the defined benefit plans are determined by actuarial valuations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Employees of the Company who are in India participate in an employee benefit plan (the “Gratuity Plan”), which is required by local law and provides a lump sum payment to vested employees upon retirement, death, incapacitation, or termination of employment based on the respective employee’s salary and the tenure of employment. The benefit costs and liabilities with regard to the Gratuity Plan are determined by actuarial valuations. The Company makes annual contributions to the employees’ gratuity fund established with Life Insurance Corporation of India, which calculates the annual contribution required to be made by the Company and manages the Gratuity Plan, including any required payouts. The Gratuity Plan is partially funded. The obligation under the Gratuity Plan is not significant at December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Benefit costs associated with the non-U.S. employee benefit plans totaled $0.1 million and $0 million for the years ended December 31, 2020 and 2019, respectively. Total benefit obligation associated with the non-U.S. employee benefit plans totaled $0.3 million and $0 million at December 31, 2020 and 2019, respectively.</p> 1 0.04 300000 200000 100000 0 300000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 14. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Facility and Equipment Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease various corporate, global logistics and supply chain centers, biostorage, manufacturing, and research and development facilities in Tennessee, California, New Jersey, the Netherlands, Texas, Georgia, Minnesota, China, Portugal and France under operating leases. These lease agreements contain certain scheduled annual rent increases which are accounted for on a straight-line basis.   In addition, we lease certain equipment which expires through July 2024 (See Note 12).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. We record a loss contingency when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We also disclose material contingencies when we believe a loss is not probable but reasonably possible. Accounting for contingencies requires us to use judgment related to both the likelihood of a loss and the estimate of the amount or range of loss. The outcomes of our legal proceedings are inherently unpredictable, subject to significant uncertainties, and could be material to our financial condition, results of operations, and cash flows for a particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indemnities and Guarantees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility and equipment leases, the Company has indemnified its lessors for certain claims arising from the use of the facilities and equipment. The duration of the guarantees and indemnities varies and is generally tied to the life of the agreements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 15. Stockholders’ Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Authorized Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has 100,000,000 authorized shares of common stock with a par value of $0.001 per share, and 2,500,000 undesignated or "blank check" preferred stock, with a par value of $0.001, of which, 800,000 shares have been designated as Class A Convertible Preferred Stock, 585,000 shares have been designated as Class B Convertible Preferred Stock and 250,000 shares have been designated as Class C Convertible Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Issuances For Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, 2,869 shares of common stock with a fair value of $82,700 were issued to two members of the board of directors as compensation for services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, 5,753 shares of common stock with a fair value of $91,000 were issued to three members of the board of directors as compensation for services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Blackstone Private Placement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the MVE Acquisition, on October 1 , 2020 (the “Closing Date”), the Company completed a private placement with an investment vehicle of funds affiliated with The Blackstone Group Inc. (collectively, Blackstone), consisting of (i) 250,000 shares of a newly designated 4.0% Series C Convertible Preferred Stock, par value $0.001 per share (“Series C Preferred Stock”), at a price of $1,000 per share, for $250.0 million, and (ii) 675,536 shares of common stock of the Company, par value $0.001 per share (“Common Stock”) for $25.0 million, for an aggregate purchase price of $275.0 million. The Company paid Blackstone $1.0 million as reimbursement for transactional expenses incurred in connection with the private placement at the Closing Date. Also, the Company incurred direct and incremental expenses of approximately $8.6 million, including financial advisory fees, closing costs, legal expenses and other offering-related expenses. The Company allocated the net proceeds of $265.4 on a relative fair value basis to the Series C Preferred Stock and the Common Stock, resulting in allocated proceeds of $28.2 and $237.2, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series C Preferred Stock ranks senior to the shares of the Company’s Common Stock, with respect to dividend rights and rights upon the voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company (a “Liquidation”). The Series C Preferred Stock has the following rights, preferences and privileges:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividend Rights.</span><b style="font-weight:bold;"> </b>Holders of the Series C Preferred Stock (the “Holders”) are entitled to dividends at the rate of 4.0% per annum, paid-in-kind, accruing daily and paid quarterly in arrears when and if declared by the Board of Directors. The Holders are also entitled to participate in dividends declared or paid on the Common Stock on an as-converted basis. The Company and Holders do not have the option to pay dividends in kind, in cash, or in other form. Paid in-kind dividends for the year ended December 31, 2020 were $2.5 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidation Preference.</span><b style="font-weight:bold;"> </b>Upon a Liquidation, each share of Series C Preferred Stock is entitled to receive an amount per share equal to the greater of (i) $1,000 per share, plus all accrued and unpaid dividends and (ii) the amount that the Holders of the Series C Preferred Stock would have been entitled to receive at such time if the Series C Preferred Stock were converted into Common Stock (the ”Liquidation Preference”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conversion Features.</span><b style="font-weight:bold;"> </b>The Series C Preferred Stock is convertible at the option of the Holders at any time into shares of Common Stock at a conversion price of $38.6152 per share and a conversion rate of 25.90 shares of Common Stock per share of Series C Preferred Stock. The maximum number of Common Stock that could be required to be issued if converted is 6,474,135 shares. The conversion price is subject to certain customary adjustments in the event of certain adjustments to the Company’s Common Stock, including stock dividends, splits, combinations, tender offers, and exchange offers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After the second anniversary of the Closing Date, subject to certain conditions, the Company may at its option require conversion of all of the outstanding shares of the Series C Preferred Stock to Common Stock if, for at least 20 trading days during the 30 consecutive trading days immediately preceding the date the Company notifies the Holders of the election to convert, the closing price of the Common Stock is at least 150% of the conversion price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the October 1, 2020 issuance date, the effective conversion price per share was less than the fair value of the underlying Common Stock and, as a result, the Company determined that there was a beneficial conversion feature on that date. Accordingly, the Company recognized the resulting beneficial conversion feature amount of $39.5 million as a deemed dividend, equal to the number of common shares into which the Series C Preferred Stock is convertible multiplied by the difference between the fair value of the Common Stock and the effective conversion price per share on that date. Because the Series C Preferred Stock does not have a stated conversion date and was immediately convertible at the issuance date, the dividend is reflected as a one-time, non-cash, deemed dividend to the Holders of the Series C Preferred Stock on the date of issuance.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Company determined that the nature of the Series C Preferred Stock is more akin to an equity instrument and that the economic characteristics and risks of the embedded conversion options are clearly and closely related to the Series C Preferred Stock. As such, the conversion options were not required to be bifurcated from the host under ASC 815, <i style="font-style:italic;">Derivatives and Hedging</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Since the paid-in-kind dividends are nondiscretionary, the Company measures the beneficial conversion feature in the paid-in-kind dividend on the issuance date of the preferred stock and records such amount when the paid-in-kind dividend are accrued</span>.<span style="font-size:10pt;"> Accordingly, the associated paid-in-kind dividends for the year ended December 31, 2020 generated a beneficial conversion feature amount of </span><span style="font-size:10pt;">$0.3</span><span style="font-size:10pt;"> million. On February 5, 2021, </span><span style="background-color:#ffffff;font-size:10pt;">the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of </span><span style="background-color:#ffffff;font-size:10pt;">50,000</span><span style="background-color:#ffffff;font-size:10pt;"> shares of the Series C Preferred Stock (See Note 18).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Redemption Rights.</span><b style="font-weight:bold;"> </b>The Company may redeem the Series C Preferred Stock for cash, as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Within 6 months of the Closing Date, up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">50,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> shares of the Series C Preferred Stock at a price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">125%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> of the purchase price paid plus any accrued and unpaid dividends (See Note 18).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">At any time beginning five years after the Closing Date (but prior to six years after the Closing Date), all of the Series C Preferred Stock at a price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">105%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> of the purchase price paid plus any accrued and unpaid dividends.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">At any time beginning six years after the Closing Date, all of the Series C Preferred Stock at a price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">100%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> of the purchase price paid plus any accrued and unpaid dividends.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon a “Fundamental Change” (involving a change of control or de-listing of the Company as further described in the Certificate of Designation), each Holder has the right to require the Company to redeem all or any part of the Holder’s Series C Preferred Stock for an amount equal to the Liquidation Preference plus any accrued and unpaid dividends.  If the Company does not have sufficient funds legally available to pay the repurchase price, then the Company is required to (a) pay the maximum amount of the repurchase price that can be paid out of funds legally available for payment, and (b) purchase any shares of the Series C Preferred Stock not purchased because of the foregoing limitations at the repurchase price as soon as practicable after the Company is able to make such purchase out of assets legally available for the purchase of such shares. If the Company fails to pay the repurchase price in full when due, then the Company will pay dividends on such shares not repurchased at a rate of 5.5% per annum until such shares are repurchased, payable quarterly in arrears.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated the Series C Preferred Stock for liability or equity classification under the applicable accounting guidance including ASC 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity</i>, and determined that equity treatment was appropriate because the Series  C Preferred Stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series C Preferred Stock would be recorded as permanent equity given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also evaluated the embedded put and call options within the Series C Preferred Stock in accordance with the accounting guidance for derivatives to determine if bifurcation is required.  The Company determined that the economic characteristics and risks of the embedded put and call options are not clearly and closely related to the Series C Preferred Stock. Therefore, the Company assessed the put and call options further and determined they did not meet the definition of a derivative under ASC 815<i style="font-style:italic;">.</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the same analysis, the Company determined that the economic characteristics and risks of the embedded participating dividend feature are considered clearly and closely related to the equity host. Accordingly, the participating dividend feature is not required to be bifurcated under ASC 815. Also, the Company determined that the value of the contingent dividend feature is minimal and insignificant relative to the other components of the Series C Preferred Stock due to the circumstances surrounding the scenarios under which the provision would be triggered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Voting Rights</span><b style="font-weight:bold;">.</b> Holders of the Series C Preferred Stock are generally entitled to vote with the holders of the shares of Common Stock on an as-converted basis, subject to certain Nasdaq voting limitations, if applicable. Also, the consent of the Holders of a majority of the outstanding shares of the Series C Preferred Stock is required with respect to (i) amendments to the Company’s organizational documents that have an adverse effect on the Holders of the Series C Preferred Stock, and (ii) issuances by the Company of securities that are senior to, or equal in priority with, the Series C Preferred Stock. Holders of the Series C Preferred Stock have the right to nominate for election one member to the board of directors of the Company for so long as they hold 66.67% of the Series C Preferred Stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Registration Rights</span><b style="font-weight:bold;">. </b>Holders of the Series C Preferred Stock have certain customary registration rights with respect to the Series C Preferred Stock and the shares of common stock into which they are converted, pursuant to the terms of a registration rights agreement. The Company is required to file within 90 days of the Closing Date, and use its commercially reasonable efforts to cause to go effective as promptly as practicable, a registration statement covering the sale or distribution of Common Stock issued or issuable upon conversion of the Series C Preferred Stock.   In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Common Stock issued or issuable upon conversion of the Series C Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Share Repurchase Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company’s Board of Directors authorized a share repurchase program (the “Repurchase Program”) authorizing repurchase of common stock in the amount of up to $15.0 million from time to time, in amounts, at prices, and at such times as management deems appropriate and will depend on a number of factors, including the market price of Cryoport’s common stock, general market and economic conditions, and applicable legal requirements. The repurchase program expired on December 31, 2020. The Company has not purchased any shares under this program in 2019 and through December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">June 2019 Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 24, 2019, the Company completed an underwritten public offering  of 4,312,500 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement, dated June 19, 2019, by and among the Company, on the one hand, and Jefferies LLC and SVB Leerink LLC, as representatives of certain underwriters at a public offering price per share of $17.00, before deducting underwriting discounts and commissions. The shares include 562,500 shares issued and sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the underwriting agreement. The Company received net proceeds of approximately $68.8 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Reserved for Future Issuance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2020, approximately 18.8 million shares of common stock were issuable upon exercise of stock options and the conversion of convertible senior notes and Series C Preferred stock, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,554,305</p></td></tr><tr><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series C Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,474,135</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of convertible senior notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,810,002</p></td></tr><tr><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock reserved for future issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,838,442</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 100000000 0.001 2500000 0.001 800000 585000 250000 2869 82700 5753 91000 250000 0.040 0.001 1000 250.0 675536 0.001 25000000.0 275000000.0 1000000.0 8600000 265400000 28200000 237200000 0.040 2500000 1000 38.6152 25.90 6474135 20 30 1.50 39500000 300000 50000 50000 1.25 1.05 1 0.055 1 0.6667 15.0 4312500 17.00 562500 68800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2020, approximately 18.8 million shares of common stock were issuable upon exercise of stock options and the conversion of convertible senior notes and Series C Preferred stock, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,554,305</p></td></tr><tr><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series C Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,474,135</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of convertible senior notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,810,002</p></td></tr><tr><td style="vertical-align:bottom;width:84.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock reserved for future issuances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,838,442</p></td></tr></table> 18800000 7554305 6474135 4810002 18838442 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 16. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants.   A summary of warrant activity is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price/Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,049,534</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.03</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,027,546)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.95</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,960)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,001,028</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.83</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (963,149)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.80</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,879)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_BREU811nZkaZlSQzKPvg8A;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> —</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested (exercisable) — December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_k_auzuT6JkW8RzgVx-yDig;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of the Company’s common stock on December 31, 2020, which was </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$43.88</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company issued 963,149 shares of common stock in connection with the exercise of warrants for proceeds of $3.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company issued 985,626 shares of common stock in connection with the exercise of warrants for proceeds of $3.4 million. In addition, during the year ended December 31, 2019, the Company issued 117,663 shares of common stock in connection with the cashless exercise of warrants to purchase 159,583 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total intrinsic value of warrants exercised during the years ended December 31, 2020 and 2019 was $17.6 million and $12.4 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have five stock incentive plans: the 2002 Stock Incentive Plan (the “2002 Plan”), the 2009 Stock Incentive Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”), the 2015 Omnibus Equity Incentive Plan (the “2015 Plan”), and the 2018 Omnibus Equity Incentive Plan (the “2018 Plan”), (collectively, the “Plans”). The 2002 Plan, the 2009 Plan, the 2011 Plan and the 2015 Plan (the “Prior Plans”) have been superseded by the 2018 Plan. In May 2018, the stockholders approved the 2018 Plan for issuance up to 3,730,179 shares. The Prior Plans will remain in effect until all awards granted under such Prior Plans have been exercised, forfeited, cancelled, or have otherwise expired or terminated in accordance with the terms of such awards, but no awards will be made pursuant to the Prior Plans after the effectiveness of the 2018 Plan. As of December 31, 2020, the Company had 921,288 shares available for future awards under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During the years ended December 31, 2020 and 2019, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.3 – 6.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.2 – 6.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.31% - 1.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.42% - 2.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">69.8% - 82.7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">70.6% - 99.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the average of the historical volatility and the implied volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Total stock-based compensation expense related to our share-based payment awards is comprised of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,479</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,946</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Engineering and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 683</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,098</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,523</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For the year ended December 31, 2019, we recognized expense of $9.6 million due to the accelerated vesting under the terms of certain outstanding stock option grants as a result of the Company meeting certain financial performance criteria defined in such grants. Of this amount, $0.4 million, $9.4 million, and $0.9 million are included in cost of revenues, selling, general and administrative and engineering and development, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of stock option activity is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price/Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,757,305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted (weighted-average fair value of $13.55 per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,544,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (544,565)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.91</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78,009)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,679,581</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted (weighted-average fair value of $13.21 per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,789,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (855,717)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.73</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,475)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Expired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,084)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.56</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,554,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254,393,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested (exercisable) — December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,862,122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.41</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 213,769,400</p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Expected to vest after December 31, 2020 (unexercisable)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,692,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,623,600</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on December 31, 2020, which was </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$43.88</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes information with respect to stock options outstanding and exercisable at December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$1.08 – 3.07</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894,024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.25</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894,024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.25</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$3.19 – 3.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 839,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 839,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.30</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$4.56 – 4.92</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 658,437</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.80</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 658,437</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.80</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$5.00 – 7.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 769,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 769,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.04</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$7.80 – 8.65</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 961,979</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.28</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 952,229</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.28</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$9.29 – 12.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,153,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,083,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.84</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$13.37 – 16.95</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,598,304</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16.41</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 498,801</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.73</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$17.36 – 55.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 679,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.53</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,554,305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,862,122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, there was unrecognized compensation expense of $21.1 million related to unvested stock options, which we expect to recognize over a weighted average period of 3.1 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The total intrinsic value of options exercised during the years ended December 31, 2020 and 2019 was $24.1 million and $6.5 million, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants.   A summary of warrant activity is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price/Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,049,534</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.03</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,027,546)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.95</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,960)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,001,028</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.83</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (963,149)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.80</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,879)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_BREU811nZkaZlSQzKPvg8A;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> —</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested (exercisable) — December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_k_auzuT6JkW8RzgVx-yDig;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of the Company’s common stock on December 31, 2020, which was </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$43.88</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share.</span></td></tr></table><div style="margin-top:12pt;"/> 2049534 4.03 0 0 1027546 3.95 20960 17.78 1001028 3.83 0 0 963149 3.80 37879 4.58 43.88 963149 3700000 985626 3400000 117663 159583 17600000 12400000 3730179 921288 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During the years ended December 31, 2020 and 2019, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.3 – 6.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.2 – 6.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.31% - 1.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.42% - 2.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">69.8% - 82.7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">70.6% - 99.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> P5Y3M18D P6Y3M18D P5Y2M12D P6Y2M12D 0.0031 0.0170 0.0142 0.0257 0.698 0.827 0.706 0.992 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Total stock-based compensation expense related to our share-based payment awards is comprised of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,479</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,946</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Engineering and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 683</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,098</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,523</p></td></tr></table> 371 1479 7862 13946 683 1098 8916 16523 9600000 400000 9400000 900000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of stock option activity is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price/Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,757,305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted (weighted-average fair value of $13.55 per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,544,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (544,565)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.91</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78,009)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,679,581</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted (weighted-average fair value of $13.21 per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,789,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (855,717)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.73</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,475)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Expired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,084)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.56</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding — December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,554,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254,393,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested (exercisable) — December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,862,122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.41</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 213,769,400</p></td></tr><tr><td style="vertical-align:bottom;width:55.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Expected to vest after December 31, 2020 (unexercisable)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,692,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,623,600</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on December 31, 2020, which was </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$43.88</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share.</span></td></tr></table><div style="margin-top:12pt;"/> 5757305 5.16 13.55 1544850 13.55 544565 3.91 78009 10.66 6679581 7.14 13.21 1789000 20.46 855717 6.73 56475 13.39 2084 19.56 7554305 10.29 P6Y7M6D 254393000 5862122 7.41 P5Y10M24D 213769400 1692183 20.24 P9Y2M12D 40623600 43.88 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes information with respect to stock options outstanding and exercisable at December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$1.08 – 3.07</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894,024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.25</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894,024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.25</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$3.19 – 3.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 839,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 839,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.30</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$4.56 – 4.92</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 658,437</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.80</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 658,437</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.80</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$5.00 – 7.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 769,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 769,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.04</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$7.80 – 8.65</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 961,979</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.28</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 952,229</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.28</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$9.29 – 12.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,153,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,083,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.84</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$13.37 – 16.95</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,598,304</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16.41</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 498,801</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.73</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$17.36 – 55.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 679,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.53</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,554,305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,862,122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 894024 P4Y8M12D 2.25 894024 2.25 839001 P4Y6M 3.30 839001 3.30 658437 P4Y6M 4.80 658437 4.80 769694 P4Y7M6D 5.04 769694 5.04 961979 P6Y 8.28 952229 8.28 1153291 P8Y 11.85 1083688 11.84 1598304 P9Y 16.41 498801 15.73 679575 P9Y3M18D 26.54 166248 18.53 7554305 5862122 21100000 P3Y1M6D 24100000 6500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 17. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Income (loss) before provision for income taxes was attributed to the following jurisdictions for the years ended December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,873)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,321)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,738)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,270)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The provision (benefit) for income taxes consists of the following for the years ended December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><div style="padding-left:54.35pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 482</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,245)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,125)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (832)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (738)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,288</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,132</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (527)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total provision (benefit) for income taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (45)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The provision (benefit) for income taxes differs from that computed using the federal statutory rate applied to loss before provision for income taxes as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computed tax benefit at federal statutory rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,875)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,837)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (610)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,683)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 286</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences and other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (375)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executive compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 609</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 985</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingencies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,131</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (45)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2020 and 2019 are shown below (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td colspan="5" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,031</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expenses recognized for granting of options and warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,119</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,816</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,740</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,217</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,447</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,913)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,220)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,227</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (529)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,631)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,138)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,253)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,413)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,248)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,448)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our net deferred tax liability as presented in our consolidated balance sheet consist of the following items (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 434</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,882)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,448)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s net deferred tax liabilities increased by $5.7 million as a result of our MVE and CRYOPDP acquisitions on October 1, 2020. During the years ended December 31, 2020 and 2019, the Company’s valuation allowance on deferred tax assets increased by $11.7 million and $2.1 million, respectively.  The increase in the valuation allowance during 2020 and 2019 was principally the result of net operating losses sustained during each of the years.  Our valuation allowance also increased during 2020 as a result of valuation allowances recorded against deferred tax assets on the opening balance sheets of some of our acquired foreign subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At December 31, 2020, the Company has federal and state net operating loss carryforwards of approximately $57.6 million and $60.9 million, respectively, which will begin to expire in 2021, unless previously utilized, and will begin to expire for state purposes in 2028. In addition, the Company has federal net operating loss carryforwards of $38.6 million generated after 2017 that can be carried over indefinitely and may be used to offset up to 80% of federal taxable income. At December 31, 2020, the Company has foreign net </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">operating loss carryforwards of approximately $9.8 million, which begin to expire in 2022. At December 31, 2020, the Company has federal and California research and development tax credits of approximately $0.4 million and $0.3 million, respectively. The federal research tax credit begins to expire in 2026 unless previously utilized and the California research tax credit has no expiration date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Utilization of the net operating loss ("NOL") and research and development ("R&amp;D") carryforwards maybe subject to a substantial annual limitation due to ownership change limitations that might have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state and foreign provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company’s formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has not completed a study to assess whether an ownership change or changes have occurred. If the Company has experienced an ownership change, utilization of the NOL or R&amp;D credit carryforwards would be subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization. Further, until a study is complete and any limitation is known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits (“UTBs”) are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">UTBs, beginning of period</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 963</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gross increase – current period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 239</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gross decrease – prior period tax positions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (113)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gross increase – prior period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expiration of statute of limitations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">UTBs, end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 963</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As if December 31, 2020, we had an immaterial amount of UTBs, which if recognized, would affect our effective tax rate. Prior to 2020, the Company did not have any UTBs that would impact the effective rate. The Company does not expect any significant increases or decreases to the Company's unrecognized tax positions within the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize interest accrued related to UTBs and penalties as income tax expense.  We accrued an immaterial amount of interest expense during 2020 in our statement of operations and as of December 31, 2020 have and an immaterial accrual for interest in our consolidated balance sheet. During 2019, there were no accrued penalties or interest as of December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Due to the NOL carryforwards, the U.S. federal and state returns are open to examination by the Internal Revenue Service and state jurisdictions for all years beginning with the year ended March 31, 2001. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax.  The Company’s subsidiary in India is currently under examination by the Office of the Commissioner of Income Tax in India for 2012-2013, 2013-2014, and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local tax authorities.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Income (loss) before provision for income taxes was attributed to the following jurisdictions for the years ended December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,873)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,321)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,738)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,270)</p></td></tr></table> -32873000 -18321000 135000 51000 -32738000 -18270000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The provision (benefit) for income taxes consists of the following for the years ended December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><div style="padding-left:54.35pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 482</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,245)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,125)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (832)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (738)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,288</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,132</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (527)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total provision (benefit) for income taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (45)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td></tr></table></div> 11000 0 110000 41000 361000 0 482000 41000 -8245000 -2125000 -832000 5000 -738000 9000 9288000 2132000 -527000 21000 -45000 62000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The provision (benefit) for income taxes differs from that computed using the federal statutory rate applied to loss before provision for income taxes as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computed tax benefit at federal statutory rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,875)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,837)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (610)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,683)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 286</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences and other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (375)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executive compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 609</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 985</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingencies</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,131</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (45)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td></tr></table> -6875000 -3837000 -1077000 -610000 -2683000 480000 286000 -375000 -126000 528000 609000 985000 408000 112000 753000 9308000 2131000 -45000 62000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2020 and 2019 are shown below (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td colspan="5" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,031</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expenses recognized for granting of options and warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,119</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,816</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,740</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,217</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,447</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,913)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,220)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,227</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (529)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,631)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,138)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,253)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,413)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,248)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,448)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our net deferred tax liability as presented in our consolidated balance sheet consist of the following items (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 434</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,882)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,448)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td></tr></table> 27106000 17031000 4119000 3816000 913000 383000 2740000 1217000 34878000 22447000 32913000 21220000 1965000 1227000 529000 110000 2631000 1138000 4253000 7413000 1248000 5448000 21000 434000 5882000 21000 5448000 21000 5700000 11700000 2100000 57600000 60900000 38600000 0.80 9800000 400000 300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits (“UTBs”) are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">UTBs, beginning of period</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 963</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gross increase – current period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 239</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gross decrease – prior period tax positions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (113)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gross increase – prior period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expiration of statute of limitations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">UTBs, end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 963</p></td></tr></table> 963000 48000 358000 239000 113000 0 64000 676000 0 0 1272000 963000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 18. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">January 2021 Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 25, 2021, the Company completed an underwritten public offering of 4,356,059 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement dated January 20, 2021, by and among the Company, on the one hand, and Morgan Stanley &amp; Co. LLC, Jefferies LLC, SVB Leerink LLC and UBS Securities LLC, as representatives of certain underwriters at a public offering price per share of $66.00, before deducting underwriting discounts and commissions. The shares include 568,181 shares issued and sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the underwriting agreement. The Company received net proceeds of approximately $269.7 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Blackstone Conversion </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. to convert an aggregate of </span><span style="background-color:#ffffff;">50,000</span><span style="background-color:#ffffff;"> shares of the Company’s Series C Preferred Stock. Pursuant to the terms of the waiver and conversion notice, the Company also agreed to waive its right under the certificate of designations of the Series C Preferred Stock to redeem up to </span><span style="background-color:#ffffff;">50,000</span><span style="background-color:#ffffff;"> shares of the Series C Preferred Stock prior to the 180-day anniversary of October 1, 2020, the issue date of the Series C Preferred Stock. Each share of Series C Preferred Stock has a liquidation preference of </span><span style="background-color:#ffffff;">$1,000</span><span style="background-color:#ffffff;"> per share plus any accumulated and unpaid dividends and is convertible into shares of the Company’s common stock, par value </span><span style="background-color:#ffffff;">$0.001</span><span style="background-color:#ffffff;"> per share, at a conversion price of </span><span style="background-color:#ffffff;">$38.6152</span><span style="background-color:#ffffff;"> per share. The forgoing conversion, effective as of February 5, 2021, resulted in the issuance of an aggregate of </span><span style="background-color:#ffffff;">1,312,860</span><span style="background-color:#ffffff;"> shares of Common Stock. The foregoing shares were issued pursuant to an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.</span></p> 4356059 66.00 568181 269700000 50000 50000 1000 0.001 38.6152 1312860 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 19. Quarterly Financial Data (Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of quarterly financial data is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quarter Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,361</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross margin</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,258</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,127</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,055</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,894</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,586)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,847)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common stockholders</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,943)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,803)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,418)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,866)</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.32)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,242</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross margin</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,454</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,338</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,627</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,932</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,141)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,304)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,352)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (878)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,387)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,528)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,469)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (948)</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.08)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.08)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.03)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Earnings per basic and diluted shares are computed independently for each of the quarters presented based on basic and diluted shares outstanding per quarter and, therefore, may not sum to the totals for the periods shown.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the fourth quarter of 2019, management identified an error in the Company's historical interim financial statements for the third quarter of fiscal year 2019 relating to its stock-based compensation expense. Specifically, in the third quarter of 2019, the Company incorrectly recorded $1,227,890 of accelerated stock-based compensation expense for nonemployee directors who were not eligible for the accelerated vesting under their stock option awards. The error impacts only the previously issued historical interim financial statements for the third quarter of fiscal year 2019. The Company corrected the error in the fourth quarter of 2019, which resulted in a reduction of $765,099 of stock-based compensation expense included in selling, general and administrative expense. The Company concluded the error is not material to the third and fourth quarter of 2019.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of quarterly financial data is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quarter Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,361</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross margin</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,258</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,127</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,055</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,894</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,586)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,847)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common stockholders</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,943)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,803)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,418)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,866)</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.32)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year ended December 31, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,242</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross margin</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,454</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,338</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,627</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,932</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,141)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,304)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,352)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (878)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,387)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,528)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,469)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (948)</p></td></tr><tr><td style="vertical-align:bottom;width:55.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.08)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.08)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.03)</p></td></tr></table> 9774000 9389000 11172000 48361000 5258000 5127000 6055000 19894000 -3586000 -5845000 -10732000 -9847000 -3943000 -5803000 -11418000 -53866000 -0.11 -0.15 -0.29 -1.32 6653000 8464000 9583000 9242000 3454000 4338000 4627000 4932000 -2141000 -2304000 -12352000 -878000 -2387000 -2528000 -12469000 -948000 -0.08 -0.08 -0.35 -0.03 1227890 765099 XML 20 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2020
Feb. 19, 2021
Jun. 30, 2020
Document and Entity Information      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Entity File Number 001-34632    
Entity Incorporation, State or Country Code NV    
Entity Tax Identification Number 88-0313393    
Entity Address, Address Line One 112 Westwood Place    
Entity Address, Address Line Two Suite 350    
Entity Address, City or Town Brentwood    
Entity Address, State or Province TN    
Entity Address, Postal Zip Code 37027    
City Area Code 949    
Local Phone Number 470-2300    
Title of 12(b) Security Common Stock, $0.001 par value    
Security Exchange Name NASDAQ    
Document Period End Date Dec. 31, 2020    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Entity Registrant Name CRYOPORT, INC.    
Entity Central Index Key 0001124524    
Entity Well-known Seasoned Issuer Yes    
Entity Interactive Data Current Yes    
Entity Voluntary Filers No    
Entity Public Float     $ 881,352,700
Entity Current Reporting Status Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Trading Symbol CYRX    
Entity Common Stock, Shares Outstanding   45,581,661  
Entity Emerging Growth Company false    
Entity Small Business true    
Entity Shell Company false    
ICFR Auditor Attestation Flag true    
XML 21 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current Assets:    
Cash and cash equivalents $ 36,873 $ 47,235
Short-term investments 56,444 47,061
Accounts receivable, net of allowance for doubtful accounts of $ 1.1 million and $0.1 million, respectively 31,377 7,098
Inventories 10,535 474
Prepaid expenses and other current assets 11,928 1,097
Total current assets 147,157 102,965
Property and equipment, net 30,036 11,833
Operating lease right-of-use assets 14,044 4,460
Intangible assets, net 213,908 5,178
Goodwill 145,282 11,000
Deposits 1,184 437
Other long-term assets 794 0
Total assets 552,405 135,873
Current Liabilities:    
Accounts payable and other accrued expenses 24,844 2,498
Accrued compensation and related expenses 7,441 1,904
Deferred revenue 445 368
Operating lease liabilities 2,231 666
Finance lease liabilities 59 25
Total current liabilities 35,020 5,461
Convertible senior notes, net of discount of $0.4 million 111,344 0
Note payable 4,912 0
Operating lease liabilities, net of current portion 12,261 4,101
Finance lease liabilities, net of current portion 112 9
Deferred tax liability 5,882 21
Other long-term liabilities 176 0
Total liabilities 169,707 9,592
Commitments and contingencies
Stockholders' Equity:    
Common stock, $0.001 par value; 100,000,000 shares authorized; 39,837,058 and 37,339,787 issued and outstanding at December 31, 2020 and 2019, respectively 40 37
Additional paid-in capital 566,451 285,609
Accumulated deficit (192,013) (159,320)
Accumulated other comprehensive income (loss) 5,376 (45)
Total stockholders' equity 382,698 126,281
Total liabilities and stockholders' equity 552,405 135,873
Class A convertible preferred stock [Member]    
Stockholders' Equity:    
Preferred stock value 0 0
Class B convertible preferred stock [Member]    
Stockholders' Equity:    
Preferred stock value 0 0
Class C convertible preferred stock    
Stockholders' Equity:    
Preferred stock value $ 2,844 $ 0
XML 22 R3.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Convertible Subordinated Debt, Discount $ 3.7  
Preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 2,500,000 2,500,000
Common stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 39,837,058 37,339,787
Common stock, shares outstanding 39,837,058 37,339,787
Class A convertible preferred stock [Member]    
Preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 800,000 800,000
Preferred stock, shares outstanding 0 0
Class B convertible preferred stock [Member]    
Preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 585,000 585,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Class C convertible preferred stock    
Preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 250,000 250,000
Preferred stock, shares issued 250,000 250,000
Preferred stock, shares outstanding 250,000 250,000
XML 23 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenues $ 78,696 $ 33,942
Cost of revenues 42,362 16,590
Gross margin 36,334 17,352
Operating costs and expenses:    
Selling, general and administrative 56,860 31,286
Engineering and development 9,484 3,741
Total operating costs and expenses 66,344 35,027
Loss from operations (30,010) (17,675)
Other income (expense):    
Investment income 761 583
Interest expense (2,560) (1,367)
Other income (expense), net (929) 189
Total other expense, net (2,728) (595)
Loss before provision for income taxes (32,738) (18,270)
Benefit from (provision for) income taxes 45 (62)
Net loss (32,693) (18,332)
Deemed dividend on Series C convertible preferred stock (39,492)  
Paid-in-kind preferred stock dividend, including beneficial conversion feature (2,844)  
Net loss attributable to common stockholders $ (75,029) $ (18,332)
Net loss per share attributable to common stockholders - basic and diluted $ (1.94) $ (0.55)
Weighted average common shares outstanding - basic and diluted 38,582,432 33,394,285
Product [Member]    
Revenues $ 23,397  
Cost of revenues 12,841  
Service [Member]    
Revenues 55,299 $ 33,942
Cost of revenues $ 29,521 $ 16,590
XML 24 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Consolidated Statements of Comprehensive Loss    
Net loss $ (32,693) $ (18,332)
Other comprehensive income (loss), net of tax:    
Net unrealized gain (loss) on available-for-sale debt securities 161 (28)
Reclassification of realized (gain) loss on available-for-sale debt securities to earnings (3) (23)
Foreign currency translation adjustments 5,263 3
Other comprehensive income (loss) 5,421 (48)
Total comprehensive loss $ (27,272) $ (18,380)
XML 25 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Stockholders' Equity - USD ($)
Common Stock [Member]
Private Placement
Common Stock [Member]
Additional Paid-In Capital [Member]
Private Placement
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Private Placement
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income [Member]
Private Placement
Accumulated Other Comprehensive Income [Member]
Class A Preferred Stock
Private Placement
Class A Preferred Stock
Class B Preferred Stock
Private Placement
Class B Preferred Stock
Class C Preferred Stock
Private Placement
Total
Balance at Dec. 31, 2018   $ 30,000   $ 179,502,000   $ (140,988,000)   $ 3,000   $ 0   $ 0     $ 38,547,000
Balance (in shares) at Dec. 31, 2018   30,319,038                   0      
Net loss   $ 0   0   (18,332,000)   0   0   $ 0     (18,332,000)
Other comprehensive income (loss), net of taxes   0   0   0   (48,000)   0   0     (48,000)
Stock-based compensation expense   0   6,871,000   0   0   0   0     6,871,000
Accelerated stock-based compensation expense   0   9,562,000   0   0   0   0     9,562,000
Stock issued during period value new issues   $ 4,000   68,806,000   0   0   0   $ 0     68,810,000
Stock issued during period, new issues (in shares)   4,312,500                   0      
Issuance of common stock for board of director compensation   $ 0   91,000   0   0   0   $ 0     91,000
Issuance of common stock for board of director compensation (in shares)   5,753                   0      
Issuance of common stock for convertible debt and accrued interest   $ 1,000   15,416,000   0   0   0   $ 0     15,417,000
Issuance of common stock for convertible debt and accrued interest (in shares)   1,172,305                   0      
Proceeds from exercise of stock options and warrants   $ 2,000   5,361,000   0   0   0   $ 0     5,363,000
Proceeds from exercise of stock options and warrants (in shares)   1,530,191                   0      
Balance at Dec. 31, 2019   $ 37,000   285,609,000   (159,320,000)   (45,000)   0   $ 0     126,281,000
Balance (in shares) at Dec. 31, 2019   37,339,787                   0      
Net loss   $ 0   0   (32,693,000)   0   0   $ 0     (32,693,000)
Other comprehensive income (loss), net of taxes   0   0   0   5,421,000   0   0     5,421,000
Stock-based compensation expense   0   8,833,000   0   0   0   0     8,833,000
Stock issued during period value new issues $ 1,000 $ 0 $ 28,159,000 237,225,000 $ 0 0 $ 0 0 $ 0 0 $ 0 $ 0   $ 28,160,000 237,225,000
Stock issued during period, new issues (in shares) 675,536 0                 0 0 250,000    
Issuance of common stock for board of director compensation   $ 0   83,000   0   0   0   $ 0     83,000
Issuance of common stock for board of director compensation (in shares)   2,869                          
Proceeds from exercise of stock options and warrants   $ 2,000   9,386,000   0   0   0   $ 0     9,388,000
Proceeds from exercise of stock options and warrants (in shares)   1,818,866                   0      
Beneficial conversion feature of the Series C convertible preferred stock   $ 0   39,492,000   0   0   0   $ 0 $ (39,492,000)   0
Deemed dividend on the Series C convertible preferred stock   0   (39,492,000)   0   0   0   0 39,492,000   0
Paid-in-kind preferred stock dividend, including beneficial conversion feature   0   (2,844,000)   0   0   0   0 2,844,000   0
Balance at Dec. 31, 2020   $ 40,000   $ 566,451,000   $ (192,013,000)   $ 5,376,000   $ 0   $ 0 $ 2,844,000   $ 382,698,000
Balance (in shares) at Dec. 31, 2020   39,837,058                     250,000    
XML 26 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Public offering    
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs   $ 103,000
Private Placement    
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs $ 914,200  
Class C convertible preferred stock    
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs $ 7,700,000  
XML 27 R8.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash Flows From Operating Activities:    
Net loss $ (32,693,000) $ (18,332,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 9,869,000 2,415,000
Amortization of debt discount 437,000 288,000
Interest expense on convertible note settled by issuance of common stock 0 418,000
Unrealized (gain) loss on investments in equity securities (845,000) 102,000
Realized loss on investments in equity securities 1,090,000 0
Realized (gain) loss on available-for-sale debt securities 32,000 (82,000)
Stock-based compensation expense 8,916,000 6,962,000
Accelerated stock-based compensation expense 0 9,562,000
Loss on disposal of property and equipment 384,000 274,000
Provision for bad debt 197,000 42,000
Changes in operating assets and liabilities, net of effects of acquisition:    
Accounts receivable (2,617,000) (3,596,000)
Inventories 1,322,000 (253,000)
Prepaid expenses and other current assets (7,520,000) (345,000)
Deposits (152,000) (86,000)
Change in operating lease right-of-use assets and lease liabilities 134,000 (6,000)
Accounts payable and other accrued expenses 4,245,000 570,000
Accrued compensation and related expenses 3,143,000 641,000
Deferred revenue (309,000) 81,000
Net deferred tax (asset) liability (499,000) 21,000
Net cash used in operating activities (14,866,000) (1,324,000)
Cash Flows From Investing Activities:    
Purchases of property and equipment (8,918,000) (5,336,000)
Purchases of short-term investments (158,736,000) (43,196,000)
Sales/maturities of short-term investments 149,233,000 5,995,000
Patent and trademark costs (200,000) (73,000)
Software development costs (551,000) 0
Cash paid for acquisitions (363,140,000) (20,317,000)
Net cash used in investing activities (382,312,000) (62,927,000)
Cash Flows From Financing Activities:    
Proceeds from exercise of stock options and warrants 9,388,000 5,363,000
Proceeds from issuance of Series C convertible preferred stock, net of issuance costs 237,225,000 0
Proceeds from issuance of common stock, net of issuance costs 28,160,000 0
Proceeds from public offering, net of offering costs 0 68,811,000
Repayment of finance lease liabilities (70,000) (23,000)
Proceeds from issuance of convertible senior notes 115,000,000 0
Payment of deferred financing costs (4,118,000) 0
Net cash provided by financing activities 385,585,000 74,151,000
Effect of exchange rate changes on cash and cash equivalents 1,231,000 8,000
Net change in cash and cash equivalents (10,362,000) 9,908,000
Cash and cash equivalents - beginning of year 47,235,000 37,327,000
Cash and cash equivalents - end of year 36,873,000 47,235,000
Supplemental Disclosure of Cash Flow Information:    
Cash paid for interest 1,823,000 707,000
Cash paid for income taxes 60,000 14,000
Supplemental Disclosure of Non-Cash Investing and Financing Activities:    
Net unrealized gain (loss) on available-for-sale debt securities 161,000 (28,000)
Reclassification of realized gain on available-for-sale debt securities to earnings 3,000 23,000
Fixed assets included in accounts payable and accrued liabilities 499,000 261,000
Purchase of equipment through finance lease obligations 205,000 0
Paid-in-kind preferred stock dividend, including beneficial conversion feature 2,844,000 0
Common stock issued for conversion of debt and accrued interest $ 0 $ 15,418,000
XML 28 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Nature of the Business
 12 Months Ended
Dec. 31, 2020
Nature of the Business  
Nature of the Business

Note 1. Nature of the Business

Cryoport, Inc. (“Cryoport”, “we”, or “our”) is a life sciences services company that is an integral part of the temperature-controlled supply chain supporting the biopharma/pharma, animal health, and human reproductive medicine markets. We are redefining logistics for the life sciences industry by providing a unique platform of critical solutions including highly differentiated temperature-controlled supply chain solutions, which include advanced packaging, informatics, specialty logistics services, biostorage services and cryogenic life sciences equipment. Through our products, services and expertise, we enable our clients to ship, store and deliver cellular-based materials and drug products as well as other life sciences commodities in a precise, defined temperature-controlled state.

Cryoport’s advanced platform, comprised of comprehensive and technology-centric systems and solutions are designed to support the global high-volume distribution of commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA) and other international regulatory bodies for distribution in the Americas, EMEA (Europe, the Middle East, and Africa) and APAC (Asia-Pacific) regions. Cryoport’s solutions are also designed to support pre-clinical, clinical trials, Biologics License Applications (BLA), Investigational New Drug Applications (IND), New Drug Applications (NDA) and Commercialized Products with the FDA, as well as global clinical trials and commercialized products initiated in other countries, where strict regulatory compliance and quality assurance is mandated. Our industry standard setting Chain of ComplianceTM solutions, which include vital analytics, such as ‘chain-of-condition’ and ‘chain-of-custody’ information in a single data stream, empower our clients’ continuous vigilance over their respective commodities. In addition, our Chain of ComplianceTM standard ensures full traceability of all equipment used and the processes employed, further supporting each client’s goal of minimizing risk and maximizing success of their respective biologics or other products and therapies as they are introduced into the global markets.

On August 21, 2020, the Company entered into a Securities Purchase Agreement to acquire CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets, headquartered in Paris, France. Under the terms of the Securities Purchase Agreement, the Company acquired 100% of the equity interests in Advanced Therapy Logistics and Solutions, a company organized under the laws of France, which is the holding company that owns CRYOPDP (the “CRYOPDP Acquisition”). The base purchase price under the Securities Purchase Agreement was €49 million (approximately $58.0 million) and is subject to a cash, net debt, working capital and other adjustments.

On August 24, 2020, the Company entered into a Purchase Agreement with Chart Industries, Inc. (“Chart”) pursuant to which the Company acquired Chart’s MVE Biological Solutions’ cryobiological storage business (the “MVE Acquisition”) for a cash purchase price at closing of $320 million, subject to customary closing working capital and other adjustments. The MVE Acquisition was structured as the acquisition of certain equity interests and assets and the transfer of certain liabilities in connection therewith.

On October 1, 2020, the Company completed both the MVE Acquisition and the CRYOPDP Acquisition, which are further discussed in Note 3.

On May 14, 2019, the Company acquired substantially all of the assets of Cryogene Partners, a Texas general partnership doing business as Cryogene Labs (“Cryogene”).  Cryogene operates a temperature-controlled biostorage solutions business in Houston, Texas (See Note 3).

The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”
XML 29 R10.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2020
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Change in Segment Reporting

The Company continually monitors and reviews its segment reporting structure in accordance with authoritative guidance to determine whether any changes have occurred that would impact its reportable operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The chief operating decision maker (“CODM”) is our Chief Executive Officer. Up until the fourth quarter of 2020, we managed, reported and evaluated our business in the following two reportable operating segments: Global Logistics Solutions and Global Bioservices. During the fourth quarter of 2020, our CODM changed how he makes operating decisions, assesses the performance of the business and allocates resources in a manner that caused our operating segments to change as a result of the MVE and CRYOPDP acquisitions. In consideration of Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”), 280, Segment Reporting, we determined that we are not organized around specific products and services, geographic regions or regulatory environments. Accordingly, beginning with the fourth quarter of 2020, we realigned our reporting structure, resulting in a single reportable segment. The Company has adjusted its financial statements for historical periods to reflect this change in segment reporting and show its financial results without segments for all periods presented.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries, Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions US LLC, and Cryoport Netherlands B.V. and subsidiaries (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.

Cash and Cash Equivalents

Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.

Short-Term Investments

Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.

Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.

Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.

Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.

Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.

Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, note payable, and the Company’s 3.00% convertible senior notes due in 2025 (the “Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, note payable and the Senior Notes, approximates fair value at December 31, 2020 due to their short-term nature. The carrying value of finance lease liabilities approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the note payable and the Senior Notes, see Note 5.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2020 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.

Our investment policy requires that purchased instruments in marketable securities may only be in highly rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.

Customers

The Company grants credit to customers within the U.S. and to international customers and does not require collateral. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables is affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at December 31, 2020, and 2019 are net of reserves for doubtful accounts of $1.1 million and $0.1 million, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.

The Company’s customers are in the biotechnology, pharmaceutical, animal health, human reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. As of December 31, 2019, there were two customers that accounted for 31.0% and 20.7%, respectively, of net accounts receivable. There were no other single customer that owed us more than 10%of net accounts receivable at December 31, 2020 and 2019.

The Company has revenue from foreign customers primarily in United Kingdom, Switzerland, France, Netherlands, Singapore, China and India. During the years ended December 31, 2020 and 2019, the Company had revenues from foreign customers of approximately $29.1 million and $5.1 million, respectively, which constituted approximately 37.0% and 15.1%, respectively, of total revenues. There  were two customers that accounted for 24.1% and 12.8% of revenues during the year ended December 31, 2019. No other single customer generated over 10% of revenues during the years ended December 31, 2020 and 2019.

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation.  We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally three to twelve years for computer hardware and software, seven to ten years for freezers, four to ten years for trucks and autos, three to fifteen years for furniture and equipment and over the shorter of the lease term or useful live of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from 20 to 45 years. Maintenance and repairs are expensed as incurred.

Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.

Leases

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.

Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received.  Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees.  Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company accounts for lease and non-lease components as a single lease component for all its leases.

Business Combinations

Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.

Goodwill

The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company compares the fair value of the reporting unit’s with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting units fair value up to the total amount of goodwill allocated to the reporting unit. The Company assessed  triggering events indicating potential goodwill impairment, including the effects of the COVID-19 pandemic, and after assessment, concluded that there was no impairment during the year ended December 31, 2020.

Intangible Assets

Intangible assets are comprised of patents, trademarks, software development costs and the intangible assets acquired in the MVE, CRYOPDP and Cryogene acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights, acquired in the MVE, CRYOPDP and Cryogene acquisitions are amortized using the straight-line method over the estimated useful lives (see Note 8). The Company uses the following valuation methodologies to value the significant intangible assets acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology.

The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. There was no impairment of intangible assets during the year ended December 31, 2020.

Other Long-lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through December 31, 2020.

Deferred Financing Costs

Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.

Income Taxes

The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, “Income Taxes”, or ASC 740. As of December 31, 2020 and 2019, there were no material unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the US based net deferred tax assets be realized. Therefore, the Company has recorded a full valuation allowance against its US based net deferred tax assets. With respect to the foreign based deferred tax assets, the Company's management has reviewed these deferred tax assets on a jurisdictional basis. Based on the weight of each jurisdiction's evidence available, the Company's management has made separate determinations for each foreign jurisdiction regarding whether it is more likely than not that a net deferred tax asset within a particular jurisdiction will be not be realized. The Company has recorded full valuation allowances in jurisdictions where deferred tax assets are not deemed more likely than not to be realized.

Additionally, the Company maintains a deferred tax liability related to indefinite-lived assets that have been netted against deferred tax assets that also allow for indefinite carryforward periods subject to limitations.  The remaining taxable temporary difference cannot serve as a source for future taxable income to realize federal net operating losses, due to the fact that post-2017 federal net operating losses are only eligible to offset  80% of income in a given year or in the case of state net operating losses, the state net operating losses will expire prior to the reversal of the taxable temporary difference.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company has immaterial accruals for interest or penalties on its consolidated balance sheets at December 31, 2020 and 2019 and has recorded only immaterial interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2020 and 2019. The Company is subject to taxation in the U.S., various state jurisdictions and in various foreign countries. As of December 31, 2020, the Company is no longer subject to U.S. federal examinations for years before 2017 and for California franchise and income tax examinations for years before 2016. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax. The Company's subsidiary in India is currently under examination by the Indian tax authorities for 2012-2013, 2013-2014 and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local taxing authorities.

In December of 2019, the FASB issued ASU 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 31, 2020. Early adoption is permitted, including adoption in an interim period. Different components of the guidance require retrospective, modified retrospective or prospective adoption. The Company has elected to early adopt ASU 2019-12 on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.

On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. At December 31, 2020, the Company has not recorded any income tax provision/(benefit) resulting from the CARES Act mainly due the Company’s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.

On December 27, 2020, the United States enacted the Consolidated Appropriations Act of 2021 (“CAA”).  The CAA includes provisions extending certain CARES Act provisions and adds coronavirus relief, tax and health extenders. The Company will continue to evaluate the impact of the CAA and its impact on our financial statements in 2021 and beyond.

In June 29, 2020, the state of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&D credit usage for the same period (for credit usages in excess of $5M). These suspensions were considered in preparation of the 2020 financial statements.

Revenue Recognition

Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

Performance Obligations

At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to

payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.

For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.

Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.

Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within one year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.

Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying consolidated statements of operations.

Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.

Significant Payment Terms

Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15 to 60 days from the date of the invoice (except for any amounts disputed by the customer in good faith).  Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component.

Variable Consideration

When a contract includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained. Variable consideration is estimated at the most likely amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Variable consideration estimates are updated at each reporting date. Revenues are recorded net of variable consideration, such as discounts and allowances.

Warranties

The Company provides product warranties with varying terms and durations for some of its products. The Company estimates product warranty costs and accrues for these costs as products are sold with a charge to cost of sales. Factors considered in estimating warranty costs include historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside of typical experience. Warranty accruals are evaluated and adjusted as necessary based on actual claims experience and changes in future claim and cost estimates.

Product warranty accrued liabilities totaled $0.2 million and $0 at December 31, 2020 and 2019, respectively, and are included in accounts payable and other accrued expenses. Warranty expense was not material for the years ended December 31, 2020 and 2019.

Incremental Direct Costs

Incremental direct costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as promised goods and services are transferred to a customer. Incremental direct costs were not material for the years ended December 31, 2020 and 2019.

Contract Assets

Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable, which are recognized when payment is unconditional and only the passage of time is required before payment is due. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed.

Contract Liabilities (Deferred Revenue)

Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $0.4 million at December 31, 2020 and 2019. During the years ended December 31, 2020 and 2019, the Company recognized revenues of $0.4 million and $0.1 million from the related contract liabilities outstanding as the services were performed.

Nature of Goods and Services

The Company provides Cryoport Express® Shippers to its customers and charges a fee in exchange for the use of the Cryoport Express® Shipper under long-term master service agreements with customers. The Company’s arrangements convey to the customers the right to use the Cryoport Express® Shippers over a period of time. The Company retains title to the Cryoport Express® Shippers and provides its customers the use of the Cryoport Express® Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Cryoport Express® Shipper is returned to the Company.

The Company recognizes revenue for the use of the Cryoport Express® Shippers at the time of the delivery of the Cryoport Express® Shipper to the end user of the enclosed materials, and at the time that collectability is probable.

The Company also provides vacuum insulated aluminum dewars and cryogenic freezers systems to its customers. Revenue is recognized when the Company satisfies performance obligations by transferring the equipment to a customer, and at the time that collectability is probable.

The Company also provides global temperature-controlled logistics services, support and management. Revenue is recognized for these services as services are rendered and at the time that collectability is probable.

The Company also provides comprehensive and integrated temperature-controlled biostorage solutions to customers in the life sciences industry and charges a fee under long-term master service agreements with customers. These services include (1) biological specimen cryopreservation storage and maintenance, (2) archiving, monitoring, tracking, receipt and delivery of samples, (3) transport of frozen biological specimens to and from customer locations, and (4) management of incoming and outgoing biological specimens. The Company recognizes revenue for its biostorage solutions as services are rendered over time and at the time that collectability is probable.

The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services over time as the customer simultaneously receives and consumes the benefit of these services as they are performed.

A significant portion of our revenues are covered under long-term agreements. We have determined that individual Statements of Work or Scope of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle) for the Cryoport Express® solutions and up to 12 months for biostorage solutions. Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services.  Prices under these agreements are generally fixed.

Revenue Disaggregation

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major markets for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Biopharma/Pharma

​

$

66,394

​

$

30,032

Animal Health

​

 

7,846

​

 

996

Human Reproductive Medicine

​

​

4,456

​

​

2,914

Total revenues

​

$

78,696

​

$

33,942

​

Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the years ended December 31, 2020 and 2019, were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Americas

​

$

49,555

​

$

28,801

Europe, the Middle East and Africa (EMEA)

​

 

20,316

​

 

4,523

Asia Pacific (APAC)

​

 

8,825

​

 

618

Total revenues

​

$

78,696

​

$

33,942

​

Cost of Services Revenues

Our cost of services revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions.

Cost of Product Revenues

Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.

Engineering and Development Expenses

Expenditures relating to engineering and development are expensed in the period incurred to engineering and development expense in the consolidated statements of operations.

Acquisition Costs

Acquisition costs consist of legal, accounting, third-party valuations, and other due diligence costs related to our MVE, CRYOPDP, and Cryogene acquisitions (See Note 3).

Stock-Based Compensation

The Company accounts for stock-based payments in accordance with stock-based payment accounting guidance which requires all stock-based payments to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.  The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and expected term. The Company accounts for forfeitures of unvested awards as they occur.

The Company’s stock-based compensation plans are discussed further in Note 16.

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

Issuances of the Company’s common stock for acquiring goods or services are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the estimated fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current estimated fair values.

Basic and Diluted Net Loss Per Share

We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt outstanding during the periods.

The following shows the amounts used in computing net loss per share (in thousands except per share data):

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Net loss

​

$

(32,693)

​

$

(18,332)

Deemed dividend on Series C convertible preferred stock

​

​

(39,492)

​

​

—

Paid-in-kind dividend on Series C convertible preferred stock

​

 

(2,844)

​

 

—

Net loss attributable to common shareholders

​

$

(75,029)

​

$

(18,332)

Weighted average common shares outstanding - basic and diluted

​

​

38,582,432

​

​

33,394,285

Basic and diluted net loss per share

​

$

(1.94)

​

$

(0.55)

​

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Stock options

​

5,920,886

 

3,636,806

Warrants

​

—

 

753,211

Series C convertible preferred stock

​

6,474,135

​

—

Convertible senior notes

​

4,810,002

 

—

​

​

17,205,023

 

4,390,017

​

Foreign Currency Transactions

Management has determined that the functional currency of its subsidiaries is the local currency.  The Company translates the assets and liabilities of its foreign subsidiaries into U.S. dollars at exchange rates in effect at the end of the reporting period.  Income

and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity.  The translation gain (loss) adjustment totaled $5.2 million and 2,900 for the years ended December 31, 2020 and 2019, respectively.  Foreign currency gains and losses from transactions denominated in other than respective local currencies are included in earnings.

Off Balance Sheet Arrangements

We do not currently have any off balance sheet arrangements.

Reclassification

Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.

Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of U.S. GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income).  ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12 on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.  

In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement," which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. We adopted this guidance on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.

In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which is intended to simplify the subsequent accounting for goodwill acquired in a business combination. Prior guidance required utilizing a two-step process to review goodwill for impairment. A second step was required if there was an indication that an impairment may exist, and the second step required calculating the potential impairment by comparing the implied fair value of the reporting unit's goodwill (as if purchase accounting were performed on the testing date) with the carrying amount of the goodwill. The new guidance eliminates the second step from the goodwill impairment test. Under the new guidance, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount, and then recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value (although the loss should not exceed the total amount of goodwill allocated to the reporting unit). The guidance requires prospective adoption and is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019.  We adopted this guidance on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.

Accounting Guidance Issued but Not Adopted at December 31, 2020

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new

guidance also requires the if-converted method to be applied for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted in fiscal years beginning after December 15, 2020. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. In November 2019, the FASB issued ASU 2019-10 "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which deferred the effective date of ASU 2016-13 by three years for smaller reporting companies. The one-time determination of whether an entity is eligible to be a smaller reporting company is based on the entity's most recent determination as of November 15, 2019 in accordance with SEC regulations.  As a result, ASU 2016-13, as subsequently amended, is effective for the Company for fiscal years beginning after December 15, 2022 based on the Company's smaller reporting company determination as of November 15, 2019.  We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.  The Company currently believes the main impact of the new standard will relate to the Company’s assessment of its allowance for doubtful accounts on trade receivables.
XML 30 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Acquisitions
 12 Months Ended
Dec. 31, 2020
Acquisitions  
Acquisitions

Note 3. Acquisitions

2020 Acquisitions – CRYOPDP and MVE

CRYOPDP Acquisition

On October 1, 2020, the Company completed its acquisition of CRYOPDP for a cash consideration of €48.3 million ($57.0 million, the “CRYOPDP Acquisition”). This acquisition was funded with existing cash on hand. CRYOPDP, based in France, is a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets. CRYOPDP conducts its business activities in the Americas, EMEA and APAC. As a result of the CRYOPDP Acquisition, the Company has extended its solutions to include broader temperature-controlled logistics and specialty courier services and has significantly expanded its global network through CRYOPDP’s 22 facilities in 12 countries.

The CRYOPDP Acquisition was accounted for under the acquisition method of accounting in accordance with FASB ASC Topic 805, “Business Combinations,” and, therefore, the total purchase price was allocated to the identifiable tangible and intangible assets acquired and the liabilities assumed based on their respective fair values on the acquisition date. Fair values were determined by management based in part on an independent valuation performed by a third-party valuation specialist and required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable; however, actual results may differ from these estimates.

The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):

​

​

​

​

Total purchase consideration paid

    

$

56,971

​

​

​

​

Purchase price allocation:

​

 

  

Cash and cash equivalents

​

 

8,346

Accounts receivable

​

 

10,603

Inventories

​

 

644

Prepaid and other current assets

​

 

2,905

Property and equipment

​

 

2,863

Operating lease right-of-use assets

​

 

1,856

Intangible assets

​

 

28,235

Other long-term assets

​

 

569

Accounts payable and other accrued expenses

​

 

(11,110)

Accrued compensation and related expenses

​

​

(1,194)

Deferred revenue

​

​

(370)

Note payable

​

​

(4,690)

Operating lease liabilities

​

 

(1,856)

Deferred tax liability

​

 

(5,311)

Other long-term liabilities

​

 

(64)

Total identifiable net assets

​

 

31,426

Goodwill

​

 

25,545

​

​

$

56,971

​

The following table summarizes the estimated fair values of CRYOPDP’s identifiable intangible assets at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

    

    

    

    

Annual

​

​

Estimated

​

Estimated

​

Amortization

​

Amortization

​

​

Fair Value

​

Useful Life

​

Method

​

Expense

Software

​

$

3,578

 

7

 

Straight-line

​

$

511

Customer relationships

​

 

5,871

 

11.5

 

Straight-line

​

 

511

Agent network

​

 

8,219

 

4

 

Straight-line

​

 

2,055

Trade name/trademarks

​

 

10,567

 

Indefinite

 

—

​

 

—

Total

​

$

28,235

​

​

​

​

​

$

3,077

​

Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Among the factors that contributed to a purchase price in excess of the fair value of the net tangible and intangible assets acquired were the acquisition of an assembled workforce, the expected synergies, and other benefits that we believe will result from combining the operations of CRYOPDP with our operations. The goodwill recognized of $25.5 million is not expected to be deductible for income tax purposes.

Our estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management’s analysis related to certain matters, including income taxes, accounts receivable, note payable and other accounts and certain valuation balances. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. Although the final determination may result in asset and liability fair values that are different than the preliminary estimates of these amounts included herein, it is not expected that those differences will be material to our consolidated financial position.

Acquisition-related transaction costs (included in selling, general and administrative expenses) totaled approximately $1.4 million.

MVE Acquisition

On October 1, 2020, the Company completed its acquisition of Chart Industries, Inc.’s MVE cryobiological storage business (the “MVE Acquisition”) for a cash consideration of $317.5 million, subject to customary closing working capital and other adjustments. The Company financed a portion of the closing cash payment of the MVE Acquisition with the net proceeds of the Blackstone Private Placement, as further discussed in Note 13. MVE is a global leader in manufactured vacuum insulated products and cryogenic freezer systems for the life sciences industry. MVE has manufacturing and distribution operations in the Americas, EMEA and APAC. As a result of the MVE Acquisition, the Company has extended its integrated logistics solutions to provide a broad range of cryogenic dewars and freezers to the life sciences industry.

The MVE Acquisition was accounted for under the acquisition method of accounting in accordance with FASB ASC Topic 805, “Business Combinations,” and, therefore, the total purchase price was allocated to the identifiable tangible and intangible assets acquired and the liabilities assumed based on their respective fair values on the acquisition date. Fair values were determined by management based in part on an independent valuation performed by a third-party valuation specialist and required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable; however, actual results may differ from these estimates.

The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):

​

​

​

​

Total purchase consideration paid

    

$

317,470

​

​

​

​

Purchase price allocation:

​

 

  

Cash and cash equivalents

​

 

2,955

Accounts receivable

​

 

10,645

Inventories

​

 

10,627

Prepaid and other current assets

​

 

256

Property and equipment

​

 

9,050

Operating lease right-of-use assets

​

 

2,154

Intangible assets

​

 

184,991

Other long-term assets

​

 

358

Accounts payable and other accrued expenses

​

 

(6,036)

Accrued compensation and related expenses

​

​

(1,139)

Operating lease liabilities

​

 

(2,160)

Deferred tax liability

​

 

(393)

Other long-term liabilities

​

 

(64)

Total identifiable net assets

​

 

211,244

Goodwill

​

 

106,226

​

​

$

317,470

​

The following table summarizes the estimated fair values of MVE’s identifiable intangible assets and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

    

​

​

    

  

    

  

    

Annual

​

​

Estimated

​

Estimated

​

Amortization

​

Amortization

​

​

Fair Value

​

Useful Life

​

Method

​

Expense

Order backlog

 

​

2,600

 

0.125

 

Straight-line

​

$

—

Customer relationships

 

​

118,600

 

14.5

 

Straight-line

​

 

8,179

Developed technology

 

​

28,700

 

12

 

Straight-line

​

 

2,392

Land use rights

 

​

2,291

 

38

 

Straight-line

​

 

63

Trade name/trademarks

 

​

32,800

 

Indefinite

 

—

​

 

—

Total

​

$

184,991

​

​

​

​

​

$

10,634

​

Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Among the factors that contributed to a purchase price in excess of the fair value of the net tangible and intangible assets acquired were the acquisition of an assembled workforce, the expected synergies, and other benefits that we believe will result from combining the operations of MVE with our operations. Of the $106.2 million goodwill recognized, approximately $62.5 million is allocated to the U.S. and Germany and is expected to be deductible for income tax purposes.

Our estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management’s analysis related to certain matters, including income taxes and certain other accounts and certain valuation balances. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. Although the final determination may result in asset and liability fair values that are different than the preliminary estimates of these amounts included herein, it is not expected that those differences will be material to our consolidated financial position.

Acquisition-related transaction costs (included in selling, general and administrative expenses) totaled approximately $8.8 million.

Revenue, Net Income and Pro Forma Presentation – CRYOPDP and MVE Acquisitions

The operating results of the CRYOPDP and MVE acquisitions have been included in our consolidated financial statements from the acquisition date through December 31, 2020. Our results for the year ended December 31, 2020, include revenue for CRYOPDP of $12.9 million and net loss of $1.8 million and revenue for MVE of $23.0 million and net income of $1.8 million.

The following unaudited pro forma information presents our combined results as if the CRYOPDP and MVE acquisitions had occurred on January 1, 2019. The unaudited pro forma financial information was prepared to give effect to events that are (1) directly attributable to the acquisition, (2) factually supportable, and (3) expected to have a continuing impact on the combined company’s results. The 2019 period includes the elimination of revenues of $1.8 million and related cost of goods sold of $0.9 million recorded by MVE from the Company. There were no transactions between the Company and CRYOPDP during the periods presented that are required to be eliminated. The unaudited pro forma combined financial information does not reflect any cost savings, operating synergies, or revenue enhancements that the combined companies may achieve as a result of the acquisitions or the costs to integrate the operations or the costs necessary to achieve cost savings, operating synergies, or revenue enhancements.

The following table presents the unaudited, pro forma consolidated results of operations for the year ended December 31, 2020 and 2019 as if the acquisition of the assets of CRYOPDP and MVE had occurred as of January 1, 2019.  The pro forma information provided below is compiled from the audited financial statements of CRYOPDP and MVE, which includes pro forma adjustments for intangible assets amortization expense and depreciation expense on the step up in fair value of property and equipment.

​

​

​

​

​

​

​

​

​

    

Year Ended

    

Year Ended

(in thousands except per share data)

​

December 31, 2020

​

December 31, 2019

​

​

(unaudited)

​

(unaudited)

Revenues

​

$

172,147

​

$

163,217

Net loss

​

$

(18,562)

​

$

(3,149)

Basic and diluted net loss per share

​

$

(2.08)

​

$

(0.09)

​

The pro forma results are not necessarily indicative of the consolidated results of operations that we would have reported had the acquisitions been completed as of January 1, 2019 and should not be taken as representative of our consolidated results of operations following the acquisitions. In addition, the unaudited proforma consolidated financial information is not intended to project the future results of operations of the Company.

Acquisition – Cryogene Partners

On May 14, 2019, Cryogene, Inc., a Texas corporation and a wholly owned subsidiary of the Company, entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) for the acquisition of the assets of Cryogene Partners, a Texas general partnership doing business as Cryogene Labs (“Cryogene”). The closing of the transaction contemplated in the Asset Purchase Agreement occurred simultaneously with the execution of the Asset Purchase Agreement on May 14, 2019.

Pursuant to the terms and subject to the conditions of the Asset Purchase Agreement, the Company acquired substantially all of the assets of Cryogene, including, without limitation, tangible personal property, intellectual property assets, and certain contracts related to Cryogene’s temperature-controlled biostorage solutions business located in Houston, Texas (the foregoing, the “Purchased Assets”), and assumed certain related liabilities.

The aggregate purchase price for the Purchased Assets was $20.3 million in cash.

As a result of this acquisition, the Company has extended its integrated logistics solutions and services to provide comprehensive temperature-controlled sample management solutions to the life sciences industry, including specimen storage, sample processing, collection, and retrieval.

Purchase Price Allocation

We funded this acquisition through available cash and accounted for it as an acquisition of a business in accordance with FASB ASC Topic 805, “Business Combinations”.  Assets acquired and liabilities assumed in connection with the acquisition have been recorded at their fair values.  Fair values were determined by management based in part on an independent valuation performed by a third-party valuation specialist.  The Company has performed a valuation analysis of the fair value of Cryogene’s assets and liabilities.  The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):

​

​

​

​

​

Total purchase price

    

$

20,317

​

​

​

​

Purchase price allocation:

​

 

  

Property and equipment

​

 

4,257

Intangible assets

​

 

5,280

Deferred revenue

​

 

(220)

Total identifiable net assets

​

 

9,317

Goodwill

​

 

11,000

​

​

$

20,317

​

The following table summarizes the fair value of intangible assets acquired at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Annual

​

    

Estimated

    

Estimated

    

Amortization

    

Amortization

​

​

Fair Value

​

Useful Life

​

Method

​

Expense

Non-compete agreement

​

$

390

 

5

 

Straight-line

​

$

78

Technology

​

 

510

 

5

 

Straight-line

​

 

102

Customer relationships

​

 

3,900

 

12

 

Straight-line

​

 

325

Trade name/trademark

​

 

480

 

15

 

Straight-line

​

 

32

Total

​

$

5,280

​

​

​

​

​

$

537

​

Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Among the factors that contributed to a purchase price in excess of the fair value of the net tangible and intangible assets acquired were the acquisition of an assembled workforce, the expected synergies, and other benefits that we believe will result from combining the operations of Cryogene with our operations. The goodwill recognized of $11.0 million is expected to be deductible for income tax purposes.

Acquisition-related transaction costs (included in selling, general and administrative expenses) totaled approximately $0.3 million.

The operating results of the Cryogene acquisition have been included in our consolidated financial statements from the acquisition date through December 31, 2019. Our results for the year ended December 31, 2020 and 2019, include Cryogene sales of $3.0 million and net income of $437,100.
XML 31 R12.htm IDEA: XBRL DOCUMENT v3.20.4
Cash, Cash Equivalents and Short-Term Investments
 12 Months Ended
Dec. 31, 2020
Cash, Cash Equivalents and Short-Term Investments  
Cash, Cash Equivalents and Short-Term Investments

Note 4. Cash, Cash Equivalents and Short-term Investments

Cash, cash equivalents and short-term investments consisted of the following as of December 31, 2019 and 2018 (in thousands):

​

​

​

​

​

​

​

​

​

​

Carrying Value

​

    

2020

    

2019

Cash

​

$

25,053

​

$

3,547

Cash equivalents:

​

 

​

​

​

​

Money market mutual funds

​

 

11,820

​

​

43,688

Total cash and cash equivalents

​

 

36,873

​

​

47,235

Short-term investments:

​

 

​

​

​

​

U.S. Treasury notes and bills

​

 

23,309

​

​

21,094

Mutual funds

​

 

33,135

​

​

25,967

Total short-term investments

​

 

56,444

​

​

47,061

Cash, cash equivalents and short-term investments

​

$

93,317

​

$

94,296

​

Available-for-sale debt securities

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale debt securities by type of security at December 31, 2020 were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Amortized

    

Unrealized

    

Unrealized

    

​

​

​

​

Cost

​

Gains

​

Losses

​

Fair Value

U.S. Treasury notes

​

$

23,179

​

$

173

​

$

(43)

​

$

23,309

Total available-for-sale investments

​

$

23,179

​

$

173

​

$

(43)

​

$

23,309

​

The following table summarizes the fair value of available-for-sale debt securities based on stated contractual maturities as of December 31, 2020 (in thousands):

​

​

​

​

​

​

​

​

​

    

Amortized Cost

    

Fair Value

Due within one year

​

$

14,084

​

$

14,111

Due between one and two years

​

 

9,095

​

 

9,198

​

​

​

​

​

​

​

Total

​

$

23,179

​

$

23,309

​

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale debt securities by type of security at December 31, 2019 were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Amortized 

    

Unrealized 

    

Unrealized 

    

​

​

​

​

Cost

​

Gains

​

Losses

​

Fair Value

U.S. Treasury notes and bills

​

$

21,122

 

$

26

 

$

(54)

​

$

21,094

Total available-for-sale investments

​

$

21,122

 

$

26

​

$

(54)

​

$

21,094

​

The following table summarizes the fair value of available-for-sale debt securities based on stated contractual maturities as of December 31, 2019 (in thousands):

​

​

​

​

​

​

​

​

​

    

Amortized Cost

    

Fair Value

Due within one year

​

$

12,044

 

$

12,047

Due between one and two years

​

 

9,078

 

 

9,047

Total

​

$

21,122

 

$

21,094

​

There were no individual securities that have been in a continuous loss position of 12 months or greater as of December 31, 2019.

The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.

We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis, as well as adverse conditions related specifically to the security such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security.

During the years ended December 31, 2020 and 2019, we had $32,400 and $81,700 realized losses on available-for-sale investments, respectively.

Equity Investments

We held investments in equity securities with readily determinable fair values of $33.1 million and $26.0 million at December 31, 2020 and 2019, respectively. These investments consist of mutual funds that invest primarily in tax free municipal bonds and treasury inflation protected securities.

Unrealized gains (losses) during 2020 and 2019 related to equity securities held at December 31, 2020 and 2019 are as follows (in thousands):

​

​

​

​

​

​

​

​

​

    

2020

    

2019

Net losses recognized during the year on equity securities

​

$

(245)

​

$

(102)

Less: net losses recognized during the year on equity securities sold during the year

​

 

(1,090)

​

​

—

Unrealized gains (losses) recognized during the year on equity securities still held at December 31, 2020 and 2019

​

$

845

​

$

(102)

​
XML 32 R13.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements
 12 Months Ended
Dec. 31, 2020
Fair Value Measurements  
Fair Value Measurements

Note 5. Fair Value Measurements

We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.

We did not elect the fair value option, as allowed, to account for financial assets and liabilities that were not previously carried at fair value. Therefore, material financial assets and liabilities that are not carried at fair value, such as trade accounts receivable and payable, are reported at their historical carrying values.

The carrying values of our assets that are required to be measured at fair value on a recurring basis as of December 31, 2020 and 2019 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Fair Value Measurements

​

    

Level 1

    

Level 2

    

Level 3

    

Total

December 31, 2020

 

​

  

 

​

  

 

​

  

 

​

  

Cash equivalents:

 

​

  

 

​

  

 

​

  

 

​

  

Money market mutual fund

​

$

11,820

​

$

—

​

$

—

​

$

11,820

Marketable equity securities:

​

 

  

​

 

  

​

 

  

​

 

  

Mutual funds

​

 

33,135

​

 

—

​

 

—

​

 

33,135

Available-for-sale debt securities:

​

 

​

​

 

  

​

 

  

​

 

​

U.S. Treasury notes

​

 

23,309

​

 

—

​

 

—

​

 

23,309

​

​

$

68,264

​

$

—

​

$

—

​

$

68,264

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Fair Value Measurements 

​

 

Level 1

 

Level 2

 

Level 3

 

Total

December 31, 2019

    

​

  

    

​

  

    

​

  

    

​

  

Cash equivalents:

 

​

  

 

​

  

 

​

  

 

​

  

Money market mutual fund

​

$

43,688

​

$

—

​

$

—

​

$

43,688

Marketable equity securities:

​

 

  

​

 

  

​

 

  

​

 

  

Mutual funds

​

 

25,967

​

 

—

​

 

—

​

 

25,967

Available-for-sale debt securities:

​

 

  

​

 

  

​

 

  

​

 

  

U.S. Treasury notes

​

 

21,094

​

 

—

​

 

—

​

 

21,094

​

​

$

90,749

​

$

—

​

$

—

​

$

90,749

​

Our equity securities and available-for-sale debt securities, including U.S. treasury notes are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.

We did not have any financial liabilities measured at fair value on a recurring basis as of December 31, 2020.

We carry the convertible senior notes (see Note 10) at face value less the unamortized discount and issuance costs on our consolidated balance sheets and present fair value for disclosure purposes only. As of December 31, 2020, the estimated fair value of the Notes was $108.2 million and was determined using the net present value of the payments, discounted at an interest rate that is consistent with market and risk-adjusted interest rates, which is a Level 2 input.
XML 33 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Inventories
 12 Months Ended
Dec. 31, 2020
Inventories  
Inventories

Note 6. Inventories

Inventories consist of the following (in thousands):

​

​

​

​

​

​

​

​

​

    

December 31, 

    

December 31, 

​

​

2020

​

2019

Raw materials

​

$

7,544

​

$

357

Work-in-process

​

​

227

​

​

—

Finished goods

​

 

2,764

​

 

117

​

​

$

10,535

​

$

474

​

​

The inventory balance at December 31, 2020 includes an $0.8 million step up in inventory related to the acquisition of MVE.
XML 34 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Property and Equipment
 12 Months Ended
Dec. 31, 2020
Property and Equipment  
Property and Equipment

Note 7. Property and Equipment

Property and equipment consist of the following (in thousands):

​

​

​

​

​

​

​

​

​

    

December 31, 

    

December 31, 

​

​

2020

​

2019

Cryogenic shippers and data loggers

​

$

5,625

​

$

4,296

Freezers

​

​

4,473

​

​

3,414

Furniture and fixtures

​

 

2,727

​

 

291

Computers and software

​

 

1,469

​

 

646

Machinery and equipment

​

 

11,998

​

 

1,093

Trucks and autos

​

​

437

​

​

37

Leasehold improvements

​

 

4,599

​

 

2,246

Buildings

​

​

5,359

​

​

—

Land

​

​

790

​

​

—

Fixed assets in process

​

 

8,070

​

 

3,407

​

​

 

45,547

​

 

15,430

Less accumulated depreciation and amortization

​

 

(15,511)

​

 

(3,597)

​

​

$

30,036

​

$

11,833

​

Total depreciation and amortization expense related to property and equipment amounted to $3.2 million and $2.1 million for the years ended December 31, 2020 and 2019, respectively.

The Company leases equipment under finance leases, with a total cost of $279,400 and $71,000, respectively, and accumulated amortization of $78,700 and $22,800 as of December 31, 2020 and 2019, respectively.
XML 35 R16.htm IDEA: XBRL DOCUMENT v3.20.4
Goodwill And Other Intangible Assets
 12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets  
Goodwill and Intangible Assets

Note 8. Goodwill and Intangible Assets

Goodwill

The following table represents the changes in the carrying value of goodwill for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

    

December 31

    

December 31,

​

​

2020

​

2019

Balance at beginning of year

​

$

11,000

​

$

—

Goodwill related to Cryogene acquisition

​

 

—

​

 

11,000

Goodwill related to MVE acquisition

​

 

107,504

​

 

—

Goodwill related to CRYOPDP acquisition

​

 

26,778

​

 

—

Balance at end of year

​

$

145,282

​

$

11,000

​

Intangible Assets

The following table presents our intangible assets as of December 31, 2020 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

​

Net

​

Average

​

​

Gross

​

Accumulated

​

Carrying

​

Amortization

​

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

​

$

390

​

$

123

​

$

267

 

3

Technology

​

​

34,245

​

​

1,630

​

​

32,615

​

11

Customer relationships

​

​

128,640

​

​

2,708

​

​

125,932

​

14

Cryogene trade name/trademark

​

​

480

​

​

51

​

​

429

​

13

CRYOPDP agent network

​

​

8,597

​

​

537

​

​

8,060

​

4

MVE Order backlog

​

​

2,600

​

​

2,600

​

​

—

​

—

MVE land use rights

​

​

2,378

​

​

16

​

​

2,362

​

37

Patents and trademarks

​

​

44,312

​

​

69

​

​

44,243

​

—

Total

​

$

221,642

​

$

7,734

​

$

213,908

​

​

​

The following table presents our intangible assets as of December 31, 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

​

Net

​

Average

​

​

Gross

​

Accumulated

​

Carrying

​

Amortization

​

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

​

$

390

​

$

45

​

$

345

 

5

Technology

​

​

510

​

​

59

​

​

451

​

5

Customer relationships

​

​

3,900

​

​

190

​

​

3,710

​

12

Cryogene trade name/trademark

​

​

480

​

​

19

​

​

461

​

15

Cryoport patents and trademarks

​

​

258

​

​

47

​

​

211

 

—

Total

​

$

5,538

​

$

360

​

$

5,178

​

​

​

Amortization expense for intangible assets for the years ended December 31, 2020 and 2019 was $6.6 million and $0.3 million, respectively.

​

Expected future amortization of intangible assets as of December 31, 2020 is as follows (in thousands):

​

​

​

​

​

Years Ending December 31, 

    

Amount

2021

​

 

14,438

2022

​

 

14,438

2023

​

 

14,438

2024

​

 

13,795

2025

​

 

12,108

Thereafter

​

 

100,124

​

​

$

169,341

​
XML 36 R17.htm IDEA: XBRL DOCUMENT v3.20.4
Accrued Compensation and Related Expenses
 12 Months Ended
Dec. 31, 2020
Accrued Compensation and Related Expenses  
Accrued Compensation and Related Expenses

Note 9. Accrued Compensation and Related Expenses

Accrued compensation and related expenses consist of the following (in thousands):

​

​

​

​

​

​

​

​

​

    

December 31, 

    

December 31, 

​

​

2020

​

2019

Accrued salaries and wages

​

$

6,048

​

$

1,386

Accrued paid time off

​

 

1,393

​

 

518

​

​

$

7,441

​

$

1,904

​
XML 37 R18.htm IDEA: XBRL DOCUMENT v3.20.4
Convertible Senior Notes
 12 Months Ended
Dec. 31, 2020
Convertible Senior Notes  
Convertible Senior Notes

Note 10. Convertible Senior Notes

In May 2020, the Company issued $115.0 million aggregate principal amount of 3.00% convertible senior notes due in 2025 (the "Senior Notes"), which includes the initial purchasers’ exercise in full of their option to purchase an additional $15.0 million principal amount of the Senior Notes, in a private placement exempt from registration under the Securities Act of 1933. The Senior Notes are governed by an indenture (the “Indenture”) dated May 26, 2020 between the Company, as issuer, and U.S. Bank National Association, as trustee (the “Trustee”). The Company received $111.3 million from the offering, net of underwriting discounts and commissions of $3.7 million, and incurred approximately $0.3 million in third-party offering related costs. The Senior Notes bear cash interest at a rate of 3.00%, payable semi-annually on June 1 and December 1 of each year, beginning on December 1, 2020 and will mature on June 1, 2025, unless earlier repurchased, redeemed, or converted in accordance with the terms of the Senior Notes. At December 31, 2020, accrued interest of $0.3 million is included in accounts payable and accrued liabilities in the accompanying consolidated financial statements.  The Notes comprise the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Senior Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.

At any time before the close of business on the scheduled trading day immediately before the maturity date, holders of the Senior Notes may convert their Senior Notes at their option into shares of the Company’s common stock. The Senior Notes are initially convertible into approximately 4,810,002 shares of the Company’s common stock based on the initial conversion rate of 41.8261 shares of the Company’s common stock per $1,000 principal amount of the Senior Notes, which represents an initial conversion price of approximately $23.91 per share of the Company’s common stock. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Also, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time and is determined by reference to a make-whole table set forth in the Indenture governing the Senior Notes. However, in no event will the conversion rate be increased to an amount that exceeds 48.10 shares of the Company’s common stock per $1,000 principal amount of Senior Notes. In addition, the holders of the Senior Notes may require the Company to repurchase the Senior Notes at par value plus accrued and unpaid interest following the occurrence of a “Fundamental Change” (as described in the Indenture).

On or after June 5, 2023, we may redeem the Senior Notes at our option, in whole and not in part, at a cash redemption price equal to the principal amount of the Senior Notes to be redeemed, plus accrued and unpaid interest, if any, if:

(1)The last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company send the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice; and
(2)A registration statement covering the resale of the shares of the Company’s common stock issuable upon conversion of the Senior Notes is effective and available for use and is expected to remain effective and available during the redemption period as of the date the redemption notice is sent.

The Senior Notes contain customary terms and events of default. If an event of default arising out of certain events of bankruptcy, insolvency, or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to the Company, the principal amount of the Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable. If any other event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding Senior Notes may declare the principal amount of the Senior Notes to be due and payable immediately by notice to the Company. There were no events of default at December 31, 2020.

The Senior Notes are accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options (“ASC 470-20”) and ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”). Under ASC 815-40, to qualify for equity classification (or nonbifurcation, if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer’s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company’s analysis, it was determined the Senior Notes do contain embedded features indexed to its own stock, but do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature meets the equity scope exception from derivative accounting, and also since the embedded conversion option does not need to be separately accounted for as an equity component under ASC 470-20, the proceeds received from the issuance of the convertible debt was recorded as a liability on the consolidated balance sheet.

The Company incurred approximately $4.1 million of debt issuance costs relating to the issuance of the Senior Notes, which were recorded as a reduction to the Senior Notes on the consolidated balance sheet. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Senior Notes using the effective interest rate method. We determined the expected life of the debt is equal to the five-year term of the Senior Notes. The effective interest rate on the Senior Notes is 3.74%.

Senior Notes payable consisted of the following at December 31, 2020 (in thousands):

​

​

​

​

​

    

December 31, 2020

Principal amount of Senior Notes

​

$

115,000

Unamortized debt issuance costs

​

 

(3,656)

Net carrying value of Senior Notes payable

​

$

111,344

​

Interest expense incurred in connection with the Notes consisted of the following for the year ended December 31, 2020 (in thousands):

​

​

​

​

​

    

Year Ended

​

​

December 31, 2020

Coupon interest

​

$

2,108

Amortization of debt issuance costs

​

​

437

Total interest expense on Senior Notes

​

$

2,545

​

The Company’s Senior Notes payable of $115.0 are due and payable in 2025.

In connection with the issuance of the Senior Notes, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) to use its best efforts to file a registration statement for the resale of the Senior Notes and the shares of the Company’s common stock issuable upon conversion of the Senior Notes, to cause the registration statement to become effective by January 31, 2021, and to keep the registration statement continuously effective for a specified period of time. If the Company fails to satisfy certain of its obligations under the Registration Rights Agreement (a “Registration Default”), it will be required to pay additional interest on the Senior Notes. Such additional interest will accrue at a rate per annum equal to 0.25% of the principal amount thereof for the first 90 days beginning on, and including the date on which such Registration Default occurs and, thereafter, at a rate per annum equal to 0.50% of the principal amount thereof. However, in no event will such additional interest, together with any special interest that accrues pursuant to the Indenture accrue on any day on a Note at a combined rate per annum that exceeds 0.50%. Additionally, if a Registration Default exists on the maturity date for the Senior Notes, then, in addition to any additional interest otherwise payable, the Company will be required to make a cash payment to each noteholder in an amount equal to 3% of the principal amount of Senior Notes outstanding and held by such holder as of the close of business on the business day immediately before the maturity date.  As of December 31, 2020, the Company has not accrued any fees or expenses associated with the Registration Rights Agreement as no Registration Default exists and, therefore, it is not probable that a payment would be required.  In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Senior Notes and the shares of the Company’s common stock issuable upon conversion of the Senior Notes.
XML 38 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Note Payable
 12 Months Ended
Dec. 31, 2020
Note Payable  
Note Payable

Note 11. Note Payable

In connection with the acquisition of CRYOPDP, the Company assumed an interest free unsecured note payable of €4.0 million ($4.9 million) repayable in two installments of €0.5 million ($0.6 million) to be repaid in 2025 and €3.5 million ($4.3 million) to be repaid in 2028.
XML 39 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Leases
 12 Months Ended
Dec. 31, 2020
Leases  
Leases

Note 12. Leases

The Company has operating and finance leases for corporate offices and certain equipment. These leases have remaining lease terms of one year to approximately nine years, some of which include options to extend the leases for multiple renewal periods of five years each. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs. As of December 31, 2020 and 2019, assets recorded under finance leases were $279,400 and $71,000, respectively, and accumulated depreciation associated with finance leases was $78,700 and $22,800, respectively.

​

The components of lease cost were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Operating lease cost

​

$

1,835

​

$

758

Finance lease cost:

​

​

​

​

 

  

Amortization of right-of-use assets

​

​

56

​

​

10

Interest on finance lease liabilities

​

​

10

​

​

3

​

​

​

66

​

 

13

Total lease cost

​

$

1,901

​

$

771

​

Other information related to leases was as follows (in thousands):

​

​

​

​

​

​

​

​

Year Ended

 

Supplemental Cash Flows Information

    

December 31, 2020

 

Cash paid for amounts included in the measurement of lease liabilities:

 

​

​

​

Operating cash flows from operating leases

 

$

1,680

​

Operating cash flows from finance leases

 

$

77

​

Financing cash flows from finance leases

​

$

67

​

​

​

​

​

​

Right-of-use assets obtained in exchange for lease liabilities (in thousands):

​

​

​

​

Operating leases

 

$

10,708

​

Finance leases

​

$

203

​

​

​

​

​

​

Weighted-Average Remaining Lease Term

​

​

​

​

Operating leases

​

 

6.6 years

​

Finance leases

​

 

2.9 years

​

​

​

​

​

​

Weighted-Average Discount Rate

​

​

​

​

Operating leases

​

​

5.5

%

Finance leases

​

​

5.4

%

​

Future minimum lease payments under non-cancellable leases that have commenced as of December 31, 2020 were as follows (in thousands):

​

​

​

​

​

​

​

​

Years Ending December 31

    

Operating Leases

    

Finance Leases

2021

 

$

3,103

 

$

67

2022

 

​

3,261

 

​

57

2023

 

​

2,498

 

​

60

2024

 

​

1,985

 

​

—

2025

 

​

1,696

 

​

—

Thereafter

 

​

5,402

 

​

—

Total future minimum lease payments

 

​

17,945

 

​

184

Less imputed interest

 

​

(3,453)

 

​

(13)

Total

​

$

14,492

​

$

171

​

​

​

​

​

​

​

​

​

​

Operating

​

Finance 

Reported as of December 31, 2020

    

 Leases

    

Leases

Current lease liabilities

​

$

2,231

​

$

59

Noncurrent lease liabilities

​

 

12,261

​

 

112

Total

​

$

14,492

​

$

171

​
XML 40 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Employee Benefit Plans
 12 Months Ended
Dec. 31, 2020
Employee Benefit Plans  
Employee Benefit Plans

Note 13. Employee Benefit Plans

401K Plan

The Company provides a 401(k) Plan (“Plan”) to provide retirement and incidental benefits for our eligible U.S. based employees.  Employees may contribute up to 100% of their eligible compensation, limited to a maximum annual dollar amount set periodically by the Internal Revenue Service.  The Company matches employee contributions dollar for dollar up to a maximum of 4% per year per person.  All matching contributions vest immediately.  During the years ended December 31, 2020 and 2019, we recognized expense of $0.3 million and $0.2 million, respectively, related to matching contributions.

Non-U.S. Employee Benefit Plans

Eligible employees outside the U.S. generally receive retirement benefits under various defined benefit plans and defined contribution plans based upon factors such as years of service and employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements. The employee benefit plan costs and liabilities with regard to the defined benefit plans are determined by actuarial valuations.

Employees of the Company who are in India participate in an employee benefit plan (the “Gratuity Plan”), which is required by local law and provides a lump sum payment to vested employees upon retirement, death, incapacitation, or termination of employment based on the respective employee’s salary and the tenure of employment. The benefit costs and liabilities with regard to the Gratuity Plan are determined by actuarial valuations. The Company makes annual contributions to the employees’ gratuity fund established with Life Insurance Corporation of India, which calculates the annual contribution required to be made by the Company and manages the Gratuity Plan, including any required payouts. The Gratuity Plan is partially funded. The obligation under the Gratuity Plan is not significant at December 31, 2020.

Benefit costs associated with the non-U.S. employee benefit plans totaled $0.1 million and $0 million for the years ended December 31, 2020 and 2019, respectively. Total benefit obligation associated with the non-U.S. employee benefit plans totaled $0.3 million and $0 million at December 31, 2020 and 2019, respectively.
XML 41 R22.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2020
Commitments and Contingencies  
Commitments and Contingencies

Note 14. Commitments and Contingencies

Facility and Equipment Leases

We lease various corporate, global logistics and supply chain centers, biostorage, manufacturing, and research and development facilities in Tennessee, California, New Jersey, the Netherlands, Texas, Georgia, Minnesota, China, Portugal and France under operating leases. These lease agreements contain certain scheduled annual rent increases which are accounted for on a straight-line basis.   In addition, we lease certain equipment which expires through July 2024 (See Note 12).

Employment Agreements

We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.

Litigation

The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. We record a loss contingency when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We also disclose material contingencies when we believe a loss is not probable but reasonably possible. Accounting for contingencies requires us to use judgment related to both the likelihood of a loss and the estimate of the amount or range of loss. The outcomes of our legal proceedings are inherently unpredictable, subject to significant uncertainties, and could be material to our financial condition, results of operations, and cash flows for a particular period.

Indemnities and Guarantees

The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheets.

The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility and equipment leases, the Company has indemnified its lessors for certain claims arising from the use of the facilities and equipment. The duration of the guarantees and indemnities varies and is generally tied to the life of the agreements.
XML 42 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity
 12 Months Ended
Dec. 31, 2020
Stockholders' Equity  
Stockholders' Equity

Note 15. Stockholders’ Equity

Authorized Stock

The Company has 100,000,000 authorized shares of common stock with a par value of $0.001 per share, and 2,500,000 undesignated or "blank check" preferred stock, with a par value of $0.001, of which, 800,000 shares have been designated as Class A Convertible Preferred Stock, 585,000 shares have been designated as Class B Convertible Preferred Stock and 250,000 shares have been designated as Class C Convertible Preferred Stock.

Common Stock Issuances For Services

During the year ended December 31, 2020, 2,869 shares of common stock with a fair value of $82,700 were issued to two members of the board of directors as compensation for services.

During the year ended December 31, 2019, 5,753 shares of common stock with a fair value of $91,000 were issued to three members of the board of directors as compensation for services.

Blackstone Private Placement

In connection with the MVE Acquisition, on October 1 , 2020 (the “Closing Date”), the Company completed a private placement with an investment vehicle of funds affiliated with The Blackstone Group Inc. (collectively, Blackstone), consisting of (i) 250,000 shares of a newly designated 4.0% Series C Convertible Preferred Stock, par value $0.001 per share (“Series C Preferred Stock”), at a price of $1,000 per share, for $250.0 million, and (ii) 675,536 shares of common stock of the Company, par value $0.001 per share (“Common Stock”) for $25.0 million, for an aggregate purchase price of $275.0 million. The Company paid Blackstone $1.0 million as reimbursement for transactional expenses incurred in connection with the private placement at the Closing Date. Also, the Company incurred direct and incremental expenses of approximately $8.6 million, including financial advisory fees, closing costs, legal expenses and other offering-related expenses. The Company allocated the net proceeds of $265.4 on a relative fair value basis to the Series C Preferred Stock and the Common Stock, resulting in allocated proceeds of $28.2 and $237.2, respectively.

The Series C Preferred Stock ranks senior to the shares of the Company’s Common Stock, with respect to dividend rights and rights upon the voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company (a “Liquidation”). The Series C Preferred Stock has the following rights, preferences and privileges:

Dividend Rights. Holders of the Series C Preferred Stock (the “Holders”) are entitled to dividends at the rate of 4.0% per annum, paid-in-kind, accruing daily and paid quarterly in arrears when and if declared by the Board of Directors. The Holders are also entitled to participate in dividends declared or paid on the Common Stock on an as-converted basis. The Company and Holders do not have the option to pay dividends in kind, in cash, or in other form. Paid in-kind dividends for the year ended December 31, 2020 were $2.5 million.

Liquidation Preference. Upon a Liquidation, each share of Series C Preferred Stock is entitled to receive an amount per share equal to the greater of (i) $1,000 per share, plus all accrued and unpaid dividends and (ii) the amount that the Holders of the Series C Preferred Stock would have been entitled to receive at such time if the Series C Preferred Stock were converted into Common Stock (the ”Liquidation Preference”).

Conversion Features. The Series C Preferred Stock is convertible at the option of the Holders at any time into shares of Common Stock at a conversion price of $38.6152 per share and a conversion rate of 25.90 shares of Common Stock per share of Series C Preferred Stock. The maximum number of Common Stock that could be required to be issued if converted is 6,474,135 shares. The conversion price is subject to certain customary adjustments in the event of certain adjustments to the Company’s Common Stock, including stock dividends, splits, combinations, tender offers, and exchange offers.

After the second anniversary of the Closing Date, subject to certain conditions, the Company may at its option require conversion of all of the outstanding shares of the Series C Preferred Stock to Common Stock if, for at least 20 trading days during the 30 consecutive trading days immediately preceding the date the Company notifies the Holders of the election to convert, the closing price of the Common Stock is at least 150% of the conversion price.

On the October 1, 2020 issuance date, the effective conversion price per share was less than the fair value of the underlying Common Stock and, as a result, the Company determined that there was a beneficial conversion feature on that date. Accordingly, the Company recognized the resulting beneficial conversion feature amount of $39.5 million as a deemed dividend, equal to the number of common shares into which the Series C Preferred Stock is convertible multiplied by the difference between the fair value of the Common Stock and the effective conversion price per share on that date. Because the Series C Preferred Stock does not have a stated conversion date and was immediately convertible at the issuance date, the dividend is reflected as a one-time, non-cash, deemed dividend to the Holders of the Series C Preferred Stock on the date of issuance.  

Additionally, the Company determined that the nature of the Series C Preferred Stock is more akin to an equity instrument and that the economic characteristics and risks of the embedded conversion options are clearly and closely related to the Series C Preferred Stock. As such, the conversion options were not required to be bifurcated from the host under ASC 815, Derivatives and Hedging.

Since the paid-in-kind dividends are nondiscretionary, the Company measures the beneficial conversion feature in the paid-in-kind dividend on the issuance date of the preferred stock and records such amount when the paid-in-kind dividend are accrued. Accordingly, the associated paid-in-kind dividends for the year ended December 31, 2020 generated a beneficial conversion feature amount of $0.3 million. On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. and converted an aggregate of 50,000 shares of the Series C Preferred Stock (See Note 18).

Redemption Rights. The Company may redeem the Series C Preferred Stock for cash, as follows:

(i)Within 6 months of the Closing Date, up to 50,000 shares of the Series C Preferred Stock at a price equal to 125% of the purchase price paid plus any accrued and unpaid dividends (See Note 18).
(ii)At any time beginning five years after the Closing Date (but prior to six years after the Closing Date), all of the Series C Preferred Stock at a price equal to 105% of the purchase price paid plus any accrued and unpaid dividends.
(iii)At any time beginning six years after the Closing Date, all of the Series C Preferred Stock at a price equal to 100% of the purchase price paid plus any accrued and unpaid dividends.

Upon a “Fundamental Change” (involving a change of control or de-listing of the Company as further described in the Certificate of Designation), each Holder has the right to require the Company to redeem all or any part of the Holder’s Series C Preferred Stock for an amount equal to the Liquidation Preference plus any accrued and unpaid dividends.  If the Company does not have sufficient funds legally available to pay the repurchase price, then the Company is required to (a) pay the maximum amount of the repurchase price that can be paid out of funds legally available for payment, and (b) purchase any shares of the Series C Preferred Stock not purchased because of the foregoing limitations at the repurchase price as soon as practicable after the Company is able to make such purchase out of assets legally available for the purchase of such shares. If the Company fails to pay the repurchase price in full when due, then the Company will pay dividends on such shares not repurchased at a rate of 5.5% per annum until such shares are repurchased, payable quarterly in arrears.

The Company evaluated the Series C Preferred Stock for liability or equity classification under the applicable accounting guidance including ASC 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the Series  C Preferred Stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series C Preferred Stock would be recorded as permanent equity given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, or (iii) upon the occurrence of an event that is not solely within control of the Company.

The Company also evaluated the embedded put and call options within the Series C Preferred Stock in accordance with the accounting guidance for derivatives to determine if bifurcation is required.  The Company determined that the economic characteristics and risks of the embedded put and call options are not clearly and closely related to the Series C Preferred Stock. Therefore, the Company assessed the put and call options further and determined they did not meet the definition of a derivative under ASC 815.

Under the same analysis, the Company determined that the economic characteristics and risks of the embedded participating dividend feature are considered clearly and closely related to the equity host. Accordingly, the participating dividend feature is not required to be bifurcated under ASC 815. Also, the Company determined that the value of the contingent dividend feature is minimal and insignificant relative to the other components of the Series C Preferred Stock due to the circumstances surrounding the scenarios under which the provision would be triggered.

Voting Rights. Holders of the Series C Preferred Stock are generally entitled to vote with the holders of the shares of Common Stock on an as-converted basis, subject to certain Nasdaq voting limitations, if applicable. Also, the consent of the Holders of a majority of the outstanding shares of the Series C Preferred Stock is required with respect to (i) amendments to the Company’s organizational documents that have an adverse effect on the Holders of the Series C Preferred Stock, and (ii) issuances by the Company of securities that are senior to, or equal in priority with, the Series C Preferred Stock. Holders of the Series C Preferred Stock have the right to nominate for election one member to the board of directors of the Company for so long as they hold 66.67% of the Series C Preferred Stock.

Registration Rights. Holders of the Series C Preferred Stock have certain customary registration rights with respect to the Series C Preferred Stock and the shares of common stock into which they are converted, pursuant to the terms of a registration rights agreement. The Company is required to file within 90 days of the Closing Date, and use its commercially reasonable efforts to cause to go effective as promptly as practicable, a registration statement covering the sale or distribution of Common Stock issued or issuable upon conversion of the Series C Preferred Stock.   In December 2020, the Company filed an automatic shelf registration statement to register the resale of the Common Stock issued or issuable upon conversion of the Series C Preferred Stock.

Share Repurchase Program

In October 2019, the Company’s Board of Directors authorized a share repurchase program (the “Repurchase Program”) authorizing repurchase of common stock in the amount of up to $15.0 million from time to time, in amounts, at prices, and at such times as management deems appropriate and will depend on a number of factors, including the market price of Cryoport’s common stock, general market and economic conditions, and applicable legal requirements. The repurchase program expired on December 31, 2020. The Company has not purchased any shares under this program in 2019 and through December 31, 2020.

June 2019 Public Offering

On June 24, 2019, the Company completed an underwritten public offering  of 4,312,500 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement, dated June 19, 2019, by and among the Company, on the one hand, and Jefferies LLC and SVB Leerink LLC, as representatives of certain underwriters at a public offering price per share of $17.00, before deducting underwriting discounts and commissions. The shares include 562,500 shares issued and sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the underwriting agreement. The Company received net proceeds of approximately $68.8 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Common Stock Reserved for Future Issuance

As of December 31, 2020, approximately 18.8 million shares of common stock were issuable upon exercise of stock options and the conversion of convertible senior notes and Series C Preferred stock, as follows:

​

​

​

​

Exercise of stock options

    

7,554,305

Conversion of Series C Preferred stock

​

6,474,135

Conversion of convertible senior notes

​

4,810,002

Total shares of common stock reserved for future issuances

 

18,838,442

​
XML 43 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2020
Stock-Based Compensation  
Stock-Based Compensation

Note 16. Stock-Based Compensation

Warrants

We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants.   A summary of warrant activity is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

​

​

    

Weighted-

    

​

​

​

​

​

​

Weighted-

​

Average

​

​

​

​

​

​

​

Average

​

Remaining

​

Aggregate

​

​

Number of

​

Exercise

​

Contractual

​

Intrinsic

​

    

Shares

    

Price/Share

    

Term (Years)

    

Value (1)

Outstanding — December 31, 2018

 

2,049,534

​

$

4.03

 

  

 

​

  

Issued

 

—

​

 

—

 

  

 

​

  

Exercised

 

(1,027,546)

​

 

3.95

 

  

 

​

  

Expired

 

(20,960)

​

 

17.78

 

  

 

​

  

Outstanding — December 31, 2019

 

1,001,028

​

​

3.83

 

  

 

​

  

Issued

 

—

​

 

—

 

  

 

​

  

Exercised

 

(963,149)

​

 

3.80

 

  

 

​

  

Expired

 

(37,879)

​

 

4.58

 

  

 

​

  

Outstanding — December 31, 2020

 

—

​

$

—

 

—

​

$

—

Vested (exercisable) — December 31, 2020

 

—

​

$

—

 

—

​

$

—

(1)Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of the Company’s common stock on December 31, 2020, which was $43.88 per share.

During the year ended December 31, 2020, the Company issued 963,149 shares of common stock in connection with the exercise of warrants for proceeds of $3.7 million.

During the year ended December 31, 2019, the Company issued 985,626 shares of common stock in connection with the exercise of warrants for proceeds of $3.4 million. In addition, during the year ended December 31, 2019, the Company issued 117,663 shares of common stock in connection with the cashless exercise of warrants to purchase 159,583 shares of common stock.

The total intrinsic value of warrants exercised during the years ended December 31, 2020 and 2019 was $17.6 million and $12.4 million, respectively.

Stock Options

We have five stock incentive plans: the 2002 Stock Incentive Plan (the “2002 Plan”), the 2009 Stock Incentive Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”), the 2015 Omnibus Equity Incentive Plan (the “2015 Plan”), and the 2018 Omnibus Equity Incentive Plan (the “2018 Plan”), (collectively, the “Plans”). The 2002 Plan, the 2009 Plan, the 2011 Plan and the 2015 Plan (the “Prior Plans”) have been superseded by the 2018 Plan. In May 2018, the stockholders approved the 2018 Plan for issuance up to 3,730,179 shares. The Prior Plans will remain in effect until all awards granted under such Prior Plans have been exercised, forfeited, cancelled, or have otherwise expired or terminated in accordance with the terms of such awards, but no awards will be made pursuant to the Prior Plans after the effectiveness of the 2018 Plan. As of December 31, 2020, the Company had 921,288 shares available for future awards under the 2018 Plan.

During the years ended December 31, 2020 and 2019, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following assumptions:

​

​

​

​

​

​

​

​

​

December 31, 

    

December 31, 

  

​

    

2020

    

2019

​

Expected life (years)

​

5.3 – 6.3

​

5.2 – 6.2

 

Risk-free interest rate

​

0.31% - 1.70

%  

1.42% - 2.57

%

Volatility

​

69.8% - 82.7

%  

70.6% - 99.2

%

Dividend yield

​

0

%  

0

%

​

The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the average of the historical volatility and the implied volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.

We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest.

Total stock-based compensation expense related to our share-based payment awards is comprised of the following (in thousands):

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

​

    

2020

    

2019

Cost of revenues

​

$

371

​

$

1,479

Selling, general and administrative

​

 

7,862

​

 

13,946

Engineering and development

​

 

683

​

 

1,098

​

​

$

8,916

​

$

16,523

​

For the year ended December 31, 2019, we recognized expense of $9.6 million due to the accelerated vesting under the terms of certain outstanding stock option grants as a result of the Company meeting certain financial performance criteria defined in such grants. Of this amount, $0.4 million, $9.4 million, and $0.9 million are included in cost of revenues, selling, general and administrative and engineering and development, respectively.

​

A summary of stock option activity is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

​

​

    

Weighted-

    

​

​

​

​

​

​

Weighted-

​

Average

​

​

​

​

​

​

​

Average

​

Remaining

​

Aggregate

​

​

Number of

​

Exercise

​

Contractual

​

Intrinsic

​

​

Shares

​

Price/Share

​

Term (Years)

​

Value (1)

Outstanding — December 31, 2018

 

5,757,305

​

$

5.16

 

  

 

​

  

Granted (weighted-average fair value of $13.55 per share)

 

1,544,850

​

​

13.55

 

  

 

​

  

Exercised

 

(544,565)

 

​

3.91

 

  

 

​

  

Forfeited

 

(78,009)

 

​

10.66

 

  

 

​

  

Outstanding — December 31, 2019

 

6,679,581

​

​

7.14

 

  

 

​

  

Granted (weighted-average fair value of $13.21 per share)

​

1,789,000

​

​

20.46

​

  

​

​

​

Exercised

 

(855,717)

 

​

6.73

 

  

 

​

​

Forfeited

 

(56,475)

 

​

13.39

 

  

 

​

​

Expired

 

(2,084)

 

​

19.56

 

  

 

​

​

Outstanding — December 31, 2020

 

7,554,305

​

$

10.29

 

6.6

​

$

254,393,000

Vested (exercisable) — December 31, 2020

 

5,862,122

​

$

7.41

 

5.9

​

$

213,769,400

Expected to vest after December 31, 2020 (unexercisable)

 

1,692,183

​

$

20.24

 

9.2

​

$

40,623,600

(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on December 31, 2020, which was $43.88 per share.

The following table summarizes information with respect to stock options outstanding and exercisable at December 31, 2020:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

Weighted-

    

​

​

    

​

    

​

​

​

​

​

​

Average

​

Weighted-

​

​

​

Weighted-

​

​

​

​

Remaining

​

Average

​

​

​

Average

​

​

Number

​

Contractual

​

Exercise

​

Number

​

Exercise

Exercise Price

​

Outstanding

​

Life (Years)

​

Price

​

Exercisable

​

Price

$1.08 – 3.07

 

894,024

 

4.7

​

$

2.25

 

894,024

​

$

2.25

$3.19 – 3.44

 

839,001

 

4.5

​

$

3.30

 

839,001

​

$

3.30

$4.56 – 4.92

 

658,437

 

4.5

​

$

4.80

 

658,437

​

$

4.80

$5.00 – 7.67

 

769,694

 

4.6

​

$

5.04

 

769,694

​

$

5.04

$7.80 – 8.65

 

961,979

 

6.0

​

$

8.28

 

952,229

​

$

8.28

$9.29 – 12.79

 

1,153,291

 

8.0

​

$

11.85

 

1,083,688

​

$

11.84

$13.37 – 16.95

 

1,598,304

 

9.0

​

$

16.41

 

498,801

​

$

15.73

$17.36 – 55.48

 

679,575

 

9.3

​

$

26.54

 

166,248

​

$

18.53

​

 

7,554,305

 

​

​

​

​

​

5,862,122

​

​

​

​

As of December 31, 2020, there was unrecognized compensation expense of $21.1 million related to unvested stock options, which we expect to recognize over a weighted average period of 3.1 years.

The total intrinsic value of options exercised during the years ended December 31, 2020 and 2019 was $24.1 million and $6.5 million, respectively.
XML 44 R25.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes
 12 Months Ended
Dec. 31, 2020
Income Taxes  
Income Taxes

Note 17. Income Taxes

Income (loss) before provision for income taxes was attributed to the following jurisdictions for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

United States

​

$

(32,873)

​

$

(18,321)

Foreign

​

 

135

​

 

51

​

​

$

(32,738)

​

$

(18,270)

​

The provision (benefit) for income taxes consists of the following for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Current:

 

​

  

 

​

  

Federal

​

$

11

​

$

—

State

​

 

110

​

 

41

Foreign

​

 

361

​

 

—

Total current expense

​

 

482

​

 

41

​

​

​

​

​

​

​

Deferred:

​

 

​

​

 

​

Federal

​

 

(8,245)

​

 

(2,125)

State

​

 

(832)

​

 

5

Foreign

​

 

(738)

​

 

9

Change in valuation allowance

​

 

9,288

​

 

2,132

Total deferred expense

​

 

(527)

​

 

21

Total provision (benefit) for income taxes

​

$

(45)

​

$

62

​

The provision (benefit) for income taxes differs from that computed using the federal statutory rate applied to loss before provision for income taxes as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Computed tax benefit at federal statutory rate

​

$

(6,875)

​

$

(3,837)

State tax, net of federal benefit

​

 

(1,077)

​

 

(610)

Stock compensation

​

 

(2,683)

​

 

480

Interest expense

​

​

—

​

​

286

Permanent differences and other

​

 

(375)

​

 

(126)

Transaction cost

​

​

528

​

​

—

Executive compensation

​

​

609

​

​

985

Rate changes

​

​

408

​

​

—

Contingencies

​

 

112

​

 

753

Valuation allowance

​

 

9,308

​

 

2,131

​

​

$

(45)

​

$

62

​

Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2020 and 2019 are shown below (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Deferred tax assets:

 

​

Net operating loss carryforward

​

$

27,106

​

$

17,031

Expenses recognized for granting of options and warrants

​

 

4,119

​

 

3,816

Accrued expenses and reserves

​

 

913

​

 

383

Lease liability

​

​

2,740

​

​

1,217

Total deferred tax assets

​

​

34,878

​

​

22,447

Valuation allowance

​

 

(32,913)

​

 

(21,220)

​

​

$

1,965

​

$

1,227

Deferred tax liabilities:

​

​

​

​

​

​

Goodwill

​

$

(529)

​

$

(110)

Right-of-use assets

​

​

(2,631)

​

​

(1,138)

Intangibles

​

​

(4,253)

​

​

​

Total deferred tax liability

​

​

(7,413)

​

​

(1,248)

Net deferred tax liability

​

$

(5,448)

​

$

(21)

​

Our net deferred tax liability as presented in our consolidated balance sheet consist of the following items (in thousands):

​

​

​

​

​

​

​

​

​

December 31,

​

    

2020

    

2019

Deferred tax assets

​

$

434

​

$

—

Deferred tax liabilities

​

 

(5,882)

​

 

(21)

Net deferred tax liability

​

$

(5,448)

​

$

(21)

​

The Company’s net deferred tax liabilities increased by $5.7 million as a result of our MVE and CRYOPDP acquisitions on October 1, 2020. During the years ended December 31, 2020 and 2019, the Company’s valuation allowance on deferred tax assets increased by $11.7 million and $2.1 million, respectively.  The increase in the valuation allowance during 2020 and 2019 was principally the result of net operating losses sustained during each of the years.  Our valuation allowance also increased during 2020 as a result of valuation allowances recorded against deferred tax assets on the opening balance sheets of some of our acquired foreign subsidiaries.

At December 31, 2020, the Company has federal and state net operating loss carryforwards of approximately $57.6 million and $60.9 million, respectively, which will begin to expire in 2021, unless previously utilized, and will begin to expire for state purposes in 2028. In addition, the Company has federal net operating loss carryforwards of $38.6 million generated after 2017 that can be carried over indefinitely and may be used to offset up to 80% of federal taxable income. At December 31, 2020, the Company has foreign net

operating loss carryforwards of approximately $9.8 million, which begin to expire in 2022. At December 31, 2020, the Company has federal and California research and development tax credits of approximately $0.4 million and $0.3 million, respectively. The federal research tax credit begins to expire in 2026 unless previously utilized and the California research tax credit has no expiration date.

Utilization of the net operating loss ("NOL") and research and development ("R&D") carryforwards maybe subject to a substantial annual limitation due to ownership change limitations that might have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state and foreign provisions. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company’s formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition.

The Company has not completed a study to assess whether an ownership change or changes have occurred. If the Company has experienced an ownership change, utilization of the NOL or R&D credit carryforwards would be subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL or R&D credit carryforwards before utilization. Further, until a study is complete and any limitation is known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance.

A reconciliation of the beginning and ending amounts of unrecognized tax benefits (“UTBs”) are as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

UTBs, beginning of period

​

$

963

​

$

48

Gross increase – current period tax positions

​

 

358

​

 

239

Gross decrease – prior period tax positions

​

 

(113)

​

 

—

Gross increase – prior period tax positions

​

 

64

​

 

676

Expiration of statute of limitations

​

 

—

​

 

—

UTBs, end of period

​

$

1,272

​

$

963

​

As if December 31, 2020, we had an immaterial amount of UTBs, which if recognized, would affect our effective tax rate. Prior to 2020, the Company did not have any UTBs that would impact the effective rate. The Company does not expect any significant increases or decreases to the Company's unrecognized tax positions within the next 12 months.

We recognize interest accrued related to UTBs and penalties as income tax expense.  We accrued an immaterial amount of interest expense during 2020 in our statement of operations and as of December 31, 2020 have and an immaterial accrual for interest in our consolidated balance sheet. During 2019, there were no accrued penalties or interest as of December 31, 2019.

Due to the NOL carryforwards, the U.S. federal and state returns are open to examination by the Internal Revenue Service and state jurisdictions for all years beginning with the year ended March 31, 2001. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax.  The Company’s subsidiary in India is currently under examination by the Office of the Commissioner of Income Tax in India for 2012-2013, 2013-2014, and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local tax authorities.  
XML 45 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Subsequent Event
 12 Months Ended
Dec. 31, 2020
Subsequent Events  
Subsequent Events

Note 18. Subsequent Events

January 2021 Public Offering

On January 25, 2021, the Company completed an underwritten public offering of 4,356,059 shares of its common stock. The shares were issued and sold pursuant to an underwriting agreement dated January 20, 2021, by and among the Company, on the one hand, and Morgan Stanley & Co. LLC, Jefferies LLC, SVB Leerink LLC and UBS Securities LLC, as representatives of certain underwriters at a public offering price per share of $66.00, before deducting underwriting discounts and commissions. The shares include 568,181 shares issued and sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the underwriting agreement. The Company received net proceeds of approximately $269.7 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Blackstone Conversion

On February 5, 2021, the Company received a waiver and conversion notice from Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund – FD L.P. to convert an aggregate of 50,000 shares of the Company’s Series C Preferred Stock. Pursuant to the terms of the waiver and conversion notice, the Company also agreed to waive its right under the certificate of designations of the Series C Preferred Stock to redeem up to 50,000 shares of the Series C Preferred Stock prior to the 180-day anniversary of October 1, 2020, the issue date of the Series C Preferred Stock. Each share of Series C Preferred Stock has a liquidation preference of $1,000 per share plus any accumulated and unpaid dividends and is convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price of $38.6152 per share. The forgoing conversion, effective as of February 5, 2021, resulted in the issuance of an aggregate of 1,312,860 shares of Common Stock. The foregoing shares were issued pursuant to an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.
XML 46 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Quarterly Financial Data
 12 Months Ended
Dec. 31, 2020
Quarterly Financial Data  
Quarterly Financial Data

Note 19. Quarterly Financial Data (Unaudited)

A summary of quarterly financial data is as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Quarter Ended

​

    

March 31

    

June 30

    

September 30

    

December 31

Year ended December 31, 2020

 

​

  

 

​

  

 

​

  

 

​

  

Total revenues

​

$

9,774

​

$

9,389

​

$

11,172

​

$

48,361

Gross margin

​

$

5,258

​

$

5,127

​

$

6,055

​

$

19,894

Loss from operations

​

$

(3,586)

​

$

(5,845)

​

$

(10,732)

​

$

(9,847)

Net loss attributable to common stockholders

​

$

(3,943)

​

$

(5,803)

​

$

(11,418)

​

$

(53,866)

Net loss per share attributable to common stockholders - basic and diluted

​

$

(0.11)

​

$

(0.15)

​

$

(0.29)

​

$

(1.32)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Year ended December 31, 2019

​

 

  

​

 

  

​

 

  

​

 

  

Total revenues

​

$

6,653

​

$

8,464

​

$

9,583

​

$

9,242

Gross margin

​

$

3,454

​

$

4,338

​

$

4,627

​

$

4,932

Loss from operations

​

$

(2,141)

​

$

(2,304)

​

$

(12,352)

​

$

(878)

Net loss

​

$

(2,387)

​

$

(2,528)

​

$

(12,469)

​

$

(948)

Net loss per share - basic and diluted

​

$

(0.08)

​

$

(0.08)

​

$

(0.35)

​

$

(0.03)

​

Earnings per basic and diluted shares are computed independently for each of the quarters presented based on basic and diluted shares outstanding per quarter and, therefore, may not sum to the totals for the periods shown.

In the fourth quarter of 2019, management identified an error in the Company's historical interim financial statements for the third quarter of fiscal year 2019 relating to its stock-based compensation expense. Specifically, in the third quarter of 2019, the Company incorrectly recorded $1,227,890 of accelerated stock-based compensation expense for nonemployee directors who were not eligible for the accelerated vesting under their stock option awards. The error impacts only the previously issued historical interim financial statements for the third quarter of fiscal year 2019. The Company corrected the error in the fourth quarter of 2019, which resulted in a reduction of $765,099 of stock-based compensation expense included in selling, general and administrative expense. The Company concluded the error is not material to the third and fourth quarter of 2019.
XML 47 R28.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2020
Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Change in Segment Reporting

The Company continually monitors and reviews its segment reporting structure in accordance with authoritative guidance to determine whether any changes have occurred that would impact its reportable operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The chief operating decision maker (“CODM”) is our Chief Executive Officer. Up until the fourth quarter of 2020, we managed, reported and evaluated our business in the following two reportable operating segments: Global Logistics Solutions and Global Bioservices. During the fourth quarter of 2020, our CODM changed how he makes operating decisions, assesses the performance of the business and allocates resources in a manner that caused our operating segments to change as a result of the MVE and CRYOPDP acquisitions. In consideration of Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”), 280, Segment Reporting, we determined that we are not organized around specific products and services, geographic regions or regulatory environments. Accordingly, beginning with the fourth quarter of 2020, we realigned our reporting structure, resulting in a single reportable segment. The Company has adjusted its financial statements for historical periods to reflect this change in segment reporting and show its financial results without segments for all periods presented.
Principles of Consolidation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly-owned subsidiaries, Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions US LLC, and Cryoport Netherlands B.V. and subsidiaries (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents

Cash and Cash Equivalents

Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.
Short-Term Investments

Short-Term Investments

Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings.

Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity.

Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss is recognized in earnings. Gains and losses are determined using the specific identification method.

Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.
Use of Estimates

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.

Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.

Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, finance lease liabilities, note payable, and the Company’s 3.00% convertible senior notes due in 2025 (the “Senior Notes”). The carrying value for all such instruments, except finance lease liabilities, note payable and the Senior Notes, approximates fair value at December 31, 2020 due to their short-term nature. The carrying value of finance lease liabilities approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. For additional information related to fair value measurements, including the note payable and the Senior Notes, see Note 5.
Concentrations of Credit Risk

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2020 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.

Our investment policy requires that purchased instruments in marketable securities may only be in highly rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.
Customers

Customers

The Company grants credit to customers within the U.S. and to international customers and does not require collateral. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables is affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at December 31, 2020, and 2019 are net of reserves for doubtful accounts of $1.1 million and $0.1 million, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.

The Company’s customers are in the biotechnology, pharmaceutical, animal health, human reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. As of December 31, 2019, there were two customers that accounted for 31.0% and 20.7%, respectively, of net accounts receivable. There were no other single customer that owed us more than 10%of net accounts receivable at December 31, 2020 and 2019.

The Company has revenue from foreign customers primarily in United Kingdom, Switzerland, France, Netherlands, Singapore, China and India. During the years ended December 31, 2020 and 2019, the Company had revenues from foreign customers of approximately $29.1 million and $5.1 million, respectively, which constituted approximately 37.0% and 15.1%, respectively, of total revenues. There  were two customers that accounted for 24.1% and 12.8% of revenues during the year ended December 31, 2019. No other single customer generated over 10% of revenues during the years ended December 31, 2020 and 2019.
Inventories

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (“FIFO”) method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.
Property and Equipment

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation.  We compute depreciation using the straight-line method over the estimated useful lives of the assets which is generally three to twelve years for computer hardware and software, seven to ten years for freezers, four to ten years for trucks and autos, three to fifteen years for furniture and equipment and over the shorter of the lease term or useful live of the assets for leasehold improvements. Buildings are depreciated over a useful life ranging from 20 to 45 years. Maintenance and repairs are expensed as incurred.

Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.
Leases

Leases

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating leases are included in ROU assets, current operating lease liabilities, and long-term operating lease liabilities on our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.

Lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using our incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received.  Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. The Company’s leases do not contain any residual value guarantees.  Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company accounts for lease and non-lease components as a single lease component for all its leases.
Business Combinations

Business Combinations

Total consideration transferred for acquisitions is allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions primarily with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While the Company uses its best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, the Company’s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill.
Goodwill

Goodwill

The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company compares the fair value of the reporting unit’s with its carrying amount and then recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting units fair value up to the total amount of goodwill allocated to the reporting unit. The Company assessed  triggering events indicating potential goodwill impairment, including the effects of the COVID-19 pandemic, and after assessment, concluded that there was no impairment during the year ended December 31, 2020.
Intangible Assets

Intangible Assets

Intangible assets are comprised of patents, trademarks, software development costs and the intangible assets acquired in the MVE, CRYOPDP and Cryogene acquisitions which include a non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The non-compete agreement, technology, customer relationships, trade name/trademark, agent network, order backlog, developed technology and land use rights, acquired in the MVE, CRYOPDP and Cryogene acquisitions are amortized using the straight-line method over the estimated useful lives (see Note 8). The Company uses the following valuation methodologies to value the significant intangible assets acquired: income approach for customer relationships, replacement cost for agent network and software, and relief from royalty for trade name/trademarks and developed technology.

The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. There was no impairment of intangible assets during the year ended December 31, 2020.
Other Long-lived Assets

Other Long-lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through December 31, 2020.
Deferred Financing Costs

Deferred Financing Costs

Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.
Income Taxes

Income Taxes

The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, “Income Taxes”, or ASC 740. As of December 31, 2020 and 2019, there were no material unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the US based net deferred tax assets be realized. Therefore, the Company has recorded a full valuation allowance against its US based net deferred tax assets. With respect to the foreign based deferred tax assets, the Company's management has reviewed these deferred tax assets on a jurisdictional basis. Based on the weight of each jurisdiction's evidence available, the Company's management has made separate determinations for each foreign jurisdiction regarding whether it is more likely than not that a net deferred tax asset within a particular jurisdiction will be not be realized. The Company has recorded full valuation allowances in jurisdictions where deferred tax assets are not deemed more likely than not to be realized.

Additionally, the Company maintains a deferred tax liability related to indefinite-lived assets that have been netted against deferred tax assets that also allow for indefinite carryforward periods subject to limitations.  The remaining taxable temporary difference cannot serve as a source for future taxable income to realize federal net operating losses, due to the fact that post-2017 federal net operating losses are only eligible to offset  80% of income in a given year or in the case of state net operating losses, the state net operating losses will expire prior to the reversal of the taxable temporary difference.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company has immaterial accruals for interest or penalties on its consolidated balance sheets at December 31, 2020 and 2019 and has recorded only immaterial interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2020 and 2019. The Company is subject to taxation in the U.S., various state jurisdictions and in various foreign countries. As of December 31, 2020, the Company is no longer subject to U.S. federal examinations for years before 2017 and for California franchise and income tax examinations for years before 2016. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Our foreign subsidiaries are generally subject to examination three years following the year in which the tax obligation originated.  The years subject to audit may be extended if the entity substantially understates corporate income tax. The Company's subsidiary in India is currently under examination by the Indian tax authorities for 2012-2013, 2013-2014 and 2015-2016 tax periods. Other than India, the Company does not have any foreign subsidiaries currently under audit by their local taxing authorities.

In December of 2019, the FASB issued ASU 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 31, 2020. Early adoption is permitted, including adoption in an interim period. Different components of the guidance require retrospective, modified retrospective or prospective adoption. The Company has elected to early adopt ASU 2019-12 on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.

On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. At December 31, 2020, the Company has not recorded any income tax provision/(benefit) resulting from the CARES Act mainly due the Company’s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.

On December 27, 2020, the United States enacted the Consolidated Appropriations Act of 2021 (“CAA”).  The CAA includes provisions extending certain CARES Act provisions and adds coronavirus relief, tax and health extenders. The Company will continue to evaluate the impact of the CAA and its impact on our financial statements in 2021 and beyond.

In June 29, 2020, the state of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&D credit usage for the same period (for credit usages in excess of $5M). These suspensions were considered in preparation of the 2020 financial statements.
Revenue Recognition

Revenue Recognition

Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

Performance Obligations

At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to

payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset.

For arrangements under which the Company provides biological specimen storage services and logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement.

Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized when the Company satisfies the contractually defined performance obligations. When a contract includes multiple performance obligations, the contract price is allocated among the performance obligations based upon the stand-alone selling prices. Approved contract modifications are accounted for as either a separate contract or as part of the existing contract depending on the nature of the modification.

Our performance obligations on our orders and under the terms of agreements with customers are generally satisfied within one year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders.

Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606 and are not considered a separate performance obligation to our customers. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying consolidated statements of operations.

Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental agencies.

Significant Payment Terms

Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15 to 60 days from the date of the invoice (except for any amounts disputed by the customer in good faith).  Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component.

Variable Consideration

When a contract includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained. Variable consideration is estimated at the most likely amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Variable consideration estimates are updated at each reporting date. Revenues are recorded net of variable consideration, such as discounts and allowances.

Warranties

The Company provides product warranties with varying terms and durations for some of its products. The Company estimates product warranty costs and accrues for these costs as products are sold with a charge to cost of sales. Factors considered in estimating warranty costs include historical and projected warranty claims, historical and projected cost-per-claim, and knowledge of specific product issues that are outside of typical experience. Warranty accruals are evaluated and adjusted as necessary based on actual claims experience and changes in future claim and cost estimates.

Product warranty accrued liabilities totaled $0.2 million and $0 at December 31, 2020 and 2019, respectively, and are included in accounts payable and other accrued expenses. Warranty expense was not material for the years ended December 31, 2020 and 2019.

Incremental Direct Costs

Incremental direct costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as promised goods and services are transferred to a customer. Incremental direct costs were not material for the years ended December 31, 2020 and 2019.

Contract Assets

Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable, which are recognized when payment is unconditional and only the passage of time is required before payment is due. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed.

Contract Liabilities (Deferred Revenue)

Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $0.4 million at December 31, 2020 and 2019. During the years ended December 31, 2020 and 2019, the Company recognized revenues of $0.4 million and $0.1 million from the related contract liabilities outstanding as the services were performed.

Nature of Goods and Services

The Company provides Cryoport Express® Shippers to its customers and charges a fee in exchange for the use of the Cryoport Express® Shipper under long-term master service agreements with customers. The Company’s arrangements convey to the customers the right to use the Cryoport Express® Shippers over a period of time. The Company retains title to the Cryoport Express® Shippers and provides its customers the use of the Cryoport Express® Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Cryoport Express® Shipper is returned to the Company.

The Company recognizes revenue for the use of the Cryoport Express® Shippers at the time of the delivery of the Cryoport Express® Shipper to the end user of the enclosed materials, and at the time that collectability is probable.

The Company also provides vacuum insulated aluminum dewars and cryogenic freezers systems to its customers. Revenue is recognized when the Company satisfies performance obligations by transferring the equipment to a customer, and at the time that collectability is probable.

The Company also provides global temperature-controlled logistics services, support and management. Revenue is recognized for these services as services are rendered and at the time that collectability is probable.

The Company also provides comprehensive and integrated temperature-controlled biostorage solutions to customers in the life sciences industry and charges a fee under long-term master service agreements with customers. These services include (1) biological specimen cryopreservation storage and maintenance, (2) archiving, monitoring, tracking, receipt and delivery of samples, (3) transport of frozen biological specimens to and from customer locations, and (4) management of incoming and outgoing biological specimens. The Company recognizes revenue for its biostorage solutions as services are rendered over time and at the time that collectability is probable.

The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services over time as the customer simultaneously receives and consumes the benefit of these services as they are performed.

A significant portion of our revenues are covered under long-term agreements. We have determined that individual Statements of Work or Scope of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle) for the Cryoport Express® solutions and up to 12 months for biostorage solutions. Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services.  Prices under these agreements are generally fixed.

Revenue Disaggregation

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major markets for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Biopharma/Pharma

​

$

66,394

​

$

30,032

Animal Health

​

 

7,846

​

 

996

Human Reproductive Medicine

​

​

4,456

​

​

2,914

Total revenues

​

$

78,696

​

$

33,942

​

Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the years ended December 31, 2020 and 2019, were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Americas

​

$

49,555

​

$

28,801

Europe, the Middle East and Africa (EMEA)

​

 

20,316

​

 

4,523

Asia Pacific (APAC)

​

 

8,825

​

 

618

Total revenues

​

$

78,696

​

$

33,942

​

Cost of Services Revenues

Our cost of services revenues is primarily comprised of freight charges, payroll and associated expenses related to our global logistics and supply chain centers, depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions.

Cost of Product Revenues

Our cost of product revenues is primarily comprised of materials, direct and indirect labor, inbound freight charges, purchasing and receiving, inspection, and distribution and warehousing of inventory. In addition, shop supplies, facility maintenance costs and depreciation expense for assets used in the manufacturing process are included in cost of product revenues.
Engineering and Development Expenses

Engineering and Development Expenses

Expenditures relating to engineering and development are expensed in the period incurred to engineering and development expense in the consolidated statements of operations.

Acquisition Costs

Acquisition Costs

Acquisition costs consist of legal, accounting, third-party valuations, and other due diligence costs related to our MVE, CRYOPDP, and Cryogene acquisitions (See Note 3).
Stock-Based Compensation

Stock-Based Compensation

The Company accounts for stock-based payments in accordance with stock-based payment accounting guidance which requires all stock-based payments to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.  The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and expected term. The Company accounts for forfeitures of unvested awards as they occur.

The Company’s stock-based compensation plans are discussed further in Note 16.
Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

Issuances of the Company’s common stock for acquiring goods or services are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the estimated fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current estimated fair values.
Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss Per Share

We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt outstanding during the periods.

The following shows the amounts used in computing net loss per share (in thousands except per share data):

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Net loss

​

$

(32,693)

​

$

(18,332)

Deemed dividend on Series C convertible preferred stock

​

​

(39,492)

​

​

—

Paid-in-kind dividend on Series C convertible preferred stock

​

 

(2,844)

​

 

—

Net loss attributable to common shareholders

​

$

(75,029)

​

$

(18,332)

Weighted average common shares outstanding - basic and diluted

​

​

38,582,432

​

​

33,394,285

Basic and diluted net loss per share

​

$

(1.94)

​

$

(0.55)

​

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Stock options

​

5,920,886

 

3,636,806

Warrants

​

—

 

753,211

Series C convertible preferred stock

​

6,474,135

​

—

Convertible senior notes

​

4,810,002

 

—

​

​

17,205,023

 

4,390,017
Foreign Currency Transactions

Foreign Currency Transactions

Management has determined that the functional currency of its subsidiaries is the local currency.  The Company translates the assets and liabilities of its foreign subsidiaries into U.S. dollars at exchange rates in effect at the end of the reporting period.  Income

and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity.  The translation gain (loss) adjustment totaled $5.2 million and 2,900 for the years ended December 31, 2020 and 2019, respectively.  Foreign currency gains and losses from transactions denominated in other than respective local currencies are included in earnings.
Off-Balance Sheet Arrangements

Off Balance Sheet Arrangements

We do not currently have any off balance sheet arrangements.
Reclassifications

Reclassification

Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.
Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of U.S. GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income).  ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12 on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.  

In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement," which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. We adopted this guidance on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.

In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which is intended to simplify the subsequent accounting for goodwill acquired in a business combination. Prior guidance required utilizing a two-step process to review goodwill for impairment. A second step was required if there was an indication that an impairment may exist, and the second step required calculating the potential impairment by comparing the implied fair value of the reporting unit's goodwill (as if purchase accounting were performed on the testing date) with the carrying amount of the goodwill. The new guidance eliminates the second step from the goodwill impairment test. Under the new guidance, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount, and then recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value (although the loss should not exceed the total amount of goodwill allocated to the reporting unit). The guidance requires prospective adoption and is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019.  We adopted this guidance on January 1, 2020.  The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or disclosures.

Accounting Guidance Issued but Not Adopted at December 31, 2020

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new

guidance also requires the if-converted method to be applied for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted in fiscal years beginning after December 15, 2020. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, “Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. In November 2019, the FASB issued ASU 2019-10 "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which deferred the effective date of ASU 2016-13 by three years for smaller reporting companies. The one-time determination of whether an entity is eligible to be a smaller reporting company is based on the entity's most recent determination as of November 15, 2019 in accordance with SEC regulations.  As a result, ASU 2016-13, as subsequently amended, is effective for the Company for fiscal years beginning after December 15, 2022 based on the Company's smaller reporting company determination as of November 15, 2019.  We have not yet adopted this standard and are currently evaluating the impact of this standard on our consolidated financial statements.  The Company currently believes the main impact of the new standard will relate to the Company’s assessment of its allowance for doubtful accounts on trade receivables.
XML 48 R29.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2020
Summary of Significant Accounting Policies  
Schedule of disaggregation of revenue by major source

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Biopharma/Pharma

​

$

66,394

​

$

30,032

Animal Health

​

 

7,846

​

 

996

Human Reproductive Medicine

​

​

4,456

​

​

2,914

Total revenues

​

$

78,696

​

$

33,942
Schedule of geographical revenues, by origin

Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the years ended December 31, 2020 and 2019, were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Americas

​

$

49,555

​

$

28,801

Europe, the Middle East and Africa (EMEA)

​

 

20,316

​

 

4,523

Asia Pacific (APAC)

​

 

8,825

​

 

618

Total revenues

​

$

78,696

​

$

33,942
Schedule of net loss per share

The following shows the amounts used in computing net loss per share (in thousands except per share data):

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Net loss

​

$

(32,693)

​

$

(18,332)

Deemed dividend on Series C convertible preferred stock

​

​

(39,492)

​

​

—

Paid-in-kind dividend on Series C convertible preferred stock

​

 

(2,844)

​

 

—

Net loss attributable to common shareholders

​

$

(75,029)

​

$

(18,332)

Weighted average common shares outstanding - basic and diluted

​

​

38,582,432

​

​

33,394,285

Basic and diluted net loss per share

​

$

(1.94)

​

$

(0.55)
Schedule of number of shares excluded from the computation of diluted loss per share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Stock options

​

5,920,886

 

3,636,806

Warrants

​

—

 

753,211

Series C convertible preferred stock

​

6,474,135

​

—

Convertible senior notes

​

4,810,002

 

—

​

​

17,205,023

 

4,390,017
XML 49 R30.htm IDEA: XBRL DOCUMENT v3.20.4
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2020
Business Acquisition [Line Items]  
Schedule of pro forma consolidated results of operations

​

​

​

​

​

​

​

​

​

    

Year Ended

    

Year Ended

(in thousands except per share data)

​

December 31, 2020

​

December 31, 2019

​

​

(unaudited)

​

(unaudited)

Revenues

​

$

172,147

​

$

163,217

Net loss

​

$

(18,562)

​

$

(3,149)

Basic and diluted net loss per share

​

$

(2.08)

​

$

(0.09)

​
CRYOPDP  
Business Acquisition [Line Items]  
Schedule of summary of allocation of the purchase price as of the acquisition date

The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):

​

​

​

​

Total purchase consideration paid

    

$

56,971

​

​

​

​

Purchase price allocation:

​

 

  

Cash and cash equivalents

​

 

8,346

Accounts receivable

​

 

10,603

Inventories

​

 

644

Prepaid and other current assets

​

 

2,905

Property and equipment

​

 

2,863

Operating lease right-of-use assets

​

 

1,856

Intangible assets

​

 

28,235

Other long-term assets

​

 

569

Accounts payable and other accrued expenses

​

 

(11,110)

Accrued compensation and related expenses

​

​

(1,194)

Deferred revenue

​

​

(370)

Note payable

​

​

(4,690)

Operating lease liabilities

​

 

(1,856)

Deferred tax liability

​

 

(5,311)

Other long-term liabilities

​

 

(64)

Total identifiable net assets

​

 

31,426

Goodwill

​

 

25,545

​

​

$

56,971
Schedule of the preliminary fair value of intangible assets acquired at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives

The following table summarizes the estimated fair values of CRYOPDP’s identifiable intangible assets at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

    

    

    

    

Annual

​

​

Estimated

​

Estimated

​

Amortization

​

Amortization

​

​

Fair Value

​

Useful Life

​

Method

​

Expense

Software

​

$

3,578

 

7

 

Straight-line

​

$

511

Customer relationships

​

 

5,871

 

11.5

 

Straight-line

​

 

511

Agent network

​

 

8,219

 

4

 

Straight-line

​

 

2,055

Trade name/trademarks

​

 

10,567

 

Indefinite

 

—

​

 

—

Total

​

$

28,235

​

​

​

​

​

$

3,077
MVE  
Business Acquisition [Line Items]  
Schedule of summary of allocation of the purchase price as of the acquisition date

The following table summarizes the allocation of the purchase price as of the acquisition date (in thousands):

​

​

​

​

Total purchase consideration paid

    

$

317,470

​

​

​

​

Purchase price allocation:

​

 

  

Cash and cash equivalents

​

 

2,955

Accounts receivable

​

 

10,645

Inventories

​

 

10,627

Prepaid and other current assets

​

 

256

Property and equipment

​

 

9,050

Operating lease right-of-use assets

​

 

2,154

Intangible assets

​

 

184,991

Other long-term assets

​

 

358

Accounts payable and other accrued expenses

​

 

(6,036)

Accrued compensation and related expenses

​

​

(1,139)

Operating lease liabilities

​

 

(2,160)

Deferred tax liability

​

 

(393)

Other long-term liabilities

​

 

(64)

Total identifiable net assets

​

 

211,244

Goodwill

​

 

106,226

​

​

$

317,470
Schedule of the preliminary fair value of intangible assets acquired at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives

The following table summarizes the estimated fair values of MVE’s identifiable intangible assets and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

    

​

​

    

  

    

  

    

Annual

​

​

Estimated

​

Estimated

​

Amortization

​

Amortization

​

​

Fair Value

​

Useful Life

​

Method

​

Expense

Order backlog

 

​

2,600

 

0.125

 

Straight-line

​

$

—

Customer relationships

 

​

118,600

 

14.5

 

Straight-line

​

 

8,179

Developed technology

 

​

28,700

 

12

 

Straight-line

​

 

2,392

Land use rights

 

​

2,291

 

38

 

Straight-line

​

 

63

Trade name/trademarks

 

​

32,800

 

Indefinite

 

—

​

 

—

Total

​

$

184,991

​

​

​

​

​

$

10,634
CryoGene Partners [Member]  
Business Acquisition [Line Items]  
Schedule of summary of allocation of the purchase price as of the acquisition date

​

​

​

​

​

Total purchase price

    

$

20,317

​

​

​

​

Purchase price allocation:

​

 

  

Property and equipment

​

 

4,257

Intangible assets

​

 

5,280

Deferred revenue

​

 

(220)

Total identifiable net assets

​

 

9,317

Goodwill

​

 

11,000

​

​

$

20,317
Schedule of the preliminary fair value of intangible assets acquired at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives

The following table summarizes the fair value of intangible assets acquired at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Annual

​

    

Estimated

    

Estimated

    

Amortization

    

Amortization

​

​

Fair Value

​

Useful Life

​

Method

​

Expense

Non-compete agreement

​

$

390

 

5

 

Straight-line

​

$

78

Technology

​

 

510

 

5

 

Straight-line

​

 

102

Customer relationships

​

 

3,900

 

12

 

Straight-line

​

 

325

Trade name/trademark

​

 

480

 

15

 

Straight-line

​

 

32

Total

​

$

5,280

​

​

​

​

​

$

537
XML 50 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Cash, Cash Equivalents and Short-Term Investments (Tables)
 12 Months Ended
Dec. 31, 2020
Cash, Cash Equivalents and Short-Term Investments  
Schedule of cash, cash equivalents and short-term investments

Cash, cash equivalents and short-term investments consisted of the following as of December 31, 2019 and 2018 (in thousands):

​

​

​

​

​

​

​

​

​

​

Carrying Value

​

    

2020

    

2019

Cash

​

$

25,053

​

$

3,547

Cash equivalents:

​

 

​

​

​

​

Money market mutual funds

​

 

11,820

​

​

43,688

Total cash and cash equivalents

​

 

36,873

​

​

47,235

Short-term investments:

​

 

​

​

​

​

U.S. Treasury notes and bills

​

 

23,309

​

​

21,094

Mutual funds

​

 

33,135

​

​

25,967

Total short-term investments

​

 

56,444

​

​

47,061

Cash, cash equivalents and short-term investments

​

$

93,317

​

$

94,296

​
Schedule of available-for-sale debt securities

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale debt securities by type of security at December 31, 2020 were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Amortized

    

Unrealized

    

Unrealized

    

​

​

​

​

Cost

​

Gains

​

Losses

​

Fair Value

U.S. Treasury notes

​

$

23,179

​

$

173

​

$

(43)

​

$

23,309

Total available-for-sale investments

​

$

23,179

​

$

173

​

$

(43)

​

$

23,309

​

The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale debt securities by type of security at December 31, 2019 were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Amortized 

    

Unrealized 

    

Unrealized 

    

​

​

​

​

Cost

​

Gains

​

Losses

​

Fair Value

U.S. Treasury notes and bills

​

$

21,122

 

$

26

 

$

(54)

​

$

21,094

Total available-for-sale investments

​

$

21,122

 

$

26

​

$

(54)

​

$

21,094

​
Schedule of investments based on stated contractual maturities

The following table summarizes the fair value of available-for-sale debt securities based on stated contractual maturities as of December 31, 2020 (in thousands):

​

​

​

​

​

​

​

​

​

    

Amortized Cost

    

Fair Value

Due within one year

​

$

14,084

​

$

14,111

Due between one and two years

​

 

9,095

​

 

9,198

​

​

​

​

​

​

​

Total

​

$

23,179

​

$

23,309

​

The following table summarizes the fair value of available-for-sale debt securities based on stated contractual maturities as of December 31, 2019 (in thousands):

​

​

​

​

​

​

​

​

​

    

Amortized Cost

    

Fair Value

Due within one year

​

$

12,044

 

$

12,047

Due between one and two years

​

 

9,078

 

 

9,047

Total

​

$

21,122

 

$

21,094

​
Schedule of unrealized gains (losses) on investments

Unrealized gains (losses) during 2020 and 2019 related to equity securities held at December 31, 2020 and 2019 are as follows (in thousands):

​

​

​

​

​

​

​

​

​

    

2020

    

2019

Net losses recognized during the year on equity securities

​

$

(245)

​

$

(102)

Less: net losses recognized during the year on equity securities sold during the year

​

 

(1,090)

​

​

—

Unrealized gains (losses) recognized during the year on equity securities still held at December 31, 2020 and 2019

​

$

845

​

$

(102)
XML 51 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2020
Fair Value Measurements  
Schedule of fair value hierarchy

The carrying values of our assets that are required to be measured at fair value on a recurring basis as of December 31, 2020 and 2019 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Fair Value Measurements

​

    

Level 1

    

Level 2

    

Level 3

    

Total

December 31, 2020

 

​

  

 

​

  

 

​

  

 

​

  

Cash equivalents:

 

​

  

 

​

  

 

​

  

 

​

  

Money market mutual fund

​

$

11,820

​

$

—

​

$

—

​

$

11,820

Marketable equity securities:

​

 

  

​

 

  

​

 

  

​

 

  

Mutual funds

​

 

33,135

​

 

—

​

 

—

​

 

33,135

Available-for-sale debt securities:

​

 

​

​

 

  

​

 

  

​

 

​

U.S. Treasury notes

​

 

23,309

​

 

—

​

 

—

​

 

23,309

​

​

$

68,264

​

$

—

​

$

—

​

$

68,264

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Fair Value Measurements 

​

 

Level 1

 

Level 2

 

Level 3

 

Total

December 31, 2019

    

​

  

    

​

  

    

​

  

    

​

  

Cash equivalents:

 

​

  

 

​

  

 

​

  

 

​

  

Money market mutual fund

​

$

43,688

​

$

—

​

$

—

​

$

43,688

Marketable equity securities:

​

 

  

​

 

  

​

 

  

​

 

  

Mutual funds

​

 

25,967

​

 

—

​

 

—

​

 

25,967

Available-for-sale debt securities:

​

 

  

​

 

  

​

 

  

​

 

  

U.S. Treasury notes

​

 

21,094

​

 

—

​

 

—

​

 

21,094

​

​

$

90,749

​

$

—

​

$

—

​

$

90,749

​
XML 52 R33.htm IDEA: XBRL DOCUMENT v3.20.4
Inventories (Tables)
 12 Months Ended
Dec. 31, 2020
Inventories  
Schedule of Utility Inventory

Inventories consist of the following (in thousands):

​

​

​

​

​

​

​

​

​

    

December 31, 

    

December 31, 

​

​

2020

​

2019

Raw materials

​

$

7,544

​

$

357

Work-in-process

​

​

227

​

​

—

Finished goods

​

 

2,764

​

 

117

​

​

$

10,535

​

$

474
XML 53 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2020
Property and Equipment  
Schedule of property, plant and equipment

Property and equipment consist of the following (in thousands):

​

​

​

​

​

​

​

​

​

    

December 31, 

    

December 31, 

​

​

2020

​

2019

Cryogenic shippers and data loggers

​

$

5,625

​

$

4,296

Freezers

​

​

4,473

​

​

3,414

Furniture and fixtures

​

 

2,727

​

 

291

Computers and software

​

 

1,469

​

 

646

Machinery and equipment

​

 

11,998

​

 

1,093

Trucks and autos

​

​

437

​

​

37

Leasehold improvements

​

 

4,599

​

 

2,246

Buildings

​

​

5,359

​

​

—

Land

​

​

790

​

​

—

Fixed assets in process

​

 

8,070

​

 

3,407

​

​

 

45,547

​

 

15,430

Less accumulated depreciation and amortization

​

 

(15,511)

​

 

(3,597)

​

​

$

30,036

​

$

11,833
XML 54 R35.htm IDEA: XBRL DOCUMENT v3.20.4
Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets  
Schedule of goodwill

The following table represents the changes in the carrying value of goodwill for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

    

December 31

    

December 31,

​

​

2020

​

2019

Balance at beginning of year

​

$

11,000

​

$

—

Goodwill related to Cryogene acquisition

​

 

—

​

 

11,000

Goodwill related to MVE acquisition

​

 

107,504

​

 

—

Goodwill related to CRYOPDP acquisition

​

 

26,778

​

 

—

Balance at end of year

​

$

145,282

​

$

11,000

​
Schedule of intangible assets

The following table presents our intangible assets as of December 31, 2020 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

​

Net

​

Average

​

​

Gross

​

Accumulated

​

Carrying

​

Amortization

​

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

​

$

390

​

$

123

​

$

267

 

3

Technology

​

​

34,245

​

​

1,630

​

​

32,615

​

11

Customer relationships

​

​

128,640

​

​

2,708

​

​

125,932

​

14

Cryogene trade name/trademark

​

​

480

​

​

51

​

​

429

​

13

CRYOPDP agent network

​

​

8,597

​

​

537

​

​

8,060

​

4

MVE Order backlog

​

​

2,600

​

​

2,600

​

​

—

​

—

MVE land use rights

​

​

2,378

​

​

16

​

​

2,362

​

37

Patents and trademarks

​

​

44,312

​

​

69

​

​

44,243

​

—

Total

​

$

221,642

​

$

7,734

​

$

213,908

​

​

​

The following table presents our intangible assets as of December 31, 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

​

Net

​

Average

​

​

Gross

​

Accumulated

​

Carrying

​

Amortization

​

    

Amount

    

Amortization

    

Amount

    

Period (years)

Non-compete agreement

​

$

390

​

$

45

​

$

345

 

5

Technology

​

​

510

​

​

59

​

​

451

​

5

Customer relationships

​

​

3,900

​

​

190

​

​

3,710

​

12

Cryogene trade name/trademark

​

​

480

​

​

19

​

​

461

​

15

Cryoport patents and trademarks

​

​

258

​

​

47

​

​

211

 

—

Total

​

$

5,538

​

$

360

​

$

5,178

​

​

​
Schedule of expected future amortization of intangible assets

​

Expected future amortization of intangible assets as of December 31, 2020 is as follows (in thousands):

​

​

​

​

​

Years Ending December 31, 

    

Amount

2021

​

 

14,438

2022

​

 

14,438

2023

​

 

14,438

2024

​

 

13,795

2025

​

 

12,108

Thereafter

​

 

100,124

​

​

$

169,341
XML 55 R36.htm IDEA: XBRL DOCUMENT v3.20.4
Accrued Compensation and Related Expenses (Tables)
 12 Months Ended
Dec. 31, 2020
Accrued Compensation and Related Expenses  
Schedule of employee related liabilities

Accrued compensation and related expenses consist of the following (in thousands):

​

​

​

​

​

​

​

​

​

    

December 31, 

    

December 31, 

​

​

2020

​

2019

Accrued salaries and wages

​

$

6,048

​

$

1,386

Accrued paid time off

​

 

1,393

​

 

518

​

​

$

7,441

​

$

1,904
XML 56 R37.htm IDEA: XBRL DOCUMENT v3.20.4
Convertible Senior Notes (Tables)
 12 Months Ended
Dec. 31, 2020
Convertible Senior Notes  
Schedule of components of notes payable

Senior Notes payable consisted of the following at December 31, 2020 (in thousands):

​

​

​

​

​

    

December 31, 2020

Principal amount of Senior Notes

​

$

115,000

Unamortized debt issuance costs

​

 

(3,656)

Net carrying value of Senior Notes payable

​

$

111,344

​
Schedule of interest expenses incurred in connection with the Notes

Interest expense incurred in connection with the Notes consisted of the following for the year ended December 31, 2020 (in thousands):

​

​

​

​

​

    

Year Ended

​

​

December 31, 2020

Coupon interest

​

$

2,108

Amortization of debt issuance costs

​

​

437

Total interest expense on Senior Notes

​

$

2,545

​
XML 57 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Leases (Tables)
 12 Months Ended
Dec. 31, 2020
Leases  
Schedule of components of lease expense

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Operating lease cost

​

$

1,835

​

$

758

Finance lease cost:

​

​

​

​

 

  

Amortization of right-of-use assets

​

​

56

​

​

10

Interest on finance lease liabilities

​

​

10

​

​

3

​

​

​

66

​

 

13

Total lease cost

​

$

1,901

​

$

771
Schedule of other information related to leases

Other information related to leases was as follows (in thousands):

​

​

​

​

​

​

​

​

Year Ended

 

Supplemental Cash Flows Information

    

December 31, 2020

 

Cash paid for amounts included in the measurement of lease liabilities:

 

​

​

​

Operating cash flows from operating leases

 

$

1,680

​

Operating cash flows from finance leases

 

$

77

​

Financing cash flows from finance leases

​

$

67

​

​

​

​

​

​

Right-of-use assets obtained in exchange for lease liabilities (in thousands):

​

​

​

​

Operating leases

 

$

10,708

​

Finance leases

​

$

203

​

​

​

​

​

​

Weighted-Average Remaining Lease Term

​

​

​

​

Operating leases

​

 

6.6 years

​

Finance leases

​

 

2.9 years

​

​

​

​

​

​

Weighted-Average Discount Rate

​

​

​

​

Operating leases

​

​

5.5

%

Finance leases

​

​

5.4

%
Schedule of future minimum lease payments under non-cancellable leases

Future minimum lease payments under non-cancellable leases that have commenced as of December 31, 2020 were as follows (in thousands):

​

​

​

​

​

​

​

​

Years Ending December 31

    

Operating Leases

    

Finance Leases

2021

 

$

3,103

 

$

67

2022

 

​

3,261

 

​

57

2023

 

​

2,498

 

​

60

2024

 

​

1,985

 

​

—

2025

 

​

1,696

 

​

—

Thereafter

 

​

5,402

 

​

—

Total future minimum lease payments

 

​

17,945

 

​

184

Less imputed interest

 

​

(3,453)

 

​

(13)

Total

​

$

14,492

​

$

171

​

​

​

​

​

​

​

​

​

​

Operating

​

Finance 

Reported as of December 31, 2020

    

 Leases

    

Leases

Current lease liabilities

​

$

2,231

​

$

59

Noncurrent lease liabilities

​

 

12,261

​

 

112

Total

​

$

14,492

​

$

171
XML 58 R39.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2020
Stockholders' Equity  
Schedule of common stock were issuable upon exercise of stock options and the conversion of convertible senior notes and Series C Preferred stock

As of December 31, 2020, approximately 18.8 million shares of common stock were issuable upon exercise of stock options and the conversion of convertible senior notes and Series C Preferred stock, as follows:

​

​

​

​

Exercise of stock options

    

7,554,305

Conversion of Series C Preferred stock

​

6,474,135

Conversion of convertible senior notes

​

4,810,002

Total shares of common stock reserved for future issuances

 

18,838,442
XML 59 R40.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2020
Schedule of warrant activity

We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants.   A summary of warrant activity is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

​

​

    

Weighted-

    

​

​

​

​

​

​

Weighted-

​

Average

​

​

​

​

​

​

​

Average

​

Remaining

​

Aggregate

​

​

Number of

​

Exercise

​

Contractual

​

Intrinsic

​

    

Shares

    

Price/Share

    

Term (Years)

    

Value (1)

Outstanding — December 31, 2018

 

2,049,534

​

$

4.03

 

  

 

​

  

Issued

 

—

​

 

—

 

  

 

​

  

Exercised

 

(1,027,546)

​

 

3.95

 

  

 

​

  

Expired

 

(20,960)

​

 

17.78

 

  

 

​

  

Outstanding — December 31, 2019

 

1,001,028

​

​

3.83

 

  

 

​

  

Issued

 

—

​

 

—

 

  

 

​

  

Exercised

 

(963,149)

​

 

3.80

 

  

 

​

  

Expired

 

(37,879)

​

 

4.58

 

  

 

​

  

Outstanding — December 31, 2020

 

—

​

$

—

 

—

​

$

—

Vested (exercisable) — December 31, 2020

 

—

​

$

—

 

—

​

$

—

(1)Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of the Company’s common stock on December 31, 2020, which was $43.88 per share.
Schedule of fair value assumptions of stock options

During the years ended December 31, 2020 and 2019, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following assumptions:

​

​

​

​

​

​

​

​

​

December 31, 

    

December 31, 

  

​

    

2020

    

2019

​

Expected life (years)

​

5.3 – 6.3

​

5.2 – 6.2

 

Risk-free interest rate

​

0.31% - 1.70

%  

1.42% - 2.57

%

Volatility

​

69.8% - 82.7

%  

70.6% - 99.2

%

Dividend yield

​

0

%  

0

%
Schedule of share-based payment awards

Total stock-based compensation expense related to our share-based payment awards is comprised of the following (in thousands):

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

​

    

2020

    

2019

Cost of revenues

​

$

371

​

$

1,479

Selling, general and administrative

​

 

7,862

​

 

13,946

Engineering and development

​

 

683

​

 

1,098

​

​

$

8,916

​

$

16,523
Schedule of stock option activity

A summary of stock option activity is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

​

​

    

Weighted-

    

​

​

​

​

​

​

Weighted-

​

Average

​

​

​

​

​

​

​

Average

​

Remaining

​

Aggregate

​

​

Number of

​

Exercise

​

Contractual

​

Intrinsic

​

​

Shares

​

Price/Share

​

Term (Years)

​

Value (1)

Outstanding — December 31, 2018

 

5,757,305

​

$

5.16

 

  

 

​

  

Granted (weighted-average fair value of $13.55 per share)

 

1,544,850

​

​

13.55

 

  

 

​

  

Exercised

 

(544,565)

 

​

3.91

 

  

 

​

  

Forfeited

 

(78,009)

 

​

10.66

 

  

 

​

  

Outstanding — December 31, 2019

 

6,679,581

​

​

7.14

 

  

 

​

  

Granted (weighted-average fair value of $13.21 per share)

​

1,789,000

​

​

20.46

​

  

​

​

​

Exercised

 

(855,717)

 

​

6.73

 

  

 

​

​

Forfeited

 

(56,475)

 

​

13.39

 

  

 

​

​

Expired

 

(2,084)

 

​

19.56

 

  

 

​

​

Outstanding — December 31, 2020

 

7,554,305

​

$

10.29

 

6.6

​

$

254,393,000

Vested (exercisable) — December 31, 2020

 

5,862,122

​

$

7.41

 

5.9

​

$

213,769,400

Expected to vest after December 31, 2020 (unexercisable)

 

1,692,183

​

$

20.24

 

9.2

​

$

40,623,600

(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on December 31, 2020, which was $43.88 per share.
Stock Options [Member]  
Schedule of Information by Exercise Price Range

The following table summarizes information with respect to stock options outstanding and exercisable at December 31, 2020:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

Weighted-

    

​

​

    

​

    

​

​

​

​

​

​

Average

​

Weighted-

​

​

​

Weighted-

​

​

​

​

Remaining

​

Average

​

​

​

Average

​

​

Number

​

Contractual

​

Exercise

​

Number

​

Exercise

Exercise Price

​

Outstanding

​

Life (Years)

​

Price

​

Exercisable

​

Price

$1.08 – 3.07

 

894,024

 

4.7

​

$

2.25

 

894,024

​

$

2.25

$3.19 – 3.44

 

839,001

 

4.5

​

$

3.30

 

839,001

​

$

3.30

$4.56 – 4.92

 

658,437

 

4.5

​

$

4.80

 

658,437

​

$

4.80

$5.00 – 7.67

 

769,694

 

4.6

​

$

5.04

 

769,694

​

$

5.04

$7.80 – 8.65

 

961,979

 

6.0

​

$

8.28

 

952,229

​

$

8.28

$9.29 – 12.79

 

1,153,291

 

8.0

​

$

11.85

 

1,083,688

​

$

11.84

$13.37 – 16.95

 

1,598,304

 

9.0

​

$

16.41

 

498,801

​

$

15.73

$17.36 – 55.48

 

679,575

 

9.3

​

$

26.54

 

166,248

​

$

18.53

​

 

7,554,305

 

​

​

​

​

​

5,862,122

​

​

​

​
XML 60 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2020
Income Taxes  
Schedule of income before income tax, domestic and foreign

Income (loss) before provision for income taxes was attributed to the following jurisdictions for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

United States

​

$

(32,873)

​

$

(18,321)

Foreign

​

 

135

​

 

51

​

​

$

(32,738)

​

$

(18,270)
Schedule of components of provision (benefit) for income taxes

The provision (benefit) for income taxes consists of the following for the years ended December 31, 2020 and 2019 (in thousands):

​

​

​

​

​

​

​

​

​

​

Years Ended December 31, 

​

    

2020

    

2019

Current:

 

​

  

 

​

  

Federal

​

$

11

​

$

—

State

​

 

110

​

 

41

Foreign

​

 

361

​

 

—

Total current expense

​

 

482

​

 

41

​

​

​

​

​

​

​

Deferred:

​

 

​

​

 

​

Federal

​

 

(8,245)

​

 

(2,125)

State

​

 

(832)

​

 

5

Foreign

​

 

(738)

​

 

9

Change in valuation allowance

​

 

9,288

​

 

2,132

Total deferred expense

​

 

(527)

​

 

21

Total provision (benefit) for income taxes

​

$

(45)

​

$

62
Schedule of provision (benefit) for income taxes differs from that computed using the federal statutory rate applied to loss before provision for income taxes

The provision (benefit) for income taxes differs from that computed using the federal statutory rate applied to loss before provision for income taxes as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Computed tax benefit at federal statutory rate

​

$

(6,875)

​

$

(3,837)

State tax, net of federal benefit

​

 

(1,077)

​

 

(610)

Stock compensation

​

 

(2,683)

​

 

480

Interest expense

​

​

—

​

​

286

Permanent differences and other

​

 

(375)

​

 

(126)

Transaction cost

​

​

528

​

​

—

Executive compensation

​

​

609

​

​

985

Rate changes

​

​

408

​

​

—

Contingencies

​

 

112

​

 

753

Valuation allowance

​

 

9,308

​

 

2,131

​

​

$

(45)

​

$

62
Schedule of deferred tax assets and liabilities

Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2020 and 2019 are shown below (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

Deferred tax assets:

 

​

Net operating loss carryforward

​

$

27,106

​

$

17,031

Expenses recognized for granting of options and warrants

​

 

4,119

​

 

3,816

Accrued expenses and reserves

​

 

913

​

 

383

Lease liability

​

​

2,740

​

​

1,217

Total deferred tax assets

​

​

34,878

​

​

22,447

Valuation allowance

​

 

(32,913)

​

 

(21,220)

​

​

$

1,965

​

$

1,227

Deferred tax liabilities:

​

​

​

​

​

​

Goodwill

​

$

(529)

​

$

(110)

Right-of-use assets

​

​

(2,631)

​

​

(1,138)

Intangibles

​

​

(4,253)

​

​

​

Total deferred tax liability

​

​

(7,413)

​

​

(1,248)

Net deferred tax liability

​

$

(5,448)

​

$

(21)

​

Our net deferred tax liability as presented in our consolidated balance sheet consist of the following items (in thousands):

​

​

​

​

​

​

​

​

​

December 31,

​

    

2020

    

2019

Deferred tax assets

​

$

434

​

$

—

Deferred tax liabilities

​

 

(5,882)

​

 

(21)

Net deferred tax liability

​

$

(5,448)

​

$

(21)
Schedule of unrecognized tax benefits, excluding amounts pertaining to examined tax returns

A reconciliation of the beginning and ending amounts of unrecognized tax benefits (“UTBs”) are as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

December 31, 

​

    

2020

    

2019

UTBs, beginning of period

​

$

963

​

$

48

Gross increase – current period tax positions

​

 

358

​

 

239

Gross decrease – prior period tax positions

​

 

(113)

​

 

—

Gross increase – prior period tax positions

​

 

64

​

 

676

Expiration of statute of limitations

​

 

—

​

 

—

UTBs, end of period

​

$

1,272

​

$

963
XML 61 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Quarterly Financial Data (Tables)
 12 Months Ended
Dec. 31, 2020
Quarterly Financial Data  
Schedule of quarterly financial information

A summary of quarterly financial data is as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Quarter Ended

​

    

March 31

    

June 30

    

September 30

    

December 31

Year ended December 31, 2020

 

​

  

 

​

  

 

​

  

 

​

  

Total revenues

​

$

9,774

​

$

9,389

​

$

11,172

​

$

48,361

Gross margin

​

$

5,258

​

$

5,127

​

$

6,055

​

$

19,894

Loss from operations

​

$

(3,586)

​

$

(5,845)

​

$

(10,732)

​

$

(9,847)

Net loss attributable to common stockholders

​

$

(3,943)

​

$

(5,803)

​

$

(11,418)

​

$

(53,866)

Net loss per share attributable to common stockholders - basic and diluted

​

$

(0.11)

​

$

(0.15)

​

$

(0.29)

​

$

(1.32)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Year ended December 31, 2019

​

 

  

​

 

  

​

 

  

​

 

  

Total revenues

​

$

6,653

​

$

8,464

​

$

9,583

​

$

9,242

Gross margin

​

$

3,454

​

$

4,338

​

$

4,627

​

$

4,932

Loss from operations

​

$

(2,141)

​

$

(2,304)

​

$

(12,352)

​

$

(878)

Net loss

​

$

(2,387)

​

$

(2,528)

​

$

(12,469)

​

$

(948)

Net loss per share - basic and diluted

​

$

(0.08)

​

$

(0.08)

​

$

(0.35)

​

$

(0.03)
XML 62 R43.htm IDEA: XBRL DOCUMENT v3.20.4
Nature of the Business (Details)
€ in Millions, $ in Millions
 12 Months Ended
Oct. 01, 2020
USD ($)
Aug. 24, 2020
USD ($)
Aug. 21, 2020
EUR (€)
Aug. 21, 2020
USD ($)
Dec. 31, 2020
segment
Restructuring Cost and Reserve [Line Items]          
Number of Reportable Segments | segment         2
MVE          
Restructuring Cost and Reserve [Line Items]          
Cash consideration | $ $ 317.5 $ 320.0      
CRYOPDP          
Restructuring Cost and Reserve [Line Items]          
Cash consideration     € 49.0 $ 58.0  
Percentage of equity interest agreed to be acquired     100.00% 100.00%  
XML 63 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
May 31, 2020
Revenue Recognition [Line Items]                      
Revenues $ 48,361 $ 11,172 $ 9,389 $ 9,774 $ 9,242 $ 9,583 $ 8,464 $ 6,653 $ 78,696 $ 33,942  
Interest rate (as a percent) 3.00%               3.00%   3.00%
Global Logistics Solutions [Member]                      
Revenue Recognition [Line Items]                      
Revenues                 $ 78,696 33,942  
Biopharma/Pharma [Member] | Global Logistics Solutions [Member]                      
Revenue Recognition [Line Items]                      
Revenues                 66,394 30,032  
Animal Health [Member] | Global Logistics Solutions [Member]                      
Revenue Recognition [Line Items]                      
Revenues                 7,846 996  
Human Reproductive Medicine (Member) | Global Logistics Solutions [Member]                      
Revenue Recognition [Line Items]                      
Revenues                 $ 4,456 $ 2,914  
XML 64 R45.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Disaggregation of Revenue [Line Items]                    
Revenues $ 48,361 $ 11,172 $ 9,389 $ 9,774 $ 9,242 $ 9,583 $ 8,464 $ 6,653 $ 78,696 $ 33,942
Americas [Member]                    
Disaggregation of Revenue [Line Items]                    
Revenues                 49,555 28,801
Europe, the Middle East and Africa (EMEA) [Member]                    
Disaggregation of Revenue [Line Items]                    
Revenues                 20,316 4,523
Asia Pacific (APAC) [Member]                    
Disaggregation of Revenue [Line Items]                    
Revenues                 $ 8,825 $ 618
XML 65 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Summary of Significant Accounting Policies                    
Net loss                 $ (32,693) $ (18,332)
Deemed dividend on Series C convertible preferred stock                 (39,492)  
Paid-in-kind preferred stock dividend, including beneficial conversion feature                 (2,844)  
Net loss attributable to common stockholders $ (53,866) $ (11,418) $ (5,803) $ (3,943) $ (948) $ (12,469) $ (2,528) $ (2,387) $ (75,029) $ (18,332)
Weighted average common shares outstanding - basic and diluted                 38,582,432 33,394,285
Basic and diluted net loss per share $ (1.32) $ (0.29) $ (0.15) $ (0.11) $ (0.03) $ (0.35) $ (0.08) $ (0.08) $ (1.94) $ (0.55)
XML 66 R47.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Antidilutive Shares (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 17,205,023 4,390,017
Product warranty accrued liabilities $ 0.2 $ 0.0
Class C convertible preferred stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,474,135  
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,920,886 3,636,806
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount   753,211
Convertible Senior Notes [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 4,810,002  
XML 67 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Additional Information (Details)
 3 Months Ended 12 Months Ended
Jun. 29, 2020
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
segment
Dec. 31, 2019
USD ($)
Significant Accounting Policies Additional Information [Line Items]                      
Maturity Period Of Highly Liquid Investments                   90 days  
Allowance for doubtful accounts receivable   $ 1,100,000       $ 100,000       $ 1,100,000 $ 100,000
Revenues   48,361,000 $ 11,172,000 $ 9,389,000 $ 9,774,000 9,242,000 $ 9,583,000 $ 8,464,000 $ 6,653,000 78,696,000 33,942,000
Impairment of intangible assets                   0  
Material unrecognized Tax Benefits   $ 0       0       $ 0 0
Operating Loss Carryforwards, Percent                   80.00%  
Period over which foreign subsidiaries subject to examination by indian tax authorities                   3 years  
Amount of maximum allowed reasearch and development credit usage $ 5,000,000                    
Omit disclosure of the transaction price allocated to remaining performance obligations                   true  
Contract liabilities           $ 400,000         400,000
Contract with Customer, Liability, Revenue Recognized                   $ 400,000 100,000
Number of Reportable Segments | segment                   2  
Foreign Currency Transaction Gain (Loss), before Tax                   $ 5,200,000 2,900,000
Maximum [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Property, Plant and Equipment, Useful Life                   45 years  
Equipment and Furniture [Member] | Minimum [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Property, Plant and Equipment, Useful Life                   3 years  
Equipment and Furniture [Member] | Maximum [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Property, Plant and Equipment, Useful Life                   15 years  
Building [Member] | Minimum [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Property, Plant and Equipment, Useful Life                   20 years  
Computer Equipment [Member] | Minimum [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Property, Plant and Equipment, Useful Life                   3 years  
Computer Equipment [Member] | Maximum [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Property, Plant and Equipment, Useful Life                   12 years  
Freezer (Member) | Minimum [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Property, Plant and Equipment, Useful Life                   7 years  
Freezer (Member) | Maximum [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Property, Plant and Equipment, Useful Life                   10 years  
Truck and Auto (Member) | Minimum [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Property, Plant and Equipment, Useful Life                   4 years  
Truck and Auto (Member) | Maximum [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Property, Plant and Equipment, Useful Life                   10 years  
Foreign Customers [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Revenues                   $ 29,100,000 $ 5,100,000
Accounts Receivable [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Concentration risk, percentage                   10.00% 10.00%
Accounts Receivable [Member] | Customer One [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Concentration risk, percentage                     31.00%
Accounts Receivable [Member] | Customer Two [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Concentration risk, percentage                     20.70%
Sales Revenue, Net [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Concentration risk, percentage                   10.00% 10.00%
Sales Revenue, Net [Member] | Customer One [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Concentration risk, percentage                   24.10%  
Sales Revenue, Net [Member] | Customer Two [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Concentration risk, percentage                   12.80%  
Sales Revenue, Net [Member] | Foreign Customers [Member]                      
Significant Accounting Policies Additional Information [Line Items]                      
Concentration risk, percentage                   37.00% 15.10%
XML 68 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details
€ in Millions
Oct. 01, 2020
USD ($)
Oct. 01, 2020
EUR (€)
May 14, 2019
USD ($)
May 04, 2019
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Purchase price allocation:            
Deferred tax liability $ (5,700,000)          
Goodwill         $ 145,282,000 $ 11,000,000
CRYOPDP            
Business Acquisition [Line Items]            
Total purchase consideration paid 56,971,000 € 48.3        
Purchase price allocation:            
Cash and cash equivalents 8,346,000          
Accounts receivable 10,603,000          
Inventories 644,000          
Prepaid and other current assets 2,905,000          
Property and equipment 2,863,000          
Operating lease right-of-use assets 1,856,000          
Intangible assets 28,235,000          
Other long-term assets 569,000          
Accounts payable and other accrued expenses (11,110,000)          
Accrued compensation and related expenses (1,194,000)          
Deferred revenue (370,000)          
Note payable (4,690,000)          
Operating lease liabilities (1,856,000)          
Deferred tax liability (5,311,000)          
Other long-term liabilities (64,000)          
Total identifiable net assets 31,426,000          
Goodwill 25,545,000          
Net assets acquired 56,971,000          
CryoGene Partners [Member]            
Business Acquisition [Line Items]            
Total purchase consideration paid     $ 20,317,000 $ 20,300,000    
Purchase price allocation:            
Property and equipment     4,257,000      
Intangible assets     5,280,000   $ 5,280  
Deferred revenue     (220,000)      
Total identifiable net assets     9,317,000      
Goodwill     11,000,000      
Net assets acquired     $ 20,317,000      
MVE            
Business Acquisition [Line Items]            
Total purchase consideration paid 317,470,000          
Purchase price allocation:            
Cash and cash equivalents 2,955,000          
Accounts receivable 10,645,000          
Inventories 10,627,000          
Prepaid and other current assets 256,000          
Property and equipment 9,050,000          
Operating lease right-of-use assets 2,154,000          
Intangible assets 184,991,000          
Other long-term assets 358,000          
Accounts payable and other accrued expenses (6,036,000)          
Accrued compensation and related expenses (1,139,000)          
Operating lease liabilities (2,160,000)          
Deferred tax liability (393,000)          
Other long-term liabilities (64,000)          
Total identifiable net assets 211,244,000          
Goodwill 106,226,000          
Net assets acquired $ 317,470,000          
XML 69 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Acquisition of CryoGene Partners - Preliminary Fair Value of Intangible Assets (Details)
€ in Millions
 12 Months Ended
Oct. 01, 2020
USD ($)
Aug. 24, 2020
USD ($)
Aug. 21, 2020
USD ($)
Aug. 21, 2020
EUR (€)
May 14, 2019
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Business Acquisition [Line Items]              
Amortization Expense           $ 6,600,000 $ 300,000
Goodwill           145,282,000 $ 11,000,000
CryoGene Partners [Member]              
Business Acquisition [Line Items]              
Annual Estimated Fair Value         $ 5,280,000 5,280  
Amortization Expense           $ 537  
Goodwill         11,000,000    
Business Acquisition, Transaction Costs         300,000    
CryoGene Partners [Member] | Non-compete agreement              
Business Acquisition [Line Items]              
Annual Estimated Fair Value         $ 390    
Estimated Useful Life         5 years    
Amortization Expense         $ 78    
CryoGene Partners [Member] | Technology              
Business Acquisition [Line Items]              
Annual Estimated Fair Value         $ 510    
Estimated Useful Life         5 years    
Amortization Expense         $ 102    
CryoGene Partners [Member] | Customer relationships              
Business Acquisition [Line Items]              
Annual Estimated Fair Value         $ 3,900    
Estimated Useful Life         12 years    
Amortization Expense         $ 325    
CryoGene Partners [Member] | Trade name/trademarks              
Business Acquisition [Line Items]              
Annual Estimated Fair Value         $ 480    
Estimated Useful Life         15 years    
Amortization Expense         $ 32    
CRYOPDP              
Business Acquisition [Line Items]              
Annual Estimated Fair Value $ 28,235,000            
Amortization Expense 3,077,000            
Goodwill 25,545,000            
Business Acquisition, Transaction Costs 1,400,000            
Cash consideration     $ 58,000,000.0 € 49.0      
CRYOPDP | Customer relationships              
Business Acquisition [Line Items]              
Annual Estimated Fair Value $ 5,871,000            
Estimated Useful Life 11 years 6 months            
Amortization Expense $ 511,000            
CRYOPDP | Trade name/trademarks              
Business Acquisition [Line Items]              
Annual Estimated Fair Value 10,567,000            
CRYOPDP | Software              
Business Acquisition [Line Items]              
Annual Estimated Fair Value $ 3,578,000            
Estimated Useful Life 7 years            
Amortization Expense $ 511,000            
CRYOPDP | Agent network              
Business Acquisition [Line Items]              
Annual Estimated Fair Value $ 8,219,000            
Estimated Useful Life 4 years            
Amortization Expense $ 2,055,000            
MVE              
Business Acquisition [Line Items]              
Annual Estimated Fair Value 184,991,000            
Amortization Expense 10,634,000            
Goodwill 106,226,000            
Goodwill expected to be deductible for income tax purposes 62,500,000            
Business Acquisition, Transaction Costs 8,800,000            
Cash consideration 317,500,000 $ 320,000,000          
MVE | Customer relationships              
Business Acquisition [Line Items]              
Annual Estimated Fair Value $ 118,600,000            
Estimated Useful Life 14 years 6 months            
Amortization Expense $ 8,179,000            
MVE | Trade name/trademarks              
Business Acquisition [Line Items]              
Annual Estimated Fair Value 32,800,000            
MVE | Order backlog              
Business Acquisition [Line Items]              
Annual Estimated Fair Value $ 2,600,000            
Estimated Useful Life 1 month 15 days            
MVE | Developed technology              
Business Acquisition [Line Items]              
Annual Estimated Fair Value $ 28,700,000            
Estimated Useful Life 12 years            
Amortization Expense $ 2,392,000            
MVE | Land use rights              
Business Acquisition [Line Items]              
Annual Estimated Fair Value $ 2,291,000            
Estimated Useful Life 38 years            
Amortization Expense $ 63,000            
XML 70 R51.htm IDEA: XBRL DOCUMENT v3.20.4
Acquisition of CryoGene Partners - Pro Forma Information (Details)
$ / shares in Units, € in Millions
 12 Months Ended
Oct. 01, 2020
EUR (€)
Oct. 01, 2020
USD ($)
May 14, 2019
USD ($)
May 04, 2019
USD ($)
Dec. 31, 2020
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
$ / shares
Business Acquisition [Line Items]            
Revenues         $ 172,147,000 $ 163,217,000
Net loss         $ (18,562,000) $ (3,149,000)
Basic and diluted net loss per share | $ / shares         $ (2.08) $ (0.09)
CryoGene Partners [Member]            
Business Acquisition [Line Items]            
Revenues         $ 3,000,000.0 $ 3,000,000.0
Net loss         437,100 437,100
Total purchase consideration paid     $ 20,317,000 $ 20,300,000    
CRYOPDP            
Business Acquisition [Line Items]            
Revenues         12,900,000  
Net loss         1,800,000  
Total purchase consideration paid € 48.3 $ 56,971,000        
MVE            
Business Acquisition [Line Items]            
Elimination of revenue           1,800,000
Elimination of cost of goods sold           $ 900,000
Revenues         23,000,000.0  
Net loss         $ 1,800,000  
Total purchase consideration paid   $ 317,470,000        
XML 71 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Cash, Cash Equivalents and Short-Term Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Cash and Cash Equivalents    
Cash $ 25,053 $ 3,547
Cash equivalents:    
Money market mutual fund 11,820 43,688
Total cash and cash equivalents 36,873 47,235
Short-term investments:    
Total short-term investments 56,444 47,061
Cash, cash equivalents and short-term investments 93,317 94,296
U.S. Treasury notes and bills [Member]    
Short-term investments:    
Short-term Investments 23,309 21,094
Mutual Funds [Member]    
Short-term investments:    
Short-term Investments $ 33,135 $ 25,967
XML 72 R53.htm IDEA: XBRL DOCUMENT v3.20.4
Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Amortized Cost $ 23,179 $ 21,122
Unrealized Gains 173 26
Unrealized Losses (43) (54)
Fair Value 23,309 21,094
U.S. Treasury notes    
Amortized Cost 23,179 21,122
Unrealized Gains 173 26
Unrealized Losses (43) (54)
Fair Value $ 23,309 $ 21,094
XML 73 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Cash, Cash Equivalents and Short-Term Investments    
Due within one year, Amortized Cost $ 14,084 $ 12,044
Due between one and two years, Amortized Cost 9,095 9,078
Total, Amortized Cost 23,179 21,122
Due within one year, Fair Value 14,111 12,047
Due between one and two years, Fair Value 9,198 9,047
Total, Fair Value $ 23,309 $ 21,094
XML 74 R55.htm IDEA: XBRL DOCUMENT v3.20.4
Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash, Cash Equivalents and Short-Term Investments    
Net losses recognized during the year on equity securities $ (245) $ (102)
Less: net losses recognized during the year on equity securities sold during the year (1,090) 0
Unrealized gains (losses) recognized during the year on equity securities still held at December 31, 2020 and 2019 $ 845 $ (102)
XML 75 R56.htm IDEA: XBRL DOCUMENT v3.20.4
Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash, Cash Equivalents and Short-Term Investments    
Losses on available-for-sale investments $ 32,400 $ 81,700
Equity Securities, FV-NI $ 33,100,000 $ 26,000,000.0
XML 76 R57.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Assets, Fair Value Disclosure $ 68,264 $ 90,749
Mutual funds    
Assets, Fair Value Disclosure 33,135 25,967
U.S. Treasury notes    
Assets, Fair Value Disclosure 23,309 21,094
Money market mutual fund    
Assets, Fair Value Disclosure 11,820 43,688
Fair Value, Inputs, Level 1 [Member]    
Assets, Fair Value Disclosure 68,264 90,749
Fair Value, Inputs, Level 1 [Member] | Mutual funds    
Assets, Fair Value Disclosure 33,135 25,967
Fair Value, Inputs, Level 1 [Member] | U.S. Treasury notes    
Assets, Fair Value Disclosure 23,309 21,094
Fair Value, Inputs, Level 1 [Member] | Money market mutual fund    
Assets, Fair Value Disclosure 11,820 43,688
Fair Value, Inputs, Level 2 [Member]    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 2 [Member] | Mutual funds    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 2 [Member] | U.S. Treasury notes    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 2 [Member] | Money market mutual fund    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member]    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member] | Mutual funds    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member] | U.S. Treasury notes    
Assets, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member] | Money market mutual fund    
Assets, Fair Value Disclosure $ 0 $ 0
XML 77 R58.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements - Additional Information (Details)
$ in Millions
Dec. 31, 2020
USD ($)
Fair Value Measurements  
Convertible Senior notes $ 108.2
XML 78 R59.htm IDEA: XBRL DOCUMENT v3.20.4
Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Inventories    
Raw materials $ 7,544 $ 357
Work-in-process 227  
Finished goods 2,764 117
Inventory, Net, Total 10,535 $ 474
Step up inventory related to acquisition $ 800  
XML 79 R60.htm IDEA: XBRL DOCUMENT v3.20.4
Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Property and Equipment    
Cryogenic shippers and data loggers $ 5,625 $ 4,296
Freezers 4,473 3,414
Furniture and fixtures 2,727 291
Computers and software 1,469 646
Machinery and equipment 11,998 1,093
Trucks and autos 437 37
Leasehold improvements 4,599 2,246
Buildings 5,359 0
Land 790 0
Fixed assets in process 8,070 3,407
Property, Plant and Equipment, Gross 45,547 15,430
Less accumulated depreciation and amortization (15,511) (3,597)
Property, Plant and Equipment, Net, Total $ 30,036 $ 11,833
XML 80 R61.htm IDEA: XBRL DOCUMENT v3.20.4
Property and Equipment - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Property and Equipment    
Depreciation $ 3,200,000 $ 2,100,000
Capital leased assets, gross 279,400 71,000
Capital leases, lessee balance sheet, assets by major class, accumulated depreciation $ 78,700 $ 22,800
XML 81 R62.htm IDEA: XBRL DOCUMENT v3.20.4
Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
May 14, 2019
Gross Amount $ 221,642 $ 5,538  
Accumulated Amortization 7,734 360  
Future amortization of intangible assets 213,908 5,178  
Goodwill 145,282 11,000  
CryoGene Partners [Member]      
Goodwill     $ 11,000
Cryoport patents and trademarks      
Gross Amount 44,312 258  
Accumulated Amortization 69 47  
Future amortization of intangible assets 44,243 $ 211  
Weighted Average Amortization Period (years)   0 years  
Non-compete agreement      
Gross Amount 390 $ 390  
Accumulated Amortization 123 45  
Future amortization of intangible assets $ 267 $ 345  
Weighted Average Amortization Period (years) 3 years 5 years  
Technology      
Gross Amount $ 34,245 $ 510  
Accumulated Amortization 1,630 59  
Future amortization of intangible assets $ 32,615 $ 451  
Weighted Average Amortization Period (years) 11 years 5 years  
Customer relationships      
Gross Amount $ 128,640 $ 3,900  
Accumulated Amortization 2,708 190  
Future amortization of intangible assets $ 125,932 $ 3,710  
Weighted Average Amortization Period (years) 14 years 12 years  
Trade name/trademarks      
Gross Amount $ 480 $ 480  
Accumulated Amortization 51 19  
Future amortization of intangible assets $ 429 $ 461  
Weighted Average Amortization Period (years) 13 years 15 years  
Order backlog      
Gross Amount $ 2,600    
Accumulated Amortization 2,600    
Land use rights      
Gross Amount 2,378    
Accumulated Amortization 16    
Future amortization of intangible assets $ 2,362    
Weighted Average Amortization Period (years) 37 years    
Agent network      
Gross Amount $ 8,597    
Accumulated Amortization 537    
Future amortization of intangible assets $ 8,060    
Weighted Average Amortization Period (years) 0 years    
XML 82 R63.htm IDEA: XBRL DOCUMENT v3.20.4
Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Goodwill and Intangible Assets    
Amortization of Intangible Assets $ 6,600 $ 300
2021 14,438  
2022 14,438  
2023 14,438  
2024 13,795  
2025 12,108  
Thereafter 100,124  
Future amortization of intangible assets 213,908 $ 5,178
Future Amortization of Finite Lived Intangible Assets $ 169,341  
XML 83 R64.htm IDEA: XBRL DOCUMENT v3.20.4
Goodwill and Other Intangible Assets - Schedule of goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Goodwill [Roll Forward]    
Beginning Balance $ 11,000  
Ending Balance 145,282 $ 11,000
CryoGene Partners [Member]    
Goodwill [Roll Forward]    
Additions   $ 11,000
MVE    
Goodwill [Roll Forward]    
Additions 107,504  
CRYOPDP    
Goodwill [Roll Forward]    
Additions $ 26,778  
XML 84 R65.htm IDEA: XBRL DOCUMENT v3.20.4
Accrued Compensation and Related Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Accrued Compensation and Related Expenses    
Accrued salaries and wages $ 6,048 $ 1,386
Accrued paid time off 1,393 518
Accrued compensation and related expenses, Total $ 7,441 $ 1,904
XML 85 R66.htm IDEA: XBRL DOCUMENT v3.20.4
Convertible Senior Notes - Components of Convertible notes payable (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
Convertible Senior Notes  
Principal amount of Senior Notes $ 115,000
Unamortized debt issuance costs (3,656)
Net carrying value of Notes payable $ 111,344
XML 86 R67.htm IDEA: XBRL DOCUMENT v3.20.4
Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Convertible Senior Notes  
Coupon interest $ 2,108
Amortization of debt issuance costs 437
Total interest expense on Notes $ 2,545
XML 87 R68.htm IDEA: XBRL DOCUMENT v3.20.4
Convertible Senior Notes - Additional information (Details)
 1 Months Ended 12 Months Ended
May 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
item
$ / shares
shares
Dec. 14, 2018
Debt Instrument [Line Items]      
Aggregate principal amount $ 115,000,000.0 $ 1,000  
Interest rate (as a percent) 3.00% 3.00%  
Underwriting discounts and commissions $ 3,700,000    
Common stock issued upon conversion of notes | shares   4,810,002  
Conversion rate   130  
Interest expense   $ 300,000  
Initial conversion price (in dollars per share) | $ / shares   $ 23.91  
Threshold maximum conversion rate   $ 48.10  
Debt issuance costs   $ 4,100,000  
Long-term Debt, Term   5 years  
Debt Instrument, Interest Rate, Stated Percentage   3.74%  
Notes payable, 2025   $ 115,000,000.0  
Threshold maximum combined interest rate (as a percent)   0.50%  
Cash payment to each noteholder (as a percent)   3.00%  
Senior Notes      
Debt Instrument [Line Items]      
Common stock issued upon conversion of notes | shares   4,810,002  
Initial conversion price (in dollars per share) | $ / shares   $ 41.8261  
Convertible Note [Member]      
Debt Instrument [Line Items]      
Debt Instrument, Interest Rate, Stated Percentage     3.00%
Private Placement      
Debt Instrument [Line Items]      
Aggregate principal amount 15,000,000.0    
Proceeds from the offering 111,300,000    
Third-party offering related costs $ 300,000    
First 90 days beginning on, and including the date on which such Registration Default occurs      
Debt Instrument [Line Items]      
Threshold trading days for redemption of notes | item   20  
Additional interest rate (as a percent)   0.25%  
After 90 days of the occurrence of Registration Default      
Debt Instrument [Line Items]      
Threshold consecutive trading days for redemption of notes | item   30  
Additional interest rate (as a percent)   0.50%  
XML 88 R69.htm IDEA: XBRL DOCUMENT v3.20.4
Note Payable (Details)
$ in Thousands, € in Millions
 12 Months Ended
Dec. 31, 2020
USD ($)
item
Dec. 31, 2020
EUR (€)
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]      
Note payable | $ $ 4,912   $ 0
CRYOPDP      
Debt Instrument [Line Items]      
Number of installment | item 2    
Note payable $ 4,900 € 4.0  
CRYOPDP | repaid in 2025      
Debt Instrument [Line Items]      
Note payable 600 0.5  
CRYOPDP | repaid in 2028      
Debt Instrument [Line Items]      
Note payable $ 4,300 € 3.5  
XML 89 R70.htm IDEA: XBRL DOCUMENT v3.20.4
Leases - Components Of Lease Cost (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Leases    
Operating lease cost $ 1,835 $ 758
Finance lease cost:    
Amortization of right-of-use assets 56 10
Interest on finance lease liabilities 10 3
Total finance lease cost 66 13
Total lease cost $ 1,901 $ 771
XML 90 R71.htm IDEA: XBRL DOCUMENT v3.20.4
Leases - Supplemental Cash Flows Information (Detail)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Cash paid for amounts included in the measurement of lease liabilities:  
Operating cash flows from operating leases $ 1,680
Operating cash flows from finance leases 77
Financing cash flows from finance leases 67
Right-of-use assets obtained in exchange for lease obligations:  
Operating leases 10,708
Finance leases $ 203
Weighted-Average Remaining Lease Term  
Operating leases 6 years 7 months 6 days
Finance leases 2 years 10 months 24 days
Weighted-Average Discount Rate  
Operating leases 5.50%
Finance leases 5.40%
XML 91 R72.htm IDEA: XBRL DOCUMENT v3.20.4
Leases - Payments Under Non-Cancellable Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Operating Leases    
2021 $ 3,103  
2022 3,261  
2023 2,498  
2024 1,985  
2025 1,696  
Thereafter 5,402  
Total future minimum lease payments 17,945  
Less imputed interest (3,453)  
Current lease liabilities 2,231 $ 666
Noncurrent lease liabilities 12,261 4,101
Total 14,492  
Finance Leases    
2021 67  
2022 57  
2023 60  
Total future minimum lease payments 184  
Less imputed interest (13)  
Current lease liabilities 59 25
Noncurrent lease liabilities 112 $ 9
Total $ 171  
XML 92 R73.htm IDEA: XBRL DOCUMENT v3.20.4
Leases - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Lessee Option to Extend 5 years  
Finance Lease, Right-of-Use Asset $ 279,400 $ 71,000
Finance Lease Right-of-Use Asset Accumulated Depreciation $ 78,700 $ 22,800
Minimum [Member]    
Lease Weighted Average Remaining Lease Term 1 year  
Maximum [Member]    
Lease Weighted Average Remaining Lease Term 9 years  
XML 93 R74.htm IDEA: XBRL DOCUMENT v3.20.4
Employee Benefit Plans (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
US employees    
Defined Contribution Plan Disclosure [Line Items]    
Maximum employee contribution 100.00%  
Maximum matching employer contribution per employee 4.00%  
Recognized expense $ 0.3 $ 0.2
Total benefit obligation 0.1 0.0
Non US employees    
Defined Contribution Plan Disclosure [Line Items]    
Total benefit obligation $ 0.3 $ 0.0
XML 94 R75.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)
 12 Months Ended
Dec. 31, 2020
shares
Class of Stock [Line Items]  
Common Stock Reserved for Future Issuance 18,838,442
Common stock issued upon conversion of notes 4,810,002
Stock Options [Member]  
Class of Stock [Line Items]  
Common Stock Reserved for Future Issuance 7,554,305
Warrants [Member]  
Class of Stock [Line Items]  
Common stock issued upon conversion of notes 18,800,000
Class C convertible preferred stock  
Class of Stock [Line Items]  
Common Stock Reserved for Future Issuance 6,474,135
XML 95 R76.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity - Additional Information (Details)
 12 Months Ended
Feb. 05, 2021
$ / shares
shares
Oct. 01, 2020
USD ($)
item
$ / shares
shares
Jun. 24, 2019
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
$ / shares
shares
Oct. 31, 2019
shares
Class of Stock [Line Items]            
Common stock, shares authorized | shares       100,000,000 100,000,000  
Common stock, par value per share (in dollars per share) | $ / shares   $ 0.001   $ 0.001 $ 0.001  
Stock Issued During Period, Shares, Issued for Services | shares     562,500      
Preferred stock, par value per share (in dollars per share) | $ / shares       $ 0.001 $ 0.001  
Preferred stock, shares authorized | shares     4,312,500 2,500,000 2,500,000  
Shares issued, price per share (in dollars per share) | $ / shares     $ 17.00      
Proceeds from issuance of stock       $ 237,225,000 $ 0  
Common stock, par value per share (in dollars per share) | $ / shares   $ 0.001   $ 0.001 $ 0.001  
Proceeds from issuance of common stock, net of issuance costs       $ 28,160,000 $ 0  
Dividends, paid-in-kind       2,500,000    
Deemed dividend   $ 39,500,000        
Proceeds from public offering, net of offering costs     $ 68,800,000 $ 0 $ 68,811,000  
Common stock, shares issued | shares       39,837,058 37,339,787 15.0
Common stock issued upon conversion of notes | shares       4,810,002    
Warrants [Member]            
Class of Stock [Line Items]            
Common stock issued upon conversion of notes | shares       18,800,000    
Director [Member]            
Class of Stock [Line Items]            
Stock Issued During Period, Shares, Issued for Services | shares       2,869 5,753  
Stock Issued During Period, Value, Issued for Services       $ 82,700 $ 91,000  
Class A convertible preferred stock [Member]            
Class of Stock [Line Items]            
Preferred stock, par value per share (in dollars per share) | $ / shares       $ 0.001 $ 0.001  
Preferred stock, shares authorized | shares       800,000 800,000  
Class B convertible preferred stock [Member]            
Class of Stock [Line Items]            
Preferred stock, par value per share (in dollars per share) | $ / shares       $ 0.001 $ 0.001  
Preferred stock, shares authorized | shares       585,000 585,000  
Class C convertible preferred stock            
Class of Stock [Line Items]            
Preferred stock, par value per share (in dollars per share) | $ / shares       $ 0.001 $ 0.001  
Preferred stock, shares authorized | shares       250,000 250,000  
Dividends, paid-in-kind       $ 300,000    
Liquidation preference (in dollars per share) | $ / shares   $ 1,000        
Conversion price (in dollars per share) | $ / shares   $ 38.6152        
Conversion rate   25.90        
Shares to be issued upon conversion | shares   6,474,135        
Threshold trading days for conversion of preferred stock   20        
Threshold consecutive trading days for conversion of preferred stock   30        
Stock price trigger as a percentage of conversion price for conversion of preferred stock   150.00%        
Dividend rate on shares not repurchased   5.50%        
Number of member to the board of directors who can be elected by the preferred stock holders | item   1        
Percentage of stock to be held to exercise the right to nominate member of board of directors   66.67%        
Class C convertible preferred stock | Prior to the 180-day anniversary of October 1, 2020            
Class of Stock [Line Items]            
Number of shares to be redeemed | shares   50,000        
Redemption price (as a percent)   125.00%        
Class C convertible preferred stock | At any time beginning five years after Closing Date (but prior to six years after the Closing Date)            
Class of Stock [Line Items]            
Redemption price (as a percent)   105.00%        
Class C convertible preferred stock | At any time beginning six years after Closing Date            
Class of Stock [Line Items]            
Redemption price (as a percent)   100.00%        
Private Placement            
Class of Stock [Line Items]            
Proceeds from issuance of common stock, net of issuance costs   $ 25,000,000.0        
Aggregate purchase price   275,000,000.0        
Reimbursement of transactional expenses   1,000,000.0        
Net proceeds from private placement   265,400,000        
Direct and incremental expenses   $ 8,600,000        
Private Placement | Class C convertible preferred stock            
Class of Stock [Line Items]            
Shares issued (in shares) | shares   250,000        
Preferred stock, dividend rate (as a percent)   4.00%        
Preferred stock, par value per share (in dollars per share) | $ / shares   $ 0.001        
Shares issued, price per share (in dollars per share) | $ / shares   $ 1,000        
Proceeds from issuance of stock   $ 250.0        
Net proceeds from private placement   $ 28,200,000        
Private Placement | Common Stock [Member]            
Class of Stock [Line Items]            
Shares issued (in shares) | shares   675,536        
Net proceeds from private placement   $ 237,200,000        
Subsequent Event | Class C convertible preferred stock            
Class of Stock [Line Items]            
Shares issued (in shares) | shares 50,000          
Liquidation preference (in dollars per share) | $ / shares $ 1,000          
Subsequent Event | Class C convertible preferred stock | Prior to the 180-day anniversary of October 1, 2020            
Class of Stock [Line Items]            
Number of shares to be redeemed | shares 50,000          
Subsequent Event | Common Stock [Member]            
Class of Stock [Line Items]            
Common stock, par value per share (in dollars per share) | $ / shares $ 0.001          
Common stock, par value per share (in dollars per share) | $ / shares 0.001          
Conversion price (in dollars per share) | $ / shares $ 38.6152          
Shares to be issued upon conversion | shares 1,312,860          
XML 96 R77.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Warrant Activity (Details) - Warrants [Member] - $ / shares
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Number of Shares      
Outstanding 1,001,028 2,049,534  
Issued 0   0
Exercised (963,149) (1,027,546)  
Expired (37,879) (20,960)  
Outstanding   1,001,028 2,049,534
Weighted-Average Exercise Price/Share      
Outstanding $ 3.83 $ 4.03  
Issued 0   $ 0
Exercised 3.80 3.95  
Expired $ 4.58 17.78  
Outstanding   $ 3.83 $ 4.03
Weighted-Average Remaining Contractual Term (Years)      
Outstanding 0 years    
Vested (exercisable) 0 years    
XML 97 R78.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Risk-free interest rate, minimum 0.31% 1.42%
Risk-free interest rate, maximum 1.70% 2.57%
Volatility, minimum 69.80% 70.60%
Volatility, maximum 82.70% 99.20%
Dividend yield 0.00% 0.00%
Minimum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected life (years) 5 years 3 months 18 days 5 years 2 months 12 days
Maximum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected life (years) 6 years 3 months 18 days 6 years 2 months 12 days
XML 98 R79.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Stock-based Compensation Expense (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Stock-based compensation expense $ 8,916 $ 16,523
Cost of Revenues [Member]    
Stock-based compensation expense 371 1,479
Selling, General and Administrative Expenses [Member]    
Stock-based compensation expense 7,862 13,946
Engineering And Development [Member]    
Stock-based compensation expense $ 683 $ 1,098
XML 99 R80.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Stock Option Activity (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Stock Options [Member]      
Number of Shares      
Outstanding 6,679,581 5,757,305  
Granted 1,789,000 1,544,850  
Exercised (855,717) (544,565)  
Forfeited (56,475) (78,009)  
Expired (2,084)    
Outstanding 7,554,305 6,679,581 5,757,305
Vested (exercisable) 5,862,122    
Expected to vest after (unexercisable) 1,692,183    
Weighted-Average Exercise Price/Share      
Outstanding $ 7.14 $ 5.16  
Granted 20.46 13.55  
Exercised 6.73 3.91  
Forfeited 13.39 10.66  
Expired 19.56    
Outstanding 10.29 7.14 $ 5.16
Vested (exercisable) 7.41    
Expected to vest after (unexercisable) $ 20.24    
Weighted-Average Remaining Contractual Term (Years)      
Outstanding 6 years 7 months 6 days    
Vested (exercisable) 5 years 10 months 24 days    
Expected to vest after (unexercisable) 9 years 2 months 12 days    
Aggregated Intrinsic Value      
Outstanding $ 254,393,000    
Vested (exercisable) 213,769,400    
Expected to vest after (unexercisable) $ 40,623,600    
Weighted-average fair value per share $ 13.21 $ 13.55  
Warrants [Member]      
Number of Shares      
Outstanding 1,001,028 2,049,534  
Granted 0   0
Exercised (963,149) (1,027,546)  
Expired (37,879) (20,960)  
Outstanding   1,001,028 2,049,534
Weighted-Average Exercise Price/Share      
Outstanding $ 3.83 $ 4.03  
Granted 0   $ 0
Exercised 3.80 3.95  
Expired $ 4.58 17.78  
Outstanding   $ 3.83 $ 4.03
Weighted-Average Remaining Contractual Term (Years)      
Outstanding 0 years    
Vested (exercisable) 0 years    
XML 100 R81.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) - Stock Options [Member]
 12 Months Ended
Dec. 31, 2020
$ / shares
shares
Number Outstanding 7,554,305
Number Exercisable 5,862,122
$1.08 - 3.07 [Member]  
Number Outstanding 894,024
Weighted-Average Remaining Contractual Life (Years) 4 years 8 months 12 days
Weighted-Average Exercise Price | $ / shares $ 2.25
Number Exercisable 894,024
Weighted-Average Exercise Price | $ / shares $ 2.25
$3.19 - 3.44 [Member]  
Number Outstanding 839,001
Weighted-Average Remaining Contractual Life (Years) 4 years 6 months
Weighted-Average Exercise Price | $ / shares $ 3.30
Number Exercisable 839,001
Weighted-Average Exercise Price | $ / shares $ 3.30
$4.56 - 4.92 [Member]  
Number Outstanding 658,437
Weighted-Average Remaining Contractual Life (Years) 4 years 6 months
Weighted-Average Exercise Price | $ / shares $ 4.80
Number Exercisable 658,437
Weighted-Average Exercise Price | $ / shares $ 4.80
$5.00 - 7.67 [Member]  
Number Outstanding 769,694
Weighted-Average Remaining Contractual Life (Years) 4 years 7 months 6 days
Weighted-Average Exercise Price | $ / shares $ 5.04
Number Exercisable 769,694
Weighted-Average Exercise Price | $ / shares $ 5.04
$7.80 - 8.65 [Member]  
Number Outstanding 961,979
Weighted-Average Remaining Contractual Life (Years) 6 years
Weighted-Average Exercise Price | $ / shares $ 8.28
Number Exercisable 952,229
Weighted-Average Exercise Price | $ / shares $ 8.28
$9.29 - 12.79 [Member]  
Number Outstanding 1,153,291
Weighted-Average Remaining Contractual Life (Years) 8 years
Weighted-Average Exercise Price | $ / shares $ 11.85
Number Exercisable 1,083,688
Weighted-Average Exercise Price | $ / shares $ 11.84
$13.37 - 16.95 [Member]  
Number Outstanding 1,598,304
Weighted-Average Remaining Contractual Life (Years) 9 years
Weighted-Average Exercise Price | $ / shares $ 16.41
Number Exercisable 498,801
Weighted-Average Exercise Price | $ / shares $ 15.73
$17.36 - 55.48 [Member]  
Number Outstanding 679,575
Weighted-Average Remaining Contractual Life (Years) 9 years 3 months 18 days
Weighted-Average Exercise Price | $ / shares $ 26.54
Number Exercisable 166,248
Weighted-Average Exercise Price | $ / shares $ 18.53
XML 101 R82.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Additional Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
May 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $ 6,500,000 $ 24,100,000 $ 6,500,000  
Warrants Exercised Intrinsic Value   17,600,000 12,400,000  
Proceeds from Warrant Exercises   9,388,000 $ 5,363,000  
Stock Issued During Period Shares Cashless Exercise Of Warrants     117,663  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 159,583   159,583  
Accelerated stock-based compensation expense $ 1,227,890 $ 0 $ 9,562,000  
Warrants [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Intrinsic value per share   $ 43.88    
Proceeds from Warrant Exercises   $ 3,700,000 $ 3,400,000  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 985,626 963,149 985,626  
Stock Options [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized compensation cost related to unvested stock options   $ 21,100,000    
Weighted average recognition period   3 years 1 month 6 days    
Intrinsic value per share   $ 43.88    
Cost of Revenues [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Accelerated stock-based compensation expense     $ 400,000  
Selling, General and Administrative Expenses [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Accelerated stock-based compensation expense     9,400,000  
Engineering And Development [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Accelerated stock-based compensation expense     $ 900,000  
Plan 2018 [Member] | Stock Options [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total shares available for future grant   921,288   3,730,179
XML 102 R83.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Loss Before Provision For Income Taxes) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest $ (32,738) $ (18,270)
Domestic Tax Authority [Member]    
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest (32,873) (18,321)
Foreign Tax Authority [Member]    
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest $ 135 $ 51
XML 103 R84.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Expense For Income Taxes) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Current:    
Federal $ 11 $ 0
State 110 41
Foreign 361 0
Total current expense 482 41
Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]    
Federal (8,245) (2,125)
State (832) 5
Foreign (738) 9
Change in valuation allowance 9,288 2,132
Total deferred expense (527) 21
Income Tax Expense (Benefit), Total $ (45) $ 62
XML 104 R85.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Schedule of Income Tax Provision) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Taxes    
Computed tax benefit at federal statutory rate $ (6,875) $ (3,837)
State tax, net of federal benefit (1,077) (610)
Stock compensation (2,683) 480
Interest expense   286
Permanent differences and other (375) (126)
Transaction cost 528  
Executive compensation 609 985
Rate changes 408  
Contingencies 112 753
Valuation allowance 9,308 2,131
Income Tax Expense (Benefit) $ (45) $ 62
XML 105 R86.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Schedule of Deferred Tax Assets) (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets:    
Net operating loss carryforward $ 27,106 $ 17,031
Expenses recognized for granting of options and warrants 4,119 3,816
Accrued expenses and reserves 913 383
Lease Liability 2,740 1,217
Total deferred tax assets 34,878 22,447
Valuation allowance (32,913) (21,220)
Deferred Tax Assets, Net of Valuation Allowance 1,965 1,227
Deferred tax liabilities:    
Goodwill (529) (110)
Right-of-use assets (2,631) (1,138)
Intangible assets (4,253)  
Total deferred tax liability (7,413) (1,248)
Net deferred tax liability $ (5,448) $ (21)
XML 106 R87.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - net deferred tax liability as presented in consolidated balance sheet (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred tax liability $ (5,882) $ (21)
Net deferred tax liability (5,448) (21)
Other long-term assets    
Deferred tax assets 434  
Deferred tax liability    
Deferred tax liability $ (5,882) $ (21)
XML 107 R88.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Schedule of unrecognized tax positions) (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Unrecognized tax positions, beginning of period $ 0  
Unrecognized tax positions, end of period 0 $ 0
Domestic Tax Authority [Member]    
Unrecognized tax positions, beginning of period 963,000 48,000
Gross increase - current period tax positions 358,000 239,000
Gross decrease - prior period tax positions (113,000) 0
Gross increase - prior period tax positions (64,000) (676,000)
Expiration of statute of limitations 0 0
Unrecognized tax positions, end of period $ 1,272,000 $ 963,000
XML 108 R89.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Oct. 01, 2020
Operating Loss Carryforwards [Line Items]      
Net deferred tax liabilities increase due to acquisition of MVE and CRYOPDP     $ 5,700
Increase in valuation allowance on deferred tax assets $ 11,700 $ 2,100  
Deferred tax liability indefinite-lived assets $ 4,253    
Operating Loss Carryforwards   9,800  
Operating Loss Carryforwards, Percent 80.00%    
Accrual for interest and penalties   0  
Federal Tax Income [Member]      
Operating Loss Carryforwards [Line Items]      
Operating Loss Carryforwards   38,600  
Domestic Tax Authority [Member]      
Operating Loss Carryforwards [Line Items]      
Operating Loss Carryforwards   57,600  
Tax Credit Carryforward, Amount   400  
State and Local Jurisdiction [Member]      
Operating Loss Carryforwards [Line Items]      
Operating Loss Carryforwards   60,900  
Tax Credit Carryforward, Amount   $ 300  
XML 109 R90.htm IDEA: XBRL DOCUMENT v3.20.4
Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Feb. 05, 2021
Jan. 25, 2021
Jan. 21, 2021
Oct. 01, 2020
Jun. 24, 2019
Dec. 31, 2020
Dec. 31, 2019
Subsequent Event [Line Items]              
Shares issued, price per share         $ 17.00    
Shares issued to underwriters         562,500    
Proceeds from issuance of common stock, net of issuance costs           $ 28,160 $ 0
Common stock, par value per share (in dollars per share)       $ 0.001   $ 0.001 $ 0.001
Class C convertible preferred stock              
Subsequent Event [Line Items]              
Liquidation preference (in dollars per share)       1,000      
Conversion price (in dollars per share)       $ 38.6152      
Shares to be issued upon conversion       6,474,135      
Prior to the 180-day anniversary of October 1, 2020 | Class C convertible preferred stock              
Subsequent Event [Line Items]              
Number of shares to be redeemed       50,000      
Subsequent Event | Class C convertible preferred stock              
Subsequent Event [Line Items]              
Shares issued (in shares) 50,000            
Liquidation preference (in dollars per share) $ 1,000            
Subsequent Event | Common Stock [Member]              
Subsequent Event [Line Items]              
Common stock, par value per share (in dollars per share) 0.001            
Conversion price (in dollars per share) $ 38.6152            
Shares to be issued upon conversion 1,312,860            
Subsequent Event | Prior to the 180-day anniversary of October 1, 2020 | Class C convertible preferred stock              
Subsequent Event [Line Items]              
Number of shares to be redeemed 50,000            
Underwritten public offering | Subsequent Event              
Subsequent Event [Line Items]              
Shares issued, price per share     $ 66.00        
Proceeds from issuance of common stock, net of issuance costs     $ 269,700        
Underwritten public offering | Subsequent Event | Common Stock [Member]              
Subsequent Event [Line Items]              
Shares issued (in shares)   4,356,059          
Shares issued to underwriters     568,181        
XML 110 R91.htm IDEA: XBRL DOCUMENT v3.20.4
Quarterly Financial Data (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Total revenues $ 48,361,000 $ 11,172,000 $ 9,389,000 $ 9,774,000 $ 9,242,000 $ 9,583,000 $ 8,464,000 $ 6,653,000 $ 78,696,000 $ 33,942,000
Gross margin 19,894,000 6,055,000 5,127,000 5,258,000 4,932,000 4,627,000 4,338,000 3,454,000 36,334,000 17,352,000
Loss from operations (9,847,000) (10,732,000) (5,845,000) (3,586,000) (878,000) (12,352,000) (2,304,000) (2,141,000) (30,010,000) (17,675,000)
Net loss attributable to common shareholders $ (53,866,000) $ (11,418,000) $ (5,803,000) $ (3,943,000) $ (948,000) $ (12,469,000) $ (2,528,000) $ (2,387,000) $ (75,029,000) $ (18,332,000)
Net loss per share attributable to common stockholders - basic and diluted $ (1.32) $ (0.29) $ (0.15) $ (0.11) $ (0.03) $ (0.35) $ (0.08) $ (0.08) $ (1.94) $ (0.55)
Accelerated stock-based compensation expense         $ 1,227,890       $ 0 $ 9,562,000
Stock-based compensation expense                 $ 8,916,000 $ 6,962,000
General and administrative expense                    
Stock-based compensation expense         $ 765,099          
EXCEL 111 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 112 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 113 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 114 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 304 570 1 false 97 0 false 7 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Consolidated Statements of Operations Sheet http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 00400 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 00500 - Statement - Consolidated Statements of Cash Flows Sheet http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 10101 - Disclosure - Nature of the Business Sheet http://www.Cryoport.com/role/DisclosureNatureOfBusiness Nature of the Business Notes 9 false false R10.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 10301 - Disclosure - Acquisitions Sheet http://www.Cryoport.com/role/DisclosureAcquisitions Acquisitions Notes 11 false false R12.htm 10401 - Disclosure - Cash, Cash Equivalents and Short-Term Investments Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents and Short-Term Investments Notes 12 false false R13.htm 10501 - Disclosure - Fair Value Measurements Sheet http://www.Cryoport.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 10601 - Disclosure - Inventories Sheet http://www.Cryoport.com/role/DisclosureInventories Inventories Notes 14 false false R15.htm 10701 - Disclosure - Property and Equipment Sheet http://www.Cryoport.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 15 false false R16.htm 10801 - Disclosure - Goodwill And Other Intangible Assets Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssets Goodwill And Other Intangible Assets Notes 16 false false R17.htm 10901 - Disclosure - Accrued Compensation and Related Expenses Sheet http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpenses Accrued Compensation and Related Expenses Notes 17 false false R18.htm 11001 - Disclosure - Convertible Senior Notes Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotes Convertible Senior Notes Notes 18 false false R19.htm 11101 - Disclosure - Note Payable Sheet http://www.Cryoport.com/role/DisclosureNotePayable Note Payable Notes 19 false false R20.htm 11201 - Disclosure - Leases Sheet http://www.Cryoport.com/role/DisclosureLeases Leases Notes 20 false false R21.htm 11301 - Disclosure - Employee Benefit Plans Sheet http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlans Employee Benefit Plans Notes 21 false false R22.htm 11401 - Disclosure - Commitments and Contingencies Sheet http://www.Cryoport.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 11501 - Disclosure - Stockholders' Equity Sheet http://www.Cryoport.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 23 false false R24.htm 11601 - Disclosure - Stock-Based Compensation Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 24 false false R25.htm 11701 - Disclosure - Income Taxes Sheet http://www.Cryoport.com/role/DisclosureIncomeTaxes Income Taxes Notes 25 false false R26.htm 11801 - Disclosure - Subsequent Event Sheet http://www.Cryoport.com/role/DisclosureSubsequentEvent Subsequent Event Notes 26 false false R27.htm 11901 - Disclosure - Quarterly Financial Data Sheet http://www.Cryoport.com/role/DisclosureQuarterlyFinancialData Quarterly Financial Data Notes 27 false false R28.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPolicies 28 false false R29.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPolicies 29 false false R30.htm 30303 - Disclosure - Acquisitions (Tables) Sheet http://www.Cryoport.com/role/DisclosureAcquisitionsTables Acquisitions (Tables) Tables http://www.Cryoport.com/role/DisclosureAcquisitions 30 false false R31.htm 30403 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Tables) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables Cash, Cash Equivalents and Short-Term Investments (Tables) Tables http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments 31 false false R32.htm 30503 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.Cryoport.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.Cryoport.com/role/DisclosureFairValueMeasurements 32 false false R33.htm 30603 - Disclosure - Inventories (Tables) Sheet http://www.Cryoport.com/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.Cryoport.com/role/DisclosureInventories 33 false false R34.htm 30703 - Disclosure - Property and Equipment (Tables) Sheet http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.Cryoport.com/role/DisclosurePropertyAndEquipment 34 false false R35.htm 30803 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables 35 false false R36.htm 30903 - Disclosure - Accrued Compensation and Related Expenses (Tables) Sheet http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesTables Accrued Compensation and Related Expenses (Tables) Tables http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpenses 36 false false R37.htm 31003 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotes 37 false false R38.htm 31203 - Disclosure - Leases (Tables) Sheet http://www.Cryoport.com/role/DisclosureLeasesTables Leases (Tables) Tables http://www.Cryoport.com/role/DisclosureLeases 38 false false R39.htm 31503 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.Cryoport.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.Cryoport.com/role/DisclosureStockholdersEquity 39 false false R40.htm 31603 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.Cryoport.com/role/DisclosureStockBasedCompensation 40 false false R41.htm 31703 - Disclosure - Income Taxes (Tables) Sheet http://www.Cryoport.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.Cryoport.com/role/DisclosureIncomeTaxes 41 false false R42.htm 31903 - Disclosure - Quarterly Financial Data (Tables) Sheet http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataTables Quarterly Financial Data (Tables) Tables http://www.Cryoport.com/role/DisclosureQuarterlyFinancialData 42 false false R43.htm 40101 - Disclosure - Nature of the Business (Details) Sheet http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails Nature of the Business (Details) Details http://www.Cryoport.com/role/DisclosureNatureOfBusiness 43 false false R44.htm 40201 - Disclosure - Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details) Details 44 false false R45.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details) Details 45 false false R46.htm 40203 - Disclosure - Summary of Significant Accounting Policies - Earnings Per Share (Details) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails Summary of Significant Accounting Policies - Earnings Per Share (Details) Details 46 false false R47.htm 40204 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Shares (Details) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails Summary of Significant Accounting Policies - Antidilutive Shares (Details) Details 47 false false R48.htm 40205 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 48 false false R49.htm 40301 - Disclosure - Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details Sheet http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details Uncategorized 49 false false R50.htm 40302 - Disclosure - Acquisition of CryoGene Partners - Preliminary Fair Value of Intangible Assets (Details) Sheet http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails Acquisition of CryoGene Partners - Preliminary Fair Value of Intangible Assets (Details) Details 50 false false R51.htm 40303 - Disclosure - Acquisition of CryoGene Partners - Pro Forma Information (Details) Sheet http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails Acquisition of CryoGene Partners - Pro Forma Information (Details) Details 51 false false R52.htm 40401 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Details) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails Cash, Cash Equivalents and Short-Term Investments (Details) Details http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables 52 false false R53.htm 40402 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details) Details 53 false false R54.htm 40403 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details) Details 54 false false R55.htm 40404 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsEquityInvestmentsDetails Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details) Details 55 false false R56.htm 40405 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetails Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details) Details 56 false false R57.htm 40501 - Disclosure - Fair Value Measurements (Details) Sheet http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.Cryoport.com/role/DisclosureFairValueMeasurementsTables 57 false false R58.htm 40502 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 58 false false R59.htm 40601 - Disclosure - Inventories (Details) Sheet http://www.Cryoport.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://www.Cryoport.com/role/DisclosureInventoriesTables 59 false false R60.htm 40701 - Disclosure - Property and Equipment (Details) Sheet http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentTables 60 false false R61.htm 40702 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 61 false false R62.htm 40801 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details) Details 62 false false R63.htm 40802 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets - Narrative (Details) Details 63 false false R64.htm 40803 - Disclosure - Goodwill and Other Intangible Assets - Schedule of goodwill (Details) Sheet http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails Goodwill and Other Intangible Assets - Schedule of goodwill (Details) Details 64 false false R65.htm 40901 - Disclosure - Accrued Compensation and Related Expenses (Details) Sheet http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesDetails Accrued Compensation and Related Expenses (Details) Details http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesTables 65 false false R66.htm 41001 - Disclosure - Convertible Senior Notes - Components of Convertible notes payable (Details) Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails Convertible Senior Notes - Components of Convertible notes payable (Details) Details 66 false false R67.htm 41002 - Disclosure - Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details) Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesInterestExpensesIncurredOnConvertibleNotesPayableDetails Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details) Details 67 false false R68.htm 41003 - Disclosure - Convertible Senior Notes - Additional information (Details) Notes http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails Convertible Senior Notes - Additional information (Details) Details 68 false false R69.htm 41101 - Disclosure - Note Payable (Details) Sheet http://www.Cryoport.com/role/DisclosureNotePayableDetails Note Payable (Details) Details http://www.Cryoport.com/role/DisclosureNotePayable 69 false false R70.htm 41201 - Disclosure - Leases - Components Of Lease Cost (Detail) Sheet http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail Leases - Components Of Lease Cost (Detail) Details 70 false false R71.htm 41202 - Disclosure - Leases - Supplemental Cash Flows Information (Detail) Sheet http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail Leases - Supplemental Cash Flows Information (Detail) Details 71 false false R72.htm 41203 - Disclosure - Leases - Payments Under Non-Cancellable Leases (Details) Sheet http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails Leases - Payments Under Non-Cancellable Leases (Details) Details 72 false false R73.htm 41204 - Disclosure - Leases - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 73 false false R74.htm 41301 - Disclosure - Employee Benefit Plans (Details) Sheet http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails Employee Benefit Plans (Details) Details http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlans 74 false false R75.htm 41501 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details) Sheet http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails Stockholders' Equity - Common Stock Reserved for Future Issuance (Details) Details 75 false false R76.htm 41502 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 76 false false R77.htm 41601 - Disclosure - Stock-Based Compensation - Warrant Activity (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails Stock-Based Compensation - Warrant Activity (Details) Details 77 false false R78.htm 41602 - Disclosure - Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details) Details 78 false false R79.htm 41603 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-based Compensation Expense (Details) Details 79 false false R80.htm 41604 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - Stock Option Activity (Details) Details 80 false false R81.htm 41605 - Disclosure - Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) Details http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables 81 false false R82.htm 41606 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 82 false false R83.htm 41701 - Disclosure - Income Taxes (Loss Before Provision For Income Taxes) (Details) Sheet http://www.Cryoport.com/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails Income Taxes (Loss Before Provision For Income Taxes) (Details) Details http://www.Cryoport.com/role/DisclosureIncomeTaxesTables 83 false false R84.htm 41702 - Disclosure - Income Taxes (Expense For Income Taxes) (Details) Sheet http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails Income Taxes (Expense For Income Taxes) (Details) Details http://www.Cryoport.com/role/DisclosureIncomeTaxesTables 84 false false R85.htm 41703 - Disclosure - Income Taxes (Schedule of Income Tax Provision) (Details) Sheet http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails Income Taxes (Schedule of Income Tax Provision) (Details) Details http://www.Cryoport.com/role/DisclosureIncomeTaxesTables 85 false false R86.htm 41704 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets) (Details) Sheet http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails Income Taxes (Schedule of Deferred Tax Assets) (Details) Details http://www.Cryoport.com/role/DisclosureIncomeTaxesTables 86 false false R87.htm 41705 - Disclosure - Income Taxes - net deferred tax liability as presented in consolidated balance sheet (Details) Sheet http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails Income Taxes - net deferred tax liability as presented in consolidated balance sheet (Details) Details 87 false false R88.htm 41706 - Disclosure - Income Taxes (Schedule of unrecognized tax positions) (Details) Sheet http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails Income Taxes (Schedule of unrecognized tax positions) (Details) Details http://www.Cryoport.com/role/DisclosureIncomeTaxesTables 88 false false R89.htm 41707 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.Cryoport.com/role/DisclosureIncomeTaxesTables 89 false false R90.htm 41801 - Disclosure - Subsequent Events (Details) Sheet http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.Cryoport.com/role/DisclosureSubsequentEvent 90 false false R91.htm 41901 - Disclosure - Quarterly Financial Data (Details) Sheet http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails Quarterly Financial Data (Details) Details http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataTables 91 false false All Reports Book All Reports cyrx-20201231x10k.htm cyrx-20201231.xsd cyrx-20201231_cal.xml cyrx-20201231_def.xml cyrx-20201231_lab.xml cyrx-20201231_pre.xml cyrx-20201231xex10d6.htm cyrx-20201231xex10d7.htm cyrx-20201231xex10d8.htm cyrx-20201231xex21.htm cyrx-20201231xex23d1.htm cyrx-20201231xex31d1.htm cyrx-20201231xex31d2.htm cyrx-20201231xex32d1.htm cyrx-20201231xex32d2.htm cyrx-20201231xex4d1.htm cyrx-20201231x10k004.jpg cyrx-20201231x10k008.jpg http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 117 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cyrx-20201231x10k.htm": { "axisCustom": 1, "axisStandard": 30, "contextCount": 304, "dts": { "calculationLink": { "local": [ "cyrx-20201231_cal.xml" ] }, "definitionLink": { "local": [ "cyrx-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "cyrx-20201231x10k.htm" ] }, "labelLink": { "local": [ "cyrx-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "cyrx-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "cyrx-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 752, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 19, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 24 }, "keyCustom": 81, "keyStandard": 489, "memberCustom": 42, "memberStandard": 49, "nsprefix": "cyrx", "nsuri": "http://www.Cryoport.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Acquisitions", "role": "http://www.Cryoport.com/role/DisclosureAcquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Cash, Cash Equivalents and Short-Term Investments", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments", "shortName": "Cash, Cash Equivalents and Short-Term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Fair Value Measurements", "role": "http://www.Cryoport.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Inventories", "role": "http://www.Cryoport.com/role/DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Property and Equipment", "role": "http://www.Cryoport.com/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Goodwill And Other Intangible Assets", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssets", "shortName": "Goodwill And Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Accrued Compensation and Related Expenses", "role": "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpenses", "shortName": "Accrued Compensation and Related Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Convertible Senior Notes", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotes", "shortName": "Convertible Senior Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Note Payable", "role": "http://www.Cryoport.com/role/DisclosureNotePayable", "shortName": "Note Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Consolidated Balance Sheets", "role": "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Leases", "role": "http://www.Cryoport.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Employee Benefit Plans", "role": "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlans", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Commitments and Contingencies", "role": "http://www.Cryoport.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Stockholders' Equity", "role": "http://www.Cryoport.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Stock-Based Compensation", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11701 - Disclosure - Income Taxes", "role": "http://www.Cryoport.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11801 - Disclosure - Subsequent Event", "role": "http://www.Cryoport.com/role/DisclosureSubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11901 - Disclosure - Quarterly Financial Data", "role": "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialData", "shortName": "Quarterly Financial Data", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-5", "first": true, "lang": null, "name": "cyrx:ConvertibleSubordinatedDebtDiscount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-5", "first": true, "lang": null, "name": "cyrx:ConvertibleSubordinatedDebtDiscount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Acquisitions (Tables)", "role": "http://www.Cryoport.com/role/DisclosureAcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Tables)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables", "shortName": "Cash, Cash Equivalents and Short-Term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUtilityInventoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Inventories (Tables)", "role": "http://www.Cryoport.com/role/DisclosureInventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUtilityInventoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Property and Equipment (Tables)", "role": "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Accrued Compensation and Related Expenses (Tables)", "role": "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesTables", "shortName": "Accrued Compensation and Related Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Convertible Senior Notes (Tables)", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesTables", "shortName": "Convertible Senior Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Leases (Tables)", "role": "http://www.Cryoport.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.Cryoport.com/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Consolidated Statements of Operations", "role": "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31603 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31703 - Disclosure - Income Taxes (Tables)", "role": "http://www.Cryoport.com/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31903 - Disclosure - Quarterly Financial Data (Tables)", "role": "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataTables", "shortName": "Quarterly Financial Data (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "Unit_Standard_segment_wv4HyIj44EuRcZxOvo2pdQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Nature of the Business (Details)", "role": "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails", "shortName": "Nature of the Business (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_10_1_2020_To_12_31_2020_RplUP5DyvkS7v8TE2diy6w", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails", "shortName": "Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementBusinessSegmentsAxis_cyrx_GlobalLogisticsSolutionsMember_QQeneaoxRUSK30eHIrRK0g", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_10_1_2020_To_12_31_2020_RplUP5DyvkS7v8TE2diy6w", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails", "shortName": "Summary of Significant Accounting Policies - Disaggregation Our Geographical Revenues by Origin (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_srt_AmericasMember_BV_iiDXwrE2iMYB9EtFwMQ", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Earnings Per Share (Details)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "shortName": "Summary of Significant Accounting Policies - Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40204 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Shares (Details)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails", "shortName": "Summary of Significant Accounting Policies - Antidilutive Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:MaturityPeriodOfHighlyLiquidInvestments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40205 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:MaturityPeriodOfHighlyLiquidInvestments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_10_1_2020_FTjjzX9bo0y6MhiqceV1Ow", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details", "role": "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "shortName": "Acquisition of CryoGene Partners - Preliminary Purchase Price Allocation (Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_10_1_2020_us-gaap_BusinessAcquisitionAxis_cyrx_CryopdpMember_x_aJ8TBYlUuCBZPkSWBW_g", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Acquisition of CryoGene Partners - Preliminary Fair Value of Intangible Assets (Details)", "role": "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "shortName": "Acquisition of CryoGene Partners - Preliminary Fair Value of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_cyrx_CryogenePartnersMember_PIMcW2J4GketSImO9kIWuw", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - Acquisition of CryoGene Partners - Pro Forma Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails", "shortName": "Acquisition of CryoGene Partners - Pro Forma Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Details)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "shortName": "Cash, Cash Equivalents and Short-Term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "shortName": "Cash, Cash Equivalents and Short-Term Investments - Available-for-sale debt securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails", "shortName": "Cash, Cash Equivalents and Short-Term Investments - Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40404 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsEquityInvestmentsDetails", "shortName": "Cash, Cash Equivalents and Short-Term Investments - Equity Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40405 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetails", "shortName": "Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ATcYhmfmoEaTIWHHK9HgHw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Fair Value Measurements (Details)", "role": "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ATcYhmfmoEaTIWHHK9HgHw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUtilityInventoryTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Inventories (Details)", "role": "http://www.Cryoport.com/role/DisclosureInventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUtilityInventoryTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ihz4sF7qnkGuwnU2exTABQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ihz4sF7qnkGuwnU2exTABQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "cyrx:CryogenicShippersAndDataLoggers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Property and Equipment (Details)", "role": "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "cyrx:CryogenicShippersAndDataLoggers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Property and Equipment - Narrative (Details)", "role": "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "shortName": "Property and Equipment - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details)", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails", "shortName": "Goodwill and Other Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2019_3O4b6u2oqkyr9yoT1nKLjw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Goodwill and Other Intangible Assets - Schedule of goodwill (Details)", "role": "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "shortName": "Goodwill and Other Intangible Assets - Schedule of goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_BusinessAcquisitionAxis_cyrx_CryogenePartnersMember_NmbXc1NFZ0CsZ2_s11C_FA", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Accrued Compensation and Related Expenses (Details)", "role": "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesDetails", "shortName": "Accrued Compensation and Related Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Convertible Senior Notes - Components of Convertible notes payable (Details)", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails", "shortName": "Convertible Senior Notes - Components of Convertible notes payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfInterestExpensesOnConvertibleNotesPayableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details)", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesInterestExpensesIncurredOnConvertibleNotesPayableDetails", "shortName": "Convertible Senior Notes - Interest expenses incurred on Convertible notes payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfInterestExpensesOnConvertibleNotesPayableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_5_31_2020_T14ZHtG3xUms7B6VB_wW7g", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Convertible Senior Notes - Additional information (Details)", "role": "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "shortName": "Convertible Senior Notes - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_5_31_2020_T14ZHtG3xUms7B6VB_wW7g", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermNotesPayable", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Note Payable (Details)", "role": "http://www.Cryoport.com/role/DisclosureNotePayableDetails", "shortName": "Note Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cyrx:NotesPayableTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_cyrx_CryopdpMember_PE8s9HuJeEKULrJI0LjDmw", "decimals": "INF", "lang": null, "name": "cyrx:NumberOfInstallments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_J74tdx7OT0W4F4VnQRjN-g", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_cyrx_PublicOfferingMember_6Txa0t8MIUysjEt9yIz5Xw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)", "role": "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_cyrx_PublicOfferingMember_6Txa0t8MIUysjEt9yIz5Xw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Leases - Components Of Lease Cost (Detail)", "role": "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail", "shortName": "Leases - Components Of Lease Cost (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfLeaseSupplementalCashFlowAndOtherDisclosuresTableTextBlock", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Leases - Supplemental Cash Flows Information (Detail)", "role": "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail", "shortName": "Leases - Supplemental Cash Flows Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfLeaseSupplementalCashFlowAndOtherDisclosuresTableTextBlock", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41203 - Disclosure - Leases - Payments Under Non-Cancellable Leases (Details)", "role": "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails", "shortName": "Leases - Payments Under Non-Cancellable Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:LesseeOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41204 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cyrx:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "cyrx:LesseeOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_cyrx_UsEmployeesMember_SCqw_SFWhESNXbLwM4sm9Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_PUxZ63o7RkW5Ayp2ULGhow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Employee Benefit Plans (Details)", "role": "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails", "shortName": "Employee Benefit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_cyrx_UsEmployeesMember_SCqw_SFWhESNXbLwM4sm9Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_PUxZ63o7RkW5Ayp2ULGhow", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails", "shortName": "Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cyrx:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41502 - Disclosure - Stockholders' Equity - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_6_24_2019_S4qhrmOfhkaEQwcvxqG7yA", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_WarrantMember_RGe5eTp45EK2lMHwm6yoTQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Stock-Based Compensation - Warrant Activity (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails", "shortName": "Stock-Based Compensation - Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R78": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_PUxZ63o7RkW5Ayp2ULGhow", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41602 - Disclosure - Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "shortName": "Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_PUxZ63o7RkW5Ayp2ULGhow", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41603 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fKEg9mGQUGTnBKeDdJ7qA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41604 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Iq2V8xUePUukFPAhAl3Sew", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1GPvhpGKzUuFTjRsQ9iitg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41605 - Disclosure - Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails", "shortName": "Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1GPvhpGKzUuFTjRsQ9iitg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_zQkxqpdziUGe-dafOXA58w", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2019_3O4b6u2oqkyr9yoT1nKLjw", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41606 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-5", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41701 - Disclosure - Income Taxes (Loss Before Provision For Income Taxes) (Details)", "role": "http://www.Cryoport.com/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails", "shortName": "Income Taxes (Loss Before Provision For Income Taxes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_vSdLP662HkaQ50SEcxvHpA", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41702 - Disclosure - Income Taxes (Expense For Income Taxes) (Details)", "role": "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails", "shortName": "Income Taxes (Expense For Income Taxes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41703 - Disclosure - Income Taxes (Schedule of Income Tax Provision) (Details)", "role": "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails", "shortName": "Income Taxes (Schedule of Income Tax Provision) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41704 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets) (Details)", "role": "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails", "shortName": "Income Taxes (Schedule of Deferred Tax Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_G87XAZxkfE-5khQCAo1LYQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41705 - Disclosure - Income Taxes - net deferred tax liability as presented in consolidated balance sheet (Details)", "role": "http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails", "shortName": "Income Taxes - net deferred tax liability as presented in consolidated balance sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_gDRIyM0syUGxXwBs0apFHw", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredIncomeTaxAssetsNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2019_3O4b6u2oqkyr9yoT1nKLjw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41706 - Disclosure - Income Taxes (Schedule of unrecognized tax positions) (Details)", "role": "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails", "shortName": "Income Taxes (Schedule of unrecognized tax positions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_12_31_2018_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_EHWk6xk5A0yB43mvrYphbA", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_10_1_2020_FTjjzX9bo0y6MhiqceV1Ow", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41707 - Disclosure - Income Taxes (Narrative) (Details)", "role": "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails", "shortName": "Income Taxes (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of the Business", "role": "http://www.Cryoport.com/role/DisclosureNatureOfBusiness", "shortName": "Nature of the Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_zSEKpM1YN0etzmziNnGrbQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_6_24_2019_S4qhrmOfhkaEQwcvxqG7yA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_CAr40VX_IEaJzh0AiacDpQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41801 - Disclosure - Subsequent Events (Details)", "role": "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "As_Of_1_21_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8l1auF0HLU-lDYt3UZ2NaA", "decimals": "INF", "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_CAr40VX_IEaJzh0AiacDpQ", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_10_1_2020_To_12_31_2020_RplUP5DyvkS7v8TE2diy6w", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41901 - Disclosure - Quarterly Financial Data (Details)", "role": "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "shortName": "Quarterly Financial Data (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "body", "html" ], "baseRef": "cyrx-20201231x10k.htm", "contextRef": "Duration_10_1_2020_To_12_31_2020_RplUP5DyvkS7v8TE2diy6w", "decimals": "-3", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_fSy8nUvoGEmsLd9IZhAVpg", "xsiNil": "false" } } }, "segmentCount": 97, "tag": { "cyrx_AdjustmentsToAdditionalPaidInCapitalAcceleratedShareBasedCompensationExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase/(decrease) in additional paid in capital due to accelerated share based compensation expenses.", "label": "Adjustments to Additional Paid In Capital Accelerated Share-based Compensation Expense", "terseLabel": "Accelerated stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAcceleratedShareBasedCompensationExpense", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cyrx_AdjustmentsToAdditionalPaidInCapitalDeemedDividend": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the deemed dividend on Series C convertible preferred stock.", "label": "Adjustments to Additional Paid in Capital, Deemed Dividend", "terseLabel": "Deemed dividend on the Series C convertible preferred stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalDeemedDividend", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cyrx_AdjustmentsToAdditionalPaidInCapitalPaidInKindDividends": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the paid-in-kind dividends on Series C Convertible Preferred Stock.", "label": "Adjustments to Additional Paid in Capital, Paid In Kind Dividends", "terseLabel": "Paid-in-kind preferred stock dividend, including beneficial conversion feature" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalPaidInKindDividends", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cyrx_AgentNetworkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agent network", "label": "Agent Network [Member]", "terseLabel": "Agent network" } } }, "localname": "AgentNetworkMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cyrx_AnimalHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Animal Health Member", "label": "Animal Health [Member]", "terseLabel": "Animal Health [Member]" } } }, "localname": "AnimalHealthMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "cyrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedcost": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Available For Sale Securities Debt Maturities After One Through Two Years, AmortizedCost", "verboseLabel": "Due between one and two years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedcost", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Available For Sale Securities Debt Maturities After One Through Two Years, Fair Value", "verboseLabel": "Due between one and two years, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_BeneficialConversionFeatureOfSeriesCConvertiblePreferredStockValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of beneficial conversion feature of the Series C convertible preferred stock.", "label": "Beneficial Conversion Feature of the Series C Convertible Preferred Stock, Value", "terseLabel": "Beneficial conversion feature of the Series C convertible preferred stock" } } }, "localname": "BeneficialConversionFeatureOfSeriesCConvertiblePreferredStockValue", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cyrx_BiopharmaceuticalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biopharmaceutical Member", "label": "Biopharmaceutical [Member]", "terseLabel": "Biopharma/Pharma [Member]" } } }, "localname": "BiopharmaceuticalMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "cyrx_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss per share" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails" ], "xbrltype": "perShareItemType" }, "cyrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndRelatedExpenses": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued compensation and related expenses, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Related Expenses", "negatedLabel": "Accrued compensation and related expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndRelatedExpenses", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 13.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities", "negatedLabel": "Operating lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of operating lease right of use assets recognized as of the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Assets", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_BusinessCombinationsAcquisitionCostsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for Business combination acquisition costs.", "label": "Business Combinations, Acquisition Costs Policy [Policy Text Block]", "terseLabel": "Acquisition Costs" } } }, "localname": "BusinessCombinationsAcquisitionCostsPolicyPolicyTextBlock", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cyrx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "stringItemType" }, "cyrx_ClassBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Convertible Preferred Stock [Member]", "terseLabel": "Class B convertible preferred stock [Member]" } } }, "localname": "ClassBConvertiblePreferredStockMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "cyrx_ClassCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Class C Convertible Preferred Stock.", "label": "Class C Convertible Preferred Stock [Member]", "terseLabel": "Class C convertible preferred stock" } } }, "localname": "ClassCConvertiblePreferredStockMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "cyrx_CommonStockIssuedForConversionOfDebtAndAccruedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "NA", "label": "Common Stock Issued For Conversion Of Debt And Accrued Interest", "terseLabel": "Common stock issued for conversion of debt and accrued interest" } } }, "localname": "CommonStockIssuedForConversionOfDebtAndAccruedInterest", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_ConvertibleSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Senior Notes Member", "label": "Convertible Senior Notes [Member]", "terseLabel": "Convertible Senior Notes [Member]" } } }, "localname": "ConvertibleSeniorNotesMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "cyrx_ConvertibleSubordinatedDebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Discount on convertible subordinated debt.", "label": "Convertible Subordinated Debt, Discount" } } }, "localname": "ConvertibleSubordinatedDebtDiscount", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "cyrx_CryogenePartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Cryogene Partners [Member]", "terseLabel": "CryoGene Partners [Member]" } } }, "localname": "CryogenePartnersMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionsTables", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cyrx_CryogenicShippersAndDataLoggers": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents storage and transportation services. Transportation and storage services shippers and water loggers who transport and customers who lease storage capacity.", "label": "Cryogenic Shippers and Data Loggers", "terseLabel": "Cryogenic shippers and data loggers" } } }, "localname": "CryogenicShippersAndDataLoggers", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_CryopdpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for CRYOPDP.", "label": "Cryopdp [Member]", "terseLabel": "CRYOPDP" } } }, "localname": "CryopdpMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionsTables", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "domainItemType" }, "cyrx_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One [Member].", "label": "Customer One [Member]", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "terseLabel": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_DebtInstrumentConvertibleThresholdMaximumConversionRatio": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Threshold maximum ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Threshold Maximum Conversion Ratio", "terseLabel": "Threshold maximum conversion rate" } } }, "localname": "DebtInstrumentConvertibleThresholdMaximumConversionRatio", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_DebtInstrumentRedemptionThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of redeemable debt instrument must exceed threshold percentage for specified number of trading days to trigger redemption.", "label": "Debt Instrument, Redemption, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days for redemption of notes" } } }, "localname": "DebtInstrumentRedemptionThresholdConsecutiveTradingDays", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_DebtInstrumentRedemptionThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of redeemable debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger redemption.", "label": "Debt Instrument, Redemption, Threshold Trading Days", "terseLabel": "Threshold trading days for redemption of notes" } } }, "localname": "DebtInstrumentRedemptionThresholdTradingDays", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_DebtInstrumentRegistrationDefaultAdditionalInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount payable as additional interest, if the Company fails to satisfy certain of its obligations under the Registration Rights Agreement (a \"Registration Default\").", "label": "Debt Instrument, Registration Default, Additional Interest Rate", "terseLabel": "Additional interest rate (as a percent)" } } }, "localname": "DebtInstrumentRegistrationDefaultAdditionalInterestRate", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_DebtInstrumentRegistrationDefaultCashPaymentToEachNoteholderPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of the note payable as cash payment to each noteholder, if a Registration Default exists on the maturity date for the Notes, in addition to any additional interest.", "label": "Debt Instrument, Registration Default, Cash Payment To Each Noteholder, Percentage", "terseLabel": "Cash payment to each noteholder (as a percent)" } } }, "localname": "DebtInstrumentRegistrationDefaultCashPaymentToEachNoteholderPercentage", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_DebtInstrumentRegistrationDefaultThresholdMaximumCombinedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold maximum percentage of combined interest rate per annum, that in no event will be exceeded by the additional interest, together with any special interest that accrues pursuant to the Indenture accrue on any day on a Note.", "label": "Debt Instrument, Registration Default, Threshold Maximum Combined Interest Rate", "terseLabel": "Threshold maximum combined interest rate (as a percent)" } } }, "localname": "DebtInstrumentRegistrationDefaultThresholdMaximumCombinedInterestRate", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_DeemedDividend": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deemed dividend recognized by the company.", "label": "Deemed Dividend", "terseLabel": "Deemed dividend" } } }, "localname": "DeemedDividend", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_DeemedDividendOnSeriesCConvertiblePreferredStockValue": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deemed dividend on Series C convertible preferred stock.", "label": "Deemed Dividend on Series C Convertible Preferred Stock, Value", "negatedLabel": "Deemed dividend on Series C convertible preferred stock" } } }, "localname": "DeemedDividendOnSeriesCConvertiblePreferredStockValue", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "cyrx_DeferredIncomeTaxExpenseBenefitTotal": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of total deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit), Total", "totalLabel": "Total deferred expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefitTotal", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_DeferredIncomeTaxLiabilitiesNetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing Deferred income tax liabilities net.", "label": "Deferred Income Tax Liabilities Net [Member]", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNetMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "cyrx_DeferredTaxAssetsLeaseLiability": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets, lease liability.", "label": "Deferred Tax Assets, Lease Liability", "terseLabel": "Lease Liability" } } }, "localname": "DeferredTaxAssetsLeaseLiability", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_DeferredTaxLiabilitiesRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities, right-of-use assets.", "label": "Deferred Tax Liabilities, Right-Of-Use Assets", "negatedLabel": "Right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_EffectiveIncomeTaxRateReconciliationContingencies": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to contingencies.", "label": "Effective Income Tax Rate Reconciliation, Contingencies", "terseLabel": "Contingencies" } } }, "localname": "EffectiveIncomeTaxRateReconciliationContingencies", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to executive compensation.", "label": "Effective Income Tax Rate Reconciliation, Executive Compensation, Amount", "terseLabel": "Executive compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpensesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible interest expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expenses, Amount", "terseLabel": "Interest expense" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpensesAmount", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_EffectiveIncomeTaxRateReconciliationTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to transaction costs.", "label": "Effective Income Tax Rate Reconciliation, Transaction Costs", "terseLabel": "Transaction cost" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTransactionCosts", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_EliminationOfCostOfGoodsSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of elimination of cost of goods sold.", "label": "Elimination of Cost of Goods Sold", "terseLabel": "Elimination of cost of goods sold" } } }, "localname": "EliminationOfCostOfGoodsSold", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_EliminationOfRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of elimination of revenue.", "label": "Elimination of Revenue", "terseLabel": "Elimination of revenue" } } }, "localname": "EliminationOfRevenue", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_EngineeringAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Engineering And Development [Member]", "terseLabel": "Engineering And Development [Member]" } } }, "localname": "EngineeringAndDevelopmentMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "cyrx_EquipmentAndFurnitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Equipment and furniture.", "label": "Equipment And Furniture [Member]", "terseLabel": "Equipment and Furniture [Member]" } } }, "localname": "EquipmentAndFurnitureMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_EquitySecuritiesRealizedGainLossSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) sold during the period", "label": "Equity Securities Realized Gain loss Sold", "terseLabel": "Less: net losses recognized during the year on equity securities sold during the year" } } }, "localname": "EquitySecuritiesRealizedGainLossSold", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsEquityInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_FederalTaxIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Federal Tax Income [Member]", "terseLabel": "Federal Tax Income [Member]" } } }, "localname": "FederalTaxIncomeMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cyrx_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of finance lease cost recognized by lessee for lease contract.", "label": "Finance Lease Cost", "totalLabel": "Total finance lease cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "cyrx_FinanceLeaseRightofuseAssetAccumulatedDepreciation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease Right-of-Use Asset Accumulated Depreciation" } } }, "localname": "FinanceLeaseRightofuseAssetAccumulatedDepreciation", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_ForeignCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Customers [Member].", "label": "Foreign Customers [Member]", "terseLabel": "Foreign Customers [Member]" } } }, "localname": "ForeignCustomersMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_FreezerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents freezer.", "label": "Freezer [Member]", "terseLabel": "Freezer (Member)" } } }, "localname": "FreezerMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_FreezersGross": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held for freezers.", "label": "Freezers Gross", "terseLabel": "Freezers" } } }, "localname": "FreezersGross", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_FutureAmortizationOfFiniteLivedIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of future amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Future Amortization of Finite Lived Intangible Assets" } } }, "localname": "FutureAmortizationOfFiniteLivedIntangibleAssets", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_GlobalLogisticsSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Global Logistics Solutions segment.", "label": "Global Logistics Solutions [Member]", "terseLabel": "Global Logistics Solutions [Member]" } } }, "localname": "GlobalLogisticsSolutionsMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "cyrx_HumanReproductiveMedicineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents human reproductive medicine.", "label": "Human Reproductive Medicine [Member]", "terseLabel": "Human Reproductive Medicine (Member)" } } }, "localname": "HumanReproductiveMedicineMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "cyrx_InstallmentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to installment one.", "label": "Installment One [Member]", "terseLabel": "repaid in 2025" } } }, "localname": "InstallmentOneMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "domainItemType" }, "cyrx_InstallmentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to installment two.", "label": "Installment Two [Member]", "terseLabel": "repaid in 2028" } } }, "localname": "InstallmentTwoMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "domainItemType" }, "cyrx_InterestAmountOnAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount on interest include in accounts payable and accrued liabilities.", "label": "Interest amount on Accounts Payable and Accrued Liabilities", "terseLabel": "Interest expense" } } }, "localname": "InterestAmountOnAccountsPayableAndAccruedLiabilities", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_InterestCostOnConvertibleNoteSettledByIssuanceOfCommonStock": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "NA", "label": "Interest cost on convertible Note Settled By Issuance Of Common Stock", "terseLabel": "Interest expense on convertible note settled by issuance of common stock" } } }, "localname": "InterestCostOnConvertibleNoteSettledByIssuanceOfCommonStock", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_InventoryRelatedToAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory related to acquisition.", "label": "Inventory Related To Acquisition", "terseLabel": "Step up inventory related to acquisition" } } }, "localname": "InventoryRelatedToAcquisition", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_IssuanceOfCommonStockForConvertibleDebtAndAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "NA", "label": "Issuance of common Stock For Convertible Debt And Accrued Interest", "terseLabel": "Issuance of common stock for convertible debt and accrued interest" } } }, "localname": "IssuanceOfCommonStockForConvertibleDebtAndAccruedInterest", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cyrx_IssuanceOfCommonStockForConvertibleDebtAndAccruedInterestShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Issuance of Common Stock for Convertible Debt and Accrued Interest Shares", "terseLabel": "Issuance of common stock for convertible debt and accrued interest (in shares)" } } }, "localname": "IssuanceOfCommonStockForConvertibleDebtAndAccruedInterestShares", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "cyrx_LeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating and finance lease.", "label": "Lease Weighted Average Remaining Lease Term 1", "verboseLabel": "Lease Weighted Average Remaining Lease Term" } } }, "localname": "LeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cyrx_LesseeOperatingAndFinanceLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee, operating and finance leases.", "label": "Lessee Operating And Finance Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingAndFinanceLeasesTextBlock", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "cyrx_LesseeOptionToExtend": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend operating and finance sublease.", "label": "Lessee Option to Extend" } } }, "localname": "LesseeOptionToExtend", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cyrx_MaturityPeriodOfHighlyLiquidInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity period of highly liquid investments.", "label": "Maturity Period Of Highly Liquid Investments" } } }, "localname": "MaturityPeriodOfHighlyLiquidInvestments", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cyrx_MutualFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mutual Funds [Member]", "terseLabel": "Mutual Funds [Member]" } } }, "localname": "MutualFundsMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "cyrx_MveCryobiologicalStorageBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for MVE cryobiological storage business.", "label": "Mve Cryobiological Storage Business [Member]", "terseLabel": "MVE" } } }, "localname": "MveCryobiologicalStorageBusinessMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionsTables", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "cyrx_NatureOfBusinessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Nature of the Business" } } }, "localname": "NatureOfBusinessAbstract", "nsuri": "http://www.Cryoport.com/20201231", "xbrltype": "stringItemType" }, "cyrx_NetProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Net Proceeds From Issuance Of Private Placement", "terseLabel": "Net proceeds from private placement" } } }, "localname": "NetProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_NonCashNetUnrealizedGainOnAvailableForSaleSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net unrealized gain on available-for-sale debt securities", "label": "Non Cash Net Unrealized gain on Available for Sale Securities", "terseLabel": "Net unrealized gain (loss) on available-for-sale debt securities" } } }, "localname": "NonCashNetUnrealizedGainOnAvailableForSaleSecurities", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_NonUsEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Non US employees.", "label": "Non Us Employees [Member]", "terseLabel": "Non US employees" } } }, "localname": "NonUsEmployeesMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "cyrx_NotesPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entire disclosure of note payable.", "label": "Notes Payable [Text Block]", "terseLabel": "Note Payable" } } }, "localname": "NotesPayableTextBlock", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayable" ], "xbrltype": "textBlockItemType" }, "cyrx_NumberOfBoardMemberWhoCanBeElectedByPreferredStockHolders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of board members who can be elected by preferred stock holders.", "label": "Number Of Board Member Who Can Be Elected By Preferred Stock Holders", "terseLabel": "Number of member to the board of directors who can be elected by the preferred stock holders" } } }, "localname": "NumberOfBoardMemberWhoCanBeElectedByPreferredStockHolders", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_NumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of installments under which notes to be repayable.", "label": "Number of Installments", "terseLabel": "Number of installment" } } }, "localname": "NumberOfInstallments", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "integerItemType" }, "cyrx_OperatingLossCarryforwardsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the operating loss carryforwards percentage.", "label": "Operating Loss Carryforwards Percent", "terseLabel": "Operating Loss Carryforwards, Percent" } } }, "localname": "OperatingLossCarryforwardsPercent", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_PaidInKindDividendOnSeriesCConvertiblePreferredStockValue": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid-in-kind dividend on Series C convertible preferred stock.", "label": "Paid-in-Kind Dividend on Series C Convertible Preferred Stock, Value", "negatedLabel": "Paid-in-kind preferred stock dividend, including beneficial conversion feature" } } }, "localname": "PaidInKindDividendOnSeriesCConvertiblePreferredStockValue", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "cyrx_PaidInKindDividendOnSeriesCConvertiblePreferredStocksValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid-in-kind dividend on Series C convertible preferred stock.", "label": "Paid In Kind Dividend On Series C Convertible Preferred Stocks Value", "terseLabel": "Paid-in-kind preferred stock dividend, including beneficial conversion feature" } } }, "localname": "PaidInKindDividendOnSeriesCConvertiblePreferredStocksValue", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_PatentsAndTrademarksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Patents And Trademarks [Member]", "terseLabel": "Cryoport patents and trademarks" } } }, "localname": "PatentsAndTrademarksMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cyrx_PercentageOfEquityInterestAgreedToBeAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity interest agreed to be acquired by the company.", "label": "Percentage Of Equity Interest Agreed To Be Acquired", "terseLabel": "Percentage of equity interest agreed to be acquired" } } }, "localname": "PercentageOfEquityInterestAgreedToBeAcquired", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "percentItemType" }, "cyrx_Plan2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Plan2018 [Member]", "terseLabel": "Plan 2018 [Member]" } } }, "localname": "Plan2018Member", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_PreferredClassCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class C stock or outstanding preferred class C stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class C [Member]", "terseLabel": "Class C Preferred Stock" } } }, "localname": "PreferredClassCMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "cyrx_PreferredStockConvertibleConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of convertible preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price Per Share", "terseLabel": "Conversion price (in dollars per share)", "verboseLabel": "Conversion price (in dollars per share)" } } }, "localname": "PreferredStockConvertibleConversionPricePerShare", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "cyrx_PreferredStockConvertibleConversionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion rate of convertible preferred stock.", "label": "Preferred Stock, Convertible, Conversion Rate", "terseLabel": "Conversion rate" } } }, "localname": "PreferredStockConvertibleConversionRate", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "cyrx_PreferredStockConvertibleStockPriceTriggerPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock as a percentage of conversion price, which would be required to be attained for the conversion of convertible preferred stock to become effective.", "label": "Preferred Stock, Convertible, Stock Price Trigger, Percentage", "terseLabel": "Stock price trigger as a percentage of conversion price for conversion of preferred stock" } } }, "localname": "PreferredStockConvertibleStockPriceTriggerPercentage", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_PreferredStockConvertibleThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible preferred stock must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Preferred Stock, Convertible, Threshold Consecutive Trading Days", "verboseLabel": "Threshold consecutive trading days for conversion of preferred stock" } } }, "localname": "PreferredStockConvertibleThresholdConsecutiveTradingDays", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_PreferredStockConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible preferred stock must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Preferred Stock, Convertible, Threshold Trading Days", "terseLabel": "Threshold trading days for conversion of preferred stock" } } }, "localname": "PreferredStockConvertibleThresholdTradingDays", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cyrx_PreferredStockIfNotRepurchasedDividendRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock, if not repurchased.", "label": "Preferred Stock If Not Repurchased, Dividend Rate, Percentage", "terseLabel": "Dividend rate on shares not repurchased" } } }, "localname": "PreferredStockIfNotRepurchasedDividendRatePercentage", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_PreferredStockOwnershipPercentageToExerciseRightToNominateBoard": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold percentage of ownership of shares to be held by preferred stock holders, to exercise their right to nominate the members of the board.", "label": "Preferred Stock, Ownership Percentage, To Exercise Right To Nominate Board", "terseLabel": "Percentage of stock to be held to exercise the right to nominate member of board of directors" } } }, "localname": "PreferredStockOwnershipPercentageToExerciseRightToNominateBoard", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_PreferredStockRedemptionPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to redemption period for preferred stock.", "label": "Preferred Stock, Redemption Period [Axis]" } } }, "localname": "PreferredStockRedemptionPeriodAxis", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "cyrx_PreferredStockRedemptionPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to redemption period for preferred stock.", "label": "Preferred Stock Redemption Period [Domain]", "terseLabel": "Preferred Stock, Redemption Period [Domain]" } } }, "localname": "PreferredStockRedemptionPeriodDomain", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "cyrx_PreferredStockRedemptionPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for redemption period for preferred stock, one.", "label": "Preferred Stock Redemption Period One [Member]", "terseLabel": "Prior to the 180-day anniversary of October 1, 2020" } } }, "localname": "PreferredStockRedemptionPeriodOneMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "cyrx_PreferredStockRedemptionPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for redemption period for preferred stock, three.", "label": "Preferred Stock Redemption Period Three [Member]", "terseLabel": "At any time beginning six years after Closing Date" } } }, "localname": "PreferredStockRedemptionPeriodThreeMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_PreferredStockRedemptionPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for redemption period for preferred stock, two.", "label": "Preferred Stock Redemption Period Two [Member]", "terseLabel": "At any time beginning five years after Closing Date (but prior to six years after the Closing Date)" } } }, "localname": "PreferredStockRedemptionPeriodTwoMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_PreferredStockRedemptionPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption price of preferred stock as a percentage of the purchase price paid by plus any accrued and unpaid dividends.", "label": "Preferred Stock, Redemption Price, Percentage", "terseLabel": "Redemption price (as a percent)" } } }, "localname": "PreferredStockRedemptionPricePercentage", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "cyrx_PreferredStockSharesToBeRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares of preferred stock, that may be redeemed by the company.", "label": "Preferred Stock, Shares To Be Redeemed", "terseLabel": "Number of shares to be redeemed", "verboseLabel": "Number of shares to be redeemed" } } }, "localname": "PreferredStockSharesToBeRedeemed", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "cyrx_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public Offering [Member]", "terseLabel": "Public offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "cyrx_PurchaseOfEquipmentThroughCapitalLeaseObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase of equipment through capital lease obligations in non cash investing and financing activities.", "label": "Purchase Of Equipment Through Capital Lease Obligation", "verboseLabel": "Purchase of equipment through finance lease obligations" } } }, "localname": "PurchaseOfEquipmentThroughCapitalLeaseObligation", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_RangeEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range eight.", "label": "Range Eight [Member]", "terseLabel": "$17.36 - 55.48 [Member]" } } }, "localname": "RangeEightMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "cyrx_RangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Range Five [Member]", "terseLabel": "$7.80 - 8.65 [Member]" } } }, "localname": "RangeFiveMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "cyrx_RangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Range Four [Member]", "terseLabel": "$5.00 - 7.67 [Member]" } } }, "localname": "RangeFourMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "cyrx_RangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Range One [Member]", "terseLabel": "$1.08 - 3.07 [Member]" } } }, "localname": "RangeOneMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "cyrx_RangeSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RangeSevenMember", "label": "Range Seven [Member]", "terseLabel": "$13.37 - 16.95 [Member]" } } }, "localname": "RangeSevenMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "cyrx_RangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Range Six [Member]", "terseLabel": "$9.29 - 12.79 [Member]" } } }, "localname": "RangeSixMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "cyrx_RangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Range Three [Member]", "terseLabel": "$4.56 - 4.92 [Member]" } } }, "localname": "RangeThreeMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "cyrx_RangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Range Two [Member]", "terseLabel": "$3.19 - 3.44 [Member]" } } }, "localname": "RangeTwoMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "cyrx_RealizedLossOnInvestmentsInEquitySecurities": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Realized loss on investments in equity securities.", "label": "Realized loss on investments in equity securities", "terseLabel": "Realized loss on investments in equity securities" } } }, "localname": "RealizedLossOnInvestmentsInEquitySecurities", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of reclassification of realized gain on available-for-sale debt securities to earnings.", "label": "Reclassification of Realized Gain on Available-For-Sale Debt Securities to Earnings", "terseLabel": "Reclassification of realized gain on available-for-sale debt securities to earnings" } } }, "localname": "ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_ReimbursementOfTransactionalExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transactional expenses reimbursed by the company.", "label": "Reimbursement Of Transactional Expenses", "terseLabel": "Reimbursement of transactional expenses" } } }, "localname": "ReimbursementOfTransactionalExpenses", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_RepaymentOfFinanceLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow of finance lease liabilities repayment", "label": "Repayment of finance lease liabilities", "negatedLabel": "Repayment of finance lease liabilities" } } }, "localname": "RepaymentOfFinanceLeaseLiabilities", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_RevenueRecognitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Recognition", "label": "Revenue Recognition [Line Items]" } } }, "localname": "RevenueRecognitionLineItems", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "stringItemType" }, "cyrx_RevenueRecognitionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Recognition", "label": "Revenue Recognition [Table]" } } }, "localname": "RevenueRecognitionTable", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "stringItemType" }, "cyrx_RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Leases Liability", "negatedLabel": "Change in operating lease right-of-use assets and lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cyrx_RightofuseAssetsObtainedInExchangeForLeaseObligationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Right-Of-Use Assets Obtained In Exchange For Lease Obligations [Abstract]", "verboseLabel": "Right-of-use assets obtained in exchange for lease obligations:" } } }, "localname": "RightofuseAssetsObtainedInExchangeForLeaseObligationsAbstract", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "stringItemType" }, "cyrx_ScenarioOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario, one.", "label": "Scenario One [Member]", "terseLabel": "First 90 days beginning on, and including the date on which such Registration Default occurs" } } }, "localname": "ScenarioOneMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_ScenarioTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario, two.", "label": "Scenario Two [Member]", "terseLabel": "After 90 days of the occurrence of Registration Default" } } }, "localname": "ScenarioTwoMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of common stock reserved for future issuance.", "label": "Schedule Of Common Stock Reserved For Future Issuances [Table Text Block]", "terseLabel": "Schedule of common stock were issuable upon exercise of stock options and the conversion of convertible senior notes and Series C Preferred stock" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cyrx_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Employee Related Liabilities Table Discloser Text block", "label": "Schedule Of Employee Related Liabilities [Table Text Block]", "terseLabel": "Schedule of employee related liabilities" } } }, "localname": "ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesTables" ], "xbrltype": "textBlockItemType" }, "cyrx_ScheduleOfInterestExpensesOnConvertibleNotesPayableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for interest expenses on convertible notes payable.", "label": "Schedule Of Interest Expenses On Convertible Notes Payable [Table Text Block]", "terseLabel": "Schedule of interest expenses incurred in connection with the Notes" } } }, "localname": "ScheduleOfInterestExpensesOnConvertibleNotesPayableTableTextBlock", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesTables" ], "xbrltype": "textBlockItemType" }, "cyrx_ScheduleOfLeaseSupplementalCashFlowAndOtherDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lease supplemental cash flow and other disclosures.", "label": "Schedule Of Lease Supplemental Cash Flow And Other Disclosures [Table Text Block]", "verboseLabel": "Schedule of other information related to leases" } } }, "localname": "ScheduleOfLeaseSupplementalCashFlowAndOtherDisclosuresTableTextBlock", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "cyrx_ScheduleOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Significant Accounting Policies [Table].", "label": "Schedule Of Significant Accounting Policies [Table]" } } }, "localname": "ScheduleOfSignificantAccountingPoliciesTable", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cyrx_ScheduleOfStockholdersEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Stockholders Equity [Table].", "label": "Schedule Of Stockholders Equity [Table]" } } }, "localname": "ScheduleOfStockholdersEquityTable", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "cyrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract].", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]", "verboseLabel": "Aggregated Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "cyrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract].", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "verboseLabel": "Weighted-Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "cyrx_SignificantAccountingPoliciesAdditionalInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies Additional Information [Line Items]" } } }, "localname": "SignificantAccountingPoliciesAdditionalInformationLineItems", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "cyrx_StatutoryCreditUsageLimitForResearchAndDevelopmentForTaxRelief": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of statutory limit of Reasearch and development credit usage limit for the purpose of allowing tax relief.", "label": "Statutory Credit Usage Limit for Research and Development for Tax Relief", "terseLabel": "Amount of maximum allowed reasearch and development credit usage" } } }, "localname": "StatutoryCreditUsageLimitForResearchAndDevelopmentForTaxRelief", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock issued during the period for cashless exercise of warrants.", "label": "Stock Issued During Period Shares Cashless Exercise Of Warrants" } } }, "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "cyrx_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options and warrants exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options And Warrants Exercised", "verboseLabel": "Proceeds from exercise of stock options and warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "cyrx_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options and warrants.", "label": "Stock Issued During Period Value Stock Options And Warrants Exercised", "terseLabel": "Proceeds from exercise of stock options and warrants" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "cyrx_TaxExaminationPeriodForForeignSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period over which foreign subsidiaries are subject to examination by Indian tax authorities.", "label": "Tax Examination Period for Foreign Subsidiaries", "terseLabel": "Period over which foreign subsidiaries subject to examination by indian tax authorities" } } }, "localname": "TaxExaminationPeriodForForeignSubsidiaries", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "cyrx_ThirdPartyOfferingRelatedCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of third party offering related costs incurred by the company.", "label": "Third Party Offering Related Costs", "terseLabel": "Third-party offering related costs" } } }, "localname": "ThirdPartyOfferingRelatedCosts", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_TruckAndAutoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents both truck and auto.", "label": "Truck And Auto [Member]", "terseLabel": "Truck and Auto (Member)" } } }, "localname": "TruckAndAutoMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cyrx_TrucksAndAutosGross": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for trucks and autos.", "label": "Trucks and Autos Gross", "terseLabel": "Trucks and autos" } } }, "localname": "TrucksAndAutosGross", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_UsEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to US employees.", "label": "Us Employees [Member]", "terseLabel": "US employees" } } }, "localname": "UsEmployeesMember", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "cyrx_WarrantsExercisedIntrinsicValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "These lines are represents warrants exercised intrinsic value.", "label": "Warrants Exercised Intrinsic Value" } } }, "localname": "WarrantsExercisedIntrinsicValue", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cyrx_WeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Discount Rate [Abstract]", "verboseLabel": "Weighted-Average Discount Rate" } } }, "localname": "WeightedAverageDiscountRateAbstract", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "stringItemType" }, "cyrx_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Lease Term [Abstract]", "verboseLabel": "Weighted-Average Remaining Lease Term" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.Cryoport.com/20201231", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas [Member]", "terseLabel": "Americas [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific (APAC) [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r194", "r297", "r302", "r573" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r331", "r334", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r570", "r574" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r331", "r334", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r570", "r574" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r194", "r297", "r302", "r573" ], "lang": { "en-us": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r190", "r297", "r300", "r531", "r569", "r571" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r190", "r297", "r300", "r531", "r569", "r571" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r311", "r331", "r334", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r570", "r574" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r311", "r331", "r334", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r570", "r574" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "label": "Scenario Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r191", "r192", "r297", "r301", "r572", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r191", "r192", "r297", "r301", "r572", "r599", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r259", "r332", "r516" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r195", "r513" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "verboseLabel": "Accrued Compensation and Related Expenses" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "verboseLabel": "Accounts payable and other accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r23", "r196", "r197" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "verboseLabel": "Accounts receivable, net of allowance for doubtful accounts of $ 1.1 million and $0.1 million, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r10", "r11", "r39" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "verboseLabel": "Accrued salaries and wages" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r10", "r39", "r309" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Vacation, Current", "verboseLabel": "Accrued paid time off" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r35", "r243" ], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r58", "r59", "r60", "r558", "r579", "r580" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r57", "r60", "r63", "r122", "r123", "r124", "r453", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Estimated Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r24" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r122", "r123", "r124", "r365", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r336", "r338", "r371", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r276", "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r338", "r362", "r370" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r198", "r214", "r215", "r217" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Allowance for Doubtful Accounts Receivable", "verboseLabel": "Allowance for doubtful accounts receivable" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r77", "r101", "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesInterestExpensesIncurredOnConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r101", "r493" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "verboseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r101", "r228", "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization Expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r115", "r177", "r182", "r188", "r212", "r447", "r454", "r476", "r535", "r557" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r55", "r115", "r212", "r447", "r454", "r476" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r465" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r202", "r219" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities, Amortized Cost Basis", "totalLabel": "Total, Amortized Cost", "verboseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r204" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "verboseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r206" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost", "verboseLabel": "Due within one year, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r205", "r206", "r550" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "verboseLabel": "Due within one year, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r201", "r203", "r219", "r541" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities", "totalLabel": "Total, Fair Value", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r340", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r9", "r242" ], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 6.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r330", "r333" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionsTables", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r330", "r333", "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionsTables", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Schedule of pro forma consolidated results of operations" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill expected to be deductible for income tax purposes" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r420", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r420", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r435", "r436", "r437" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase consideration paid" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 10.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 12.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable and other accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "negatedLabel": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 14.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred tax liability", "verboseLabel": "Net deferred tax liabilities increase due to acquisition of MVE and CRYOPDP" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets", "verboseLabel": "Annual Estimated Fair Value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r424", "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r424", "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 11.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "negatedLabel": "Note payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 15.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedLabel": "Other long-term liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other long-term assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r424", "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r425" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Purchase price allocation:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisitions" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r111", "r419" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r106", "r107", "r108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Fixed assets included in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasedAssetsGross": { "auth_ref": [ "r496" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of leased physical assets used in the normal conduct of business to produce goods and services.", "label": "Capital Leased Assets, Gross", "terseLabel": "Capital leased assets, gross" } } }, "localname": "CapitalLeasedAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation": { "auth_ref": [ "r495", "r496" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total charge for the use of long-lived depreciable assets subject to a lease meeting the criteria for capitalization.", "label": "Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation", "terseLabel": "Capital leases, lessee balance sheet, assets by major class, accumulated depreciation" } } }, "localname": "CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r613" ], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "verboseLabel": "Computers and software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r32", "r582", "r583" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Short-Term Investments" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r32", "r103" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0 }, "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r13", "r104", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r32" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "totalLabel": "Cash, cash equivalents and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.", "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]", "verboseLabel": "Cash, Cash Equivalents and Short-Term Investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r96", "r103", "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents - end of year", "periodStartLabel": "Cash and cash equivalents - beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r96", "r481" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value [Abstract]", "verboseLabel": "Cash equivalents:" } } }, "localname": "CashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r113", "r115", "r136", "r137", "r138", "r141", "r143", "r150", "r151", "r152", "r212", "r476" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r258", "r543", "r562" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r255", "r256", "r257", "r260" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common Stock Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share (in dollars per share)", "verboseLabel": "Common stock, par value per share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized; 39,837,058 and 37,339,787 issued and outstanding at December 31, 2020 and 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefit Plans" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "verboseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r66", "r68", "r69", "r74", "r546", "r565" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r229", "r232", "r433" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software Intangible Asset [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r160", "r161", "r194", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r160", "r161", "r194", "r474", "r475", "r581" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r156", "r553" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r160", "r161", "r194", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "verboseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r111", "r449" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r242" ], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 10.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "verboseLabel": "Fixed assets in process" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r287", "r288", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r287", "r288", "r298" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Convertible Senior notes" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Note [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "verboseLabel": "Convertible senior notes, net of discount of $0.4 million" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of components of notes payable" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r43" ], "calculation": { "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "totalLabel": "Net carrying value of Notes payable" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Class A convertible preferred stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r20", "r21", "r277", "r280" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Shares to be issued upon conversion", "verboseLabel": "Shares to be issued upon conversion" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r79", "r115", "r212", "r476" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "verboseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of Revenues [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal, State and Local, Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "verboseLabel": "Current:" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r116", "r403", "r411" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r119", "r403" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r116", "r403", "r411", "r413" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current expense" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt and equity securities. Excludes other-than-temporary impairment (OTTI).", "label": "Available-for-sale Securities, Gross Realized Gains", "terseLabel": "Losses on available-for-sale investments" } } }, "localname": "DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r106", "r108" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Common stock issued upon conversion of notes" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Senior Notes" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r17", "r266", "r537", "r555" ], "calculation": { "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleLongTermNotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "verboseLabel": "Principal amount of Senior Notes" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Initial conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r42", "r277", "r280", "r282" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion rate" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r492", "r494" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r41", "r268", "r492" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r43", "r117", "r277", "r281", "r282", "r283", "r491", "r492", "r494", "r552" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureNotePayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r207" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities, Gross Realized Gain (Loss)", "negatedLabel": "Realized (gain) loss on available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities [Table Text Block]", "verboseLabel": "Schedule of available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r36", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "verboseLabel": "Deferred Financing Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability": { "auth_ref": [ "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the liability as of the balance sheet date to an individual under a deferred compensation arrangement. This amount may be the result of periodic accruals made over the period of active employment, or reflect termination benefits resulting contractual terms or a death benefit.", "label": "Deferred Compensation Arrangement with Individual, Recorded Liability", "terseLabel": "Total benefit obligation" } } }, "localname": "DeferredCompensationArrangementWithIndividualRecordedLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r116", "r404", "r411" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails": { "order": 4.0, "parentTag": "cyrx_DeferredIncomeTaxExpenseBenefitTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r36", "r493" ], "calculation": { "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleLongTermNotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesComponentsOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r116", "r404", "r411" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails": { "order": 2.0, "parentTag": "cyrx_DeferredIncomeTaxExpenseBenefitTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r379", "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r116", "r404", "r411", "r412", "r413" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Net deferred tax (asset) liability" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r18", "r19", "r393", "r536", "r554" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Total deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r379", "r380" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "negatedLabel": "Deferred tax liability", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOtherTaxExpenseBenefit": { "auth_ref": [ "r119", "r405", "r410" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails": { "order": 1.0, "parentTag": "cyrx_DeferredIncomeTaxExpenseBenefitTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.", "label": "Deferred Other Tax Expense (Benefit)", "terseLabel": "Change in valuation allowance" } } }, "localname": "DeferredOtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r116", "r404", "r411" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails": { "order": 3.0, "parentTag": "cyrx_DeferredIncomeTaxExpenseBenefitTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r394" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r396" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred Tax Assets, Net of Valuation Allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r401", "r402" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "verboseLabel": "Net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r401", "r402" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "verboseLabel": "Expenses recognized for granting of options and warrants" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r401", "r402" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "verboseLabel": "Accrued expenses and reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r395" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r380", "r396" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net.", "negatedTotalLabel": "Net deferred tax liability" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": { "auth_ref": [ "r401", "r402", "r440", "r441" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.", "label": "Deferred Tax Liabilities, Goodwill", "negatedLabel": "Goodwill" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r401", "r402" ], "calculation": { "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "Intangible assets", "terseLabel": "Deferred tax liability indefinite-lived assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r329" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Recognized expense" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Maximum matching employer contribution per employee" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum employee contribution" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsAssets": { "auth_ref": [ "r36" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.", "label": "Deposits Assets", "verboseLabel": "Deposits" } } }, "localname": "DepositsAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r101", "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r101", "r172" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r297", "r300", "r301", "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue by major source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r101", "r240", "r245" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPaidinkind": { "auth_ref": [ "r284", "r551" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid paid-in-kind dividends (PIK) declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Paid-in-kind", "terseLabel": "Dividends, paid-in-kind" } } }, "localname": "DividendsPaidinkind", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "E M E A [Member]", "terseLabel": "Europe, the Middle East and Africa (EMEA) [Member]" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "definitionGuidance": "Basic and diluted net loss per share", "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share attributable to common stockholders - basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r111", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Basic and Diluted Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r481" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "totalLabel": "Accrued compensation and related expenses, Total", "verboseLabel": "Accrued compensation and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAccruedCompensationAndRelatedExpensesDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Compensation and Related Expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted average recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "verboseLabel": "Unrecognized compensation cost related to unvested stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r122", "r123", "r124", "r126", "r131", "r133", "r149", "r213", "r276", "r284", "r365", "r366", "r367", "r407", "r408", "r482", "r483", "r484", "r485", "r486", "r487", "r575", "r576", "r577" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r472" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r210", "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Net losses recognized during the year on equity securities" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsEquityInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r210", "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "totalLabel": "Unrealized gains (losses) recognized during the year on equity securities still held at December 31, 2020 and 2019" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsEquityInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of fair value hierarchy" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r326", "r466", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r465", "r466", "r467", "r468", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r312", "r314", "r319", "r326", "r466", "r518" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r312", "r314", "r319", "r326", "r466", "r519" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r326", "r466", "r520" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r326", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r111", "r471", "r473" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r499", "r504", "r512" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail": { "order": 2.0, "parentTag": "cyrx_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "verboseLabel": "Interest on finance lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r501", "r506" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "verboseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Leases Future Minimum Payment [Abstract]", "verboseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r498", "r511" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r498" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities", "verboseLabel": "Current lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r498" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Noncurrent lease liabilities", "verboseLabel": "Finance lease liabilities, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payments, Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Capital Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, Payments, Due Year Three", "verboseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, Payments, Due Year Two", "verboseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r511" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r500", "r506" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "verboseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r499", "r504", "r512" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail": { "order": 1.0, "parentTag": "cyrx_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "verboseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r509", "r512" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r508", "r512" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Schedule of the preliminary fair value of intangible assets acquired at the date of acquisition and their estimated useful lives and amortization expense based on their respective useful lives" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Weighted Average Amortization Period (years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r233" ], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r229", "r231", "r233", "r236", "r532", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r233", "r533" ], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Gross Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r229", "r232" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r233", "r532" ], "calculation": { "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Future amortization of intangible assets", "verboseLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Country [Member]", "terseLabel": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r477", "r478", "r479", "r480" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r111", "r489" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r242" ], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "verboseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r223", "r224", "r534" ], "calculation": { "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "verboseLabel": "Additions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r111", "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "verboseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r78", "r115", "r177", "r181", "r184", "r187", "r189", "r212", "r476" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross margin", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r101", "r237" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r111", "r239", "r248" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "verboseLabel": "Other Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r118", "r177", "r181", "r184", "r187", "r189" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r383", "r391", "r398", "r409", "r414", "r416", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Accrual for interest and penalties" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r116", "r132", "r133", "r175", "r381", "r410", "r415", "r568" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Benefit from (provision for) income taxes", "totalLabel": "Income Tax Expense (Benefit), Total", "verboseLabel": "Income Tax Expense (Benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesExpenseForIncomeTaxesDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r70", "r111", "r377", "r378", "r391", "r392", "r397", "r406", "r600" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "verboseLabel": "Valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r376", "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Rate changes" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Computed tax benefit at federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount", "verboseLabel": "Stock compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "verboseLabel": "Permanent differences and other" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State tax, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r98", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "verboseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r100" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and other accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r100" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "auth_ref": [ "r100" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "label": "Increase (Decrease) in Deposit Assets", "negatedLabel": "Deposits" } } }, "localname": "IncreaseDecreaseInDepositOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r100" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "verboseLabel": "Accrued compensation and related expenses" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r100" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent": { "auth_ref": [ "r100" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due within one year (or one business cycle) of receivables that were originally due beyond one year (or one business cycle).", "label": "Increase (Decrease) in Long-term Receivables, Current", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInLongTermReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities, net of effects of acquisition:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r100" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "verboseLabel": "Goodwill and Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r111", "r232", "r528", "r529", "r530", "r532" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "verboseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r71", "r171", "r490", "r493", "r547" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r83", "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total interest expense on Notes" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesInterestExpensesIncurredOnConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Coupon interest" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesInterestExpensesIncurredOnConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r94", "r97", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r49" ], "calculation": { "http://www.Cryoport.com/role/DisclosureInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "verboseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r52" ], "calculation": { "http://www.Cryoport.com/role/DisclosureInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventory, Net, Total", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoriesDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r12", "r53", "r111", "r146", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r51" ], "calculation": { "http://www.Cryoport.com/role/DisclosureInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "verboseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r50" ], "calculation": { "http://www.Cryoport.com/role/DisclosureInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r81", "r83" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "terseLabel": "Investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r211", "r566" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "verboseLabel": "Short-Term Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "verboseLabel": "Schedule of investments based on stated contractual maturities" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Land": { "auth_ref": [ "r8", "r34" ], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 7.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r510", "r512" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Cost [Abstract]", "verboseLabel": "Finance lease cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "verboseLabel": "Schedule of components of lease expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r9", "r242" ], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 9.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "verboseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule Of Future Minimum Operating And Finance Lease Payments Under Non Cancellable Leases Table Text Block", "terseLabel": "Schedule of future minimum lease payments under non-cancellable leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r511" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r511" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r115", "r183", "r212", "r448", "r454", "r455", "r476" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r115", "r212", "r476", "r538", "r560" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40", "r115", "r212", "r448", "r454", "r455", "r476" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r120", "r263" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "Notes payable, 2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTerm": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Long-term Debt, Term" } } }, "localname": "LongTermDebtTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r43" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Note payable" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNotePayableDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable" } } }, "localname": "LongTermNotesPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r43", "r264" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r9", "r242" ], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 8.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "verboseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MajorCustomersPolicyPolicyTextBlock": { "auth_ref": [ "r159", "r160", "r161", "r194" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.", "label": "Major Customers, Policy [Policy Text Block]", "verboseLabel": "Customers" } } }, "localname": "MajorCustomersPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "verboseLabel": "Money market mutual fund" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market mutual fund" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MutualFundMember": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.", "label": "Mutual Fund [Member]", "terseLabel": "Mutual funds" } } }, "localname": "MutualFundMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r153", "r165" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of the Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r96" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows From Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r96" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash Flows From Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r96", "r99", "r102" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows From Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r64", "r67", "r73", "r102", "r115", "r125", "r127", "r128", "r129", "r130", "r132", "r133", "r139", "r177", "r181", "r184", "r187", "r189", "r212", "r476", "r545", "r564" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r127", "r128", "r129", "r130", "r134", "r135", "r140", "r143", "r177", "r181", "r184", "r187", "r189" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders", "verboseLabel": "Net loss attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-compete agreement" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": { "auth_ref": [ "r199", "r218" ], "lang": { "en-us": { "role": { "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.", "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]", "verboseLabel": "Off-Balance Sheet Arrangements" } } }, "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating costs and expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r177", "r181", "r184", "r187", "r189" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "presentationGuidance": "Loss from operations", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r505", "r512" ], "calculation": { "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r498" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "verboseLabel": "Current lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r498" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent lease liabilities", "verboseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r502", "r506" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "verboseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r497" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r509", "r512" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r508", "r512" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "verboseLabel": "Operating Leases" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesPaymentsUnderNonCancellableLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r271", "r461", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed To Issuers Equity Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_OrderOrProductionBacklogMember": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination.", "label": "Order Or Production Backlog [Member]", "terseLabel": "Order backlog" } } }, "localname": "OrderOrProductionBacklogMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r56", "r58", "r445", "r452" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Net unrealized gain (loss) on available-for-sale debt securities" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r445", "r446", "r452" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r65", "r68", "r445", "r446", "r452" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r58", "r61", "r62", "r208" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "negatedLabel": "Reclassification of realized (gain) loss on available-for-sale debt securities to earnings" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other long-term assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherShortTermInvestments": { "auth_ref": [ "r54", "r544", "r563" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term investments classified as other.", "label": "Other Short-term Investments", "verboseLabel": "Short-term Investments" } } }, "localname": "OtherShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Underwritten public offering" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r93" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Payment of deferred financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "verboseLabel": "Direct and incremental expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates": { "auth_ref": [ "r87" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Payments to Acquire Businesses and Interest in Affiliates", "negatedLabel": "Cash paid for acquisitions" } } }, "localname": "PaymentsToAcquireBusinessesAndInterestInAffiliates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r87", "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r88" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Patent and trademark costs" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r88" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r89" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-term Investments", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopSoftware": { "auth_ref": [ "r88" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments to Develop Software", "negatedLabel": "Software development costs" } } }, "localname": "PaymentsToDevelopSoftware", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r311", "r313", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r335" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureEmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r340", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class A [Member]", "terseLabel": "Class A Preferred Stock" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class B [Member]", "terseLabel": "Class B Preferred Stock" } } }, "localname": "PreferredClassBMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred stock, dividend rate (as a percent)" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r21", "r113", "r277", "r278" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Liquidation preference (in dollars per share)", "verboseLabel": "Liquidation preference (in dollars per share)" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value per share (in dollars per share)", "verboseLabel": "Preferred stock, par value per share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r30", "r31" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Policy [Policy Text Block]", "verboseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from the offering" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r90" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from public offering, net of offering costs", "verboseLabel": "Proceeds from public offering, net of offering costs" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r90" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r90" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of stock", "verboseLabel": "Proceeds from issuance of Series C convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Aggregate purchase price" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "auth_ref": [ "r86" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments", "verboseLabel": "Sales/maturities of short-term investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r91" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-term Debt", "verboseLabel": "Proceeds from issuance of convertible senior notes" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r90" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of stock options and warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r261", "r262", "r542" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "verboseLabel": "Product warranty accrued liabilities" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r64", "r67", "r95", "r115", "r125", "r132", "r133", "r177", "r181", "r184", "r187", "r189", "r212", "r445", "r450", "r451", "r457", "r458", "r476", "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r35", "r244" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r249", "r601", "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r34", "r242" ], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r244", "r561" ], "calculation": { "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, Plant and Equipment, Net, Total", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r33", "r111", "r244", "r601", "r602" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Schedule of property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r242" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r76", "r216" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for Doubtful Accounts", "terseLabel": "Provision for bad debt" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Data" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "verboseLabel": "Quarterly Financial Data" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialData" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r374", "r613" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Engineering and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r111", "r374" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "verboseLabel": "Engineering and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r284", "r368", "r559", "r578", "r580" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r122", "r123", "r124", "r126", "r131", "r133", "r213", "r365", "r366", "r367", "r407", "r408", "r575", "r577" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r160", "r194" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue From Contract With Customer [Member]", "terseLabel": "Sales Revenue, Net [Member]" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r112", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition, Policy [Policy Text Block]", "verboseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of geographical revenues, by origin" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedient was elected not to disclose amount of transaction price allocated to remaining performance obligation and explanation of expected timing of revenue recognition for reporting period presented prior to date of initial application under retrospective method.", "label": "Revenue, Practical Expedient, Initial Application and Transition, Nondisclosure of Transaction Price Allocation to Remaining Performance Obligation [true false]", "terseLabel": "Omit disclosure of the transaction price allocated to remaining performance obligations" } } }, "localname": "RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r72", "r115", "r168", "r169", "r180", "r185", "r186", "r190", "r191", "r194", "r212", "r476", "r548" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenues", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOurGeographicalRevenuesByOriginDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r507", "r512" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "verboseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r507", "r512" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureLeasesSupplementalCashFlowsInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of number of shares excluded from the computation of diluted loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryPurchasePriceAllocationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersProFormaInformationDetails", "http://www.Cryoport.com/role/DisclosureAcquisitionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "verboseLabel": "Schedule of cash, cash equivalents and short-term investments" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of components of provision (benefit) for income taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of provision (benefit) for income taxes differs from that computed using the federal statutory rate applied to loss before provision for income taxes" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r229", "r232" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "verboseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "verboseLabel": "Schedule of income before income tax, domestic and foreign" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "verboseLabel": "Schedule of quarterly financial information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of summary of allocation of the purchase price as of the acquisition date" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r350", "r352", "r354" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Compensation, Activity [Table Text Block]", "verboseLabel": "Schedule of share-based payment awards" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r340", "r364" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]", "verboseLabel": "Schedule of Information by Exercise Price Range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r343", "r352", "r354" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "verboseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Schedule of fair value assumptions of stock options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r46", "r113", "r150", "r151", "r272", "r273", "r275", "r277", "r278", "r279", "r281", "r282", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r285", "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "verboseLabel": "Schedule of warrant activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.", "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]", "terseLabel": "Schedule of unrecognized tax benefits, excluding amounts pertaining to examined tax returns" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUtilityInventoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all information related to inventories for utilities.", "label": "Schedule of Utility Inventory [Table Text Block]", "verboseLabel": "Schedule of Utility Inventory" } } }, "localname": "ScheduleOfUtilityInventoryTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureInventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of expected future amortization of intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r194", "r569" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segment [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling General And Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Share-based Payment Arrangement, Accelerated Cost", "terseLabel": "Accelerated stock-based compensation expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Total shares available for future grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "verboseLabel": "Weighted-Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "terseLabel": "Intrinsic value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Issued", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r345", "r364" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding", "periodStartLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding", "periodStartLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "verboseLabel": "Weighted-Average Exercise Price/Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested (exercisable)", "verboseLabel": "Vested (exercisable)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Vested (exercisable)", "verboseLabel": "Vested (exercisable)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested (exercisable)", "verboseLabel": "Vested (exercisable)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "verboseLabel": "Expected to vest after (unexercisable)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "verboseLabel": "Expected to vest after (unexercisable)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "verboseLabel": "Expected to vest after (unexercisable)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r337", "r341" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Issued", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r111", "r340", "r342" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options", "terseLabel": "Number Exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options", "terseLabel": "Number Outstanding" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r359", "r369" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAssumptionsUsedToEstimateFairValueOfStockOptionsDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested (exercisable)", "verboseLabel": "Vested (exercisable)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Expected to vest after (unexercisable)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Life (Years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issued, price per share (in dollars per share)", "verboseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r16", "r539", "r540", "r556" ], "calculation": { "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0 }, "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Total short-term investments", "verboseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-term Investments [Abstract]", "verboseLabel": "Short-term investments:" } } }, "localname": "ShortTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r194", "r226", "r247", "r250", "r254", "r569" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregatesOurRevenuesByMajorSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r20", "r21", "r22", "r113", "r115", "r136", "r137", "r138", "r141", "r143", "r150", "r151", "r152", "r212", "r276", "r476" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r48", "r122", "r123", "r124", "r126", "r131", "r133", "r149", "r213", "r276", "r284", "r365", "r366", "r367", "r407", "r408", "r482", "r483", "r484", "r485", "r486", "r487", "r575", "r576", "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Quarterly Financial Data", "verboseLabel": "Consolidated Statements of Comprehensive Loss [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails", "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationTables", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Comprehensive Loss" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r122", "r123", "r124", "r149", "r531" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails", "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesNetDeferredTaxLiabilityAsPresentedInConsolidatedBalanceSheetDetails", "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails", "http://www.Cryoport.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureQuarterlyFinancialDataDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets", "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock Issued During Period, Shares, Issued for Services", "verboseLabel": "Shares issued to underwriters" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r21", "r22", "r276", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued during period, new issues (in shares)", "verboseLabel": "Shares issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r21", "r22", "r276", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock for board of director compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r276", "r284", "r347" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r21", "r22", "r276", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock issued during period value new issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r21", "r22", "r284", "r339", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock for board of director compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r27", "r28", "r115", "r200", "r212", "r476" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Stockholders' Equity", "verboseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r115", "r122", "r123", "r124", "r126", "r131", "r212", "r213", "r284", "r365", "r366", "r367", "r407", "r408", "r443", "r444", "r456", "r476", "r482", "r483", "r487", "r576", "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r114", "r284", "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r110", "r111", "r274" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]", "verboseLabel": "Equity Instruments Issued to Non-Employees for Acquiring Goods or Services" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r488", "r515" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r488", "r515" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r488", "r515" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r488", "r515" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r514", "r517" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureSubsequentEventsDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Disclosure of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalDeferredTaxLiabilityElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Deferred Tax Liability Elements [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "SupplementalDeferredTaxLiabilityElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks And Trade Names [Member]", "terseLabel": "Trade name/trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryNotesSecuritiesMember": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "U S Treasury Notes Securities [Member]", "terseLabel": "U.S. Treasury notes" } } }, "localname": "USTreasuryNotesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsAvailableForSaleDebtSecuritiesDetails", "http://www.Cryoport.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r312", "r326", "r549" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "U.S. Treasury notes and bills [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r101" ], "calculation": { "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized (gain) loss on investments in equity securities" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "verboseLabel": "Schedule of unrealized gains (losses) on investments" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r375", "r386" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax positions, end of period", "periodStartLabel": "Unrecognized tax positions, beginning of period", "terseLabel": "Material unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Gross decrease - prior period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r388" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "verboseLabel": "Gross increase - current period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "negatedLabel": "Gross increase - prior period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r389" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "verboseLabel": "Expiration of statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r154", "r155", "r157", "r158", "r162", "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseRightsMember": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Legal right to use or benefit from the use of natural resources or access. Examples include, but are not limited to, drilling rights, water rights, air rights, timber cutting rights and route authorities.", "label": "Use Rights [Member]", "terseLabel": "Land use rights" } } }, "localname": "UseRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureAcquisitionOfCryogenePartnersPreliminaryFairValueOfIntangibleAssetsDetails", "http://www.Cryoport.com/role/DisclosureGoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance on deferred tax assets" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.Cryoport.com/role/DisclosureStockBasedCompensationWarrantActivityDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.Cryoport.com/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails", "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Weighted average common shares outstanding - basic and diluted", "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average common shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.Cryoport.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningsPerShareDetails", "http://www.Cryoport.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919272-210447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r257": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21459-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r373": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r418": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "740", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121554379&loc=d3e9972-128506" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "740", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121554379&loc=d3e9979-128506" }, "r442": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r489": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 2)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121569800&loc=d3e45014-112735" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r517": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.5)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r614": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r615": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r616": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r617": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r618": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r619": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r620": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r621": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" } }, "version": "2.1" } ZIP 118 0001104659-21-030112-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-030112-xbrl.zip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Ý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ƳN6J8 MZL DR:'M)%W5)(I.!I[B$LUWT+J,E>8XLA5'MG[#R-9;!=&UE;/\Z\K&WG]4 MN/0"V7),14O#*@N)4K>=#I4GG4"2;(E]7;G^W6/6.^_T5F//&ES[W6JI6>X7 M$&TO78A;C,;2*)9&OVF_O;>*K/\3^;.S95[UJML]*><+LTEF4AM52_/.9':* M@JCPY7MFL]'59KN\V$$2&Y"Q ?EI#(Q])K&5$ELIL<]DS699%S2-8?M9R^6("IC0>NG: M-2Y=MI@OO6P[7Z_?%T][';^:?_32U70CW^H7\MBU(/:BQ/(IED^?03Z]J4_E M#>73ZF8U'JK#^D7J,5U0TV?U8>?A=@'R"=PK+Q!0L7&L2AJLX,3S5KRQFQ=,/S'>*>6M0:<8A>\;TKV[LC MWHZ2:['M4QJ3'J-3J5R-Z'F" )7Y@X/8X=)+(1B(?09A-!;PSO\ M R%T5_2&9K,S4FN/Y6RZ=9JNCB\S+1!"X!-Y2>Y;[!2)C<;8:/RT1F/,WS%_ M?V;^_G.=(DW?T<:JBT /Y-$W9@ !H7AC.O/16!DBQ@-13(*7#.B,4:6)72&Q M%1);(;^C%?*F:25"F#2&-2%*NDR2<./D N1((Q C6TR1RT4ZWZU<7J]JY_?4 M\C"TZ]G=4;E?0+3+3.H%/>9C211+HE@2[;\D^@7^D"?BV+KJCG^U$"(7R5S_ MZ-A[J#5N[YI'Q>54+]VW0 @5V$Y+9_Z.?2*QS1C;C'^PS1CS=\S?GYF__V"? MB&KH2<-*3@Q+5V8.&1((HM#K;6VBZ,;Z40:!%#M08@,S-C!C M S/F[YB_/SE__[D.E*H]G=H6=Y@8K@MU-- 157*.V$.&6B*7VAB\\7ILF\2V M26R;_(:VR2_PF&RU39@\09/C%*5)W7:J@2QI#*'\OVSI929'3KD8V6*7U$ZJ M5C[;>\S5CH?5SDG)L5.=BU&_B""O+[9+8G$4BZ-8'.V_.'I3B))?)I/NG4[? M/#TVAJG,P)^KAP8Q/&T!,@F:KN83N?0FYNMV7?,_'E0OOZ>T>(6L^#6#DKA/ M(T!3]HUAT?=Z?V4W]FV'$"SOGM)QK"!49]D> \BC?./:IJ&K'BBGK)>=:M)! MTB\@9\@]^(7#WDW+ETI:W9A__R_]C[A/,XGJ@,P8\X<'$@%>(B1&ZM^_[O38 M)#V?528G&0ALBO5D.B6-&__[?_^///Y-JM0F$%)-B+)@4/425(= MTG?_I9H+=>7RB99*!YF<$(U_!2(02*'D#TJE?ROAGT"0#6I.U652HAF7FTF3 M#+V_V%WB*Y1YXCO;-6 [_N40D\J=.8%G1YZ*"^/9L[=;E34;+2O)7E49.R 5 M_]5M5+?MX)]])?L(#Z(RB8I*,])/DG\E<0M0D8ZGB] *U.ZK@L2F&RS@;_4E M/!Y=H&V4?P\)L[F9HTTVHTTUJ\[*GMF.E_C??Z4+J;]/+>T #=Z./W -W5 = M!)48L.FK>"!<@7SR[*HDG>I".'4"V=3/?V%T>_\Y!VX Y04$P-FPR5.1*T]* M"6:EA-,*:,&.NRM_2H>K_1*+(UHK>X69&8UA8T;8XUQ^' _Z1=6L7N1SBT+M M^+Q1J9V3\=)SRU\40@_N&7V$1X_S7\9L&R3;36<@):-D^H#]RR8!.\H;$Z7B MNX9%7/=M#ML'W_6,X>JYTW9]P-N8_RL<;9G4W^(W_)C^.Z'P[QV M[_!OORF&JZB*:0P)U:,,8FET/G3L

I1&#N6QF>IX@E*4 MV7#9*?&2P%J.;9J0W@,=<%>*-@:<7?A QP<: ]PR,.S96*6"[3_LGP1].&B$ MRIBHIC=.X*X>^Y2HBD-FU(+UH24N4:9$-S2Z+ HETX10G4*YH?H(732'Z(0J M'?!\TQX9E+B:BRXR>%MT?I3:E/C.2AFL%/KHN8$I1RKHRH\^4694 (+&"K/3 M /]. RW&-GUD:RE):4RYC,Y/-X9#JHI:GH';\$7$$$]+*-0ZT<8"/$=1]3F4 MA^F4O-I$I7PP@JPHIC_3"244=T9@BWLK:99BO1) 52KJ''JTAXL(A-0H=XR( M17=^E!)!?=J!PC.Z%PS U!/ED&@X*&>"9%0"I^"MUT%^SF]%)4OS;E=:>,V " M-Z!C ,& %^$#&1/+A8T =/.(-K:HKC=:)>&4 6RQ&7%OC$Q[ /N.,G-R3N^8TDLI8SG&P!>(V4!RXN#10CD,&$]C;$67B2]H MN'HP+KIJZ@P6R"$CNNJP+08K?!N8H?03GE"N4K=M'>\X @XHZU.Z@>FK&53W MU_I1^1O^RM@ G=D6_D8'PI]LPS:F[$#89H^,G'('O+*,9YY*N;EV62LK7VN^ M8\\HN\!OE]1"H$Q<4UV/B9SR$*YEKRTWRU7E:]DUU&13U0 Z\QN\%BAZH&PL M7Y3:E+7MK22? 5.:=)Y4JB04\9?BX6Y(*!5.7U>YH/O. 8U5G@6WHF3<&C01]\H#1\)Q3M+O=T4 GFX:%31<&+RK)XZ'_IFFQ: MX$5TI="YD20WEU!!!IL#-NZ:CXE^#9KX)56]_=GWW8)]#G4R=!:JN>*"W*>_ M4F(B_Q3^QG,A:0]!8.FHB7/&PIEO7$0G:>LK<4EP0C"F5Q6JN(P Q5[U5" K M4:DLH4+17E"Z2P);W ]"TK!\VW?I.$>&B;2U06S3E3(=B"S6ENX/ &51AKX)7*AJA"'+K6 (*OTNK+_V04AQV01L24\2 M%PY .DQ[1?0$?8:#;"GI*42E2\1(%>SRD4V7D3X=)-74>(++J(">X*.I226^ MHZL+;^ *4I2$@V"+4X'%]L(.Z4G9@WY8H4 QX!RC%[&HGBV+;J$*[@Z4AI4VW>- MYE$S 1HK45$'XR1@:AQP]Y ^U;+G:,/NT@0DU2D0VIRD@5"C"T9M98UJHDQ! MU8C/-$%Q\.$?5*DB?,%68AT2H,/J5%@Y8I9*DQJF]/LZ2JT#>@CJ;&_1 3I3 MP27/TR%*04X1_:7^WAFE0+_96]X7LG:Q/;G)EU>S3._B>&PO=CA\2_U,: Z& M'[B]UQ?&41D&PEP'Y:7A]L&3V\>S49]=DNF ./U%_='79^?J4XKJ<:XZ+NC% MV^NR["/.O#C'EYXME!94OV6UB-Y*N(&13GK7KI R)TW@&$YFF"EZI3I.OSM^ M>.R:374V25:[1XW!J#J\/VE]^4[%SX9/^-]B80B^*HBFH]Y9%MI:EZ_^1UXGBL]KIY.U,)#:P]8+IE_!1!84UVA-Z5K<^820R'NL6.[(2AZ M0>*T0CM-"M>'37=2.#L[S&=000A!N,1D\3TT255YU1249/$:K14&/Q M?]XJFO.Y*'UZ>GES9QV;=LTX[;=.G?[3)%U>?/F>+QUL;FI!:Z;[TGWF^H,' M>C+C.:-0,X%*?(MXF$M#=Z/M3' #LD)GR1I1=3@8?WEX5.2[5E9)& 9D^W*%74_8$,],SJ!FY0EN2ZX*<.\#&94Y5 MJ] M9Q$'5;TN68*'A'XMG.3PR]B8*;J-A:U"@M&K@@=$ MC88LK\P: 5#.;]JFH4$K(?JNBDG7+(@/7A?.>_2(2#N3SL/]?>'ZOG;H9;B- M8%@^T,]?UX;+T/D43,SR:V/&G>*A142%11 E)H@B:O,NJ5%370>= .2Z7F\$YM550;GS^[=*NTG': M59QV]:YI5W3+<"G+0SK/G9-"TK[BM,SL?L>STGPOY'>5*7!43'7("%T6;<(# M-GLEQ4/KBE$9A"S55PVJES/;TB%S@RQ49ORHL#76PH YDQ>V;U*A3\=*;7$8"AL" M8W&6RP6C8>.C)G=CXSN>7,!2+U26-&1;^ M$X2SF=,(T!D4=V+['#487#BMZ MNDBG6B2.Z89]N8,$)&H-F#X>A2Q*[)@KD5B@C0TRE(8,'@ZLBYNJ$TP>P&]8 MWHZ]0&^?214>& !5!&S?$5DN0&]P>##W4/ \^@<.#@,XW1^_,##G&D>7U^V9C;F9F^RX?_ MTV5+IU?UB*,JZ1(-G%4+ROE43]O(-_3!_P5=3 6[YLVK MNT;-L,WFH6U6^_GW0)_*<SIAY@==!?YSA=K@/'GJ M0*'D$8EONU85^8+R"M^L.G+IF" WN5O8#+P-R*:$>;@D_A2NBM#7 %XMSNVN MQ.Z8*T!OL= 6!J^HBG%R&,OFS-%5QZ2O"K8Y?8YO!CF X#+";!+N(I(\;BQ3 M #19"-&JP@D7YJM*)I'@/E>IV/2?P&$LME.]W*D$VVGK?55;#[K5.U5Q M5T+)E"B]_VM$LQ+DXPBJ'#;.%N,[;KU P@H!RM(/+=N3PGLJ*H0L68^.)1K? M#]/U1L0>.>J,BD.15P0I 5("#+'FAF-;7/:6\1B U(Y5@FK\]/#!=,<@3^<9 M@>$0/,SXVFXY9A)\.>%+.85$V@N<#YCT$\?;&%@!?;*$N66VVBC@BA\;X)-" M=SYE+B&YC^++@+$B0W#D2D'.R)Z$O8J%FR$IPM ;.B]]\,WS5C MYA[10SM%5H#>WOX.<[7IHW99W?M@KK6F1K^7Q6WTK=/9N*SP ;ER,Z=&Z2MH+BSN.125"(KA-Z;"\ MS(1R<5%-!)Y?Z6F)G3$QI==A=Z%X%0^\0O7.I-]147EPS48COUSYJH$W&'.. M0&#(B0*,(J&'N6R:+ BB!7YP/G7T_$,$A!V.LKN!F :5@VID2\FF_IMO*-4= MERT=_H%<$*K\P KNVEG9[F+L'3T>&9.&VKWM5\ M["O(M-3$*/$/$HX2\_51UM*S@#_X81) ?2NLP5 MQ[5 @"P6K&:!>62^*<0[6.R-;LPW8+-U+53WG34M%).1+MDX5DT\81K#$RP' MN# H*726H,OUT4 +O<\>&9YYGK)ZF4+-G^2LZBH[;WWY?IAB],2H9_=G!UJ>'O)+E4!%6F-]VIG&N&XE##&[8;9 M7<@R+FKN4]_SZ5G#MR$HDF('"CT75;^A:C@*6)=$WJP:Y6D#6-&3+F!/$1X' M^G[I)X=H]HAIR# PU0']=8_29TZCE$,X'8EN.&>36EU4IV>^CL!#D:0R(^FJ MHM/U+N(D&'5\"_5QH,-(-;C=:-I@R['D(["IU*5LWKMP)/M37DPA,NCE@A"J MN=A3HGR%Y_#D)M&1&\VUP-\2.&C@-1@^A31#X@3)-XQC]F=9CM=HQ$^*@)=0 M,@J*'B@W\)':/'A8K)MKJB@_H)\LC)_;#@3IJ%D-V>AK# O6C?"7,0U*G8)> MI*"[EA5VJ(I&?S4\'!QX>'9PN;)U&M+X?%?X" *[$5 CO=":G5*=S];W9V&8 M,(0)1(3.YCY!"E*R\>0),B?@D\)Z,^DTGZK4XEUZA%)H0%8VY/Q8/*:ZHF2D M7Z)_@N7$AUJ&_&K(T4'%)' =@AUH!T6I'W, ]K!W"B4OY'6&A;$E][I]M#KN MG:0R;O?>Z(R7K=[58M.5O_VZ_0VQ]ECSNV#">\.O7:S]8'*0.Z'0=?P"JQ N M KT0CE*4X4'\DW(BY@RYW"LKBA; <:<000.16>9/9[S> *71<,B<'T02]=/ MZ)0RT>2,,]2I#1>2Y7BY,N.8D;3%-NYA;X$YOGS:(NUKV]@6/FL,G3L:4"NX$T19U-8:B>E4X04CICNX.M& M7RA6!=K^P!OZ9F#6)F0A#Z?@5D&64)A#/7#MKJ>1,I.38"U#"8$()7&1VW+#/7",SA2HFI45*G(4+ M$E %';IT5"(XP-=&@_(NJ5K*M"%,3/4(D?^8D!9#5O^PP,:CVAW:9A*WC6Q; M7QBFF=CX'<8 U(?'\XTP!=9XDD\UL XCBP8+8:$7U!Y0/J5BCF"!!--.>-DI M/5&IW..K154F+-MQQ&LVI^EMX2:6[E?&0W?V.9Y6K_5!;RB;7E>5,Y3 +H(=/0?G'"G1UL$8GEKVPHA$C$-PL MZR%\+%T.*3R$.!.(]H R>*[2Y_ONEI..I05X]&6F0>8,A6R 3D379HZ+,,]7 M,QQJ/T-.-T1D]T8EK3-E )0I.,)"30#K#L$8\@(U3/>C>FNU<7UZE$P?!J<4 MI;EE3\%NQ'P.[G!E!<@$54W*!*H%L-()1ANW M'IM21F&XD%P7YJ,') !F"SSX.@L>?E#PK4XU&&RMT!@&8>?34'=@?LG ,#LL MGG5GAZ.6,3FWIB6G-)JGS?UT1\*\E&NAQH81=6EN>\/JVS1Y.?3N6 ].5,7:%DD&&RA?F26&O/+AE0"<0Y%'<'&VMC0K^Z M'KOL]AM#F=^/2\7;\OUR,JPE\Y-QJUJVTQ=WD4R:W"L*O@!3,^0544S=IGL9 M,W_UL.!Z>SGUT^&@;QP?DTJJT9K[_9O5W"_=0NW7P=9Z:CFLXQ++H&H^@X_4 M?72]T1GF([5]'7811SV3:YG!OXHQ76;$B7 _PFI$K *RA,SFEZYLL+#RF^ER MAW6YKFP[TO/GB'(9Y"(I65Y=A9-A< +T.HE++2S4V3I\RND[![CSY9(_+"AA M0U,Q>@ 5K$F3)SZ+9P(,+%3Y?$9@2;YQIM.5TH^Z.R3.>.6YS^RQ,R MP>D!;L)M3]S]0*H-(]H.4[.7 C-&^-D,!+@)P+/J1,>RPB,64(=3G@,A5:4" MN2!5[N@T2'J3]E80SF+1+KK1F@ZE*3NNMCVG<]JLAK*W&="/%T7:/!G@573< M+C@7A.4[_Y@0=&H,9H..+6I>\#Q(L"E&6'%))"<>4YQ=@FQE>"'T"Z2R>+RL M4.(BQCI4/4!/*V(-,BOR;)#BR(&,K>%V"9\JZ MG"%8MK8T)DTP(P7]C:D^H%#1S6CTC L\ NV(8>9A)W 1Z,!EMJ, M0S]PWSO ]9EAD ==1!:E6S".[9$9X6K'XQBS#R4K#*/C+.3%1'G@KQB:D(6L M"H!5!FX6)D>KL&-Y2H/ ),$TZO!$X ,Y4-HB #S\"V1 XGZ)3],F)1 P#!= M87$$*NIGJNNMNY[4,!2/T'V\=%1.#A6B1PK^!>XH1)>!V@X#\Z;+FX;IUG.0 MB2$ )V"IY2PAQ)$GMA'1>@L@DY^P/5\%]E,6H11J4ASQ"0D:M0,2;<4U MW+E3+)BI\]N\W;Q-W=P,C,67[^F#]&YT):#JV](H?=C/-G*#@I^Q'R!V%EL/]C2HA8G$*2XW MU-'((=2,)0G)IVRN6#H0R$S0+HG.RQ5"A_<^'AN!7)7$/U.1.89VB "\CE.X M :C]')AV&$B6L98E:7N &?[T"*'CY\GD#F$0'5&%&72B+6(N/.-<^;$2W)V$ M!\3B4++U1AD1)=R:J.3H+70D:#EX"_E890D6;"R\6]Z;@27NZ([C.EX_JII) M,&K\JX9%.):3P(7:<#A45A6Z'&/0D/%^<>&F'.!/NLE6O/G=@V%."N[MU9'= M;=VLZA%0MI;AO&JO7E>S:] M!9#MW\A]^[@TW87]RY?&2IY3E68X+TW4MEXN3R[/1Y7SQ?LM37947;9JVH/6 M\[,%M37HU]IMERY-)G50W%R:Z'&0@"T(VLB6'8ZR6VQ$R^;2A)M&8E,*_$I, M=E2F-@:*J%!Z[\7_=(\>UEGWU\Z9&FY-H MJS%1+!_JBV69C&JKVZ?[XZJ93Z5G97IN'+ZWQ?5/3O8=A"S,"Z7;WF,O/3E> M=NDNJJOUX[/1VQ#RJ#CNVM[CY&@R?5CU)OJ9FK,<>@#G7VR5":49(AKHQ 8+ M*L*[[RW]?X+DKSXP.%$A_ )9:#"U&VI4B.>*E;1/\VK-G0U2OOG8&JL3\[IY MWGH_]^?=IS+=02I;O$R-^QUZ'F>+OX7F^[Z+9:Z.G$7KYN2T1Q[= MPV+V^,Z?J^^H"^YATFS/IF2YM73L3&ZG17+T")TRU[.TOWW%_>HWD\&AQ>TQZ?K);:5X1'W9DI;+7J?8N6D=U9+],]*R%POG^.H=[57GZ&QV M_W#EK2;3FU'Z9E ?CI;WOX.]^L(3[=SW5J/AP[1GU,^JQ;G?JUZ-1N]'WO+0 M;G8NZ)M3R6ZI;A\=&5JQ_%+C=<<&VFUW[;)C/VUA3#8NC(D+8_:\,";[JL*8 MW.YW/)O_\1$Y_*>B('!79HMV>WFQ< ^?KB<9M?TPOBX-JZ/T7D+\B*D8>U0< M+8T)@XQ8!ZR+PF&3]0Z$4F.7Q5[!T%IO!-F*'.A 61\3PTR%QI)8<\0CNYC#3 >8G-IS!.UT>,FHQV;A MKT66%XZ!.>?V@L51-W.Q#1)6I6++2HBR$A?2W@QW#!@3.+:DCCV^UIZVAO9#24"9 K-+PYXH01L[&,U ME?)5 HI0ZO#\2NGA!TI;7:QUY85NRC HK.P-RZO%1?@.EV$312+T/WJ3O!2B M*IEA6 J8")-J(>;Z],746>?EH%C,HW?H8;0A^Q'^"Y(%<+LA2"M-,$KXMSUA1 L$UE$;\?& MZ6)H7'X"K+=4S">D3 UN'X72Q M=L.4&"R0+WI3TN.(SM7R!&&C!?O(VAQ;@\]ALQJ,Y6GY6!2+M1-84V97E1"+"J4': M,?17M0CLSO7IH%0,TQ1P5_$D8P#GH8KTSAIS"#AH*FUAZ3317W74>5P?SV\J#.;Y(J>K \)OMX\:PO9?G ML9@:DCJ8U]XF:GV_G3JRLNJL9B3@NJFRAG> :_JS^8=XMNM=/)Y-D MT^E/LDE_G!V_"/SPA_*@ATQQ80R)[)K(>Q4][?1/4S?I0L6^+RQ[1\X($+B) M.6=>NDWL0S@-.*]D,//B1>PE2'U5&K,O.S#Y/&H-4F6F[P M>%-9["53N>" V5NF8D$BRO9/@]8>9\CMXNWXZ+JL MI_I7F9D]>5RU_?GX=K;0)F7*1\1ZAHF&;,SNB]BEU;XIIA_K^D4MZAK ME66WW=I+=@'([_WFEJ[CT_6Q]++OB7!%I3CLG+KGC9,>61XWU.I"/3[NC-Z. M9;H/A]4;Z^9ZTFM,+QKU:GYQZ\U^R#* C#[A<$5T["]CG8=>X7Y5GY6>)G[S M9NF6SD_H^;R?DF:_CR_DG> '>E'==RP#+ 7^L.;U535CWU\\I&ZTFN8I;:Z3=V@#DSM 8>N1YV2-&OJZ^69)*A662S,." M[A8L L>:/RAC";6L-25KB.C ]%J \ 38#X<^D5>J5GP#NX<+H$FNZ(F(EAH^ M=D@4!Q"[J/*'5MT+&)T\%'/MFX?4K);VM/JXGWH:M*'=X/(?S[!? MZ0]6H\R#/RE,5\GIO.C;F=/]G&$NOS9#9,8#Y1)** B#%6!H9C/5X#4$'/," MX3D-BT&<[D\-1(5XP/RLMI.:Q&0AO%+T&8Z*P#3@ Q$SPM0*CAV*^V>+0<)0 M>;$?*("S_AWX-SA1 )M<(IA&]898#,=!N$,%]L$NVVL3]TZ=S:B9*K 8 M^" =:O1CWV+T=DYM*'$+*F;"FC-1S@WPP8@0#MBS])G,A\7Y>29S._&+G8[^=&=>.:O%&[D47M6>=9V# M-V-3SSLGOGQG,Y<;M>[#3I2]M8%3'UV+='KT8(3SGM5&0S$0.[< E?ZM(41*X-%DCPC*9U7'<(.#-'CY!A5$(1='Z*:[DU(@ M@-X4CO!G!LK1 @)H@.?F9#.$@LC>Y\ 35/$@!'$M9/B9S='-MKJ@PI$^ Z\3 M'>=NF)L7C')O=@7N56G)V"0WD7N0B@:'*Y&D<224(!@N"#]AK(RYQ>EN PUZ MGUA1/(0=*A M%+X!IYF@NPP=C(@X-(4K#8XXA(?-9N> @PB- %A!A)% GJQ-:JKJ*#N@RI. MQYQ?$)D5TP'6GV%@I@P>^JSF LYGYNP$5(J02JP450S"%D""ME >P/!CH^=0 MN>Q6A)@W/#Y-ABZX$I!Y02,P@+\-8>]8L1,7@DRX\_:-7+$?4HZ"=BC>V VZ M?(A>8A*OV%M.[O7=NZUFE.]DW<8'PGD-8V78D:ZA^P)'6!GY*J 3$ C.,9HQ M]N9:#QH9._@PJF/8V#@LXCKF,&(=/D:GJG LZJH$1;T&=MB_R;3==..DE\HXA[79.%EHYFM; M\$"V7_>F>"#OK( )8BDRM?9.'\.<\V@S10Q6 !973NF#">" RX!RK/JJ?"=(([H6W>BI8,RH;&T@=W(^=LQWM=1 M],/*,]Z\!C/T.7Q*%*2<"0< )/A,ZP*;Q[NQV(@#(;Z0HSC;2-S"]!0J3!>$"DS$ M>1%=D[&A0835(0T""BM"-26Q54^/!NT-"V["- G?$H0U&S6 :Z1/@DT MJ06@[ V'8 K)Z_YIDW-S<7)NG)R[Y\FYN5PCDG./N7PI6_II M:8]; BEN#(#?2$,O"]P"9&3$948_Y2OJ:_H?45*HFJ3C4FETA-I$TR M@MZ&/&V1Y?B%S7E,5! 2RM?,-ZH5T"<8FC%#-4G*O4O ;5^SWY L_ 6\1,EV MI&1&4.W4L'-W-,D5F^HZ/,=U4YT+&R5!U5.@PN"1CHBD(CV9]Y[COG\KM+Q! M9Y))RT(702XEOX\.44I77GLH \5RMPPH CG-%!RXB-6^\KOI3 (>VC VHH^+ MDH;WKM"YW\&CI]V(I?BRC@B",S!_5R#_AN\*Y[S1.H&W.UAOE4#?JI.IH7&H M3SC:I65,()H5-8/^X)!P M&?4!\%Q,X7I%?Q:34!PPHHIL M_8"N(1(PC[9"6<4+,UNA3\IF;NN0X_.+-$4%ZC*9YQ['P$"%^0@0+P?[HR,@ M, \3[RG!$S_+4!'R_M.\X:\!Q'_I6Y0%?%>D%NS?17Z)G+J*GJ)1K,-]TQSK08\Q4>1 "H_[H:9.782TQE6<%&&3(' &. MO5)-;\63RS87E4/[;EFZ_?251VMW-GOM_<"Y!B$5 IS!3WH@?=AR*M*N26@! M/*8"RL[:X_[W7]G#OS=5)7#+\&Y'P?@@*(5*9_05/ZUWZD1S> R*.8E8=4>@ MXH'FR()GH&G^2&?UPK9/H&-359PX8:&9>!:X]:"Q8T0]%8DG'(:3BNCRP1*_+ MK0TRZ:TVSUWC:C%=PS&N&&YW?RI>LMYE$WRETH,&1.$!3'57[5\XU &1^@< ML:-:-N;<+' 0 [D?-:/,S@NEB*SJ_E@_WS(NH:M'=7/V6D%2/+%"O5WV9(M^ M:J$D14EC4$-NHS^+M"K!0*2^H.L+Q<<0/EDTL97)(34$"!E(J@\+&YG*]6'2 M(H;11'XT[URRH*Q.>JHH2I/WH6A/QKM"18KHUJ&+ T^VU&8U"F',+89W!I#; M91N$V!.IS>Q8RY_NR(X]#1:L,5PW*&I+SB/"SQ&@4:2DC-F'XWQJ7C'OO911 M/%T4SG,7X_+AXLMWR]X$.I/88VN#V?VVMT)2.4>\B+0QO+"M$=IK]]9YY];UTMF]-,$:F"YY$38*WC=#;/@#9Q-VZF'&_@Z5!06) M:%"PT1(9)+2(Y@$W4@T&2;)=7O/R8[R1"IE(Y3>]Q4%8]6WG7IC))0O6T\A\ MC% GTED#(G8 1PYU40<;WC80SJB@(C\\(D3E>&0BV/*&^_+DM"1)&@=%[9AU M(^6];9"/I\? X24%M[C#:^W%"=&@3_2@Q%D&&.Y2T@F<'FN'+9XMC,#;L6H^ M1DX<\2;35999O$LBW.S(#L*J8,NSKBE#UGU [EXD4B+!MA/O MH3OVF9>;LG]TX]E1XSK0=D32&&[#X)'A0"0SG'D_P6$1] 7DMCCN*B?(.=R1 M&!Y-+V-!>1%,EA5X,1,8]H'2 "4IG"8#"%BGBVAI@DJ3]*B1 UHR9H: ;KLI M3S8I_$'.57 9=-7EKNWK3T9'_>:BLZ@5JIFD=4VRIE9L;0;^ME^WO_V5V,05 M.O,] JW9F;O'/3L>C%;J HUM?UPC[*$<=AHLA_V,A6[N*A4;>B,%E3B7( M4M]Z?=76T:9 Z2%N*W?"/GS%7"HAFIO^U]@=5(S2F]].F?T[FOSTB?"D'6TQ MUH&P!2S_Q[>^>94%TK/"4YY2H4(L,J0F[U9;(S<9TN$/SNYZY/YJ4,YKV+%N()OV!'IS:8\;]_?]\UT/E6[&:5/:5UN I06(CR^]$78+ MU>78.R/9_Z+X"#<:D_"[3PN6#0WNC@0$ALTKM*#,>V7_O-2( $$EE_NL%?IP$UR$PXBE,M W M+M[<" X<)+"BUY/^S ,D>-PS82MCKDHHB2'4;S!PH M#'30GBE-KNMB$;0UZ;@SE)IC&!O&1T\8.O0"1RA/A_X(=@7@0, M+\N/$GZ#J"\&T!'+SY0;M;2 M[UG0EG598;=NN6V-4!C"6R-3@/CHH2-_VZ2QZNC!=PQ7-U"]$;EK.Y>,0*Q7 MOH._6RQ@N*8O&"%6K;EDIF(=7%#\QH(-P+F$1Y:1%O);(5],1?=6X$K\$1>H M.U9 --A3%3H.SX DQ-]%S+]@(3A4(E-MO/&+LY D20_V^5)^5NE"8^AZI#R MH.^8F1T9T=X8EV6=X?-!7#2ZA\+>E&ITUD)PKF0G#[QMB#E847\HKBBZ-#%? M9,TILHV:C >@C!)7@UNZXNG,A4J_6V!#7Y2_D<:*&,@6XHR=,5WTXDQY3HTX MC+8=,N#$AM5"I$]>_&;[CD8XR G*R[73#.LJF(P=\M[UV,TVK%7FO3OUT $- M^9ILHE2S\9+4LBP^>S.R&/8()W2A#5ZYRIU5;)+OC2[_XU#<2V#@ 0+GKZ!L M_().MBJMK\O!X+<#P1<:N9EV=7@X[B6SY_KJ/*]F9VUJ'):V=:'!B)LXNE5E M1'F4X=GPG%D6%G!95 ,@(W8L(DL VO6[9XAJI*L.ME4%PEQ!&,"G^^-;8?Y 2 /"I55/+(%^@Y[N3C0A<[) M[('M6@#\$C970C1VJK$8S,P'S2;!H;@F43CTL/0DFE:X^1:F!XO'\! MTO/&0YI#>B^'W\$EQB4$V>B :ND1:2.MH:B@K1\L*.;.8D]:X)T?\ T, :]E M[C)Y%\&FIKLQ W9-%IN09>'/G!!P>?A4P-OX9J('S.C'!FL @!PV4]C8]GO4E/C4"L\%NO?#/K\0EN75%DJYT\-?DNF, M(D=0E:]=>T8W6#&7^J9T$+MHN!(\*85R87WD^QA3L# P?X4'X!:]F8 M (>+ MZ!G"'RP"P*<(_<2"7+9 YP2YH.*I($J#\#=@ M$1V63D -(QL;_";%M9DSD;*&YO%L[%#D,6-K:L]#6PO2L68"SXS5'(784$%= M!,O)=-2D<.H"5X=X'HB.Q +-# 4.A# F;G#-#[$(PG-?.L HN1'#$*^VN0\, M>C5\1=<9W5?Q.["@BM"!^*RM!=X^K>#"#_0L8511ZS>8(6N M?*,E!)8&_3@-CS+F6&/.]_4;!H3R*JX*JR3<3$A5:JI#]YRJ,R H=&N#@]## MQ+TPV3J\P.+U#=(H#I0C;@![,@ 17\*13_4LT.U$9K-#/,<6K4H3RA1S$H@> M_1Y51NFC&,"F\DG,(*Q PLE$*$O'?:92TE Q&>A&HH@MF!D?KLO=+71-=4EN MA2%IQKSHQ%F'@QL&V1JA3KD__L*&I5RJ#MTNF:*L(/*&Z!UV\@1A(:2R8UOJ MW'"H[EDV*#^T6;D0=J$0'5LZA(IN$ 5E2I2OU7*[UH$_1:44%A;#3P8F:5&: M.%3IH"9*T/(%4$NGX68E8CYT&$M")EQ MGZ1<&,303=S 7;BELM=%P<*X#1W.8 K*5 M7K7=]8524PWR[T(M%)PV(A0FA[%$FJHMU14* 11YE/ GTRMU.":\T/CBYF(B M IXSY:LI7B3-EY-D!C$5:NZ QY0S(SWJE*K/@W]G]@ YB@K/+5;B9C!)Y..R M@)*UDFV3X.W_^G7H?20V(LIX3+OK6UK-SBR55U''3R0?JQ.,L%(#=X'HIK>6.CUSGH#-_ D M"WT SR5>\,,T&'9^B,I_.EK<5A GYK\PH-%MAPE(&*0!]OLB*]O:HW@458#/ M?&IK9P[E]69&*8C4T%".9??1,D;6V2VY=#G(K4.Q&.!1:PEQ0S];+LUK/?' M%/I!S^6=;<=Z)\7+P<.]GCIOCDZ/R7VCIO6W %INOVY_$[ Y.:B2B%YGH._> MB*:VZ!O-=*H@*P@M0Z"H8YMH@4I(E:@;\N[V"6[W<-<>:JB\?:*P8B. EW(9 M.J8]B3HD]/R8PM\.(H5E+C$I!#8AZN9Z9.;^I7PUO@45[UID7VF<=S%S6WP H J&!2QH\#=]Q,YG4+F) MT@>UF,!7)KO;\:GX#/J02!9*$%8%VG-YBAB3UZ.V7[TV) (V0JO_]S^#C@,,@_<4+%C2$\T\( ".>R5\$!N;"E2^ M*0+@K#$'1[8*MCYWB0 %N-K^'$N([<&S C&W2J=& 1V@)UZ)W,H%35#6*% ] M5!PKRXG$D2I? 6^@9#\XD<-WRO$7=<$2%%+N1=ZQ!V+.U@*9TKH0IG$']%CC7$N%K M]\>-4<>#*F@<),HSPX"PH&3@"QX8B/(%$4J(5]"QP?ZDZM2(A 2J!C"XO4SZZ$1:P!@-S^K*G0)4+_*_IVL:LAZ_L3 M+@V6RT.W02*JQ2WA$):U(E;Z(1N)VS25[>LG*U(^[A7,D2;ZKE4%.'P"R:^R MQLL\G+!PQLS\@=87W,?LI0CL/C5JN3-_%T^Q"@E4C8(0&5T, ))WB6DBW*'# MM#;TV\X1I9:_<2K5''-D/BV %&%&%C%0>53#.H7@;G:!"&*SD##JTZ/P&IV( M&!$?(#4LL3I&Q%C" >P/2S9VZK!!JRG4@AA#AKN+=0F"4('89AL6RUIFC[!2 M1:SX!MS%A%-^T78EU-CT-$?C@\%A[;B5GZ$S ,,'><%]G;,QF(JHZ MIO_!30PSG1OK>:$[+>.M>YF!:T#@T#>'"-KM.]LM7W;T"^ \>@GX\K$O"P". M!(>A&F:_\.Q6C/@'P3$B=@?+H"FD"@&*"&\L)?S*DGS983V*H+Z8X@'FW@00 M/[(T#[IB,&0UJ@28)J>"NYVX+LIOT8(I=#Y#VRYRT^+H9\A1F\99 85/3SM@^7QA([:$%\7M-$ _IUN54QJ M8!TIQ:#);80NG"0?ZL5;GWIS;>NOA]?7)!%F MD86&J0(ZCW:R7+6YC1X\EL7&<[I6P4"A&Z[OA>,(#2Z+>0&'*GU7$-S>*8HV M:W4W2!4*;=YO3X!M!ZFIPG+D^H6S!@4K@T1Q$?:Y=\RUZC!HX&HDM+-7^V6G M43 7@U_K3A4)3$7PD65@5OB\_0DLS8=S6P1@,+C?8GT:,-H%]P+BM@7)TM?; MGVBX,DRIQS5VUQ-EN'+(S7#7402HJH;4MZE,_EV>(Y MON,&!M:]%F<+5BQL=+J!$;N;6$!29@J:@!!(%XVRYL]TP6,8EHD:!4&\ M(=0],&&,:QZ[-A1'T0R B%TQ15Z+_BMEY#^*SJ_)R)VFUC^4FC?H.0,+8J\$ MI1P'"MQV7"%0%L&8V2ZD:\U2[_$DQ'WDRR5A(G\3O7!-8Y!XTRIOU3601NESKO(A3-HN'C0 2'Z #$ M[@_W'M-U'/N!B=?P>E,UIE2[VGDE/! 2[Y-X)?,'3RQ[076P$:O)!I\HE9\! M,;!00: %@+'M>S!H%!ZK&;X"Q+QC8$6U',O JS=P5\+%P7F%[AEJ/P$SE\R_(#]-)%;QR8EU+[-EWYIZ-G)F^5G&NSCMW=R=CGL52ZWGDHLO MWU,'F2VHI) M/!DZ3<'PR:K\;-C/"-5T=%*NP0J)MV6&JF%B9Y GNY;2SR*4VQ-C_I!M\:&?LYRI*2,-L3Z\:FU&5SG MVSH(;[]EW=U/ R7^NJ7A6[ =S'SK6FG'$]+)%([4E#_I9%KDL'=6Z?UPK=[ MW[%&.LK'$NGHIYQ%SC/)[FVY=_-XD52GPWSKL?.AI*LNK=.;Z>U-IV?4M3OO MSNIV&[D6D"Z]FW1!7%?DPVC;A!(X,(& /,T#<^3$(8/JW!]RREP%>7?'@3[< MX838JZ-E:SP 6@EC4FYM"=4=[G]=/SI6?'OQ($\? >1(<@<+FM3@I8!G4^O M R60CXU^35_WO_]*%W-_4X/=GWUGR3X0B8<@G)S!()S1T'P+@ (V5(B2.2$ M[?<=,4^SPL9IF#,[A>!<6*BT,R%Q#;F*'[V1'&NZK>9DM9[_S"&!1(E-4(GS MS@N%)I\J6Z24-:,1'X7W5PO"A4S"+@F>FOB(V:#9@<5=!;1UQ*5]B<^U-VF3+F!8OOA MLL05J1YH/?(A!&5W'\.E(A>$M:!W@GQS"Y*" 1R>FZD<"$>> #JF>$ZB0,21 M,DGVDR\0J#V0%W-5\_TI].L3W9]-G^Y&^I5.%@)%0Z,K,B*6H5'%B) G6$=W MY2(@VOII]FP!Y_:RB)WE!ZO0B@]:"#[ZQDS4S*A2Q>E$:L?7]+>M ME6FPA[%ZV9FSHU9,A#%+ $>54+YFOBD !V/,Z:X#H#YJ*=H._@TVT 3_0F?+ MS./Y9J$ =Q$:D?+BU^PWMGV1(Z'ONV,_T7%L&1N2$%._Y*1N1> _<,'[-?=- MKID3[0%$_CPUQD8VEAIN><&ZUK;U9#0PB7C+ N_<%5)0X//MCY^ND@.(/LB5 MDK/S@7>QL,$S0O6) 8H*O6][95R(AG)#MKC0A:$N[X1(J.8?U3MR76!-0@9@ M!Q]AWO^H.4P451"B5XRZ$"MPY%1'T89K70"%$@=)CI[ZC4QS2Z?"08?I#C M,C\H+=THI.,W"Z!7U5H#[X%<:FMD$I%/#(6GT/M9O&<#?D24/C2=:(VQ&SD0 MHZLX-)9B(W[.U*##.#4H3@UZU]0@%;WH_6)1U8KI0JF?SA3R_5Q13_4/TZ5T MOZ"KAQHIJ:EB*?V%O97=T=7Z%W[2?TQJ=UHO4RO=-%L5O3N_74#,8/W*64KK M%-KYUD.JD;_LWQ\]M/K%3+F?V;SRJ#RLDVSW0DV1TS(YS/BV95W!E?GU*W.3 M\W;[T!N=]HQT>WEQTR93+]WJ9_NI]2O]TC#?Z%V5[FI^-7Z\J\O9B%ZY M\7:SKA8S^7II6GNLKPI'9W>YE3>%*S?>?CRIWYGWHT8]19*GQ8>+DU9>5T?] MW.;;KZ^-\9VJ-4>IQTPV^WA\;DTNU$4_OWGE)3D]/IW>71F33+*^NJ\YM472 M6/0+FU=:A5[UV$T2HS<],WNJ6S^9YBVX M*_UV>SK4%^5MZS\O%>](Y^@R.SF^*3PU[DZ/+DJ-K>O_,#ZJCW/59KMW4UJ6 MM=.!77LB6]>_<)>BQ"FF+GO$.ZM41N[0/A^7MZU_)OFP''8+^<=)TG9Z';^5 M?;([6]??FUW6+T97J[.>OTHWM>GMI-^G;]^R_O43ZZIPT1KXD\S9<'RT='K^ M]5-+6O_7IP8>OBHU,)WZJ=S SYSM)SPU1X:KCD8 ML8 -3\6R+XV*4EV&[ACU$Q_8"S7L.H(#E;-"?T96\5.QY 1JL,+_!7,-A// M8=5 \JM9<3&ANB!=QPGQ6 $G-8<\MAX!6(HHGTZ P2Q<*7*MHHPTP+HBN=22 M-^V%*V#]&)(WX/J%!37K$B^2[]QO_V%F^>M@8&C>[8QY'L9U;1-/.!N(>/FS4IFV2LWX-N2F!IH%(+M,=>:2O\0? M\EM!AG!S U1-C:FHPK1".T#U/5M\P:P _"9B*Z305)$MA5#O+S&UWW/$N(1Q MS6;IZ<$)2=8 V/'EC^V:=%:0+P2OQ,L:0[-'__L?37T#V,70[ 0AP>94KP0>[ 0L6C:DX6(1=.>+$0L MFG[M0OS'N;)A\O-BF'/QJHS5?_3Q'^V,?QK)_.Q.^$?.U[?:/8_,J3>8/;_\Y;S M^9$]\LMW*CJCY>A@-I*OH[QSR:KK>'V.%=5P>*Y<>6FX?6C^V _VE49\I.HE MJEE]'KGH!TE\%1Z"Z[!XFQL^XAB3T2]$(FA'))GQ)PV\1FTV?S@\FI!Z*W>E M9B\?KQZC=9_95]1]"E#&H*(S^T5$K;/'YDWS^K[V-"')R8U=2)T\U)80L<]^ M^5XH)+*'FQ6QL1B)Q4@L1EY2OOW18L2HDYN*__A8H'-H&#=F?Z@MTJ.W$"/= M>^W&T#(3+=5HW#;:M\?^F4L65(P4OGS/IA*I[":0X&]E@I8M((AR@AVK?QO# MX5?+N?T79\*X^<=C_\-$URLU(+8=V&[XY5)K-:L8)^E4VJH5^E;92S[5;S6W M_!92BXRO!^0F7;GOJ=W+J]OV++VLILO]'"@_Q40I5WB1[A-O_7CK_\9;_Y5: MRYMN_7DR>?*0R>=8;W4A MJY@J+(>'SVW\W]DC=.+36Y0VX1CB4*E[271#,Z#]5VS5O:55]]%NT7VE#I.V M'TV=O9'&KU3$<$/+^UELYU\NFA>E]+R?-F_N:JNG;*F93Y_=IR[>1"M[N#L> M72\S@T7*/]//U=YCNSRQ1_T\:&6Y1"[_,JTLEEVQ[(IEUSYKDN\GNY+]MI_6 M6\UR34U6VO-2MGU_H;Z)[&K4>YUQ\<8]["7U\>!8+XVN)@Z4(%*U,I,X3#_G M37^Y&VP7/[Z[2AF451?P^5UHE1)4G<2V\L_+V"R5(KKM0Y7(APC9K6&!7R = M/V!>>R,>-U2[7R?@6BUB$=5>MGN=\VR*G)PZ[?/4F]C-Y73UU%G6FN64<=L> M'"WUF\[A%.IAP6562A2>-9UC.1#+@5@.;*A)O]!_UO(RM\E&X315..QX*RMW M5BQZ;Z+HZ+=N9Y ZS:@&\,AP0:F MHX ,4 +/:N-%/;=H&DI_ *Q-F^,!TEN@P3T*J.!:WFW:0Y L_B2ZIM "AY5< M1VJX=]=N/S^/2#TW@XL*)R IQ@FHQ[:I$#*LQ"LKL1,,"5UU>?6WN[4T>T^V M4%SE_/GJ==@Q>9#*A\ =>U1']>=6%N[WNORYA8;[O2Y_;MWA?J]++,?VD6>G[ZVNL_<%_]8C;XH\IO M?S'M?JW/F90Q'J%MS*W[7C+50YK7GUQ^2;%V4>N4SUT MBL-V:JK>/C5SG=;=57[!BK-SAXE\/O^I4V%CP1 +AO<3#%NS5U\E&)S>_5+/ MFY5^C5P?GUVY]>[IY>!-LK"LY6)YUCMIS2:/Z>HT7>G:MCLOLW+K3"E12FTV MX_Z=KZ292:ZC+\^O(0ED#Y6KNLE;_]#J;">PBYWTZ6?;;B MS?U5:$2R&>P7+K$O'6_H]59$M6WI9Z,_N_4-KGB)G[NKI>-I9 MG3^^B2IRD=%U^\HK/]2.%_;TZ*QU>S5.\T+J7"*?R7[&4NHMCAG74)6FJD&O M4.5KN5FN;E5&8E/L#RA2?(TL_,-*$?=7+T)[CFYBOH>Y'"VI*Z,[>FB/:H96 M);W3?L>=W[V)'/6.2VG>KY^>&;%.P4AP_'T^KH^BGU>*TV5[G& MC38V1JPRN9 N?1)_$324_/L3%"+OCPGYX75[KW:!?]+RQ(]4G7:5M/UZ,76N MWC_>#?1K<_*HCCT[=T<1YMN7?S>)%4 MI\-\Z['S)KO;,T[WEPNO# M@=I9C0_)%4,**FT-5YDYE/4<.@QZV91^@"[4]-JA@[.%YLG.""IM9^K*L4T3 M0X6JZ]J:@57&9#DCEHO/#+I/0\?D$=;7*Z8HL,?[7'\V,[$ALV$I+#V-/EF' M9M?P.-BAP?/H&. Y56=E0T]MI;:$EMCN?^DS-M-FBP=TS_\-GX;\M2;IZ-?,U"OF@'O\V7>E,S9F,SJ:<)B&*$2V+=>?PEYQ%1^( W7&,#)7 M0 8<[!OK<:2H/>(\#DWU$L833$(,9F]K9"UF:A2[, ON(, M&7 @%8& \TWW&8,'_N$8*?^=T@*L&+A>> *QPX3)3/".,U]T )^%16.]Z* M2P'LY2\! U.UIP/#8N,H:X^^P4K,0&ZZC%/9?S$@HHM>TELOK6D*I MMN\:S:,FNQ7T#\!4H>\*QN,J7SN$*%>V1Y3LMX.M_+PIAUD9H%3LJ)E4;H+9 M-?X[JO%F@0)O4>VXLS@@DQ-68T#_>A**1J)%C/_W_T2*-3<\XMP$E";&M;$, M6H,CDF2UH.J0OOLOU5RH*U? B90.,D'UQ%^!&0FD4/('I=*_E?!/(,@&-0'G M1*)9!,>$W15%,N'?_: @E2\,*))OMBIK>R ;KL%_567L@ S\5[=1W58S]@MD MA@76J!F1&?PKB5N BN -1AP:NO^J-@+*N('MIS@[4PA?V5E58Q+W"0Z.52I4>4H^7 M]UGG<-;(+,]'<&2L7^FT;V9'M^XCJ54+3^FS^N3Z6L^.^IG-*TE_F+]N7F9. M>JJ_.IM>S+/E>:M%K\RO7UG/G^>=0Z]EU#+C^T'RI%%II)JM?K:?6K^RM'RR M9V=F@?2J^2=M^;B\3R4;D'&Z\?;>9>]I/,Q4RK7S^WN_?C08D>4$GKGQ]I9] M46GV*K=Z:EHPCLW'T^5UUX)LL(VW>[-^_^EI=> =;;QS&RZ55_Z5G'8JR[2>;V0'*<*3PMZ MY0:53LRSX;UZM>I-&L<9\_*^TWHZ&@&.X@:5BO>74TO-3Z:UX]PJXWCSW$WU ML-4O;K[]OJ&W1\GSS$V-5!XS^<+M::VX:O5+FU?J:G-P\3!;SGK)F]HBW9VO M5N.',KUR8YSU>C)_6:@-\Y."=I\[ZK9'@],9/#,Z3OK$-,D<4OU&R^:U?BZO MYOHE5:5_:?IP.,P2-:4=KC^[>3MYRIXVW7K/:)C7A^.2-RI66MMXWS!GY7^QE?>[R4Q!7>6OSB:=7"-SJIG;D^L,&7+DQSN*PD+LOE.[T5/4X[=[>71)*T]8V/BV;:7>EI5;% M2=4HM\VGX47).80K-V94N3V^&]^?U&:3SJUS>]>C]O!Z M\EBOG'0O^Y7&0Q?\<.*9:VI #A7.._95CWM3#H/]_>%Z_O:H9=I,3TQM:E6 M/G=Y^LO.MSRKC7Z$K=BA9CJIJ-3B / W:CO@,QLS^"^U'T\M4$OH6= T50;_.*QH8VIDDU59S!- M5=/<_@JJ?@\ 3U"S1Q:=HZZPW_V9C9:EX2A#E?X']'I"+4@8?_@%NC:EIZH+ MU='1Q40H9::HWW/HQ)&CTI&"@:HP/P]\63&I(IOL:&,;?'R,&96F PCJ(^72 MUHFI? 5?T$]!ZMAV\%Y$:Z>M]D[W>7*&EK'%#8TZ'!3]+ MTU5==(()1N$^GCEAB(9(/ZHM$>'!Y7;Z@<+258 <.J$J]90;M^C #>G#IAJ= M)GV_.ARR,0U66_$8D:;@IM,0)W%!P/OK@N/*G\Z8'>10.\S1T36@6#XB+=)7 MPU1,LN2^U,$#80URYJICH!\UP?U9<%] &/EM"=5-PW*]3ISN(64IO1@K+*5U>G_AX2[3.B8?0N6)>0>.E%*DY5B M:YKO_$H/[R_;N=%UXKP?X:(92%'T\^B&J_DN>J]]!XUANJG1?DT7MMNO;WX2 MP* I*U)KSZU1]O9VNE[&LZ1:'-W,%Y-I\6KN71_E/IN'L='NCF\;@3[K&54!/DQ13H&Y1>!!@"]/JPDA< /=01M 5 MV4;4?^2?-M3C]W0DT,;>7 7* MFD@\3QP=Y 3YAQ_T7_K:"K3X\+YBX -23F M'X%Q]CCO\[M7.YN=T^G2SOAKGTK $ !S!,5<;QEF3[9/:2(P4P&V.1-;NCNC M /O"8 [++P9Z*[@X0V"E.PJ@'0F $">P?Q$@OTC/TT)[\!EP]F%3&!E>T1 M);8[GLUT#389+S/=[0%&O-V2G>5G>QL%Q@2]P7!B""3[>&8@XU&/3*/CZ,:/ M1S9T6Z9'6_ANS3[5.5A$=J;BF:7/-.>^R),BT/.!4O2,2,8\=1)T;#)%S3 8F"1#9WDQ>-Z&52TH(N;Y)JAD.R.7 MG)&K,'(%1PX+CC%PY!X]V28'+C$ 3P$$=D_CH[L /@%+VC(-#*W!![?+F'BD M@QCH?9;HP:K[+96S7?^.=S!P8I!'X]CO'0>-W1FP[FZ8K"/D[L/$67^>&;H$ MH=TM 5 D).S[IPQR[R(C[17AS-X?M9ES* $ZID[W *HB.^/>!550&\O9 *%C M8PL,*HUD0">L1/KF"X2^^93T^PW<$*&] MS/)@H(@$Y''W,VP*PH?FF_^BX*M+S%(?3]XDDQ^1J)Z]B4;_SL2HY\F$^@?1 MMHF_M&+ Q3&"\R7B(AC!W<22/B,?YX(1ZZEST\1'[^)QB\Z4_&_+Z0F[M(:;_Q> MC;<.(.>LF:B1,AH83Y1O^.&Z7FXETY5[.3JH=#@5CR.&/A65/Y MG7WG\F7Y0>+4HL]T[W7QLS._X]6J2EKK#[&H87]IIT+E$ M(!P^3B?Q\WJ,J^W-MAA]?X:0J2=LE &V-N -\/+TWA'[3"<#0J_!TM/[:S"Q MSH)0EP]$7S!)7]-XOZ9![V3;4IAQA+"BVB*83N\$L.K*'XT5?L"@M5/I^*J+ M1[8C@9B"2?A:[+-9,O8I7_):+\M8J&G;9JEY*. MQE:'_OT&1OS!QEL59"DHJ\&)K'[,]NM[ 3[.E+'@\_HQ@VJG9:$0QO3:U"[9W+@WZYOC[I?5+L],^Y3C\B W\ MLO+17O$.?M*#F%H(LD)O<6AI*I#>2[STML=S/L9B<-R>-L5%B$W+E9IX7]Z$ MDK.:DY Z&F!#2=]0]X7\Y5WWKY/Q3STE^#,95_OB1!LVEQ5VRJ_N9KEZ*U/7 MAG9:ZG>=(UR'G^-?O%CY[*5$[TV]X/&=1M^Y\9G&RE;U.;K.8S:2.WNS'TZU+Q#M?L2J)DL[F]K"8F4^&"RVZR4$GJX-,/4F7:YD7 R$@@E MGBNL^'KGTU.KYRN4NMM7),CP_5#7"XZ^'\K%,ON(AEJH#IJE4WJ$?>CT\KQP MOQFQ*5D0,[/:1RM.H3>@V0OY18[M4@]^B8+VT%O6PJUI14L)?*W6KK/#7@)5 M)>XF^ 1AQC, *CA).?:D@3;N2KBOGH8<#+)RKJ=%(SF\K+3)XZ$!6'ZA&#U*5,. MNO3W,T&=)1-4@OV(-%#A&S;LYS/8OO;K$DN$;D(^(RZ!$6C_)'Q.7 G0K2" MDL^(+V<$Q][$_81<'\B)MX:NO;1+?\/L'2_MA]\FZTWXW5EO(C?Q\%6G=SA[ MUAM?;BZ/Z:].@/)'ZML52\4'YKYY28/Z\KF>>S'8BLM5+X:S9<#Y G!L>+/& MG_-H_G.TAPL.3'C>A/U^@0=''F/')]S[0T_P[?KT"U(KV=CVX99!HLO;KK=6 MHLI,KQ9<14JQD=5N56*#L9B?F$(YG/(>+>3+V3<<+OSA;%(TR_^)DX=0OS?* MKD*9P217;?0:C[?M>J;M%'&-!I(A-I!(Q#XU\NKL6]>77+IZR9#^?H)Y=-IV M&8)Y:VZT[L-#(M(2QN'QDB]NY.YF>'F"F56:HF!4)M66,)A.6XE%0^<'0Q#, MR(_?X4 L' LDV.<$\PHLIK93.^8:C)^+B%"XN-W]Z&KFY1HL;T%]']PO&MP= MW' 7>O-([5,+FRP0I//FU)&";>$Y>4!NJ9P]U75"&=Y895,]>38[&ZA8,'Z M"-X:# ="'/X^^+DZ)YLE&YU\[4+-.W:<2T:S=;,_B0]+NG](2G. MFTM,-0*F72P0B4<"7/BY2/=O8=I=DB!>G)KPQYDUOF S\4@G8Q!5IM5U3>(; M$5=S3'(]V\4YE5E[P]DMY@9=RUC)WG#VF<:Z58X^3*4)&ZK,%:,R#';6B]KE M[3/FIA\L5!M\C6\7!HEID7\4N3"FPX!])A)(<&R 95]W>?/RMY./MAFO2 S/ ME\SQJP_KOU8MN,Y=YX.MDTN^GO+U^]'+M\\N8R=@*YW@*CL(BVRCNI$*B7'B M+C3$>_RP$W#Q0(C%Y$C'M12^F6NRQ":6MG:%->KV(9MK-;9 MC;8*SN>](0A-!-6G!R2ZI%#_!=O/#F"Z%"&<4G#>&GS>?>UCF^RE015 M&%+?'#,2#)!2D^A362428XX$DUY3&U@J':>@,*([?&W R*;!&%;? .D4J*-9 MIO?4&."GI^4-8^,RWIA#0174-6,Z"X'8#P@&O3J'61(46:#+&%_G=#%P*+?? ME6IJ3.NF<0/0JR@8U IC)2MQ)*A#PNCTU;+* ,83T62<>=!(].UF3W%'::[.G.&@R&N,/P^/_]O_;B_H\V2F='\TS,N6\0HIO;D 3M:P7" /K^ M)2A+86VX]^425 >P=\M?VUT12<%$;Q*)_\/L/B)!CJB)%_D\--N[J&<_M7]5 MS_GNA;L-#F-,;78^KAS@0'C'@_\(S$A'P/VO9B5]*GCY ]!)Q:U5V4,GYRO/ M:D$JXD56>M$2I")MWY@TMMN%X+U*\=0:WV?0*!Q#DR&I&5 /Z /5DAX42PA0L M!C?]WQZ:(0I2X++ABF*EC6.&I5 <,W>;*S,4 /O^P6O$/QE!PD$AOMO]":)H M32VG0_B*,,J<%>"7W] M]^6EL8V^00M]6K/)P;PQ[^4MP9VJ*:RVNF;,UFK*@J[W^'7S?E5YT*K\M"6. MR?INV)_$ES]^1V^.770,K$,%2810^V(EWM$V M]59GEL*4_4F6/2:<*R5K>L^%[-US8<)<@,&E0!64 15)(T1(69:)Y)L\BN =4LGML+^E-H>;*_$ MVBPZY5II*]?C-X_2ICT:7J(B#I-DG%DR=)I,"J-:;!7X$S7Q$VH"'678KG33 M)J#9X@F;LV!,96VG>T#]68,Y])TY&'0.@F<.-R>UUW,OGBKL2WJ5[DYU(N*! MOCR01?KBU'8WR,!ZT&4:%KI=.J5.:M(.3W2A5;BO#A\*VGVO29:7N'0.Y_5E M9MOAP"CM*>@Q G5W4./' #2U<0N>G!"J)3BJAR=SB+Z=%)I\&J@#L/>HPP S M)"HH(@I]@2 !NLF&J5.U;OL66E=!QI'.EG(FF6 N-@VGB?EWM<(!BR"E"@B5V!.55U3X:-H2^KSF-JNL\76:-[K M\7*GT.EL+/.QU*L=Z\:GVUVN*P3$R,:SE*3-D#\[\C#[]+D8 =@]:/FCX MINM/<5[LB!&\"&PV6ZQ!AN$W7<-=!HQZZH&A/I9<*E6E. :@242*ICT;S09 M%+("JP"%&PS)*>A*)OR+P[0,,K 4E1C. /$W!E\OTQ1&U+T$_0F(!5X<<-Q( M.IEJ"\ ?QV,#YA"A&X<+-: YZ729($;-X+T"@ O.404@"3H 9 HK1E!0\Z*/ M+D>$P@0J7FC[T$Q+5)USA K'[0"0YBA]LDUIH#FU<&AK6\&333(%IB$[R$I M2@0823:V\GGX)OLII)E.8" &TMQ^^T]7^80ELET:,$(;V[ ==B*HH HJ#K8: M 6=T)OPY=;]DEC*P'N>H&>3H@3Z!]4UY0]TUNS7-16W5^(;A!1TD4Y#L*X,X MAAGZ TV0TX"CK-+GMPW02CD8A2\ >J*,@R#N\VLYNQQ(00&=\B"5CW/H]N$61 MPA4:A!X[K]J6GXQLKPL:NN8.^-0ZL-H?L\5A@ 194(),=P3!A;H@NFT6;OGT/$-O'"(VG5$: MSC9TC",#&2UMQTA^ 1.XY+.80-]'9,?>11>[";/<]0V_:BH\; .ZAP04_6VZ M82.BR+;]3%L^0;< 1;!SN @AHL+(.=2>]P1%$=71UBB)[A M8$U.TZ2EK-@F285RU &Q(#F27 MS#,-#PYP*7I>UE]314?0W5:4HKAP=X!W=!:'OLW_^U_A)"SV[73_@:'#/&:6 M+H(F0;PL6.+40$[1 "62*S8 [/17E).?-F)0RU30=;HR; O9[=SMYV:+FUL. M;3').*+%-H/G=IB>J>, ;I@6K"7]:,M TE*0!(W9&-$DGLX$J&YN*VP!%&1' MI0H\V<4QB?=)*QP0UB8%]G) BBV[J3- &ZH@]0=+ TBO#W>'$ X)^VM'>D[1 M%_5U(ADG.>P FF>\_P@*J*S6<.2<(,/2=\B#^&B_R^:N1O7]+0]W(FAK^;;\ M'G?ZTV;PH?@9W@UCA]14LWY"_=[QYDG64&WAK;NLO6'\Q7O,'SD5/.9QSIUZ MWMY<^I;)E($"KKL!@._X3. K0S"\.CUJ>:=WQQ ;9&,!&'K?=/9#_&A+M1W/ M;KA+U]X;[>OW8* VK+Y)M\E(G V"ND_;9&#L"VKWV\;I'9%@1$/GU7@:K%/+ M'%8R3_%JNT8J2_B*'@5Z7IW@HL$(;L('?@KOM9&\:IBZY6A?T.5>)\(S_;AH MND<(JFX"$R7T9KZYTG^K"W4=J1N=LA 8'ZVYW*49)I;,V.Y!:=4-.E'85\^C+'ZV\?[%(W M+J@?IF!OL*",3F5K:AR_&_!'@A4&,#Q#X;E!XCI:"]6#]Z8FX<+9S8^A&'9J MQ )H0NH0GG#C4!51T,2G'\?R"^K7=OR>50B.G+ ]C/ MA2W6.ON._?<>H7;[\K>-R0GY,3E^3,ZEQ^0\$V3S[/G#EP39;)4?03&TG:I' MS9!!T$%"0*PI :5S"]>./X!"'^#A$WO!C7<7^C/?2HAS/!IDW\&R\ZZ\48U$ MG3"UIPEZ7#%;,J!U.G2=-H+MA#ERA.!^)# #"PBQ_[WK:J?N$*I4XG:UQC-H MK]ZZ[99Z8'3B.<8FJ/+OS$=7(1TSFZU2[6?>OE"'$_ \R3#Y3LU8P$O]? 1&$>H W==K?/AW\&GE/^MCYA+@J: M7%H!TW+G3:;K19K)S[(!N.CQ3L;:FO!V>Y@JUZ\(X>(^MOM#39<>-Z'H6)#=-(GT4 MVBYQ%8I;'14[M-T\T/N6!5XXX/X0#ECO"UW[4FJ."&34.FF*(=)P93SFYGZ#%^=IYZ(!"^5"@XGVN-TXMEL#=S9'9!! MLN2<6]I^I#X /EHK-,0(O\+#84VE6@H^:U@S=+4(]DYIQP92*PDMJEU/##KF MIM2?!C^ZXF>N9W:L_VXQ>'9;[_H%.91H' @![$*W\ T0%<];9#N\!+'%>]0C M[(X/)-JTK"V>/<+?GD:R[D'+*>XQP0,V;]$U]C/P&F2U\;$(--P]G(B$ ''Y M+79DD$S[QV*2F[=G[XR+NCF1?)[%B8XY$S1:-PX2^6" JJG0(Q#7*T9]AZKL MFEB:2H+ 'K*] ;)= ,L1L56%K><280ZDBJI&CO+T9 >T==_&5W5[1H1F/O7S M3M$&UVE$R$'/=OS!EF>NHXRB%V"Z;N\A=,TW^#2\8V@Y=XNVA^D&=8*B(1W8 M%U[!\'CU$3NGU/4?. 9P;V#"FP$]M#_QK;.-SOQI@KV*#AZ'X47 ]HEK/KO. M^K!B/L(U+7EWOHIL0;0X;AHBYU0V M+KHBD$MX'],$ MY=7=_2GB'./'$W&VQ]]\T7;T3"&,]Y?6NH2YO'_TYX[6NW7.[M*[H[M=/,-Q MC-YZT%*4;$;2>)+HWFX2]?Y=M7;BNN+I=F>-T7MG_+'#K>=2I&.R%"8,FB^J MP[9";FQ3IE_ 60!UZ'L'9^?0 !,D7>]6JAD[EJWTP'_T@%\WO&=H2QDD$=C= MZ,K[1;W$"BS(PU\.7($_?KLS\TS[@UGR9[9Q164JHJG1'2S@,8^W>P6-)*0^ M#T3SW2RH6NU,CKIF&%$P1L=J*K X'(O\^\KK,GRKWLN&K0V_G$EK/K>().;K MS9T0&S]9R93UHLKV#S=CD0L;'O)[L@WI:VTFS9ST0BI;)AJKP/]BW4IV_:BO M@_+M\MT7DTX 5MI+&WKEQM8;B]7\M\X:[:FH9G\B(AIG[\CL9O3MQEW;C2%7"455#. M8! T5L&.D24"-;^&BM:G1U :E@36[5!;55LXL<-D2H-=89>DQ3=U35&H#3O$ M/D6#H<7#*!B[5P4 US#W!FKHH$V+HP S&PG "Y%8-"F''6%,G'@?O(Y HUF$ MV=JYT&!LQXXK2;+H22+\NXV_05(N;!>:$[Z7HGJ# '8E7^)3],6I:BH->]G. M5G"5TA/$WL:Q!ZQFC$-W[;5^!4,Q>W?89%*3!H?"38@#:EP)K+5GL$N&0BB>\T>*,.% M&*HFX]7ZRW&G-D_S@"[K/6WR^(1L0/_!Z[9[)YK6-B;'*R:.PW#?Y^CHG">, M3>HR2#72KH>3C6Y]N<]'S+KXP7@ Q,#XV8#K(7WUK%0I8$=VX=W)@"MC2RRY.*HH\BO\U3L<4I.TS8\69*9$;HNF(< MR]8^27&"P^ - IJVNA3$I]:>1H[,R;^<8&=Z3K,@ MJN4@@GN7?!>S1\^Q1,I<>AD! Z5T>WSV3:K=X.APMMSS3FR;^\/%NIT%3_T] M.P_@OWB/"W[1 PBWEHWG@*(&C2>4Y,$ P"H"IE+Y)() ]G@C /RR/"%KC\HFI,*T.QGT)M_+"E M=A\R,YWFFN.#=YHLJY'Z:*PM>^'C=U:*W6"9%>>)24&IS6)L,RBT'H:]R''+ M0K>?)(O'"L?&*N59IYE>Z^H0[CM9?*\0%:#E=3/Y:=ZJA<_;EE7[\6&(&5';.AQ4FK6!F([DZGU$LIB%UG&V4JD4V+%82^%!LYQ MT\=2(KAXZ-3Y1C":WM167'9=KO6X$UP:Q\?#Q_9M?LU;5K$A+JO9J!Q*H=OK MJ&FK.6YFBE:[RPO"F$0?^8?%8@"L/\&GQ\EM51@6-K>M=FH^*N?;R38;@Z8G M&-6>U>K)3"*?;9%09Z0\9BI]<0$#.,$IK<1/F_WUO,&VY<=I5M 7P=X,WGJ" M5;WU^*';")=$=EI*F;E*K)=*=I<][@2O&LUV?U'IKRO\G/3U2B?=K.BP4K@3 MS.JOQ-E]-S,J\HUL>CTO-<=I+@YC/<&MI&)TY)9^I[>$<3U:OL_FY?%@"9;H MB04XW?2K15Z":?46F<%M_KX4:0Y[H4-)Z8D)22!1CO22H7"D%Q'8:"\1CH5Z MH800XL2P&($/1VLV42U,AQEE,RF4T^UA.=N)-A]A*?22ARU51>0F#;44!#E0 MFSU>JN:K.HSXA+Q*.94U.FQILIZ$,O':,!NW*M@R>H0!PR(?J7>7ZTFPSINI M;F$@I=+M.]1LML858=33.W*+6+]QOHH2=QV?6 MD*]-!HOU2:Q:#U;)D'&WO&W)BQD![*O6>P*V/)J1.C=:BXS\T)Y4^L&'Z*8\ MVBPB2VAY-$ZSTBP.^;R1Y4FQ%.Z.1U(LW,%W'HU34%>DTYP'QY/U()V-K5K) M3C9?.X64B:F5O"7!G,#G,K,^$6N12&*^A)9'O3]V)+Z_S'J\O%S(I#J:\D+5D$I$5JO\ [8\>J:;WABC/CIK)%O5#5L><3WNZ(>F4PF(6-2RZ44+5WMVZE'SKYY3BUM&:%%+0\8GR]$6N9H^!CCB7#GC%-@2%2E'%#V6=G M[TZ9Q%@NRG(QSOGAB9B[Y\\3WG#ZX,3UO?-,Y1U.N2J?,))WUCWA"ZVB?I]G MB^/,='GH:VN((R)9"JD,ZNZ5%"GOV*TP+6JT5*E$J8&#T '3N+$WGS&[F'SN8R#+ ;C1^_K+#JYU>',O%3G,K8H+%F4%^N1^\T\0I M.-8+:JZBK?&ZEAHU*P3+U-PO;*."?K-G>K"[3+E.FV,SPM3=@3D=RY?,0>;=SS>KR$BY:X>R3I_AW$I,"_;#-M"61ZT4)R;%;:L=M4Z%-_ M(3FSN?3\.?)KLY#OS-L_+AX0>;8JDL^(3V($=Q./^HRX $8D;CB?$1_(B(^J MC_'2EG$&:C3WG?C[A]QXQ>N\*?N?1^:SI>P__N]9D_A3W/OR'/Y[=/COKN,6/$;;1BA?*X_IA"DY7KA7_\ MCL8"R?@;*YQ>&"I^?K&V+X#"+ZA(]X("^"TF^9)R=4F3O&+%I7K@=]@Z)GY] M,XWEDDIX?;[\GE\[^QQY?487.=!*KV:?W 8FV/FCTQA$0@/H\ .&M"Q :7!S MJOJ[XW5)U[4)T9D5^I31JPS^3(%?]83[1/.VJ[2L].UC==)HW[9[PX]4X(\/ M+M"Y_HJC"Q1=^('?R>P)E5^WFIVR$==):SY::]$\9QF26.M%4.5/!,*1V-LT M_JO0,PX@+N7>[=I=Z?*5#5_9\''R;\%)^WJIW;*^N]9Y BWY=7 :2R;S.E\P M0N/4W2U7;8\Q2 +0DF,#,?:YXJC7I?AA>A#5U#"4WU?UKA#;? C[BR#,%=;U M*0TOPD>"@_YCLT6ZMP\*7Z_)H=ZR%T/,BD4BWU^_J^H$C[R\I1.:;4*A6B-2(<8]1YQ3-$K$WFK+7J!E6MB4"%_:T T1[1\? MTMY^[.']P9'IJBW2)^"MU^3*0:EO9MBTN!YFFK.25+]=TK0-8.!R 8X[SC;Z M\]OI@RD'X#"Q,""3S5<0K51$O:/8^VEZ7'_$DU"*$I#T( D_6 M;?QP#I]/Z9>S:2)E2MF@Q).E%B\.LFQ]'JEAIC7J8>22Q\$[S^/O!<-LQJU* MXV0E]?7([XR-/@1>$@1^CL+I2GC=%O 3>%?IKCO=4J\P:ZUOPYE(25-$]C&% MZ2(![\+QOT';I"51'"O;5RA]A=)7*'TT!33=.2,]OQ4U==@D^C1#^J?B>U;A M7'Q5R(J)UCP1$M.Y9"48RB\QHRZ@:2002[X53R\8-@\#>3S5!7Q%\F(QT7=( M7@>B?;B)?!+.]N-O/#^&M?:_Q&6N-?<%+]O:'S',J@*_=-8?4\2HY&MQ6RB<\ZD\HB%>?G MZ_AH%*75#_!\.A#FCM.Y7:\&>!"VXVN []0 ]_,[4+&_%[T.&S/4'L=P0"UGA@0L7 MB(2N^ X+O-.-=?7@3)1J(1K[C393+TF*N$_'\Z@Y^=8?O I#O5 !=7'V#(AC,=-5H0YY-)VN] M5VO=I9LM:T)KC[ZZ\L/_T)IOOX\*<7_@LG#JW87B'X$;%UBL,"O#PB5%>4&5 M^#S,=K#[YO!"YU;=-ZJ";E8&)Q;+$[4+-7D9SS6+7(\E23+AFH(:2>:&UUJ[ MT*T#+S$#0=:9A:!@27NLFEWO5JJ9*K*>B_]K[+M!Y,,;[8Q3IY[6-(2GO74. M,=H??H.W[SJS##*P%$:1L98]-A"F&N#MQKX?X-P)8/J" 6TUU7E<)\:,B%@[ M:__Y@QJ*W[R$8HR[B4;\0F7;UWYEZ3Z_AN)%,(*]289\1EP (V(W'. M<+_HU_B\62?>,.NS0O ?3SEQ^D#XA5+?HJ;@#/_?C]"/=ZN];/A3PUU$HII$ M][G[^D+N'VS(?,AD7F#H&:?WK7CUDHKM\^I243/YU6Q+J:HE*.^.4O,W\2N; M\A5L]:]8M;Q[L/BWL_-Z]W:?A5>_Y:<\9_A_.Q>_AS)PDJ&^2N OW=>H!%\8 M+/Z*M9W%<*<'#'?ZV_G])SK#9?.X1:/$;%.M* ]\3O^!:G'9G"X1R M?23[=/C_[;HDC#4]K0CP1GR-^PQFF;8 UFSLNS9B6,#T7CBF=LKWP*O MSG___^PNMC>*[:LN\+#>&SR7+9'W]_7A8E(R2ZUN@9M61' M%)8"BE$48#)^=+7+%Z$+*[5"+:TH\?P#'PQ6>Z5>O#LJ1Z_70ET.X163=7S=:L_&Q?98DM.*GNI%[52L MB6?S*UP3OEQ/N.;WM3>?D:I>O75?76QJ89X\)H)+,5$T;^]JGVMEIF]),!.+ MW8D\T9/K+ALNR.-L#40!K4P.]O?7&)I_D21@]V>9>4W#9).1=3XS2<=7Z<=!3.*D)B+WN\R\JSGC3 U!/<3,R4M- MG_A^LF]TT'E^GZ]O09X%+>EKJ%R6;;%TWI5<=H+WP4YO- EJ,?:.L.W0K/-^ M1]B76XV9^YJ15LBF%:J%1ZDU-X@LHK4>+7.4"(2XI'^NZ9]K7HKL">$[OM8T MTBUV.GHTM&ZTR0U'GWR"V2G&)VRX49JV2/=N&JJWM6FO. 2!0=LRXI]@^B>8 M5\/-"]+,+LEX]8\QK\FJ?>M>\5F6;,4:\$9]TN^U*K-,NQJ'?WID"?L$6K*A M !M]8W[Y2S-9F[H@$4HD&"Q\A!\G_HGEFPS1KRX5<VU]GK[K/-+?" M"#8B_:,,,NKZ]\+MA1038U::K30512JMF^.N\7[_WE=;K\E&;]JN=:L;?CK, M+_/IT6-/7]1ZM/PDQP:BL;A_Z'G9QN@N!_U?SIA+,WP8FM8^=!7):"YA2Z<6 MS%?O>F<\GOOJJ?W)RKW:HZ&#$L2TVJ;OA#CO\="7%RCZ[(MR7S[AJ];5+Z,B MTX=IU(^]FK$<:$I[DJYSY8>HSEJS:JI'JQB'$H%0^#FWA0](W^SDZ++(\77O+AUYAL,6E2T3C57@?[%N);M^U-=!^?83#TC" M=\=Y]5$/+INH+ITY$DP0'TN1&%4SX5$&)BLO9,D2%&6]K=/H=&R0 MF0#21> 7?:MJWS"PH+$B)!V_:&JZX;Y6-76Y;R$53(T1#F +128+PE V PLLQ;2)*U(;1':HH,V(C4'>VI?PD#EB M-$OW_'S#8%'-H;MP=C3%Y_[[*BVXZ)\4'8_9D%<6=+W'DKM)G^_,JVR;VQ1" MK88L%6&% M2W*F&<2XN1@8J5B[TJ9/"P;6+@6Y%/>D5#@E%KBFP(%*@%P4)(' \!#U;2'0O<T:U@75MP*Q\1,(8@JX#0FSF:ZM* M ?K\_TI_H.0VTK Q; Q@Z#VY+]A+#']%.LFJ#12_ MG0)#GKI)H@("BS;6R%DF6QL*5\@Y"B<]F: P%/'HRO;ZS 9#D=?6Z,12<%$ M;Q*)_\/L/B)!CJB)M:\]--NK;6T_M5_=VOGNA=I6#F-,;78^KAQ@1'C'@_\( MS$A'*?NO9B5]*M_F>[NT_\07P1(&N5+L;Y8VMYRO/*L%J8@G773W03U3HT7& MC:U=)/SVK)6GUO@^@TY17J"BU[M3)C&6BX98-OK#?KGS R&)2#P<)CTNTH_V M(GTAVNNS;+Q'0A$NDA BB20;WWL"+-I5L/K ]GEM,&FK1KX7S:0KXB(%>,4> MMDSF]5RDS$5*H7 M/GZGOM 6M4%T%N] MZ'%+/OHH5.YY8\.FE_644$]5^M(*@QB/6EJ-\2S2->+S2 M_+CE],&Z&X3[M[?\6JD&38Z;2YF[)=C]1RW3T_SMYKX>%EJ%Q70N%@?%Z6VX MUDL>MPSQB=M:3+NML+%(JYE+=HKJ<%G#S>)X\MF)VFAJY0D?&J;E870@X.LD5:[EQ4NZMQD%H&CIN>A<+CZT.!VQ99ZIZ22BLEYLB ML/X$GXR[(1\*=H7X)%A\R//A<+67$^&M)Q@U5N4"OTSWVSQA<_6..,U.LDEH M>H)3\[O$;>Q^(,Q:)+AI]J+];BHM0=,3K&*-;G"L#&X;K)"*A^]*#]5Y)P-C M/<&KR'TBF$C4C=M):%8J6Z98)<41O/4$LVJ15#.;E0MBB[!5G0Q+]X*\A*;) M@S7=8P5.2HH)TNLG(K%>A(L+/8%$A%XXS,4C_<%@$(\D#E^>KZK#=A7,43XW MWSP,V$B$J\7AY;WD$2,JT<']K5!;3-+!:;7?*2?RS;MA+W0L6<&*P1/3-(:3 M>7TFK;2R/HMQ-6@9/6S9J:_GW9(>DEG+C(6+J\*#,8RDH.41 JA\:VG&^&J. M+:0C>J8[*!J+%?9^-,YDI9Y8!TO&8A):BR1;+5:R*VL(3/G M@\48ORX]M.L/)6QY-,Z'^OW=;;34[;*"J4S[:2.MR1O$BJ-Q=OJC\OU$J;79 MD#(M[ MJ[+)_I52&Q-.;E5*L0[<\>8S5%$S1, GC4^[*DEY)WK17/6PL^ MKZG1Y7UAD'*R/AV021;+V>Z83['SB;H9WQ>5QV&H=@K4@K-BN]%83LNM]*Q> MB,ZSU6"\LX261P/EVMFT$LX%I=:T-GS,+T>U:-M(G8*_MI"7N^6JU6VM;[.P M\06[C=80;P4=O;/[6 UUB3P93>;1>4-:3^)]0:B= LKU;6&P4FIR9-*HK>+S MB/@P3DK8\NB=\U)+>2RUZ^:$W$^)F:[TU:4R/ 6IP?@\.^F6[J*MX&;%9E?! M9ES?H-/U:#'Q7;79+4S-R*32&XV,6CF;NX_5H.51[^MB8UP)9V?YR5PE(;X8 MRX<:PYKCR-UO*H]G[>XX%NI.YB7)3$[7#Q7)')Y"](=B48P-PL$XVR@;786_ M7XS"O67O$$TP,UB^E+HS[^I:JTVF=XM>/4^""6SIKJ8#_=A^KM];#UJ*DLU( M&D\2W=M-HMZ_J]:&/6P:LBT/>()(*?.EUN$/T\^\JE%?4Z1GC+K_]/=Z]#Y$ MM2DP633;'_<+U&:BX_6EPU\.E.D?OTL//.,Q9O[S/_W+<4175*8BFAJ8<0P7 M8- "M)V=F+Y.4-<>_X;L.HIVWM+T2-!-)J]*T*]._:%Y5;S9NGAPWB)8BGT9 M"#)$_Q-,6,,+@$S?L?&8?[ S?"+$_GM )_HM]^]/ZH83&%$P1M0[($N.2_0< MCL\/.1$J+4AZ;]X->]KN0X[=S);#&[8Q;)J\T.F&^-A8B74:M7?;S55AC1XV MHZDYAK+;'3%RNF:<-I -3C0?,M9C>-)0:[7YN%;4[T*U'[]!:WC&=1KP.OQ$ MFO@"/46BHM$S!'2'XXR3<(W28=H.-W>=V9X>]'8P,SSQVOK= MMB^E_)_9T+QE$@!DJ6A\F!881+$2&NBM5"P\S+'2A M+@31LJ;PM>& /:+!T++1M']8&C#W!8@K M]-/7-4%B=$$=4OMS1P>)+ 7=)HY#$L/U(C]!BHO!SN:I%0A$VC/SCYTL _H/ M/.]XIM'/""+D#)#_WP$'AE\_*U6BZT8G,"OG MZ(RZ,@^/])!4@J)HHNO^QY9[QQ.O/]KG\\.W0=[]C#VG.^X?0'K)GAW@CO :+AQA+$,*DL&+%]ZO*.:]JQGMOQA M^ZWO_H9)ZS(-#?'X\UW?=( >2-!YH>L>/?\V2P+;\V+7FT]1&*O,[YW.@)R/ M[=]ULB J4HGV[OBR UL.";,9K#?*7$197-",;H^O24\6=H.CP]ERSSLQYT1A MATS.4:OAG.#I1# T%3OYEQEI2_A%QR,CTQ+<@UB#'I78QQ';$Q=O[S;(O":C M@U=+"/7"9U 3YJMQJ3<5DQ8K6[R LB.?GAZO-53="CD7XBUVISZW3ZKA>>E6:@I!!0)F;0OZE;Y!S^ M[7?B\4 #1%G2PW6ZRF!J\ !T8(<_.'CC42\.0&EWTGF(!7B4@^=8E@&+V?CY MBZX0IQ,'%.U *@!$19@9Y)?[P3M+G('C4T=_JFC[8?_UAK((EJFY7]BN;OK- MGD/<$XOEM#EV;INZ.S"G0\XV<5YW^3D1OXD_>RG#XR3VO!^C4Q >W @<]^\@ M1IW]LD\/0#V47G3<.T\-&=V;AZ4)9W.N#CCR',']X M;2CT0H2FSY>OX0MW$_/9*DQ[08-&*(&%"187=R)2?].>1MGB(M5F8ZIAS'.WF48MAJ>O8>I^ M#43B[,?E,KH ?/W\Y %?#ZI?D3#A637T.T[Y)17O@N?\C=2GZH$C9>MI^?6] M]::+NK[XQ;)_?HWQ^Z!O%*LT.IQ]BR+.7;K3EG5<:6)!9BVF5D!T29AQ_X MG;"?,%1()=>H;%;W)C]-B/%)*LTMT\.A7:0[%$B^->7J]2DX,>?"S]&E,U^S M\36;[Z/9^"![)I"U=+Q=:;>L;\'C%-2:AI5@M9FR:@F)5?=1[(P?Q)E3;9)C M ['(!Z:WO@!(S:L+((R&L:.^DNDKF3[^?4O\D*E17O7<((=?4W3US1]3=-'VC=H MF@ZD\'80+K2GB4J?3!SV>*\+YJ _5OC@,)7,&FV2X-8I.^E_*!K[5GIG5<=[ M$N;:CE(&@LXP=MM707T5U ?&;PF,KL!7%0'@T79X4ID_ 821@F[JX4Z'3*S' MQ_R4CV_JZG1HYVI.!MCH&Z,RKE4CK=@WR=0AWG0S"$/7:E ;!/':B:^4^DJI MKY1^/^S%+C\4>+L> M/8&VB4Y42^5Z)=)JM-AE/)>--2IJ"I,8XI6,:.);J9[;<*:3*;-UB^SR-_A* MJ:^47EK4-?./CXT?>&3D_<$!AJJ-"R=PTI(+_)"+%4:3>3"=XHK67$U-EC3_ MR8_?L0 ;/CXM^ODME=*4 Y28)0^0TKXJ;.?IL9-_/8>@OI[Z'?74"Z*%C]H7 M@=H?[E,]"=F(0VD/#,&3=1N$G " 4PIO++VLCE8D/FJE-S/Q(5NJI*05S:^- M[H4 %TZ^$<@O'*\/S[0\">-\'=?7<7VT_(9HN;/[/;_M'TMY?CCE@^W&K= \ MVEFVIK?9W"85*JH^F7X"FIY5:Q)*3]_U1;Q%IL5$*UP@+4M?8N$_] ]P7" 4^2Y!JW87;KR:KZ#Z"NJ5 M*Z@^4NZ0\IDPU/MUIQ(RA[7J9)WHUH<1H5%83U)8L)1>TX\%0J$W7A"]5BWR M@E2I;X&=?B9Q/Y/XWP>U[U1*781^@W*:F_=8]B%AM=CUK,-5I7'W/E)+8?WH MUV<9_Q]:Y>BWV\RIA_4U-9\.4J/75[;9:=XV)7IG,&V,VHFK16IHLK[76EUO, M3=JO]#? FHW;&K5[_J 3)0;MNG7P^.YMED$&EL(H\L(I1KSQR/U%Q\;GS3KQAEF?%8/_>,J)HQGW]UZYM!=R7U.D[9'T MJ>*T_8^8[4MV^H=[/$6BFD2_+):_9"/_%43X_'7_EKK+'VSC?/8C](-WO>RV ZU44?*9_,M,O0?MX?D?S MQ%7X?#\+VE^^5O/D&O!U&W^UOTNW^<+["'\J#5D,9'O 0#8?#S]8^;GB5=&R M PJ+\L!?%A^M'EWQLB@11"N ] MQ5Q"DT[7&JY*U4GP/K6NJ'D^(R^'/2>/8(Q][B*6#V.7XP%F!JMK6#QLY6L/H/]?%X%EPM)U9)K'=S][VZF*B!8$4!2MD;+A0]NKOH M"]:%.8O?*%@-4Q=H05(%UODWX^8%*48O1(">8?)GO2;_4B#EI^MY]!YJZ-^K M\FJG+0,&0'2[R 5L",9(GGU$MLJ+ LZ_PG[RS:2K,)-GE2;TP%Y:'<6J1Y-_LMQB5=;27\1 M]/@VSZ<*'+M=;)7J\<;\4A"J7VNP:.)D7QV0.Z:;.5^K7<$30K6 MXS60$C1XN,C-J^R=OTA$KLYZN7S>?$7>Q,^V13X0HB_,[OA@Q>D[X_H[%2EO MX%)E<#C"$YI/OKCLE1\7]XD6N5M%ZXE@5NN+J/EP[(_?B0 7/Z[%]3T.[C)D M011MAG5EB#A2D?MG+2IS41N9?W[GG]]=KV&Z%=WF5G+K2!GWW;'[^6TP-(N% MV8:5G5AZZ984>\.K-4X3G*64>*'!3D+;+/1+-S!*;5F,D\+(:3Z670@I$ MBUJT(?_\SC^_NQIN7I!B=$DV\[<]Q/M+C>GW;BN?95#G(HE91Q(>YFQ:F+>3 M^F-ST%1JL*6@01T*A).ACZO*\A5VCZ] ]@K]$ ]NW2;Q8H%VB4AA/^(>MUFYB7SQO_D-6W"[\MDG_:P6K8;!5J?'HSF=Y7 M4B%^4"E8.J(XVH&QXWKRW^-4M:D+$J&D@UG 1_AQU=7WLL>I75["\ M5.^B;8Y^-75\<_40@9M;@0<3D?Y1!AQPWYRN\'E?*_5J/EB8-AP()_U#V^QW*[BK@^:R\W2U*3[ZDWZ2\X(OWK2W_DBH#MX)F:;&YJ)R8=])\M[K8HOK5;] MU+W;#[ '+K$*]54:!)=1@OK#U/:F/!/CL[158.O.";^8G7]JUS7WY^U7ZZ^^ZP]Z]'+EV^>YU *CE3QOTHI^,QS&[8< MWK"-8=/DA4XWQ,?&2JSS!]D WGS6LN!',4',<-;$:A=7LT5M-1YN4K"KXUD+ MQP9BXFGJ@004?9&3G=;44#NSU'4;TGDX6&(AYKSIYT-H@IL_9+Y_WO_[57 M$_#(4'?DV#,QIQ9AB(KTD 3MDH/" /K^)2A+86VXR503-Z$M]OW:8@&2@HG> M)!+_A]E]1((<47,JK((>FCD $E3(P/QE/^5^167?_>Z%NH<.8TQM=CZN'!C4 MX1T/_B,P(QWQX[^:E?2I;+CO[=+^$U\$\@5 H.RETW6^\JP6I"):^"B6C#9@ MTHAM*@:<.BM>^.U9*T^M\7T&G:*\0$&DEQ1(B)7Z@YXT$ :]"!>*]Q+1:*(G M<$(XPD8&)"ER/^Q>A6T^!&N4G:]Z=[.)T&JL.M&*%&J-4@BPARV;(K>XZUNA M6Y8,ZWF]UM$?-W%L&3UL*3\.TTW=ZVG/D#+UNQAR^%BPRX? MYTEV,BWDU8I:'$J1RA):'O6NI@1R/[ RMVR0?UBF:G*W5TOB.X]Z-\ MZ95X:VVE^7JN*S[6AKWP\3L;DU5Y$AG/PJW8PN@G,G=)0QJGH.71.R?SA[XT M7^7&;,SD[\1&>-*](YA_\FA&_5R\EPUMJ@]L,'17RLE$72KF$EH>]1[G].R< MR&R)+;3[A2J;ZS3F])U'O5NE7&_EV-B: M<*.UUI(S5FBLS#K91LZYLT1;'FP#]G/]WGK04I1L1M)XDNC>;A+U_ET5>(M- MP[;J $^ J6V^U#IRCLWAU+88CAU#%1?:0I5KYC.RP8!&(%H*ENIA!(,Q1X0A M*Q$4%$0._&MFZ>)(,. #[.J )Z!-TN\'6-I@@:4-L*5*3'@@!B:%-99/I$)0,9'])AIU:'S$#7IHR&[HBCUYDCP01B M6XK$J)H)CS(P67DA2Y:@*&O@E>T"<3HVR$P -8[ +_K637+#@(($O=CC%T$C M,]S7JJ8N]RVD@JDQPN&L9?6 *ONSQV^0 JZZ14<@J[L_#Z:R)$ $?$C8J8[X M'M@PL.D4GH%&FCX!Q4\D 8, <,9JE>WZZ82KV'/_[>[G?HF_0 MK(\\8S%;ARX+NMZ[:]1232GUN&X%%XUN93V89DK%)2K0L9OC2RL,B+R"U!NZ M8KA;H<#3V4S75K1X%JS=OYCB)X94=:2RBD*94A1-I O4Y0WOB$A36&4(37Z+ MIL\4E%[S)-NX8&HE3H79B@^FHJ7U)IT=W,G#'[]CH5U"IF.N 68*=MMLP^)(JZ@_9^0"/80^H(BJ+ UW#!-=W3 9^ACZGCI MG>D97O(9-B[#DH"N9PIQ=E^T>? 1>(6LVH)"NR X0/AY(<@*)2[L5+ ),C@[ MW(UAW]!4PF!FP+= M:@38R21Y,( =337MH5"M 4@OXWOU]785&3M*"%.;I#838/) :"*KP!4368[[ M^TYTL!L8N+'K2/00$-^LRS 58#)N6X!V]-"8,AXGJ8KXJVO!7(Z >7 MN%VH MNJ :#M*+F@$4^F=+(N"(00""U&& &<)VK\.LD#F"!'26#5.GAAFEFPI(\A,( M8@JH2/@[RM,[2AJ(7!FXAV4\P)>Y;NZ8@#\;)_>.7J7YJ)*RU)M4ELUA*#R- M23,#MOS$3>+)K>,CUY['*2 #FV7QN,;.TTMOSS=!ERQ03+.UO5\6K%X=KV#\ M>_#+@>/HQ^\Z*)A@^ 1@V":3MU$45V15UY@L,@4^4>7?1A>*S]R_3+K>K50S M5=H4-4X/.PRO5^X2A+2YTY%AI["Q<;MA'4[$@[@&,Q(6J(43E?%*\#,(90"9 MZ#YF/(WA\*5.$3Q#1"HB3)@+,"AWH*-;^G: J%W@\W1'("IV?O2$NP42>(KR MD3[ES@FF^-%(L?.K>]WJH5[X+F MRX\$" ,6,UW+SF(_"0;"K&L,FH-2BIT^EI3.@YE=/.1JH/^';HZ3P&T525PV M:#4JFFU7^O3VTALPQ8:4(I#G)-7[@ZD6X>N]V*0R3ZQGQ?6ZF;"0ZL] L..4 MV*UWE-M+I?TK=\GY:ESJ3<6DQL9:X#Y)_23NC!MYZ=AS6::3EO;7L%_ MPC_WG ]4&Q%<7S6U>J!RGB>_>D@SM44%=;VUIAX3VW)$*#&A#LB:YRH/C M,K:-/=?<=0#V,W8U+ND59_CK(\5YTK'NFPNC,IBTF^:]/A@L'O+OL#^PRU_\ MCD25P7,X&MWP@P+7J21;0K\AWHT:W3RW?D%LG6W--B+1<$3*HWO1P AJR>?# M$WRPS3_T'QH-H--)?H2;0]5BXR&%M^[T4J_:FU '^YQNAQY='=7N_IKB MS%:C3]OR1>4)A)Z>!*B:U_ WP&HPEV@X>-I3!KO@)5FZZ[^WA=%P\<]UER"> MZ,0].*&^1U=$\13D*1S;HL!I0),T8OMF=#)0$,5P8'2U&<("1F0$/+:2YYA" MT[Q!=48(XHF<8Z!ES_5*.Z;6'VXZQ8SM,8+8R$&*H MV^;2_A&'MZ%*\$ '\1U/?)RNWC^;2]TY[2UD[Q1NR_K 'N\]5JG'T/60[S56 M)5VH=)_8;;H'IUST*]L[C-$)!SORWB9L.X>/]F'[/DJ3^AE/:P/:0J;21X * M])03%I:,SK"=:>VL_I,&^/&X LQR)(NCW;:WZUF0D$F.Y4[=^D<'?YZP+-=! M1U\LX?$H=+[W@[,E&R:9,=8,O0;[?G?H&7ABVIB 0C[#ONWU]YJ\,J?5X$V# M+\Q*7+?,$G,SW&;4-+GQ"5PPL>F2V&$CTV7P0C IF!LGWGIW M_@4=]?,FG7C#I,\*PG\\Y<1S-TZ<3OI[G7A##=P4$"\M(C?)\UZ7_5-B=-%!PE,'R='\??Y_!/\OFQA/\O_2@"YQB'/_R.A\ MTBQ#4"6#QKS/3'0R,\:(1OH)IO#S&I;S\S?H7L3T(YZ^$>0_#.2^,"/.GPJ! MZQJV<2#,!>P/Z&R\%E#\%JOH:Y-)G6T5<:0%Y/1AB.[\;NU@\Z6VC6%X4\:Y2ZZU0O0O.\Q4,! M+A+_Y/S,GR'VOHQ_GHS_)44_3H=%1E12" 6;G52K/2\&A>D@6IO_0<*G]\EX MQV"'P^+]?,X3H;JI%G+=[+A6 QF/@8S'PH$0]YR,7Z2E]=*^778NVKQ!I?Y> M6L>5 L_5Z1"(*?]\7\7A\-H)D #>?@)CJDVI,AN:Q>YD/4W<6MU\8C/I8:H? MFB\V$(T=)\:X'GO7%\ZSG)M_!^'\RAW_U<*I5YX7XS8E.R(&9FM8]60D*OO:/US"T#7M Q>9E1)7H#QT[% M-Z5*&5MXCT&/W8)>*MU/=?A@/,:2^]"@/"M+%:.#*06Q:O(->WR[[J0^XOLU M?+F_4M7F0^3^'?K-%\O]WJYU=Q>M90Q29PJR:*=JLJY"_B*FX=N5LLE3?]) M+[/K!&^\8^HP03J^$DH3[^SE5CN^1VCG"1UY,XJ:PH1@XK-=WM+M2(\R]SQU M1W)[\?)@3#=,7MUF> OL7\1$VIVXAGGZ&JZ3( UON=(0,U/#Q^T<>;L' MYV8NDGSI.9/7^A%0>W-AEF]+7&J9+8ZJ";JI$O[@44Q65*0FP M*"/VJ@QL1QS G%HW 49@FF0EX!U6?>;,W$[\QBQ'&F9_T)9X=]JP^H8LR;C M][D<8.@)-$U A5>=58:6 V#<;)I,:J@3>O&5^0R?B[4AU9&YQM"*GDW6DXK MH[O:JK50MFXB6,(__T3NCMT6^T5LMBVQN-%K=]?A2 M3C=/YO&W:L%",LB/8I/*1#8J8KU=#7>6IW+NEZ4UFYDKP= DO7A,6R/6M9;::F]4:P1/T]I:CEF'R( \WCX4\;W5*F\)!%/]")L*-X3 M^N%!+RH(_3[\*P(?#]^ME

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

H/N2=?8O4$L#!!0 ( "B) M85(;;[_WF0( #,& 9 >&PO=V]R:W-H965TFM(.V$E>-!R8$&SR[R6ECX=C!=BC\^QT[(:3C(FU[ M:7R.S_?YW#O;*'UG"D0+CZ609AX4UE;[86BR DMFAJI"23Y!I0B3*-H+2\9EL)AYW:5>S%1M!9=XJ<'498G2<"5!XVH>',;[1ZFS]P8W'#>F=P87R5*I.R>< MY_,@<@ZAP,PZ!D:?!SQ&(1P1N7'?<@;=DP[8/S^SG_G8*98E,WBLQ"W/;3$/ MI@'DN&*UL%=J\QW;>,:.+U/"^%_8-+;Q*("L-E:5+9@\*+ELONRQS4,/,(W> M 20M(/%^-P]Y+T^898N95AO0SIK8W,&'ZM'D')>N*-=6TRTGG%V45FF. M9A9:(G3J,&O!1PTX>0<<)W"AI"T,G,H<\VV"D#SIW$F>W3E*/F0\P6P(HW@ M291$'_"-NO!&GF_TM^%ML:4=6^K9TG]+UL?@'\HB[ VA1[)USA1UNK&@5F + MA)42-#!C2=P2V.YR^5NI56&QKQF3R9O^A@G!W#&):?F MSF&M5/X"30:3O9=GXO@UP0[$T6 \&O<4Z21]9?:3,LW;(CS1> LF,P1FM_/A MX^E0:!:4G!ZM\-5EV7W/#_2*B E_< MG [?ZL>P-\@EZK5?5ZXU:FF;F>ZTW48\;!;!BWFS3B^87G-I0."*H-%P,@Y M-RNJ$:RJ_%I8*DM+QA\+VNJHG0'=KQ0U;"NX![K_B<5O4$L#!!0 ( "B) M85+?' >5R , &P) 9 >&PO=V]R:W-H965TTE46U5,[I90BLW<"9R# MXBM?%]HHO,6L86OX!OJ?YEZBY/4H.:^@5ES41,)J[GP(KI>1L;<&WSELU&!- M3":/0CP9X:]\[OB&$)20:8/ \.\GW$!9&B"D\6./Z?0AC>-P?4"_M;EC+H], MP8TH_^6Y+N;.U"$YK%A;ZJ]B\QGV^<0&+Q.ELK]DT]G2T"%9J[2H]L[(H.)U M]\^V^SH,'*;^"PYT[T M[RZ09?F1:;:82;$ATE@CFEG85*TWDN.U:W$OLK]0[PNJ>1FQCX65[G&6'0U_ "2BY$[4N%/E4YY"? M GA(JF=&#\R6]%7$CY"-21BXA/K4?P4O[#,-+5[XADQ/@*,>.++ T9M+^#K. MWT(#2<;D,MZI&GIU)O""*$W$BN@"R$J4>,]XO2;O>(T:T2JT5U?7Y,\_IM0/ MW[_Y'_L"U2-(VYL3X;FE:=Q "%)R(W=B#37/B"IX@^DHFTV.)Y>48KTVBH/# MB,3NA,8#.7)I.B&W$N#7T/#P'[E1$IYI0S<*(G+;RIKK5H*-M^);LSY"4#>A MR5%* W(CJJ;5!X)*K/2&H??!)'"C2=I+DVA"[EA68$/E\_[T'H&;IM,!@)^& MY$&VV5,7@K5:7,@I3,XS2L@7P(>H$&5.>-5(\1-,*#6H1)RF@^0H\ENVO,SQ M7)S'B-TP3B^V.Z#OR1=#[OEFDOHO.MSR+6 Z2@$RPC.(_#)0Q[!3UT_\87O\ M\Q2CV(VCHSJ(W2CT,6N$85G65FW)- ;) 0=1QEGWOILB5D)J_JM3'+S?H7L< M!%='18CU2:[.HHY(Z+M^.!DHL&O3\'BH'H1FY6_"PA8'I@*<6!U)+4P)+EU= M=&OKOY]&=$DQ79U M@48)'F'?/XWE=N48M.BD- 8CF;K) 8)2=VK6RNS\[WPN/=G>8 )6(-=VSBMD MC@7NAF&O[3\E/G03]&C>?8?<,;GFM<)2K-#5'R>Q0V0WVSM!B\;.TT>A<3K; M98&?0R"- >ZO!#[D>\$$Z#^P%O\!4$L#!!0 ( "B)85*(Z#<3#P4 "02 M 9 >&PO=V]R:W-H965TIR"?,]^-)P3,Q.CYTLKDZ/I2ER3,! _FK\U<86_2H"RR H3.I" *ED>C$_KB-+3Z3N%C!EO=:1,;R;64 M-[;S9G$T\JU#D$-J+ +'SRV<09Y;('3CRPYSU)BT$[OM&OV5BQUCN>8:SF3^ M*5N8]=%H.B(+6/(R-U=R^R?LXHDL7BIS[7[)MM(-DA%)2VUDL9N,'A29J+[\ M;K<.G0E3_X$);#>!.;\K0\[+5JCL 53* MR%LIS%J3"[& Q3[ !%UL_&2UGZ?L4<1S2,#)IFHNERI>ZM\R_,2B%R250V&Q>]4[H$K3<#N*<$=@>(:\Z7> M%><1\^F,/'.(LM0HT<]?D-]_FS(_>/G#WXZI?;-?*SHWV@ZZ#$)0/_$B/^Q!#OIR]?ER?CX?Q&&QER33'DQG27 GAQ8C MC#PV90\O3S_MAK*MR359*LRQ9@JOIG!M3?>SZ*F3YU=_/[F# 7?K9X'>X1%= MMT]N0>&9V=-YK:36K5::ED59Y4HM.ZNKO%$JI#+9WWPO=5!8"K,_MI/-065R M09XY+GA.WDGQ1RJ+#2 ]\94"P!.[]?. !+-N65$6='HL3DA /D"Z%C*7J_M> M.$'HL3#JB:D7!WY?F7DQ;94I)6?N_,3D<@6#,>AUMM%].#;UXK /R+S$GPYH M1]XL:*N#ABTA&,470 0O8.*:>,^YZ0&$T[ZIB/;5V*RU$;2%OK+K*\#8VTYO MTM2+9DD?/>C+IIX?MWZ$CHPNU0+L)2>]P=T86([8'UJD(>G7+%CWK97 M;'!Q2>; M[^,$%O6+,^RS)J/T01:(O"B8=KQ;?( M$P?Q.,;'8YZ[=S".'/CCH!9XN-%Z ^YUG-^/&YE*16:[[J(S//] M-[K,#57TIG^8GSZ[>/$]:8MOS\BNL-!6)P5"+\3=0!D;D 4#LI:ND:N3661E MG=L$\RCR-_*T KXTT-Z7J>][E(4]?_&R$\^\(&Q\&GI43CHO=ZRYE?M_0I/4 M!E0]XAMI\Q?(2?7R;]6K_T_>&PO=V]R:W-H965TWJO\ M8SW'3J]4W/@OZ0=LD46D[(Q58B1C!H+)8:0/XS[L$6;),X1L)&0^[R&0S_*2 M6KI::-43[="HYB:^5,_&Y)ATAW)G-:XRY-G5>5GJ#BIRH02>LZ'#5LF*W *G M%A>N'IP?S"*V&,Z1XG*47@_2V3/2:4:NE;2-(5>R@NI0(,8\0[+9+MEU]J+B M)913DJ<3DB59\H)>'HK/O5[^;XL_B%6$6(6/5?R/C7Y9^I.R0.93\L7M&7K^:94G^[J]'/&,0 M&]#^G ^,ITAW"?:,=![*,I13S3![5U*/O<4$W!$YF23%;,].)_GL)%!;RBIB ML>U@Q75 (6:>!^LXG?V2S!$YG11%>J [3XJ=_;L+%.^]6@%ZZWN3V_%.VN$! M!V]H?^?#J_\)'WKG-=5;)@WA4",UF9X>1T0/_6@PK&I]#]@HBQW%3QMLX: = M -=KA7=H-%R \%-8_0!02P,$% @ *(EA4GL#^A1V# ?28 !D !X M;"]W;W)K&ULQ5IKC]LV%OTKQ&RZF $"=K% D'&DLG[YKF'I%]L MC?WJUDI5XJ[(2_?R;%U5FV>7ERY9JT*ZL=FH$M]DQA:RPJ-=7;J-53+E245^ M.9M,GEP64I=GKU[PNX_VU0M35[DNU4J]QL7YY-SYH7G_1J7=&+ MRU1?BT)EP/3DR818FS-ANKXBM?"LK^>J%-5MA:32DT0=VE6?#.%U24CY7 M%M]JS*M>O3'EK;*57N9*?%:E-E;\8BKE7EQ6D$YC+I,@Z;67-#LB:3H3[TU9 MK9WXH4Q5VA=P";.B;;/&MM>SDQ+?JF0LYM.1F$UFDQ/RYM'7.Z(7 M4?2"12_^@3">ED33Q'0R%L=$BG>E>"]W')21J-8*(XN-+'=".U>K5#R:3J_& M$Q1+GG/=KU96K22D;JPN$[V1N9"%J5\FZTEH)79*N M*W%.NLZZIIQ=C,1VK9,UQB1YG6("C=&EKC2T;&J;K+%BK/OWOZYGTZ?/A;I3 M-M&.969UGI,%F*&M,!M>I)6)LX2$[6FJZ3V$/>HY->0*J>Y:-R(MDH;>LO>Y M3!3@I"(KBDTE,FL*X,I*N\I*UEZC<&V0D]06JN'13<+2I]_/YV/Q94^'D%:) ME4'P2D1^N2.C-:2458TO.&+D^VSR_%WSEI^GSR]$"JM2G\HGOL;%4E5;IA^)C=Q)7^R%?BS+LI8Y+(#>G^L2 MRX_-!/RH8HF"F-)$)5'F.T@?0<=*ER59@PGMJ)!#FKJ%%T!I+H(HE+^_&B%T MN7(. FVN,<^JIN+3$1Y2A2+%)W@45J5*N9"3Q-A4EHF"]&K-68&#A1LJ_;&X MJ5K+&@@=D1!;L[P0&\I/+^RN6>UB1Z1*V$RJX"B]H'8;T^;S1/$O(T"G]@!HN0!)%SM&ZA#BSS/6*"][7 M'"W#["<%WT,VKYP=0< ('M)3E9SS@X5TJ)>PI$2J7L. M5= 5@')(&6#LH:JZ@C$)Q:II(!B69C7A[Z.&@'JKE(MSM[*O%;- S@(+4I+R67>\[TF_"@HJ2U= 8YT)1N7@^T&IUDNG4RVM#JN0Q%>@L4 -4&A?WTEN'$=O63O- M#AF_?HASIW5.D8 ##*UH#[H (F@/DATIC"^PB1O)*)@^" <8NFO0)/3;?A.K M^ET8\&"$6V-1N6-^$LAC)/AI\O5(6PPT(-_UZ 7+[@/_8G0]G8PFD]DWZ&0J MGC9Q:QB'5^0W# 'P%]/Q]>S)]%M$;U !CZ8P:/) GN$Y$( <&I1O@T,F05C" M-NWUO=E\_/V4M;*1#P_YOKN^^^[I(XFHRM\!#[2^_)X"^R^0J]_QF9%8U)L0 M29-P;RZ]H0FRAHV=4+<>KV]R9W@)-%^@)VT,Z_9#_+HGY*]T59-)#?]X+[^J MQ[^A2)7X$>1!DEZ$Y\U:EJN&E8ASD!=LJ73IVP\9%'G3A;>-*6\9<*?O/G5= M)GW1.FV3ND##@3N.^C8A!+:N5#E81C#.;52B,XUGA%^;E&-/JY5Y"AE#/58' MFE\)#V%&/*R MYP7943:UR;%7=XE2J1.+Z_%T\@]6?=_D=RTW]WN0^]#'$G[:7GLGXUOR83(8F9+9-@/ME'(OPOLISB=7+H=H;BP\E43*9 M09WG MUH3^]1!,HK$HE)9.WA>_MK'I[)DXGUXPP.02D46.#+-0)W,5#/HFL(HU.9UC MKQE)PSXNEI[!$<^FG%4B5Z0>E+K3#!EM%;=^OTEEL 'K(.XSPG[5-B4PGW2_ MZLD0JDP]?8\;$L\;?"T_H/=2R^W5,G _Y1?-!J630U@)!QL"!!__CA*B&(A0 M3^;L0MST=[*19",&MRK&!)FF'(84? ,XT :4(8X;12=W0[5'!+:AHYZ=WTJ= M\W1"W=I%> 7/Q3"/8U85W&J.S.QDMKL\/&K+Z$6,V4'\21]UYP&V G]\OXB] MT>^LR(+0UR ^G/4!_&BE!)ANWZ/1:L=555>'O9/9'C;MMMY4":TRVAOA&_IL M:!-H[$J6^D\9"-@MOFW\;=+O.Y9>E>A8B83R2#9WC%_'VT_HG<[O@I#T36 # MO8.&!X-+=Q=X$DNXB$?Q/D!),$U M!4:9U67-2UMIED?CPV$(172O>;6P<_4=[X!/GIYQJZDK8AB\F _:7JJ27(;E M_ VXO1>1/D#LFH+NYX_K&JJV]%]#(URO0 ?.!(YP][#Q#SQIX/CAYO,;L7@Z M>4RG"F^Q,?-OW[3 0.9_X(!_V/A].KX$/"45GQ;\@+Q4+=A\V.(5[[#$6(QZ M9U/'3HL6XVD\MF GEY6'*;*1CX<\%O,J\I&*7Y]@\1P^J\A;Q< B"4KJI#F> M/,B8B62T/>U8RISU\+F\#_&0?13II>*-;H%UJ_\,ZXG48Y7_&0QH#T$CVR'@ M+&D/>1LJ.B)IKK-!_T3M&CQI(3;*8V99H*^:="Q^4UW>>U1Z\*A/3C*(?4S' M9 RAPV=37T[8$**YWT_FXZ>+[\;]U\WBH,BC\ZFTT=92P:&*1PLF':9V"+6[ M>,;<<#)_?N_?0TD?[^')<>HC,9U>,;7^M6Q3/502S8SS^>C)U9,+\0LP/9'6 M\HE:/'49C$-7V70T7RSBFW?[91/7%&_ARC)&*4FLHC8*L]%T2S# ML]'5XBH^=Q L@MQ@UN@$UE_8$!H< +^_>^$-UU"B3B-:ESPH]B0-YR]]MLCG MEP :M#I/&KL7!Y^Z(S_YD3?-R'B9 :'$ZW1%1_ 4KXR8"/>S3--NYQ@_;2JI M3TT/Z,;_D*_R$6[MU,J7@5X.I?^M9 M1)-QD+QP2,'[3-[=L^,HW<&6-8#L '3:RPR-]LR1.6;G H>VG71;4[1-9S(F MIA;2>D"QPD%NK+),6PC_?N*W@=V+G+V=8+N9H.7&S(#W74,AZ7#.D=?(QP2C M^PR_FMQK^*G#(7^?%;DX^OHRI5@).X(VF.KD 'F MJ])'SEXXKS#%DFG"GIN]LRAV=2QNHJUY.$@?#BY*X]P," M*;+;-@T2JR!<1JNT;5.G 8>EGBR%=F61_0P]X^49=*.7W-=I78>YZ=Z ?^&_7_[E_CH=^O7'9^$E0HN^(?/I$2E)W_ M=5!\&W];=>-_4M0.]S_,>B\M8-)A7YQAZF3\].K,,X;FH3(;_H'1TE0('7]< M*XE:I0'X/C,P,SR0@OB+LU=_ 5!+ P04 " HB6%2?$I8P5X" !?!0 M&0 'AL+W=O!M4F0#RZR:6QYMC!OI#MVW-VTBR3V 2\Q+[S_7^^=MK< MV@H V5TME5T%%6)S%D4VKZ#F-M0-*%HIM:DYDFD.D6T,\,*+:ADE<7P:U5RH M8+WTOIU9+W6+4BC8&6;;NN;F?@-2=ZM@%AP=U^)0H7-$ZV7##W #^+79&;*B MD5*(&I056C$#Y2HXGYUM,A?O [X)Z.QDSEPE>ZUOG7%9K(+8)0026M1UX.8,JB%ZD=^-YS#1+"(GQ D@R#Q>?<;^2PO./+U MTNB.&1=--#?QI7HU)2>4^RDW:&A5D [7GS4"V_%[OI>PC)"(SA_E@WK3JY,G MU+.$76F%E64?5 '%8T!$J8SY),=\-LFSQ O(0Y;.3E@2)_$SO'2L+_6\])_K M>X3+1ESF<=E_'M=?J&>SD$TQ[%*Q7"LU7--.8,6P KJO/UMAA7?JDFVO?WS9 M7>Q._-I6UPU7]XQ;:B8H&%=,* 0#%EEI %BK+.2MH27EMFJ&K8CSZL4B/ M9V%,UTE*1W_],@O?':TWU&K'<*$8=IH&BUQ*:D6T$T0(.#Q]0*!F>_ @ M43@*_DC:1:FSTH7X9_^7#2Y]#68@V]M2T?9*NSO_^@=7X_SOFD> MPONGYXJ; Q7)))0DC<.W\X"9OIU[ W7C6VBOD1K23RMZ <&X %HO-9WR8+@- MQC=U_1M02P,$% @ *(EA4D#G1/*(!0 91 !D !X;"]W;W)K&ULM5A9;]LX$/XK V]VT0**K<-G-PF0I%ML@>V!M-VB MC[1$640E426I.ME?OS.D+CMQ6A?MBR6.YOAF. ?ILZU4GW7&N8';(B_U^2@S MIGHVF>@XXP738UGQ$K^D4A7,X%)M)KI2G"56J,@GH>_/)P43Y>CBS-+>JHLS M69M@R>'8U)7[+\*_@6SUX!_)D+>5G6KQ,SD<^ >(YCPUI8/CXRJ]Y MGI,BA/&ET3GJ3)+@\+W5_L+ZCKZLF>;7,O\H$I.=CY8C2'C*ZMSM-((3)6W*.Z/PJT Y<_$/1Y?TV<2@+J),XD;NRLF%!^2" M$%[)TF0:_BH3GNPJF""(#DG8(KD*']7XG,=CB (/0C_T']$7=9Y%5E]TA&<[ MBJ:=HJE5-#TZ1(_+O9:&0Q".P2F ]QF':UE4K+R#C&G PE+,B'(#K$P@%24K M8PZY8\9R@UBJ2B(+!YFF(D8J,<9<&2PVX%]J46%YF#%IUIUDQKYR+!9 B.!5962MP)3F^=W@-SND_9 RX*,PC83<0:BC/,Z04)% MA:1)E-\:CEA,M@.XP%(054[F2[YE.:"'0B;6<(K%Y]0#9W$VA@^8-\IJZ,#1 M(F6QR(41J-)I]BRY#9S0J!P]5SPA'!5#DM& CF"H"!Z%2V=,6?Q$QG#=@6&W MI$F4NE8VS!3)DLHZ!XH4>F/)L=38X^#2PL&,Y,4:0;99::5"/UAYP+3FAK#@ M)F'^0VV]V=O$+4<8)^%BY4U])WRR"#S?]ST4U!6W'2F_\^PG%L()Y9C)9:U2LGS[KE/RLYTZ$6Z*--$49WG05,L#8 MLIU X"VCV6"]F"WAQ3 X5N#;J"\+2IW_7+0Q((HZ^:E,3VO-VXW>EYG-[Y$" M'UYB(F'8#9;9[C9!+MBZS>L'!/=)T4&P\]YP$,%[:3"##T1GY0?#Z"SZU1LL M*875X(:ZFZ\N\["F!GGU"U/A$S4A.SO@75UATZ!6AKY<,YW!"VORY0#?_5JT MC!43B6T]K) UY7/3JQ*P<#D4Z$RMK/(^UP>;<=B1/OEBLI1:2*F2Q:!Q-Z&B M8,^7_G>([M4N[4HGY5+W.Z3Z/9TOCH[[S0/)+=VX_X!P^CO;NHSV%\>3T\BO:12]NND%HIS"\QUES/.BN^,;S M9H9] WTX7NTQ_K 'SX6.*;?AAD;;#T/O&M=X!K\?@MTS39&I\[$V6$)T^A1% M731)@9.WL!/$3;Y2EJRS+^IF00[J1*@)>H M8X+UT%UF,KCZ%5QM[ 57@^T8[A;84;L[]*6[.O;L[@+^BJD-'I 1?XJB_G@Q M&[FC4+LPLK(7R;4T>"VUKQEG6/W$@-]3B3>>9D$&NG\6+OX'4$L#!!0 ( M "B)85)Y[SN!-04 "D- 9 >&PO=V]R:W-H965T.K1 YF>Z=FT2H$G;K=A:!,VZ?::E:YL(1:HD9=?[]3N7 ME&2Y38H._9!8I"X/S[DO4F<[YV_#ACG2I\K8<#[:Q%@_FTQ"L>%*A;&KV>+- MROE*10S]>A)JSZI,BRHSF4^GOTPJI>WHXBS-7?N+,]=$HRU?>PI-52F_OV3C M=N>CV:B;>*_7FR@3DXNS6JWYAN.'^MIC-.E12EVQ#=I9\KPZ'[V8/;L\%?MD M\+?F71@\DRA9.G[W[G5\UCP"F="^D^[;#M?C*AH0G15 MNQ@,*FWSK_K4^F&PX.GTG@7S=L$\\O*IJX_;,=,F65SK2M5$VG$TBL,5B4K0XEQEG?@_.;$YOG8V; M0*]LR>4QP 2D>F;SCMGE_*N(+[D8TV)V0O/I?/H5O$6O=)'P%M^A] CXM <^ M3<"GW^W"K^.\[?5)0=28O#P]E$V M>?C3#T_G\^ES&:3'V?-'%%UGCGJ*VC.J*Y*R)6E;8-9&96B9-PV$BB?7>&*C MUWIIF#Z,;\:I!$KBEF(XL U(RST52 *OEPVD-+5L.)M.'Y!;4=RP'F 5H(_2 M5E*:)V1TI2-@8:\DNW755.!E&_ IG3'*DZI< [(!?:IFKUVI"V7,GI9[@:8W M-K*W,'_/6[8-TPW[K2YX?.0L5#&Z6NCI'^B"1NBV$N'M8]9PX 0AIP^$ .T9 MK^4!?\'9,;TP)N-KN_X,=\LADJXJ+K6*;/9C>MEX,1/F @1&4C6$G.=J"= N M[U-PYM/9KR>TDZ 5;FWUOQ* 3^(^%D(_3L<+M 9C4I>#/2;FW<0)%H6:4^\S M>QD9U7KZ;K)C>N?LSRG4]^3AJRZ&?1(@36*0K!(]:>D:*WR*#S@S]AXF7)]A M#41[VBJ$LPG22U$19?>:ZK2;".K>#(FVKW,Z-C4F5NCP#JX,3;$A%5K'PD$A MIT*"&D3^D(!DD#1&DP4%$RTJM*)+0<)87SI;+ W.FX(>.0BQ2B MB@T8B.:/32LVY 3LMQV* X<0LT*C5=I6PYD)TO-:^10F\>D]KO$\)(9*@ <: M>!-DMLHTJ@WHH4)S'?;EL-NX! ));RQRDVKEHRYTC11).NT]Q!\*2MMA?O.0 M+0X;MAJDZT8C#'!BZXS$+SO*J%T2/6A=IJEJN1B P3[E"(1+U0Q;38[R(8]. M(%[%S8DT+U6K0L>VFZ!\LU-R<"$Z8^3D2PF#:9%PJ(U^&U$P>_(<::30 /:) MJ)A&=!7/QV YMIUGOCF:1Q[[YB@>][%;<5MND,>]IMVC]UJKA];=IJM&R@#) MNC0:]X8R,_Q3KZ2)AL:GM+YROG:^]U_*CBZF"&'12!<)::<[6!QB#C9+!EWT MAK91=Q+$3Y6RN/B%+YV28FJ:4KJ3&/=X2 _I-=D;QWY$JJ7T3?4J(KG,9@Y" MUUE*;CA?Q@!KK63D2 M'QRRG)KT[+.NW0_E /H_1\.PQ4.S&QSC0_7?2??S0^8PO,-5][&[Z[XU&5Q? M*_;K=$D/\#$._'R3[6?[[X 7^?I[,,\?$6^57VO0-KS"TNGXR>,1^7PQSX/H MZG097KJ(JW5ZW.!;AKT8X/W*X1;6#F2#_NOHXC]02P,$% @ *(EA4JX9 MJ*%M!@ P@X !D !X;"]W;W)K&ULK5?; M5,[=\>"=.E\<,2$R5$=&D/B[IVLRAH% X_N N9B69,/#YQ']=?8=OE0RT+4S M7[6*[?GB^4(H:F0R\;/;O:7!GV>,5SL3\J_8E;DG1PM1IQ!=-QB#0:=M^9)X--'[(KF9KD-.6DW(;/;YJV,6+ M:]=U.B+*,0AIE;AV-FJ[)5MK"F?KB"5XXKH>X*X*W.8G<,<;\1$(;1"OK"+U M&& -;A/!S4CP:O,DXDNJ5^+D>"DV1YNC)_!.)H=/,M[)?W?X$?[IA'^:\4__ MKX ^#??)11+'IROQ)*YX+6MM=-SG3Z^^)]WS3/&!(-@@OI(P_"3NI=HZP(>4M^;O:A;5+6H@40^+$6E'?3H4:M+2-"F!B65 M/$@LLY&G0-+7;1XHND?!%Q9-(<<\ ?>%K*40""#7TFCT%:OE4GQ" ;_',K1? MBM@2QOCU!EA8^0L]2/R](70?GOQ1,X:+>+QNM<7?C?,Q;>$(+_[:2UN32)"@ M%^A?\!0L2PS"2GQIP72(B-QZHA+5&A$M_OK\SPU0)4,*F#8!VK,SVM:^1'77 M:G;6 Z2N74*0E( W@GN-"-%+;@B_<4*Y;V@L_ Y?E-+#K8(UJXCGB$K M0YQHSB)4@.F ! =T+YD[<;47T""'2MJ]X&CBI>-TPT8B 3(%J /?4Y^#"1U" MZ8S).?)HD@-)%$4/C#P7J'G%["'BP_A;Y]2PP$I\0."WA0$4,-I"R?N1O 1] MCR)"H'KO5*JC,+/1X)+ES<" 28)8F4B5@F9%KQ[!0A,^47&3MU!1&ZF[D+<0 MQ1KAT+6:"TK7P$.VR6MBW7)TY;W49HAD2$7/M;LGKKX5Y]:#LL<\5&XHVBW= M8(]4$:,+'=B+*H,@KI'G:EF5/M%*4"&>:.OD?1:YRO[)CK6<$ P<3 JMT@&='8%D:$6#X]A0A%GUNDY&>L$B=(I;E:+.EJ;--F^2 MA/.1,#Q4.82Q06(Q&93WV!C="*;1C&)6DSJTSRD+1RHQ[OM:*I2QF-W;!FI+G*L,-9?9W)=Y.7< ,F]]A>)E-KM39 MTN9(3'6[GY=DNC%O;\/L' /XF'%QX'4>FK-NZ@3L4+' MALB[7Z;+I0D%!F>TRCQQL,B-*Q]/?^B/HX@JU[3K1NB9A* M_I'PGA OG^_&UT$@7"A\B$I$7?166E\S=[;I#+#ZMZ/O^N!>T9'?YML3;S9H MA^6*,;V=+FB7Y5XR3R^WNX\2)S?+$6I@>K3ZX]E"^')C*H/H^GQ+08O&G2<_ MMKADDN<)^-XXU-DPX 6F:^O%WU!+ P04 " HB6%2P)G,\W\. N*P M&0 'AL+W=OC(?#\Y-,ZOSHW1M^=F/?O3%5F>IS0ZJA]\U8ME M20].WKTIY$+=JO+7XL;BUTE#)=&9RITVN;!J_O;H9 M=.K:I+_II%R^/9H>B43-99667\WZ)Q7TF1"]V*2._R_6?NT8'./*E28+F_$[ MT[G_5]X'.W0V3(=[-HS#AC'+[1FQE.]E*=^]L68M+*T&-?J#5>7=$$[G="BW MI<5;C7WEN]O2Q'=+DR;*NG^+#[]7NMR\.2E!F=Z?Q('*E:"!.1Y$8#\?# _1.&SU/F=[IG]:S1_:L M(7O&9,_^HOD.4_FO*94830:B2^Y?_YB.1Q>O U%Q695+8_4?*O&KQ+>E$MB MQ,%N%*RF*)8$(D%E,YQ)'0WX?S0]?_G(ROKU/CR#K(S8H?C5X_CYA4';HD M8:K8E1!"7HZBD<.;)1<:KN5*?K12")R4[3-'1$+-^5RGFKV1EU-BZ"CW'VNJ M @HAGQZC6G Y7*ET$W4602:HZ[0K25A0/M;/M]T?3Z7(U3K==/W_;##\)WFP M5H^$0-1)!-N)1AP'%(XF2<)W WK6LA:AJX(] C'*!<+JQ9\Q)6-D;551Y?Q M16?+H)??"ZF3[ID^&[4KR MKLDAO(BMZW=.+T -MR4?>T7@1_L3O=()TKNP!'6]J<.?58%M1'%ET@H'CL," M3V2MYF>JD383Z=-F@F2.-R&'6G#*^PA/9\ KQAB2?YYJ6L87F#T(K0G_N3A<2UWT]^1P7SY\5:JTT238+<#$(BB56(T01T+BSK6X\T#\<4[=U/J M0Z77 <>QQ)ZK0M+AZ'Q I5,]UO#$5#G21WK*?=Q#3PALVW1#&O2$QN%%E/)E M2!]]ETB )"S:1,YF/G4'?A+0-5=SS1FU(]O<^ZK@^,6.Q"?X.#:6#H1P0I@PX3 A,>AXN]'453>4[QV>VF1S3?AA3F'D M^QD)<=6+4F=8F)O\12P=^K2M0ZI/9RL:]ZH3R@/+C+6U//"TQ./*D$>IZ/EN[& VT/E^5K6G]#RV MMOW6C,$?CJ)4Y>U6YYGU4AUB0S;J3VV8'S]2),N%K" M]2."I^?&X>"T;0"^$)"8V8J@PH2ICA[D8H63) YK2:C"^US+@>HF+,@>T>D> M/J)]_@,-&LP OI\'-P/>V%GQC3J'&.)^*0ICRRI'B-*T M[$^<>BT^OF^W MAHQ#HG2;'*CTH(<\&+?'MVCL_31L"CCW524J\\BF1E_4F/X&7 H70M?@9XX[ M<12@)$+CQ]AWFLNF!(W&DP88;#5MW)45:46AM&D C",/=MS\I[%C7V-7CLJB:.9Q7U* '4.WU_<#GUS"W^^S'5AW^#ZJSL M7FT?D_ZO"#_\.X3_M>#6+S0=% R=+37P&Z+>J@#):G769'/3%O3_5VI74J22\ R$*N0G8M'_NG#SS_M3"]0KIL7S> M[,[DO#H9:JN5,IX1?\2,@V9BN'7QJH%#S0(\!3('V)APAP W) M#$=84%#F;+1ZPD:H\&PZ!"KT>:G2;DG//P=N) ]CAW %U9^:.;.E00.,B\J# MZYB33(UT(N>EHHB(6'),KKSYZ8, MX#3G)LP/^5N[]ML'@7+8>)E#'01YF6Z<=H\W;G_&K @@9/M"\LDWX+V!S7[. MY?"4+/8$.X? H;YHQX3C$7;:/=)W]4RU:T2^RRR]^0*!!?"F\K:+/;;JC,;A M/%HG',#1GY?M8#HHZN??=+,$,)^7CQ<3Y,YZ;ZQM7&4T)*1I*#HZB]AK1G,N M5NC\M'%!W7;^4EBSTMQUK$V54D42);#(0G'4?3=L58_B!2'[!<[?R@ZVQ]-; M'I9\;=/\C34+*S.ZCJMG;_XN<=?P^JJ^ 7S?W@"V]^ RC&)Z1<13[U[8/63> M7.O4Q'ARK+I5K'>+%))FUW1CJ_1KS=I6,0GN;UMN(9QOBG7DUB]\6)']9$X*(Y \U<<>IJ/N" PT\ M'W37@P=?/_3A4 ='U751NX8R+$U>% 9 \._%+GRN4$EYX4\V@@/@2+I2H M,_6UU60*8%)Y.?3%%9CZ+3D?\A44']]% OVMMKVUXW[T+ M)P4<$#MI3M.2,LRZ&J;:8@";<9C7 T-O2= MVY99'DQ/Z:+W8C $4IEQ-81G)U7,VO54I>D41U 82F09#$5^V+.@]WLE)N<] MPQ^R:3.0#W+7W^:H>V5C[5HDZA.MMO6%#*'7!MPWD\Y]%]![6?;.L>_\S1!H M^^9RZY;U?#J8;J4?.MO:YA[L_ZA=?=RCD&?^FZ":6G,;6Z/A,&H/0F]]#O-5 MT5<9-+H$J/M8<;VK/Y&AB2CWO0\^@NGK-^JJM^\;DSIT6"2^LFP.D'H1/ZBN M\5N8[_>OTKJC]7"QBLP3AJD[RFO(EM3A\ZVC>\6%9GCZ>N^_'_:*=!%-)L@7 MPTGWKA&K]O%M2)Y'9Q=GT>AT>^->;>J-9]%T1!.TL?AFROU^:[L'.*\"8*F_ M<1I-H^GI-#H[&]=T=WUX=]+YAC%3=L%?:E(>A-_YSQF;I\W'H)?^&\AVN?^2 M]!=I%P!(*#9S;!T.+B9'?BQ2_RA-P5]$SDQ9FHS_7"H)AZ<%>#\WL$+X00R: M3V3?_1]02P,$% @ *(EA4JQ#UH/E"P 6B< !D !X;"]W;W)K&UL[5IIC]M&$OTKC5EE,0-P.+R/^ !\)%D#F]BPO3;V M8XMLC0A3I-PD1]'^^GW5S:.I8SR.'2P"[ =[Q&9U=55UU:M#>KRKY:=F+43+ M?M^45?/D8MVVVQ]O;IIL+3:\L>NMJ/!F5[)A7LQ++PM;MB+(D1Q/C<\[P8CZ2-YN>!^\]*=^BRY(UX49 M%MC7/GW7UMFGZ^?0*V^[6NVG7# M?JIRD<\9W$"L439OD.VY=R_'ER*SF>]:S',\YQY^_JBKK_CYWZ3KC'4PL@X4 MZ^ [F/%^3K_5K6!N9+-S+-E'+B6OVH9]%*S=;XN,E^6>%4W3";8;WK4UVW8R M6V,[:]9,-VW+9$B%GJZ+B5594MZP% MQX;K(*HEZ,&BJOJHVA7MFC5"WA49CI "5R\A\'+/MB7/!,*W90AN$HE7.>UL M$"\DHLV>#5! )_:2ZS M6E*(!%K5)7"C^9']_6^)Y_B/_F=_/ZKX%OGU=]CY M[$Y(&.4/RW*X_ZT@^*6[&BEN;Z6XY>WQ&;]UFZ609/%AY:??A.E^/:*RP5@.)L7'FGO>J-Q,W?J ?V7L@-N_RWX+*Y8A]X"8>\=*_8ZZYM M<.7Y(*#K/6*(;:$$T?'M)LRSG""U0C\83UBPP';\203R\'SD8"IF/@_JY#C; M)'S1Q'\>%(5XOMUD6VQB$-6P2XM(1M M\5JAL=E*!*SCO$3",D#,_Q<0X6X-\SGJ/,(!])LP)A)Z98$);PE<)->M, MB%PQ6OAVC#JC++'U@4*ZZ6DAD]"*O.A/$C*8A'R%VB[/"^)CL?P;)';=V(HB M_RLESGBS+D73G!;=S,-N"'Q+SO&WV7MP:^L6J'OHXR9',2+#@:[-.1]2[JTP M2KDBP"T:K*=>+5QOLJ>%@&JV0A7+Y;XO0]CK+2FM2HXUOQ.H#O#?8)8,P4?/ MR/@5,C7)@Y[ Z[>^&M^_P7MV2:\IB#SGD:*B5?7L/KJRALWI@S:G)S>[[D,V M@^KDYI"]WE3%LD,9^[FC.N1^+N$!EP%)5$K[*D[) :=+E/;E< ]:O)Z8Z)J! M4+O-:$G#@N9CKZTI7G@L!7(Y(FW&7E_WDF"TZ0!?\#M=WHU*$KD*PE_Y7JWH M,Y5SK.L2]2 *N2W"]T[D\UTJKBGV.*%UMZ5@\:W8=RPW'L!-JV<(AL K2_@H M53P4D@)PG[6L@V%+ADJ8<40*8.*6H@4G=E210G8 LM"AY4"G3207UF%DM2<7A!=DDI;,T1XHSU=@IX%2Z0WGJ A[^AQE7,@SM?B%?++F MP&G/M3SDIAZ5^!TO2LKBZG967=NAL.O%U+8\..CEUZ(0\J(8KZ=/GSV\\/8@ M48/;9RI#80I(@Q* :_VYSNJ?NYJ8'*;KHS:GUN3J4):#AW:K%2_DA+""XWZT M)#TEP27*FV*C[K=G0MN)7)-TJEYXCE[GT_6[#/XNFNGJ=?-"!!Q>OM%*?K]6 M9F;BV<- H>RND-\H%^$VT*8L5JC.][I6']Z&MBY47?<1BVS?6/>,=8^]+9I/ MURLI5#6&:JMIF32;#/]0E.MF2(''8$*5V M0A2)9Q-%[-@1/:8I#ON!O41'F,.MV+X093Z=@E?T;WA^K^J'7K_^(I6:D_6I MJYQN=*F:Z_Y>FV*S!75!_B3:=9TCAE0XX_X& )[B!L% *ORGQS3>=V1]'&9& M!T7Q/ZR/?M[#\*YO#4)<.T[XM MSUS1W!;: MV66OLEM?$*QPSZ'KL16K29Y)D=.RA'$2=@OWHOQ#RF[?FUW$UW M/Q[?7\"!#=<%325HNF%N&BRG+FO.KQ=#GT[A+ZJF4SH;U:7I_?U!:L.U%D4! MG4UE3EX#GZDS:(NLV!*7+=_3U>2],S:#W(=%HHY\ZDF$QE&%H8JI%%E]6\%K M9H=FYG0GJV%Y*LQ (CFYQS6-B,A4,!B2J+Z!N:,,TZ(3_$CE"G!:--/I9/)R MW]]FW8SX#EP%HI4Z/$! A^#^5$EZ5N#A "E*%50$U5W?YO3TL)P>!.EC"M4\ MP:74Y:\.H/)2F;#N&EQU<_7]!S\TGM CRB]AY@MU%2MHABS;(12FUM2/7>/) MM0(4+.]0+T !B]TB)TN8C'R5YR@/"KI*5?@->]"K1]XT;O"M-(@@U"UN6JAT M2GMSG%O66V6Z$2B-48)K.>GQM&'!$BMU(U.\R J]:=O/?1#?WQ_MA.DOPR53 M\Y4:[4/>B:%,0>TC2B&5#PS>.14,8Q64"=E2Z58;$PD3,'1>5;,_3JT(W/&@ M P<\"\5]8-6/*F%Q1(/ZGH(*L$RBD@-LT8P>9E7UF2K!] $V>TU<:5)ODV.G4-TD"UJSLS6GJ6-:84]5A\6NGJZ$5A['E.]/PN;X?A-,FZ @R%06 EH7.DG"8],=*D#6$4SL:R$Z#^/+1A M[#).++2RQF 6A>$D\\,&LY$5Q31X<8_DBVTW^$,&\%S3 !,>QTD*>8\-X0%: MHK,.><) 28@+<^.)=V3'_M$&PU!AA!QD&!1"^NF)$X:!M^4D@4&=VN&Q? \; M&L=6& 8'GH5K\F!XV\Q"'E&EOK+/5PZ-0\J6ENMY!KO8#EQX<&J>@#P:1ZD5 MX(2QST%VHFS4=\['O"^[:B:%:T4ISC+2[(*NSPM8:IOG!XX5>;X5X:P_;SX] MH/H#QM/?.(Y^/ZO!6E6XZB2#_(^2K=+?_X^3SSXQD7GG+;R9UU5ZFXQ+[?V1 M6'_EW/30#//E$QXNPXEL]85\>.Y]G\ONRUM'R>U@S_A^_* 2V%D$H;5_JL'# M03J;;_O)\)DYQ<*U'5WRTBC"MYV8)6E@.0C/P([-D+6]<'QUL+SP[7XBHID$ M 4M\ FZ7OC0SJ(&ASOCJ8'D1#)!)3 ([]5@4)E;@QP=, OJV;GAUL+P([3Y; M$)/8CF)& !:EI(X)GJ +QE<'RXMX^#Z0F"1V%+(T>GA,LI=;[*)Z]DQ?:/IAK[E(3,G,SZN:R&PO=V]R:W-H965T8621U,MYS21QVF:F;3RQTTX_0B1D MH2$)%B C^_[ZVUV )"A2SF/:N;LOMD@"BWW^]D$^.RC]T>R%J-A=GA7F^61? M5>63\W.3[$7.S4R5HH G.Z5S7L&EOCTWI18\I4UY=A[-YZOSG,MB\N(9W;O2 M+YZINLID(:XT,W6>E?Q67(OJ0WFEX>J\ MI9+*7!1&JH)IL7L^>1D^>;7 ];3@5RD.QOO-4)*M4A_QXFWZ?#)'AD0FD@HI MR1N]'\WU+\GV4&6+3?BM<5?/-/JP#2N!FKX@T2EW<"<+- HUY6&IQ+V52_>%HG*!;OA=\(\ M.Z^ (MX_3]SN5W9W=&)W&+&?55'M#7M3I"+M$S@'5EI^HH:?5]&#%"]%,F-Q M&+!H'LT?H!>W\L5$+_YJ^7KD%BVY!9%;?*.Z'MR- ?;$E#P1SR<004;H3V+R MXA=5"1:N9\RGW5Q,,V7,&=L*"#_!2JT^20H'N&32+JEH_8$;QJM*RVU=B915 MBE5[ ":\,$VHZ!YD6^%;K5/N-%"C_""S:5 M!2Q7M8$[YNP)^^X?FV@>/_W+_O].;+P9LM$L(':(E0^%1/FN*UZ!U,WS1VP: M1\%F'9_YM\)-$$?A&8/PA> LVD=AO&Q_+\,!-Y;8.MX<$XO6\^[6S=ZWQW0K M"K&3U=G0,@DH7)K*,+4[LLG_KQ5>UUJ+HAKR\+U(A>:9I[@P]"[P5Q@]M>;K M[!'.V]^+<&"N>-6W$1*X416%9SF]70F7B1 M=%0O@FBSZ6P6A''DU)4Z>0;ZFBZC=7=0%+KU7^3>7HCX$C]BJ\X&7QPKJ=P! MBX!/6N7@Z[R"Z,E+0K3:8,A0 #EE&U!F72E]SS1JE9=E)BWT(6A^ 69RXX+1 M_.VQ];EX:J0$QIA3#\#Y*5$]G:\ ]7IJG\;!)EXWK@;T E9 ;0?@TQ!KZ+?6 M#X/YVK/_=!7.<;]*/I+ZP56LKWG>O-IX4+O8S"%?50)2VC 6CR/W^'ZT6;$K M ?55@9%L'4" /QL"/@4&U]W!L2_K-(Q69^Q&<^#/EGB),M7@@&6T.".+\MV/N))PK6^ M!PPY<)UZ.HW603A?^0EO' %0-'3Y* H6B_6#OHSE%O#LITLX//**+4^[P<5J MV;N.HG7?EIY3?KU3_:!4>I"97\% =KSHEX*(C]2^/E:[QS7H]H1*$"CC<"@& M(&Z(J1U $[!#;K,1^)@N@F@9#_>V.75HF-,6GJZ#13A"#!B)%L (NOMG2*$> MP)+]HCCRA'M7:\HT)^@ /%#/4V":@\A7L!Q+8Y7)E..]+<_(*^PLPE7-PZ(9 MRO_\[\O77X\9GCH6\<*[:K#^E&]ZU5>PV40][_]K+'(S@N0G+80<076D$2O M&/?LT7*V9CF$ @4M0 T"39V12=!X/__ZAN#G]?O?WUU=7C&>_%E#H641#;:\ M2RJ%FG1Y8,8NH05U)=R7=3S!:"X:JWWA8@RB^O*$H2\0G/$HFH7-C0"E*P7- MB++[&>FNV<[(V<3HR:D5JI_I#N3LL%V6L/*>-G?**P:Y!51O:JCQ9 &L.HJ" M)_O&^TE=,XJP,1YX9I0G:X^EOMU&=ML$I=$2_!8X,-6H*I55 0X#D7@O6"GQ M&ZRKG6N0*VB;\*BC,?76R%1R#5XV8R^KH=%[MF9[+,U=N8I:-53,#A772\K$ M!G0!6MW)'-9GZ,/KV:IO\]5\=C%N]( =]A*43O"_%;=H=86I%D1!%P V@=FZ M +0F+/LD 7_@$"@@,TSO@9UK?(-1+V:;SH+69N/FBK[%UU[S M3,+AA:3 @<@#\G@_%> DJLRQ3<' @' #JXWQ-Y\M^CXWG\4/X4QS>GM<1]X* M9@:2K1[P0SJ3)!R1Q".-@A>.K@4%3,0S]H'HV#L.@$:,-)W\\NZGR5E;@8[J M:3IY_QW/RZ>7L+!O5? O<"_ A3] %R@>)Y"HL#@F0Q0U_,MD+BO'6RW($0_@ MUF8O2]=W>4N,=>\<"S,0#IHZE="$"'Q<-].$.DOM[0;4=W55:Q$@4FKA8 NR MQ;5[:Q!OHD8)U.(6P-5[D+"HT8-2@KSP8K,B CRW*6V*RS%A1?.GN(A^AD_/ M:-%! $# ?P.,9[S!!=1<$Q+MR,*0?T ".I::]&=%)]9XKNJ"$!Z,0K2I$+.4D5)QB: M^26PPSL[[L@$9480KD[)X[',,:@001.G4>_0;?3UT 5P$7;HX)U@BG1< MUGJ(LAB[<,B#H7L@_1Q!9S&"ES4@D3X56$W:E!B%@&IY$X@[J:$ S#%,RNR^ M*=>Q;!2G9D/6O;@%HDKF[<*! K>V$J9!;4*(DJGB]C&>CX#R6-R)O*QHQ!DT M2:QP'G$DL2N8,%.D?T#IC-G&]$ <4G]Q[RL$?;'S*R_K4>B62G^M*=R V3/D MC'U?:_0?+!/A=NM@TK1>1X+Q/FOP^&,!Z@HP'ULL-S0NVPHT ?7"8$UT)1SY M /$&7C"==^>?D32,_>2F_\Y V7K79&L@*5KZ[4@!8&$Z?J^>I11T'![.=@ M5__"DAR .+70/=91$-8@9FK,(\J"*:RI$]\0(QT+\$X]"[17T+SZBZE8HOX$ ME2PLR4:?L.:4-J":<>GJP\TKTV1KLL#_SCL"9"WP1 1Y7%[KVO^+5>S/(S;L M!XVU6MO(4M!"]FU>G#D"OA=U+-MW)81"OE\>GWY\;=4K\)W#B&+#(%I')Q3]$H08&7P# MQ@I(!03_,L?>0%-EVY9J]D0'Q#MO3APXE.>['>(==M2"?N*+"M2(ICK]J@G/ M84^3RI12'>4IO(%GN0 GTA+6)1:R.]*6K)\R4R5LSL1T!NOQGO'>'#3&H]*F M\0S3?'W@J/S+# .OLRG"@$OHA;BK6!A!#8:?E,S8;Z)3"ASE7C!Q-P/7(N/N M4P>2#D.^%) 2FK<1W;N^9EY.))O]I\PBC]]D^?,4-[BDFITZ')KB"\V[0?ZI M]R#.%H.#D1WX;]].NJ,_.Q]MIVGMG RPZH!_,(,X"3MM^+1'^0LOD*)H+(?I MKY<8>@=W;C=Z;H\$ M\]BPI9('_$M!47_K$$C+6R2#%@2+U[KV;OLUXDO[$5ZWW'[*",Y(4YM,[&#K?+9>3IBVGP?:BTJ5]$G>5E65 MRNGG7G#@'Q? \YU257.!![3?:+[X#U!+ P04 " HB6%2 8V85SL% !V M# &0 'AL+W=O"\OEDAQ#N?, MY9 ^W1E[X[:('NXJI=W98.M]_68TGYK&*ZEQ8<$U527L_1R5V9T-LL%^XK/<;#U/C,Y/ M:['!)?JO]<+2:-2AE+)"[:318'%]-GB7O9F?\/JPX)O$G>N] S-9&7/#@]_+ MLT'*#J'"PC."H,? [;A2\?"^\.#^U9@>65Q,:OP2JP9JX/: MPX=;^CT=>4+E;Z.B19A'A/P)A"R'3T;[K8,/NL3R(<"(W.E\RO<^S?.CB.^Q M2&"<#2%/\_0(WKCC. YXXW_)T1W!/.DP3P+FR?_#C#2/0_QA/$(V2^ G+/@H M=$,MP@'(8-&LE"S@>KU&*_4&KO7A^R0$B4+EMP@7IJJ%OH>"G@H]EB T-)04 MN[/2>]101RBSAS)K.!F.)]-A.GD-;BLL.IZ3Y *!5-0U5(#%30)?"+[]OD.+ M()UK GX)SJB2@*UK!!'PYL&FO(G86,2*V96"G3J0VSN_N@](@C;<])D,@3S@ ML=$(6UHR#.L^D0;1)DLOM,)[>"ZJ^BV9)'!U=3&$CQC8D:=AN/PVARMDNC<\ M$0"^SI>PQ*)A!_?KA".-(5USY*A@I0B1*-!Z4K8#(;0.A ?Q4RAK*PN$&FV, M$QL_FTZ3E$BND,0322O*I@@1>1">4KK"-)QU=HW#3L$EP7(/HBYUH9H283*= M#;-9UDT?R0,'KN_W\U]F>?;J+> =VD(Z2J*&=:,4NTIKI053!Z4D6\(IMB1V M(,I2\J10O?KHU\;36S[(?22SKU"+!5*(2]!T[-36%(AE0!8UC>XDJ2VJ>WB6 M3U\GKTCVE&*_UM94L1SV01=K(O:? QO&Z'S8ICR@X1T==8XHUN)>K!1R7?:J M,8&Y$L4-L=8\IV\IINP6]>,EKFRHZ4?[L6,K8"?HQ;8.=0C:>"Z>P*^WQR7% M[B^$!86=PGN5+))@V%OQA0^U@G)S7=?&^D;'@KZD.$!(=_86+M]'4TI/W-)S MAXH-969#_#GJDW28IFDOP3WOVZIQU#"AJ2Y@0><C M:R%+ZI=;6:(N8W](MR\7R:T@-;$^7B!]51A2#UFX%8I8/TM)!;.#(\,HH+UJ MB-K)/H]GR32;Y(?%43=(/S>&6_1@- 36^7"G8^TFXY^;D)RERQFQE+K+@FC# M\V,/9,-QE@]GTWXM7$1&R\,9R$(>/7GD-/SA$"2=K:*@AL8F0^F\W:?*<+!+ MEIAE>T$]>2%>OLA?'@JD.Z#>%3ZX^'H\#@>5($4EX^2Q>\RH=Q>LT&["C9>3 M0TH8KX7=;'>I?A?ODH?E\4;^2=B-I)Y2N";3-'DU&<1>W ^\JB*TPYX@^ZOQOG?4$L#!!0 ( "B)85)^L;X7,04 ,D. M 9 >&PO=V]R:W-H965TOV!I MM?5JRUT2H.G;.JQ%U[0;]I&1:(NH1+HD%*=><^] M\(Z\.U\K_=E4G%NZ:VII+D:5M:NGDXDI*MXP,U8K+O'/0NF&69!Z.3$KS5GI MA9IZ$H?A=-(P(4>7YY[W7E^>J];60O+WFDS;-$QOKGBMUA>C:+1C?!#+RCK& MY/)\Q9;\FMM/J_<:U&2/4HJ&2R.4),T7%Z-GT=.KU.WW&_X0?&UZ:W*>W"CU MV1%ORHM1Z SB-2^L0V#XW/+GO*X=$,SXLL4<[54ZP?YZA_[*^PY?;ICASU7] MIRAM=3'*1U3R!6MK^T&M?^%;?S*'5ZC:^%]:=WOC;$1%:ZQJML*PH!&R^[*[ M;1QZ GEX1"#>"L3>[DZ1M_(%L^SR7*LU:;<;:&[A7?72,$Y(=RC75N-? 3E[ M^7O+M.6ZWM K(9DL!*O) 9U/+-#=GDFQ1;KJD.(C2%%,;Y6TE:&7LN3E$& " ML_:VQ3O;KN('$5_P8DQ)%% ,G>U\3C)?_*UP%TNH=./73Z'<+X,-([ M93E%\S$=@Z3'GR1K2V%Y>4;/=M5$:D%?]A*+O43I)(0A9FBA:I2@H<="DJU4 M:Y@LS=E3^O&'/ Z3G_^S[];1+FWVW+=,%Q5.GWYM):4?E464-+_ELN5FSWY$\V V2P=TDL][=!0%T2SN,=(\ M2*81O=;*&%2H7B+,]_]F09SE SJ*9SUZ&H19UH>?!_D\I=\R,WN'2KYT&9JT6-ZUE-S4GJZA0 M38,K$[=/\;E2=-\N&F),BGTYY:N$2F8IK_(P.>N.M7 M%(2TI5+4K>UE"]##<12='3"R T8\']HX[L?E__(]7@_1_*3PT7J8!M,LZ=%Y MD$Z']9'ER8".T_A8-21!FO6%TR!)\@$]'51'&LR3^&0QQ$&4#E,@#I(P'1XY M6-FP&/)9WLO)H70^.\#+XOP0+YT.LVJ>YM_,\9/Y&^9G)QC)84+WB^XETU+( M9:?R:U7>")0Z+$%UK3Q/($M6+E6D=:^&0MXPW+IX2VS%=^\) "&(+1!P#5!) MJ,RC^&C\C 4?EGA#MB!N:^!0T70IS0/DQ(:DLN[]<@7O]%F7>\:;X4A("U4: M *NU'-,;Z;D+U6I;[6%AJLMKAR?11*)=M"27UI(N8BS@Z69^SQ._L4+V F8>A/L3/Q*4>=?SWKL+)36Z&MQ:/@H M[6K]413$\0RO1NB$6%&@\T61N),Y88CW42K)FU6M-ISC2!VXPLFO*T5KG)D_ M*EZ+I7 7]"XF?26WW'CG6V23_U?H3C&*M>N_UTR79DP?(;@]$WA3(%!*P@]_ MXKAW!!H3D,*8%JC?_90Z_;M ;L,(1?;>JH?S;%T)5 @R'6V_KR!BH,JV&S*P M[=%LF@7A?.[6)R./DZS;LL/!J()F6_]2V"HY@N(AN,9QB+=#4X=8=7*#RLWRF+T\KK(./S75N7C^='1V>-55E2/?OB.OGO3_/!=W7=E4;DW3=+VJU76;)ZYLK[__M'L MD7[QMKBY[?"+QS]\M\YNW)7KWJ_?-/#IL6\E+U:N:HNZ2AJW_/[1Q>R;9_.G M^ (]\6OA[EOS=X)3N:[K#_CA9?[]HR,/DMPML[[LWM;W_W RH5-L;U&7 M+?TWN>=GGYP^2A9]V]4K>1E&L"HJ_C?[* MA7C@_FGAA+B_,:=S<$8WR>=9E M/WS7U/=)@T]#:_@'397>AL$5%>[*5=? KP6\U_UPQ;N1U,ODJKBIBF6QR*HN MN5@LZK[JBNHF>5.7Q:)P;;*G?^U_][B#KK&!QPOIYAEW,Y_H9C9/7M55=]LF M+ZK96W1 MXC*\:5SKJBY#HAF;Z!Y<S4 MC:M._P,"4%3*N5)AK?1-LU_:+K&SNAI/7N08. M!#QXZV!J34)CH+'*ZM6+1=_@PG6W60?NM[Q+8!3SQT&F>9&V"^UE7] NL9%8E\*=K8!]:V.UK8($PM&)Q"^_# M_L&"FXTN*F:H2!Q +]E=5I0T$AHJ?./NLK(GZFC<35]F#2SJ]8;V<'%;N*49 MK>M:UM\-+0' M?]#@8*$/:8,_T:&2SN7KYZ^4:G *T!/0#K[ZXJ-;]+2#KY? 8%QSF+Q?)TBW M)$UDI^?%77KFCL8.U#& M\[ZAQG>,G.8.ZR$$F=-.W#I:L79D*=M4M@)^Q7;-'F"C^)6?)0Y+=[0U6XK; MB>L%9Y_):)'UK2S1]LR1+GAP2,H9M@."3#M[]>L+ZN?R[7^_?O/\#9S+?_4P M4%J7P^1E10RLR*E1( 1XZT=/VT9V )^I\JS)V^19#?\@=?-MZDOGQXNJ9 M)YG1]R[KG&02=:.O75Q=ZEO _\]AO;YHKT0&<,/-IL852&&/0#[2*8=?[F_A2&P.ZGOD7&U_#5M7 M9 V(\M2_D5QM6F@=OOGYYTO^&L4(-Y020< A*.&8+& HX9"\O^(7B%JTK5^( M(Y?P'>S\X:\\$-MOL@>*"VEF=Z[0U MG-.%_DI_./,KL#'6*(!GK/")'$@=3F3+2P\"UX'8S9H/H,DO>UQX%CXHLU!= M+TJ2T'<.C@?R0EC1FGI)>=5 & %;ZPHFT*='29YMX,\F*9'G@(P%103XS&W6 M"@_&AI4+((,#]1>Z* L8LS!I4(7@&]B@W"'[W;419WXCSG:NWA5H ]W!.Y#\ M0)=WKNU64[OP)>W0%A3F,[!4W(-N VQSH7LKBRR!HX"K%5G'N!65(V!_LU/C5O4H*+_P>J)A[5>@P)"P)CT-CW'C;M&RNT,ZA,\NV<-V]D4M(=[&;P?E MR6M;V W818L/P-2 ]EJ1*K)3H+T.QB9'P*\=T;+.Y##Y#3^"ID&GP&N5HC2" M4L>#AD^@7#@80H/F$LAM)*G!!L'A\$HG\[1LA9P*>N,%0%TL6<"O14>#0S5I M:E='IV'&U[>JA+1KT") 2"9P%$%^>G&Y BY6/:RR3>(^=@Y&=NTV-?P#VY)L8.3PF70.'-7&<"S;*VP>,SFO M\@(-JGZ"VL4.+O'$@T*U021KC#Y_7 LEH-L2\QD.Z^ ,D M-3Z$RARR$3I'WL:")0*:;6A-4 $*CJ)= $FAQ86;05;;C=GVK7>X%YSCPZ=-HGEB M; T25B^C<1_7P G@0QZTZF < ED4=0ZGX6)!G):U5.3!:,R!:KB$L[ELZI5? M+M_3H35.O>;9&I CK'"D3J'Q0(HW$F9>]]?=LB^]TI': X^<:/1PI0E;*-Z. M4-F)9OK"J?Y./QOFX'5\8';7J+ZP:8!KM*"E[LE0I@.TA&'JR'&I;N"0H #" M":6TR1!N5-;5S4$) MO#P7"DK-9EC1!\^"U@&2C1000VTW=9W?%V69;OV.8\#5Q^;E(*R0-/ZP' Y5 MH&C3<"- O4%8ZQKHU+4+!S^E(B$.KDF' >[:-;WL%H@MI"TP\9QB%L-I=B/4 MA$(O=T"#A#) &V92NJV>$,(@4:<5OFI:-9:^M05;PPI21#$GSP$^TA2$O]"1 M&+RL2 ZK-8&[B'1L\@ 3\;'#3ZRN$#\'YHZ2^D,%9D1TN @697@G- OSO04M MJ6[(7D *!KT"-PC7Y@Z,@+IO1RB0\8\..BL+AYN!IX(TV+9F90IT+9+'< R* M!G0+8#H5F>4_\N% YH);&DX&/DL"J_-L"9A-Q,>T%YOE/,_8BG\U=E9<&$?QG.QICL_.I& M1UFS1=M3QM:$C@^/COX:&5V@#17 G_!U%'BD/\Z/YJ?)GC& K_BA M7_"A8 43$ ?*.0$$+'V0U<%I!\,:CFC$SMQ'A'T?.@,_ =LS3&N];NJ/0HU& MZ,$!?0ZKN;J&8Z@ /$T&CBH?$+,;%>J-;G3XL*.3 YSLW&B8# K 7I.,B]\0 M0[AA#A?0U1H$"JU;6ZS@.U \K\OB1@0QG5U2J+.5-8B!M>!*YSGA7P/TUDAO M,\P53 CFO1IC10]8^M8Y^C,YW77*G_I3_G0WY%##&E>=*-@,$Y$)\K9H/XR= M[Z]HSIQW>XJ)K:]KY,$LH-K^^G?47WL&(K>:%".IP2:5!8#J!/N*UK4P@W0; M)B&@:909P"Z24"Q63*GPKR#,J'2@FC[6XG2#(/5*DCPD3N' M:QXBYX+L^]1 M*Q#0_D>'8&D))X=0&V2&((*0]B_K!HW*".#\\?E+CW :$O$F/5O\0"]O&EA3 M]F^.M7/U\LUE8"%O_/HAUX"QUH(X?=8ZCI__>\<.G$\O!$R-6L>QQ6J$@-ZH M.]S4) R-$LV"NG5$5D4GZ"-L) )][-")J(A)![@Y63I@YJLO@=DE_DH[AVN MUL82[)D:!\E3Q>Z+*D:U4OW89-U0@62CB49BWR?=F%90V,G&OG8X )Q@(&6Q MV 2SD(^-A]WLB2HJ87(9"Y:%-<_K"MU%SLQ@9,@!B0H'BTS3=PUQ+V@!='+" M #OY!E3GQ0>$D'UWJ;@C6MD(=ON8*<$0S.#(3P:G'W4A&!XH?J[9Q>)F1\&/ M?;2;*Y&OW#6C"LM#WXW(\0;.)U(5GB< MK.X:IH_JHNIU"("CPIZ5\2D(SEM/!EE^QYZ@1D<#HC1'&<*TP#9/@:PU&-=D M E3N/HQCW")6$X?8,&'R1EDBA(JA!C["7B]>ENBUE<,I:W'C:EBT-= 5DE6F M7L800%CHA"V,G?.*%9!O/Z3K+&6YF_PZLJ<+!0A'9S0U8M=!N:JQ!(&T" M6_$TH+QP9'E:ZW&<4LV!8F%#;M$")>!MA:XIL+?6MQEH9@L'\@%ZPFV!%LOD MUF6P>#"('C:=D,DZ[VEA054#TPVQW ")E,426.J"B2K0[R'Y[>!0 FF(TPK' M@2AU+'J0RXT03N :K6U6R9%(C[4BV,P*-2R(QM3XUB%8)4RNAT_^&A-9BAT@]8Z,GS9%NZEJ62MAY=HE]UC?$T"= MK&HR8&')9T=_G6YY7*70$Q53(F+LPN.8>F%.KKBIS*2#.(/5EHB7_P/#S.M5 MFES!+OS!OLD4-,*,@"'CKX0GX-$,5 +X_A+V*Z.!O*SR(HM<_PAX \EB.-.. MP:?18;W-\@&#WAX]$D\P96 2?YD_'3*)TRDFH;2$*C-I27B@H]:.G^CVSZ"5 ML>WOZL[(D6C7/TE<\Q-HDUN?'Y[_-4)[\WCMQI<.M_N7*=IBT4B>)#"ID:9V M=?#IS=FI>9@(NME.[>&EH(W%N*/AX6\G]F]D<82GYPK EW"J&H;L6^:X>)S8 MD46GB$Q/9%(MA1"-^HJ61=-V!T65RE\8I>2MCI<_OO96ASJ/AF/B8"YHDS%" MX>=D4L, #U8@HS&:J!'HM>-9] -Y<@_Z(.Y8?<]M"('-XK6A%S B"KG BH;OH_GN-/!X$#ZQ@T=ZBWX[&=H!#:X>M M#7S>L 0@3LA*S'_OU3YB&(1'-UYSA7T:2H$7/VCBH(Z75@,5@-:*1]6P<; =ZK&1A8\<7D;8X3V4.VR@R MXRSD6&3G@DR0PA1EA!)8@@0T!F>*SL16L%V!LW0ICB M.J!0"F#5% 8BR+=*;$6+IQ9ZV\4)VEL)#$;0:QED W2) H@%,IPE5+_4E MF MKB*'&*U#H5P8<@)M,ILM-/HXCD#9\N\;KWZ]?&"DQBR$W<]V!\S_C-#_N.+T MD!8U'N*[8'6 5H$>3P:BT$YC1P.Z&"OTD!!IAT!O_K4A*@86A'X&U8W> MOGX? %G=!(UO&6,WU H['-"T9+=E23H.>[:-MLK]XMAYS^K!B*QC9'>OP9WA MV3TWX;$B,(SHR'IRH=^W5D%M; G% KJ %?#^?=42=@Q4(%&/?^Z:4\TP;$1U M@JXGE-J"X+UU%6V/;CW*Z<)(=[C"XG%.NZ0>,DHB2K-4W/BV=XM&7X@OQ)R_ M2+_1C?8Z,2GP+*N!RHM5OQKNKN>W@:28Q:]6"&;00:! 'M#;%L)_F(4S;+M@ MGQ4H,-=UTW 0O7K7#!L*/= T4Z!NDA_DE5OADX5XY8B];(=$'D9KA.BQZK9X MC@>36F4YG5D$G!R*<7D@FA5S_6$;!<$RQ.89;B"5OV_,^C >IMW7:^]8$$&! MVA"/6R)@^%6*(BPZF2 ')VS4\R\9)PCYE&7PWC,V(FQ'^!>GN?!.P1;/YAC* MBXE2&GI+>"+AQIY*ZA$N/:3$,0!-SDY>4X,8^85CY= 34.Q[#0]*;OH,P6_G M/$F+;"/E<(+V8DF"HFN@$X@QM$VBL4'B :)EK?M$QFY='?A]U[P;#A%EF&#P MHW>/%YW.?*?$"FD!L]VA_,\T2.O2!&F-"K O:"=Y1^A+G%Y!EI!$&=&L3#8& MR37)!LGU;.K!6I#RGV^']&'$S8#=%$T4K&6B_AB3"GWB=D&ODR%MR(P7;)-. MAS>.!^(-0QT#E"?1U815B:\ECB1C(HJ#\S0@-I.(]T'L&4S"KP!PIZPH;;R6 MZ(L]L9'@\!\.T< LUQLST\/D@N!Y]8<.ELL?@WC$%" VD$8*KE0MJ+F=&>' MNZ^A=!C77)0N0A][C=*ZQJ")'?&EM1A3!!A*T,<#*4K(QE +RQLXJ/<.#B,Y MA317D*).(U)'&QN!QB!NTE$])[8(BPI?(AN\KY0%2\J)FHH-Y>W)QH2$I]3J M829J0^"MX"HB?VJ_QJ9\N+-1N>/IQJCO!#;Q.0?5AZ9 2W@(T&Y%H;U%N<+M!&<)@=4]:)_^-!%U M402%PK"2MR &9!4$.QY?N[1L_WK,2-Z#(1I8=M HN_S:D0%%D5Y\UO A=DC( MVS 33T-;PFRW@DHE$'081 K] MY6Y5+"0X8MDYNX$I>0O9^9!8-=N=$?4RR)@+ M8DJC9_\SVTA>;DNNAG4TS)+.22YFG<1@8Z(8 G,('-?+[IX37NY<63-LQ9"Q M@AJ[A"(SDE>_ODA#!JOD)R*T%"M0@CJI_4&*)I]+]%\WSO&F62^SAVT)S\%6 M;HNU3B&ILI5[[&<#1$!R#J0Z%JA(!3O%2!IH+-49(C'X'E@.X']Z!20&J'V MJ-H I=?7*/F(C'E1%4?WZQIB?@1D0H?' S$\C'S>1O&6$LAYITZWFA+TT7RE M,7#XD(R O+>4GTFA/X*._8/JE!!4M[]I.5'3L2QS95@JA&MFZ7-VL[B^,3%@%:]0YW1"0#3CDD340) M!RHUQ*Q'L3AH[N_; A7U2,D9\&-#-(14D[CY+]9.P4HSJ$;3KN#5&B%[5<+#4*^=B8K%Q8YU,8+WNK2TI2(FAWUO36;*# O>AT%Z#N;P7/FUWQ M S'99L.-DC&$EC4UTBZ'";<-!&2\I2$]SGI+S28&2$O$X>26>2>S:55=M/8< M:I*/I*9$+N5A^)XWO4WR7AS&-ZI=CF;C_1DJ9\C2G>U.LGU-GK6?0_K@#L7S MBUI*7BX_8112!@"KYA,"@[92 V"W4AWQC"@ A NGM8C&3XR$0]"+L,U1) HZ M-BFX))>V7T7R*()%R3FQ@%ABQ5?7+A]>NU6CT$4+AD&HD2S01\@6+ MS6T]$N8\^" ; MR-JVEK^00?1_9A\!#-Z(\[3C5/2W/I4I^V/\#'\?P.V!V= M;E[@SZ/FD$HWVYWV]ESS0"4#!H:-D5CCY/QE327^AZ7_@:5J\ KR9W4_2_IY M)3DB'D9"]5N+"U$ KTTM4!<:JF/:#Y8]FNZ\M$;X5MNQ/NR9I;H\B(9\DV$@ M1G-F0YO+14C.EZC/6K="IC_APHZ=(PQ"*GAFY;_.!(=]B,6J&";@:7*TS7!= M--Z;>*YIZJ9!(4M(.(K&[<.PO<*[R##D>LUV9V>]9*W]7?9QPJO^\->GO3)B M&G3T5$C(I0C]UJ35/J0HU)]8#"IYG-5 MQM&#F"9.UH4-*$2PFA0&^%GL"NI9*)'-8A.I6)/;RY<2(5'N2.?7*)*Q4$74 MK&&\7:D*'1\*]EU\>E:H^%BUWL]D*P D'KVD@G->-ALC+"II3;Q#^3"Y&,MT MQ]9]W@89D(+.CPVY6(I#E?#>LOC@* (CBKR=X7*0@PIR@[F_ 2$V*:4U\?R MDR+DGED7^SU5[:3%\4FB#D=+8>%CG@<#/".8,2P8\Y )O+\2W7>J? GO)=> M=V_(ZST,)6]#VGX&$RW+T0U0GH2Z^:@*=;$?1&A7[L '!C2 M&*>'*6H@-F3;;L7?-LI!!&W($9#+)V96QR.Z\$G26M5M.X,HBWM3)K6Q>@1H MLNBOPT#L2%^DE0Q5W@9R=VP6O/8884*K(.)+6V<5$[Z[IX0ZKC9CW88$M9C@ M6@RW$XQ5N?T8*]?:$!23+5$*5*:1^A>N-! 7Y*1D3K:4;&'*(PN!4Y);%7+M MR>.42')UVQW,CV9/=KY,FTK9H:# L^6'#DW6A,XYGR+P_RRY*3#PDDQ!=FJQ M/<"5*"@P<&*,C'=._:YZ_[K@[-.Z"1X>]M0,8GJZGQ/BZ3&W!^;31,L2Y[/A1G+ :*NGA7W,8LY/T]8 MPLWH6&EH_"4<4?BW*D#H8OK8;=%JE(8ADT\T=W:8_*.^1UI/E?*U0@UR*8XE M*;/[5 \!H9=2#%FSO(D/TJ'16%/N5X^4LC-F\>/G$'\):55<7(4K I3E/*2 M!(69^(7@G8TQU>U>F,5J<_+X%J500!K':E(4!YH49A5Q.:(-0V5XFV8XMD\I M)2HXFOF)VO(3?LT$=Z3@DSDE$ 2 MCBU$?5M08C!U.AH6PO\2%TJKT'*I[H54=W"&S*)%_'L;YDNX.F4LXM)^8EFQ M>WJ6C0)+9)31=S2;HUPYINR\8_SS1 _\*7XZH]=\H;;7G2^72*W&A]%GP1/M MXC>CFS4<,J\=#[; .'9*.]HZ%529V+,#*L:L&9AH7(K3,;FX>D^_',SFD9&8 M[+VKU\4"K(/*!+*S+.\7)I. TZ8^4E%!BO12!8NB'\B#B,$G M/#;\S5CG;*EP82L1!OX@LA!>U7=!!G,U(8DI9]=[B!/V[D'&DYOL0"U&)*80 M$TCQLEW(F";60&"(U(TW1<@#]Z=%AN6F# 9ZNA9E&Y.)]DA'!W)>HZI/L"DU MY?)A2].51[' L*$'++WNP29R8G*$DM!WJO%X\'$5&*PF=M?08+*9T1+I",D-_H_P0"7N1C.*P^2Y*$;=H# ]H5%:.5^= M#8WKFEH3?U-0[G.N AI]3TJ+^:@#V%9_Z)8-UJ%NMD)""JI0/-NTP6I?5Z>0[5ALPF9D,*&QES# FJ[XI2$Z6D MO,"V*4+<*O-8/^MKHBA@6J-52(8(D3I&&"6J-E9) M];T_WKL&Q6A9=/OB8XSR@\+^HQ3!/(X^"BOVAA=G!&^F-F*@9G8BEC21CO#) M!Z%8D^#5:R/\'W[,#>NX0%D&NK,0V 4?!VAF%BZYN+B(:_+!%^&\F@UE#<_N M]N @M5XX97E."I[G-QP8PU5)R=*CZB6J-#;#7'JTI57R;=5K%4ZI(8HP6B)D MA%OE%TYKFBI>3+//?*UG4K'^V8.-,7]J5YB5<60>P3Q:9Q1OB;[8%2;'/,.! MGI_JK2@]<3?QNH>W1BP(/EQ($6J/8L>@?,[GM$:L:RM5O?T;* 3?/M?2*7V; MF0!5*NTG9Y[4!_O4H)3;7TY?[:O#GD?+>T9&DRD#4%1CI:'),AX51KMN/PKU MKN:[:U:]E1HH;QGAF+J5XO-;2=[Z\LPC==.1SIJZ)$W19*78ZEBIZ"=B&))$ MDSQ\U3:CY!8;O16*&5V+450J,H,;P^X+WDO4M;@L D66^=M9=$J-F5)TH8[Z M!AC;5B./6'W;N77[3;)7[ ]KJ8?"US#M14=Q3OJA336+2]?@6VABLHWH;A=3 M?C( ,]0JM0&-1+"TA\7"K1><3X)/W^U;A7OJ217.#QX&+N_>W7ZTH*'L"I,% M1:@CA#W:*$%!\%>+*N9A\L8\]-KT?-'Y7D-^;JH!7A+]K@KMULXC5UT5;>0! MYNV1HKR^;@WKUS@$D46[QJU[*/XK\@CD>%50Q8Q\58B^(Z?!!TUHI&1&8V7O M'8TTV<-$1M#*2J?1[*WYN46>4VN_FUU[%-*KX/OEAC6W')S/V.#+]],W4'OB0X=4P MQB],6+D2K#V#8H8U]6ORD*(;H=E$]6.MHI3Y;%L/IDEB(Z!(I?JT/7_L#H\J2HZ6[]K3&^DF5E-N.,DBWLKJ*BX8WDFUF[_X]UA\1!F'(./%%IK:2_8:TR'T MEOU!5F(.75P5Z)#5[SO*BI(>5R;@0^+JHW)CB#P4Q*:BBV+D;7Y L3=&L@HN MS>J?R9V:V#) +E@=3-0P :7I^8I:C3E&C A!&KB-'.T<)2LMF32 )Y68:G0 M$B[7U6VQ7BL8 )I07G+9FZZX*X:.K$G9-[J&'-^$]FY?+BDYKV_&91NS& U] M]A6!UGV#,5_^\-MK*=D=%ZYA%?\&KPX#KF='9SZ02S+35;PXG=6+JHO-6P2H56*/,EZ[1, MYN3M;Y/%5R;5=*D]2C',A&I+Z4]E7$9/#]E *&U\>B5(&,(>.:\4Q&:E6"^B M5X2SV[MBWXBTVCJ"R @QR*F:G>(HS^2N,X]XV)MNBNJN)IU-2^K7?-&HK[%:M.N^"^,( M@KYBO6^905_[.XAR.X)H:Y'"\972#9JLYMU(JJL(IVD&:1TV8E.(^3#Y-6LX M#>8RLLKSAAE*Q"*FW99+A@9@YQ MBT5K(^$[8>5MI_$KUC0MVF'('=[!A8V_& ;3;YWGG0:6.'0Y+@@H]SI<\!KO MCHUYT)29.^<-+*L7:,@;W3(6U 2?]=YMME)3=BQ\P=>'EG=VML1H)E[@'*R! M/>IW+!1QV4I#F%XL7%+6$4K,),;B_M6XR6?SIJTLX +D\:T,>Z$\8:@!)!Y\ MJ@+G\GV__:9^BX\=).1=>.\BO M\],?]+$QZ;E\EXJ/'FF=_F:*")+4J<2$ZZ"PM)O)<0"S])4GT,N,DX M* O'H#2H"E022*@J7_G0QZ>+[,"+SR=?!(;1'?F 3W)YAE>?P2BZ88CH+34 MN"X&N7\UZ S5R+[#01,);]:#JY#\/FY"S!!9VAZJ8G08HRXH! X(![%)LJ\U M+%+K>]-B^/7!$UN)W'+)U6)KH7=X?W$7YN[-)+X]5^SK8Y9UW8'\1H#^J= M+_K'!:$T[\*SYJB8GP#/48:8N9P\!#;:B.PV%!R1FE!2E/"^0 >3=<9[H1W& M9]-BVI"O:>H,.LW)P)M1,@,0C6!LV.( ]PVHY^'T2DG-\*_8G4N=FJ1VO>/C M)%E JJ;%R%N5FP! %:>4GZZ)0\'0FD:@!KJ;.)QY,)K,)04-QN^;LA?QQB:^ MJFV8/5OY8J3"ARBDCTQKZ"5CAD-[5/B\RMA MBN%"1HV.B"?5%APP, ;:90%S\Q#FP"7 IN4X@F.V\V?#7?9\>H;(S?WPW#!# MPPM3=DM@\IFI<6BRSXHJW)\Q7ADVNO#>#\'CVS +8'(C0JEM\K?_FCTY^?8A_[P;F[\I\R^LPL"KG^C,-DBQWWZ4=]FB[_$^ MHU93GLL>E%GX*G?WZD5<<%D'O.6D<>X/-+Q:OAV=E%QKLNY$M<<1O$FD;!/. MCT]\\S5[(TXK\I,-&[[1ZI;*/)*EKV$)QNPXW+$D-R4\4U*$-:J@L.T'&K9UPQ#NQ&2OB]J#WOZ& M^QBGY5VU-X10WBV7CA:=BRL"(Q@D,)>]!JK%(#!U!4T"@M[OK,ND:BW6>Q@# MZY%FUUP$GG4-G8L"/[RW]R(DF3NCPWXFU42O\KU(EQ\P!&\I]&(H8LX/@SU59X5:F&--:XU M2W)XX,()HZF.WO*.>?-W7/_T*L);?\/"-4 Z5XMZ[?P7_G:]U[]I+! J>;4O M*"OSEM+R29=]<)7:N:^8 7A9>J'C\\V^NKH(S6*\F43R!*SM33. WMM MG_HS]MSAS6&:S$X/\FP3T.[%9E&"EN5+_D^(567LSXM6;W3"?;!$CCE^[-4+ M('5*>0.(UBXDW"FDS=W6]\06Q)5$0!0F2+5&JDBU2G4E9VP),<8BU]Z%*AGA MIU#_+2KT2/$>YG;*@!;)C>@.(ZT:5U0AG3[RI0?;9;2501J\O]Z, -7 M@:PZW@_O_U(D/L4#KRS8HHSUX!IW6QNGT:@S"0HPMTX/YB(U6T.F!>VJ'7 ; MGW2JL/H[%2+"\7]N@E*RQV':?0O?M/O?4*[XT?&W?]J_4=?Z)0V!NG]6U'Q! MV>,W](]_Y"_)V5EZ_/3$?'%\E!X=SY,+OL#L'QP"J#\_2<]/SORGIT_/DG_0 MS69O[^9&T+7D$/(]WVYI^- MXO&E):VG)8'CAM*G*7SW/"*J9^=PF(!9PQ2IEM.#TL^DUY3MLDRSD=K_VP1\ M >(>)F?IXN1I>GIZ:KZ8GZ?G1[/D18\E^9G#O2IRC'9ZD4GRRL426TGV7KQZ M<;%ONDF/9V>&2D_GQ\#"BRQYDS',NG?QYN(RO =S4//9[/S+Z?>2P&=O5SV MR/UKPGL$DM9?@P/7UJB.ZEHN&TY6%WL@17@"S0S6)8.31B%-*S^0YXE9%NN( M:'F5Q%+1FXP%3U -C&X0\>V)EC0ETW7&BON.3EAQ[0?,U]]7OD/8S\ M:/7S*>?_<$UWQ@.'6^CFN^^1>V&L!QS_ER!Q$/KGVA"]^JSKK)) M=NU!N,YIOOL6I@M3F7"R]M/GMI'8;Y@^]4)TF ,5GDY-P TRW*+)#S#L:6.* MV:?&FX)A$3D0_XT+-#_@/K;4*;\Z7NMT[TK+DQ[O[R3D<"'0?/>]/E==O?AP MP&4_4/C"9F:3T>U?UM1T8:.6WF#G6KC8HI*J8\0BR(X;>1:CU$UT$HV%S\=T,8S<=V%:S>ZJ6-!8$07=:EMT^C1K1OJU3Y7QSHB&'+MJ VQP+O!Q_P)9H.85VJE M,%J_%LMU*&ZF.8^X$%L!";:(.$TRGN#@1NLQ)8]64P,43 )75+51+=DLJ7I- M.):L7)'5E/N-FKAZ^J-REGY);&]W-3)*E$LI7?I[@ AT2"MKJ(Z\?Y-@"W_Y M8ECCW7>JP/^73A@SC+FGR]H#W2@40S$FXS4V++5%^[8N,PG41)NZI_R?)9;S MYX@H8A2SLYV,(MS#,M]]?\H++J#VTE2N>RG9US7T5!V\@+VH-TX"$8B-DL3X M26/B5=D;92W_6YW3>UR<9\+DP'N.&- %,O'WOU!KV^']4?6R;%C6=OM*@#BZ MQ7O-ZF%1ZNTWI8"=K1S(V>_B\:0ZREH2"5/:*,*&QQ9 4GOG!O&EY==T+;&O M+<&17+\9E*R\Y@AK@_OIRF0-:(-T=#'IQT?_H4N>H35:_8(+G2WKV$?,V<[5 M]) PM&B!][?N95J6SKX?FM;Z=-SIO2W]3-DI%17'-@ 1"PQ*FEQEF)6#3RK? MSQ3Y>9B=!'LF(M6\64GT!8'N&4^=S)LH:FE M&R!F)CK67K(H($R*SP9T+HC!@IE\;\N !U.7+X#%9T8(( *FI&2(^1G.9_9O M@*O^FV"T%]LPVC9T]8N..6! >\?S].SI\;[]:G:>'A_/]Z$UJGJG&A:&VETY M*DYS&:TPD*D$C/#F#4>X=_PT/7DZWQ^=PFS^;?(F*_*#HCKX4%1?T=W>/#T_ M.=G?:MW/.NL8--'L,TN8H!=3UHI9AB>GZ='\Z>C*_+;[8%EJ.Q@YE\-U.#Y/ M3\_GZSS"/8L/7ERDLZ.3[>:NS1O M@P0H2%7I#)I[DI[/CM*CH[E_93C_V9-T?H04? P/'S^%AV=/=@GE<$O2?/<- M1S]*M:I+DO^+3?(NZ"_C9L17M)>\VEUKEAR:?:4%4Q?:A@1P1Q6UI+(35\[2 M)V,;D52QTB=O3-<1+KI0C2_NI-*Z>CF<+8JFZD+:OI0;KK32C*K@E0^('>I[ MAUIF2ZW;2DM8^K&26H91K<*+HMZ\(BH0HN(4H'AW8]*W4G* MG+^OFZMYAFQ#DQU&)"[<5(O8LU+)2_WI[D*$]>D@PGJ>/CTZ^FS_D8VZ)C6' M:R@JJ=QP1=8JUR(MS-LL$8(XJOGV6U("ZL[7=PMMQW05;C@.X+U@1"?E*:T:3H<-,!!&.AC5Z@*,?4H M0%T:8V-4X2,R&C8.SHI6-_KB&H?<3%S?$,;C'41Q@@0]U:BV1#>)^CDHK]!H +&>#Y9"_7\ N\/OH10:Q?"6E]9< U M.](-\L?9Z;HR>A)>SYUEFO'L8P^AKKY'$DN5!%FBN M ?O2&Y^E)N/PZ+6C56Q9]$S(I[ WDUO#:;7 #>%QK>^^4S1A=MAOTK\J-GZH M_WFBPZAI/VF?XN/$RTA_@:Y5W1Q-B;.B1\M$;HN"^='!T5D*KU]WPOSQ3R;C MRX!K!T'P>JV1)_UU1S+AY G6@MR74*2FN",=D!65?[@<]N1&FK[T@?.P=2_H M@/H%>GT/7[$#*#1]/CL].$&),]!9+4;UHDKK$P"77*C0C]8Z*#GE:*0/G[_.]6-%'+#/ M<:MZ4&Z6W%;U.4>J)UX"C8GYS,A+$M\W@N%YW37FCOE!- MRF5*8F>'<=[IO3E;K6+YC>JF=.;N&>OE(Q[M-9])MI&+=6NO6'\N,T3^=C%5]MLO@UR_IC6^ILN42^W@^'NUI4+F M#]+@!A$:RX-]MUJ4(( \>G-L4&U\,5W[HA3_>D =\DA!WLT59T9!Q@@=:D$8 MF3 JJ3]>!(/[>#[;3Y/)%UZ%6Q/_68. 2WZ%9XB&_?O'^^DN3NJ-@=DIL,7+ M$A23H(>_1)&IP.&UZ^X1*O(#2_V?Q]R%;^E0XQ^V3L6".M#"=T5HGY2?F"EW MBK!*T==*T@[QTMXX<,1<'DF:3MP.\X*H4+?HI;EWE$@M&;K2)*1C88=L(% 4 MLFR!/8:SKSR&1]: W6DWVV;_+)/X/^H841'JH]G9I)%YQD:MM62Q0#47?/Z9 M\6[H,EQ2:23YX2.@11@;-B67VRL)2A@RJ:_6J"*:HBOIR5DND&9 G20!T#X7 MUT;V\7M2DUJO[*H,0XS#M<@ N 8>AU*7,&>.>I%Z1L[G#&C"G,U7,]6O:2ZA MM \&8 KE=YLU.WULSIM?I>AV[@9OTPMU+]I!^#T>:Z-?2J8MJQ;TZ"_UW4Y8 MTN,L1\FCT3U+#@:;ZWG:V7[Z$'[&7.EG6+[P\OG)'/C<"W]BG^,*I8_$)@IU MZ&_M+;5:0:VNN%0'E;@?#&G?-&#)&47UNZ0VS5AX]-6+2TW4XO#Z*!$S M.IY9&Q!& #R6OC/2F#D38*I^8UR7K> ,6;FE 7S=(MX=6CPR>GC[BPLWX \PZ;3*[KKJM7].>M0S:*#\#OR[KN] -V@"@G M#>^'_P%02P,$% @ *(EA4D]-$D]L!0 90\ !D !X;"]W;W)K&ULM5=M;]LV$/XKA#<,,<#$>K?<)@&<+%OW(9O1="OV MD99.%A>)U$@J;O[]CI0MR[7KIFCV12_DO=\]O./E6JI'70(8\JFNA+X:E<8T M;R83G950,WTA&Q"X4TA5,X._:C71C0*6.Z:ZF@2>ETQJQL7H^M*M+=3UI6Q- MQ04L%-%M73/U? .57%^-_-%VX3U?E<8N3*XO&[:"!S!_-@N%?Y->2LYK$)I+ M01045Z.Y_^9F:ND=P5\>FO!JE(Y)#P=K*O)?K=[#Q)[;R M,EEI]R3K#:TW(EFKC:PWS&A!S47W9I\V<7@)0[!A")S=G2)GY<_,L.M+)==$ M66J49C^/")N7!*-SER&>N'[ID$%F0![X2O. 9$X;,LTRVPG"Q(@M9 M\8R#)F5< ML]5*P8JY(L45!4\@6B#+9\SS/Q(!)%N5P;&HGU;STP]IX(5OR6N],>90+T&Y MN&\7;?SQX<_(#9=-R1 HDX5[]20_DB2AX2P:+(0>]<* S 6O647> :M,V6]/ M:1HE_=]LEI!W;0^-DGGK8$SN(<=T"#BP,J)1G!RL!G3F1^2#-*AN$V ] ML&>:TF26# T,Z2P*3N0Z[G,=OSC7*Y KQ9H2:VMG!;6)EHJON#B6XM/2?\50 M"&)*9O !Y%;6#1//U@U_^E;O/&4*4+L Q0SDA LLNZ( !5CB.Z.0?(4UB!85 M>%9*I?&DSDK"K)Q56S%<>B9,Y):E0308Y\>6=LU-R:TM4L-6$D'T5*@/KPR2L_EB?KMC0$7!3G/BIZ^)JJ1'5?)B5 F<7"JI-6DP@AJ/ MGJ-'Y6EY'S!>7;9M5>K29MW&D-7V^->DU1UL,BS,UK6#0ZW[94+@4P:-&6SG MV)[_A^+YVQ7UW6%1'Q;2[UN;=QDY"P/,43@>+ODI#<-@C-*@1J$Y?^(Y@H9@ M>WK 2L04WV(@Q!.BEN- 0' 8Q+-$(2E.*]GC@85GX8Q&LV!\U 4_>(N5QO-S M+LX?N?@.=6QH M9#ZZ60\M8&@5CJY[HC3!V5<;+ );)^=V9D04,>=:U5JNS^,0IC1. QIA1SS8 M"FWGI$$:DYL#.4=J<&CLQ2S:L]Z[B./Q"?!->_!-7PZ^UM4;?FU\Q[*O6EN+ MA9*UPU"'F7Z\V1K_=MF(?LEU2-1A[:BL<)ERS>27CJ&T&2,T5G@$HP5U( MUJZUE5@!9 G8A'%.'WOR]\/\&V#]X& @&^-:[G8_IC,\V],T(2%-P@3; M0T(^,J68/<\^Q\@T#FG@^]\&N(1&TXCZ87P@[G; K4%P[+]"FD%OB&CJXPCH M!3W+Y_[[4QIX%H$A$H&SR$Z6Y!_6I_AYQW5Z<= M>7&ULY5KO;]LV$_Y7"&]X$0-J3%*_NR1 DG9;@:8- MVJPOAF$?&)FVB4JB1U)QLK_^/5*V),>V[+;INW7[$DOD\7AWO'OND923A50? M]8QS@^Z+O-2G@YDQ\^>CDF #%8#[\1T9NS Z.QDSJ;\ M/3>_S*\5W(T:+6-1\%(+62+%)Z>#<_+\@D1V@9/X(/A"=ZZ1=>56RH_VYM7X M=("M13SGF;$J&/S<\4N>YU83V/''4NF@V=,N[%ZOM/_HG =G;IGFES+_KQB; MV>D@&: QG[ J-^_DXF>^="BT^C*9:_<7+9:R>("R2AM9+!>#!84HZU]VOPS$ M(0OH<@%U=M<;.2M?,,/.3I1<(&6E09N]<*ZZU6"<*.VIO#<*9@6L,V?GV1^5 MT,)&2*.C&W:;^OG*GZR+J71Z)$9B8KS3WB,34(T'<'8E\ MCY(8O0$,RZ7N"A^1Q LC.NP.^; \':(+ID6&P$$T%GEECZ9P%!]OO6,Y+TZ9_XOE!!#F0R@46A0$Z%IQ9[;=14*(%#0DI4 4HJ9Y9R?JI3@$<8MHYL')6X/FA95MA9+( M1V]KT(/SRKEU4-FN^4Q.GE6:/U9+O"2,P#K#RJFP=C_>-O&H'Z*WSK1JC,"/.L,AJ4LC)L*9:4'S4< ![0,: MH9^D'"]$GK?'%7IA$&XXMBJ*'E!*&E!*#@8E5^MP0@)(DP6G"1,*08E4;E9L M))4K?QLK9MQ:!P$6T3JP8 \=YD 1UT84[O A;R=5#C&[@VA9 59(9<2?=9HL M4\,11\BX/]C2/6)P58.9):,S,>^ IY= MNR+D.-RAQ>HXGUJRC<=!8M]$X M.T7C3V!R0+CV\+@4*A=_$H^#![8PZ.%Q) F\-"7[B)P?)I]'Y"(/^]&7\C@_ M/9![@;<1WL^]_-1_S@7(8E3 M1H*=K"OQ2)P"Q-SQ'+ :)4*_SN0C8% M0/:3'8OA0;Z?NOGPM ^[?P9U6S6#P[F;[7%^T(=@[3MBXO>_@U,/\B<.CEXS M94JN-/KMRKW"[.5;[>MA$GP]5M>^1R3]+Q+_3ZRNWXA#C^\1W:HM 0*//>A, M3T&P]K"9P*-AW,--0H\F>/<+G"-*\:'=.74N;?9FXF&\R257,>A+B?:%,(G^ M?9VYW^4#.O.WX/E?WIF?J*.W?;N]6FO27[%COY'E,T?ZX?C85'&^A@# @5., M=G?M.$$WF^TU)+O7$$SW]7C?2_N:LT^WOQMI80M B>S:WZ<;7;6&L<-[:NAO M!9Y1YT,S.#=UG],U?ZANQ>OO_5=,346IX4EJ DOQ<0S] M1-6?T.L;(^?NL_6M-!!)=SGC$ =E!6!^(J59W=@-FG]D./L?4$L#!!0 ( M "B)85+U9N](" 4 % 4 9 >&PO=V]R:W-H965T\B7D M^&;.14853L6B+Y<":&R8,M9W;3OL9S3-.^.1H=V*\8@7BJ4YW HBBRRC8GT) MC*_..TYG0_B2+A*E"?WQ:$D7< ?J?GDK<-:OI<1I!KE,>4X$S,\[%\[99:37 MFP5?4UC)QIAH3Z:_HRY1*N.+L[S16R7EGT"$QS&G!U!>^^A,J?P(M;\:9-$^R*M>&7H?, M"JEX5C&C!5F:E__T>Q6'!L/ WL/@5@RNL;M49*R\IHJ.1X*OB-"K49H>&%<- M-QJ7YCHI=TK@VQ3YU/B*RL0B^DD^?"O21\H@5Y+0/"9W"1?J9 (B(Y_R1Y J M,Z^Z$SIE('NCOD+]6DI_5NFZ+'6Y>W0Y+KGAN4HD^9#'$#\5T$?#:^O=C?67 M[D&)US [)9YC$==V[0/RO#H:GI'G_:QH'-#IUSI]H]/?H_,.ZRPN&! ^)S.C M7S\)/-,OC7ZE]:?[])B_O3NU,RP:8N M"[$F.5=0(F*:,K:UP?4LSQ[N,+N.90]] M2#04=X^I(A)FA4A5"JW%?%C^!*N19NAF^@^6YXQ+99&%X%*2(L=L,D->X-8L M6^@,YU6>YS05Y-&4T%&6DNF:J/72K*ZH:T+5\TZ L%^! -TFRIXA?WE#./;_ MHH[:_38BC>&+C0=C74_^T!&N9Y_+N&ZF'W5LR_;45F:-WH2U$@T;!"=J=JJN M[_6>KM;%6)902\;:(?]#.C:$-XXV[/;_H^T%M.TV]7>Z?SNNJP>AAD#@]YZ^ MU,W]M3!KB&R@JU7TR]TVK+MM>'2W;=JE3^UX>,F)5%09Y.9*X'5 ;U=XKC_0 M?0_KFSPY"RD=F.IR@TF5Y5'IU5 _RM;V@Q>VVU\%^"V #10;*+O&WRI5"2K& MHQ!9 Q7-]N);]L!_2G 47.QN;RZYKF7CR:P:1,'Y;D6Z MY>;4TZEYX7)U6,O]7LDQ)A=Q9(JTNAT-B0!F<*"X.;SBKM8 2P(L;C]3U?ST MO]GMMK>IO_"24VWD F9\D1M7*]]T21B$8!1WW6EL ZX?-/>!KF.[/?(9)%Y8 M\A]7(#G;7;G1TM5XLGNM+CKN>[(_<:\V0^'V>DSRM@$8^,'S<+0AOM_XRI.! M6)AO6?IZ7N2J_.!34^O/91?E5Z+M\O);VPT5"^TE@SFRVJ<17C-$^?VJG"B^ M--^,IEPIGIEA C0&H1?@^SG'XT0UT0KJCXCC?P%02P,$% @ *(EA4M[. MEYJQ P U0L !D !X;"]W;W)K&ULW5;;;MLX M$/V5@5HL6L"U;HYCI[:!)&W1 AL@:-+VF9+&%A&*=$G*CO^^0TI6G)L; ]L^ M[(MYFSESYG!HS62M](TI$2W<5D*::5!:NSP)0Y.76#'35TN4=#)7NF*6EGH1 MFJ5&5GBG2H1)% W#BG$9S"9^[U+/)JJV@DN\U&#JJF)ZV_PG>/:[,S!99(I M=>,67XII$#E"*#"W#H'1L,)S%,(!$8V?+6;0A72.N_,M^B>?.^62,8/G2OS@ MA2VGP2B N>L%O:K6G_&-I\CAYM,#"HNFY'=MCKL M.(RB9QR2UB'QO)M GN4'9MELHM4:M+,F-#?QJ7IO(L>ENY0KJ^F4DY^=?6)< MPW"C++"X M#Q 2O8YCLN5XENQ%_(!Y']*X!TF41'OPTB[GU..EA^6\!WG0(0\\\N 9Y"MZ M,T4M$-0%RT: 9!ZYJ#>F3S06ES^>./A56U("_/V M!/YY-4JB]/U?'Y][J-OS?W&% N)V3-HQA6ME2=''5_N[>.?N5EQ%D4 NT.\S MIU>/&_IOTC?T+:EJ6U/<>4T5M#5X#7'<&^W$?NUGG1/=O=T _7K?GIBG'A>+RC;^([0_)0T63V(#H/ MQV_]JSY<:W^Q&Y#*XAW+).VET?C%+)\P;W0C R^@=?H#U9\<]<;#XY?756/^7U3_WFJ/>]%X\')6C\T;W<91[W@P M/E#L^TY/-03A3JM5H5[XAM+0)ZZ6MNFZNMVN9SUM6K4[\Z;AI2M=T,<0!,[) M->H?'P6@FR:R65BU](U;IBRU@7Y:4M^-VAG0^5R1@Z^=DO4$L#!!0 M ( "B)85*\$@\[9P( *X% 9 >&PO=V]R:W-H965T/932Z)A6-GMD/HMY_M MM"$,VCWL)?&=[WYW9_MNV@KYK$I$#:\5XVKFE5K7Y[ZOTA(KHDY$C=SLY$)6 M1!M1%KZJ)9+,.57,CX+@U*\(Y=Y\ZG3WL%,M'.O-#; M*I:T*+55^/-I30I\0/U8WTLC^3TEHQ5R104'B?G,NPS/%XFU=P:_*+9JL 9; MR4J(9RO<9C,OL DAPU1; C&_%[Q"QBS(I/%[P_3ZD-9QN-[2;USMII8547@E MV!/-=#GSSCS(,"<-TTO1_L!-/6/+2P53[@MM9QL''J2-TJ+:.)L,*LJ[/WG= MG,/ X6R70[1QB%S>72"7Y3719#Z5H@5IK0W-+ERISMLD1[F]E WR34I]7 MM,UK$>TE7F-Z G$X@BB(@CV\N*\S=KSXWW7NH24]+7&T9 ?MP?1&UC $D<.C MIHSJ-6PCK#\[OOVXX26DPCQXI2U9EPBY8*9O*"_@D'*C$8TB/%-'Y_#URUD4 MQ!?__34']=2I*C41WHT^33',+J &\JI>>,9%$)D;Z[1:'+Z%B8,/P(.( Q&XW@\ M4"23Y+,7X ]ZJ$)9N$EAKZ/ANFNG7ML/H\NN!]_,NTEV1V1!N0*&N7$-3B9C M#V0W'3I!B]IUY$IHT]]N69J!BM(:F/U<"+T5;(!^1,__ %!+ P04 " H MB6%2*'Q1V$@# #;!P &0 'AL+W=O)"_M?OU1=N*X M35O@L"^62/%Y2(H6N=Q)=:\K1 ,/M6CTRJF,:2\]3V<5UDQ?R!8;.BFDJIDA M496>;A6RO ?5P@M]?^;5C#?.>MGK;M5Z*3LC>(.W"G17UTP];E#(W>MFR$N_0_-/>*I*\D27G-3::RP84%BOG4W"YB:U];_ OQYV>[,%F MLI7RW@I_YRO'MP&AP,Q8!D;++[Q"(2P1A?%SS^F,+BUPNC^P7_>Y4RY;IO%* MBA\\-]7*63B08\$Z8;[)W5^XSR>Q?)D4NO_";K"-0P>R3AM9[\$40', M^E91?95Y!-;D\.5GQUNZ<0-GW]E6H#Y?>H:<6%,OVQ-N!L+P%<(@A!O9F$K# MER;'_"F!1]&-(8:'$#?AFXR?,;N *' A]$/_#;YH3#GJ^:+_E?(;Q/%('/?$ M\2O$=_1B\DX@R +:O1,76L'H0JTO?-G7< =O4S^)>>2!3-+KT,8Z-!5"(04] M,MZ4<,8;TLA.D[T^OX0/[Q:A'WW\XY5J@?4655^/)\)S2UNLB1"D<*4>98D- MST!7O*5T=)]-3K\M"%F65G$ O(?$G87)1([=,)W!M4+\/34\K+$;SZ,3;>3& M00S7G6JXZ13V_@K^8/='BM"=A_.CE 9P)>NV,X< M2S,CA'Z8!*X\2P=I5D\ M@QN6550Q];P^(R)PTW0Q(?#3"+ZK+KL?7+#.R!=RBN:G&I_RK@FC\@ MI:,U4D3T#U)\&>JCVX7KS_UI>?S3%./$3>*C.DC<./(I:Z)A6=;5G6"&G.1( M4RCC;&CN]A)KJ0S_/2@.Z#.")T%P?E1$=#_S\Q.O[R'R73^:3114M444O=08 MO$G#K5&5_5C1]!R[Q@R]=]2.D^O3T+"/YL/8NV&JY(T&@05!_8MYXH :1LD@ M&-GV[7LK#0V#?EO1]$5E#>B\D-(&UL[5A+;]LX M$/XKA+=8M("V%JF'[38)D*2/[2&-D61;],A(8UN(1+HD53?[ZW=(V9)<*D:V M[:*7O9CBTCS:"/5G5X!&/*U*H4^'JV,6;\8CW6V@HKKYW(- E<64E7< MX%0MQWJM@.=N4U6.61BFXXH78G1RY&AS=7(D:U,6 N:*Z+JJN+H_@U)NCD=T MM"-<%_LY%U^/ JM0E!"9BP"Q^$+G$-96B!4X_,6<]2*M!O[WSOT-\YV MM.66:SB7Y<U&Y0IA M@W)M%*X6N,^P">,G(AA5EI\EKDD.\#C%'75F&V4_B,'41\!=ES$M& L)"% M!_"BU@&1PXL>XP#/] ,"XE9 [ 3$#PBXQCK*:T24"[+<"AMRY&&4FQ60A2RQ MA@JQ),;& VL"ZU"#P AAX$BV0MU!DT(T4Z[4O67^PLMZ3SH"*<=R#UQI C8R M!/T*U2V&?^=;YQ 6TAEYZA!EK9&BG[T@O_\V96'T\KO'GJA]L=\R.C6Z":IR MQDLN,B#DC;:"DINT&PCR;FZETL0 M")I]K@M=N&[15\5NW,VWR$,X%Q]>#T+0Q!#NIR]>ER_FH^B,/28#*9 M>C ]EV DAYP1)P&;L@?=-'5$!^HH2;9#\,-)7N;ZK)6O@P< MK&P_B7]V[O[J\:,[9C!9?A3H/1[XN^_3+Z#P!/9XWBJI=<>59755-ZFZHYWO MFDS+5$EEBK_Y7N8BL19F?VU+FX,J9$Z>NE;TC+R7XH],5FLP&-FE L#SO]/S M"8EF_:JF+.K-6#HA$;F!;"5D*9?WGCE1'+ X\<@T2*/09V9!2CMF2LFY.XTQ MN5R]H@UZ5:RU#\>F01K[@"R8A-,![B2815UQTKCK1T;Q'(C@%8S=)]Z:[CR M>.J+2JC/QF:=C*CK,TOK7P'&WIV\3=,@F4U\],BG38,P[?2(72^\5#G8*U-V MA]$8<$<:#CEIB/IM$][-K932'E.UQM/0%H8?#A9$DP&WIT.,:1<'M'&.F6X; MCA70^M\7$,=!1)E'3F=#G"R./"MNI.%E/X\99F3<[]>38!+%?0X:!;.!9-J- M/ZM__@=G_Z\>_^^?O5FO&>(2SI)#[3.A YUF(,M[W2=Y;-.T^>RCT]E 7PXF M/3VP\'Z\7=(!(]+."#P%K(PU.I^L']<36.(79^QW34;I@UT@"9)HV@]/&NZM MTH&NMAT/7.C2]D*7/OI"!U_7^!<:DW91FUIA7O73\+$7OL/B=@:\_K>B'KSW M%6ZI:8+ZN[O8)_<'"?^ZVA+=$[(M/Y352Y0XB#%F2&,#M&B UC5U[.B366)I MO3L'"RAV>>SF"OC"0'>IIV$84!9[^N*5*)T%44R'4F#<>R7 BERZMQ!-,FM( M\V#04MOGEM/FE:%C;]YJ+KC"/U^:E+# K>'S"=[G5?/^T4R,7+LWAUMIL/S= MYPJP7)1EP/6%E&8WL0+:1ZB3?P!02P,$% @ *(EA4L8VEB-Y @ [@4 M !D !X;"]W;W)K&ULI53;;MLP#/T5P2N&%@CJ M:]*D2P(T;8?MH4#0[/*LV'0L5!=/DN?T[T?)L9=V:U[Z8HD4>0XO)N>MTD^F M K!D+[@TBZ"RMKX.0Y-7(*BY5#5(?"F5%M2BJ'>AJ370PCL)'B91- D%93)8 MSKUNK9=SU5C.)*PU,8T05#^O@*MV$<1!KWADN\HZ1;BI4Y>V_P@T%KCN[$9;)5ZLD)7XM%$+F @$-N'0+%XS?< M N<.",/X=< ,!DKG>'SOT3_[W#&7+35PJ_A/5MAJ$4P#4D!)&VX?5?L%#OF, M'5ZNN/%?TG:V8V3,&V.5.#BC+)CL3KH_U.'(81J]X9 <'!(?=T?DH[RCEB[G M6K5$.VM$?JO?&X)AT3=E8C:\,_>SR)L]U P6Y50+[;&A7*EF01^#4XL/] MWNG!D/-O=,O!7,Q#B[S..\P/'*N.(WF#(T[(@Y*V,N1>%E"\! @QX"'JI(]Z ME9Q$O(/\DJ3QB"11$IW 2X@; W[OCX8QN&6>6O:;JJG(:N<\B?YU%CPY]+W.%4V6L"\%60$K%<3B9W)%S M)E&C&H-NYN*:?/PP3:+TT[M/;!B(+6C?M!?":TO7T2,AGI$^+4,YU5@8GU*+ M&\,,=F=D,HJRZ9$#%=K,TD$:Q]-_@CDC5Z,LBU_@ MSJ+L?W]!>#2# O3.;QI7Z4;:;AP'[;#,;KH9_FO>;<('JG=,&L*A1-?H\FH< M$-UMETZPJO83O546]X._5KB003L#?"^5LKW@"(85O_P#4$L#!!0 ( "B) M85(OTOV'\P( ,(' 9 >&PO=V]R:W-H965T] MQ.V O5@231X>7D2-UE+=ZQ31P&.>"3WV4F.*,]_7<8HYTR>R0$%_EE+ES-!1 MK7Q=*&2),\HS/PJ"@9\S+KS)R,EF:C*2I8Y4YLI9G(]]D)O*[CA MJ]18@3\9%6R%^?AV;1O]9W"#XYKO;<'&\E" MRGM[N$S&7F )88:QL0B,E@>\P"RS0$3C=XWI-2ZMX?Y^B_[-Q4ZQ+)C&"YG] MY(E)Q][0@P27K,S,C5Q_QSH>1S"6F79?6%>Z U*.2VUD7AL3@YR+:F6/=1[V M#(;! 8.H-H@<[\J18_F%&389*;D&9;4)S6Y M4!F^R!#F*+A4<"T-:CBZ9233QR/?D!NK[,,3Z(8=B((H:,'K-D%W'5[W'X-N@>XUT#T'W3L /:=; MDY2$*Y<0R[R0 H71]B1<6@NVL7E]+:MO .\7IT8A#W0[M,'$.C IPE)F=,VX M6 $S0&G#?(&J21T<<4%JLM1,)/KX##Y]&$9!]_.;ZTNDF>(BY@7+@.6R%,82 M>$)Q:_H1PK#?"8( [@2I4M;_$-T$%P:XUB43L0U#FYW%4;7"H$)M !]I*FIB0%DHE:*( M*+-4#5$/FS4WJ2O(*WU55;O=Z>4S1^_ST]8/-+^=9(-, =J+^1_[XY<%=;?] M':US(4NZ%KM<[HH7=<)@".=5ES 7(,71UBO;M=<]A5MIJ!V?EP@(Y$!C1IU^ MK]_6*?[>7,U1K=SK8;-,#5^-V$;:/%#GU5S>J5>OVQ53*RXT9+@DT^#DE.JO MJA>C.AA9N"F]D(9FOMNF],BBL@KT?RF)?7VP#IIG>_(74$L#!!0 ( "B) M85(N51!JD00 $/ 9 >&PO=V]R:W-H965T!MNIXYD\+M/,])J,D_:F'V58#',@44G$2?_ZK@0& M'-LX2=LO@,3N;Q_:EV9K+K[+&$"1YRQE\KP7*Y6?#8&\UE.5_ ZO?\7N!J6*.$209,)IP1 =%Y[\(^N_0UO2'X(X&U M;'T3;]RRM$*00*(U \?4$5Y"F&@C5^*O"[-4B-6/[>X-^8VQ' M6Y94PA5/OR6ABL][DQX)(:)%JA9\_0M4]G@:+^"I-$^R+FG'*#$HI.)9Q8SK M+&'EFSY7?F@Q3*P##$[%X!B]2T%&RVNJZ'PF^)H(38UH^L.8:KA1N83I0WE0 M O\FR*?FOP*:),GG1[I,09[,A@I!]:]A4 %)8SE6!YY;F^@:/+?3Q Z@40TT,D"C T /F!%A MD0+A$0EXEG,&3$F]2K4( L^8*A+V^; ;^*4>5-9O!-LN>>2*IH>\,[7LMG?&=D=H>75H>6\.+:YB/+J$E16W+'XI51 2 MQ4N=Y+X0ZQ9P=QR4K*G$ M5V[^8K*F-P8D;!/K#>P;L6K- %3063O5[JN"P.?O&#@RF/:.X/I*\(/6W"=R$#' M-EE@@GY<];JF#CSRZ9#:#=&(?.HH9'Y=R/PW%[*H4)B(>FI)LB*K0BNG+YEI MFP56 D$89Z>!5BQ-]0324=^ZY=Y\6!8&-U4DID^ZU&=('V!:4-/6=TO0&OO0 M_UTCS22ES[,EOG7*U<2V.<]JB=K9F$%NW\8<,F4"=YRF\?4=O^E:GOG;Y)K3 M'TV;]/3UF.",FG[8GTZ\+4UMQXP37HO$G_H[)(_8P2FG;; M'2ZUJ'%_.FI)GHS0!1+;0)87RA2T:E;84'QV^R///6G6-BY*B:VN/D(7..V- ML?VO#_-PIKZN)0O(<5;JB+OJE*O752&$;F^'9R"LI7W';<\IWI3\QEEPE--V MMD+%QOG^+<[:5SJ&K6M)!F)E+E^2F-I6WE#JW?I^=U%>:QKR\G+XE8I5PB3J M'2&K-1CCM"/*"U>Y4#PWEYPE5WAE,I\QWE%!: +\'W&N-@LMH+[USO\!4$L# M!!0 ( "B)85(=/EP=IP( ) & 9 >&PO=V]R:W-H965T2 MF_;M1\F.UPY-L-WMQCJ1'W_2,CW;2W6O*T0#3[5H]-RKC&DO@D#G%=9,3V2+ M#9V44M7,T%+M MTJ9(5SJD40A^%94#/>>(N9VUNKQ4QV1O &UPIT5]=,/2]1 MR/W6\7WXJY%UI!*# WEL!H>,05"F%!).-A8'IC2.OXF&KN91X46+).F%NY_XI#/E/+RZ70[@G[P3;T(.^TD?7@3 IJ MWO0C>QKJ\#<.\> 0.]U](*?RBAFVF"FY!V6MB68G+E7G3>)X8U_*QB@ZY>1G M%ALC\_M*B@*5_@#7#QTWS_#QCFT%ZD^SP% (:QCD V[9X^(CN"B&&]F82L-U M4V#Q&A"0ME%@?!"XC$\2KS"?0!+Y$(=Q>(*7C DGCI?\0\(GL.F(31TV/8:E MKZ7H!((L(9=U31=.VTBP1X7 M>YL2:%KZ0"?4.5<.]O>2+;VBFI@30&F0B(T MCZ3/7EO'LRO#+4!CPZ6"1AKLS3>H.$U7L*;KC$IAT3/?>G>G4[C4-AC5&^LM MJK'F/K"V5?*)TR> XAFB;)+1313"JM,54ZC_FZ1)JX92"FHU^@+>O\OB,/E\ M=+P^*NGI'R5_.A[-YN"8^ED4^F$8PYTT3!PK M+.VA>J2PU(ZA[$QWJ'.3DW64^5F2^6D:OW6C@Q==HD:U<[U0$[]K3-\PQMVQ MW5[V7>:W>=^K;YC:<:J3P))LY6&NI@;EK1+P.5-:#S M4E+VP\(&&']"BU]02P,$% @ *(EA4MA?I6I&" :QP !D !X;"]W M;W)K&UL[5EM;]LX$OXKA,\])(!"2]1[FP1HVNY> M@>UMD>1:' [W@9%H6X@LN:04U_?K=X9ZHVS'=?>ZN#O@/B06R>&\<3C/C'2Y M*>6C6@I1D:^KO%!7DV55K5_.9BI9BA57M%R+ E;FI5SQ"H9R,5-K*7BJ-ZWR M&;/M8+;B63&YOM1S'^7U95E7>5:(CY*H>K7B.R]O(J37!)\RL5'&,T%+'LKR M$0?OTZN)C0J)7"05B#Q'1J#&EY;GI!>)&\WGCOM/VG:PY8$K\:;, M/V=IM;R:1!.2BCFO\^JVW/Q%M/;XR"\IRKKN^J,GF\N &[4O*F7,%9*Z[==7;/'W*ASB]G%8A!XEG2LKQI6+)G6#J, M?"B+:JG(NR(5Z9C!#/3KE62=DC?L*,>W(J'$=2S";&8?X>?V1KN:G_>12*)19UI(DY6H%;E;H?R3+BBY-5BV)$O(I2T"$%.!X"2?ZL"7KG"<";A%8N!"H$B]2W*D@;%%% M2EYW-_*0.\ @5&A>YG!]U4ORYS]%S'9?_<=^/^MK)M*+'[#S]9.0X)3?K:Y_W<>YC* M(",F_T7@ M9@FM2'.[G(@PR_9BRW>]7L*4>-1V!Q4PPM.>@VF8.>[,24&V9;/0\KW@O%]U M:>P;I.L,H_6,V58GZ!\3$&:CP&C/Y2Z-_ATKXL"U'"\V;8CL M?1O9P.P])::CF<,KGR!YH'C1*(RY^_P'B\ 8&@(ZZR/Q24>8 M%% 4*)UAJJ4@:3:?0PHJ$D$>1+41HM#3H@OR-<8KAC_.]DD'4A..D[Q4Z")( M2H]0EXQH$:1XL=5*A:_4.(_"PYZM%MDLLV0)0A29>G!H$5G#LL[&] B8>#V8 M>">#R9QGLO4'AP!;K3$YZY3?ZM=,',*8XT+>UE)C #A@B_>:8(9/#QPLNA#O M 5@MR *]"F0CX817.\< W+Y@D@$4 F"! X;SE2"+-V?VI2Z1R>YA[(%8V9!K MH20%'I3P2'(ZBT:2EQ'.!X,V@P@(I+1/0!M*#=^,XW_NR@N#5,=AR3,Q"5GS%9TQ0N8XP MC/):'M$ 2Q[D('7>;]/.$&5G&89H62NX:NK\QU=$B-M-Y?RM<'M3*ETE2O$D MBAKNQ)"SW= Q1H[EA3&Y@]8'#+ (U(%0N.0Z5_ 4FHI,0:&!W5&_!T L8 ,. MNU;L!:#4 EPO=";"O2G(SF!LA4W M^($_*KV'W/!3*>%04-*-#TCH MFAK+CCR#.J;^OGZG-0;01/G>3F3!,3%P/#43*D.JV-7^^<[&P,?$;SF,&>Q" MZCD0P;$I 2 A#&++ PE]M0/(BN\P")]C_;C/^ZPN1EHX5A"#+ ,QIGA\S",Q M->5[MA4PUPI UA_7@W19_806Y ]K.<(>Y\+C.*%W _*J4JC(,68+-_06[.#)FZP(?C MQ.#"T!HW,:5Q8?#,C,#"!F?O2/Z7?GTG")_+GCCWBVZ]=J!\O.V=$3-CBJE#[:9RQ6;,I79(HMBS;$A-'O1. M1KJBS.^7=J:G+FU[PH:)YY'(1=!R\*6000WX8?=+.]-3KX,+9.+1F)' CRS/ M#7>8>/@VJEO:F9[ZM$5*9!+2("28O(,8S3&! ^B\?FEG>AIV[[N0240#G\2! M8\4AHH]M4$>4123VF<58O#L]C2D;?.) (XIO[!S?M1A4)=&(C^/0R,I% M1)P\^CU 8 M #P8 9 >&PO=V]R:W-H965T5F#=@B;ML$=:HFVNDNB15)SLU^^0DB7:LAUW][W$HD1^ M/-?O'#+G:R&_J"5C&CT4>:DN!DNM5R_'8Y4N64'5"[%B)7R9"UE0#4.Y&*N5 M9#2SBXI\3'P_&A>4EX/+<_ON1EZ>BTKGO&0W$JFJ**A\O&:Y6%\,\&#SXB-? M++5Y,;X\7]$%NV7ZT^I&PFC&R 0X]<&<]!N:1:ZSQOTMU9WT&5& M%7LE\I]XII<7@V2 ,C:G5:X_BO5WK-%G8O!2D2O[%ZV;N?X I972HF@6@P0% M+^M?^M#8X90%I%E K-SU1E;*UU33RW,IUDB:V8!F'JRJ=C4(QTOCE%LMX2N' M=?KR?9F*@J$[^L 4&M[16<[4Z'RL =I,&*<-S'4-0P[ 8((^B%(O%7I39BS; M!AB#3*U@9"/8-3F*^)JE+U" /41\XA_!"UI% XL7G*#H$;BPA0LM7'@ [A:R M(ZMRAL0<\1IZQB!'V&:DZ8.',GA2FJ>(EADR7_FBW&?7F^R.C M4B%FW(? ^*R8,=DZP"I ?#Q%0U["=%$I>*-&+]&WWR3$#\[^LM^?K1AO^F)L M)EAQK"B?2F[TN]54@]:;[\_0,"!>$@TKL4FF&B9=JA3CR1)YS,/ M!Z0Q5];HT[/7<$+B;B."F_DGA;>3S*[&SU!$CF1UU&9U=')6GR1.QN>@)'"Q M% 5D"]66#"Q[5\HDG4W!QET*W%%I(1^1-'ZAJU7.:YHW!>+I^K"/-8[KTB2NC- M(9(V8!O\-@^PY\=.)@PC[)OU(OUBS0])4V>=D]=1XI3',/'1^U(S";U*+\MV M.6SW/4DB=,.@/S:5JPD !IFM; D0X'#9;1RXN@XQB4;H3E*0KV[14Z%T;X,) M20X*\^:!I95IZ_3P+T^2C?!?XVW^UM/KZ"G.*6G.*3R:GE5A.W5"FF:[?EG,YXSC7?SQ9/ M; #5@,]Y2DN]T].8[#>I0LM':\GX3)TB@DET6'VDR:! %&HIUB4D!UCZWZ:# MUWV=.AE^,-F\@DPV$51374JE? 1Z6U.9.>XFL8?]R.U*8L^'.'E3IZB"0W$J MP-:_,7NX0 M()0L*QA*KNKLW)@)8\Z4+U-##N,L((!PN5P A, MWCLA/L5!MRX)T/<,3L2MKQ[[[.#%H=][BSWP_6YY=_R_.S\(@27[V4B(%X;Q MT30SW3O([/8TL#GQ1WN2#7O3:+(U)B3>]J43E%\?5.^$R-8\=]M,:&&FVR<+ M0]WV9N2YF#^OP+8'3&(X/,!]-: 88--_ 9\#K7%SG._/"3TR"?IK-[][''/8 MP\/8"_$>,!"$A""("?T*4.'8M-ID;TD M(5O1_Z<\ [ M+0"Y7B:9KF2YMU0=%^;*4BA4<3"!99 F)F9LP4N[E6%!...Z@AP3' V-P8A_ M]NGN6ME'?#:RY>F_TZP:T3Q'17-(89(+M_1,H\"-O@2]DZ900?LM+>/;",1G M[5FV 3"F6 G%Z]K3TO?$Z72":8.5L1VL%4#(XTC CSM48]+@@&PGX$5=5D5Q M9 HKEVT@U$V[#=2<%US3[;7[&F(SKLW+3/.[Q[# BC'9-O2^I!H[-[H%DPM[ M;VUN92 "Z\O=]FU[-7Y5WPAWT^M[]0]4@J<5RMD#,P&[3\,+G\'4$L#!!0 ( "B)85**+&;3 M>0, &D* 9 >&PO=V]R:W-H965T'6ZS;L4;&5V#C;2B6Y:?]]*3MQ[>!RZ9X* M["42/Y,?28E4N-@K_6AR*2U\JLK:++W M!F:GIKQ:JL651RWL-IJDJH3_?RE+MEU[D'8%W MQ3:W#@A6BYW8R@=I_]K=:Y2"GB4K*EF;0M6@Y6;IW437M\SIMPI_%W)O!GMP MF:R5>G3"ZVSIA2X@6\HD=7ZI*T_["OM-ES(.T,595!V.,H"KJ M;A6?#N-;&[3IMI:8W!%[2[EP6K\ M6J"=7?W9"&VE+C_#JZ(6=5J($AP17+T7ZU*:R2*PZ,8I!^F!\K:C)& MFK74[ SU W9-UI02U 8^]&XVO9NB[AH)*_*IDWV>_.;8.^?8,W=SA0%A8*-* M;#@#5T4--E>-$75F)M?PTP^SKZKC1Z]$SK-\8KA35-+H"$\R)V5 MU1H54<#[/^PC^%<*#;(U'L!=:5QT_EY9/"4M/\JZD::'?X2Y/YNQD4SY?"!' MD1_-R !@W*=)!+]I90SVH][B,7_]&OLDYB,Y(K.!G/AA' _IYSZ?,WCKR#9: M58"/KFZ+9!CD%?5CGDR&2.QS%H^0*/1GE(P@)&>S"?R!3WSI/ AK=;%NK&MP ML I2557X0.);DS[FJLRD/O$Z9_34:SA&\'Q8Q,=*U.=),G"+*8')A9;?%,#/ M[K$M4L"RA:PH&SNH%F0/IU$T.0'B$X#,QS%.A^?R?UG/]T,TOVA\MA\2/XGI M0.8^2\;]$7,ZD@DCY[J!^BP>&C.?4CZ2DU%W,'].R<5F('[$QB5 ?!JR\94C M%(^;@<_XH";'UGQVPA<3?LK'DG%5S1E_LL8OUF_()Q< >EK0V'1/_44%@[__ M2NIM.^08[*JFMMTDT*/]''73C0]?U;LA[*Z].P.EW*!I.)W%'NANL.D$JW;M M,+%6%D>3=IOC+"BU4\#O&Z7L47 .^NER]0502P,$% @ *(EA4E0L%[H( M P >PD !D !X;"]W;W)K&ULO59M3]LP$/XK MIXQ-(*'FI4E?6%L)VJ(AC5&U@FF:]L%-KHE%$G>VTX+$CY^=A%"T-"O[P)?6 M+_<\=_?8OLM@R_B]B! E/"1Q*H9&).7ZS#2%'V%"1(NM,54[*\83(M64AZ98 M%Z8TS"2 M>L$<#=8DQ 7*V_6,JYE9L00TP510E@+'U= XM\\N;4L#SVY"H:&I2/"&'VI*8CZV^ 8XU@SJ3A^EZ1&Y5,#=\?/[)=Y\BJ9)1$X9O%W M&LAH:/0,"'!%LEC.V?8+E@EYFL]GLP_ *0'.H8!V"6@?"G!+@'LHP"L!WJ& 3@GHY-H78N5*3X@DHP%G6^#: M6K'I07Y<.5H)3%-]LQ:2JUVJ<'+TCQ>*]@WZ=RENG,>8Q$1'XZG71 #G)B_ 3'-4] MM8*GNR-7V^ZVO$JRXBD55MZNE6/5R]JM0NPVASC_<3.;S!J2[55,O7>0ME]Y MZ[]1VKJJ47"HEOFBF-M_+>JT_Y>H7J]>4]MZJ<=68W0SY+YZ&*JKZ\>#OS,J M'U6UE$A3 3&N%)75ZBJE>-'IBXEDZ[PS+9E4?2X?1NKK"+DV4/LKQN3S1#>[ZGMK M] =02P,$% @ *(EA4D,PSL@Z! KQ$ !D !X;"]W;W)K&ULM9AM;^(X$(#_BA7M2:UTU\1)R$M%D=K2%BAHJW)[]V%U M'TQB@F\3F[6=LI7NQZ_S0B 088A3F4Q+II&(Z>($*U03_O>^*# M/DME3"A^XD"D28+XZPV.V>9*@]JVXYE$*YEUZ(/^&D5XCN67]1-7+;W2$I($ M4T$8!1POK[1K>#F%;@;D$G\0O!%[[R ;RH*Q;UEC'%YI1N81CG$@,Q5(/5[P M+8[C3)/RXWNI5*ML9N#^^U;[?3YX-9@%$OB6Q7^24*ZN-$\#(5ZB-);/;#/" MY8!ZF;Z Q2+_!9M2UM! D K)DA)6'B2$%D_THPS$'J#T- -F"9B'@'T"L$K MZ@K8)6!W!7HET.L*."7@= 7<$G"[ EX)>%T!OP3\0\ YE3ACFSFCJPU8)?LH MV]8I9)MNF.=;+R96/BN'2*)!G[,-X)F\TI>]Y%,[Y]5D)#2KPKGDZE^B.#F8 M%]4'V!+,243)D@2(2G =!"REDM (/+&8! 0+\!L8$H&BB.,(2=7^G'+PC%\P M355C\0IFZ&_&P9RE/,#@;(@E(K$X5]B7^1"CK4OF? M>:$'I:\WA:_F"5\M,&-4K@2XHR$.&_A).P_-%@6Z"EP5/7,;O1NS5>,0!Q? M@K\"TS"-!H=NV_$Y7BO<.(D/V_%)2EOQNW9\AGBK\_>=QP[]!ORA\]@;\5'G ML3?BX\YC;\0G[\O[X_M"-_TWYU]/&*]-8JM: JQY8#^_K+?B$=2T$(7;,N M-3R6\BW/KPO=-0BYKET7NF\0,NT#@:;) ML9#K.;Y3EWH\EK(L?\_U6@)[50)[K0D<4XDY%A)PM?2#,R0 FNL%GHJSYN2 MVJ[-NC",7YJJ[FW8]#]CM1@X50R<5CT/,5N@&$Q91(0D@5!;79QFU2+ UQE. M%IBWE8I;67$_JAJ]RH3WUFJ<>)WF6"'E=)MC?N66W^K6#6'K%5(G:_TI?U11 M!?^ ]\4>&KO3D/%1T8=[1R[XYOB7J%-;"51L#Q+0(&89AG4B ]#U52]VNWR,+V ME6J4)HBJH:\Y"]/\>@IF.%2G;S7\LR+*Y^_/Q6Z]@\Z'Y6*WW$'W[;EPC\\& M=N\H%\=2I@_M@V3H>W>D!/,HO_D+D%]SBK-2U5M]7;C.[U@'_3?P<@P;^B?P M\K'X=K!37WS*4(?-B*CDQ'BI3!D7KG*5%U\'BH9DZ_R&MF!2W?CRUQ5&(>:9 M@/I_R9C<-C(#U3>:P4]02P,$% @ *(EA4B&;]5W+ P BPX !D !X M;"]W;W)K&ULM9??;Z,X$,?_%0OM0ROM%(W=(,^/KH&:RH;2'^IF'HXT0T6$ M$QP(90+)OU=\CY-$69)Q_%\9U6J?"CR^/EA_*"8O)[-!'-_3Y%\2BGBD>1H( M\1;EB7BA^R=<3#V!085,.@+>!7@]07\"O";@'MIX8S# MRAE]?^JBJ-."EY5%,M52:\'D4R(Y,5Z7 MK03H%JQ)E)$M"5 FP"0(:)X)DD5@11,2$,S!7V!*.(HBAB-4M,.7G(%'3".& M=K'$$O""7W&62^GF%_C"2$0R<#7% I&$7TO\ZWH*KCY=@T] /O@GICE'62%F"RQI)F(.9EF(PQ9^T^QCN)&Q?Q:3>^R+-.?-:-+Q'K#/ZA]]RAWX(_]IY[ M*_[4>^ZM^+SWW%OQQ9^M^_.[4W=2AE;=S%9AS[ID[[0_94]7'0F^_RVE8"YP MRO_K<&37CNS"D7W!T:'1VWJW))V"5!_TU['M62X[#7?S1' M#DRV*MW@:K:<3:[[)-VOG?H?FW1HO.T4C'>GO4)/,FI8L%G++3+;,:WVO,.C M/0SLKF9.$%BA0.U>P-5D-;GOE6-HOCDP/SC+;Z]P:+T_R];YN\P97RA3EK%%O7-?'E, MD]]QJ/@K! * \ !D !X;"]W;W)K&ULI5?;CN(X$/T5"\W#C-1T[B%IT4@-](W6K-"PO?-L M$@-6)S9K.S#[]UM.0A;2)HIV7B!VSJDZY2K'Y?&1BP^Y(T2A7WG&Y/U@I]3^ MSK)DLB,YEK=\3QB\V7"18P5#L;7D7A":$R MRLA2(%GD.1;_3$G&C_<#9W":^$&W.Z4GK,EXC[=D1=3[?BE@9#564IH3)BEG M2)#-_>#!N7N+-;X$_$7)49X](QW)FO,//7A-[P>V%D0RDBAM #5!*\OP:\) M?E]"4!."OH2P)H1]":.:,.I+B&I"U)<0UX2X30BO)!')#0>[.F'LDY+/E0697I'K92 MQ1X:K*J=A+B&[2B6T8W-,%, MH8 M64I2 W_1S7?<#@,6K%JS=.YIZ:9NI\4Y26Z1Y]P@UW9M@Z!9-WU%]D"WK]+G MW?1%P3KIC]WT[UATBG_J';L3&^C/O6,WTE]ZQVZDO_:.W4A?_%[>W_[WTEV4 MH=?L8*^TY_WV#NYPYC?._-*9?\79'W#&9UR:]N^B8@8E4Q_DA\G0<\/8&UN' M\]4QP)S(\]P&=B$L:(0%G<+FA.0D12D]T)2P%,%IO2)"?[9F*.'L0(2BZXP@ M:#LV1 B PL]4HXPDH)NBX4UJNH M.&C*<]!3ZM_Q+ 5]IH_ZZ'.V R\*P\NBF!E@CN,[T25L;K(6V:T*>S2@(($M MU),!%?LMA\\F7:X?QI>P%P/,#=R6L5<3RHM&EZB% 34*;+?E\LVD[/HVBIIT M1YWI_EFVH%"7& H..NHFS=5Q#BVY5'!^Z_HRMM,:W[JW+TZAOD%7 .K!OH_\]4=$IJ# M+642960#KNS;$6PQ4=W+JH'B^[*=7G,%[7GYN(.K+!$: .\WG*O30#MH+L>3 M?P%02P,$% @ *(EA4I_Q/;UX P 4@T !D !X;"]W;W)K&ULS5??;]HZ%/Y7CJ(];-+6V DD, $2I9TV:;T7#>WN8=J# M21RPZMC,=DKWWU_;24-*(>K+U+Z ?YQS_'W^G./CR5ZJ6[VEU,!]R86>!EMC M=A_#4&=;6A)](7=4V)E"JI(8VU6;4.\4);EW*GD8(92$)6$BF$W\V%+-)K(R MG FZ5*"KLB3JSR7EXC]&][K3!D=E+>6MZWS)IP%RB"BGF7$AB/V[HPO*N8MD MU#.VD9S#;\WWMNR8<+)N#+*SC+K9V:K6CZ0!:S81K""9408F&>9 MK(1A8@-+R5G&J(8/,+.5VWE8;8FRHV^OJ"&,ZW=V_OOJ"MZ^>0=O@ FX M89Q;H?0D-!:G6RW,&DR7-:;H#"8^WCQF7B/]Y%FE6+&[?#U?<8KRQ@*)4M8 MR')7&>)/NY7GFBAA]="PI*K>?/CYU0:&+X:6^EMW2.*PY;BL)?B4LF\R@SL MB5+VG/^Q:213E:7&&5DS[OF>PEU'33MPT$5T!+FV&79M3H--6K!)+]@%)UK# M C(I[J@R;,TIV%Q=4*4L8IL:LML>U=-VE?0U'<91"VOTTH=Q].2,)8-T@./A M:=G&+?)Q+_*5$P;^W3E0&G[>T')-5=^68'1(UN@U:84[MPA^:;4:!%VYAN,( MC4;)T7=XPC!.XF2$DM.ZXNC ,NIE^:/.&L\3]7 9X%=U&^##=8!?^CY8X*=Y M/AW&$<9GI#KD>=R?Z!>=G+FB@DD%_TA#GR?=(4'CY%5)=\CI.'WQ[S%]>D6/ M,$(H.M(N[%2G)54;7[1K\ 5F7<*UH^W#8.[+X:/Q2_=@\%7O(4S]VK@A:L-L MLN6TL"'116H/AZH+^+ICY,[7P&MI;$7MFUO[Z*'*&=CY0MK#T73< NTS:O8_ M4$L#!!0 ( "B)85(.\8V$#0@ (\P 9 >&PO=V]R:W-H965TK'BXH=<4*K0SS3) MY&5OH=3RMWY?1@N:$GG.ES33O\RY2(G2'\5S7RX%)7%AE"9][#AA/R4LZUU= M%-\]B*L+GJN$9?1!()FG*1'K#S3AJ\N>V]M^\%\I\T;^Z6))G^D35]^6# MT)_Z.Y28I323C&=(T/EE[]K];1J.C$$QX@]&5W+O/3)3F7'^PWRXBR][CO&( M)C12!H+HEQ'^^RWZ;3%Y/9D9D73,DW^S6"TN>\,> MBNFBG*I>%H::P]2EFU>R<\R$'L&V#U@ M@$L#W-; *PV\M@9^:>"W-0A*@Z"M05@:A&T-!J7!H*W!L#08MC48E0:CM@:N MLV7.^:?)\)#)CNS6;+M;NMV"[_YF816K\H8H_L/F\OC Y;_DV3G"HS.$'>Q\ M?[I![_Y5AS*&46YH=(X\MPGE!D9YHDN-XC2A?&PQHV:46QCEGH@V,_K4.B[N MZ##*Y]9Q@5#N6L<%0OG2.BX0RN3MZT729UU<5 W8]-0@]W5.[A(3[Q(3%[#> MH:@W9..!7/QSJG'0G:*I_ _@A;?SPBN\\ _&6^6"J35ZH(+Q&'V=H\^ZKB5K M-&5_Y2S6UWZA4IG(R3H>8/21@V*REH"?_LY/'T2Z3G0[0;*((AT*%/-\IN9Y MHFM\$3BI^X6(LAZ%9CK!?O>[G&KQ@Z%7&W57'#?VP>MTOU7%A&%3Q)E7_!L-P%%;) MK0[TO-'KF;RB-]S1&X+TWJ5+PH1).%.S6:9(]LSTND9$2EJ?A&'%E0,^#'8^ M#)I40^2#%$?U)="^YJ1>S MM5Y#>DR&E*:/Y&K!M=ZS6OF8P(YX:$V)@-3<=6Q7ZL!ZGAK=-BM<-[LLS5-$ MC,+K5::WFE)?1D^39+'>;[WHC>2R2(=(4%T242[U[K&V$W4JBR=P ,%U]WIH M%UXBJ;YNS&24<)D+:MQ6"XJ4()DDF]WF4C!=G,PD(IT\L:%!4+-+-@M+K["B M@IOZQ6<)>RZXJ:6@P1,E<@H18+L/%X- 8YYI]_5Z21B9L>30DOA4PNP'U:^K M=>6X\/"XUX[:!L6%>XB=HRNF%FA<[)FH.-/]R<;O]1DJ*Z)^W6I5;62]EC/Q M*C.!RK9K6Q@7[F%^S].9SF&]>![ID@MENA7TM&E+)?H?.MRA3DKD?9_P 7=L M&^'"?<1MJ2+C7 B:16OT;6\Y?](K%[TS@OC^#,VH41RC_[6^54MK@&L#6RV9 M> 1%UI9,%ZZ9]Z6&_'E/38BAQMBU-= ==-B@N[8\N7 A>1!B>(:^2VHZX2F;UXGBI '<#YI%W18J%RX0.Z\*'V]SD3%EY')+BU[C M]UH06S*%;3'!3H=,85LF,"S.IS'5 -YUA,6_S9$M4\I;+4<>UT29948 MPTI\(E$PN-N<4MB*-(9%^D/.DMC$Z,@XWS MK+9ZG9[K[1WLP7WSB1S!X"YN)LFJL0<+YJV@]&_-T;L-#>_?ECV>U5(OZ)(9 M*[4>W*V>R P,/F@FQFJQ!\ME'3%O2!FKI-ZP2V*LO'H-)RVG$0.#N\VUQ[<" M[,,:^4WDT8_"O^M<\2,SQ['1?%Z>__N<7?_K@T1@17*H,NC@< J M:-#4B&;F-H+8P LF?YR94V'S7?UI]J0!T*VYO5#>F'J[X>M)63D.8,6$V--2 MM\TM]#5KQZJ5UZ#+3LW26&Y;(M.=]6O!4Y5EJ# M+D\2 JO! =R]'D%.T^G!^0 FQ^IR .OR$TFHW-ZW.$._4]6* ZNK09<'!:&5 MWQ#N4]\N>PV AV7O",/7D[):'L(*"I!WA.J%5F[#+D\60JN^8>,=N;>2"@-B M_]R%N;&*',("VI*;EJ(76K4-NSQ;"/<>'H'[VB.X@0%=?#Z$N;&"',+Z"7-S M5$<>6L4-NSQC"*TRAW#'>P1!#4]E# XJ8L.!1' HZ_I[CQN;1_7OB7AFF40) MG6LD705U+HC-T^^;#XHOBR>09UQI[HJW"TIB*LP _?N<<[7]8!YJWOT?A*O_ M U!+ P04 " HB6%2W 4V:H<& !((0 &0 'AL+W=OE8J"2Z%)V';S]*5D0W%,]NZN9%(LF\XU_D\<<[.H?W2G\I%U(:])!G17G4 M6QBS?#T8E,E"YJ(\4$M9V$_F2N?"V%M].RB76HI9;91G Q)%\2 7:=$[/JR? M3?7QH5J9+"WD5*-RE>="/Y[*3-T?]7#OZ<%U>KLPU8/!\>%2W,H/TGQ<3K6] M&[1>9FDNBS)5!=)R?M0[P:\O>%P9U"T^I?*^W+A&U:O<*/6ENKF<'?6B2I', M9&(J%\+^N9-G,LLJ3U;'U\9IK^VS,MR\?O+^IGYY^S(WHI1G*OLGG9G%46_4 M0S,Y%ZO,7*O[M[)Y(5[Y2U16UK_1?=,VZJ%D51J5-\9609X6Z[_BH1F(#0." M P:D,2"[&M#&@#XW"$EBC0';U8 W!GQ727%C$.]J,&P,AO5DK4>WGIJ),.+X M4*M[I*O6UEMU4<]O;6UG)"VJ4/Q@M/TTM7;F^"3YNDK+M X+-4=G^E%=R$*B MJ="FD+I$?335,DMMUS92T72EDX6=>?LP320ZR3*5B-KXU40:D68E^NV7$8W9 MGR@MT%6:9?:S\G!@K-2JPT'2R#I=RR(!6>\3>T=4YKYRRH>2ZUEC-DQ /*4G&3 M9JEY[(JNM1]>^ZEH?'?EHB2- '6_5<5#=V?6_[Z>3*3#2<>LI!J?Q=%7:)V6)-OGP^2_[#%T: MF9?_ 7T,VSZ&H-J_E1$96CX%3&)!D0)P%$UU?S_LK> (/"_-@8<2 X'=\P#+C+PHCB-K4Q"77/.\:#4&!2'!5Q# ]( M'1:9*F[[1NH<$A%W@2HLP4$3P]1LU^=2/(IZ(-IP%4FB5W9WE ^V4"D#J\<' M:!_C]?83D.;@B$?;I-7])RJO!*Q!7LFS":0PVX2-NH2-@87MN(IAL+9I@Y:6 M+*MNGOE [=-A>%2( RJ!@?I.&?DT65T]$Y^D?5:'2JAK1U("D_3Y^GU*F0)D M)3Y9^^#")1M9(&^9SB@") M-'.88C"F=C\68#ZTUB<3(0V.66Q+%?RR8P'F)W,$\W!"S1S"&(RPG8X%F%_Y MXA$;C\/))'/L8W#EN_NY //+7,I'80D.C P&XP^>"[".^C>.:#ADN2,DWWJB M^/)C =Y1'6-,PR^U M..;?5QQS1UN^Y^*8=Z 68P(<"?.-[U->7AWSCJ30[CA 5RF/N9X6A MO&:P\15Q]3\&5T+?ID5I0W]N;:.#H76BUU_;KV^,6M;?&M\H8U1>7RZDL*E6 MU&ULM9IM;]LX$H#_"N%;'+K ;BR2 M(D7WD@!Q7MH"S3;HVV*QN ^,3=M"9=%+T4USN!^_E*QZE)5$R:G<#XTDJ-3]LM!F+:V[-/3] MP?MXN;+Y@_'YZ48NU0=E/VWNC+L;[[7,X[5*LUBGR*C%V>@"OWPM6"Y0M/@< MJX>L3,_&P6Y12I1,YNKD.[/5W6IDB37Y.SXJU0ZVO>9"U:O MOVN_*0;O!G,O,W6ID]_CN5V=C<0(S=5";A/[7C^\5N6 "@-G.LF*_]%#V388 MH=DVLWI="CL+UG&Z^RN_E8ZH"!#<(D!* =)7@)8"M*] 6 J$?058*<#^*= V M:%X*\+X]1*5 U%= E *BF-W==!1S>26M/#\U^@&9O+73EE\4 5%(NRF,TSQV M/UCC?HV=G#V_F/VUC;.XB".]0)?F4;]2J4)WTMA4F0S]BNZ,2F+7M0MM="-C M@S[+9*ORUF]2*]-E?)\H=)%ERF;HQ96R,DZRG]&__R4H#_^#XA3=QDGB]&>G M8^LLSOL=STKKICOK2(MU[V;V! 7X%T0"$GSZ<(5>_/1S@Y9+OY:+[?($D;!+ MRU4?+9VV7!^@Y?K3>_2B=%23KAN_KEOYB' Q+#QI-^B57\F5FIT@VCFLU[VU MM-@R=H&YCTZRCTY2J*4M:J?;S#W),E0-TS_?NF?HC57K[+^>/NB^#UKT$;;- MR%H;&_]/%KJOO[E-(5--;MQI8866?$?X>LYYD/\['7^M.JK>CCYM]L3*<&]E MZ+7RE=;S![>.FBS;2?)*CSAD1)"Z;6'--HP#CW5L;QWS6E?'QI^W:GVOC&^" M^%XY/UH01/L^(G\0I.E6)N@ZL[';#]6\ KJF=1G5_.C\78^%5U%M9O)VS;X6 M>U/%(/$JZC;2J+GKR;[KR7.#\&92#T)O:.$ =JC VVO3_/^"/AJ99G*7 %WJ MS#;M+C>E9MYS,>+*KHF?&?#H_^@WG?XZT^N-L@K)I5'*Y7K6$Z08<(B/QT,, M0,0=1#QL,> &XDW:/ R\PW[@0>^?,K78)NAMO&CNWJ^'H49S#% .^S'7 M<^G=E&JJ'HE$BT. @I@_/^0^JMDJU8E>/OH&"C3$T?'B#$"&.TAV8)PU$ VW MQ1D@#?N9UC_._'JZXXP \8B?>'WCK%3S9#\/2+-'"+"-_ #;+HN21!E7MR:% M?=DJWGA'7H(T(T,1+<./9ATAQW@C0R#-U+'&R6L MQ27 -_(C?#-RKE JUVIL\\NU-%^\@P;4D>.AC@#JR*"H(W74A6UY(P'4D8%0 MUZ$'=[.. NOH,*RC==;1%M110!WM0-W[/][=7=WY!@+XHD>L52O%ZI#XFM(Z MOEQA2%EK"DP!8=2/GIX3-Z7U\I0&4=1N ?"*^GGE*4>FI6BU5\)8Z!DX@(KZ M0?7\>F1::GY:JGL*$@H8H_X"]E)F*S1SVW$\5Z:8DZ8W7+2AX!8(9^8$+('9I#A)5W M<^'Q(@YP%W:D9P=&7)V .&"\';PA$##L2-7V/OV@%_9!&N4;(# L/%XJ%@*# MPB%3L6E83\4HBT2[%X%3X3#IV+1#3]29C3&@&ALD&YNR!IQYEBL#FK%>&9D+ MK8NE2BU*ET)\T4XF7A6 M)N"*^3'3>^H:3@("3L-6$SC0B?OIY$OX>?U5O^N6$-[>+T")^Z'TO5^DW+!G M^318C>X5FJOYUF7\^?GW0AL4IS.7TB(KOZ'-UFQTIAJ+@+*SJJ6<,$\5P(%P MW)]M_4!I4FJN6B6$SR@ (N_(P/J4)M-2R9,R$4>LH3:YY WOY$C@.VSB $WN MAYW#PW.J$PX$Y.QHW."5(U,_Y0[D1JGMZ<&PX#Z/ BBYOS+MO0UUZ,%A__J$ M V#Y(*>I4UY/ P6.VK=I#ESE?J[N(N[0XB0":$;!\8[/ 9&1'Y$'!EQ49R E M/MQ$P,#(S\"=/]\9!QMT+V=?$KWTC1 P%M'C^1'X$W6\53O0C_4O.HAOV4; MJMAUZ\&ZU(LS07#YZ0QKH%G7F<&Z*K]17E>A-OAOW.?V,*M^"'"^U MBX \T:"I750'$!&1;ZJ!0-% A6B'GAZ'40*P)8:I1$6]$B5T0EK=(@!IPH^T M792]E>D<;3.%3/X5K'=L@"AQO$)4 +#$H(6H:#@J()[*00#3Q$"%:(<>*KKC M"_@FAJE$1;T2Y;3NE''E$]S\H^];:99QFJ%$+9Q<<))3TNR^H][=6+TIOLJ] MU]:EFL7E2KF-W^0-W.\+K>WWF_Q#W_W7[.=_ U!+ P04 " HB6%2^MWF MQPP$ _$ &0 'AL+W=OQ_>:QS6#/^#>Q(42"'TFY;M=),$U;HT'6MN"C =O)F*9DP8'8)0GF3V,2L_VP M!5O/#4NZWDC=X(P&6[PF=T3>;Q=DK2*G!E;OG]FO ML\ZKSCQ@028L_HM&Q7+)]I^(Z5!'\X4L%ME_L#>Q;@N$.R%9 M8L!*04+3_(I_F(&H !!L " #0.<"/ /PC@%-DGP#\,\%= R@#3C; ZZC%9N^R>8W0ZL9H:DNQ3O)U5NJ<'+T,?R^ MHX)F9<%68,*?V U)"5A@+E/"!7@/%IR!;-K!;9K7O@Z^FA*):2S>@C? 6*# M.1& IN ^I5*\ [_^$GA=_S?=,J=QK!!BX$@E6*=U0B-NG(M##>(^A[(-7/@. M(!>YL_LEN#*T;VNX)C_!=7\W!5=OZEBF=I8Y?@+0UR2PWTPR>YG$?9'DVDXR M)6$;>(?]*6>BAN_F;+Y"51.?HXJLJ#145!K*$G@-"<8[H5J$ -62^_J[:@.W MDB3B'TL.K\CA93G\AAQ+\DC276WWKW-D)T-J@WX?Y)TOJ M_]2[OLY)\D"XK;)Z!7GOU:HW*'($%U=O<#+IGIO]'8WLRW$'TOJ%M/[%E9LC MNY64OM>#)\I>##L0!MUR 7.MTOYD$L=@N^/A1FU)0*A6&AH1GJ]26TRC6I=W M3\8)N1X\-8-9?:1E2&%EZ87V@EW^_7DQ75@J!Y;F"E_/76%IK_!R?S70Z@1# MU+<-5&F;\'+?--"#M($M:VF'T.Z'EQ36V'!"6*WSH.T=5M7$A%6KJM/MZ\^A M27;I@M!N@_,O,]M_?V,1P'BQRL)?MY(X%.963D3Y:SS%?TU2 F*P4UFWW M% G/3ZOY@V3;[+#TP*0Z>F6W&W7")UP'J/"3*P, *T* 9 >&PO=V]R:W-H965TM%Y&J)MTNIETXQ E6#4YMD[1O M/]M00@.EV;2;@/%W3LXYQA\>[1E_$BG&$KQD-!=C*Y5R>V7;(DEQAL2 ;7&N M9M:,9TBJ(=_88LLQ6AE01FW7<4([0R2W)B/S[)Y/1JR0E.3XG@-19!GBK]>8 MLOW8@M;;@P>R2:5^8$]&6[3!R:944RG O"FQ]A5=3&&B MJ?A!\%XT[H&VLF3L20_N5F/+T8HPQ8G4%$A==GB**=5,2L=S16K5_ZF!S?LW M]EMC7IE9(H&GC/XD*YF.K:$%5GB-"BH?V/X[K@P9@0FCPOR"?57K6" IA&19 M!58*,I*75_12!=$ 0/\#@%L!W%,!7@7PC-%2F;%U@R2:C#C; ZZK%9N^,=D8 MM')#("? &/\QMP?G8!S@#)P2)EA5! ,;*E4J;Y[:12<5VJ<#]0<8.3 M ?#@)7 =U^F 3T^&P_@]W%9YU*&X=2BNX?-Z0C$1'.?2P^W5W)[A]GNXNP(J M48%!Z;VWF[B!$W@C>]?,H5WE!7Y4%[U3Y->*_,_=XH/)JQZ704/ZE.E!6R0!2LBWS5Y;QD"AN>(!SJU^"=\W:5[X7#8;?UL)89]LI<,*F$ M)6_+G1PET:4V;.E0,J+C=6I7^9'K!=UJHUIMU+M0Y8:4>D.2PX;L6ZYAS3P\ M(0?1R=\5PK!E+PA]WS\*H5WE1TX(NT.(:ZGQI_OGLK529OE.UQ^WE,6>!Z,C M_1U5OAN'W?JA<^BX3J^#Q\%\ !;JFRL*_@IR)G$I?TDH%>#7#&=+S'_WK"IL M-'?XG]\8>.B1T.VUT>"^ZT^[(FH&Z7J>$Q_%W54&G=C_(.]#PX7]'7=6MI]; MU7Y.B_?0.&%_Y_R'> \-%/9WT+^(-VA_%#S8:#95O.TR-XC#XX^'W3A+Z(/< M#/$-R06@>*UPSB!2!+P\&Y4#R;;F>+%D4AU6S&VJSI.8ZP(UOV;J#:\&^L12 MGU G?P!02P,$% @ *(EA4GO.U]W$ @ V0@ !D !X;"]W;W)K&ULI59=;]HP%/TK5M2'5BKDB\\*D%I8MTJ;5)6V>S;A M0JPZ,;4=:/?K=VW2C(+3(?%"[/BC2U&O MVM,0=\V>"QF1A6,!?_-YCH=>CV/S&%!"ZX?Q.8'E 6UC5XBN+*_9%-B M X\DA=(B*\GH(&/Y]DK?RD;L$,)6#2$J"=&QA+@DQ+;0K3-;UH1J.AI(L2'2 MH%'-#&QO+!NK8;EYC%,M<94A3X_&5*67Q/R2;Z\%6U,.N5:$YG,R3874C4>0 M&;G+UZ!T9I<:Y'I-&:,W>(B3IN9ZW*6>M89S^% M4N"TUCK8MM':M^; M%MN;^W*6_M+;[>42?),>0$N4^W#7L1QL/\X':@PZ-<8 MZU3&.E\WK3EMDD=LG"KD.\F%WF_;)]5NI=H],<%=1\F'"7:@ZA/W_A-@%;':;X[0'2 '!](3#:Y<2<;M77 MS.@O4$L#!!0 ( "B)85(1B\R[N ( "(( 9 >&PO=V]R:W-H965T MM%*;1,G@80*D%I8M5Y4JDK;71LX M$*N.36V'M'OZV4Z:40B,:;LA=GS^_WSGQ(GIET*^J@Q H_><<37P,JU75[ZO M9AGD1%V*%7"SLA R)]I,Y=)7*PED[D0Y\\,@Z/HYH=P;]MV]!SGLBT(SRN%! M(E7D.9$?-\!$.?"P]WGCD2XS;6_XP_Z*+&$"^GGU(,W,;USF- >NJ.!(PF+@ M7>.K46KC7< +A5)MC)&M9"K$JYW8(& P4Q;!V(N:Q@!8];(8+S5GEZ3 MT@HWQY_NMZYV4\N4*!@)]H/.=3;P4@_-84$*IA]%^1WJ>CK6;R:8BPU!3GEU)>]U'S8$.-XC"&M!>*P@J@61*[0B8ZN1A*M_6U,NTX M4_LJKX JZ!*B0;7MT*1RZ.H:]LN]N M4/6"7F<+O2TH2=O).PUYYR#YD]"$'4/8V4D>1CCI;2&V1&$R6H+W4 M:4.='K,/#M.E.^].&$7!]AYHB<)!;_L-\S>^X/;TO"=R2;E"#!9&%UPFQD!6 M)U(UT6+E/NI3HY)A:.76RGA?WZG9TT:^F+ MMFE?$OM\]]SSG.US?ZGTB\D1+;P50II!D%L[OPI#D^18,'.NYBAI9:9TP2Q- M=1::N4:6^J!"A'$4]<*"<1D,^][VH(=]55K!)3YH,&51,/T^0J&6@Z 5K R/ M/,NM,X3#_IQE.$'[/'_0- L;E)07* U7$C3.!L%UZVK<<_[>X3O'I5D;@U,R M5>K%3>[201 Y0B@PL0Z!T6^!8Q3" 1&-UQHS:%*ZP/7Q"OVSUTY:ILS@6(D? M/+7Y(+@((,49*X5]5,LO6.OI.KQ$">._L*Q]HP"2TEA5U,'$H."R^K.WN@YK M :W>GH"X#H@_!G3V!+3K@+876C'SLFZ89<.^5DO0SIO0W,#7QD>3&B[=+DZL MIE5.<78X9B8_!?>%V]>2+YA :0TPF<(D5]J>/:$NX$XNT-C"+YUY1_N^83R^ M0T_#RY@>.C$S@"+N$I5Z4A--,/+=%U2<.DIC:JJ,5[J+5BN%?2Y@9N M98KI)D!(.ANQ\4KL*#Z(>(/).;1;IQ!'<;2#T/B/PUN7!^BTF]JW/5[[?]7^ M0,Y.D[/CW&ULK53;3N,P$/T5*]H'D"BY MM85%;:1>0(L$*T07]ME-IHV%+\5V6OC['3MIM@5:[)E'4#P5E M,L@&?NU!9P-56V+*U;"+/!BBYA!O9I]:#1 M"EN6@@F0ABE)-"R&P2B^FO2*,VV(81$X0<,BM8Z#X M6\,$.'=$*..UX0S:D ZX.]^RW_C<,9/F%%V>9E-R M\NUT$%K4Z"*%>:-G7.M)#NB)$W*OI"T-N98%%/L$(2;79IAL,QPG1QFGD)^3 M-#XC291$7PB:_#,\_GY$3MH6//5\Z?\J^)&8W39FU\?L'HAYIXP!0]RK6>,) MT3F'#IY;QV!PP@Z%JHM;,_<\LVL)ZRQ-NA$6E_'%CM>>[%XKNW=4 MMJN/?2D'^T[UF+#G4UK5]MV-O*O^,/Z&-M&ULK9C1;]HZ M%,;_%2O:PR9U)+8AP 1(6]%T)ZU2U:[;P]5]<.$ 49.8:SMEE?;'SPY9G#3! M96E>($Z^<_C.E_ #>7;@XD'N !3ZF<2IG'L[I?8??%^N=I P.>![2/65#1<) M4WHIMK[<"V#KO"B)?1($H9^P*/46L_S*;B*(5K@626)$P\?8*8'^8> M]OZ MP4%6CI$9Y9[S![/XLIY[@7$$,:R4:<'TVR-<0AR;3MK'_T53K_Q,4U@]_M/] M2;CD\8]HK79S;^*A-6Q8%JL;?O@'BH%&IM^*QS)_18="&WAHE4G% MDZ)8.TBB]/C.?A9!5 KP\$0!*0K(N06T**#YH$=G^5A+IMAB)O@!":/6WK:>)4G,;;Y705R-=IQ:?6230=Q9G@*Z R4R OD=*HK=+4"R*Y3OT'EG- M14UT@6Y@E0D1I5OT[Q4D]R#^T_*[VR5Z^^8=>H.B%'W;\4RR="UGOM)VS8?Z MJ\+:IZ,U0I/FA'B0?\* M)/9)<,0P*5M/^HUATA@0XXGY-M=B:*J&-)Q,VF.8EEZG3J]5:GU)]YGQ_14> M(4:XI)4C$AQ8@@;]AE+T"U\@0XO,@09<(3Y^=3#H%SJ3(=CR$_<,T*+?2QAI MD3DX@BU#L1NB9^;T=\#!EKFX9^CB%IZV,*=-=AHZV'(7N\%[[F/U]W3"EM*X M9TSC)H'; -4BV(1E8NR=&G7]F/,IN!5TQLHU2B&#:Z)AB,=;$X[J\=%XKO\RVJ M>ZX43_+#'; U""/0US=&ULE5-1:]LP$/XK MA^A#"UODV&M3BFUH$LKZ$ @-[9X5^QR+RI(GR7'W[R?)KO%@&>S%UDGW??=] M=U+:*_UN:D0+'XV0)B.UM>T#I::HL6%FH5J4[J12NF'6A?I$3:N1E0'4"!I' MT1UM&)7N>IZJS@$O<:3-MNR$![2O M[5Z[B$XL)6]0&JXD:*PR\KA\6"<^/R2\<>S-; W>R5&I=Q\\EQF)O" 46%C/ MP-SOC!L4PA,Y&3]'3C*5],#Y^I/]*7AW7H[,X$:)'[RT=4;N"918L4[8%]5_ MQ]'/K>0$0CX XZ!X*!95; M9EF>:M6#]MF.S2^"U8!VXKCT0SE8[4ZYP]G\B7$-;TQT"#MDIM/H.FX-?(7' MLN2^<4S LQRF[]MXO47+N# W< 5#Y7C"Y6W6"P@ M67Z!.(JCU\,6KJ]N_F2ASLMD*)X,Q8$V^3]#_V!.)N8D,'^[P+Q1\HS:\J- M.*#D2H-4%O]J?6!:!2;_+L[Y,KI?Q"D]SP70V=S\$]@Q?>+2@,#*X:+%ZI: M'J[5$%C5AE$>E747(RQK]Q)1^P1W7BDG: S\[9C>=OX;4$L#!!0 ( "B) M85++MBX);@( (,& 9 >&PO=V]R:W-H965T#OQW;2J-"TPR;Q MXYYSS_'C.NNX>)45@$+O-65RYE1*-=>N*XL*:BPO>0-,SZRXJ+'27;%V92, MEQ944S?PO,2M,6%.GMFQ>Y%GO%64,+@72+9UC<7'#5#>S1S?V0X\D'6ES("; M9PU>PQ+44W,O=,\=64I2 Y.$,R1@-7-^^M?SU,3;@+\$.KG31L;)"^>OIG-7 MSAS/" (*A3(,6/\V, =*#9&6\39P.F-* ]QM;]EOK7?MY05+F'/Z3$I5S9PK M!Y6PPBU5#[S[!8.?V/ 5G$K[15T?&Z4.*EJI>#V M8*:L/Z/WX=UV 'XT0% M, ""[P+" 1!:H[TR:VN!% M@)R4UA,D.UF#X$#6>,P:'\UZ2QC1)[%$:\ZGSTJ\GS1-OJ['?I#O'U"6C,J2 MH\JVV_YQCOZ .D>/7&$Z)3#9S^W%8?Q%8;*W8U$:32M,1X7I485+!0UJ&WW; M!J6Z1%)]M$JDN*YU;RV1Q-2]*='IGIPKS_LBQ]TI$:8\_\9B39A$%%8:Y5VF M&B[ZDM=W%&]LU7CA2M<@VZST*P'"!.CY%>=JVS&%:'QW\G]02P,$% @ M*(EA4AT.YR*> P , P !D !X;"]W;W)K&UL ME9=M_BH;IBW8F#8A'T[$]BY*FNY<@JEF@^N*[."5D1>\X;6\,N. MBXHHN!5[5S:"DKPSJDK7][S8K0BKG?6R6]N*]9*WJF0UW0HDVZHBXN6&EORP M'E])#KTV G'62L6K MHS$05*SNO\GSL1 7!CB<,/"/!O[O&@1'@Z!+M"?KTKHEBJR7@A^0T&KPIB^Z MVG36D VK=1OOE(!?&=BI]5; CA#J!9$Z1W_^:%D#/5+H[2U5A)7R'7J/OMW= MHK=OWJ$WB-7HON"M!*U5 M?+^'!5OQ>J=1YU0_?$_K*/:CI?MT62)3%/II/(A>\88#;SC+^U%0^G,"JK>, M+^.%23"",D5!B$,[5#1 1?-0K:B9:@7M:K=CS_K:BA@9T?W$3T:(%E&*[83Q M0!C/MYE73:M.W95\IPY$4!MA; 3'89R."$U1'$XT-AD(DUG"+R0K8$GT6YS: MMWB/F)B(.$T7(T:+RDL#.^1B@%S,0MZ+-GOL:TA:Q:TM7IB[,!AWV-1<2%Z1 MI0-9.DOVF<)X*'B9(U8U@C]173PK7VKR1>FXP:;(]ZF]_'WM&S"B(QF 6E3>!=3%5\'SMH)]6(FS$2E)O#&2*IH#.+WOLS[]/V#.% M'28E55+/,6AH1J6]:KX1?N$E!J2I"D)O8LOA\^S \\/C-)6NT+8D,(A?#:%(EK556Q(%E'_H?!QSQ4IK?"1 M,9<#SPOB,;LIPW@1C-^@[L5Q3I^EOQ"Q9[5$)=V!G7>=@ /1'T_[&\6;[H3W MP!6<%[O+ H[T5&@!_+[C7)UN]*%Q^).P_@]02P,$% @ *(EA4C4*^>:* M @ D 8 !D !X;"]W;W)K&ULE57?3]LP$/Y7 MK&@/(#'RJTT!I9%HR[0],%4@MFCAULAX[_?FM#8Y_O^^Z[ M<^Z2;J5ZU"6 (;\K+O34*XVIKWQ?YR545)_+&@2>K*6JJ,&MVOBZ5D +!ZJX M'P5!XE>4"2]+G6VILE0VAC,!2T5T4U54O<;>"1OM)%5!T8%%1/MD_[NZK '"),#@*@#1&\! MHP. N /$+M%6F4MK00W-4B6W1%EO9+,+5QN'QFR8L+=X;Q2>,L29;*GPA5#F MA5!1D)NGAM5X189\)M^I4M26F)PLP%#&]2E:'^X7Y.33:>H;C&T9_+R+,VOC M1 ?BA!&YE<*4FMR( HK7!#Z*[I5'.^6SZ"CC O)S$H=G) JBX!U!\P_#P\LC M(1SWQR!&/#@K%]LP9M6_]>W5OT6.'MCW[G,78POA+_>?] M<@S]HO"UWRMYXU[>^*B\.:V9H9QPP&8J"-4:C#XC&R6U?D]NRY;LRYA:?%PKBN2 :@'' *L,]^245RCA8TYWE3-9P: MS++XQYTD@UI/+B:#'(=>470QR-'?:^X*U,;-/$URV0C3=DMO[&ULM5E=;]LV%/TKA-&'%%@C\4.R73@&DGCM M"BQKT+3KP[ 'Q6)LH9+HD73<[->/E!51%D6JG>.7Q)+NO3J7O/<1L$8KFF12+.V8:6ZLD#XT4BU25?!6+#:9)63D4>H#", M@R+)RM%\5MV[Y?,9V\H\*^DM!V);% E_NJ(YVUV,X.CYQJ=LM9;Z1C"?;9(5 MO:/RR^:6JZN@B9)F!2U%QDK ZC$*-2*:TZ74(1+U[Y%>TSS7D12.?^J@H^:=VK']^SGZNRIYEV!(0D[U"GDC+NCR'&#X"T A"GL M7?^P.YSVN"_\[C?)$X"DS_L@&=S,&Z["$=>\<28$N"S8MI1]@[OWCBIOW?N/ M&RG;)M%$9XT1@?02 .->*%=+I?;8ILGDJ8:()?9OXGN\3Z8^TAQ MZ_WC,28=D+81CL-^C%&#,?)B?+>56TY!TH*G2SLSI9U4I=V'.;+@((BGX:2# MVC:+X-@QM'$#._;/>MVM?;!BZWV01&C2G?$>,QB&CN$<-[C&7ES7_(F]IR4% MMPF7)>4"_'5#BWO*__:4^J0)/OF_22\F5OUZLIDV+YP.9K-1A0$VJH9+Q6^: M&R5/4B6Y2HX]*<'0T&YX5/_6[NUY(@3#[FSVF*'(462PI0GPQ3JX#M5&$$^[ M*&T;,G: 1 8D.ED+UZ$/1Q<1W,6-;!:%T '<,#?T4_?7:BVBA_:14_MNLZ'G=1VT;8"=MP.?23^9'%?S40'O<5?YV/WS,:;ANC'] O()_I?,M6HQ7H.*VHW0]G"K7FJE[>VF81='0+,EJ!7DXKD*T#,,;=KNZQBJ8. MF$8MT.G4 MDR@%$,K?&US4CD4 MDU *=5"VN!L)#Z.Z8 =?ACD%&:)!?:*ZK M+UWU\U0%=3^P^HQBA_3@UA;3::5G(#ST+-:&7(>U!QOMP7[M^/E]_4BLT7T4@./DYRL"TE*'9)"392@E].2G"/E+@A&)7 ?I7X76^5; 4% M7)>.=WX,?>.!_9^AT9S8J6#73ALV=(K]=/I3HSGM6=@Z=E$-ZQ(_ZQ[#&L0F M6X1CY(!DV);XV?981A@(C\>#;4T,Z1(_Z5ZN:"E!2:4^>/)%-'Q(CMMS)_9N M^B2:.C:Z2&L[_07WT^V]\@B[$!@^(Z?;+2AE=1S8N7\%WU[OCS=-F/UIZTW"5UDI M0$X?5,CP?*Q&C^\/,/<7DFVJ([U[)M5G4_5S3=62CVL#]?R!,?E\H5_0'"// M_P-02P,$% @ *(EA4B:Z6L/Q @ *0D !D !X;"]W;W)K&ULE99=;]HP%(;_BA7UHI6V)G9"@ J0^%BW2NM6]6.[-N1 MK"8VLTWI]NMG.R&D$*"](;'C\S[O.<@^[JV%?%8I@$:O><95WTNU7E[YOIJE MD%-U*9; S9>YD#G59B@7OEI*H(D+RC.?!$'LYY1Q;]!SQM)N[9(M5VPA_TEG0!#Z"?EG?2C/Q*)6$Y<,4$1Q+F?6^( MK\:8V "WXA>#M:J](YO*5(AG.[A)^EY@'4$&,VTEJ'F\P!BRS"H9'W]*4:]B MVL#Z^T;]VB5ODIE2!6.1_6:)3OM>QT,)S.DJT_=B_0W*A%I6;R8RY7[1NEP; M>&BV4EKD9;!QD#->/.EK68A: (X/!) R@.P&1 <"PC(@=(D6SEQ:$ZKIH"?% M&DF[VJC9%U<;%VVR8=S^C0]:FJ_,Q.G!5R&2-(:G&$4)"\F6D[3; M_640QX&IUDN]4/N+PMJ:-V9;E=G64;/F/\%-?HJHN(;"411VFF%Q!8M/P4@3 M+/X(K%W!VJ=@81.L_1%8IX)U3L&B)EAG'Q:VNZUF6+>"=4_!6DVP[CZ,X.! M9CC8GDK!4=RC.8B SC7(QM,DV*<& ;;E:,36#D-\%'N]TBL)B.[L)K;=3?3@ M;BJEZZ8(#KNU6A0;JEQ7WU$MW#Y4,;*U3MYC??<@N&:<:4#?S=%]\N0I\R![ M_G#<#2.\X]"O-9T,*93 WDL%EVYB215\N!EHL76N;"FT:I7M-S5T&I%U@OL^%T)N!!52WH\%_ M4$L#!!0 ( "B)85+4FO.XXP( $) 9 >&PO=V]R:W-H965TW[SG>.[7/*KM002.U#&_# (VGY&*/<&/3V&A&.BB&%=DP/1?Y-R@=:EF^2##EOB@OUP8>BC9* MBZP$&P49Y<6?/)6!V /@]A% 6 +"UX#F$4"C!#2$)73) 0Z5 *_0% M+@7%"U'8:_XXP#C(#!Q>3Q@N559;M5:-EOUAMD"W]XWVVR%W;"R6VQ%ZSWJ MVI6Z=JVZL7P65\ !S8C4'*1"]U/(EB#K@MZIR#L?O)W=BKE;*WL8Q]1FND.7 M:-Q]3Z#.*XOGM1:G=YC8]L?7=%:D=3/ ZF1)I4I1"#E:$,SCI&DRSJ;='1 M8NU*UE)H4P!=,S5O%)!V@9E?":&W'6N@>O4,_@!02P,$% @ *(EA4A@> M2NQ' @ Z@4 !D !X;"]W;W)K&ULI53+;MLP M$/P50L@A 5)33S\"64!BMV@/!0P[:<^TM+*(4*)*TI;[]R4I6? KK8%>+"ZY M,SL[]#)NN'B7!8!"^Y)5X)+1RDMCN+402\ZUBM(*%0');ED3\?@'&FZGC.8>-)=T4RFS@)*[) M!E:@WNJ%T!'N63):0B4IKY" ?.H\>T^SR.3;A!\4&GFT1J:3->?O)OB631W7 M" (&J3(,1']V, /&#)&6\:OC=/J2!GB\/K!_L;WK7M9$PHRSGS13Q=09.RB# MG&R96O+F*W3]6($I9]+^HJ;-'8T;H_NX!W2%:H=>";Z6& MR!@KKY-3.-8^]&;XO1F^Y0O^ MUXR_U KZ6H&M%?ZCEB2,"*K]-74:/3A7;6RY(LME!G.7#-UP'./=L5F725XP M'O9))S+#7F9XD\R:T PI/;^(Y_DUA2W-\*3X)#A3>)D4>>/K J->8'23P/3\ MSD1W9]#=V2-ZY8JP:]JC"^-&8>B=:;],\B9N>"8>'TVB>06_$[&AE40,<@US M!R.-%^W+T@:*UW8XUUSI4;?+0C_&($R"/L\Y5X? S'O_O"=_ %!+ P04 M" HB6%2@'\3!4 " 9!0 &0 'AL+W=OJ+5EK)'PB;JA!I@*;MQ2I4UNVU20YBU?%EM@/M/GUM M)XVR"2KM#?'9=X]_SV$[.Y%ZTA6B@>=:2+T(*F.:NS#4184UTQ-J4-J5/:F: M&1NJ0Z@;A:ST1;4(DRB:AS7C,L@S/[=1>4:M$5SB1H%NZYJIER4*.BV".'B; M>."'RKB),,\:=L MFL=FHVP4#BHEKU%J3A(4[A?!Y_ANF;I\G_"3XTF/QN"< M[(B>7/"M7 21 T*!A7$*S'Z.N$(AG)#%^-UK!L.6KG \?E/_XKU;+SNF<47B M%R]-M0@^!5#BGK7"/-#I*_9^/&!!0OM?./6Y40!%JPW5?;$EJ+GLONRY[\.H M((DO%"1]0>*YNXT\Y9H9EF>*3J!V$NNEZC85SH&[@"+N%'1:UF MLM19:"R@VR8L>IAE!Y-<@%EC,8%I_ &2*(D>MVNXOKKY6R6T]@:/R> Q\;+3 M__3XCO1TD)YZZ=D%Z8WBLN -$\!J:J5QG;J\1=>#3C'UBN[.'/,X3J,HRL+C M&9+90#)[E^116@)K\@^6]E3N#'"M6R8+A(*T.0O2"3H_SY$.'.F[ M'/?V(2F84B]<'N#(1(NN)_?C$W..)3W3E'@ZF_T#$XY.NGLTOC-UX%*#P+TM MC"8?K8+J+F(7&&K\X=^1L5?)#RO[=J%R"79]3Y:L#]Q]&E[#_!502P,$% M @ *(EA4M^,@/ED @ GP4 !D !X;"]W;W)K&ULE53;;MLP#/T5P>A#"VRQXUQ:%(Z!7#:L#QV"IMV>%9N)AMB4!]F*+$L_A(24RV6OS:@L 9&^E5'82%(C5?1C:K("2VYZN0-')1IN2 M(YEF&]K* ,\]J)1A'$7CL.1"!6GB]Y8F372-4BA8&F;KLN3F?092[R=!/SAL M/(EM@6XC3).*;V$%^%(M#5EAQY*+$I056C$#FTDP[=_/QL[?.WP3L+=':^8R M66O]ZHR'?!)$3A!(R- Q!O,H%1YXF1N^9<=[$YA8^58\F<4*Y2UFAH5-!.$SG6NW MH%A+8"M00AOV52-8]I$]* 0#%AF\T1.PM"=45AL#.:-R'@.51U3\G3OK>@'( MA;0W[(H0[+G0M>4JMTF()-B%#;-6W*P1%Y\1UX_9HU986/9)Y9#_21!2IEVZ M\2'=67R1<0%9CPWZ'U@ _JWB!>MA1#SWU\"QU M75&Y17L9IXK8$(P\@6O"71KWH[LDW)T(.^K"CBZ&G9::\OG)?>OH#3WT-3)A M;9T,Z/I(R'-R>5C+NE(PO*GG6R&67_^$QNB=XHL2-BO&_!1D- M1W_)"(^:I@2S]:/!4FJUPJ9_NMUN^DR;IOOMWHRN1VZV0EDF84/0J'=+H4TS M#AH#=>5;<*V1&MHO"YJ@8)P#G6\TI=(:+D WD]-?4$L#!!0 ( "B)85+8 MD+=XJP4 ,T7 9 >&PO=V]R:W-H965T%?#/ M5LB<:KB5NT#M):.)%W/)=JLV#8#'?TQV[8_K+?BWA+FBT)#QGA>*B0))M+P:7^,,J.C<" M=L5?G!U4ZQH95S9"?#,WU\G%(#2(6,9B;510^+EG2Y9E1A/@^+=6.FAL&L'V M]0_M'ZWSX,R&*K84V=\\T>G%8#I "=O2,M.WXO 'JQT:&WVQR)3]1H=Z;3A M<:FTR&MA0)#SHOJEW^N-: F0/@%2"Y!' B/<(Q#5 M$C 3SJ$1C5 B.[,Y4K M=A]65-/%7(H#DF8U:#,7=C.M-+C/"Q/W.RWA7PYR>K$4Q3V3FF\RANY8P85$ M?PK-%'J/+I.$F]C0#/&BRC 3J;?1N-K@NE90EG M5Z.OGV !N@:LZA^/^E&C?F35CWK47^YVDNVH9F@O>1'S/:0.S459Z*YA_+';DS*1Q9N+5\P6.@SQ(.*[%#B5?K$,HYZ=F766)T]+^?8 M=ZC;JM/L[&E //' H>/Y\(1MR XXCZT P"&-(?5Y@1*1950J+I4N3O;2 C8J%TMU;09[$;(1]07-TC2,O@$^BV+V'G,F1@7*&/L-E)P*_ MFC%Z8!!>#]%@1_'8S_&/2L@9:I+Z%H)SANXT_"1H75$IM(Z=>/TVHN'YR$>+ MV)$\]A-LU79Q)(Z$B9^$?W6QJ,UAPEYVG/Z:P%Q9$7\9+66(F8L46@K18YT MRN"@;QE@VG4"Z6A!,?:U@\2Q'/&WHI]3+I/W>RKU0X,!29;9;.OK=*[(R[K3 MR'%BY.?$CUQ"RL]"E- 'A39LQXO"(!+%F7V+@:AE96*>F$U+3"B!DPXIA[JD M2OBZ!1%(H&I$L:KF/DC$<>EM>R+'B!%^C1R-'(]%?AYS;0)X83VU6[&%VB99 MPO*]?E07S(2ABVMK.^VL(7WQ:[Y,"DAF^G=XTI4E/MN.&*/QJZ2'X\CHN5TDU&3%XM*,2W\Z529/ M4J7O%3=R9!N=(-N?2!6_YM[^-FC-/W,F=W:.K)"=@E2CT.9I,ZN^M!/:P"VO M!MTW5 +W*)2Q+8B&PW.(NZQFQ]6-%GL[3=T(K45N+U-&H2DV"^#_K8!-KV^, M@6:"O_@?4$L#!!0 ( "B)85+U$_W3 P, /$) 9 >&PO=V]R:W-H M965TJ7!)M[S^_>X;.##>-W(@*0Z"&AJ1A: MD939N6V+900)$1V60:K>K!A/B%1#OK9%QH&$!I10VW66HQ4!A:74%$3]W<,$*-5, M2L>ODM2JUM3 ^O,S^WN3O$IF001,&/T6AS(:6GT+A; B.95SMOD 94*^YELR M*LPOVA2QOF>A92XD2TJP4I#$:?%/'DHC:@#7WP-P2X#[)P#O 7@EP#L4T"T! MQFJ[2,7X,"62C +.-HCK:,6F'XR9!JW2CU-=]QO)U=M8X>3H$Y. 9N21+"B@ MXRE($E-Q@HY0G*(O$QU3JBHF ENJ]36+O2S7&A=K MN7O6PBZZ9JF,!+I,0PA?$MA*>*7>?58_=EL9I[#L( ^?(M=QG=N;*3H^.HDE M) W:)G_!='D[1\=ERB<-7-.#N?"@5-62K%>5RC.TWE[:A417J9 \5QM/HA\? M50"Z4NF*GRWTW8J^:^B[;5]"5GX)3^BHJ;X%@V\8=$>Y'W4'V WL^[HYNT%. M%?%"F5\I\UN53>;?/\^FLY8<>Q53[S4L/*OHS]HMS),%<,16:I\(22@UBSRA M/9_DN&#KU9QRFYWJ5P+Z!]>P:<%^0_TKK5%%,:U,&_'6KMV1B; U^:N(="2 MY:DLCLMJMKK/7)A3W-Z&%Y>A:\+7:H,C"BL%=3IG2B O[A?%0++,G+@+)M7Y M;1XC=2<#K@/4^Q53B9<#O4!URQO]!E!+ P04 " HB6%2?JI%-'KLJ3JSPRXW$R\T-L9'MFJ,-;@3\<57<$3F)?J M0>',;U R5H+03 JB()]X-^'U?&3]G<-/!AN]-R96R5+*5SOYGDV\P!("#JFQ M"!1_;S 'SBT0TOB]Q?2:E#9P?[Q#OW7:4OH6+Y5FQ;Y"(A?/3 M;=)9G30ZD32,R)T4IM#DJ\@@^PC@HX)&1K23,8LZ$1>07I$X_$*B( J.$)I_ M.CP<==")FZK&#B_NK&H'4*\!ZCF@W@F@^PH4-4RL"'<[DN*.'*MWC=)W*/;B MODW#8=P?^V_[-3AT&O2'C<\'?OV&7[]3Z"T35*2PQ^ZZ0W72H":=JF]*J0S[ M2]U%ESE1]BY>ROQRC4FHUF".'KH:--G3UT]:)3AT"8/C%1@T7 >=7+\+ PKP MGB#5_$,U.*-+QIEA[9-0LQUT4:G9'KK$Q\D.&[+#3K+/TE#>HGGJ2 T/DB?M M:AZZA"<(CAJ"HT\0["8V.CSKHR!L43MT&@S"%C=_[]DL0:U<-]&8=RU,_?0T MUJ9AW;AWNF6?82.K^\Y_F+H+WE&U8D*CHAPA@ZL!,E)U9ZDG1E;N<5Y*@T^] M&Q;8C$%9!US/I32[B4W0M/?I/U!+ P04 " HB6%239^ ;$,# !A"@ M&0 'AL+W=OJ)&;)X60%=%F*9>AJB62W!E5+$RB* TK M0GDPF[A[-W(V$8UFE..-!-54%9'/%\C$:AK$P>;&+5V6VMX(9Y.:+/$.]7U] M(\TJ[+SDM$*NJ. @L9@&Y_'913RT!F[';XHKM7,--I6%$'_LXCJ?!I$E0H:9 MMBZ(^7O$2V3,>C(T_>5H+L6.0I <,DK5!XKC; M0(YR3C293:18@;2[C3=[X5)UU@:.P8CH!R^%6*1A&>JTFH#8GU%V;KJ!=MU.1 MU#B!'X+K4L%7GF/^OX/0I-#ED6SRN$B\'N>8]: ??X$D2J+[NSE\/CKVN.UW M\O2=V_X!MTZ(FM 4@&'5H?0^=;_NB/L[B M=!Q-PL<]1,..:/A.HH)RPC/T\+2>TQV>T6@_3=K1I%Z:*Q?S?33I"YKT ,VH MHQEYSXWK;B>B.&G,22!*H3DU8F%>'MZ>&GS*2L*7Z(Y5>U[$@M&E>\^\YV7< M$8S?6)W#>8]?Y!U'HVB\/_73+O#I&PKAD_OTQ6%,HO[^H'&T[6.15_$'UW\Q M/SE_-(D;96_1?I2L *['P2^4E4?7>*=CQA]6]A47*3PCD0I&4+5M,(6-N&&OL[ZHLZS:G*;%N%6Z+1%V+;*>.WMDJ/ M!GX7P]XP^N2#V3;)V-\EWU .OX-A;[ ?)=SYZE#$; > [FXW/YVW M4\-V>SM\_2!R2;DRD(4QC7HC@R3;>:9=:%&[&6(AM)E(W&5I9D"4=H-Y7@BA M-PL;H)LJ9_\ 4$L#!!0 ( "B)85+)!ITSB@, )D- 9 >&PO=V]R M:W-H965TM%*G8%C/A*J)-(VHZJ5 MNKNC3J>]=A(GL0J8VF;2_ONU"0/IV(:9O4DP^)SW/0?\8!8G+G[((Z4*_2J+ M2BZ#HU+UNS"4VR,MB;SF-:WTE3T7)5%Z* ZAK 4ENS:H+$(<15E8$E8%JT5[ M[E:L%KQ1!:OHK4"R*4LB?K^G!3\M P@>3WQAAZ,R)\+5HB8'>D?5?7TK]"CL ML^Q822O)>(4$W2^#O^#=&F,3T,[XQNA)7APC4\J&\Q]F\&FW#"+CB!9TJTP* MHO\>Z)H6AS(9*N>?&=[=1Q&M-&Z&E:9VWBGA+[*=)Q:?::Z!Q)= MH5OR6]\=)=%]M:,"_<.KJS6IMKJ_9%-0U,U[?4,5885\HR/N[V[0ZU=OT"O$ M*O3UR!M)JIUC M[PCN.X+;?+$GW[\U%42QZM#5/)(R[E/&;JUL2BMQ:666 M%N3SU*TUZ[5F4UJI2VMF:V5YYM::]UKS4:VO1ZKQNU=4N!3GEF*:1-BMF/>* M^;@B5Z1 ^T8U@AJDL+(I46&>=51W$'!9R>WB9WGBZ31$ W^B43>?J92(E76C MZ$Z#1/>!2N6$2&09N(J3U+-%A&';# 6MA9YGE.8. 2X%&C&LG;%WG%]AW#EVN^,VM/2R#RD $&Y,$X\]JG MS&DKMFTE2>YYJ&'@'B2CW/[ *O.^FJ8V#'B#2;XYN0TVX+*9Q__ -Y@$G!/< M8!,N]8D-@(-)PCG)#3;BLL@C-A .)A#W_X #-OQ@GGC,#/"#*..!B7BZZCH>J;#Q?D[X#Q0O&ZWTANN M],:\/3SJ;RAR8W7G_-;;Z#U!+ P04 " HB6%29T<6H< " M $" &0 'AL+W=O;2BT12,X_O M/9$SPXV0KRH#T&C+*%)5,$8EF\3H&(S\D)OM_!(5IFV"WX\S/$* MGD _YP_2S/P:)24,N"*"(PG+D3<.KZ<#&^\"?A#8J+TQLDH60KS:R5TZ\@)+ M""@DVB)@\UK#%"BU0(;&[PK3J[>TB?OC'?JMTVZT++""J: O)-79R.M[*(4E M+JA^%)NO4.GI6+Q$4.6>:%/&=DQP4B@M6)5L&##"RS?>5C[L)83=$PE1E1!] M3&B?2&A5"2TGM&3F9,VPQO%0B@V2-MJ@V8'SQF4;-83;O_BDI?E*3)Z.[\%X MH- E&J3JLS6.V3+BH%@+[ESC,MT,U6 T^/.=4,U$%O@*5JH-2N*;4;D6X)QSP!Y'[P M!7+7\U(L+Y\5H+%AJX^1*R$[#M+>_W4<]0;MP#B\WC?W,*P7!GM1[PAW:L*= MSQ,^PA>-DZ1@!<4:4C0#4[,2XL[H,2&=0X;]WH&.PZ@HZI_2T:UU=!MUS DG MK&#HYQS8 N2OAG_9JR%[_SA>UI(75Y*,^/$:I*FPZ!%LF29\57GV'20[9D8S M>.B.7 /+?LVRWRP<;S\K?%!##OZG\&;PP>F[YN\55 9RY?J,0HDHN"Z+5+U: MM[*QJ^ ?UB>FQ94=Z2],V1_G6*X(5XC"TD &5SUS#&79<\J)%KDKVPNA31-P MP\RT:9 VP'Q?"J%W$[M!W?CC/U!+ P04 " HB6%2*"-?^M\" #!" M&0 'AL+W=OV"D@%.JW2F%!9MQ?37ICD2*PZ=F8[A>[3SW9"&BK(^F+:&["=N__][AS[ M$FVY>)09@$*[G#(Y=C*EBFO7E7$&.98]7@#33S9*DH8; 42)9YCL7S%"C?CAW?V2_,9(J 0 M*R.!]=\3S(!2HZ0Y?M6B3A/3.+;'>_6/-GF=S!I+F''ZG20J&SN7#DI@@TNJ M[OGV$]0)#8Q>S*FTOVA;V0Y&#HI+J7A>.VN"G+#J'^_J0K0<_.$)AZ!V"%X[ M]$\XA+5#:!.MR&Q:4'Y M,P": H,-46A),9/H? X*$RHOT ?TL)JC\[,+=(8(0PM"J2Z_C%REHQL--ZXC M3:M(P8E(?H 6G*E,HEN60'(HX&KLACW8LT^#3L4YQ#T4^N]1X 7>$:#9F]W] MJPZ5@CJ:LH.N7XCU[=RX4F\C5Y)T$P739!U:=]ZLSMH3F1, MN2P%H!^?M0VZ4Y#+GQTQ!TW,06<*"[PC>9DW>:"X%?S8EG?+^9[7\[QW'6## M!FSX)C!];N.,L'1/* X(4:$7]NS'<+N#]/\".VI@1YTZ]Q#SE)'?>O-@I^]; M>92ETAA9#7/9/DV\7ABY3^T7^)A-T-@=<%^YPA2MZ]/.UY2D^-3N M5DI^>!#??\58&0W;-L<)KQK"JT["+WHCWWB6?._EFO/^VVGR6Y>K_\^*74MU MOQ"UT:"CVFZK&>0@4MLCI3XG)5/5W=JL-GWXQG:?5^M3TY]MDWF1J9K[ HN4 MZ"Y!8:,EO=Y(\XBJ7U83Q0O;=J/S$!FJ^6R1]0 M2P,$% @ *(EA4AV7N@?8 @ '@D !D !X;"]W;W)K&ULM59=3]LP%/TK5EZV21N)TZ0-J*U$"].0AH9 &P]H#VYRVUCX M(]A."_]^MA/2#MJ(E_:A\=<]]]QC^UZ/-U(]ZA+ H&?.A)X$I3'561CJO 1. M](FL0-B9I52<&-M5JU!7"DCAC3@+XR@:AIQ0$4S'?NQ&3<>R-HP*N%%(UYP3 M]3(#)C>3 >O [=T51HW$$['%5G!'9C?U8VRO;!#*2@'H:D42,%R$ISCLQE. MG(%?\8?"1N^TD0ME(>6CZUP5DR!RC(!!;AP$L9\US($QAV1Y/+6@0>?3&>ZV M7]&_^^!M, NB82[9/2U,.0FR !6P)#4SMW+S ]J 4H>72Z;]/]HT:T=I@/): M&\E;8\N 4]%\R7,KQ(Y!'!TPB%N#V/-N''F6%\20Z5C)#5)NM45S#1^JM[;D MJ'"[4G:76SDSOC,P?2\D*4/H3NGRJJ7E!W]!<0'Z"!O@KBJ,XTB51H'M0!YU& X\Z.( Z9T1K))>M' \_ M[3RZ,L#UWQ[TI$-//'IR"/VC4N\3N($>>FAW ==3G&6#+$GB<;C>0RKM2*4? M(:4]*6H)6$IU94=R*=;VJ+@+9041TKQ5N.&5ON.59#B*H@.TAAVM82^M1J1? ME;O0&CU< U^ ZMN$40<\.L(69QUZ=KPMSMY).4K39!"E^Z4\[3B=]G*Z)TH1 M83ZD(HZVV20Z@HYX)UOAHY[+%O[-A8G<;[^<.-Y2B_NI^=#G+1-#%PR0+91+ M4,J2](S[)-@F(WR,;(2WZ0@?,1_A]PEIF(P2/'A[6L.=DL5!K7QAUE:\6IBF M>G6C7?$_;TK>=GGS>@>Q)-_P%02P,$% @ *(EA4C(N[/;C"0 P3D !D M !X;"]W;W)K&ULQ5O;;N,X$OT5PIC%=H!NVY1$ M21XD 1([Z>G%7(+.SLS#8!]DB;&)UL5-4;DL]N.7E!A3LBA*=B),/Z1MF2Q6 ML8KG%(O4^5-&O^5;C!EX3N(TOYAL&=O].)OEX18G03[-=CCEOSQD- D8_THW MLWQ'<1"5G9)X9LWG[BP)2#JY/"^?W='+\ZQ@,4GQ'05YD20!?;G&-82.)Z?)=")_LQ1F,5Y^1<\R;;S M"0B+G&6)[,PU2$A:_1\\RXFH=;"[.EBR@W70P8$='6S9P3X